PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Welte, T; Leitenberg, D; Dittel, BN; al-Ramadi, BK; Xie, B; Chin, YE; Janeway, CA; Bothwell, ALM; Bottomly, K; Fu, XY				Welte, T; Leitenberg, D; Dittel, BN; al-Ramadi, BK; Xie, B; Chin, YE; Janeway, CA; Bothwell, ALM; Bottomly, K; Fu, XY			STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; ANTIGEN RECEPTORS; ACTIVATION; LYMPHOCYTES; EXPRESSION; INDUCTION	The role of STAT (signal transducer and activator of transcription) proteins in T cell receptor (TCR) signaling was analyzed. STAT5 became immediately and transiently phosphorylated on tyrosine 694 in response to TCR stimulation. Expression of the protein tyrosine kinase Lck, a key signaling protein in the TCR complex, activated DNA binding of transfected STAT5A and STAT5B to specific STAT inducible elements. The role of Lck in STAT5 activation was confirmed in a Lck-deficient T cell Line in which the activation of STAT5 by TCR stimulation was abolished. Expression of Lck induced specific interaction of STAT5 with the subunits of the TCR, indicating that STAT5 may be directly involved in TCR signaling. Stimulation of T cell clones and primary T cell lines also induced the association of STAT5 with the TCR complex. Inhibition of STAT5 function by expression of a dominant negative mutant STAT5 reduced antigen-stimulated proliferation of T cells. Thus, TCR stimulation appears to directly activate STAT5, which may participate in the regulation of gene transcription and T cell proliferation during immunological responses.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	Fu, XY (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St, New Haven, CT 06520 USA.			Leitenberg, David/0000-0002-0622-9522	NIAID NIH HHS [AI34522] Funding Source: Medline; NIGMS NIH HHS [GM46367, GM55590] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055590, R01GM046367] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRamadi BK, 1996, J IMMUNOL, V157, P4751; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leitenberg D, 1998, J IMMUNOL, V161, P1194; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; PERLMUTTER RM, 1995, CANCER SURV, V22, P85; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELTE T, UNPUB; YOKOYAMA WM, 1989, IMMUNOL REV, V109, P153, DOI 10.1111/j.1600-065X.1989.tb00024.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	26	115	123	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					222	225		10.1126/science.283.5399.222	http://dx.doi.org/10.1126/science.283.5399.222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880255				2022-12-24	WOS:000077976700040
J	Kennerdell, JR; Carthew, RW				Kennerdell, JR; Carthew, RW			Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway	CELL			English	Article							SEGMENT-POLARITY GENE; CELL FATE DETERMINATION; DROSOPHILA-MELANOGASTER; TISSUE POLARITY; LARVAL CUTICLE; ZYGOTIC LOCI; PATTERN; EXPRESSION; EPIDERMIS; ARMADILLO	We investigated the potential of double-stranded RNA to interfere with the function of genes in Drosophila. Injection of dsRNA into embryos resulted in potent and specific interference of several genes that were tested. In contrast, single-stranded RNA weakly interfered with gene activity. The method was used to determine the reception mechanism of the morphogen Wingless. Interference of the frizzled and Drosophila frizzled 2 genes together produced defects in embryonic patterning that mimic loss of wingless function. Interference of either gene alone had no effect on patterning. Epistasis analysis indicates that frizzled and Drosophila frizzled 2 act downstream of wingless and upstream of zeste-white3 in the Wingless pathway. Our results demonstrate that dsRNA interference can be used to analyze many aspects of gene function.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carthew, RW (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	carthew@pop.pitt.edu			NEI NIH HHS [R01 EY10111] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010111] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER PN, 1990, GENETICS, V126, P401; ARIAS AM, 1988, DEVELOPMENT, V103, P157; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; Hays R, 1997, DEVELOPMENT, V124, P3727; Heberlein U, 1998, DEVELOPMENT, V125, P567; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Heldens JGM, 1997, J VIROL METHODS, V68, P57, DOI 10.1016/S0166-0934(97)00109-2; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Reifegerste R, 1997, MECH DEVELOP, V68, P69, DOI 10.1016/S0925-4773(97)00127-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WILDER EL, 1995, DEVELOPMENT, V121, P477; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhang J, 1998, DEVELOPMENT, V125, P3075; ZHENG L, 1995, DEVELOPMENT, V121, P3045	48	866	1017	1	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					1017	1026		10.1016/S0092-8674(00)81725-0	http://dx.doi.org/10.1016/S0092-8674(00)81725-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875855	Bronze			2022-12-24	WOS:000077759100016
J	Raman, CS; Li, HY; Martasek, P; Kral, V; Masters, BSS; Poulos, TL				Raman, CS; Li, HY; Martasek, P; Kral, V; Masters, BSS; Poulos, TL			Crystal structure of constitutive endothelial nitric oxide synthase: A paradigm for pterin function involving a novel metal center	CELL			English	Article							ESCHERICHIA-COLI; OXYGENASE DOMAIN; DIFFRACTION DATA; L-ARGININE; TETRAHYDROBIOPTERIN; ZINC; REDUCTASE; SITE; INHIBITION; PROTEIN	Nitric oxide, a key signaling molecule, is produced by a family of enzymes collectively called nitric oxide synthases (NOS). Here, we report the crystal structure of the heme domain of endothelial NOS in tetrahydrobiopterin (H4B)-free and -bound forms at 1.95 Angstrom and 1.9 Angstrom resolution, respectively. In both structures a zinc ion is tetrahedrally coordinated to pairs of symmetry-related cysteine residues at the dimer interface. The phylogenetically conserved Cys-(X)(4)-Cys motif and its strategic location establish a structural role for the metal center in maintaining the integrity of the H4B-binding site. The unexpected recognition of the substrate, L-arginine, at the H4B site indicates that this site is poised to stabilize a positively charged pterin ring and suggests a model involving a cationic pterin radical in the catalytic cycle.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague 6, Czech Republic	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine; University of Chemistry & Technology, Prague	Poulos, TL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	masters@uthscsa.edu; poulos@uci.edu	Kral, Vladimir/I-9518-2017; Martasek, Pavel/G-6622-2017	Kral, Vladimir/0000-0001-5034-4184; Raman, C. S./0000-0002-1036-3193; Martasek, Pavel/0000-0001-6165-4444	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM32688, GM57353] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Alderton WK, 1998, BIOCHEM J, V332, P195, DOI 10.1042/bj3320195; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barber HJ, 1932, J CHEM SOC, P1365, DOI 10.1039/jr9320001365; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Birdsall DL, 1996, J MOL BIOL, V255, P522, DOI 10.1006/jmbi.1996.0043; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Cronk JD, 1996, PROTEIN SCI, V5, P1963, DOI 10.1002/pro.5560051002; Crow JP, 1997, J NEUROCHEM, V69, P1936; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Goodwill KE, 1998, BIOCHEMISTRY-US, V37, P13437, DOI 10.1021/bi981462g; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hampele IC, 1997, J MOL BIOL, V268, P21, DOI 10.1006/jmbi.1997.0944; Hemmens B, 1998, METH MOL B, V100, P1; Hennig M, 1998, NAT STRUCT BIOL, V5, P357, DOI 10.1038/nsb0598-357; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; HYUN J, 1995, BIOCHEM BIOPH RES CO, V206, P380, DOI 10.1006/bbrc.1995.1052; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Kaufman S., 1997, TETRAHYDROBIOPTERIN; KAW S, 1992, P NATL ACAD SCI USA, V89, P6886, DOI 10.1073/pnas.89.15.6886; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1989, J BIOL CHEM, V264, P20496; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Luykx DMAM, 1998, BIOCHEMISTRY-US, V37, P11366, DOI 10.1021/bi972972y; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MATTHEWS RG, 1982, FED PROC, V41, P2600; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MCTIGUE MA, 1993, BIOCHEMISTRY-US, V32, P6855, DOI 10.1021/bi00078a008; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VALLEE BL, 1993, ACCOUNTS CHEM RES, V26, P543, DOI 10.1021/ar00034a005; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Werner-Felmayer G, 1996, METHODS NITRIC OXIDE, P271; WILKER JJ, 1995, J AM CHEM SOC, V117, P8682, DOI 10.1021/ja00138a031; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	79	559	576	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					939	950		10.1016/S0092-8674(00)81718-3	http://dx.doi.org/10.1016/S0092-8674(00)81718-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875848	Bronze			2022-12-24	WOS:000077759100009
J	Jones, AM				Jones, AM			Botany: Auxin transport: Down and out and up again	SCIENCE			English	Editorial Material							ARABIDOPSIS-THALIANA; POLAR TRANSPORT; ACID		Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu						BELL CJ, 1990, MOL GEN GENET, V220, P289, DOI 10.1007/BF00260496; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; DARWIN C, 1980, POWER MOVEMENT PLANT; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Fujita H, 1997, PLANT J, V12, P583, DOI 10.1046/j.1365-313X.1997.00583.x; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; GOLDSMITH MHM, 1977, ANNU REV PLANT PHYS, V28, P439, DOI 10.1146/annurev.pp.28.060177.002255; JONES AM, 1990, PLANT PHYSIOL, V93, P1154, DOI 10.1104/pp.93.3.1154; Lomax Terri L., 1995, P509; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Meinhardt H., 1984, Positional controls in plant development, P1; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; RAVEN JA, 1975, NEW PHYTOL, V74, P163, DOI 10.1111/j.1469-8137.1975.tb02602.x; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; Stowe-Evans EL, 1998, PLANT PHYSIOL, V118, P1265, DOI 10.1104/pp.118.4.1265; Uggla C, 1996, P NATL ACAD SCI USA, V93, P9282, DOI 10.1073/pnas.93.17.9282; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310; WENT F. W., 1928, REC TRAV BOT NEERL, V25, P1; WOLPERT L, 1989, MOL BASIS POSITION S, P3	21	67	74	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2201	2202		10.1126/science.282.5397.2201	http://dx.doi.org/10.1126/science.282.5397.2201			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890827				2022-12-24	WOS:000077645800028
J	Wills-Karp, M; Luyimbazi, J; Xu, XY; Schofield, B; Neben, TY; Karp, CL; Donaldson, DD				Wills-Karp, M; Luyimbazi, J; Xu, XY; Schofield, B; Neben, TY; Karp, CL; Donaldson, DD			Interleukin-13: Central mediator of allergic asthma	SCIENCE			English	Article							EOSINOPHILIC INFLAMMATION; AIRWAY HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; PERIPHERAL-BLOOD; T-LYMPHOCYTES; TRENDS; HOSPITALIZATION; EXPRESSION; IL-13; MICE	The worldwide incidence, morbidity, and mortality of allergic asthma are increasing. The pathophysiological features of allergic asthma are thought to result from the aberrant expansion of CD4(+) T cells producing the type 2 cytokines interleukin-4 (IL-4) and IL-5, although a necessary role for these cytokines in allergic asthma has not been demonstrable. The type 2 cytokine IL-13, which shares a receptor component and signaling pathways with IL-4, was found to be necessary and sufficient for the expression of allergic asthma. IL-13 induces the pathophysiological features of asthma in a manner that is independent of immunoglobulin E and eosinophils. Thus, IL-13 is critical to allergen-induced asthma but operates through mechanisms other than those that are classically implicated in allergic responses.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Genet Inst, Dept Immunol, Cambridge, MA 02140 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wills-Karp, M (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.	mkarp@welchlink.welch.jhu.edu		Karp, Christopher/0000-0002-0832-2659	NHLBI NIH HHS [HL58527] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058527] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FRIEDHOFF LR, 1993, INT ARCH ALLERGY IMM, V100, P355; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HERSHEY GK, 1977, NEW ENGL J MED, V337, P1720; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; LUYIMBAZI J, UNPUB; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; PAUWELS R, 1989, CLIN EXP ALLERGY, V19, P395, DOI 10.1111/j.1365-2222.1989.tb02404.x; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rosenwasser LJ, 1997, NEW ENGL J MED, V337, P1766, DOI 10.1056/NEJM199712113372412; SLY RM, 1984, ANN ALLERGY, V53, P20; TESSLER DC, 1991, GENE, V2, P177; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; VOLLMER WM, 1992, J CLIN EPIDEMIOL, V45, P999, DOI 10.1016/0895-4356(92)90115-4; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	43	2201	2326	2	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2258	2261		10.1126/science.282.5397.2258	http://dx.doi.org/10.1126/science.282.5397.2258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856949				2022-12-24	WOS:000077645800047
J	Bliss, DZ; Johnson, S; Savik, K; Clabots, CR; Willard, K; Gerding, DN				Bliss, DZ; Johnson, S; Savik, K; Clabots, CR; Willard, K; Gerding, DN			Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding	ANNALS OF INTERNAL MEDICINE			English	Article						Clostridium difficile; diarrhea; enteral feeding; hospitalization; Clostridium infections	CRITICALLY ILL PATIENTS; MICROBIAL-CONTAMINATION; ENTERAL FEEDS; COLONIZATION; INFECTION; SYSTEMS; HYPOALBUMINEMIA; ENVIRONMENT; DELIVERY; SEVERITY	Background: Clostridium difficile is the most common infectious cause of nosocomial diarrhea, but its role in diarrhea associated with tube feeding has not been rigorously investigated. Objective: To determine the incidence of C. difficile acquisition and C. difficile-associated diarrhea in tube-fed and non-tube-fed patients. Design: Prospective cohort study. Setting: A university-affiliated Veterans Affairs Medical Center. Patients: 76 consecutive hospitalized, tube-fed patients and 76 hospitalized, non-tube-fed patients. The two cohorts were matched for age, unit location, duration of hospitalization before surveillance, and severity of illness. Measurements: Incidence of C. difficile acquisition, incidence of C, difficile-associated diarrhea, and C. difficile restriction endonuclease analysis typing results. Results: More tube-fed patients than non-tube-fed patients acquired C. difficile (15 of 76 patients [20%] compared with 6 of 76 patients [8%]; P = 0.03) and developed C. difficile-associated diarrhea (7 of 76 patients [9%] compared with 1 of 76 patients [1%]; P = 0.03). The mean proportion (+/-SD) of surveillance days with diarrhea was greater for tube-fed patients after the development of C. difficile-associated diarrhea than for tube-fed patients without this diarrhea (0.68 +/- 0.4 compared with 0.22 +/- 0.2 [95% CI for the mean difference, 0.08 to 0.84]). Postpyloric tube feeding (odds ratio, 3.14 [CI, 1.008 to 9.77]) and duration of surveillance (odds ratio, 1.08 [CI, 1.0009 to 1.16]) were risk factors for the acquisition of C. difficile. Nineteen restriction endonuclease analysis types of C. difficile were identified from 20 patients. Conclusions: Hospitalized, tube-fed patients, especially those receiving postpyloric tube feeding, are at greater risk for the acquisition of C. difficile and the development of C. difficile-associated diarrhea than are hospitalized, non-tube-fed patients. Clinicians should test for C. difficile in tube-fed patients with diarrhea.	Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; Vet Affairs Chicago Healthcare Syst, Chicago, IL 60611 USA; Vet Affairs Med Ctr, Res Serv 151, Minneapolis, MN 55417 USA; Northwestern Univ, Sch Med, Chicago, IL USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Northwestern University	Bliss, DZ (corresponding author), Univ Minnesota, Sch Nursing, 6-101 Weaver Densford Hall,308 Dr Johnson & Gerdi, Minneapolis, MN 55455 USA.	bliss@tc.umn.edu		Johnson, Stuart/0000-0001-9548-229X	NINR NIH HHS [1F32-NR06746] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [F32NR006746] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ANDERSON KR, 1984, JPEN-PARENTER ENTER, V8, P673, DOI 10.1177/0148607184008006673; ANDERTON A, 1993, CLIN NUTR, V12, P16; ANDERTON A, 1990, CLIN NUTR, V9, P157, DOI 10.1016/0261-5614(90)90048-W; ANDERTON A, 1988, J HOSP INFECT, V11, P364, DOI 10.1016/0195-6701(88)90090-4; BETTIN K, 1994, INFECT CONT HOSP EP, V15, P697; BLISS DZ, 1992, AM J CLIN NUTR, V55, P753, DOI 10.1093/ajcn/55.3.753; BRINSON RR, 1987, CRIT CARE MED, V15, P506, DOI 10.1097/00003246-198705000-00011; BRINSON RR, 1988, CRIT CARE MED, V16, P130, DOI 10.1097/00003246-198802000-00007; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CLABOTS CR, 1989, J CLIN MICROBIOL, V27, P2386, DOI 10.1128/JCM.27.10.2386-2387.1989; CLABOTS CR, 1993, 33 INT C ANTI AG CHE; CROCKER KS, 1986, AM J INFECT CONTROL, V14, P250, DOI 10.1016/0196-6553(86)90037-4; DONIUS MA, 1993, JPEN-PARENTER ENTER, V17, P461, DOI 10.1177/0148607193017005461; EDES TE, 1990, AM J MED, V88, P91, DOI 10.1016/0002-9343(90)90454-L; FREEDLAND CP, 1989, JPEN-PARENTER ENTER, V13, P18, DOI 10.1177/014860718901300118; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; GOTTSCHLICH MM, 1988, JPEN-PARENTER ENTER, V12, P338, DOI 10.1177/0148607188012004338; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; Holdeman L.V., 1975, ANAEROBE LAB MANUAL; HORN SD, 1986, MED CARE, V24, P159, DOI 10.1097/00005650-198602000-00007; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY TWJ, 1983, CRIT CARE MED, V11, P7, DOI 10.1097/00003246-198301000-00003; Keohane P P, 1983, Clin Nutr, V1, P259, DOI 10.1016/0261-5614(83)90003-1; KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42; KOTILAINEN HR, 1983, P ROSS LABORATORIES, P16; LEVY J, 1989, JPEN-PARENTER ENTER, V13, P228, DOI 10.1177/0148607189013003228; MALAMOULADAS H, 1983, J CLIN PATHOL, V36, P88, DOI 10.1136/jcp.36.1.88; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; METCALF AM, 1986, CLIN GASTROENTEROL, V15, P705; MICKSCHL DB, 1990, HEART LUNG, V19, P362; PETERSON LR, 1986, AM J CLIN PATHOL, V86, P208, DOI 10.1093/ajcp/86.2.208; ROLFE RD, 1983, INFECT IMMUN, V42, P480, DOI 10.1128/IAI.42.2.480-486.1983; ROLFE RD, 1984, INFECT IMMUN, V45, P185, DOI 10.1128/IAI.45.1.185-191.1984; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SCHROEDER P, 1983, JPEN-PARENTER ENTER, V7, P364, DOI 10.1177/0148607183007004364; SIEGEL DL, 1990, JAMA-J AM MED ASSOC, V263, P979, DOI 10.1001/jama.263.7.979; THURN J, 1990, J HOSP INFECT, V15, P203, DOI 10.1016/0195-6701(90)90028-M; WAGNER DR, 1994, JPEN-PARENTER ENTER, V18, P453, DOI 10.1177/0148607194018005453; WILSON KH, 1985, J INFECT DIS, V151, P355, DOI 10.1093/infdis/151.2.355; YANNELLI B, 1988, AM J INFECT CONTROL, V16, P246, DOI 10.1016/S0196-6553(88)80003-8; ZIMMARO DM, 1989, JPEN-PARENTER ENTER, V13, P117, DOI 10.1177/0148607189013002117	47	206	210	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1012	+		10.7326/0003-4819-129-12-199812150-00004	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867755				2022-12-24	WOS:000077471900003
J	Herrick, AL				Herrick, AL			Advances in treatment of systemic sclerosis	LANCET			English	Editorial Material							SCLERODERMA		Univ Manchester, Hope Hosp, Ctr Rheumat Dis, Salford M6 8HD, Lancs, England	University of Manchester	Herrick, AL (corresponding author), Univ Manchester, Hope Hosp, Ctr Rheumat Dis, Salford M6 8HD, Lancs, England.			Herrick, Ariane/0000-0003-4941-7926				Akesson Anita, 1998, Current Opinion in Rheumatology, V10, P579; Black C, 1998, BRIT MED J, V317, P294; Casale R, 1997, ARCH PHYS MED REHAB, V78, P767, DOI 10.1016/S0003-9993(97)90087-3; Clements P. J., 1997, Arthritis and Rheumatism, V40, pS173; Grassegger A, 1998, BRIT J DERMATOL, V139, P639; Menon N, 1998, ARTHRITIS RHEUM-US, V41, P466; Pope J, 1998, ARTHRITIS RHEUM, V41, pS102; Pope JE, 1996, RHEUM DIS CLIN N AM, V22, P893, DOI 10.1016/S0889-857X(05)70307-0; Seibold JR, 1998, J RHEUMATOL, V25, P302; Silman Alan, 1997, Arthritis and Rheumatism, V40, pS123; SJOGREN RW, 1994, ARTHRITIS RHEUM-US, V37, P1265, DOI 10.1002/art.1780370902; STEEN VD, 1990, ANN INTERN MED, V113, P352, DOI 10.7326/0003-4819-113-5-352; Tyndall A, 1997, LANCET, V349, P254, DOI 10.1016/S0140-6736(05)64864-7; WHITE B, 1995, ARTHRITIS RHEUM, V38, P351, DOI 10.1002/art.1780380309; Wigley FM, 1998, ARTHRITIS RHEUM-US, V41, P670, DOI 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.3.CO;2-9	15	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1874	1875		10.1016/S0140-6736(05)60391-1	http://dx.doi.org/10.1016/S0140-6736(05)60391-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863781				2022-12-24	WOS:000077544600004
J	Yano, S; Tokumitsu, H; Sodeling, TR				Yano, S; Tokumitsu, H; Sodeling, TR			Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway	NATURE			English	Article							MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; DEATH; AKT; CASCADE; PHOSPHORYLATION; CALMODULIN; BAD; DEPOLARIZATION; 3-KINASE	The protection against apoptosis provided by growth factors in several cell lines is due to stimulation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway, which results in activation of protein kinase B-1,B-2 (PKB; also known as c-Akt and Rac) and phosphorylation and sequestration to protein 14-3-3 of the pro-apoptotic Bcl-2-family member BAD(3-7). A modest increase in intracellular Ca2+ concentration also promotes survival of some cultured neurons(8,9) through a pathway that requires calmodulin but is independent of PI(3)K and the MAP kinases(10,11), Here we report that Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK) activates PKB directly, resulting in phosphorylation of BAD on serine residue 136 and the interaction of BAD with protein 14-3-3, Serum withdrawal induced a three- to fourfold increase in cell death of NG108 neuroblastoma cells, and this apoptosis was largely blocked by increasing the intracellular Ca2+ concentration with NMDA (N-methyl-D-aspartate) or KCl or by transfection with constitutively active CaM-KK. The effect of NMDA on cell survival was blocked by transfection with dominant-negative forms of CaM-KK or PKB. These results identify a Ca2+-triggered signalling cascade in which CaM-KK activates PKB, which in turn phosphorylates BAD and protects cells from apoptosis.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Sodeling, TR (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	soderlit@ohsu.edu	Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FURBER S, 1987, J NEUROSCI, V7, P1816; GALLO V, 1987, J NEUROSCI, V7, P2203; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SEBERT MA, 1995, J BIOL CHEM, V270, P17616; Soler RM, 1998, J NEUROSCI, V18, P1230; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	28	527	552	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					584	587		10.1038/25147	http://dx.doi.org/10.1038/25147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859994				2022-12-24	WOS:000077466800060
J	Matsukawa, Y; Nishinarita, S; Horie, T; Naruse, S				Matsukawa, Y; Nishinarita, S; Horie, T; Naruse, S			Anaphylaxis induced by gabexate mesylate	BRITISH MEDICAL JOURNAL			English	Letter									Nihon Univ, Sch Med, Itabashi Ku, Tokyo 173, Japan	Nihon University	Matsukawa, Y (corresponding author), Nihon Univ, Sch Med, Itabashi Ku, Tokyo 173, Japan.							BUCHLER M, 1993, GASTROENTEROLOGY, V104, P1165; Cavallini G, 1996, NEW ENGL J MED, V335, P919, DOI 10.1056/NEJM199609263351302; Novelli G P, 1995, Minerva Anestesiol, V61, P509	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1563	1563		10.1136/bmj.317.7172.1563	http://dx.doi.org/10.1136/bmj.317.7172.1563			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836656	Green Submitted, Green Published			2022-12-24	WOS:000077451700026
J	Peltola, H; Leinikki, P				Peltola, H; Leinikki, P			Rubella gene sequencing as a clinician's tool	LANCET			English	Editorial Material							INFECTION; OUTBREAK		Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare	Peltola, H (corresponding author), Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.							Adams MS, 1997, EPIDEMIOL INFECT, V118, P253, DOI 10.1017/S0950268897007450; Bellini WJ, 1998, EMERG INFECT DIS, V4, P29, DOI 10.3201/eid0401.980105; Frenkel LM, 1996, CLIN INFECT DIS, V22, P287, DOI 10.1093/clinids/22.2.287; Frey TK, 1998, J INFECT DIS, V178, P642, DOI 10.1086/515370; Liitsola K, 1998, AIDS, V12, P1907, DOI 10.1097/00002030-199814000-00023; MELLINGER AK, 1995, PEDIATR INFECT DIS J, V14, P573, DOI 10.1097/00006454-199507000-00004; Mulders MN, 1997, J INFECT DIS, V176, P617, DOI 10.1086/514081; PELTOLA H, 1998, 38 INT C ANT AG CHEM; POYRY T, 1990, J GEN VIROL, V71, P2535, DOI 10.1099/0022-1317-71-11-2535; ZgorniakNowosielska I, 1996, EUR J EPIDEMIOL, V12, P303, DOI 10.1007/BF00145421	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1799	1800		10.1016/S0140-6736(05)79885-8	http://dx.doi.org/10.1016/S0140-6736(05)79885-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851377				2022-12-24	WOS:000077337900005
J	Gat, U; DasGupta, R; Degenstein, L; Fuchs, E				Gat, U; DasGupta, R; Degenstein, L; Fuchs, E			De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin	CELL			English	Article							DROSOPHILA PATCHED GENE; GARDNERS-SYNDROME; SONIC HEDGEHOG; HUMAN HOMOLOG; STEM-CELLS; PROTEIN; APC; CARCINOGENESIS; ACTIVATION; MUTATIONS	An effector of intercellular adhesion, beta-catenin also functions in Wnt signaling, associating with Lef-1/Tcf DNA-binding proteins to form a transcription factor. We report that this pathway operates in keratinocytes and that mice expressing a stabilized beta-catenin controlled by an epidermal promoter undergo a process resembling de novo hair morphogenesis. The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. As in embryologically initiated hair germs, transgenic follicles induce Lef-1, but follicles are disoriented and defective in sonic hedgehog polarization. Additionally, proliferation continues unchecked, resulting in two types of tumors also found in humans. Our findings suggest that transient beta-catenin stabilization may be a key player in the long-sought epidermal signal reading to hair development and implicate aberrant beta-catenin activation in hair tumors.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Fuchs, Elaine/G-1565-2016	Dasgupta, Ramanuj/0000-0001-9015-3729	NIAMS NIH HHS [AR31737] Funding Source: Medline; NIDCR NIH HHS [5P50-DE11921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COOPER PH, 1983, J AM ACAD DERMATOL, V8, P639, DOI 10.1016/S0190-9622(83)70071-X; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fitzpatrick TB, 1987, DERMATOLOGY GEN MED, P1841; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hardy M.H., 1992, TRENDS GENET, V8, P159; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LEPPARD BJ, 1976, CLIN EXP DERMATOL, V1, P75, DOI 10.1111/j.1365-2230.1976.tb01400.x; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Manabe M, 1996, INT J DERMATOL, V35, P325, DOI 10.1111/j.1365-4362.1996.tb03632.x; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NARISAWA Y, 1995, J CUTAN PATHOL, V22, P115, DOI 10.1111/j.1600-0560.1995.tb01392.x; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; SENGEL P, 1990, International Journal of Developmental Biology, V34, P33; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZHOU P, 1995, GENE DEV, V9, P570	43	897	994	2	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					605	614		10.1016/S0092-8674(00)81631-1	http://dx.doi.org/10.1016/S0092-8674(00)81631-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845363	Bronze			2022-12-24	WOS:000077253700008
J	Gan, WB; Lichtman, JW				Gan, WB; Lichtman, JW			Synaptic segregation at the developing neuromuscular junction	SCIENCE			English	Article							POSTSYNAPTIC CHANGES; AXON WITHDRAWAL; SKELETAL-MUSCLE; INNERVATION; ELIMINATION; SYNAPSES; INVITRO; MATURATION; DEPRESSION; RECEPTORS	Throughout the developing nervous system, competition between axons causes the permanent removal of some synaptic connections. In mouse neuromuscular junctions at birth, terminal branches of different axons are intermingled. However, during the several weeks after birth, these branches progressively segregated into nonoverlapping compartments before the complete withdrawal of all but one axon. Segregation was caused by selective branch atrophy, detachment, and withdrawal; the axon branches that were nearest to the competitor's branches were removed before the more distant branches were removed. This progression suggests that the signals that mediate the competitive removal of synapses must decrease in potency over short distances.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Lichtman, JW (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108, St Louis, MO 63110 USA.							BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BANK M, 1992, J NEUROSCI, V12, P2960, DOI 10.1523/JNEUROSCI.12-08-02960.1992; BRAVIN M, 1995, J COMP NEUROL, V357, P395, DOI 10.1002/cne.903570306; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; FOREHAND CJ, 1984, J NEUROSCI, V4, P1; GAN WB, 1995, J NEUROSCI, V15, P3243; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; PURVES D, 1985, PRINCIPLES NEURAL DE; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RILEY DA, 1977, BRAIN RES, V134, P279, DOI 10.1016/0006-8993(77)91073-3; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; YOUNG SR, 1986, J COMP NEUROL, V254, P425, DOI 10.1002/cne.902540402; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	26	82	86	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1508	1511		10.1126/science.282.5393.1508	http://dx.doi.org/10.1126/science.282.5393.1508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822385				2022-12-24	WOS:000077110800060
J	Cardone, MH; Roy, N; Stennicke, HR; Salvesen, GS; Franke, TF; Stanbridge, E; Frisch, S; Reed, JC				Cardone, MH; Roy, N; Stennicke, HR; Salvesen, GS; Franke, TF; Stanbridge, E; Frisch, S; Reed, JC			Regulation of cell death protease caspase-9 by phosphorylation	SCIENCE			English	Article							CYTOCHROME-C; AKT PROTOONCOGENE; KINASE AKT; KI-RAS; APOPTOSIS; SURVIVAL; ACTIVATION; TRANSFORMATION; MITOCHONDRIA; 3-KINASE	Caspases are intracellular proteases that function as initiators and effectors of apoptosis. The kinase Akt and p21-Ras, an Akt activator, induced phosphorylation of pro-caspase-9 (pro-Casp9) in cells. Cytochrome c-induced proteolytic processing of pro-Casp9 was defective in cytosolic extracts from cells expressing either active Ras or Akt. Akt phosphorylated recombinant Casp9 in vitro on serine-196 and inhibited its protease activity. Mutant pro-Casp9(Ser196Ala) was resistant to Akt-mediated phosphorylation and inhibition in vitro and in cells, resulting in Akt-resistant induction of apoptosis. Thus, caspases can be directly regulated by protein phosphorylation.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Sanford Burnham Prebys Medical Discovery Institute; Massachusetts Institute of Technology (MIT); Columbia University; University of California System; University of California Irvine	Reed, JC (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org	Roszak, Joanna/F-4003-2010		NATIONAL CANCER INSTITUTE [R01CA069515, P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69381, CA-69515] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CARDONE MH, UNPUB; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewska M, 1997, CANCER RES, V57, P1605; Kuwata H, 1998, BIOCHEM BIOPH RES CO, V245, P764, DOI 10.1006/bbrc.1998.8466; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	33	2601	2717	1	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1998	282	5392					1318	1321		10.1126/science.282.5392.1318	http://dx.doi.org/10.1126/science.282.5392.1318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812896				2022-12-24	WOS:000076982200045
J	Fero, ML; Randel, E; Gurley, KE; Roberts, JM; Kemp, CJ				Fero, ML; Randel, E; Gurley, KE; Roberts, JM; Kemp, CJ			The murine gene p27(Kip1) is haplo-insufficient for tumour suppression	NATURE			English	Article							DEPENDENT KINASE INHIBITOR; CELL LUNG-CANCER; P53-DEFICIENT MICE; MOLECULAR ANALYSIS; BREAST-CANCER; CYCLE; MUTATION; RETINOBLASTOMA; TUMORIGENESIS; ACTIVATION	p27(Kip) is a candidate human tumour-suppressor protein, because it is able to inhibit cyclin-dependent kinases and block cell proliferation(1-5). Abnormally low levels of the p27 protein are frequently found in human carcinomas, and these low levels correlate directly with both histological aggressiveness and patient mortality(6-10). However, it has not been possible to establish a causal link between p27 and tumour suppression, because only rare instances of homozygous inactivating mutations of the p27 gene have been found in human tumours(11-14). Thus, p27(Kip1) does not fulfil Knudson's 'two-mutation' criterion for a tumour-suppressor gene(15). Here we show that both p27 nullizygous and p27 heterozygous mice are predisposed to tumours in multiple tissues when challenged with gamma-irradiation or a chemical carcinogen. Therefore p27 is a multiple-tissue tumour suppressor in mice. Molecular analyses of tumours in p27 heterozygous mice show that the remaining wild-type allele is neither mutated nor silenced. Hence, p27 is haplo-insufficient for tumour suppression. The assumption that null mutations in tumour-suppressor genes are recessive excludes those genes that exhibit haplo-insufficiency.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Fero, Matthew/0000-0002-9967-4659	NCI NIH HHS [R01 CA118043, K08 CA071464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA071464, R01CA118043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RC, 1989, ACTA ARITH, V53, P217, DOI 10.4064/aa-53-3-217-250; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hayette S, 1997, LEUKEMIA, V11, P1696, DOI 10.1038/sj.leu.2400814; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Takeuchi S, 1996, CANCER RES, V56, P738; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	30	668	681	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					177	180		10.1038/24179	http://dx.doi.org/10.1038/24179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823898	Green Accepted			2022-12-24	WOS:000077013300054
J	Margolin, A; Avants, SK; Kleber, HD				Margolin, A; Avants, SK; Kleber, HD			Investigating alternative medicine therapies in randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COCAINE ADDICTION; ACUPUNCTURE; COMPLEMENTARY		Yale Univ, Sch Med, Subst Abuse Ctr, New Haven, CT 06519 USA; Columbia Univ, Ctr Addict & Subst Abuse, New York, NY USA	Yale University; Columbia University	Margolin, A (corresponding author), Yale Univ, Sch Med, Subst Abuse Ctr, 34 Pk St, New Haven, CT 06519 USA.				NIDA NIH HHS [DA00277, DA08513] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008513] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; AVANTS SK, 1995, J SUBST ABUSE TREAT, V12, P195; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; BREWINGTON V, 1994, J SUBST ABUSE TREAT, V11, P289, DOI 10.1016/0740-5472(94)90040-X; BRUMBAUGH AG, 1995, TRANSFORMATION RECOV; Cassidy C M, 1995, J Altern Complement Med, V1, P19, DOI 10.1089/acm.1995.1.19; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; Cook T.C., 1979, QUASIEXPERIMENTATION; *COUNC SCI MED, 1997, SCI REV ALTERN MED, V1, P2; Culliton P D, 1996, J Altern Complement Med, V2, P149, DOI 10.1089/acm.1996.2.149; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; KLAJNER F, 1984, ADDICT BEHAV, V9, P41, DOI 10.1016/0306-4603(84)90006-6; KRAMER MS, 1984, JAMA-J AM MED ASSOC, V252, P2739, DOI 10.1001/jama.252.19.2739; Kranz R, 1998, SCHWEIZ MED WSCHR, V128, P616; LEVINE RJ, 1994, PRINCIPLES MED BIO A, V1, P37; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; LIAO SJ, 1994, PRINCIPLES PRACTICE; MARGOLIN A, 1994, J SUBST ABUSE TREAT, V11, P549, DOI 10.1016/0740-5472(94)90006-X; Margolin A, 1996, J SUBST ABUSE TREAT, V13, P471, DOI 10.1016/S0740-5472(96)00065-7; MARGOLIN A, 1993, AM J CHINESE MED, V21, P103, DOI 10.1142/S0192415X93000133; MARGOLIN A, 1995, AM J CHINESE MED, V23, P105, DOI 10.1142/S0192415X95000146; Meinert CL, 1986, CLIN TRIALS DESIGN C; National Institutes of Health, 1994, ALT MED EXP MED HOR; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pocock SJ, 1983, CLIN TRIALS PRACTICA; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P373; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shapiro A, 1984, BEHAV HLTH HDB HLTH, P371; Vickers A, 1997, INT J TECHNOL ASSESS, V13, P111, DOI 10.1017/S0266462300010278; VINCENT C, 1995, J ROY SOC MED, V88, P199; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; Wiseman N, 1985, FUNDAMENTALS CHINESE; Woolf SH, 1997, ARCH FAM MED, V6, P149	35	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1626	1628		10.1001/jama.280.18.1626	http://dx.doi.org/10.1001/jama.280.18.1626			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820270				2022-12-24	WOS:000076852000036
J	Jones, AM; Im, KH; Savka, MA; Wu, MJ; DeWitt, NG; Shillito, R; Binns, AN				Jones, AM; Im, KH; Savka, MA; Wu, MJ; DeWitt, NG; Shillito, R; Binns, AN			Auxin-dependent cell expansion mediated by overexpressed auxin-binding protein 1	SCIENCE			English	Article							PLASMA-MEMBRANE; MAIZE; PROTOPLASTS; STIMULATION; PLANTS; SITE; WALL	To test the hypothesis that auxin-binding protein 1 (ABP1) is a receptor controlling auxin-mediated plant cell expansion, ABP1 complementary DNAs were expressed in a controllable fashion in tobacco plants and constitutively in maize cell lines. Induction of Arabidopsis ABP1 expression in tobacco leaf strips resulted in an increased capacity for auxin-mediated cell expansion, whereas induction of ABP1 in intact plants resulted in leaves with a normal morphology, but larger cells. Similarly, constitutive expression of maize ABP1 in maize cell lines conferred on them the capacity to respond to auxin by increasing cell size. These results support a role of ABP1 as an auxin receptor controlling plant growth.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; AgrEvo USA, Agr Res Ctr, Pikeville, NC 27863 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu	Shillito, Ray/AAK-3834-2021	Shillito, Ray/0000-0003-0485-3353	NIGMS NIH HHS [GM7369-06] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BARBIERBRYGOO H, 1991, PLANT J, V1, P83, DOI 10.1111/j.1365-313X.1991.00083.x; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BROWN JC, 1994, J BIOL CHEM, V269, P21136; CHU CC, 1975, SCI SINICA, V18, P659; DIEKMANN W, 1995, P NATL ACAD SCI USA, V92, P3425, DOI 10.1073/pnas.92.8.3425; EDGERTON MD, 1994, PHYTOCHEMISTRY, V35, P1111, DOI 10.1016/S0031-9422(00)94807-6; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; HARNDEN D, 1995, J PLANT GROWTH REGUL, V14, P109, DOI 10.1007/BF00203122; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; JONES AM, 1989, P NATL ACAD SCI USA, V86, P6153, DOI 10.1073/pnas.86.16.6153; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; KAPLAN DR, 1991, BIOSCIENCE, V41, P693, DOI 10.2307/1311764; Keller CP, 1997, PLANT PHYSIOL, V113, P603, DOI 10.1104/pp.113.2.603; KRAMER C, 1993, PLANTA, V190, P454, DOI 10.1007/BF00224783; KUTSCHERA U, 1987, P NATL ACAD SCI USA, V84, P2747, DOI 10.1073/pnas.84.9.2747; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; Napier RM, 1995, J EXP BOT, V46, P1787, DOI 10.1093/jxb/46.12.1787; RAY PM, 1977, PLANT PHYSIOL, V60, P585, DOI 10.1104/pp.60.4.585; RAY PM, 1992, CURRENT TOPICS PLANT, V11, P18; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SHILLITO RD, 1989, BIO-TECHNOL, V7, P581, DOI 10.1038/nbt0689-581; SHIMOMURA S, 1986, J BIOCHEM-TOKYO, V99, P1513, DOI 10.1093/oxfordjournals.jbchem.a135621; TILLMANN U, 1989, EMBO J, V8, P2463, DOI 10.1002/j.1460-2075.1989.tb08381.x	26	216	239	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1114	1117		10.1126/science.282.5391.1114	http://dx.doi.org/10.1126/science.282.5391.1114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804548				2022-12-24	WOS:000076887700048
J	Hagar, RE; Burgstahler, AD; Nathanson, MH; Ehrlich, BE				Hagar, RE; Burgstahler, AD; Nathanson, MH; Ehrlich, BE			Type III InsP(3) receptor channel stays open in the presence of increased calcium	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PANCREATIC ACINAR-CELLS; RAT HEPATOCYTES; IDENTIFICATION; TRISPHOSPHATE; OSCILLATIONS; LOCALIZATION; NUCLEOTIDES; CEREBELLUM; RELEASE	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is the mai(n) calcium(Ca2+) release channel in most tissues. Three isoforms have been identified(1-6), but only types I and II InsP(3)R have been characterized(7,8). Here we examine the functional properties of the type In InsP(3)R because this receptor is restricted to the trigger zone from which Ca2+ waves originate(9-11) and it has distinctive InsP(3)-binding properties(12,13). We find that type III InsP(3)R forms Ca2+ channels with single-channel currents that are similar to those of type I InsP(3)R; however, the open probability of type III InsP(3)R isoform increases monotonically with increased cytoplasmic Ca2+ concentration, whereas the type I isoform has a bell-shaped dependence on cytoplasmic Ca2+. The properties of type III InsP(3)R provide positive feedback as Ca2+ is released; the lack of negative feedback allows complete Ca2+ release from intracellular stores. Thus, activation of type III InsP(3)R in cells that express only this isoform results in a single transient, but global, increase in the concentration of cytosolic Ca2+. The bell-shaped Ca2+-dependence awe of type I InsP(3)R is ideal for supporting Ca2+ oscillations, whereas the properties of type III InsP(3)R are better suited to signal initiation.	Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06030 USA	Yale University; Yale University; Yale University; Yale University; University of Connecticut	Hagar, RE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar st, New Haven, CT 06520 USA.	rob@hermen.med.yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061747, R01DK045710] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK045710-06A2, R01 DK061747, R01 DK061747-01A1, R01 DK045710] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cao DR, 1997, J CELL SCI, V110, P497; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; DIXON CJ, 1990, BIOCHEM J, V269, P499, DOI 10.1042/bj2690499; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Morgan JM, 1996, PFLUG ARCH EUR J PHY, V431, P697, DOI 10.1007/s004240050054; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; PARKER I, 1996, J PHYSL, V49, P663; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; PETERSEN CCH, 1991, FEBS LETT, V293, P179, DOI 10.1016/0014-5793(91)81181-7; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591	30	223	225	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					81	84		10.1038/23954	http://dx.doi.org/10.1038/23954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817204	Green Accepted			2022-12-24	WOS:000076852700058
J	Black, AJ; McLeod, HL; Capell, HA; Powrie, RH; Matowe, LK; Pritchard, SC; Collie-Duguid, ESR; Reid, DM				Black, AJ; McLeod, HL; Capell, HA; Powrie, RH; Matowe, LK; Pritchard, SC; Collie-Duguid, ESR; Reid, DM			Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-TRANSPLANT RECIPIENT; INDUCED MYELOSUPPRESSION	Background: Substantial hematologic toxicity limits the use of azathioprine. Objective: To evaluate 1) polymorphic inactivation of azathioprine by thiopurine methyltransferase and 2) clinical toxicity. Design: Prospective cohort study. Setting: Two rheumatology units. Patients: 67 patients for whom azathioprine was prescribed as second-line therapy for rheumatic disease. Measurements: Polymerase chain reaction-based assays were used to detect mutations in thiopurine methyltransferase. The primary end point was discontinuation of azathioprine therapy because of toxicity. Results: Six of 67 patients (9%) were heterozygous for mutant thiopurine methyltransferase alleles. Five of the 6 patients discontinued therapy within 1 month of starting treatment because of low leukocyte counts. The sixth patient did not adhere to treatment. Patients with wild-type thiopurine methyltransferase alleles received therapy longer than did patients with mutant alleles (median duration of therapy, 39 weeks [range, 6 to 180 weeks] and 2 weeks [range, 2 to 4 weeks], respectively; P = 0.018). Conclusion: Analysis of thiopurine methyltransferase genotype is a quick way to identify patients at risk for acute toxicity from azathioprine.	Univ Aberdeen, Inst Med Sci, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Aberdeen Royal Hosp Trust, Aberdeen, Scotland; Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland	University of Aberdeen; University of Glasgow	McLeod, HL (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland.	h.l.mcleod@abdn.ac.uk	McLeod, Howard/ABD-8364-2021; Collie-Duguid, Elaina S R/A-4432-2017	McLeod, Howard/0000-0002-9004-9232; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLARY S, 1995, ANN INTERN MED, V123, P32, DOI 10.7326/0003-4819-123-1-199507010-00004; Bergan S, 1997, THER DRUG MONIT, V19, P318, DOI 10.1097/00007691-199706000-00013; COLLIEDUGUID ES, IN PRESS PHARMACOGEN; GomezReino JJ, 1996, LANCET, V347, P343, DOI 10.1016/S0140-6736(96)90531-0; HOLLANDER AAMJ, 1995, LANCET, V345, P610, DOI 10.1016/S0140-6736(95)90520-0; KERSTENS PJSM, 1993, LANCET, V342, P1245, DOI 10.1016/0140-6736(93)92231-H; MCLEOD HL, 1995, BLOOD, V85, P1897, DOI 10.1182/blood.V85.7.1897.bloodjournal8571897; MCLEOD HL, 1993, LANCET, V341, P1151, DOI 10.1016/0140-6736(93)93168-Z; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; Palace J, 1997, LANCET, V350, P261, DOI 10.1016/S0140-6736(97)24030-4; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; SCHUTZ E, 1993, LANCET, V341, P436, DOI 10.1016/0140-6736(93)93028-Y; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003	14	290	304	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					716	718		10.7326/0003-4819-129-9-199811010-00007	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841604				2022-12-24	WOS:000076785200006
J	Bindman, AB; Osmond, D; Hecht, FM; Lehman, JS; Vranizan, K; Keane, D; Reingold, A				Bindman, AB; Osmond, D; Hecht, FM; Lehman, JS; Vranizan, K; Keane, D; Reingold, A		MESH Study Grp	Multistate evaluation of anonymous HIV testing and access to medical care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTH-CAROLINA	Context.-Infection with the human immunodeficiency virus (HIV) is the only infectious disease for which anonymous testing is publicly funded, an exception that has been controversial. Objective.-To assess whether anonymous HIV testing was associated with earlier HIV testing and HIV-related medical care than confidential HIV testing. Design.-Retrospective cohort. Setting.-Arizona, Colorado, Missouri, New Mexico, North Carolina, Oregon, and Texas. Participants.-Probability sample of 835 new acquired immunodeficiency syndrome (AIDS) cases reported to the state health department's HIV/AIDS Reporting System from May 1995 through December 1996. All had responded to the AIDS Patient Survey; 643 had been tested confidentially for HIV, and 192 had been tested anonymously. Main Outcome Measures.-First CD4(+) cell count; number of days from HIV-positive test result to first HIV-related medical care, from first HIV-related medical care to AIDS, and from first HIV-positive test result to AIDS. Results.-Persons tested anonymously sought testing and medical care earlier in the course of HIV disease than did persons tested confidentially. Mean first CD4(+) cell count was 0.427x10(9)/L in persons tested anonymously vs 0.267x10(9)/L in persons tested confidentially. Persons tested anonymously experienced an average of 918 days in HIV-related medical care before an AIDS diagnosis vs 531 days for persons tested confidentially. The mean time from learning they were HIV positive to the diagnosis of AIDS was 1246 days for persons tested anonymously vs 718 days for persons tested confidentially. After adjustment for the subject's age, sex, race/ethnicity, education, income, insurance status, HIV exposure group, whether the respondent had a regular source of care or symptoms at the time of the HIV test, and state residence, anonymous testing remained significantly associated with earlier entry into medical care (P<.001). Conclusion.-Anonymous testing contributes to early HIV testing and medical care.	San Francisco Gen Hosp, Primary Care Res Ctr, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Div Aids, San Francisco, CA 94110 USA; Univ San Francisco, Dept Med, San Francisco, CA 94117 USA; Univ San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94117 USA; Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA USA; Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of San Francisco; University of San Francisco; Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	Bindman, AB (corresponding author), San Francisco Gen Hosp, Primary Care Res Ctr, Bldg 90,Ward 95,1001 Potrero Ave, San Francisco, CA 94110 USA.			Hecht, Frederick/0000-0002-5782-1171	BHP HRSA HHS [DHHS 282-92-0048] Funding Source: Medline	BHP HRSA HHS		Cunningham WE, 1997, J CLIN EPIDEMIOL, V50, P829, DOI 10.1016/S0895-4356(97)00061-9; FEHRS L, 1988, LANCET, V332, P379; HertzPicciotto I, 1996, AM J PUBLIC HEALTH, V86, P1446, DOI 10.2105/AJPH.86.10.1446; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; Hoxworth Tamara, 1994, AIDS Public Policy J, V9, P182; Kassler WJ, 1997, J ACQ IMMUN DEF SYND, V14, P281, DOI 10.1097/00042560-199703010-00013; KEGELES SM, 1990, AIDS, V4, P585, DOI 10.1097/00002030-199006000-00016; RICHARDSON L, 1997, NY TIMES        0821; Rosenbaum S, 1997, HEALTH AFFAIR, V16, P90, DOI 10.1377/hlthaff.16.1.90; Steinbrook LD, 1997, NEW ENGL J MED, V337, P779, DOI 10.1056/NEJM199709113371109; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011	11	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1416	1420		10.1001/jama.280.16.1416	http://dx.doi.org/10.1001/jama.280.16.1416			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130YA	9801001	Bronze			2022-12-24	WOS:000076546900036
J	Clark, AG; Begun, DJ; Prout, T				Clark, AG; Begun, DJ; Prout, T			Female x male interactions in Drosophila sperm competition	SCIENCE			English	Article							ACCESSORY-GLAND PRODUCTS; MULTIPLE INSEMINATION; POPULATION-GENETICS; MELANOGASTER; DISPLACEMENT; PROTEIN; PSEUDOOBSCURA; POLYMORPHISM; ASSOCIATION; DIVERGENCE	In several organisms, the success of a male's sperm in multiply inseminated females depends on the male's genotype. In Drosophila, the female also plays a role in determining which sperm are successful. Pairwise tests among six isogenic lines of Drosophila melanogaster were performed to determine whether there is a genotype-specific interaction in the success of sperm. The success of a particular male's sperm was found to depend on the genotype of the female with which he mates, providing evidence for an interaction with profound evolutionary consequences.	Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California Davis	Clark, AG (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.	c92@psu.edu		Clark, Andrew/0000-0001-7159-8511				Aguade M, 1998, GENETICS, V150, P1079; AGUADE M, 1992, GENETICS, V132, P755; Bertram MJ, 1996, INSECT BIOCHEM MOLEC, V26, P971, DOI 10.1016/S0965-1748(96)00064-1; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Chen PS, 1996, EXPERIENTIA, V52, P503, DOI 10.1007/BF01969718; CHEN PS, 1984, ANNU REV ENTOMOL, V29, P233, DOI 10.1146/annurev.en.29.010184.001313; Civetta A, 1995, J MOL EVOL, V41, P1085, DOI 10.1007/BF00173190; Civetta A, 1998, MOL BIOL EVOL, V15, P901, DOI 10.1093/oxfordjournals.molbev.a025994; Clark AG, 1998, GENETICS, V149, P1487; CLARK AG, 1995, GENETICS, V139, P189; COBBS G, 1977, AM NAT, V111, P641, DOI 10.1086/283197; Gilchrist AS, 1997, P ROY SOC B-BIOL SCI, V264, P1271, DOI 10.1098/rspb.1997.0175; GRIFFITHS RC, 1982, THEOR APPL GENET, V62, P89, DOI 10.1007/BF00276292; Gromko M.H., 1984, P371; Harshman LG, 1998, EVOLUTION, V52, P1334, DOI 10.1111/j.1558-5646.1998.tb02015.x; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HERNDON LA, 1995, P NATL ACAD SCI USA, V92, P10114, DOI 10.1073/pnas.92.22.10114; Hughes KA, 1997, GENETICS, V145, P139; LEVINE L, 1980, AM NAT, V116, P493, DOI 10.1086/283644; Noreen E. W., 1989, COMPUTER INTENSIVE M; Pitnick S, 1997, EVOLUTION, V51, P833, DOI [10.2307/2411158, 10.1111/j.1558-5646.1997.tb03665.x]; Price CSC, 1997, NATURE, V388, P663, DOI 10.1038/41753; Prout T, 1996, GENETICS, V144, P401; PROUT T, 1977, GENETICS, V85, P95; Rice WR, 1998, P NATL ACAD SCI USA, V95, P6217, DOI 10.1073/pnas.95.11.6217; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Wolfner MF, 1997, INSECT BIOCHEM MOLEC, V27, P179, DOI 10.1016/S0965-1748(96)00084-7	28	278	280	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					217	220		10.1126/science.283.5399.217	http://dx.doi.org/10.1126/science.283.5399.217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880253				2022-12-24	WOS:000077976700038
J	Merkel, R; Nassoy, P; Leung, A; Ritchie, K; Evans, E				Merkel, R; Nassoy, P; Leung, A; Ritchie, K; Evans, E			Energy landscapes of receptor-ligand bonds explored with dynamic force spectroscopy	NATURE			English	Article							AVIDIN-BIOTIN COMPLEX; MOLECULAR ADHESION; STREPTAVIDIN; BINDING; ORIGINS	Atomic force microscopy (AFM)(1,2) has been used to measure the strength of bonds between biological receptor molecules and their ligands(3-6). But for weak noncovalent bonds, a dynamic spectrum of bond strengths is predicted as the loading rate is altered, with the measured strength being governed by the prominent barriers traversed in the energy landscape along the force-driven bond-dissociation pathway(7). In other words, the pioneering early AFM measurements represent only a single point in a continuous spectrum of bond strengths, because theory predicts that these will depend on the rate at which the load is applied. Here we report the strength spectra for the bonds between streptavidin (or avidin) and biotin(8)-the prototype of receptor-ligand interactions used in earlier AFM studies(3-5), and which have been modelled by molecular dynamics(9,10). We have probed bond formation over six orders of magnitude in loading rate, and find that the bond survival time diminished from about 1 min to 0.001 s with increasing loading rate over this range. The bond strength, meanwhile, increased from about 5 pN to 170 pN. Thus, although they are among the strongest noncovalent linkages in biology (affinity of 10(13) to 10(15) M-1)(8,11), these bonds in fact appear strong or weak depending on how fast they are loaded. We are also able to relate the activation barriers derived from our strength spectra to the shape of the energy landscape derived from simulations of the biotin-avidin complex.	Univ British Columbia, Dept Phys, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Pathol, Vancouver, BC V6T 1Z1, Canada; Tech Univ Munich, Dept Phys, D-85748 Garching, Germany; Inst Curie, F-75231 Paris, France; Boston Univ, Boston, MA 02215 USA	University of British Columbia; University of British Columbia; Technical University of Munich; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Boston University	Evans, E (corresponding author), Univ British Columbia, Dept Phys, 6224 Agr Rd, Vancouver, BC V6T 1Z1, Canada.	evans@physics.ubc.ca	Merkel, Rudolf/G-3647-2013; Nassoy, Pierre/AAC-2606-2019	Merkel, Rudolf/0000-0003-3178-3282; 				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Brunk DK, 1996, BIOPHYS J, V71, P2902, DOI 10.1016/S0006-3495(96)79487-0; CHILKOTI A, 1995, J AM CHEM SOC, V117, P10622, DOI 10.1021/ja00148a003; Chu V, 1998, PROTEIN SCI, V7, P848; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; EVANS E, 1995, BIOPHYS J, V68, P2580, DOI 10.1016/S0006-3495(95)80441-8; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; Izrailev S, 1997, BIOPHYS J, V72, P1568, DOI 10.1016/S0006-3495(97)78804-0; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LEE UG, 1994, LANGMUIR, V8, P354; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873	23	1408	1436	8	379	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					50	53		10.1038/16219	http://dx.doi.org/10.1038/16219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892352				2022-12-24	WOS:000077959400043
J	Hanberger, H; Garcia-Rodriguez, JA; Gobernado, M; Goossens, H; Nilsson, LE; Struelens, MJ				Hanberger, H; Garcia-Rodriguez, JA; Gobernado, M; Goossens, H; Nilsson, LE; Struelens, MJ		French Portuguese ICU Study Grps	Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECTRUM BETA-LACTAMASES; ANTIMICROBIAL RESISTANCE; BACTEREMIA; FEATURES; CEPHALOSPORINS; EPIDEMIOLOGY; KLEBSIELLA; EMERGENCE; HOSPITALS; INFECTION	Context Surveillance of antibiotic resistance is especially important in intensive care units (ICUs) because the infection rates are much higher there than in other hospital wards and most epidemics with multiresistant bacteria originate in ICUs, Objective To evaluate the incidence of decreased antibiotic susceptibility among aerobic gram-negative bacilli isolated from patients in ICUs. Design Consecutive specimens collected on clinical indications from ICU patients were cultured and tested. Minimum inhibitory concentrations for amikacin, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, piperacillin, and piperacillin-tazobactam were determined using E test. Setting Eighteen hospitals in Belgium, 40 in France, 20 in Portugal, 30 in Spain, and 10 in Sweden. Subjects A total of 9166 gram-negative strains were initially isolated from 7308 patients between June 1994 and June 1995. Main Outcome Measures The incidence of decreased susceptibility, defined as the sum of resistant and intermediate categories with use of the minimum inhibitory concentration break points recommended by the National Committee for Clinical Laboratory Standards. Results The most frequently isolated organisms were Enterobacteriaceae (59%) followed by Pseudomonas aeruginosa (24%). The main sources were respiratory tract (42%), urine (26%), blood (14%), abdomen (11%), and skin and soft tissue (7%), Decreased antibiotic susceptibility across all species and drugs was highest in Portuguese ICUs followed by French, Spanish, Belgian, and Swedish ICUs. The highest incidence of resistance was seen in all countries among P aeruginosa (up to 37% resistant to ciprofloxacin in Portuguese ICUs and 46% resistant to gentamicin in French ICUs), Enterobacter species, Acinetobacter species, and Stenotrophomonas maltophilia, and in Portugal and France among Klebsiella species. Conclusion The high incidence of reduced antibiotic susceptibility among gramnegative bacteria in these ICUs suggests that more effective strategies are needed to control the selection and spread of resistant organisms.	Linkoping Univ Hosp, Dept Infect Dis, S-58185 Linkoping, Sweden; Linkoping Univ Hosp, Dept Clin Microbiol, S-58185 Linkoping, Sweden; Univ Hosp, Dept Microbiol, Salamanca, Spain; Hosp La Fe, Dept Microbiol, E-46009 Valencia, Spain; Univ Hosp, Dept Microbiol, Antwerp, Belgium; Univ Brussels, Erasme Hosp, Dept Microbiol, Brussels, Belgium	Linkoping University; Linkoping University; Hospital Universitari i Politecnic La Fe; Universite Libre de Bruxelles	Hanberger, H (corresponding author), Linkoping Univ Hosp, Dept Infect Dis, S-58185 Linkoping, Sweden.	hakan.hanberger@inf.liu.se		Struelens, Marc/0000-0001-5150-4944				[Anonymous], 1997, M7A4 NCCLS; Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211; BROWN DFJ, 1991, J ANTIMICROB CHEMOTH, V27, P185, DOI 10.1093/jac/27.2.185; BUIRMA RJA, 1991, SCAND J INFECT DIS, P35; BURWEN DR, 1994, J INFECT DIS, V170, P1622, DOI 10.1093/infdis/170.6.1622; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; Cisneros JM, 1996, CLIN INFECT DIS, V22, P1026, DOI 10.1093/clinids/22.6.1026; DavinRegli A, 1996, J CLIN MICROBIOL, V34, P1474, DOI 10.1128/JCM.34.6.1474-1480.1996; EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8; Glupczynski Y, 1998, ACTA CLIN BELG, V53, P28; Goetz A, 1997, CURR OPIN INFECT DIS, V10, P319, DOI 10.1097/00001432-199708000-00013; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; Hanberger Hkan, 1997, Clin Microbiol Infect, V3, P208, DOI 10.1111/j.1469-0691.1997.tb00599.x; Itokazu GS, 1996, CLIN INFECT DIS, V23, P779, DOI 10.1093/clinids/23.4.779; JACOBSON KL, 1995, CLIN INFECT DIS, V21, P1107, DOI 10.1093/clinids/21.5.1107; Jarlier V, 1996, INTENS CARE MED, V22, P1057, DOI 10.1007/s001340050213; LIVERMORE DM, 1995, CLIN MICROBIOL REV, V8, P557, DOI 10.1128/CMR.8.4.557; Livermore DM, 1996, J ANTIMICROB CHEMOTH, V38, P409, DOI 10.1093/jac/38.3.409; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; Riley TV, 1996, PATHOLOGY, V28, P359, DOI 10.1080/00313029600169354; SHAH PM, 1991, SCAND J INFECT DIS, P22; TILLEY PAG, 1994, CLIN INFECT DIS, V18, P896, DOI 10.1093/clinids/18.6.896; VERBIST L, 1991, SCAND J INFECT DIS, P45; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	25	231	247	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					67	71		10.1001/jama.281.1.67	http://dx.doi.org/10.1001/jama.281.1.67			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892453	Bronze			2022-12-24	WOS:000077829300037
J	Paxton, LA; Kiwanuka, N; Nalugoda, F; Gray, R; Wawer, MJ				Paxton, LA; Kiwanuka, N; Nalugoda, F; Gray, R; Wawer, MJ		Rakai Project Study Grp	Community based study of treatment seeking among subjects with symptoms of sexually transmitted disease in rural Uganda	BRITISH MEDICAL JOURNAL			English	Article									Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY 10032 USA; Uganda Virus Res Inst, Rakai Project, Entebbe, Uganda; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	Columbia University; Uganda Virus Research Institute; Johns Hopkins University	Paxton, LA (corresponding author), Ctr Dis Control & Prevent, Mailstop E45,1600 Clifton Rd, Atlanta, GA 30333 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI34826] Funding Source: Medline; NICHD NIH HHS [5P30HD06826] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Hayes R, 1997, GENITOURIN MED, V73, P432; *MIN HLTH, 1996, REP BAS SURV SEX TRA; Wawer MJ, 1998, AIDS, V12, P1211, DOI 10.1097/00002030-199810000-00014; *WHO, 1997, WHOGPASTD951	4	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1630	1631		10.1136/bmj.317.7173.1630	http://dx.doi.org/10.1136/bmj.317.7173.1630			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848902	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000077602100026
J	Aronin, SI; Peduzzi, P; Quagliarello, VJ				Aronin, SI; Peduzzi, P; Quagliarello, VJ			Community-acquired bacterial meningitis: Risk stratification for adverse clinical outcome and effect of antibiotic timing	ANNALS OF INTERNAL MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS MENINGITIS; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; RAT; PREDICTION; PROGNOSIS; MANAGEMENT; MORBIDITY; EMERGENCY; CHILDREN	Background: Community-acquired bacterial meningitis causes substantial morbidity and mortality in adults. Objective: To create and test a prognostic model for persons with community-acquired bacterial meningitis and to determine whether antibiotic timing influences clinical outcome. Design: Retrospective cohort study; patients were divided into derivation and validation samples. Setting: Four hospitals in Connecticut. Patients: 269 persons who, between 1970 and 1995, had community-acquired bacterial meningitis microbiologically proven by a lumbar puncture done within 24 hours of presentation in the emergency department. Measurements: Baseline clinical and laboratory features and times of arrival in the emergency department, performance of lumbar puncture, and administration of antibiotics. The target end point was the development of an adverse clinical outcome (death or neurologic deficit at discharge). Results: For the total group, the hospital mortality rate was 27%. Fifty-six of 269 patients (21%) developed a neurologic deficit, and in 9% the neurologic deficit persisted at discharge. Three baseline clinical features (hypotension, altered mental status, and seizures) were independently associated with adverse clinical outcome and were used to create a prognostic model from the derivation sample. The prediction accuracy of the model was determined by using the concordance index (c-index). For both the derivation sample (c-index, 0.73 [95% CI, 0.65 to 0.81]) and the validation sample (c-index, 0.81 [CI, 0.71 to 0.92]), the model predicted adverse clinical outcome significantly better than chance. For the total group, the model stratified patients into three prognostic stages: low risk for adverse clinical outcome (9%; stage I), intermediate risk (33%; stage II), and high risk (56%; stage III) (P = 0.001). Adverse clinical outcome was more common for patients in whom the prognostic stage advanced from low risk (P = 0.008) or intermediate risk (P = 0.003) at arrival in the emergency department to high risk before administration of antibiotics. Conclusions: In persons with community-acquired bacterial meningitis, three baseline clinical features of disease severity predicted adverse clinical outcome and stratified patients into three stages of prognostic severity. Delay in therapy after arrival in the emergency department was associated with adverse clinical outcome when the patient's condition advanced to the highest stage of prognostic severity before the initial antibiotic dose was given.	Yale Univ, Sch Med, New Haven, CT 06510 USA; Waterbury Hosp & Hlth Ctr, Waterbury, CT 06721 USA; Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program, West Haven, CT 06516 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Quagliarello, VJ (corresponding author), Yale Univ, Sch Med, 800 LCI, New Haven, CT 06510 USA.							BAIRD DR, 1976, LANCET, V2, P1344; BEHRMAN RE, 1989, ARCH INTERN MED, V149, P1596; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; BRYAN CS, 1986, ANN EMERG MED, V15, P544, DOI 10.1016/S0196-0644(86)80990-8; CARPENTER R R, 1962, Am J Med, V33, P262, DOI 10.1016/0002-9343(62)90024-4; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; DAVEY PG, 1982, J HYG-CAMBRIDGE, V88, P383, DOI 10.1017/S002217240007025X; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; FEINSTEIN AR, 1996, MULTIVRIABLE ANAL IN; FEINSTEIN AR, 1989, PUBLICATION PHS, P189; FINE MJ, 1990, AM J MED, V88, pN1; FINLAND M, 1977, J INFECT DIS, V136, P400, DOI 10.1093/infdis/136.3.400; FONG IW, 1984, Q J MED, V53, P289; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HERSON VC, 1977, PEDIATRICS, V59, P35; HODGES GR, 1975, AM J MED SCI, V270, P427, DOI 10.1097/00000441-197511000-00003; ISPAHANI P, 1983, J HYG-CAMBRIDGE, V91, P189, DOI 10.1017/S0022172400060198; JENSEN AG, 1993, ARCH INTERN MED, V153, P1902, DOI 10.1001/archinte.153.16.1902; KALLIO MJT, 1994, JAMA-J AM MED ASSOC, V272, P787, DOI 10.1001/jama.272.10.787; KILPI T, 1993, PEDIATR INFECT DIS J, V12, P184, DOI 10.1097/00006454-199303000-00002; LEBEL MH, 1989, PEDIATRICS, V83, P161; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; Magnussen C R, 1980, N Y State J Med, V80, P901; MEADOW WL, 1993, AM J DIS CHILD, V147, P40, DOI 10.1001/archpedi.1993.02160250042014; OLSSON RA, 1961, ANN INTERN MED, V55, P545, DOI 10.7326/0003-4819-55-4-545; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; QUAGLIARELLO VJ, 1991, J EXP MED, V174, P657, DOI 10.1084/jem.174.3.657; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; RASMUSSEN HH, 1992, AGE AGEING, V21, P216, DOI 10.1093/ageing/21.3.216; ROMER FK, 1977, DAN MED BULL, V24, P35; SCHELD WM, 1994, HARRISONS PRINCIPLES, P2296; SCHLESINGER LS, 1987, MEDICINE, V66, P148, DOI 10.1097/00005792-198703000-00006; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TALAN DA, 1993, ANN EMERG MED, V22, P1733, DOI 10.1016/S0196-0644(05)81314-9; TUNKEL AR, 1995, MANDELL DOUGLAS BENN, P831; TUREEN JH, 1990, J CLIN INVEST, V85, P577, DOI 10.1172/JCI114475; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WIEBE RA, 1972, SOUTH MED J, V65, P257, DOI 10.1097/00007611-197203000-00001	48	308	318	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					862	869		10.7326/0003-4819-129-11_Part_1-199812010-00004	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867727				2022-12-24	WOS:000077239200003
J	Berger, A				Berger, A			Science commentary: Protection against malaria	BRITISH MEDICAL JOURNAL			English	Editorial Material							MEFLOQUINE											Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W	2	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1508	1508		10.1136/bmj.317.7171.1508	http://dx.doi.org/10.1136/bmj.317.7171.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831585	Green Published			2022-12-24	WOS:000077338300037
J	Sarkar, PS; Chang, HC; Boudi, FB; Reddy, S				Sarkar, PS; Chang, HC; Boudi, FB; Reddy, S			CTG repeats show bimodal amplification in E-coli	CELL			English	Article							ESCHERICHIA-COLI; DISEASE GENES; TRINUCLEOTIDE REPEAT; TRIPLET REPEATS; DNA PALINDROMES; LAGGING-STRAND; IN-VITRO; INSTABILITY; REPLICATION; RECOMBINATION	Trinucleotide repeats in human genetic disorders showing anticipation follow two inheritance patterns as a function of length. Inheritance of 35-50 repeats show incremental changes, white tracts greater than 80 repeats show large saltatory expansions. We describe a bacterial system that recapitulates this striking bimodal pattern of CTG amplification. Incremental expansions predominate in CTG tracts greater than or equal to Okazaki fragment size, while saltatory expansions increase in repeat tracts greater than or equal to Okazaki fragment size. CTG amplification requires loss of SbcC, a protein that modulates cleavage of single-stranded DNA and degradation of duplex DNA from double-strand breaks. These results suggest that noncanonical single strand-containing secondary structures in Okazaki fragments and/or double-strand breaks in repeat tracts are intermediates in CTG amplification.	Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA	University of Southern California	Reddy, S (corresponding author), Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.	sitaredd@hsc.usc.edu						Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; BOUDI FB, 1989, HUM GENET, V84, P293; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; DAVIES J, 1992, J MED GENET, V29, P766, DOI 10.1136/jmg.29.11.766; DePamphilis ML, 1995, METHOD ENZYMOL, V262, P628; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY GA, 1995, CELL, V81, P533; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Gourdon G, 1997, NAT GENET, V15, P190, DOI 10.1038/ng0297-190; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HUTCHINSON F, 1996, ESCHERICHIA COLI SAL, V2, P2225; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; NAOM IS, 1989, NUCLEIC ACIDS RES, V17, P8033, DOI 10.1093/nar/17.20.8033; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Pohjanpelto P, 1996, EMBO J, V15, P1193, DOI 10.1002/j.1460-2075.1996.tb00458.x; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SETLOW P, 1972, J BIOL CHEM, V247, P224; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Trinh T, 1994, FOCUS, V16, P78; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WU CA, 1992, J BIOL CHEM, V267, P4030	36	56	57	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					531	540		10.1016/S0092-8674(00)81620-7	http://dx.doi.org/10.1016/S0092-8674(00)81620-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827805	Bronze			2022-12-24	WOS:000077049400011
J	Wang, HB; Bedford, FK; Brandon, NJ; Moss, SJ; Olsen, RW				Wang, HB; Bedford, FK; Brandon, NJ; Moss, SJ; Olsen, RW			GABA(A)-receptor-associated protein links GABA(A) receptors and the cytoskeleton	NATURE			English	Article							GLYCINE RECEPTOR; A RECEPTOR; TUBULIN; PHOSPHORYLATION; BINDING; KINASE; SITES; GEPHYRIN; SUBUNIT; BRAIN	Type-A receptors for the neurotransmitter GABA (gamma-aminobutyric acid) are ligand-gated chloride channels that mediate inhibitory neurotransmission. Each subunit of the pentameric receptor protein has ligand-binding sites in the amino-terminal extracellular domain and four membrane-spanning regions, one of which forms a wall of the ion channel(1). Each subunit also has a large intracellular loop that may be a target for protein kinases and be required for subcellular targeting and membrane clustering of the receptor, perhaps by anchoring the receptor to the cytoskeleton(2-4) Neurotransmitter receptors need to be positioned in high density in the cell membrane at sites postsynaptic to nerve terminals releasing that neurotransmitter, Other members of the superfamily of ligand-gated ion-channel receptors associate in postsynaptic-membrane clusters by binding to the proteins rapsyn or gephyrin(5-7). Here we identify a new cellular protein, GABA(A)-receptor-associated protein (GABARAP), which can interact with the gamma 2 subunit of GABA(A) receptors, GABARAP binds to GABA(A) receptors both in vitro and in vivo, and co-localizes with the punctate staining of GABA(A) receptors on cultured cortical neurons, Sequence analysis shows similarity between GABARAP and light chain-3 of microtubule-associated proteins 1A and 1B. Moreover, the N terminus of GABARAP is highly positively charged and features a putative tubulin-binding motif. The interactions among GABA(A) receptors, GABARAP and tubulin suggest a mechanism for the targeting and clustering of GABA(A) receptors.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; UCL, MRC, Lab Mol & Cell Biol, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of London; University College London; University of London; University College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Olsen, RW (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.	rolsen@mednet.ucla.edu		Brandon, Nicholas/0000-0002-3917-0096				CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GAO B, 1994, EUR J NEUROSCI, V6, P837, DOI 10.1111/j.1460-9568.1994.tb00994.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; HILL JA, 1992, MOL NEUROBIOL, V6, P1, DOI 10.1007/BF02935564; ITEM C, 1994, J NEUROCHEM, V63, P1119; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; MANN SS, 1994, J BIOL CHEM, V269, P11492; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Nishimura RN, 1996, MOL BRAIN RES, V36, P227, DOI 10.1016/0169-328X(95)00261-P; NUSSER Z, 1995, J NEUROSCI, V15, P2948; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SANCHEZ C, 1994, ARCH BIOCHEM BIOPHYS, V310, P428, DOI 10.1006/abbi.1994.1188; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	21	471	488	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					69	72		10.1038/16264	http://dx.doi.org/10.1038/16264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892355				2022-12-24	WOS:000077959400049
J	Lot, F; Seguier, JC; Fegueux, S; Astagneau, P; Simon, P; Aggoune, M; van Amerongen, P; Ruch, M; Cheron, M; Brucker, G; Desenclos, JC; Drucker, J				Lot, F; Seguier, JC; Fegueux, S; Astagneau, P; Simon, P; Aggoune, M; van Amerongen, P; Ruch, M; Cheron, M; Brucker, G; Desenclos, JC; Drucker, J			Probable transmission of HIV from an orthopedic surgeon to a patient in France	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; SURGICAL-PROCEDURES; INFECTED SURGEON; HEPATITIS-B; TYPE-1	Background: Transmission of HIV from infected health care workers to patients has been documented in only one cluster involving 6 patients of a dentist in Florida. in October 1995, the French Ministry of Health offered HIV testing to patients who had been operated on by an orthopedic surgeon in whom AIDS was recently diagnosed. Objective: To determine whether the surgeon transmitted HIV to patients during operations. Design: Epidemiologic investigation. Setting: The practice of an orthopedic surgeon in a French public hospital. Participants: 1 surgeon and 983 of his former patients. Measurements: 3004 patients who had undergone invasive procedures were contacted by mail for counseling and HIV testing. One HIV-positive patient was interviewed, and DNA sequence analysis was performed to compare the genetic relation of the patient's and the surgeon's viruses. Infection-control precautions and the surgeon's practices were assessed. Results: Of 983 patients in whom serologic status was ascertained, 982 were HIV negative and 1 was HIV positive. The HIV-positive patient, a woman born in 1925, tested negative for HIV before placement of a total hip prosthesis with bone graft (a prolonged operation) performed by the surgeon in 1992. She had no identified risk for HIV exposure. Molecular analysis indicated that the viral sequences obtained from the surgeon and the HIV-infected woman were closely related. Infection-control precautions were in accordance with recommendations, but blood contact between the surgeon and his patients occurred commonly during surgical procedures. Conclusions: An HIV-infected surgeon may have transmitted HIV to one of his patients during surgery.	Reseau Natl Sante Publ, F-94415 St Maurice, France; Hop St Germaine en Laye, F-78105 St Germain En Laye, France; Inst Biomed Cordeliers, Ctr Interreg Coordinat Lutte Contre Infect Nosoco, F-75006 Paris, France; Direct Dept Affaires Sanit & Sociales Yvelines, F-78007 Versailles, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Lot, F (corresponding author), Reseau Natl Sante Publ, 14 Rue Val Dosne, F-94415 St Maurice, France.	Lot@b3e.jussieu.fr	Astagneau, Pascal/AAF-3473-2020					BELL DM, 1995, SURG CLIN N AM, V75, P1189; BELL DM, 1992, INFECT AGENT DIS, V1, P263; Blanchard A, 1998, J VIROL, V72, P4537, DOI 10.1128/JVI.72.5.4537-4540.1998; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Crawshaw S C, 1994, Commun Dis Rep CDR Rev, V4, pR125; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Folin AC, 1997, INFECT CONT HOSP EP, V18, P244; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; Heptonstall J, 1997, NEW ENGL J MED, V336, P178, DOI 10.1056/NEJM199701163360304; Hochuli V, 1995, Commun Dis Rep CDR Rev, V5, pR7; JONSTON BL, 1994, C PREV TRANSM BLOODB, pA52; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; Porter KR, 1997, J ACQ IMMUN DEF SYND, V14, P1, DOI 10.1097/00042560-199701010-00001; ROBERT LM, 1995, ANN INTERN MED, V122, P653, DOI 10.7326/0003-4819-122-9-199505010-00002; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; Simon F, 1996, AIDS RES HUM RETROV, V12, P1427, DOI 10.1089/aid.1996.12.1427; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807	19	66	68	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					1	6		10.7326/0003-4819-130-1-199901050-00002	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890844				2022-12-24	WOS:000077744500001
J	Garman, SC; Kinet, JP; Jardetzky, TS				Garman, SC; Kinet, JP; Jardetzky, TS			Crystal structure of the human high-affinity IgE receptor	CELL			English	Article							FC-EPSILON-RI; IMMUNOGLOBULIN-E-RECEPTOR; STRUCTURE-BASED DESIGN; BINDING-SITE; ALPHA-CHAIN; GAMMA-RII; BETA-SUBUNIT; DOMAIN; ANAPHYLAXIS; ATOPY	Allergic responses result from the activation of mast cells by the human high-affinity IgE receptor. IgE-mediated allergic reactions may develop to a variety of environmental compounds, but the initiation of a response requires the binding of IgE to its high-affinity receptor. We have solved the X-ray crystal structure of the antibody-binding domains of the human IgE receptor at 2.4 Angstrom resolution. The structure reveals a highly bent arrangement of immunoglobulin domains that form an extended convex surface of interaction with IgE. A prominent loop that confers specificity for IgE molecules extends from the receptor surface near an unusual arrangement of four exposed tryptophans. The crystal structure of the IgE receptor provides a foundation for the development of new therapeutic approaches to allergy treatment.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Harvard Univ, Sch Med, Lab Mol Allergy & Immunol, Boston, MA 02215 USA	Northwestern University; Harvard University; Harvard Medical School	Jardetzky, TS (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	jardetz@tochtli.biochem.nwu.edu			NIAID NIH HHS [AI-38972] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038972, R37AI038972] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASU M, 1993, J BIOL CHEM, V268, P13118; BLANK U, 1991, J BIOL CHEM, V266, P2639; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; HEMMING SA, 1995, J MOL BIOL, V246, P308, DOI 10.1006/jmbi.1994.0086; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; HULETT MD, 1995, J BIOL CHEM, V270, P21188, DOI 10.1074/jbc.270.36.21188; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1994, J BIOL CHEM, V269, P15287; JEFFERIS R, 1990, MOL IMMUNOL, V27, P1237, DOI 10.1016/0161-5890(90)90027-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; Kim H S, 1998, Curr Opin Pulm Med, V4, P46, DOI 10.1097/00063198-199801000-00009; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACROIX EL, 1993, MOL IMMUNOL, V30, P321, DOI 10.1016/0161-5890(93)90060-O; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; LUND J, 1991, J IMMUNOL, V147, P2657; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; Mao XQ, 1998, CLIN GENET, V53, P54, DOI 10.1034/j.1399-0004.1998.531530111.x; Maurer D, 1998, J IMMUNOL, V161, P2731; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; McDonnell JM, 1997, BIOCHEM SOC T, V25, P387, DOI 10.1042/bst0250387; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; METZGER H, 1994, CURR BIOL, V4, P644, DOI 10.1016/S0960-9822(00)00143-3; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRESTA L, 1994, J BIOL CHEM, V269, P26368; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SCARSELLI E, 1993, FEBS LETT, V329, P223, DOI 10.1016/0014-5793(93)80226-K; Sechi S, 1996, J BIOL CHEM, V271, P19256, DOI 10.1074/jbc.271.32.19256; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0	60	142	151	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					951	961		10.1016/S0092-8674(00)81719-5	http://dx.doi.org/10.1016/S0092-8674(00)81719-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875849	Bronze			2022-12-24	WOS:000077759100010
J	Carlezon, WA; Thome, J; Olson, VG; Lane-Ladd, SB; Brodkin, ES; Hiroi, N; Duman, RS; Neve, RL; Nestler, EJ				Carlezon, WA; Thome, J; Olson, VG; Lane-Ladd, SB; Brodkin, ES; Hiroi, N; Duman, RS; Neve, RL; Nestler, EJ			Regulation of cocaine reward by CREB	SCIENCE			English	Article							VENTRAL TEGMENTAL AREA; KAPPA-OPIOID RECEPTOR; NUCLEAR-PROTEIN CBP; MESSENGER-RNA; DOPAMINE; RAT; EXPRESSION; SENSITIZATION; AMPHETAMINE; MORPHINE	Cocaine regulates the transcription factor CREB (adenosine 3',5'-monophosphate response element binding protein) in rat nucleus accumbens, a brain region that is important for addiction. Overexpression of CREB in this region decreases the rewarding effects of cocaine and makes Low doses of the drug aversive. Conversely, overexpression of a dominant-negative mutant CREB increases the rewarding effects of cocaine. Altered transcription of dynorphin Likely contributes to these effects: Its expression is increased by overexpression of CREB and decreased by overexpression of mutant CREB. Moreover, blockade of kappa opioid receptors ton which dynorphin acts) antagonizes the negative effect of CREB on cocaine reward. These results identify an intracellular cascade-culminating in gene expression-through which exposure to cocaine modifies subsequent responsiveness to the drug.	Yale Univ, Sch Med, Ctr Genes & Behav, Div Mol Psychiat, New Haven, CT 06508 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Genet, Belmont, MA 02178 USA	Yale University; Harvard University; McLean Hospital	Nestler, EJ (corresponding author), Yale Univ, Sch Med, Ctr Genes & Behav, Div Mol Psychiat, 34 Pk St, New Haven, CT 06508 USA.		Hiroi, Noboru/E-2215-2013; Jansen, Heiko T./A-5770-2008	Hiroi, Noboru/0000-0002-6846-5969; Jansen, Heiko T./0000-0003-0178-396X; /0000-0002-4162-3947				BALSKUBIK R, 1993, J PHARMACOL EXP THER, V264, P489; Bartlett E, 1997, NEUROPSYCHOPHARMACOL, V16, P77, DOI 10.1016/S0893-133X(96)00164-9; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Carlezon WA, 1996, J NEUROSCI, V16, P3112; CARLEZON WA, 1995, PSYCHOPHARMACOLOGY, V122, P194, DOI 10.1007/BF02246095; CARR GD, 1989, NEUROPHARMACOLOGICAL; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; DAUNAIS JB, 1993, NEUROREPORT, V4, P453; DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V13, P165, DOI 10.1016/0169-328X(92)90058-J; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; Lim F, 1996, BIOTECHNIQUES, V20, P460; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; Mendelson JH, 1998, NEUROPSYCHOPHARMACOL, V18, P263; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0; RICHARDSON NR, 1991, LIFE SCI, V49, P833, DOI 10.1016/0024-3205(91)90248-A; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Self DW, 1998, J NEUROSCI, V18, P1848; Shippenberg TS, 1997, PHARMACOL BIOCHEM BE, V57, P449, DOI 10.1016/S0091-3057(96)00450-9; SHIPPENBERG TS, 1991, PSYCHOPHARMACOLOGY, V103, P209, DOI 10.1007/BF02244205; SPANAGEL R, 1993, NEUROSCI LETT, V153, P232, DOI 10.1016/0304-3940(93)90329-J; SPANGLER R, 1993, MOL BRAIN RES, V19, P323, DOI 10.1016/0169-328X(93)90133-A; STEINER H, 1995, J COMP NEUROL, V353, P200, DOI 10.1002/cne.903530204; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; Unterwald EM, 1996, EUR J PHARMACOL, V318, P31, DOI 10.1016/S0014-2999(96)00841-2; WISE RA, 1989, NEUROPHARMACOLOGICAL; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	38	570	589	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2272	2275		10.1126/science.282.5397.2272	http://dx.doi.org/10.1126/science.282.5397.2272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856954				2022-12-24	WOS:000077645800052
J	Wulfing, C; Davis, MM				Wulfing, C; Davis, MM			A receptor/cytoskeletal movement triggered by costimulation during T cell activation	SCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CO-STIMULATION; COMPLEXES; ANTIGEN; LFA-1; REQUIREMENTS; RESPONSES; CD28; MICE; CYTOSKELETON	During T cell activation, the engagement of costimulatory molecules is often crucial to the development of an effective immune response, but the mechanism by which this is achieved is not known. Here, it is shown that beads attached to the surface of a T cell translocate toward the interface shortly after the start of T cell activation. This movement appears to depend on myosin motor proteins and requires the engagement of the major costimulatory receptor pairs, B7-CD28 and ICAM-1-LFA-1. This suggests that the engagement of costimulatory receptors triggers an active accumulation of molecules at the interface of the T cell and the antigen-presenting cell, which then increases the overall amplitude and duration of T cell signaling.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Davis, MM (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Wuelfing, Christoph/0000-0002-6156-9861; Davis, Mark/0000-0001-6868-657X				Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Blair PJ, 1997, BIOCHEM SOC T, V25, P651, DOI 10.1042/bst0250651; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; BROWER RC, 1994, MOL IMMUNOL, V31, P1285, DOI 10.1016/0161-5890(94)90079-5; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; Croft M, 1997, CRIT REV IMMUNOL, V17, P89, DOI 10.1615/CritRevImmunol.v17.i1.40; Delon J, 1998, J EXP MED, V188, P1473, DOI 10.1084/jem.188.8.1473; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH JP, 1993, SYM SOC EXP BIOL, V47, P35; HOLIFIELD BF, 1990, J CELL BIOL, V111, P2499, DOI 10.1083/jcb.111.6.2499; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Maciver SK, 1996, BIOESSAYS, V18, P179, DOI 10.1002/bies.950180304; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; SAGERSTROM CG, 1993, P NATL ACAD SCI USA, V90, P8987, DOI 10.1073/pnas.90.19.8987; SCHLICHTER LC, 1992, J PHARMACOL EXP THER, V261, P438; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHEETS ED, 1995, CURR OPIN CELL BIOL, V7, P707, DOI 10.1016/0955-0674(95)80113-8; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Sperling AI, 1996, IMMUNOL REV, V153, P155, DOI 10.1111/j.1600-065X.1996.tb00924.x; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; TAKEI F, 1985, J IMMUNOL, V134, P1403; TING AE, 1990, J BIOL CHEM, V265, P5337; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; vanKooyk Y, 1997, BIOCHEM SOC T, V25, P515, DOI 10.1042/bst0250515; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; WULFING C, UNPUB; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YANO H, 1993, J BIOL CHEM, V268, P25846	47	532	547	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2266	2269		10.1126/science.282.5397.2266	http://dx.doi.org/10.1126/science.282.5397.2266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856952				2022-12-24	WOS:000077645800050
J	Dieterich, DT				Dieterich, DT			Testosterone replacement therapy for HIV-related wasting - Abstracts and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University	Dieterich, DT (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.							Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Grinspoon S, 1998, ANN INTERN MED, V129, P18, DOI 10.7326/0003-4819-129-1-199807010-00005; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; PORETSKY L, 1995, METABOLISM, V44, P946, DOI 10.1016/0026-0495(95)90250-3; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1959	1960		10.1001/jama.280.22.1959	http://dx.doi.org/10.1001/jama.280.22.1959			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851485				2022-12-24	WOS:000077364500044
J	Yao, S; Ghosh, I; Zutshi, R; Chmielewski, J				Yao, S; Ghosh, I; Zutshi, R; Chmielewski, J			Selective amplification by auto- and cross-catalysis in a replicating peptide system	NATURE			English	Article							SELF-REPLICATION; HEXADEOXYNUCLEOTIDE; SEQUENCE; LINKAGE	Self-replication has been demonstrated in synthetic chemical systems based on oligonucleotides(1-7), peptides(8-12) and complementary molecules without natural analogues(13-16). However, within a living cell virtually no molecule catalyses its own formation, and the search for chemical systems in which both auto- and cross-catalysis can occur has therefore attracted wide interest(17). One such system, consisting of two self-replicating peptides that catalyse each other's production, has been reported(10). Here we describe a four-component peptide system that is capable of auto- and cross-catalysis and allows for the selective amplification of one or more of the products by changing the reaction conditions. The ability of this system selectively to amplify one or more molecules in response to changes in environmental conditions such as pH or salt concentration supports the suggestions that self-replicating peptides may have played a role in the origin of life.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chmielewski, J (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.		Yao, Shao Q/B-8825-2008	Zutshi, Reena/0000-0002-2582-1484				ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; KRAMER FR, 1974, J MOL BIOL, V89, P719, DOI 10.1016/0022-2836(74)90047-3; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; Lee DH, 1997, NATURE, V390, P591, DOI 10.1038/37569; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; NOWICK JS, 1991, J AM CHEM SOC, V113, P8831, DOI 10.1021/ja00023a036; ORGEL LE, 1995, ACCOUNTS CHEM RES, V28, P109, DOI 10.1021/ar00051a004; Severin K, 1997, NATURE, V389, P706, DOI 10.1038/39556; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351; WINTNER EA, 1995, J ORG CHEM, V60, P7997, DOI 10.1021/jo00129a046; WINTNER EA, 1994, J AM CHEM SOC, V116, P8877, DOI 10.1021/ja00099a003; Yao S, 1998, ANGEW CHEM INT EDIT, V37, P478, DOI 10.1002/(SICI)1521-3773(19980302)37:4<478::AID-ANIE478>3.0.CO;2-V; Yao S, 1997, J AM CHEM SOC, V119, P10559, DOI 10.1021/ja9710619; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0	20	124	128	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					447	450		10.1038/24814	http://dx.doi.org/10.1038/24814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853750				2022-12-24	WOS:000077370100048
J	Zachariae, W; Schwab, M; Nasmyth, K; Seufert, W				Zachariae, W; Schwab, M; Nasmyth, K; Seufert, W			Control of cyclin ubiquitination by CDK-regulated binding of Hct1 to the anaphase promoting complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEOLYSIS; YEAST; PHOSPHORYLATION; REPLICATION; DEGRADATION; EXPRESSION; KINASES; ENTRY	Proteolysis of mitotic cyclins depends on a multisubunit ubiquitin-protein Ligase, the anaphase promoting complex (APC), Proteolysis commences during anaphase, persisting throughout G(1) until it is terminated by-cyclin-dependent kinases (CDKs) as cells enter S phase. Proteolysis of mitotic cyclins in yeast was shown to require association of the APC with the substrate-specific activator Hct1 (also called Cdh1). Phosphorylation of Hct1 by CDKs blocked the Hct1-APC interaction. The mutual inhibition between APC and CDKs explains how cells suppress mitotic CDK activity during G(1) and then establish a period with elevated kinase activity from S phase until anaphase.	Univ Stuttgart, Inst Ind Genet, D-70569 Stuttgart, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Stuttgart; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Seufert, W (corresponding author), Univ Stuttgart, Inst Ind Genet, Allmandring 31, D-70569 Stuttgart, Germany.		Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064; Nasmyth, Kim/0000-0001-7030-4403				Amon A, 1997, EMBO J, V16, P2693, DOI 10.1093/emboj/16.10.2693; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fitzpatrick PJ, 1998, MOL GEN GENET, V258, P437, DOI 10.1007/s004380050753; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Schwab M. M., UNPUB; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SCHWOB E, UNPUB; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, UNPUB; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Volff JN, 1996, MOL MICROBIOL, V21, P1037, DOI 10.1046/j.1365-2958.1996.761428.x; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZACHARIAE W, UNPUB	26	435	445	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1721	1724		10.1126/science.282.5394.1721	http://dx.doi.org/10.1126/science.282.5394.1721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831566				2022-12-24	WOS:000077246600051
J	Tamura, N; Lottspeich, F; Baumeister, W; Tamura, T				Tamura, N; Lottspeich, F; Baumeister, W; Tamura, T			The role of Tricorn protease and its aminopeptidase-interacting factors in cellular protein degradation	CELL			English	Article							TRIPEPTIDYL PEPTIDASE-II; ESCHERICHIA-COLI; THERMOPLASMA-ACIDOPHILUM; PROCESSIVE DEGRADATION; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; PROTEOLYSIS; MUTANTS; COMPLEX; 20S		Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Baumeister, W (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	tamura@biochem.mpg.de	Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; CAPRIOGLIO DR, 1993, J BIOL CHEM, V268, P14310; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HIRSCH HH, 1988, EUR J BIOCHEM, V173, P589, DOI 10.1111/j.1432-1033.1988.tb14040.x; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kratzer R, 1998, ELECTROPHORESIS, V19, P1910, DOI 10.1002/elps.1150191109; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Mason R W, 1996, Subcell Biochem, V27, P159; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; MILLER CG, 1975, ANNU REV MICROBIOL, V29, P485, DOI 10.1146/annurev.mi.29.100175.002413; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; Osmulski PA, 1998, CURR BIOL, V8, P1023, DOI 10.1016/S0960-9822(07)00423-X; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; Roberts D.V., 1977, ENZYME KINETICS; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Ruepp A, 1998, FEBS LETT, V425, P87, DOI 10.1016/S0014-5793(98)00205-1; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; Tamura T, 1996, FEBS LETT, V398, P101, DOI 10.1016/S0014-5793(96)01163-5; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; Wang JM, 1997, CELL, V91, P447, DOI 10.1016/S0092-8674(00)80431-6; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; Wolf S, 1998, J MOL BIOL, V277, P13, DOI 10.1006/jmbi.1997.1589; YEN C, 1980, J MOL BIOL, V143, P21, DOI 10.1016/0022-2836(80)90122-9; YEN C, 1980, J MOL BIOL, V143, P35, DOI 10.1016/0022-2836(80)90123-0	45	95	100	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					637	648		10.1016/S0092-8674(00)81634-7	http://dx.doi.org/10.1016/S0092-8674(00)81634-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845366	Bronze			2022-12-24	WOS:000077253700011
J	Butterworth, RF				Butterworth, RF			Excitatory neurons and schizophrenia	LANCET			English	Editorial Material							HIPPOCAMPUS		Univ Montreal, Dept Med, Neurosci Res Unit, St Lucia, Qld H2X 3J4, Australia		Butterworth, RF (corresponding author), Univ Montreal, Dept Med, Neurosci Res Unit, St Lucia, Qld H2X 3J4, Australia.							DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Porter RHP, 1997, BRAIN RES, V751, P217, DOI 10.1016/S0006-8993(96)01404-7; Zaidel DW, 1997, AM J PSYCHIAT, V154, P812	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1643	1643		10.1016/S0140-6736(05)61442-0	http://dx.doi.org/10.1016/S0140-6736(05)61442-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853431				2022-12-24	WOS:000077110300003
J	Gunnell, DJ; Smith, GD; Holly, JMP; Frankel, S				Gunnell, DJ; Smith, GD; Holly, JMP; Frankel, S			Leg length and risk of cancer in the Boyd Orr cohort	BRITISH MEDICAL JOURNAL			English	Article									Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bristol, Bristol Royal Infirm, Div Surg, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol	Gunnell, DJ (corresponding author), Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.		Gunnell, David/ABE-6653-2020; Davey Smith, George/A-7407-2013	Gunnell, David/0000-0002-0829-6470; Davey Smith, George/0000-0002-1407-8314				ALBANES D, 1988, CANCER RES, V48, P1658; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; Gunnell DJ, 1998, J EPIDEMIOL COMMUN H, V52, P142, DOI 10.1136/jech.52.3.142; Holly J, 1998, LANCET, V351, P1373, DOI 10.1016/S0140-6736(05)79438-1	5	73	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1350	1351		10.1136/bmj.317.7169.1350	http://dx.doi.org/10.1136/bmj.317.7169.1350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812931	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000077081600019
J	Hurwitz, B				Hurwitz, B			Commentary: Bevan's covenant continues intact	BRITISH MEDICAL JOURNAL			English	Editorial Material									Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England	Imperial College London	Hurwitz, B (corresponding author), Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.							*DEP HLTH, 1998, 1 CLASS SERV; *GEN PRACT COMM, 1998, PRIM CAR GROUPS; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; *NAT HLTH SERV EX, 1998, PRESCR INC SCHEM; *NAT HLTH SERV EX, 1998, DEV PRIM CAR GROUPS; Prayle D, 1998, J MED ETHICS, V24, P93, DOI 10.1136/jme.24.2.93; TOWSE A, 1997, GUIDELINES EVALUATIO	7	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1365	1365						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9882107				2022-12-24	WOS:000077081600025
J	Itzkowitz, SH				Itzkowitz, SH			Heads or tails in a positive faecal occult blood test	LANCET			English	Editorial Material							NEGATIVE COLONOSCOPY; UPPER ENDOSCOPY; STOOL		Mt Sinai Sch Med, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Itzkowitz, SH (corresponding author), Mt Sinai Sch Med, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA.							CHEN YK, 1993, AM J GASTROENTEROL, V88, P2026; HSIA PC, 1992, AM J GASTROENTEROL, V87, P1571; Rockey DC, 1998, NEW ENGL J MED, V339, P153, DOI 10.1056/NEJM199807163390303; Skoletsky JE, 1998, GASTROENTEROLOGY, V114, pA681, DOI 10.1016/S0016-5085(98)82793-5; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	7	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1490	1490		10.1016/S0140-6736(05)60324-8	http://dx.doi.org/10.1016/S0140-6736(05)60324-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820295				2022-12-24	WOS:000076862300005
J	Yin, MJ; Yamamoto, Y; Gaynor, RB				Yin, MJ; Yamamoto, Y; Gaynor, RB			The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta	NATURE			English	Article							SODIUM-SALICYLATE; ACTIVATION; ALPHA; PHOSPHORYLATION; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; INDUCTION; PATHWAY; TNF	NF-kappa B comprises a family of cellular transcription factors that are involved in the inducible expression of a variety of cellular genes that regulate the inflammatory response(1,2). NF-kappa B is sequestered in the cytoplasm by inhibitory proteins, I kappa B, which are phosphorylated by a cellular kinase complex known as IKK. IKK is made up of two kinases, IKK-alpha and IKK-beta, which phosphorylate I kappa B, leading to its degradation and translocation of NF-kappa B to the nucleus(3-9). IKK kinase activity is stimulated when cells are exposed to the cytokine TNF-cu or by overexpression of the cellular kinases MEKK1 and NIK10,11. Here we demonstrate that the anti-inflammatory agents aspirin and sodium salicylate specifically inhibit IKK-beta activity in vitro and in vivo. The mechanism of aspirin and sodium salicylate inhibition is due to binding of these agents to IKK-beta to reduce ATP binding. Our results indicate that the anti-inflammatory properties of aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappa B of genes involved in the pathogenesis of the inflammatory response.	Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dept Med,Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	gaynor@utsw.swmed.edu						AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; INSEL P, 1996, PHARM BASIS THERAPEU; Kalgutkar AS, 1998, SCIENCE, V280, P1268, DOI 10.1126/science.280.5367.1268; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	26	1340	1402	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					77	80		10.1038/23948	http://dx.doi.org/10.1038/23948			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817203				2022-12-24	WOS:000076852700057
J	Roesler, FL; Moos, HW; Oliversen, RJ; Woodward, RC; Retherford, KD; Scherb, F; McGrath, MA; Smyth, WH; Feldman, PD; Strobel, DF				Roesler, FL; Moos, HW; Oliversen, RJ; Woodward, RC; Retherford, KD; Scherb, F; McGrath, MA; Smyth, WH; Feldman, PD; Strobel, DF			Far-ultraviolet imaging spectroscopy of Io's atmosphere with HST/STIS	SCIENCE			English	Article							PLASMA TORUS; GALILEO MAGNETOMETER; GLOBAL DISTRIBUTION; EMISSION; TELESCOPE; STABILITY; MODEL; SO2	Well-resolved far-ultraviolet spectroscopic images of O I, S I, and previously undetected H I Lyman-alpha emission from lo were obtained with the Hubble space telescope imaging spectrograph (STIS), Detected O I and S I lines (1250 to 1500 angstroms) have bright equatorial spots (up to 2.5 kilorayleighs) that shift position with jovian magnetic field orientation; limb glow that is brighter on the hemisphere facing the jovian magnetic equator; and faint diffuse emission extending to similar to 20 lo radii. All O I and S I features brightened by similar to 50 percent in the last two images, concurrently with a ground-based observation of increased iogenic [O I] 6300-angstrom emission. The H I Lyman-alpha emission, consisting of a small, similar to 2-kilorayleigh patch near each pole, has a different morphology and time variation.	Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; NASA, Astron & Solar Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Atmospher & Environm Res Inc, Cambridge, MA 02139 USA; Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Space Telescope Science Institute; Atmospheric & Environmental Research; Johns Hopkins University	Woodward, RC (corresponding author), Univ Wisconsin, Dept Phys, 1150 Univ Ave, Madison, WI 53706 USA.		Strobel, Darrell5/AAO-6643-2021	Strobel, Darrell5/0000-0002-0944-8675; Woodward, Carey/0000-0002-5441-7579; Retherford, Kurt/0000-0001-9470-150X				Bagenal F, 1997, GEOPHYS RES LETT, V24, P2119, DOI 10.1029/97GL01254; BALLESTER GE, 1987, ASTROPHYS J, V319, pL33, DOI 10.1086/184950; BALLESTER GE, 1997, MAGNETOSPHERES O MAR; BALLESTER GE, 1997, B AM ASTRON SOC, V29, P980; Carlson RW, 1997, GEOPHYS RES LETT, V24, P2479, DOI 10.1029/97GL02609; CHUST T, 1997, ANN GEOPHYS 3 S3, V15, pC824; CLARKE JT, 1994, J GEOPHYS RES-PLANET, V99, P8387, DOI 10.1029/93JE02547; DURRANCE ST, 1995, ASTROPHYS J, V447, P408, DOI 10.1086/175884; Fox GK, 1997, ASTRON J, V113, P1158, DOI 10.1086/118335; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; FRANK LA, 1998, EOS, V79, pS201; GEISSLER PE, 1998, B AM ASTRON SOC, V30, P1116; JUDGE DL, 1974, SCIENCE, V183, P317, DOI 10.1126/science.183.4122.317; Kimble RA, 1998, ASTROPHYS J, V492, pL83, DOI 10.1086/311102; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1996, SCIENCE, V274, P396, DOI 10.1126/science.274.5286.396; LELLOUCH E, 1992, ICARUS, V98, P271, DOI 10.1016/0019-1035(92)90095-O; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; MANATT SL, 1993, J QUANT SPECTROSC RA, V50, P267, DOI 10.1016/0022-4073(93)90077-U; McEwen AS, 1997, GEOPHYS RES LETT, V24, P2443, DOI 10.1029/97GL01956; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; MCEWEN AS, 1988, ICARUS, V75, P450, DOI 10.1016/0019-1035(88)90157-1; NASH DB, 1989, SCIENCE, V244, P454, DOI 10.1126/science.244.4903.454; OLIVERSEN RJ, 1997, B AM ASTRON SOC, V29, P1315; SALAMA F, 1994, ICARUS, V107, P413, DOI 10.1006/icar.1994.1033; SANDEL BR, 1982, J GEOPHYS RES-SPACE, V87, P212, DOI 10.1029/JA087iA01p00212; SAUR J, UNPUB; SCHERB F, 1993, J GEOPHYS RES-PLANET, V98, P18729, DOI 10.1029/93JE00539; SCHERB F, 1996, B AM ASTRON SOC, V28, P1155; SMITH TE, 1995, B AM ASTRON SOC, V27, P1157; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; TRAUGER JT, 1997, B AM ASTRON SOC, V29, P1002; VOIT M, 1997, HST DATA HDB; Williams DJ, 1996, SCIENCE, V274, P401, DOI 10.1126/science.274.5286.401; WOLFGLADROW DA, 1987, J GEOPHYS RES, V92, P9949, DOI 10.1029/JA092iA09p09949; Wong MC, 1996, J GEOPHYS RES-PLANET, V101, P23243, DOI 10.1029/96JE02510; Woodgate BE, 1998, PUBL ASTRON SOC PAC, V110, P1183, DOI 10.1086/316243; WOODWARD RC, 1994, B AM ASTRON SOC, V26, P1139; WU FM, 1995, J GEOPHYS RES-SPACE, V100, P3481, DOI 10.1029/94JA02557	39	91	91	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					353	357		10.1126/science.283.5400.353	http://dx.doi.org/10.1126/science.283.5400.353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888844				2022-12-24	WOS:000078067000038
J	Kawasaki, H; Springett, GM; Mochizuki, N; Toki, S; Nakaya, M; Matsuda, M; Housman, DE; Graybiel, AM				Kawasaki, H; Springett, GM; Mochizuki, N; Toki, S; Nakaya, M; Matsuda, M; Housman, DE; Graybiel, AM			A family of cAMP-binding proteins that directly activate Rap1	SCIENCE			English	Article							LONG-TERM POTENTIATION; CYCLIC-AMP; KINASE-A; SIGNALING PATHWAY; MAP KINASE; SITE-A; RAS; HIPPOCAMPUS; LTP; PHOSPHORYLATION	cAMP (3',5' cyclic adenosine monophosphate) is a second messenger that in eukaryotic cells induces physiological responses ranging from growth, differentiation, and gene expression to secretion and neurotransmission. Most of these effects have been attributed to the binding of cAMP to cAMP-dependent protein kinase A (PKA). Here, a family of cAMP-binding proteins that are differentially distributed in the mammalian brain and body organs and that exhibit both cAMP-binding and guanine nucleotide exchange factor (GEF) domains is reported. These cAMP-regulated GEFs (cAMP-GEFs) bind cAMP and selectively activate the Ras superfamily guanine nucleotide binding protein Rap1A in a cAMP-dependent but PKA-independent manner. Our findings suggest the need to reformulate concepts of cAMP-mediated signaling to include direct coupling to Ras superfamily signaling.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); National Center for Global Health & Medicine - Japan	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, Bldg E25,Room 618, Cambridge, MA 02139 USA.	arng@wccf.mit.edu		Matsuda, Michiyuki/0000-0002-5876-9969; Graybiel, Ann/0000-0002-4326-7720	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028341] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA042063] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA42063] Funding Source: Medline; NHLBI NIH HHS [P01 HL41484] Funding Source: Medline; NICHD NIH HHS [R01 HD28341] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BINU JO, 1998, SCIENCE, V280, P1082; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BROWN EE, 1992, J NEUROSCI, V12, P4112; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GALLISTEL CR, 1985, J NEUROSCI, V5, P1246; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU FC, 1995, J NEUROSCI, V15, P2367, DOI 10.1523/JNEUROSCI.15-03-02367.1995; LONDON ED, 1985, EUR J PHARMACOL, V110, P391, DOI 10.1016/0014-2999(85)90572-2; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; OGREID D, 1988, J BIOL CHEM, V263, P17397; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; SANDYK R, 1991, INT J NEUROSCI, V61, P189, DOI 10.3109/00207459108990738; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	47	1117	1157	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2275	2279		10.1126/science.282.5397.2275	http://dx.doi.org/10.1126/science.282.5397.2275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856955				2022-12-24	WOS:000077645800053
J	Jones, KA; Borowsky, B; Tamm, JA; Craig, DA; Durkin, MM; Dai, M; Yao, WJ; Johnson, M; Gunwaldsen, C; Huang, LY; Tang, C; Shen, QR; Salon, JA; Morse, K; Laz, T; Smith, KE; Nagarathnam, D; Noble, SA; Branchek, TA; Gerald, C				Jones, KA; Borowsky, B; Tamm, JA; Craig, DA; Durkin, MM; Dai, M; Yao, WJ; Johnson, M; Gunwaldsen, C; Huang, LY; Tang, C; Shen, QR; Salon, JA; Morse, K; Laz, T; Smith, KE; Nagarathnam, D; Noble, SA; Branchek, TA; Gerald, C			GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2	NATURE			English	Article							MUSCARINIC RECEPTORS; EXPRESSION CLONING; K+-CHANNEL; RAT-BRAIN; DIMERIZATION; ANTAGONISTS; NEURONS; AGONISTS; PROTEINS; CELLS	The principal inhibitory neurotransmitter GABA (gamma-aminobutyric acid) exerts its effects through two ligand-gated channels, GABA(A) and GABA(C) receptors, and a third receptor, GABA(B) (ref. 1), which acts through G proteins to regulate potassium and calcium channels. Cells heterologously expressing the cloned DNA. encoding the GABA(B)R1 protein exhibit high-affinity antagonist-binding sites(2), but they produce little of the functional activity expected from studies of endogenous GABAB receptors in the brain. Here we describe a new member of the GABA(B) polypeptide family, GABA(B)R2, that shows sequence homology to GABA(B)R1. Neither GABA(B)R1 nor GABA(B)R2, when expressed individually, activates GIRK-type potassium channels; however, the combination of GABA(B)R1 and GABA(B)R2 confers robust stimulation of channel activity. Both genes are co-expressed in individual neurons, and both proteins co-localize in transfected cells. Moreover, immunoprecipitation experiments indicate that the two polypeptides associate with each other, probably as heterodimers. Several G-protein-coupled receptors (GPCRs) exist as high-molecutar-weight species, consistent with the formation of dimers by these receptors(3-7), but the relevance of these species for the functioning of GPCRs has not been established We have now shown that co-expression of two GPCR structures, GABA(B)R1 and GABA(B)R2, belonging to the same subfamily is essential for signal transduction by GABAB receptors.	Synapt Pharmaceut Corp, Paramus, NJ 07652 USA		Jones, KA (corresponding author), Synapt Pharmaceut Corp, 215 Coll Rd, Paramus, NJ 07652 USA.	kjones@synapticcorp.com	Shen, Qirong/AAB-6531-2020					ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Bon C, 1996, BRIT J PHARMACOL, V118, P961, DOI 10.1111/j.1476-5381.1996.tb15493.x; BOWERY NG, 1987, NEUROSCIENCE, V20, P365, DOI 10.1016/0306-4522(87)90098-4; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; BRUGGER F, 1993, EUR J PHARMACOL, V235, P153, DOI 10.1016/0014-2999(93)90836-7; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DURKIN MM, 1995, MOL BRAIN RES, V33, P7, DOI 10.1016/0169-328X(95)00101-W; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; Graham J., 1984, CENTRIFUGATION PRACT, P161; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Kaupmann K., 1997, Society for Neuroscience Abstracts, V23, P954; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; QUICK MW, 1994, METH NEUROSCI, V19, P261; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SALON JA, 1995, METH NEUROSCI, V25, P201; SEABROOK GR, 1990, BRIT J PHARMACOL, V101, P949, DOI 10.1111/j.1476-5381.1990.tb14186.x; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	30	865	908	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					674	679		10.1038/25348	http://dx.doi.org/10.1038/25348			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872315				2022-12-24	WOS:000077694200053
J	Lo, YMD; Hjelm, NM; Fidler, C; Sargent, IL; Murphy, MF; Chamberlain, PF; Poon, PMK; Redman, CWG; Wainscoat, JS				Lo, YMD; Hjelm, NM; Fidler, C; Sargent, IL; Murphy, MF; Chamberlain, PF; Poon, PMK; Redman, CWG; Wainscoat, JS			Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA AMPLIFICATION; PERIPHERAL-BLOOD; CELLS; POLYPEPTIDE; CLONING; SERUM; PCR	Background The ability to determine fetal RhD status noninvasively is useful in the treatment of RhD-sensitized pregnant women whose partners are heterozygous for the RhD gene. The recent demonstration of fetal DNA in maternal plasma raises the possibility that fetal RhD genotyping may be possible with the use of maternal plasma. Methods We studied 57 RhD-negative pregnant women and their singleton fetuses. DNA extracted from maternal plasma was analyzed for the RhD gene with a fluorescence-based polymerase-chain-reaction (PCR) test sensitive enough to detect the RhD gene in a single cell. Fetal RhD status was determined directly by serologic analysis of cord blood or PCR analysis of amniotic fluid. Results Among the 57 RhD-negative women, 12 were in their first trimester of pregnancy, 30 were in their second trimester, and 15 were in their third trimester. Thirty-nine fetuses were RhD-positive, and 18 were RhD-negative. In the samples obtained from women in their second or third trimester of pregnancy, the results of RhD PCR analysis of maternal plasma DNA were completely concordant with the results of serologic analysis. Among the maternal plasma samples collected in the first trimester, 2 contained no RhD DNA, but the fetuses were RhD-positive; the results in the other 10 samples were concordant (7 were RhD-positive, and 3 RhD-negative). Conclusions Noninvasive fetal RhD genotyping can be performed rapidly and reliably with the use of maternal plasma beginning in the second trimester of pregnancy. (N Engl J Med 1998;339:1734-8.) (C) 1998, Massachusetts Medical Society.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China; John Radcliffe Hosp, Dept Hematol, Oxford OX3 9DU, England; John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	Chinese University of Hong Kong; Prince of Wales Hospital; University of Oxford; University of Oxford	Lo, YMD (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Rm 38023,Clin Sci Bldg,30-32 Ngan Shing St, Hong Kong, Peoples R China.		Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293				Aubin JT, 1997, BRIT J HAEMATOL, V98, P356, DOI 10.1046/j.1365-2141.1997.2193040.x; BENNETT PR, 1993, NEW ENGL J MED, V329, P607, DOI 10.1056/NEJM199308263290903; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; BLAKEMORE KJ, 1986, AM J OBSTET GYNECOL, V155, P988, DOI 10.1016/0002-9378(86)90332-7; Chen XQ, 1996, NAT MED, V2, P1033; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; CLARKE CA, 1987, BRIT MED J, V294, P1001, DOI 10.1136/bmj.294.6578.1001; COLIN Y, 1991, BLOOD, V78, P2747; Dildy GA, 1996, OBSTET GYNECOL, V88, P207, DOI 10.1016/0029-7844(96)00143-3; GeifmanHoltzman O, 1996, AM J OBSTET GYNECOL, V174, P818, DOI 10.1016/S0002-9378(96)70306-X; HAMERTON JL, 1989, LANCET, V1, P1; Hamlington J, 1997, LANCET, V349, P540, DOI 10.1016/S0140-6736(97)80090-6; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KWOK S, 1989, NATURE, V339, P490; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LO YMD, 1993, LANCET, V341, P1147, DOI 10.1016/0140-6736(93)93161-S; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; LO YMD, 1994, ANN NY ACAD SCI, V731, P204, DOI 10.1111/j.1749-6632.1994.tb55772.x; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; MOLLISON PL, 1993, BLOOD TRANSFUSION CL, P204; Robson SC, 1998, BRIT J OBSTET GYNAEC, V105, P129, DOI 10.1111/j.1471-0528.1998.tb10039.x; Schumacher B, 1996, OBSTET GYNECOL, V88, P137, DOI 10.1016/0029-7844(96)00113-5; Sekizawa A, 1996, OBSTET GYNECOL, V87, P501, DOI 10.1016/0029-7844(95)00496-3; TABOR A, 1987, BRIT J OBSTET GYNAEC, V94, P528, DOI 10.1111/j.1471-0528.1987.tb03145.x; Toth T, 1998, J REPROD MED, V43, P219	28	496	606	1	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1734	1738		10.1056/NEJM199812103392402	http://dx.doi.org/10.1056/NEJM199812103392402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845707				2022-12-24	WOS:000077459700002
J	Delwart, E				Delwart, E			A new HIV-1 group - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA		Delwart, E (corresponding author), Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.			Delwart, Eric/0000-0002-6296-4484				Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1960	1960		10.1001/jama.280.22.1960	http://dx.doi.org/10.1001/jama.280.22.1960			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851486				2022-12-24	WOS:000077364500045
J	Yujiri, T; Sather, S; Fanger, CR; Johnson, GL				Yujiri, T; Sather, S; Fanger, CR; Johnson, GL			Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption	SCIENCE			English	Article							KINASE KINASE KINASE; PROTEIN-KINASE; DOMAIN; RAS	Targeted disruption of the gene encoding MEK kinase 1 (MEKK1), a mitogen-activated protein kinase (MAPK) kinase kinase, defined its function in the regulation of MAPK pathways and cell survival. MEKK1(-/-) embryonic stem cells from mice had Lost or altered responses of the c-Jun amino-terminal kinase (INK) to microtubule disruption and cold stress but activated JNK normally in response to heat shock, anisomycin, and ultraviolet irradiation. Activation of JNK was Lost and that of extracellular signal-regulated protein kinase (ERK) was diminished in response to hyperosmolarity and serum factors in MEKK1(-/-) cells. Loss of MEKK1 expression resulted in a greater apoptotic response of cells to hyperosmolarity and microtubule disruption. When activated by specific stresses that alter cell shape and the cytoskeleton, MEKK1 Signals to protect cells from apoptosis.	Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA.	johnsong@njc.org	Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456	NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FANGER GR, UNPUB; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESINGER TK, UNPUB; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; WIDMANN C, UNPUB	17	281	289	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1911	1914		10.1126/science.282.5395.1911	http://dx.doi.org/10.1126/science.282.5395.1911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836645				2022-12-24	WOS:000077338100055
J	Migaud, M; Charlesworth, P; Dempster, M; Webster, LC; Watabe, AM; Makhinson, M; He, Y; Ramsay, MF; Morris, RGM; Morrison, JH; O'Dell, TJ; Grant, SGN				Migaud, M; Charlesworth, P; Dempster, M; Webster, LC; Watabe, AM; Makhinson, M; He, Y; Ramsay, MF; Morris, RGM; Morrison, JH; O'Dell, TJ; Grant, SGN			Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein	NATURE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; SYNAPTIC PLASTICITY; GUANYLATE KINASES; PSD-95 FAMILY; K+ CHANNELS; IN-VIVO; MEMBRANE; SYNAPSES; HIPPOCAMPUS	Specific patterns of neuronal firing induce changes in synaptic strength that may contribute to learning and memory. If the postsynaptic NMDA (N-methyl-D-aspartate) receptors are blocked, long-term potentiation (LTP) and long-term depression (LTD) of synaptic transmission and the learning of spatial information are prevented. The NMDA receptor can bind a protein known as postsynaptic density-95 (PSD-95), which may regulate the localization of and/or signalling by the receptor, In mutant mice lacking PSD-95, the frequency function of NMDA-dependent LTP and LTD is shifted to produce strikingly enhanced LTP at different frequencies of synaptic stimulation. In keeping with neural-network models that Incorporate bidirectional learning rules, this frequency shift is accompanied by severely impaired spatial learning. Synaptic NMDA-receptor currents, subunit expression, localization and synaptic morphology are all unaffected in the mutant mice. PSD-95 thus appears to be important in coupling the NMDA receptor to pathways that control bidirectional synaptic plasticity and learning.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Edinburgh, Ctr Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	University of Edinburgh; University of Edinburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Grant, SGN (corresponding author), Univ Edinburgh, Ctr Genome Res, Roger Land Bldg,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.		Morris, Richard G M/C-9982-2013; Morrison, John/F-9229-2012	Migaud, Martine/0000-0002-9496-0517; Grant, Seth/0000-0001-8732-8735	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allison DW, 1998, J NEUROSCI, V18, P2423; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Hancock PJB, 1991, NEURAL COMPUT, V3, P201, DOI 10.1162/neco.1991.3.2.201; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hunt CA, 1996, J NEUROSCI, V16, P1380; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morrison BM, 1998, J COMP NEUROL, V395, P523; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1997, J NEUROSCI, V17, P5687; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P314; Niethammer M, 1996, J NEUROSCI, V16, P2157; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; RAYPORT S, 1992, J NEUROSCI, V12, P4264; SEJNOWSKI TJ, 1977, J THEOR BIOL, V69, P387; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang JH, 1997, J NEUROPHYSIOL, V78, P2707, DOI 10.1152/jn.1997.78.5.2707; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Willshaw D, 1990, NEURAL COMPUT, V2, P85, DOI 10.1162/neco.1990.2.1.85; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	38	921	959	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					433	439		10.1038/24790	http://dx.doi.org/10.1038/24790			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853749				2022-12-24	WOS:000077370100044
J	Sokal, EM; Melchior, M; Cornu, C; Vandenbroucke, AT; Buts, JP; Cohen, BJ; Burtonboy, G				Sokal, EM; Melchior, M; Cornu, C; Vandenbroucke, AT; Buts, JP; Cohen, BJ; Burtonboy, G			Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children	LANCET			English	Article							LIVER-FAILURE; HYBRIDIZATION ASSAY; DNA; ARTHROPATHY; PERSISTENCE	Background The cause of fulminant hepatitis (FH) in children is unexplained in up to 50% of cases. We report parvovirus B19 as an agent associated with FH in children and compare clinical characteristics of these patients with those of age-matched patients with FH of other origin. Methods 45 patients presented with FH. No cause was apparent in 21 patients. Parvovirus B19 genome was retrospectively sought by PCR in serum collected admission in 41 patients. Findings Parvovirus B19 genome was detected in serum from four of 21 patients with unexplained FH (four of 11 younger than 5 years). No B19 DNA was detected in serum from patients with other types of FH or from 82 patients with biliary atresia. Parvovirus B19 IgM was detected in one of the four patients. Patients with parvovirus B19 infection had significantly lower bilirubin concentrations than age-matched patients with FH due to hepatitis A (nine) or other causes (nine) (poisoning with amanita excluded). All patients with parvovirus B19 survived without orthotopic liver transplantation, with restoration of normal liver function within 17 days. Interpretation In patients younger than 5 years with FH of unexplained origin, evidence of acute parvovirus B19 was associated with a distinct clinical pattern. In particular, low bilirubin concentrations and rapid recovery of liver function without transplantation were distinctive features.	Clin Univ St Luc, Dept Pediat, B-1200 Brussels, Belgium; Clin Univ St Luc, Dept Virol, B-1200 Brussels, Belgium; Publ Hlth Lab Serv, Div Virus Reference, London NW9 5EQ, England	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Public Health England	Sokal, EM (corresponding author), Clin Univ St Luc, Dept Pediat, 10-1301 Av Hippocrate, B-1200 Brussels, Belgium.	sokal@pedi.ucl.ac.be		Sokal, Etienne/0000-0001-5597-4708				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CAMES B, 1992, J PEDIATR-US, V120, P33, DOI 10.1016/S0022-3476(05)80593-1; Clewley Jonathan P., 1993, P367; COHEN B, 1995, BMJ-BRIT MED J, V311, P1549, DOI 10.1136/bmj.311.7019.1549; Debray D, 1997, HEPATOLOGY, V26, P1018, DOI 10.1053/jhep.1997.v26.pm0009328329; DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1002/hep.1840160509; Durand P, 1996, PRESSE MED, V25, P1501; FOTO F, 1993, J INFECT DIS, V167, P744, DOI 10.1093/infdis/167.3.744; HICKS KE, 1995, J CLIN MICROBIOL, V33, P2473, DOI 10.1128/JCM.33.9.2473-2475.1995; Hillingso JG, 1998, LANCET, V351, P955, DOI 10.1016/S0140-6736(00)80016-1; Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; MORI J, 1989, J CLIN MICROBIOL, V27, P459, DOI 10.1128/JCM.27.3.459-464.1989; Soderlund M, 1997, LANCET, V349, P1063, DOI 10.1016/S0140-6736(96)09110-6; YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1; Yoto Y, 1996, LANCET, V347, P868, DOI 10.1016/S0140-6736(96)91348-3; YOUNG N, 1988, SEMIN HEMATOL, V25, P159	17	90	94	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1739	1741		10.1016/S0140-6736(98)06165-0	http://dx.doi.org/10.1016/S0140-6736(98)06165-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848349				2022-12-24	WOS:000077246500008
J	Zheng, P; Guo, Y; Niu, QT; Levy, DE; Dyck, JA; Lu, SL; Sheiman, LA; Liu, Y				Zheng, P; Guo, Y; Niu, QT; Levy, DE; Dyck, JA; Lu, SL; Sheiman, LA; Liu, Y			Proto-oncogene PML controls genes devoted to MHC class I antigen presentation	NATURE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; EXPRESSION; T(15-17); CELLS; TRANSLOCATION; ADENOVIRUS-12; INTERFERON; MOLECULES; PATHWAY	Fragments of foreign antigens associated with class I molecules of the major histocompatibility complex (MHC) are presented at the cell surface to elicit an immune response. This presentation requires the coordinated expression of several genes contained in the MHC1-5, including those encoding the MHC class I heavy chain, the proteins LMP-2 and LMP-7, which are involved in the proteasomal degradation of cytosolic antigens into peptide fragments that are destined for association with MHC class I molecules, and TAP-1 and TAP-2, which transport these fragments across the membrane of the endoplasmic reticulum at the start of their journey to the cell surface. In many virus-transformed cell lines(6,7) and spontaneous tumours(8-10), these genes are simultaneously repressed. However, the key factor(s) that are essential for their expression and repression have not been identified. Here we report that the proto-oncogene product PML induces expression of LMP-2, LMP-7, TAP-1 and TAF-2 in an MHC-class I-negative, recurrent tumour, leading to the re-expression of cell-surface MHC in tumours and to rejection of the tumours. PML also regulates MHC expression in untransformed fibroblasts. We conclude that malfunction of PML may enable a tumour to evade the immune defence of its host.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	New York University; New York University; University of California System; University of California San Diego	Liu, Y (corresponding author), NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA.	liu-3@medctr.osu.edu	Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022; Zheng, Pan/E-8691-2011	Levy, David/0000-0002-7320-7788; Zheng, Pan/0000-0003-2598-3544; Liu, Yang/0000-0002-9442-700X				BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Gambacorta M, 1996, AM J PATHOL, V149, P2023; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo Y, 1996, J EXP MED, V184, P955, DOI 10.1084/jem.184.3.955; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Korkolopoulou P, 1996, BRIT J CANCER, V73, P148, DOI 10.1038/bjc.1996.28; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1995, ONCOGENE, V11, P871; MATINEZ CK, 1991, NATURE, V353, P554; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; RAMARATHINAM L, 1994, J EXP MED, V179, P1205, DOI 10.1084/jem.179.4.1205; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VEGH Z, 1993, CANCER RES, V53, P2416; Whitley EA, 1996, J EXP THEOR ARTIF IN, V8, P365, DOI 10.1080/095281396147375; Yoshida H, 1996, CANCER RES, V56, P2945	30	145	149	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					373	376		10.1038/24628	http://dx.doi.org/10.1038/24628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845074				2022-12-24	WOS:000077204000051
J	Owen, WF; Chertow, GM; Lazarus, JM; Lowrie, EG				Owen, WF; Chertow, GM; Lazarus, JM; Lowrie, EG			Dose of hemodialysis and survival - Differences by race and sex	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UREA REDUCTION RATIO; DIALYSIS TREATMENT; MORTALITY; PREDICTORS; ADEQUACY; DEATH	Context.-Although blacks receive lower doses of hemodialysis than whites, their survival when receiving dialysis treatment is better than that for whites. Previous studies of the relationship between the dose of dialysis and patient survival have not controlled for differences in patient characteristics. Objective.-To examine the association of mortality with the lose of hemodialysis for clusters of patients categorized by race and sex. Design.-Retrospective analysis of laboratory data and mortality outcomes from 1994, using a national database of hemodialysis patients. Patients.-A total of 18144 black and white patients receiving hemodialysis 3 times weekly who either lived the entire year receiving hemodialysis or died. Main Outcome Measures.-The fractional reduction of urea in a single dialysis session as the measured hemodialysis dose (urea reduction ratio [URR]) after controlling for race, sex, age, and diabetes mellitus. Mortality was determined by strata of URRs and albumin and creatinine levels. Results.-Across all age categories, blacks had lower URRs than whites, and men had lower URRs than women. In an age-adjusted model for evaluating interactions among URRs, race, sex, and diabetes, the association of URR with mortality risk was weak among blacks, particularly black men. After adjustment for age and diabetes, death probability curves were most steep for white women with URR values less than 60%. The death probability curves were least steep for black men. There was no meaningful difference between death probability and albumin or creatinine concentration among the race by sex clusters. Conclusion.-Using URR, the usual measure of hemodialysis dose, the assumption that the association between dialysis dose and survival is uniform across demographic groups appears incorrect. Comparisons of the quality of dialysis patient cave should not rely on URR alone to predict patient survival.	Brigham & Womens Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA; Fresenius Med Care N Amer, Lexington, MA USA	Harvard University; Brigham & Women's Hospital	Owen, WF (corresponding author), Brigham & Womens Hosp, Dept Med, Div Nephrol, 75 Francis St, Boston, MA 02115 USA.	wfowen@bics.bwh.harvard.edu		Chertow, Glenn/0000-0002-7599-0534	NIDDK NIH HHS [DK520521] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acchiardo S R, 1992, ASAIO J, V38, pM282, DOI 10.1097/00002480-199207000-00038; *AM ASS KIDN PAT, 1995, AM ASS KIDN PAT ADV, P1; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; Chertow GM, 1997, KIDNEY INT, V51, P1578, DOI 10.1038/ki.1997.216; COLLINS AJ, 1994, AM J KIDNEY DIS, V23, P272, DOI 10.1016/S0272-6386(12)80984-X; *DEP HLTH HUM SERV, 1995, KNOW YOUR NUMB; *DEP HLTH HUM SERV, 1997, ESRD COR IND PROJ 19; DEPNER TA, 1993, SEMIN DIALYSIS, V6, P242, DOI 10.1111/j.1525-139X.1993.tb00152.x; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; Eknoyan G, 1996, SEMIN DIALYSIS, V9, P24, DOI 10.1111/j.1525-139X.1996.tb00897.x; FINESTEIN AR, 1996, MULTIVARIABLE ANAL, P164; Gotch FA, 1990, CLIN DIALYSIS, P118; HAKIM RM, 1990, KIDNEY INT, V37, P822, DOI 10.1038/ki.1990.52; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HAKIM RM, 1992, AM J KIDNEY DIS, V20, P107, DOI 10.1016/S0272-6386(12)80538-5; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; *HEM AD WORK GROUP, 1997, AM J KIDNEY DIS S, V30, pS15; *HLTH CAR FIN ADM, 1997, HCFA PUBL A B, V60; HORNBERGER JC, 1993, J AM SOC NEPHROL, V4, P1004; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; IFUDU O, 1995, DIALYSIS TRANSPLANT, V24, P292; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 1997, SEMIN DIALYSIS, V10, P115, DOI 10.1111/j.1525-139X.1997.tb00865.x; LOWRIE EG, 1994, DEV NEPHROL, V35, P121; LOWRIE EG, 1994, AM J KIDNEY DIS, V24, P255, DOI 10.1016/S0272-6386(12)80191-0; Lowrie EG, 1996, SEMIN NEPHROL, V16, P242; LOWRIE EG, 1991, CONT DIAL NEPHROL, V2, P11; LOWRIE EG, 1992, KIDNEY INT, V42, P22; Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523-1755.1998.00032.x; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; OWEN WF, 1997, ADV RENAL REPLACE TH, V4, P3; PARKER TF, 1994, AM J KIDNEY DIS, V23, P670, DOI 10.1016/S0272-6386(12)70277-9; *REN PHYS ASS WORK, 1993, CLIN PRACT GUID, V1; SHERMAN RA, 1995, KIDNEY INT, V47, P319, DOI 10.1038/ki.1995.41; *US REN DAT SYST, 1996, USRDS 1997 ANN DAT R	37	170	173	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1764	1768		10.1001/jama.280.20.1764	http://dx.doi.org/10.1001/jama.280.20.1764			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842952				2022-12-24	WOS:000077081400032
J	Thresher, RJ; Vitaterna, MH; Miyamoto, Y; Kazantsev, A; Hsu, DS; Petit, C; Selby, CP; Dawut, L; Smithies, O; Takahashi, JS; Sancar, A				Thresher, RJ; Vitaterna, MH; Miyamoto, Y; Kazantsev, A; Hsu, DS; Petit, C; Selby, CP; Dawut, L; Smithies, O; Takahashi, JS; Sancar, A			Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses	SCIENCE			English	Article							HUMAN PHOTOLYASE HOMOLOG; DNA PHOTOLYASE; ESCHERICHIA-COLI; SUPRACHIASMATIC NUCLEUS; CRYSTAL-STRUCTURE; RHYTHMS; GENE; PHOTOTRANSDUCTION; EXPRESSION; DROSOPHILA	Cryptochromes are photoactive pigments in the eye that have been proposed to function as circadian photopigments. Mice lacking the cryptochrome 2 blue-light photoreceptor gene (mCry2) were tested for circadian clock-related functions. The mutant mice had a lower sensitivity to acute Light induction of mPer1 in the suprachiasmatic nucleus (SCN) but exhibited normal circadian oscillations of mPer1 and mCry1 messenger RNA in the SCN. Behaviorally, the mutants had an intrinsic circadian period about 1 hour Longer than normal and exhibited high-amplitude phase shifts in response to Light pulses administered at circadian time 17. These data are consistent with the hypothesis that CRY2 protein modulates circadian responses in mice and suggest that cryptochromes have a role in circadian photoreception in mammals.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Northwestern Univ, Natl Sci Fdn Ctr Biol Timing, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Northwestern University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	bsiler.biochem@mhs.unc.edu	Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012; Jansen, Heiko T./A-5770-2008	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Jansen, Heiko T./0000-0003-0178-396X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031082, R37GM020069, R37GM031082, R01GM020069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011412] Funding Source: NIH RePORTER; NIA NIH HHS [P0 AG11412] Funding Source: Medline; NIGMS NIH HHS [GM20069, GM31082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ASCHOFF J, 1979, Z TIERPSYCHOL, V49, P225; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Benloucif S, 1997, BRAIN RES, V747, P34, DOI 10.1016/S0006-8993(96)01182-1; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Deng TS, 1997, PLANTA, V202, P502, DOI 10.1007/s004250050155; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDGAR DM, 1991, AM J PHYSIOL, V261, pR928, DOI 10.1152/ajpregu.1991.261.4.R928; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; HAYS JB, 1984, MOL CELL BIOL, V9, P767; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOHNSON CH, 1989, J BIOL RHYTHM, V4, P417, DOI 10.1177/074873048900400403; Johnson CH, 1996, MOL MICROBIOL, V21, P5, DOI 10.1046/j.1365-2958.1996.00613.x; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Oren DA, 1996, NEUROSCIENTIST, V2, P207, DOI 10.1177/107385849600200408; Ozer Z, 1995, BIOCHEMISTRY-US, V34, P15886, DOI 10.1021/bi00049a002; PAIETTA J, 1981, P NATL ACAD SCI-BIOL, V78, P5573, DOI 10.1073/pnas.78.9.5573; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PROVENCIO I, 1995, BRAIN RES, V694, P183, DOI 10.1016/0006-8993(95)00694-L; RONNENBERG T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549; RONNENBERG T, 1997, PLANTA, V202, P494; RONNENBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206; ROSENBERG RS, 1991, AM J PHYSIOL, V261, pR491, DOI 10.1152/ajpregu.1991.261.2.R491; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SOKOLOVE PG, 1978, FDN P, V38, P2589; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; Valentinuzzi VS, 1997, AM J PHYSIOL-REG I, V273, pR1957, DOI 10.1152/ajpregu.1997.273.6.R1957; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; WICKLAND CR, 1991, AM J PHYSIOL, V261, pR1109, DOI 10.1152/ajpregu.1991.261.5.R1109; WINFREE AT, 1970, J THEOR BIOL, V28, P327, DOI 10.1016/0022-5193(70)90075-5; YAMAMOTO K, 1983, MOL GEN GENET, V192, P282, DOI 10.1007/BF00327679; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zhang Y, 1996, NEUROSCIENCE, V70, P951, DOI 10.1016/0306-4522(95)00408-4; ZIMMERMAN WF, 1971, SCIENCE, V171, P1167, DOI 10.1126/science.171.3976.1167	56	320	329	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1490	1494		10.1126/science.282.5393.1490	http://dx.doi.org/10.1126/science.282.5393.1490			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822380				2022-12-24	WOS:000077110800055
J	Shima, K; Tanji, J				Shima, K; Tanji, J			Role for cingulate motor area cells in voluntary movement selection based on reward	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; RHESUS-MONKEY; PREFRONTAL CORTEX; ACTIVATION; CORTICES; INPUT	Most natural actions are chosen voluntarily from many possible choices, An action is often chosen based on the reward that it is expected to produce. What kind of cellular activity in which area of the cerebral cortex is involved in selecting an action according to the expected reward value? Results of an analysis in monkeys of cellular activity during the performance of reward-based motor selection and the effects of chemical inactivation are presented. We suggest that cells in the rostral cingulate motor area, one of the higher order motor areas in the cortex, play a part in processing the reward information for motor selection.	Tohoku Univ, Sch Med, Dept Physiol, Sendai, Miyagi 980, Japan	Tohoku University	Tanji, J (corresponding author), Tohoku Univ, Sch Med, Dept Physiol, Sendai, Miyagi 980, Japan.							AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; BALEYDIER C, 1980, BRAIN, V103, P525, DOI 10.1093/brain/103.3.525; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; JENKINS IH, 1994, J NEUROSCI, V14, P3775; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; MATELLI M, 1991, J COMP NEUROL, V311, P445, DOI 10.1002/cne.903110402; Matsuzaka Y, 1996, J NEUROPHYSIOL, V76, P2327, DOI 10.1152/jn.1996.76.4.2327; MORECRAFT RJ, 1993, J COMP NEUROL, V337, P669, DOI 10.1002/cne.903370411; MORECRAFT RJ, 1992, J COMP NEUROL, V322, P471, DOI 10.1002/cne.903220403; PARTIOT A, 1995, NEUROREPORT, V6, P1397, DOI 10.1097/00001756-199507100-00009; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; PLAYFORD ED, 1992, ANN NEUROL, V32, P151, DOI 10.1002/ana.410320206; SHIMA K, 1991, J NEUROPHYSIOL, V65, P188, DOI 10.1152/jn.1991.65.2.188; Van Hoesen G. W. M., 1993, NEUROBIOLOGY CINGULA, P249, DOI DOI 10.1007/978-1-4899-6704-6_9; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208	18	517	520	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1335	1338		10.1126/science.282.5392.1335	http://dx.doi.org/10.1126/science.282.5392.1335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812901				2022-12-24	WOS:000076982200050
J	Andersson, DI; Slechta, ES; Roth, JR				Andersson, DI; Slechta, ES; Roth, JR			Evidence that gene amplification underlies adaptive mutability of the bacterial lac operon	SCIENCE			English	Article							EPISOMAL FRAMESHIFT MUTATION; ESCHERICHIA-COLI; REVERSION; RECOMBINATION; CONJUGATION; DELETIONS; MUTANTS; OCCUR; CELLS	Adaptive mutability is the apparent alteration in specificity or rate of mutability seen in bacteria during stress. A model is proposed by which gene amplification during selective growth can give the appearance of adaptive mutability without requiring any change in mutability. The model is based on two assumptions, that a mutant lac locus with residual function allows growth if its copy number is increased, and that true reversion events are made more likely by replication of chromosomes with many copies of the locus. Apparent directed mutability, its recombination requirement, and its apparent independence of cell growth are all accounted for by the model. Evidence is provided far the required residual function and gene amplification.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Swefdish Inst Infect Dis Control, S-10521 Stockholm, Sweden; Uppsala Univ, Dept Microbiol, S-75123 Uppsala, Sweden	Utah System of Higher Education; University of Utah; Swedish Institute for Infectious Disease Control; Uppsala University	Roth, JR (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	roth@bioscience.utah.edu		Andersson, Dan/0000-0001-6640-2174	NIGMS NIH HHS [GM27068] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027068] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RP, 1977, ANNU REV MICROBIOL, V31, P473, DOI 10.1146/annurev.mi.31.100177.002353; [Anonymous], UNPUB; ATKINS JF, 1972, P NATL ACAD SCI USA, V69, P1192, DOI 10.1073/pnas.69.5.1192; BOE L, 1990, MOL MICROBIOL, V4, P597, DOI 10.1111/j.1365-2958.1990.tb00628.x; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; FOSTER PL, 1995, P NATL ACAD SCI USA, V92, P5487, DOI 10.1073/pnas.92.12.5487; FOSTER PL, 1995, J BACTERIOL, V177, P6670, DOI 10.1128/jb.177.22.6670-6671.1995; FOSTER PL, 1992, GENETICS, V131, P783; Foster PL, 1996, GENETICS, V142, P25; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; Foster PL, 1997, J BACTERIOL, V179, P1550, DOI 10.1128/jb.179.5.1550-1554.1997; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; Galitski T, 1996, GENETICS, V143, P645; HALL BG, 1990, GENETICS, V126, P5; Harris RS, 1996, GENETICS, V142, P681; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kurland C. G., 1996, CELLULAR MOL BIOL, P979; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; Peters JE, 1996, J BACTERIOL, V178, P3037, DOI 10.1128/jb.178.11.3037-3043.1996; RADICELLA JP, 1995, SCIENCE, V268, P418, DOI 10.1126/science.7716545; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; Rosenberg SM, 1998, GENETICS, V148, P1559; ROTH JR, 1996, ESCHERICHIA COLI SAL, P2256; SLECHTA ES, UNPUB; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; TLSTY TD, 1984, CELL, V37, P217, DOI 10.1016/0092-8674(84)90317-9; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; TORKELSON J, 1998, GENETICS, V148, P1453; WHORISKEY SK, 1987, GENE DEV, V1, P227, DOI 10.1101/gad.1.3.227; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	32	138	144	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1133	1135		10.1126/science.282.5391.1133	http://dx.doi.org/10.1126/science.282.5391.1133			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804552				2022-12-24	WOS:000076887700052
J	Lin, JH; Saito, T; Anderson, DJ; Lance-Jones, C; Jessell, TM; Arber, S				Lin, JH; Saito, T; Anderson, DJ; Lance-Jones, C; Jessell, TM; Arber, S			Functionally related motor neuron pool and muscle sensory afferent subtypes defined by coordinate ETS gene expression	CELL			English	Article							CHICK HIND-LIMB; DORSAL-ROOT GANGLIA; TRANSCRIPTION FACTORS; SPINAL-CORD; CELL-DEATH; DIFFERENTIAL EXPRESSION; SYNAPTIC CONNECTIONS; PROJECTION PATTERNS; AXON GUIDANCE; PEA3 GROUP	Motor function depends on the formation of selective connections between sensory and motor neurons and their muscle targets. The molecular basis of the specificity inherent in this sensory-motor circuit remains unclear. We show that motor neuron pools and subsets of muscle sensory afferents can be defined by the expression of ETS genes, notably PEA3 and ER81. There is a matching in PEA3 and ER81 expression by functionally interconnected sensory and motor neurons. ETS gene expression by motor and sensory neurons fails to occur after limb ablation, suggesting that their expression is coordinated by signals from the periphery. ETS genes may therefore participate in the development of selective sensory-motor circuits in the spinal cord.	Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Natl Inst Genet, Mishima, Shizuoka 411, Japan; CALTECH, Pasadena, CA 91125 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	Columbia University; Howard Hughes Medical Institute; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	tmj1@columbia.edu		Arber, Silvia/0000-0002-6261-250X; Saito, Tetsuichiro/0000-0002-1538-1454; Lin, Jonathan/0000-0002-7438-6941	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025676] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25676] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Appel B, 1995, DEVELOPMENT, V121, P4117; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Caldero J, 1998, J NEUROSCI, V18, P356; Carpenter EM, 1997, DEVELOPMENT, V124, P4505; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DAVIS BM, 1989, J COMP NEUROL, V279, P556, DOI 10.1002/cne.902790405; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Doe CQ, 1996, CURR OPIN NEUROBIOL, V6, P18, DOI 10.1016/S0959-4388(96)80004-3; ECCLES JC, 1957, J PHYSIOL-LONDON, V137, P22, DOI 10.1113/jphysiol.1957.sp005794; Ensini M, 1998, DEVELOPMENT, V125, P969; FRANK E, 1990, J NEUROSCI, V10, P2250; FRANK E, 1993, NEURON, V10, P779, DOI 10.1016/0896-6273(93)90194-V; Frank E, 1988, MESSAGE MIND, P180; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; HOLLYDAY M, 1995, J COMP NEUROL, V357, P242, DOI 10.1002/cne.903570205; Hollyday M., 1980, Current Topics in Developmental Biology, V15, P181; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; LAING NG, 1982, DEV BRAIN RES, V5, P181, DOI 10.1016/0165-3806(82)90155-9; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; LANCEJONES C, 1979, J MORPHOL, V162, P275; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER L, 1986, DEV BIOL, V118, P511, DOI 10.1016/0012-1606(86)90023-0; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LEE MT, 1988, J NEUROSCI, V8, P2530; Lefcort F, 1996, J NEUROSCI, V16, P3704; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Matise MP, 1996, DEVELOPMENT, V122, P659; MENDELSON B, 1991, J NEUROSCI, V11, P1390; MU XJ, 1993, J NEUROSCI, V13, P4029; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OPPENHEIM RW, 1978, BRAIN RES, V154, P148, DOI 10.1016/0006-8993(78)91062-4; Pearson KG., 1997, NEURONS NETWORKS MOT, P225; Romer AS, 1942, J MORPHOL, V71, P251, DOI 10.1002/jmor.1050710203; SAITO T, 1995, MOL CELL NEUROSCI, V6, P280, DOI 10.1006/mcne.1995.1022; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tanaka H, 1997, DEV NEUROSCI-BASEL, V19, P106, DOI 10.1159/000111193; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tiret L, 1998, DEVELOPMENT, V125, P279; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wenner P, 1995, J NEUROSCI, V15, P8191; WHITELAW V, 1983, J NEUROSCI, V3, P1199; WILLIAMS C, 1987, DEV BRAIN RES, V34, P215, DOI 10.1016/0165-3806(87)90210-0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	59	271	272	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					393	407		10.1016/S0092-8674(00)81770-5	http://dx.doi.org/10.1016/S0092-8674(00)81770-5			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814709	hybrid			2022-12-24	WOS:000076789600012
J	Wasserman, JD; Freeman, M				Wasserman, JD; Freeman, M			An autoregulatory cascade of EGF receptor signaling patterns the Drosophila egg	CELL			English	Article							DORSAL-VENTRAL PATTERN; ALPHA-LIKE PROTEIN; DORSOVENTRAL AXIS; TRANSCRIPTION FACTOR; RHOMBOID GENE; SPITZ GENE; BODY AXES; OOGENESIS; PATHWAY; MELANOGASTER	Intercellular signaling through the EGF receptor (EGFR) patterns the Drosophila egg. The TGF alpha-like ligand Gurken signals from the oocyte to the receptor in the overlying somatic follicle cells. We show that in the dorsal follicle cells this initial paracrine signaling event triggers an autocrine amplification by two other EGFR ligands, Spitz and Vein. Spitz only becomes an effective ligand in the presence of the multitransmembrane domain protein Rhomboid. Consequent high-level EGFR activation leads to localized expression of the diffusible inhibitor Argos, which alters the profile of signaling. This sequential activation, amplification, and local inhibition of the EGFR forms an autoregulatory cascade that leads to the splitting of an initial single peak of signaling into two, thereby patterning the egg.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	MF1@mrc-lmb.cam.ac.uk	Wasserman, JD/AAF-8145-2019; Wasserman, Jonathan D/M-4298-2013	Wasserman, JD/0000-0001-7088-8146; Wasserman, Jonathan D/0000-0001-7088-8146; Freeman, Matthew/0000-0003-0410-5451				BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; Chou TB, 1996, GENETICS, V144, P1673; Deng WM, 1997, DEVELOPMENT, V124, P4639; Dominguez M, 1998, CURR BIOL, V8, P1039, DOI 10.1016/S0960-9822(98)70441-5; Duffy JB, 1998, DEVELOPMENT, V125, P2263; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Hsu T, 1996, GENE DEV, V10, P1411, DOI 10.1101/gad.10.11.1411; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1972, J MORPHOL, V137, P29, DOI 10.1002/jmor.1051370103; Mantrova EY, 1998, GENE DEV, V12, P1166; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; Morimoto AM, 1996, DEVELOPMENT, V122, P3745; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; NEUMANSILBERBERG FS, 1994, DEVELOPMENT, V120, P2457; NeumanSilberberg FS, 1996, MECH DEVELOP, V59, P105, DOI 10.1016/0925-4773(96)00567-9; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NOLL R, 1994, DEVELOPMENT, V120, P2329; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sapir A, 1998, DEVELOPMENT, V125, P191; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Schnorr JD, 1996, GENETICS, V144, P1545; SCHUPBACH T, 1994, CURR OPIN GENET DEV, V4, P502, DOI 10.1016/0959-437X(94)90064-A; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; Twombly V, 1996, DEVELOPMENT, V122, P1555; Wasserman JD, 1997, TRENDS CELL BIOL, V7, P431, DOI 10.1016/S0962-8924(97)01143-4; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; XU T, 1993, DEVELOPMENT, V117, P1223; Yarnitzky T, 1997, GENE DEV, V11, P2691, DOI 10.1101/gad.11.20.2691; zurLage P, 1997, CURR BIOL, V7, P166, DOI 10.1016/S0960-9822(97)70087-3	51	211	212	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					355	364		10.1016/S0092-8674(00)81767-5	http://dx.doi.org/10.1016/S0092-8674(00)81767-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814706	Green Published, Bronze			2022-12-24	WOS:000076789600009
J	Berger, A				Berger, A			Science commentary: What is fetal nuchal translucency?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	12	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					85	85						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880279				2022-12-24	WOS:000078087500022
J	Kupferminc, MJ; Eldor, A; Steinman, N; Many, A; Bar-Am, A; Jaffa, A; Fait, G; Lessing, JB				Kupferminc, MJ; Eldor, A; Steinman, N; Many, A; Bar-Am, A; Jaffa, A; Fait, G; Lessing, JB			Increased frequency of genetic thrombophilia in women with complications of pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; PLACENTAL PATHOLOGICAL FEATURES; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; VENOUS THROMBOSIS; FETAL LOSS; COMMON MUTATION; PREECLAMPSIA; RESISTANCE	Background Obstetrical complications such as severe preeclampsia, abruptio placentae, fetal growth retardation, and stillbirth are associated with intervillous or spiral-artery thrombosis and inadequate placental perfusion. Whether these complications are associated with an increased frequency of thrombophilic mutations is not known. Methods We studied 110 women who had one of the above-mentioned obstetrical complications and 110 women who had one or more normal pregnancies. The women were tested several days after delivery for the mutation of adenine to guanine at nucleotide 506 in the factor V gene (factor V Leiden), the mutation of cytosine to thymine at nucleotide 677 in the gene encoding methylenetetrahydrofolate reductase, and the mutation of guanine to adenine at nucleotide 20210 in the prothrombin gene. Two to three months after delivery the women were tested for deficiency of protein C, protein S, or antithrombin III and for the presence of anticardiolipin antibodies. Results The mutation at nucleotide 506 in the factor V gene was detected in 22 of the women with obstetrical complications and in 7 of the women with normal pregnancies (20 percent and 6 percent, respectively; P=0.003). Twenty-four women with complications, as compared with nine women without complications, were homozygous for the C677T mutation in the gene encoding methylenetetrahydrofotate reductase (22 percent and 8 percent, respectively; P=0.005). The G20210A mutation in the prothrombin gene was found in 11 women with complications as compared with 3 women without complications (10 percent and 3 percent, respectively; P=0.03). Overall, 57 women with obstetrical complications had a thrombophilic mutation, as compared with 19 women with normal pregnancies (52 percent and 17 percent, respectively; P<0.001). Deficiency of protein S, protein C, or antithrombin ill or anticardiolipin antibodies were detected in an additional 14 women with complications, as compared with 1 woman with a normal pregnancy (13 percent and 1 percent, respectively; P<0.001). Conclusions Women with serious obstetrical complications have an increased incidence of mutations predisposing them to thrombosis and other inherited and acquired forms of thrombophilia. (N Engl J Med 1999;340:9-13.) (C) 1999, Massachusetts Medical Society.	Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Lis Matern Hosp,Dept Obstet & Gynecol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-64239 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Kupferminc, MJ (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Lis Matern Hosp,Dept Obstet & Gynecol, 6 Weizman St, IL-64239 Tel Aviv, Israel.							*AM COLL OBST GYN, 1996, TECHN B AM COLL OBST, V219; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1996, BLOOD, V88, P877; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; CREASY RK, 1994, MATERNAL FETAL MED P, P609; DAHLBACK B, 1994, HAEMOSTASIS, V24, P139; DEKKER GA, 1995, AM J OBSTET GYNECOL, V173, P1042, DOI 10.1016/0002-9378(95)91324-6; deVries JIP, 1997, BRIT J OBSTET GYNAEC, V104, P1248; DizonTownson DS, 1996, AM J OBSTET GYNECOL, V175, P902, DOI 10.1016/S0002-9378(96)80022-6; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P1052; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; KANG SS, 1991, AM J HUM GENET, V48, P536; KHONG TY, 1987, AM J OBSTET GYNECOL, V157, P360, DOI 10.1016/S0002-9378(87)80172-2; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; Lindoff C, 1997, AM J OBSTET GYNECOL, V176, P457, DOI 10.1016/S0002-9378(97)70515-5; Lindqvist PG, 1998, THROMB HAEMOSTASIS, V79, P69; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1049, DOI 10.1016/0002-9378(95)91325-4; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1097, DOI 10.1016/0002-9378(95)91333-5; Seligsohn U, 1997, THROMB HAEMOSTASIS, V78, P297; SHANKLIN DR, 1989, AM J OBSTET GYNECOL, V161, P735, DOI 10.1016/0002-9378(89)90392-X; Sohda S, 1997, J MED GENET, V34, P525, DOI 10.1136/jmg.34.6.525; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801	33	841	880	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					9	13		10.1056/NEJM199901073400102	http://dx.doi.org/10.1056/NEJM199901073400102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155JQ	9878639				2022-12-24	WOS:000077943700002
J	Fitzgerald, FT				Fitzgerald, FT			Curiosity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA	University of California System; University of California Davis	Fitzgerald, FT (corresponding author), Univ Calif Davis, Med Ctr, Dept Internal Med, Box 179002, Sacramento, CA 95817 USA.								0	47	48	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					70	72		10.7326/0003-4819-130-1-199901050-00015	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890857				2022-12-24	WOS:000077744500014
J	Osborn, EHS; Papadakis, MA; Gerberding, JL				Osborn, EHS; Papadakis, MA; Gerberding, JL			Occupational exposures to body fluids among medical students - A seven-year longitudinal study	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE WORKERS; UNIVERSAL PRECAUTIONS; NEEDLESTICK INJURIES; BLOOD; EPIDEMIOLOGY; MANAGEMENT; ABUSE; RISK; HIV	Background: Medical students may be at high risk for occupational exposures to blood. Objective: To measure the frequency of medical students' exposure to infectious body substances, to identify factors that affect the probability of such exposure, and to suggest targets for the prevention of such exposure. Design: Review of all exposures reported by medical students at the University of California, San Francisco, School of Medicine. Setting: Teaching hospitals affiliated with the University of California, San Francisco. Participants: Third- and fourth-year medical students from the classes of 1990 through 1996 at the University of California, San Francisco, School of Medicine. Interventions: A needlestick hotline service was instituted at teaching hospitals affiliated with the University of California, San Francisco, and a required course was created to train students in universal precautions and clinical skills before the beginning of the third-year clerkship. Measurements: Reports of exposures made to the needlestick hotline service, including type of exposure, training site, clerkship, and time of year. Results: 119 of 1022 medical students sustained 129 exposures. Of these exposures, 82% occurred on four services: obstetrics-gynecology, surgery, medicine, and emergency medicine. The probability of exposure was not related to graduation year, clerkship location, previous clerkship experience, or training site. Surveys of two graduating classes at the beginning and end of the study showed that the percentage of exposures reported increased from 45% to 65% over the 7-year study period. Thus, the reported injury rates represent minimum estimates of actual occurrences. Human immunodeficiency virus infection and hepatitis were not reported, although follow-up was limited. Conclusions: Instruction in universal precautions and clinical procedures is not sufficient to prevent exposures to blood during medical training. Medical schools must assume greater responsibility for ensuring that students are proficient in the safe conduct of clinical procedures and must develop systems that protect students so that they can report and learn from their mistakes.	Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30329 USA	Palo Alto Medical Foundation Research Institute; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Osborn, EHS (corresponding author), Palo Alto Med Fdn, 300 Home Ave, Palo Alto, CA 94301 USA.							Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Christakis DA, 1997, JAMA-J AM MED ASSOC, V278, P739, DOI 10.1001/jama.278.9.739; Diekema DJ, 1996, ACAD MED, V71, P1090, DOI 10.1097/00001888-199610000-00016; Diekema DJ, 1996, J GEN INTERN MED, V11, P109, DOI 10.1007/BF02599587; EVANS SE, 1996, 34 ANN M INF DIS SOC; GERBERDING JL, 1995, SURG CLIN N AM, V75, P1091; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Hanrahan A, 1997, J ADV NURS, V25, P144, DOI 10.1046/j.1365-2648.1997.1997025144.x; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEWIS FR, 1995, SURG CLIN N AM, V75, P1105; *LIAIS COMM MED ED, 1995, FUNCT STRUCT MED SCH, P75; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MANSOUR AM, 1990, AM J INFECT CONTROL, V18, P208, DOI 10.1016/0196-6553(90)90186-V; Orenstein R, 1995, AM J INFECT CONTROL, V23, P344, DOI 10.1016/0196-6553(95)90264-3; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; SHEEHAN KH, 1990, JAMA-J AM MED ASSOC, V263, P533, DOI 10.1001/jama.263.4.533; SILVER HK, 1990, JAMA-J AM MED ASSOC, V263, P527, DOI 10.1001/jama.263.4.527; STOTKA JL, 1991, INFECT CONT HOSP EP, V12, P583; Tereskerz PM, 1996, NEW ENGL J MED, V335, P1150, DOI 10.1056/NEJM199610103351512; VERGILIO JA, 1993, ARCH SURG-CHICAGO, V128, P36; 1991, MMWR MORB MORTAL WKL, V40, P1; 1997, MMWR MORB MORTAL WKL, V46, P21	24	90	99	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					45	51		10.7326/0003-4819-130-1-199901050-00009	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890850				2022-12-24	WOS:000077744500008
J	Mughal, MZ; Salama, H; Greenaway, T; Laing, I; Mawer, EB				Mughal, MZ; Salama, H; Greenaway, T; Laing, I; Mawer, EB			Lesson of the week - Florid rickets associated with prolonged breast feeding without vitamin D supplementation	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Cent Manchester Healthcare Trust, Manchester M13 0JH, Lancs, England; Alexandra Practice, Manchester M16 8NG, Lancs, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Mughal, MZ (corresponding author), St Marys Hosp, Cent Manchester Healthcare Trust, Manchester M13 0JH, Lancs, England.		MUGHAL, Zulf/AAA-1230-2021					BROOKE OG, 1981, BRIT J OBSTET GYNAEC, V88, P18, DOI 10.1111/j.1471-0528.1981.tb00931.x; CLEMENS TL, 1982, LANCET, V1, P74; Department of Health, 1991, DIET REF VAL FOOD EN; DUNNIGAN MG, 1985, BMJ-BRIT MED J, V291, P239, DOI 10.1136/bmj.291.6490.239; ELDRISSY ATH, 1984, CALCIFIED TISSUES IN, V36, P266; SPECKER BL, 1985, AM J DIS CHILD, V139, P1134, DOI 10.1001/archpedi.1985.02140130072032	6	66	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					39	40						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872885	Green Published			2022-12-24	WOS:000078013100028
J	Barton, GM; Rudensky, AY				Barton, GM; Rudensky, AY			Requirement for diverse, low-abundance peptides in positive selection of T cells	SCIENCE			English	Article							SELF-PEPTIDES; MICE; RECEPTOR; LIGAND; THYMOCYTES; REPERTOIRE; DEFICIENT; THYMUS	Whether a single major histocompatibility complex (MHC)-bound peptide can drive the positive selection of large numbers of T cells has been-a controversial. issue. A diverse population of self peptides was shown to be essential for the in vivo development of CD4 T cells. Mice in which all but 5 percent of MHC class II molecules were bound by a single peptide had wild-type numbers of CD4 T cells. However, when the diversity within this 5 percent was lost, CD4 T cell development was impaired. Blocking the major peptide-MHC complex in thymus organ culture had no effect on T cell development; indicating that positive selection occurred on the diverse peptides present at low levels, This requirement for peptide diversity indicates that the interaction between self peptides and T cell receptors during positive selection is highly specific.	Univ Washington, Howard Hughes Med Inst, Sch Med, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rudensky, AY (corresponding author), Univ Washington, Howard Hughes Med Inst, Sch Med, Box 357370, Seattle, WA 98195 USA.			Barton, Gregory/0000-0002-3793-0100				Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BARTON G, UNPUB; Barton GM, 1998, INT IMMUNOL, V10, P1159, DOI 10.1093/intimm/10.8.1159; Benoist C, 1997, CURR OPIN IMMUNOL, V9, P245, DOI 10.1016/S0952-7915(97)80143-4; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; DENZIN L, COMMUNICATION; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; FOWLKES BJ, 1995, CURR OPIN IMMUNOL, V7, P188, DOI 10.1016/0952-7915(95)80003-4; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; Hogquist KA, 1997, IMMUNITY, V6, P389, DOI 10.1016/S1074-7613(00)80282-4; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hu QH, 1997, IMMUNITY, V7, P221, DOI 10.1016/S1074-7613(00)80525-7; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kovats S, 1998, J EXP MED, V187, P245, DOI 10.1084/jem.187.2.245; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; Marrack P, 1997, CURR OPIN IMMUNOL, V9, P250, DOI 10.1016/S0952-7915(97)80144-6; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; Tourne S, 1997, P NATL ACAD SCI USA, V94, P9255, DOI 10.1073/pnas.94.17.9255; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; WONG P, UNPUB; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83	32	93	92	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					67	70		10.1126/science.283.5398.67	http://dx.doi.org/10.1126/science.283.5398.67			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872742				2022-12-24	WOS:000077976600050
J	Iyer, VR; Eisen, MB; Ross, DT; Schuler, G; Moore, T; Lee, JCF; Trent, JM; Staudt, LM; Hudson, J; Boguski, MS; Lashkari, D; Shalon, D; Botstein, D; Brown, PO				Iyer, VR; Eisen, MB; Ross, DT; Schuler, G; Moore, T; Lee, JCF; Trent, JM; Staudt, LM; Hudson, J; Boguski, MS; Lashkari, D; Shalon, D; Botstein, D; Brown, PO			The transcriptional program in the response of human fibroblasts to serum	SCIENCE			English	Article							GENE-EXPRESSION PATTERNS; SYNCHRONIZATION; MICROARRAY	The temporal program of gene expression during a model physiological response of human cells, the response of fibroblasts to serum, was explored with a complementary DNA microarray representing about 8600 different human genes. Genes could be clustered into groups on the basis of their temporal patterns of expression in this program. Many features of the transcriptional program appeared to be related to the physiology of wound repair, suggesting that fibroblasts play a larger and richer role in this complex multicellular response than had previously been appreciated.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Res Genet Inc, Huntsville, AL 35801 USA; Incyte Pharmaceut, Fremont, CA 94555 USA; Natl Human Genome Res Inst, Canc Genet Lab, NIH, Bethesda, MD 20892 USA; NCI, Metab Branch, Div Clin Sci, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Incyte; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.		Staudt, Louis/AAC-5324-2019	Shalon, Tidhar Dari/0000-0003-2646-6215; Eisen, Michael/0000-0002-7528-738X	NCI NIH HHS [CA 77097] Funding Source: Medline; NHGRI NIH HHS [T32 HG00450, HG00450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450, R01HG000450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KREK W, 1995, METHOD ENZYMOL, V254, P114; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEPPALUOTO J, 1992, ANN MED, V24, P153, DOI 10.3109/07853899209147813; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41	15	1590	1671	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					83	87		10.1126/science.283.5398.83	http://dx.doi.org/10.1126/science.283.5398.83			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872747				2022-12-24	WOS:000077976600055
J	Xoconostle-Cazares, B; Yu, X; Ruiz-Medrano, R; Wang, HL; Monzer, J; Yoo, BC; McFarland, KC; Franceschi, VR; Lucas, WJ				Xoconostle-Cazares, B; Yu, X; Ruiz-Medrano, R; Wang, HL; Monzer, J; Yoo, BC; McFarland, KC; Franceschi, VR; Lucas, WJ			Plant paralog to viral movement protein that potentiates transport of mRNA into the phloem	SCIENCE			English	Article							CELL-TO-CELL; TOBACCO PLANTS; PLASMODESMATA; TRAFFICKING; RNA; PATTERNS	CmPP16 from Cucurbita maxima was cloned and the protein was shown to possess properties similar to those of viral movement proteins. CmPP16 messenger RNA (mRNA) is present in phloem tissue, whereas protein appears confined to sieve elements (SE). Microinjection and grafting studies revealed that CmPP16 moves from cell to cell, mediates the transport of sense and antisense RNA, and moves together with its mRNA into the SE of scion tissue. CmPP16 possesses the characteristics that are likely required to mediate RNA delivery into the long-distance translocation stream. Thus, RNA may move within the phloem as a component of a plant information superhighway.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Washington State Univ, Ctr Electron Microscopy, Pullman, WA 99164 USA	University of California System; University of California Davis; Washington State University	Lucas, WJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA.							Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; Esau K., 1969, ENCY PLANT ANATOMY, V5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FISHER J, 1992, NEW THEAT Q, V8, P100; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Itaya A, 1997, PLANT J, V12, P1223, DOI 10.1046/j.1365-313X.1997.12051223.x; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kopka J, 1998, PLANT MOL BIOL, V36, P627, DOI 10.1023/A:1005915020760; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LOMMEL SA, 1988, NUCLEIC ACIDS RES, V16, P8587, DOI 10.1093/nar/16.17.8587; Lough TJ, 1998, MOL PLANT MICROBE IN, V11, P801, DOI 10.1094/MPMI.1998.11.8.801; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; Sambrook J., 1989, MOL CLONING; TIEDEMANN R, 1994, J PLANT PHYSIOL, V143, P189, DOI 10.1016/S0176-1617(11)81685-8; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Wang HL, 1998, VIROLOGY, V245, P75, DOI 10.1006/viro.1998.9154	30	362	397	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					94	98		10.1126/science.283.5398.94	http://dx.doi.org/10.1126/science.283.5398.94			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872750				2022-12-24	WOS:000077976600058
J	Callister, TQ; Raggi, P; Cooil, B; Lippolis, NJ; Russo, DJ				Callister, TQ; Raggi, P; Cooil, B; Lippolis, NJ; Russo, DJ			Effect of HMG-Coa reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	70th Scientific Session of the American-Heart-Association Meeting	NOV 09-13, 1997	ORLANDO, FLORIDA	Amer Heart Assoc			ELEVATED SERUM-CHOLESTEROL; HEART-DISEASE; RISK-FACTORS; DENSITY-LIPOPROTEIN; HELICOBACTER-PYLORI; ATHEROSCLEROSIS; CALCIFICATION; PROGRESSION; REGRESSION; REPRODUCIBILITY	Background Angiographic studies of the regression of coronary artery disease are invasive and costly, and they permit only limited assessment of changes in the extent of atherosclerotic disease. Electron-beam computed tomography (CT) is noninvasive and inexpensive. The entire coronary-artery tree can be studied during a single imaging session, and the volume of coronary calcification as quantified with this technique correlates closely with the total burden of atherosclerotic plaque. Methods We conducted a retrospective study of 149 patients (61 percent men and 39 percent women; age range, 32 to 75 years) with no history of coronary artery disease who were referred by their primary care physicians for screening electron-beam CT. All patients underwent base-line scanning and follow-up assessment after a minimum of 12 months (range, 12 to 15), and a volumetric calcium score was calculated as an estimate of the total burden of plaque. Treatment with 3-hydroxy3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors was begun at the discretion of the referring physician. Serial measurements of low-density lipoprotein (LDL) cholesterol were obtained, and the change in the calcium-volume score was correlated with average LDL cholesterol levels. Results One hundred five patients (70 percent) received treatment with HMG-CoA reductase inhibitors, and 44 patients (30 percent) did not. At followup, a net reduction in the calcium-volume score was observed only in the 65 treated patients whose final LDL cholesterol levels were less than 120 mg per deciliter (3.10 mmol per liter) (mean [+/-SD] change in the score, -7+/-23 percent; P=0.01). Untreated patients had an average LDL cholesterol level of at least 120 mg per deciliter and at the time of follow-up had a significant net increase in mean calcium-volume score (mean change, +52+/-36 percent; P<0.001). The 40 treated patients who had average LDL cholesterol levels of at least 120 mg per deciliter had a measurable increase in mean calcium-volume score (mean change, +25+/-22 percent, P<0.001), although it was smaller than the increase in the untreated patients. Conclusions The extent to which the volume of atherosclerotic plaque decreased, stabilized, or increased was directly related to treatment with HMG-CoA reductase inhibitors and the resulting serum LDL cholesterol levels. These changes can be determined noninvasively by electron-beam CT and quantified with use of a calcium-volume score. (N Engl J Med 1998;339:1972-8.) (C) 1998, Massachusetts Medical Society.	Electron Beam Tomog Res Fdn, Nashville, TN USA; Vanderbilt Univ, Nashville, TN USA	Vanderbilt University	Raggi, P (corresponding author), EBT Res Fdn, 64 Valleybrook Dr, Hendersonville, TN 37075 USA.		Cooil, Bruce/X-8664-2019; Cooil, Bruce/B-1004-2009	Cooil, Bruce/0000-0002-1276-269X				AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BREEN JF, 1992, RADIOLOGY, V185, P435, DOI 10.1148/radiology.185.2.1410350; BROWN BG, 1995, ANN NY ACAD SCI, V748, P407; Callister TQ, 1998, RADIOLOGY, V208, P807, DOI 10.1148/radiology.208.3.9722864; CLARKSON TB, 1994, JAMA-J AM MED ASSOC, V271, P289, DOI 10.1001/jama.271.4.289; Cobbaert C, 1997, J AM COLL CARDIOL, V30, P1491, DOI 10.1016/S0735-1097(97)00353-7; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; DEVRIES S, 1995, AM J CARDIOL, V75, P973, DOI 10.1016/S0002-9149(99)80706-1; FROHLICH JJ, 1995, CAN J CARDIOL, V11, pC18; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; GOULD KL, 1994, CIRCULATION, V90, P1558, DOI 10.1161/01.CIR.90.3.1558; HATANAKA K, 1995, PATHOL INT, V45, P635, DOI 10.1111/j.1440-1827.1995.tb03515.x; Herd JA, 1997, AM J CARDIOL, V80, P278, DOI 10.1016/S0002-9149(97)00346-9; Hernigou A, 1996, EUR RADIOL, V6, P210; Holvoet P, 1997, CURR OPIN LIPIDOL, V8, P320, DOI 10.1097/00041433-199710000-00012; JANOWITZ WR, 1993, AM J CARDIOL, V72, P247, DOI 10.1016/0002-9149(93)90668-3; JANOWITZ WR, 1991, AM J CARDIOL, V68, P1, DOI 10.1016/0002-9149(91)90700-U; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KAJINAMI K, 1993, CORONARY ARTERY DIS, V4, P1103, DOI 10.1097/00019501-199312000-00011; LARSEN RJ, 1997, STAT APPL PROBLEM SO, P633; Levenson J, 1997, ARTERIOSCL THROM VAS, V17, P45, DOI 10.1161/01.ATV.17.1.45; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; *MAAS INV, 1994, LANCET, V344, P762; MAUTNER GC, 1994, RADIOLOGY, V192, P619, DOI 10.1148/radiology.192.3.8058924; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; OLIVER MF, 1994, LANCET, V344, P633; PACKARD CJ, 1997, CIRCULATION S1, V96, P107; Pasceri V, 1998, CIRCULATION, V97, P1675, DOI 10.1161/01.CIR.97.17.1675; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PATEL P, 1995, BRIT MED J, V311, P985; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; RAYA SP, 1990, IEEE T MED IMAGING, V9, P32, DOI 10.1109/42.52980; RAYA SP, 1990, COMPUT MED IMAG GRAP, V14, P353, DOI 10.1016/0895-6111(90)90109-O; RAYA SP, 1990, IEEE T MED IMAGING, V9, P327, DOI 10.1109/42.57771; RUMBERGER JA, 1995, CIRCULATION, V92, P2157, DOI 10.1161/01.CIR.92.8.2157; RUMBERGER JA, 1994, CIRCULATION, V90, P300; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; Sangiorgi G, 1998, J AM COLL CARDIOL, V31, P126, DOI 10.1016/S0735-1097(97)00443-9; SANGIORGI G, 1995, J AM COLL CARDIOL, V25, pA386; Schmermund A, 1998, J AM COLL CARDIOL, V31, P1267, DOI 10.1016/S0735-1097(98)00082-5; SIMONS DB, 1992, J AM COLL CARDIOL, V20, P1118, DOI 10.1016/0735-1097(92)90367-V; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; SUPERKO HR, 1995, CURR OPIN CARDIOL, V10, P347, DOI 10.1097/00001573-199507000-00002; SUPERKO HR, 1994, CIRCULATION, V90, P1056, DOI 10.1161/01.CIR.90.2.1056; TANENBAUM SR, 1989, AM J CARDIOL, V63, P870, DOI 10.1016/0002-9149(89)90060-X; Wang SJ, 1996, AM HEART J, V132, P550, DOI 10.1016/S0002-8703(96)90237-9; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1995, CAN J CARDIOL, V11, pG110; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	52	564	577	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1972	1978		10.1056/NEJM199812313392703	http://dx.doi.org/10.1056/NEJM199812313392703			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	152XX	9869668				2022-12-24	WOS:000077803800003
J	Takechi, H; Eilers, J; Konnerth, A				Takechi, H; Eilers, J; Konnerth, A			A new class of synaptic response involving calcium release in dendritic spines	NATURE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; CENTRAL-NERVOUS-SYSTEM; INOSITOL TRISPHOSPHATE; NEURONS; MGLUR1; RAT; PLASTICITY; CURRENTS	In the classical view, transmission of signals across synapses in the mammalian brain involves changes in the membrane potential of the postsynaptic cell. The use of high-resolution cellular imaging has revealed excitatory synapses at which postsynaptic, transient alterations in calcium ion concentration are tightly associated with electrical responses (reviewed in ref. 1). Here, by investigating the synapse between parallel glutamatergic fibres and Purkinje cells in the mouse cerebellum, we identify a class of postsynaptic responses that consist of transient increases in dendritic Ca2+ concentration but not changes in somatic membrane potential. Our results indicate that these synaptic Ca2+ transients are mediated by activation of metabotropic glutamate-responsive mGluR1-type receptors(2-4) and require inositol-1,4,5-trisphosphate-mediated Ca2+ release(5,6) from to postsynaptic microdomains, which range, depending on the frequency of stimulation, from individual spines to small spinodendritic compartments. Thus, the synaptic Ca2+-release signal may be one of the critical cues that determine the input specificity of longterm depression, a well-established form of activity-dependent plasticity at these synapses(7-9).	Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany	Saarland University	Konnerth, A (corresponding author), Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany.		Eilers, Jens/E-6251-2012	Eilers, Jens/0000-0003-0497-5625				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BATCHELOR AM, 1993, NEUROPHARMACOLOGY, V32, P11, DOI 10.1016/0028-3908(93)90124-L; Batchelor AM, 1997, NATURE, V385, P74, DOI 10.1038/385074a0; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Eilers J, 1997, CURR OPIN NEUROBIOL, V7, P385, DOI 10.1016/S0959-4388(97)80067-0; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; EILERS J, 1997, PFLUGERS ARCH S, V433, P549; FRENGUELLI BG, 1993, NEUROPHARMACOLOGY, V32, P1229, DOI 10.1016/0028-3908(93)90017-W; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Ito M., 1984, CEREBELLUM NEURONAL; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; Khodakhah K, 1997, BIOPHYS J, V73, P3349, DOI 10.1016/S0006-3495(97)78359-0; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; Korkotian E, 1998, EUR J NEUROSCI, V10, P2076, DOI 10.1046/j.1460-9568.1998.00219.x; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; TAKEI K, 1992, J NEUROSCI, V12, P489	30	333	337	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 31	1998	396	6713					757	760		10.1038/25547	http://dx.doi.org/10.1038/25547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874373				2022-12-24	WOS:000077742800034
J	Krautwurst, D; Yau, KW; Reed, RR				Krautwurst, D; Yau, KW; Reed, RR			Identification of ligands for olfactory receptors by functional expression of a receptor library	CELL			English	Article							CYCLOPHILIN HOMOLOG NINAA; ODORANT RECEPTORS; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; PROTEIN; CHANNEL; CELLS; RHODOPSINS; EPITHELIUM; NEURONS	The recognition of odorants by olfactory receptors represents the first stage in odor discrimination. Here, we report the generation of an expression library containing a large and diverse repertoire of mouse olfactory receptor sequences in the transmembrane Il-VII region. From this library, 80 chimeric receptors were tested against 26 odorants after transfection into HEK-293 cells. Three receptors were identified to respond to micromolecular concentrations of carvene, (-) citronellal, and limonene, respectively. We also found that the mouse 17 receptor, unlike the rat 17 receptor, prefers heptanal instead of octanal, as a result of a single valine-to-isoleucine substitution. This finding represents the beginning of a molecular understanding of odorant recognition. The identification, on a large scale, of cognate receptor-odorant interactions should provide insight into olfactory coding mechanisms.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Reed, RR (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Reed, Russell/HGU-0528-2022; Krautwurst, Dietmar/AAD-5579-2019	Krautwurst, Dietmar/0000-0002-3350-8682				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARGRAVE PA, 1986, EXP EYE RES, V42, P363, DOI 10.1016/0014-4835(86)90030-8; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; Qasba P, 1998, J NEUROSCI, V18, P227; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SCHILD D, 1995, J NEUROPHYSIOL, V73, P862, DOI 10.1152/jn.1995.73.2.862; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	40	473	518	2	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					917	926		10.1016/S0092-8674(00)81716-X	http://dx.doi.org/10.1016/S0092-8674(00)81716-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875846	hybrid			2022-12-24	WOS:000077759100007
J	Wenzel, SE				Wenzel, SE			Antileukotriene drugs in the management of asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RECEPTOR ANTAGONIST; INDUCED BRONCHOCONSTRICTION; INFLAMMATION; INHIBITION; POTENT; MK-571; TRIAL		Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wenzel, SE (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	wenzels@njc.org						Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; *NIH, 1997, 2 NIH; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P347, DOI 10.1016/S1081-1206(10)63195-X; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; Virchow J. C., 1997, European Respiratory Journal Supplement, V10, p437S; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Wenzel S, 1997, AM J RESP CRIT CARE, V155, pA203; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112	22	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2068	2069		10.1001/jama.280.24.2068	http://dx.doi.org/10.1001/jama.280.24.2068			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875862				2022-12-24	WOS:000077606100013
J	Hira, K; Fukui, T; Endoh, A; Rahman, M; Maekawa, M				Hira, K; Fukui, T; Endoh, A; Rahman, M; Maekawa, M			Influence of superstition on the date of hospital discharge and medical cost in Japan: retrospective and descriptive study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	2nd Asian-Pacific Congress of Epidemiology	JAN   28, 1998	TOKYO, JAPAN				PLACEBO	Objectives To determine the influence of superstition about Taian (a lucky day)-Butsumetsu tan unlucky day) on decision to leave hospital. To estimate the costs of the effect of this superstition. Design Retrospective and descriptive study. Setting University hospital in Kyoto,Japan. Subjects Patients who were discharged alive from Kyoto University Hospital from 1 April 1992 to 31 March 1995, Main outcome measures Mean number, age, and hospital stay of patients discharged on each day of six day cycle. Results The mean number, age, and hospital stay of discharged patients were highest on Taian and lowest on Butsumetsu (25.5 v 19.3 patients/day, P = 0.0001; 43.9 v 41.4 years, P = 0.0001; and 43.1 v 33.3 days, P = 0.0001 respectively). The effect of this difference on the hospital's costs was estimated to be 7.4 million yen (pound 31 000). Conclusion The superstition influenced the decision to leave hospital, contributing to higher medical care costs in Japan. Although hospital stays need to be kept as short as possible to minimise costs, doctors should not ignore the possible psychological effects on patients' health caused by dismissing the superstition.	Kyoto Univ, Dept Gen Med & Clin Epidemiol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Human & Environm Studies, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Hira, K (corresponding author), Kyoto Univ, Dept Gen Med & Clin Epidemiol, Sakyo Ku, Kyoto 6068507, Japan.							BLACHER RS, 1983, GEN HOSP PSYCHIAT, V5, P279, DOI 10.1016/0163-8343(83)90007-5; DOBRILLA G, 1994, DIGEST DIS, V12, P368, DOI 10.1159/000171471; EDWARD A, 1990, HUM BEHAV, P64; KAKU K, 1975, AM J PUBLIC HEALTH, V65, P170, DOI 10.2105/AJPH.65.2.170; KAKU K, 1972, SOC BIOL, V19, P60, DOI 10.1080/19485565.1972.9987966; KAKU K, 1975, ANN HUM BIOL, V2, P391, DOI 10.1080/03014467500001011; KAKU K, 1975, ANN HUM BIOL, V2, P111, DOI 10.1080/03014467500000651; KIM YS, 1979, J BIOSOC SCI, V11, P457, DOI 10.1017/S0021932000012530; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; *ORG EC COOP DEV, 1993, OECD HLTH SYST FACTS, P215; REISS RE, 1988, OBSTET GYNECOL, V71, P270; SCANLON TJ, 1993, BRIT MED J, V307, P1584, DOI 10.1136/bmj.307.6919.1584; SCOTT R, 1994, BRIT MED J, V309, P1691, DOI 10.1136/bmj.309.6970.1691; *STAT INF DEP, 1993, PAT SURV, P566; *SURV DEP I SOC IN, 1997, DRUG TAR; UCHIDA M, 1991, CALENDARS TALE 12 MO, P106	17	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1680	1683		10.1136/bmj.317.7174.1680	http://dx.doi.org/10.1136/bmj.317.7174.1680			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	151VX	9857123	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000077742300009
J	Douek, DC; McFarland, RD; Keiser, PH; Gage, EA; Massey, JM; Haynes, BF; Polis, MA; Haase, AT; Feinberg, MB; Sullivan, JL; Jamieson, BD; Zack, JA; Picker, LJ; Koup, RA				Douek, DC; McFarland, RD; Keiser, PH; Gage, EA; Massey, JM; Haynes, BF; Polis, MA; Haase, AT; Feinberg, MB; Sullivan, JL; Jamieson, BD; Zack, JA; Picker, LJ; Koup, RA			Changes in thymic function with age and during the treatment of HIV infection	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELLS; V(D)J RECOMBINATION; LYMPHOCYTES; CD4+; THYMOPOIESIS; REGENERATION; PRODUCTS; THERAPY; VIRGIN	The thymus represents the major site of the production and generation of T cells expressing alpha beta-type T-cell antigen receptors(1). Age-related involution(2) may affect the ability of the thymus to reconstitute T cells expressing CD4 cell-surface antigens that are lost during HIV infection(3); this effect has been seen after chemotherapy and bone-marrow transplantation(4,5). Adult HIV-infected patients treated with highly active antiretroviral therapy (HAART) show a progressive increase in their number of naive CD4-positive T cells(6,7). These cells could arise through expansion of existing naive T cells in the periphery(8) or through thymic production of new naive T cells(9,10). Here we quantify thymic output by measuring the excisional DNA products of TCR-gene rearrangement. We find that, although thymic function declines with age, substantial output is maintained into late adulthood. HIV infection leads to a decrease in thymic function that can be measured in the peripheral blood and lymphoid tissues. In adults treated with HAART, there is a rapid and sustained increase in thymic output in most subjects. These results indicate that the adult thymus fan contribute to immune reconstitution following HAART.	Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; NIAID, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Univ Massachusetts, Med Ctr, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Mol Med, Worcester, MA 01605 USA; Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; UCLA Inst, Los Angeles, CA 90095 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; Emory University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Koup, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Polis, Michael/0000-0002-9151-2268				ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; Chun TW, 1997, J VIROL, V71, P4436, DOI 10.1128/JVI.71.6.4436-4444.1997; COSSARIZZA A, 1992, J IMMUNOL RES-ITALY, V4, P118; Dybul M, 1998, J CLIN INVEST, V101, P2299, DOI 10.1172/JCI3929; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HAYNES B, UNPUB J CLIN INVEST; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; Livak F, 1996, MOL CELL BIOL, V16, P609; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PETRIE HT, 1995, J EXP MED, V182, P121, DOI 10.1084/jem.182.1.121; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PICKER L, 1995, FUNDAMENTAL IMMUNOLO, P145; PICKER LJ, 1993, J IMMUNOL, V150, P1105; SCHNITTMAN SM, 1990, T ASSOC AM PHYSICIAN, V103, P96; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; Steinmann G G, 1986, Curr Top Pathol, V75, P43; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; WithersWard ES, 1997, NAT MED, V3, P1102, DOI 10.1038/nm1097-1102; Wykrzykowska JJ, 1998, J EXP MED, V187, P1767, DOI 10.1084/jem.187.11.1767; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	30	1452	1543	2	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					690	695		10.1038/25374	http://dx.doi.org/10.1038/25374			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872319				2022-12-24	WOS:000077694200057
J	Kaupmann, K; Malitschek, B; Schuler, V; Heid, J; Froest, W; Beck, P; Mosbacher, J; Bischoff, S; Kulik, A; Shigemoto, R; Karschin, A; Bettler, B				Kaupmann, K; Malitschek, B; Schuler, V; Heid, J; Froest, W; Beck, P; Mosbacher, J; Bischoff, S; Kulik, A; Shigemoto, R; Karschin, A; Bettler, B			GABA(B)-receptor subtypes assemble into functional heteromeric complexes	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; RECTIFYING K+ CHANNELS; GABA(B) RECEPTORS; BINDING; NEURONS	B-type receptors for the neurotransmitter GABA (gamma-aminobutyric acid) inhibit neuronal activity through G-protein-coupled second-messenger systems, which regulate the release of neurotransmitters and the activity of ion channels and adenylyl cyclase(1). Physiological and biochemical studies show that there are differences in drug efficiencies at different GABA(B) receptors, so it is expected that GABA(B)-receptor (GABA(B)R) subtypes exist(2). Two GABA(B)-receptor splice variants have been cloned(3) (GABA(B)R1a and GABA(B)R1b), but native GABA(B) receptors and recombinant receptors showed unexplained differences in agonist-binding potencies. Moreover, the activation of presumed effector ion channels in heterologous cells expressing the recombinant receptors proved difficult(3-4). Here we describe a new GABA(B) receptor subtype, GABA(B)R2, which does not bind available GABA(B) antagonists with measurable potency. GABA(B)R1a, GABA(B)R1b and GABA(B)R2 alone do not activate Kir3-type potassium channels efficiently, but co-expression of these receptors yields a robust coupling to activation of Kir3 channels. We provide evidence for the assembly of heteromeric GABA(B) receptors in vivo and show that GABA(B)R2 and GABA(B)R1a/b proteins immunoprecipitate and localize together at dendritic spines. The heteromeric receptor complexes exhibit a significant increase in agonist- and partial-agonist-binding potencies as compared with individual receptors and probably represent the predominant native GABA(B) receptor. Heteromeric assembly among G-protein-coupled receptors has not, to our knowledge, been described before.	Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland; Kyoto Univ, Fac Med, Dept Morphol Brain Sci, Kyoto 606, Japan; Max Planck Inst Biophys Chem, D-37030 Gottingen, Germany	Novartis; Kyoto University; Max Planck Society	Bettler, B (corresponding author), Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland.		Shigemoto, Ryuichi/E-3628-2013; bettler, bernhard/AAO-8018-2020	Shigemoto, Ryuichi/0000-0001-8761-9444; Bettler, Bernhard/0000-0003-0842-8207; Kaupmann, Klemens/0000-0001-8903-2508				Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; Bischoff S, 1997, J COMP NEUROL, V379, P541, DOI 10.1002/(SICI)1096-9861(19970324)379:4<541::AID-CNE6>3.0.CO;2-2; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; HILL DR, 1984, J NEUROCHEM, V42, P652, DOI 10.1111/j.1471-4159.1984.tb02732.x; INOUE M, 1985, BRIT J PHARMACOL, V84, P843, DOI 10.1111/j.1476-5381.1985.tb17378.x; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KAUPMANN K, IN PRESS P NATL ACAD; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KERR DIB, 1995, PHARMACOL THERAPEUT, V67, P187, DOI 10.1016/0163-7258(95)00016-A; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Malitschek B, 1998, MOL CELL NEUROSCI, V12, P56, DOI 10.1006/mcne.1998.0698; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Morris SJ, 1998, J NEUROCHEM, V71, P1329; Mosbacher J, 1998, FEBS LETT, V436, P104, DOI 10.1016/S0014-5793(98)01066-7; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Slesinger PA, 1997, P NATL ACAD SCI USA, V94, P12210, DOI 10.1073/pnas.94.22.12210; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Uezono Y, 1998, NEUROREPORT, V9, P583, DOI 10.1097/00001756-199803090-00004; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614	25	944	996	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					683	687		10.1038/25360	http://dx.doi.org/10.1038/25360			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872317				2022-12-24	WOS:000077694200055
J	Lasky, T; Terracciano, GJ; Magder, L; Koski, CL; Ballesteros, M; Nash, D; Clark, S; Haber, P; Stolley, PD; Schonberger, LB; Chen, RT				Lasky, T; Terracciano, GJ; Magder, L; Koski, CL; Ballesteros, M; Nash, D; Clark, S; Haber, P; Stolley, PD; Schonberger, LB; Chen, RT			The Guillain-Barre syndrome and the 1993 and 1993-1994 influenza vaccines	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; VACCINATION; ASSOCIATION	Background The number of reports of influenza-vaccine-associated Guillain-Barre syndrome to the national Vaccine Adverse Event Reporting System increased from 37 in 1992-1993 to 74 in 1993-1994, arousing concern about a possible increase in vaccine-associated risk. Methods Patients given a diagnosis of the Guillain-Barre syndrome in the 1992-1993 and 1993-1994 influenza-vaccination seasons were identified in the hospital-discharge data bases of four states. Vaccination histories were obtained by telephone interviews during 1995-1996 and were confirmed by the vaccine providers. Disease with an onset within six weeks after vaccination was defined as vaccine-associated. Vaccine coverage in the population was measured through a random-digit-dialing telephone survey. Results We interviewed 180 of 273 adults with the Guillain-Barre syndrome; 15 declined to participate, and the remaining 78 could not be contacted. The vaccine providers confirmed influenza vaccination in the six weeks before the onset of Guillain-Barre syndrome for 19 patients. The relative risk of the Guillain-Barre syndrome associated with vaccination, adjusted for age, sex, and vaccine season, was 1.7 (95 percent confidence interval, 1.0 to 2.8; P=0.04). The adjusted relative risks were 2.0 for the 1992-1993 season (95 percent confidence interval, 1.0 to 4.3) and 1.5 for the 1993-1994 season (95 percent confidence interval, 0.8 to 2.9). In 9 of the 19 vaccine-associated cases, the onset was in the second week after vaccination, all between day 9 and day 12. Conclusions There was no increase in the risk of vaccine-associated Guillain-Barre syndrome from 1992-1993 to 1993-1994. For the two seasons combined, the adjusted relative risk of 1.7 suggests slightly more than one additional case of Guillain-Barre syndrome per million persons vaccinated against influenza. (N Engl J Med 1998;339:1797-802.) (C) 1998, Massachusetts Medical Society.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Ctr Dis Control & Prevent, Vaccine Safety & Dev Act Epidemiol & Surveillance, Natl Immunizat Program, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Lasky, T (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St, Baltimore, MD 21201 USA.		Lasky, Tamar/AAR-3410-2021; Nash, Denis/AFI-7485-2022; Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367; Nash, Denis/0000-0002-3280-5386	PHS HHS [U50/CCU 300860-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; ASBURY AK, 1981, ANN NEUROL, V9, P1, DOI 10.1002/ana.410090703; BREMAN JG, 1984, AM J EPIDEMIOL, V119, P880, DOI 10.1093/oxfordjournals.aje.a113810; Chen R, 1992, POST MARKETING SURVE, V6, P5; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; CHEN RT, 1994, PHARMACOEPIDEM DR S, P581; *DHHS, 1980, DHHS PUBL, V1; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; HURWITZ ES, 1981, NEW ENGL J MED, V304, P1557, DOI 10.1056/NEJM198106253042601; Johnston Jr RB, 1994, ADVERSE EVENTS ASS C, P464; KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698; KOOBATIAN TJ, 1991, ANN NEUROL, V30, P618, DOI 10.1002/ana.410300418; KOSKI CL, 1992, NEUROL CLIN, V10, P629, DOI 10.1016/S0733-8619(18)30201-9; KOSKI CL, 1994, SEMIN NEUROL, V14, P123, DOI 10.1055/s-2008-1041069; LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809; *MACR INT, 1995, RAP ASS INFL VACC US; MARKS JS, 1980, JAMA-J AM MED ASSOC, V243, P2490, DOI 10.1001/jama.243.24.2490; Ropper AH., 1991, CONT NEUROLOGY SERIE, P73; ROSCELLI JD, 1991, AM J EPIDEMIOL, V133, P952, DOI 10.1093/oxfordjournals.aje.a115974; RUBIN DB, 1986, J AM STAT ASSOC, V81, P366, DOI 10.2307/2289225; SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; *US BUR CENS, 1992, RPOTU REG STAT SEL A; *US BUR CENS, 1993, RPOTU REG STAT SEL A; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; 1997, MMWR MORB MORTAL WKL, V46, P913; 1997, MMWR MORB MORTAL WKL, V46, P974	30	356	372	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1797	1802		10.1056/NEJM199812173392501	http://dx.doi.org/10.1056/NEJM199812173392501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854114	Green Published			2022-12-24	WOS:000077545800001
J	Ginsberg, JS; Wells, PS; Kearon, C; Anderson, D; Crowther, M; Weitz, JI; Bormanis, J; Brill-Edwards, P; Turpie, AG; MacKinnon, B; Gent, M; Hirsh, J				Ginsberg, JS; Wells, PS; Kearon, C; Anderson, D; Crowther, M; Weitz, JI; Bormanis, J; Brill-Edwards, P; Turpie, AG; MacKinnon, B; Gent, M; Hirsh, J			Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article						sensitivity and specificity; pulmonary embolism; D-dimer assay; ventilation-perfusion ratio; ultrasonography	FIBRIN DEGRADATION PRODUCTS; DEEP-VEIN THROMBOSIS; PERFUSION LUNG-SCAN; SIMPLIRED-D-DIMER; VENOUS THROMBOSIS; PLASMA; AID	Background: Patients with suspected pulmonary embolism often have nondiagnostic lung scans and may present in circumstances where lung scanning is unavailable. Levels of D-dimer, a fibrin-specific product, are increased in patients with a cute thrombosis; this may simplify the diagnosis of pulmonary embolism. Objective: To determine the sensitivity and specificity of a whole-blood D-dimer assay in patients with suspected pulmonary embolism and in subgroups of patients with low pretest probability of pulmonary embolism or nondiagnostic lung scans. Design: Prospective cohort. Setting: Four tertiary care hospitals. Patients: 1177 consecutive patients with suspected pulmonary embolism. Measurements: All patients underwent an assessment of pretest probability by use of a standardized clinical model, a D-dimer assay, ventilation-perfusion lung scanning, and bilateral compression ultrasonography. Patients in whom pulmonary embolism was not initially diagnosed were followed for 3 months. Accordingly, patients were categorized as positive or negative for pulmonary embolism. Results: Of the 1177 patients, 197 (17%) were classified as positive for pulmonary embolism. Overall, the D-dimer assay showed a sensitivity of 84.8% and a specificity of 68.4%. In 703 patients (3.4%) with a low pretest probability of pulmonary embolism, the likelihood ratio associated with a negative D-dimer test result was 0.27, resulting in a posterior probability of 1.0% (95% CI, 0.3% to 2.2%). In 698 patients with nondiagnostic lung scans (previous probability, 7.4%), the likelihood ratio associated with a negative D-dimer test result was 0.36, resulting in a posterior probability of 2.8% (CI, 1.4% to 4.8%). Conclusions: A normal D-dimer test result is useful in excluding pulmonary embolism in patients with a low pretest probability of pulmonary embolism or a nondiagnostic lung scan.	McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; Dalhousie Univ, Halifax, NS, Canada; Univ Ottawa, Ottawa, ON, Canada	McMaster University; Dalhousie University; University of Ottawa	Ginsberg, JS (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,Room 3W15, Hamilton, ON L8N 3Z5, Canada.		Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				BELL WR, 1977, AM J MED, V62, P355, DOI 10.1016/0002-9343(77)90832-4; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BOUNAMEAUX H, 1989, AM J CLIN PATHOL, V91, P82, DOI 10.1093/ajcp/91.1.82; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRENNER B, 1993, THROMB HAEMOSTASIS, V69, P832; DEMERS C, 1992, THROMB HAEMOSTASIS, V67, P408; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; GINSBERG JS, 1993, CHEST, V104, P1679, DOI 10.1378/chest.104.6.1679; GOLDHABER SZ, 1988, AM HEART J, V116, P505, DOI 10.1016/0002-8703(88)90625-4; HEATON DC, 1987, J LAB CLIN MED, V110, P588; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; PETZER H, 1988, THROMB HAEMOSTASIS, V59, P101; ROWBOTHAM BJ, 1987, THROMB HAEMOSTASIS, V57, P59; SHAUKAT N, 1993, THROMB HAEMOSTASIS, V69, P839; Turkstra F, 1998, THROMB HAEMOSTASIS, V79, P91; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; WELLS PS, 1993, BLOOD, V82, P407	25	187	198	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1006	+		10.7326/0003-4819-129-12-199812150-00003	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867754				2022-12-24	WOS:000077471900002
J	Huxford, T; Huang, DB; Malek, S; Ghosh, G				Huxford, T; Huang, DB; Malek, S; Ghosh, G			The crystal structure of the I kappa B alpha/NF-kappa B complex reveals mechanisms of NF-kappa B inactivation	CELL			English	Article							DNA-BINDING; CYTOPLASMIC RETENTION; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; REL PROTEIN; INHIBITOR; ACTIVATION; ANKYRIN; P50; PHOSPHORYLATION	I kappa B alpha regulates the transcription factor NF-kappa B through the formation of stable I kappa B alpha/NF-kappa B complexes. Prior to induction, I kappa B alpha retains NF-kappa B in the cytoplasm until the NF-kappa B activation signal is received. After activation, NF-kappa B is removed from gene promoters through association with nuclear I kappa B alpha, restoring the preinduction state. The 2.3 Angstrom crystal structure of I kappa B alpha in complex with the NF-kappa B p50/p65 heterodimer reveals mechanisms of these inhibitory activities. The presence of I kappa B alpha allows large en bloc movement of the NF-kappa B p65 subunit amino-terminal domain. This conformational change induces allosteric inhibition of NF-kappa B DNA binding. Amino acid residues immediately preceding the nuclear localization signals of both NF-kappa B p50 and p65 subunits are tethered to the I kappa B alpha aminoterminal ankyrin repeats, impeding NF-kappa B from nuclear import machinery recognition.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	gghosh@chem.ucsd.edu		Huxford, Tom/0000-0002-1939-7373; Malek, Shiva/0000-0002-9526-7968	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09523] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; ERNST MK, 1995, MOL CELL BIOL, V15, P872; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Govind S, 1996, MOL CELL BIOL, V16, P1103; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	61	487	510	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					759	770		10.1016/S0092-8674(00)81699-2	http://dx.doi.org/10.1016/S0092-8674(00)81699-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865694	Bronze			2022-12-24	WOS:000077498800006
J	Lund, E; Dahlberg, JE				Lund, E; Dahlberg, JE			Proofreading and aminoacylation of tRNAs before export from the nucleus	SCIENCE			English	Article							PRECURSOR TRANSFER-RNAS; SACCHAROMYCES-CEREVISIAE; NONSENSE MUTATIONS; YEAST MUTANT; PROTEIN; TRANSPORT; SYNTHETASE; MECHANISM; SIGNALS; LAEVIS	After synthesis and processing in the nucleus, mature transfer RNAs (tRNAs) are exported to the cytoplasm in a Ran.guanosine triphosphate-dependent manner. Export of defective or immature tRNAs is avoided by monitoring both structure and function of tRNAs in the nucleus, and only tRNAs with mature 5' and 3' ends are exported. ALL tRNAs examined can be aminoacylated in nuclei of Xenopus oocytes, thereby providing a possible mechanism for functional proofreading of newly made tRNAs. Inhibition of aminoacylation of a specific tRNA retards its appearance in the cytoplasm, indicating that nuclear aminoacylation promotes efficient export.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dahlberg, JE (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	dahlberg@facstaff.wisc.edu			NIGMS NIH HHS [GM30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman Sidney, 1995, P67; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; ARTS GJ, IN PRESS EMBO J; CARRARA G, 1995, P NATL ACAD SCI USA, V92, P262; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Dahlberg JE, 1997, SEMIN CELL DEV BIOL, V8, P65, DOI 10.1006/scdb.1996.0123; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Deutscher Murray P., 1995, P51; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DREHER TW, IN PRESS J BIOL CHEM; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1980, CELL, V19, P741, DOI 10.1016/S0092-8674(80)80050-X; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUGLER W, 1995, NUCLEIC ACIDS RES, V23, P413, DOI 10.1093/nar/23.3.413; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LUND E, UNPUB; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MULLER F, 1980, CELL, V19, P345, DOI 10.1016/0092-8674(80)90509-7; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; Pasquinelli AE, 1995, RNA, V1, P957; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SANDERS J, 1996, J CELL SCI, V109, P113; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1080, P126, DOI 10.1016/0167-4838(91)90138-P; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; WOLIN SL, INPRESS GENES DEV; WSTAWAY SK, 1995, TRNA STRUCTURE BIOSY, P79; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	45	258	266	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2082	2085		10.1126/science.282.5396.2082	http://dx.doi.org/10.1126/science.282.5396.2082			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851929				2022-12-24	WOS:000077467100047
J	Nguyen, JT; Turck, CW; Cohen, FE; Zuckermann, RN; Lim, WA				Nguyen, JT; Turck, CW; Cohen, FE; Zuckermann, RN; Lim, WA			Exploiting the basis of proline recognition by SH3 and WW domains: Design of n-substituted inhibitors	SCIENCE			English	Article							PHAGE DISPLAY; PEPTIDE LIGANDS; RICH PEPTIDES; BINDING; SRC; IDENTIFICATION; SPECIFICITY; LIBRARIES; PROTEINS; AFFINITY	Src homology 3 (SH3) and WW protein interaction domains bind specific proline-rich sequences. However, instead of recognizing critical prolines on the basis of side chain shape or rigidity, these domains broadly accepted amide N-substituted residues. Proline is apparently specifically selected in vivo, despite Low complementarity, because it is the only endogenous N-substituted amino acid. This discriminatory mechanism explains how these domains achieve specific but Low-affinity recognition, a property that is necessary for transient signaling interactions. The mechanism can be exploited: screening a series of Ligands in which key prolines were replaced by nonnatural N-substituted residues yielded a Ligand that selectively bound the Grb2 SH3 domain with 100 times greater affinity.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Novartis	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu	Zuckermann, Ronald/P-3436-2019; Zuckermann, Ronald N/A-7606-2014	Zuckermann, Ronald/0000-0002-3055-8860; Zuckermann, Ronald N/0000-0002-3055-8860				BRUNER AT, 1996, XPLOR; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Figliozzi GM, 1996, METHOD ENZYMOL, V267, P437; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; NGUYEN J, UNPUB; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; SICHERI F, 1997, NATURE, V385, P595; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	36	264	274	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2088	2092		10.1126/science.282.5396.2088	http://dx.doi.org/10.1126/science.282.5396.2088			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851931				2022-12-24	WOS:000077467100049
J	Rambukkana, A; Yamada, H; Zanazzi, G; Mathus, T; Salzer, JL; Yurchenco, PD; Campbell, KP; Fischetti, VA				Rambukkana, A; Yamada, H; Zanazzi, G; Mathus, T; Salzer, JL; Yurchenco, PD; Campbell, KP; Fischetti, VA			Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae	SCIENCE			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; PERIPHERAL-NERVE; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHIES; EXTRACELLULAR-MATRIX; AGRIN RECEPTOR; CHAIN GENE; LAMININ; MEROSIN; MEMBRANE	alpha-Dystroglycan (alpha-DG) is a component of the dystroglycan complex, which is involved in early development and morphogenesis and in the pathogenesis of muscular dystrophies. Here, alpha-DG was shown to serve as a Schwann cell receptor for Mycobacterium leprae, the causative organism of leprosy. Mycobacterium leprae specifically bound to alpha-DG only in the presence of the G domain of the alpha 2 chain of laminin-2. Native alpha-DG competitively inhibited the lminin-2-mediated M. leprae binding to primary Schwann cells. Thus, M. leprae may use Linkage between the extracellular matrix and cytoskeleton through lminin-2 and alpha-DG for its interaction with Schwann cells.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Phys & Biophys, Iowa City, IA 52242 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA	Rockefeller University; University of Iowa; University of Iowa; New York University; New York University; New York University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rambukkana, A (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA.	rambuka@rockvax.rockefeller.edu		Campbell, Kevin/0000-0003-2066-5889; Yurchenco, Peter/0000-0003-0387-2317; rambukkana, anura/0000-0002-6286-9145; Salzer, James/0000-0001-9126-7197	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JOB CK, 1989, INT J LEPROSY, V57, P532; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; RAMBUKKANA A, UNPUB; RUTKOWSKI JL, 1991, EXP BIOL M, P343; STONER GL, 1979, LANCET, V2, P994; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; *WHO, 1995, WEEKLY EPIDEMIO 0920, P269; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; Yamada H., UNPUB; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	38	186	191	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2076	2079		10.1126/science.282.5396.2076	http://dx.doi.org/10.1126/science.282.5396.2076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851927				2022-12-24	WOS:000077467100045
J	Tsukazaki, T; Chiang, TA; Davison, AF; Attisano, L; Wrana, JL				Tsukazaki, T; Chiang, TA; Davison, AF; Attisano, L; Wrana, JL			SARA, a FYVE domain protein that recruits Smad2 to the TGF beta receptor	CELL			English	Article							SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; PHOSPHORYLATION; KINASE; SER(465); SCAFFOLD; MEDIATOR; GENES	Smads transmit signals from transmembrane ser/thr kinase receptors to the nucleus. We now identify SARA (for Smad anchor for receptor activation), a FYVE domain protein that interacts directly with Smad2 and Smad3. SARA functions to recruit Smad2 to the TGF beta receptor by controlling the subcellular localization of Smad2 and by interacting with the TGF beta receptor complex. Phosphorylation of Smad2 induces dissociation from SARA with concomitant formation of Smad2/Smad4 complexes and nuclear translocation. Furthermore, mutations in SARA that cause mislocalization of Smad2 inhibit TGF beta-dependent transcriptional responses, indicating that the regulation of Smad localization is important for TGF beta signaling. These results thus define SARA as a component of the TGF beta pathway that brings the Smad substrate to the receptor.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Wrana, JL (corresponding author), Hosp Sick Children, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jwrana@sickkids.on.ca	Wrana, Jeffrey/F-8857-2013					Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	38	740	795	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					779	791		10.1016/S0092-8674(00)81701-8	http://dx.doi.org/10.1016/S0092-8674(00)81701-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865696	Bronze			2022-12-24	WOS:000077498800008
J	Nurminsky, DI; Nurminskaya, MV; De Aguiar, D; Hartl, DL				Nurminsky, DI; Nurminskaya, MV; De Aguiar, D; Hartl, DL			Selective sweep of a newly evolved sperm-specific gene in Drosophila	NATURE			English	Article							MELANOGASTER; TRANSFORMATION; DIVERGENCE; EVOLUTION; RATES	The pattern of genetic variation across the genome of Drosophila melanogaster is consistent with the occurrence of frequent 'selective sweeps' in which new favourable mutations become incorporated into the species so quickly that linked alleles can 'hitchhike' and also become fixed(1). Because of the hitchhiking of linked genes, it is generally difficult to identify the target of any putative selective sweep. Here, however, we identify a new gene in D. melanogaster that codes for a sperm-specific axonemal dynein subunit. The gene has a new testes-specific promoter derived from a protein-coding region in a gene encoding the cell-adhesion protein annexin X (AnnX), and it contains a new protein-coding exon derived from an intron in a gene encoding a cytoplasmic dynein intermediate chain (Cdic). The new transcription unit, designated Sdic (for sperm-specific dynein intermediate chain), has been duplicated about tenfold in a tandem array. Consistent with the selective sweep of this gene, the level of genetic polymorphism near Sdic is unusually low. The discovery of this gene supports other results that point to the rapid molecular evolution of male reproductive functions(2-4).	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA	Harvard University; Tufts University	Nurminsky, DI (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.							BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; BENEVOLENSKAYA EV, 1994, DNA CELL BIOL, V14, P349; CACCONE A, 1988, GENETICS, V118, P671; Civetta A, 1998, MOL BIOL EVOL, V15, P901, DOI 10.1093/oxfordjournals.molbev.a025994; COULTHART MB, 1988, MOL BIOL EVOL, V5, P182; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; Long MY, 1995, P NATL ACAD SCI USA, V92, P12495, DOI 10.1073/pnas.92.26.12495; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; Nurminsky DI, 1996, MOL BIOL EVOL, V13, P132, DOI 10.1093/oxfordjournals.molbev.a025551; Nurminsky DI, 1998, MOL CELL BIOL, V18, P6816, DOI 10.1128/MCB.18.11.6816; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; WU CI, 1993, AM NAT, V142, P187, DOI 10.1086/285534	17	209	215	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					572	575		10.1038/25126	http://dx.doi.org/10.1038/25126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859991				2022-12-24	WOS:000077466800057
J	Sandler, RS				Sandler, RS			Appendicectomy and ulcerative colitis	LANCET			English	Editorial Material							INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; APPENDECTOMY; TONSILLECTOMY; RISK		Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Sandler, RS (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.							Breslin NP, 1997, INFLAMM BOWEL DIS, V3, P1, DOI 10.1002/ibd.3780030102; Duggan AE, 1998, GUT, V43, P494, DOI 10.1136/gut.43.4.494; GENT AE, 1994, LANCET, V343, P766, DOI 10.1016/S0140-6736(94)91841-4; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; Minocha A, 1997, DIGEST DIS SCI, V42, P1567, DOI 10.1023/A:1018847617560; Mizoguchi A, 1996, J EXP MED, V184, P707, DOI 10.1084/jem.184.2.707; RATH HC, IN PRESS GASTROENTER; Russel MG, 1997, GASTROENTEROLOGY, V113, P377, DOI 10.1053/gast.1997.v113.pm9247453; RUTGEERTS P, 1994, GASTROENTEROLOGY, V106, P1251, DOI 10.1016/0016-5085(94)90016-7; SMITHSON JE, 1995, J CLIN GASTROENTEROL, V21, P283, DOI 10.1097/00004836-199512000-00006; WURZELMANN JI, 1994, DIGEST DIS SCI, V39, P555, DOI 10.1007/BF02088342	11	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1797	1798		10.1016/S0140-6736(05)79883-4	http://dx.doi.org/10.1016/S0140-6736(05)79883-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851375				2022-12-24	WOS:000077337900003
J	Narayan, SS; Temchin, AN; Recio, A; Ruggero, MA				Narayan, SS; Temchin, AN; Recio, A; Ruggero, MA			Frequency tuning of basilar membrane and auditory nerve fibers in the same cochleae	SCIENCE			English	Article							OUTER HAIR-CELLS; GUINEA-PIG; RECEPTOR POTENTIALS; MECHANICAL RESPONSES; HYDRODYNAMIC-FORCES; MOSSBAUER TECHNIQUE; CHINCHILLA-COCHLEA; BASE; MICROMECHANICS; SENSITIVITY	Responses to tones of a basilar membrane site and of auditory nerve fibers innervating neighboring inner hair cells were recorded in the same cochleae in chinchillas. At near-threshold stimulus Levels, the frequency tuning of auditory nerve fibers closely paralleled that of basilar membrane displacement modified by high-pass filtering, indicating that only relatively minor signal transformations intervene between mechanical vibration and auditory nerve excitation. This finding establishes that cochlear frequency selectivity in chinchillas (and probably in mammals in general) is fully expressed in the vibrations of the basilar membrane and renders unnecessary additional ("second") filters, such as those present in the hair cells of the cochleae of reptiles.	Northwestern Univ, Dept Commun Sci & Disorders, Audiol & Hearing Sci Program, Hugh Knowles Ctr, Evanston, IL 60208 USA; Northwestern Univ, Inst Neurosci, Evanston, IL 60208 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	Northwestern University; Northwestern University; University of Wisconsin System; University of Wisconsin Madison	Ruggero, MA (corresponding author), Northwestern Univ, Dept Commun Sci & Disorders, Audiol & Hearing Sci Program, Hugh Knowles Ctr, Evanston, IL 60208 USA.	mruggero@nwu.edu	Recio-Spinoso, Alberto/F-7744-2013; Ruggero, Mario A/A-9860-2009	Recio-Spinoso, Alberto/0000-0003-1909-832X; Ruggero, Mario A/0000-0001-8240-3644	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P50DC000110, F32DC000419, P01DC000110, R01DC000419] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC000419, DC-00419, F32 DC000419, P50 DC000110, DC-00110] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALLEN JB, 1993, J ACOUST SOC AM, V94, P809, DOI 10.1121/1.408182; ALLEN JB, 1992, PHYS TODAY, V45, P40, DOI 10.1063/1.881349; ALLEN JB, 1980, J ACOUST SOC AM, V68, P1660, DOI 10.1121/1.385198; ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BRAUN M, 1994, HEARING RES, V78, P98, DOI 10.1016/0378-5955(94)90048-5; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; Cheatham MA, 1998, J ACOUST SOC AM, V104, P356, DOI 10.1121/1.423245; COOPER NP, 1992, HEARING RES, V63, P163, DOI 10.1016/0378-5955(92)90083-Y; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; ELDREDGE DH, 1981, J ACOUST SOC AM, V69, P1091, DOI 10.1121/1.385688; EVANS EF, 1972, J PHYSIOL-LONDON, V226, P263, DOI 10.1113/jphysiol.1972.sp009984; EVANS EF, 1975, SCIENCE, V190, P1218, DOI 10.1126/science.1198110; FREEMAN DM, 1990, HEARING RES, V48, P17, DOI 10.1016/0378-5955(90)90196-V; FREEMAN DM, 1990, HEARING RES, V48, P31, DOI 10.1016/0378-5955(90)90197-W; GREENWOOD DD, 1990, J ACOUST SOC AM, V87, P2592, DOI 10.1121/1.399052; HARRIS GG, 1970, SCIENCE, V167, P76, DOI 10.1126/science.167.3914.76; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; KHANNA SM, 1982, SCIENCE, V215, P305, DOI 10.1126/science.7053580; LIBERMAN MC, 1978, J ACOUST SOC AM, V63, P442, DOI 10.1121/1.381736; Murugasu E, 1996, J NEUROSCI, V16, P325; NEELY ST, 1983, HEARING RES, V9, P123, DOI 10.1016/0378-5955(83)90022-9; Nuttall AL, 1996, J ACOUST SOC AM, V99, P1556, DOI 10.1121/1.414732; Patuzzi R., 1996, COCHLEA, P186; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; Ruggero M A, 1992, Curr Opin Neurobiol, V2, P449, DOI 10.1016/0959-4388(92)90179-O; RUGGERO MA, 1990, J ACOUST SOC AM, V87, P1612, DOI 10.1121/1.399409; RUGGERO MA, 1991, HEARING RES, V51, P215, DOI 10.1016/0378-5955(91)90038-B; RUGGERO MA, 1991, J NEUROSCI, V11, P1057; RUGGERO MA, 1986, J ACOUST SOC AM, V79, P1491, DOI 10.1121/1.393763; Ruggero MA, 1996, AUDIT NEUROSCI, V2, P159; RUGGERO MA, 1995, ACTIVE HEARING, P321; RUSSELL IJ, 1983, J PHYSIOL-LONDON, V338, P179, DOI 10.1113/jphysiol.1983.sp014668; RUSSELL IJ, 1986, NATURE, V321, P517, DOI 10.1038/321517a0; Russell IJ, 1995, ADV HEARING RES, P136; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SPOENDLIN H, 1971, ARCH KLIN EXP OHR, V200, P275, DOI 10.1007/BF00373310; WILSON JP, 1992, ADV BIOSCI, V83, P71; ZWISLOCKI JJ, 1979, SCIENCE, V204, P639, DOI 10.1126/science.432671; ZWISLOCKI JJ, 1982, AM J OTOLARYNG, V3, P48, DOI 10.1016/S0196-0709(82)80032-X; ZWISLOCKI JJ, 1986, HEARING RES, V22, P155, DOI 10.1016/0378-5955(86)90091-2	46	153	158	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1882	1884		10.1126/science.282.5395.1882	http://dx.doi.org/10.1126/science.282.5395.1882			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836636	Green Accepted			2022-12-24	WOS:000077338100046
J	Strang, J; Sheridan, J				Strang, J; Sheridan, J			Effect of government recommendations on methadone prescribing in southeast England: comparison of 1995 and 1997 surveys	BRITISH MEDICAL JOURNAL			English	Article									Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; The Maudsley, London SE5 8AF, England	University of London; King's College London	Strang, J (corresponding author), Inst Psychiat, Natl Addict Ctr, De Crespigny Pk,Denmark Hill, London SE5 8AF, England.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Sheridan, Janie/0000-0002-0312-3095				*ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; *HOM OFF, 1997, STAT MIS DRUGS ADD N; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; Strang J, 1998, J SUBSTANCE MISUSE, V3, P240; Task Force to Review Services for Drug Misusers, 1996, TASK FORC REV SERV D	5	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1489	1490		10.1136/bmj.317.7171.1489	http://dx.doi.org/10.1136/bmj.317.7171.1489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831575	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000077338300024
J	Butty, AC; Pryciak, PM; Huang, LS; Herskowitz, I; Peter, M				Butty, AC; Pryciak, PM; Huang, LS; Herskowitz, I; Peter, M			The role of Far1p in linking the heterotrimeric G protein to polarity establishment proteins during yeast mating	SCIENCE			English	Article							MAP KINASE CASCADE; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; BETA-GAMMA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; CELL POLARITY; FUNCTIONAL-ANALYSIS; TISSUE POLARITY; BUDDING YEAST; STE5	Heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) determine tissue and cell polarity in a variety of organisms. In yeast, cells orient polarized growth toward the mating partner along a pheromone gradient by a mechanism that requires Far1p and Cdc24p. Far1p bound G beta gamma and interacted with polarity establishment proteins, which organize the actin cytoskeleton. Cells containing mutated Far1p unable to bind G beta gamma or polarity establishment proteins were defective for orienting growth toward their mating partner. In response to pheromones, Far1p moves from the nucleus to the cytoplasm, Thus, Far1p functions as an adaptor that recruits polarity establishment proteins to the site of extracellular signaling marked by G beta gamma to polarize assembly of the cytoskeleton in a morphogenetic gradient.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Shrewsbury, MA 01545 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Swiss Institute Experimental Cancer Research; University of Massachusetts System; University of California System; University of California San Francisco	Peter, M (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	matthias.peter@isrec.unil.ch	Pryciak, Peter/P-7205-2019; Huang, Linda/C-9903-2014	Pryciak, Peter/0000-0001-9142-1369; Huang, Linda/0000-0002-9033-4391	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017494, R01GM048052, R01GM057769] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57769, GM48052, R01 GM057769, F32 GM017494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BLONDEL M, UNPUB; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1994, GENETICS, V136, P1287; CHOI KY, 1994, CELL, V78, P499; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Harlow E, 1988, ANTIBODIES LAB MANUA; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang L., UNPUB; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; PRINTEN JA, 1994, GENETICS, V138, P609; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schrick K, 1997, GENETICS, V147, P19; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Valtz N, 1997, METHOD ENZYMOL, V283, P350; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	61	175	177	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1511	1516		10.1126/science.282.5393.1511	http://dx.doi.org/10.1126/science.282.5393.1511			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822386				2022-12-24	WOS:000077110800061
J	Dominguez, M; de Celis, JF				Dominguez, M; de Celis, JF			A dorsal/ventral boundary established by Notch controls growth and polarity in the Drosophila eye	NATURE			English	Article							DORSAL; EXPRESSION; FRINGE; GENE	In the Drosophila compound eye the dorsal and ventral fields of eye units (ommatidia) meet along the dorsoventral midline, forming a line of mirror image symmetry called the equator(1), The molecular mechanism establishing the equator is not fully understood, but it involves the transcription factors' encoded by the Iroquois gene complex(3), The Iroquois genes are expressed in the dorsal half of the eye(2) and here we show that they regulate the expression of the secreted molecule Fringe. A boundary between fringe-expressing and fringe-non-expressing cells is essential, from the time of the second larval instar, for eye growth and formation of the equator. Boundaries of fringe expression determine where the transmembrane receptor Notch is activated(4,5). We find that Notch is activated at the dorsoventral midline, where it is required to promote growth and set up the axis of mirror symmetry. As boundaries of fringe expression and Notch activation are also important during Drosophila wing formation(6) and vertebrate somitogenesis(7-9), we suggest that these boundaries constitute a general mechanism that directs growth and patterning of large fields of cells.	Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	de Celis, JF (corresponding author), Univ Cambridge, Dept Genet, Downing St, Cambridge CB2 3EH, England.	jdc@mole.bio.cam.ac.uk	de+Celis, Jose/AAE-8142-2019; Dominguez, Maria/G-2171-2014	Dominguez, Maria/0000-0002-3329-7862; de Celis, Jose F./0000-0003-4808-9844	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAKER WK, 1978, DEV BIOL, V62, P447, DOI 10.1016/0012-1606(78)90227-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; CAMPOSORTEGA JA, 1978, DEV BIOL, V184, P155; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; de Celis JF, 1998, DEVELOPMENT, V125, P4617; DIAZBENJUMEA G, 1993, CELL, V75, P742; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; Heberlein U, 1998, DEVELOPMENT, V125, P567; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Klein T, 1997, DEV BIOL, V189, P123, DOI 10.1006/dbio.1997.8564; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Reifegerste R, 1997, MECH DEVELOP, V68, P69, DOI 10.1016/S0925-4773(97)00127-5; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WOLFF T, 1993, PATTERN FORMATION DR, P1277; Zeller R, 1997, BIOESSAYS, V19, P541, DOI 10.1002/bies.950190703; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	25	207	208	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1998	396	6708					276	278		10.1038/24402	http://dx.doi.org/10.1038/24402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834035				2022-12-24	WOS:000077110400050
J	Newdick, C				Newdick, C			Primary care groups and the right to prescribe	BRITISH MEDICAL JOURNAL			English	Article									Univ Reading, Dept Law, Reading RG6 6AH, Berks, England	University of Reading	Newdick, C (corresponding author), Univ Reading, Dept Law, Reading RG6 6AH, Berks, England.							*AUD COMM, 1994, PRESCR IMPR RAT PRES, P27; *DEP HLTH, 1995, VAR HLTH WHAT DOH NH; *GEN MED COUNC, 1994, RES CONSTR CONTR PRO; HUNTER DJ, 1992, SOC SCI MED, V35, P557, DOI 10.1016/0277-9536(92)90349-U; Klein RDP, 1996, MANAGING SCARCITY PR; Light DW, 1997, BRIT MED J, V315, P112, DOI 10.1136/bmj.315.7100.112; MOONEY G, 1988, MED ETHICS EC HLTH C; Newdick C, 1998, J Contemp Health Law Policy, V14, P335; NEWDICK C, 1995, WHO SHOULD WE TREAT, P178; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; *SECR STAT HLTH, 1997, CMND 3807; *SECR STAT HLTH, 1998, 1 CLASS SERV QUAL NH; Stevens A, 1991, Health Trends, V23, P20; TOWSE A, 1998, GUIDELINES EC EVALUA; WEBSTER C, 1998, NATL HLTH SERVICE PO, P30; WEST P, 1998, MANAGED CARE MODEL U	16	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1361	1364		10.1136/bmj.317.7169.1361	http://dx.doi.org/10.1136/bmj.317.7169.1361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812936	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000077081600024
J	Smith, GD; Shipley, M; Leon, DA				Smith, GD; Shipley, M; Leon, DA			Height and mortality from cancer among men: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT HEIGHT		Dept Social Med, Bristol BS8 2PR, Avon, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Smith, GD (corresponding author), Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013; Leon, David A/G-2195-2010	Davey Smith, George/0000-0002-1407-8314; Leon, David A/0000-0001-9747-1762				ALBANES D, 1988, CANCER RES, V48, P1658; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; Hebert PR, 1997, CANCER CAUSE CONTROL, V8, P591, DOI 10.1023/A:1018442329319; KRISTAL BS, 1994, MODULATION AGING PRO, P1; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5	5	37	39	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1351	1352		10.1136/bmj.317.7169.1351	http://dx.doi.org/10.1136/bmj.317.7169.1351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812932	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000077081600020
J	Peschon, JJ; Slack, JL; Reddy, P; Stocking, KL; Sunnarborg, SW; Lee, DC; Russell, WE; Castner, BJ; Johnson, RS; Fitzner, JN; Boyce, RW; Nelson, N; Kozlosky, CJ; Wolfson, MF; Rauch, CT; Cerretti, DP; Paxton, RJ; March, CJ; Black, RA				Peschon, JJ; Slack, JL; Reddy, P; Stocking, KL; Sunnarborg, SW; Lee, DC; Russell, WE; Castner, BJ; Johnson, RS; Fitzner, JN; Boyce, RW; Nelson, N; Kozlosky, CJ; Wolfson, MF; Rauch, CT; Cerretti, DP; Paxton, RJ; March, CJ; Black, RA			An essential role for ectodomain shedding in mammalian development	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-ALPHA; SELECTIN ADHESION MOLECULE; AMYLOID PRECURSOR PROTEIN; SPERM-EGG FUSION; TGF-ALPHA; CONVERTING-ENZYME; FACTOR RECEPTOR; DEFICIENT MICE; TNF-ALPHA	The ectodomains of numerous proteins are released from cells by proteolysis to yield soluble intercellular regulators. The responsible protease, tumor necrosis factor-a converting enzyme (TACE), has been identified only in the case when tumor necrosis factor-alpha (TNF alpha) is released. Analyses of cells lacking this metalloproteinase-disintegrin revealed an expanded role for TACE in the processing of other cell surface proteins, including a TNF receptor, the L-selectin adhesion molecule, and transforming growth factor-alpha (TGF alpha). The phenotype of mice Lacking TACE suggests an essential role for soluble TGF alpha in normal development and emphasizes the importance of protein ectodomain shedding in vivo.	Immunex Res & Dev Corp, Seattle, WA 98101 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Pathol Associates Int, Frederick, MD 21701 USA	University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Vanderbilt University	Peschon, JJ (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.		Russell, William/A-7307-2009		NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053804, R01DK053804] Funding Source: NIH RePORTER; NCI NIH HHS [CA43793] Funding Source: Medline; NIDDK NIH HHS [DK53804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HARRIS MJ, 1982, ANAT EMBRYOL, V164, P207, DOI 10.1007/BF00318505; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; LEE DC, 1990, HDB EXP PHARM, V95, P611; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Peschon JJ, 1998, J IMMUNOL, V160, P943; PESCHON JJ, UNPUB; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SLACK JL, UNPUB; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Wen CH, 1997, DEVELOPMENT, V124, P4759; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	41	1328	1363	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1281	1284		10.1126/science.282.5392.1281	http://dx.doi.org/10.1126/science.282.5392.1281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812885				2022-12-24	WOS:000076982200034
J	Studdert, DM; Eisenberg, DM; Miller, FH; Curto, DA; Kaptchuk, TJ; Brennan, TA				Studdert, DM; Eisenberg, DM; Miller, FH; Curto, DA; Kaptchuk, TJ; Brennan, TA			Medical malpractice implications of alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUPUNCTURE; TRIALS; METAANALYSIS; HEALTH; PAIN	Although use of alternative therapies in the United States is widespread and growing, little is known about the malpractice experience of practitioners who deliver these therapies or about the legal principles that govern the relationship between conventional and alternative medicine. Using data from malpractice insurers, we analyzed the claims experience of chiropractors, massage therapists, and acupuncturists for 1990 through 1996, We found that claims against these practitioners occurred less frequently and typically involved injury that was less severe than claims against physicians during the same period. Physicians who may be concerned about their own exposure to liability for referral of patients for alternative treatments can draw some comfort from these findings. However, liability for referral is possible in certain situations and should be taken seriously. Therefore, we review relevant legal principles and case law to understand how malpractice law is likely to develop in this area. We conclude by suggesting some questions for physicians to ask themselves before referring their patients to alternative medicine practitioners.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res,Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Law, Boston, MA 02115 USA; Boston Univ, Sch Law, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston University	Eisenberg, DM (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U2AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baer H A, 1992, Med Anthropol, V13, P369; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; Blecher MB, 1997, HOSP HEALTH NETWORK, V71, P50; BLECHER MB, 1997, CRAINS CHICAGO  0127, P4; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; COHEN MH, 1996, ARIZ L REV, V38, P83; COVALESKI J, 1997, BESTS REV PC     APR, P61; DUFF C, 1997, WALL STREET J   0414, pB1; EDLIN M, 1997, MANAGED HLTH     JUN, P14; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; *FED CHIR LIC BOAR, 1997, OFF DIR CHIR LIC PRA; FIELDS DH, 1996, NY TIMES        1017, P26; Firshein J, 1995, Bus Health, V13, P28; GONZALES M, 1997, SOCIOECONOMIC CHARAC, P39; GRANDINETTI DA, 1997, MED ECON, V74, P73; Greely H T, 1996, Health Matrix Clevel, V6, P53; HALL MA, 1994, NEW YORK U LAW REV, V69, P693; HILTS PJ, 1996, NY TIMES        0102, P10; HOBSON SM, 1989, INDIANA LAW J, V64, P737; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; Morreim E. H., 1995, WIDENER LAW S J, V1, P89; *NIH OFF ALT MED, 1998, PROGR AR RES DEV INV; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; *PHYS INS ASS AM, 1997, PIAA DAT SHAR REP 19; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; WHITAKER B, 1996, NY TIMES        1124, P11; 1997, WALL STREET J   0403, P1; 1991, NCAHF NEWSLETTE 1121, P1; 1996, NATL UNDERWRITE 1126, P18	38	73	73	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1610	1615		10.1001/jama.280.18.1610	http://dx.doi.org/10.1001/jama.280.18.1610			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820265				2022-12-24	WOS:000076852000030
J	Detels, R; Munoz, A; McFarlane, G; Kingsley, LA; Margolick, JB; Giorgi, J; Scharager, LD; Phair, JP				Detels, R; Munoz, A; McFarlane, G; Kingsley, LA; Margolick, JB; Giorgi, J; Scharager, LD; Phair, JP		Multicenter AIDS Cohort Study Investigators	Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CUBIC MILLIMETER; CONTROLLED TRIAL; MULTICENTER; COHORT; SEROCONVERSION; ZIDOVUDINE; INCUBATION; INDINAVIR; PROTEASE	Context.-Time to development of acquired immunodeficiency syndrome (AIDS) and time to death have been extended with the increased use of combination therapy and protease inhibitors. Cohort studies following up persons with human immunodeficiency virus (HIV) infection in periods characterized by different therapies offer the opportunity to estimate therapy effectiveness at the population level. Objective.-To assess the effectiveness of self-reported, long-term potent antiretroviral therapy in a cohort of 536 men whose duration of HIV infection was known (seroconverters). Design.-Cohort study. The cohort was compared for time to development of AIDS and time to death in 1984 to 1990, 1990 to 1993, 1993 to July 1995, and July 1995 to July 1997 when the major treatments were no therapy, monotherapy, combined therapy, and potent antiretroviral therapy, respectively. Survival analysis methods with time zero set as the date of seroconversion and incorporating staggered entries into each period were used. Mean CD4 cell change, stratified by infection duration, was determined for each period using a random effects model. Setting.-The Multicenter AIDS Cohort Study (MACS) in 4 urban areas (Baltimore, Md; Chicago, III; Los Angeles, Calif; and Pittsburgh, Pa). Participants.-A total of 5622 men who were 18 years or older were enrolled into MACS. Of the 5622, there were 2191 HIV-positive individuals at enrollment. Of the 3431 men who were HIV-negative, 536 were observed to seroconvert and were followed up for up to 13 years. The group of 536 who seroconverted constituted the study population. Main Outcome Measures.-Time from seroconversion to development of AIDS and to death and change in CD4 cell count. Results.-A total of 231 seroconverters developed AIDS, and 200 men died. Using 1990 to 1993 as the reference period, the relative hazard of AIDS was 1.04 (95% confidence interval [GI], 0.73-1.48) during 1993 to July 1995 and 0.35 (95% CI, 0.20-0.61) during July 1995 to July 1997. Relative hazards of death were 0.87 (95% CI, 0.58-1.31) and 0.62 (95% Cl, 0.38-1.01) for the same periods. The relative time (the factor by which times are contracted or expanded) to development of AIDS was 0.97 (95% CI, 0.86-1.09) for 1993 to July 1995 and 1.63 (95% CI, 1.40-1.89) for July 1995 to July 1997. Relative survival time for 1993 to July 1995 was 1.01 (95% CI, 0.91-1.12) and for July 1995 to July 1997 was 1.21 (95% Cl, 1.07-1.36) relative to 1990 to 1993. The rate of CD4 cell count decline in July 1995 to July 1997 was significantly lower (P<.05) compared with the previous 2 periods. Conclusions.-In the calendar period when potent antiretroviral therapy was introduced, the time to development of AIDS and time to death were extended, and rate of CD4 cell count decline was arrested.	Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21218 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA; NIAID, Div AIDS, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Chicago, IL USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Northwestern University	Detels, R (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, POB 951772, Los Angeles, CA 90095 USA.	detels@ucla.edu		Kingsley, Lawrence/0000-0002-7000-8556	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P155; CHIASSON MA, 1997, 4 C RETR OPP INF JAN; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; Detels R, 1997, Antivir Ther, V2, P21; DETELS R, 1992, J EPIDEMIOL, V2, pS11; Diggle PJ, 2002, ANAL LONGITUDINAL DA; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; GAIL MH, 1995, AIDS CLIN TRIALS, P403; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hills, 1993, STAT MODELS EPIDEMIO; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KINGSLEY LA, 1987, LANCET, V1, P345; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LEVITT R, 1997, 4 C RETR OPP INF JAN; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Munoz A, 1997, AIDS, V11, pS69; Munoz A, 1996, AM J RESP CRIT CARE, V154, pS234, DOI 10.1164/ajrccm/154.6_Pt_2.S234; MUNOZ A, 1995, AIDS CLIN TRIALS, P423; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Sorvillo F, 1997, J ACQ IMMUN DEF SYND, V15, P179; STEIN D, 1997, 4 C RETR OPP INF JAN; Veugelers PJ, 1998, AM J EPIDEMIOL, V148, P487, DOI 10.1093/oxfordjournals.aje.a009674; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI LJ, 1992, STAT MED, V11, P1871, DOI 10.1002/sim.4780111409; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	34	582	596	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1497	1503		10.1001/jama.280.17.1497	http://dx.doi.org/10.1001/jama.280.17.1497			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809730	Bronze			2022-12-24	WOS:000076757200023
J	Armstrong, N; Sun, Y; Chen, GQ; Gouaux, E				Armstrong, N; Sun, Y; Chen, GQ; Gouaux, E			Structure of a glutamate-receptor ligand-binding core in complex with kainate	NATURE			English	Article							AMPA RECEPTOR; SITE; IDENTIFICATION; DETERMINANTS; DOMAIN; DIFFRACTION; MODULATION; SUBUNIT; REGION	Ionotropic glutamate receptors (iGluRs) mediate excitatory synaptic transmission in vertebrates and invertebrates through ligand-induced opening of transmembrane ion channels. iGluRs are segregated into three subtypes according to their sensitivity to the agonists AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), kainate (a structural analogue of glutamate) or NMDA (N-methyl-D-aspartate) (Fig.1). iGluRs are important in the development and function of the nervous system, are essential in memory and learning, and are either implicated in or have causal roles in dysfunctions ranging from Alzheimer's, Parkinson's and Huntington's diseases, schizophrenia, epilepsy and Rasmussen's encephalitis to stroke(1,2). Development of iGluR agonists and antagonists has been hampered by a lack of high-resolution structural information. Here we describe the crystal structure of an iGluR ligand-binding region in a complex with the neurotoxin (agonist) kainate. The bilobed structure shows the determinants of receptor-agonist interactions and how ligand-binding specificity and affinity are altered by remote residues and the redox state of the conserved disulphide bond, The structure indicates mechanisms for allosteric effector action and for ligand-induced channel gating. The information provided by this structure will be essential in designing new ligands.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360				AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN GQ, IN PRESS PROTEIN SCI; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JACOBSON BL, 1992, J MOL BIOL, V223, P27, DOI 10.1016/0022-2836(92)90712-S; Keinanen K, 1997, BIOCHEM SOC T, V25, P835, DOI 10.1042/bst0250835; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; LI F, 1995, MOL PHARMACOL, V47, P148; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paas Y, 1998, TRENDS NEUROSCI, V21, P117, DOI 10.1016/S0166-2236(97)01184-3; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Swanson GT, 1997, NEURON, V19, P913, DOI 10.1016/S0896-6273(00)80972-1	28	566	578	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					913	917		10.1038/27692	http://dx.doi.org/10.1038/27692			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804426				2022-12-24	WOS:000076713400060
J	Lester, BM; LaGasse, LL; Seifer, R				Lester, BM; LaGasse, LL; Seifer, R			Drug abuse - Cocaine exposure and children: The meaning of subtle effects	SCIENCE			English	Editorial Material							PRESCHOOL-AGE; MOTHERS		Brown Univ, Sch Med, Providence, RI 02905 USA	Brown University	Lester, BM (corresponding author), Brown Univ, Sch Med, Providence, RI 02905 USA.	barry_lester@brown.edu		Seifer, Ronald/0000-0003-4879-2839	NATIONAL INSTITUTE ON DRUG ABUSE [U10DA024119] Funding Source: NIH RePORTER; NIDA NIH HHS [U10 DA024119] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AZUMA SD, 1993, PEDIATRICS, V92, P396; Bender SL, 1995, J DEV BEHAV PEDIATR, V16, P418; Cohen J., 1988, STAT POWER ANAL SOCI, V2; HAWLEY TL, 1995, AM J ORTHOPSYCHIAT, V65, P364, DOI 10.1037/h0079693; Jensen A.R., 1980, BIAS MENTAL TESTING; Lester BM, 1997, J DRUG ISSUES, V27, P487, DOI 10.1177/002204269702700304; LESTER BM, 1998, ANN NY ACAD SCI, V846, P295; MALAKOFF ME, 1994, AM J ADDICTION, V3, P346; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; *NAT I DRUG AB, 1996, NIH PUBL; NULMAN I, 1994, CAN MED ASSOC J, V151, P1591; Richardson GA, 1996, NEUROTOXICOL TERATOL, V18, P627, DOI 10.1016/S0892-0362(96)00121-3; Rosenthal R., 2008, ESSENTIALS BEHAV RES; ROTHOLZ DA, 1995, ED TREATMENT CHILDRE, V18, P1; *US GEN ACC OFF, 1990, DRUG EXP INF GEN RIS; *US NAT CTR ED STA, 1996, PATT SPEC ED SERV DE; VANBAAR A, 1994, DEV MED CHILD NEUROL, V36, P1063	17	166	167	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					633	634		10.1126/science.282.5389.633	http://dx.doi.org/10.1126/science.282.5389.633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	132AM	9841414				2022-12-24	WOS:000076607500025
J	Bongaarts, J				Bongaarts, J			Global population growth - Demographic consequences of declining fertility	SCIENCE			English	Editorial Material																		BONGAARTS J, 1994, SCIENCE, V263, P771, DOI 10.1126/science.8303293; Bongaarts J, 1998, POPUL DEV REV, V24, P271, DOI 10.2307/2807974; Coleman D, 1996, EUROPES POPULATION 1; *COUNC EUR, 1996, REC DEM DEV EUR; DEMENY P, 1997, P EXP GROUP M REPL F; Eberstadt N, 1997, PUBLIC INTEREST, P3; *UN POP DIV, 1997, P EXP GROUP M REPL F; UN (United Nations), 1998, WORLD POP PROJ 2150; UNITED NATIONS, 1997, WORLD POP PROSP 1996; WATTENBERG B, 1997, NY TIMES        1123, P61	10	34	36	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					419	420		10.1126/science.282.5388.419	http://dx.doi.org/10.1126/science.282.5388.419			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	129TT	9841398				2022-12-24	WOS:000076479600033
J	Tabara, H; Grishok, A; Mello, CC				Tabara, H; Grishok, A; Mello, CC			RNAi in C-elegans: Soaking in the genome sequence	SCIENCE			English	Editorial Material							EMBRYOS		Univ Massachusetts, Sch Med, Dept Cell Biol, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Ctr Canc, 373 Plantat St, Worcester, MA 01605 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD33769-01] Funding Source: Medline; NIDDK NIH HHS [DK32520-15] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSHER J, COMMUNICATIN; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GRISHOK A, UNPUB; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Korf I, 1998, DEVELOPMENT, V125, P2469; MELLO CC, UNPUB; MONTGOMERY M, COMMUNICATION; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; TABARA H, UNPUB; TIMMONS L, IN PRESS NATURE; Wagner RW, 1998, NATURE, V391, P744, DOI 10.1038/35750	13	453	583	4	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					430	431		10.1126/science.282.5388.430	http://dx.doi.org/10.1126/science.282.5388.430			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9841401				2022-12-24	WOS:000076479600040
J	Soldan, K; Ramsay, M; Collins, M				Soldan, K; Ramsay, M; Collins, M			Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England	Public Health England	Soldan, K (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640; Soldan, Kate/0000-0002-0361-3174				BZUKA H, 1992, VOX SANG, V63, P107; Jongerius JM, 1998, TRANSFUSION, V38, P56, DOI 10.1046/j.1537-2995.1998.38198141499.x; SALISBURY D, 1996, IMMUNISATOIN INFECT; Williamson LM, 1996, BRIT MED J, V313, P1221, DOI 10.1136/bmj.313.7067.1221	4	27	28	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					95	95		10.1136/bmj.318.7176.95	http://dx.doi.org/10.1136/bmj.318.7176.95			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880282	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000078087500026
J	Kerr, JM				Kerr, JM			Vergil	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					9	9		10.1001/jama.281.1.9	http://dx.doi.org/10.1001/jama.281.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892429				2022-12-24	WOS:000077829300001
J	Young, ID				Young, ID			Achondroplasia: a case of neglect?	LANCET			English	Editorial Material							CERVICOMEDULLARY-JUNCTION COMPRESSION; INFANTS		City Hosp, Dept Clin Genet, Nottingham NG5 1PB, England	University of Nottingham	Young, ID (corresponding author), City Hosp, Dept Clin Genet, Nottingham NG5 1PB, England.							HECHT JT, 1987, AM J HUM GENET, V41, P454; Hunter AGW, 1998, J MED GENET, V35, P705, DOI 10.1136/jmg.35.9.705; Hunter AGW, 1998, AM J MED GENET, V78, P1, DOI 10.1002/(SICI)1096-8628(19980616)78:1<1::AID-AJMG1>3.0.CO;2-V; Mahomed NN, 1998, AM J MED GENET, V78, P30, DOI 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P; PAULI RM, 1995, AM J HUM GENET, V56, P732; RIMOIN DL, 1995, AM J HUM GENET, V56, P824; SEASHORE MR, 1995, PEDIATRICS, V95, P443; Tasker RC, 1998, ARCH DIS CHILD, V79, P99, DOI 10.1136/adc.79.2.99; Wilkin DJ, 1998, AM J HUM GENET, V63, P711, DOI 10.1086/302000	9	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1950	1951		10.1016/S0140-6736(98)00093-2	http://dx.doi.org/10.1016/S0140-6736(98)00093-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872238				2022-12-24	WOS:000077663000002
J	Hutcheon, ID; Krot, AN; Keil, K; Phinney, DL; Scott, ERD				Hutcheon, ID; Krot, AN; Keil, K; Phinney, DL; Scott, ERD			Mn-53-Cr-53 dating of fayalite formation in the CV3 chondrite mokoia: Evidence for asteroidal alteration	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; HIGH-TEMPERATURE CONDENSATION; PARENT BODY; AQUEOUS ALTERATION; ALLENDE METEORITE; CARBONACEOUS CHONDRITES; NEBULA; OLIVINE; AL-26; KABA	Fayalite grains in chondrules in the oxidized, aqueously altered CV3 chondrite Mokoia have large excesses of radiogenic chromium-53. These excesses indicate the in situ decay of short-lived manganese-53 (half-Life = 3.7 million years) and define an initial Mn-53/Mn-55 ratio of 2.32 (+/-0.18) x 10(-6). This ratio is comparable to values for carbonates in CI and CM chondrites and for several classes of differentiated meteorites. Mokoia fayalites formed 7 to 16 million years after Allende calcium-aluminum-rich inclusions, during hydrothermal activity on a geologically active asteroid after chondritic components had ceased forming in the solar nebula.	Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Hawaii System; University of Hawaii Manoa	Hutcheon, ID (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA.			Scott, Edward/0000-0002-5137-3830				BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; BIRCK JL, 1985, GEOPHYS RES LETT, V12, P745, DOI 10.1029/GL012i011p00745; Brearley A, 1997, SCIENCE, V278, P76, DOI 10.1126/science.278.5335.76; Brearley AJ, 1997, SCIENCE, V276, P1103, DOI 10.1126/science.276.5315.1103; BROWNING L, UNPUB; CAMERON AGW, 1995, METEORITICS, V30, P133, DOI 10.1111/j.1945-5100.1995.tb01110.x; EBER DS, 1997, METEORL PLANET SCI, V32, pA37; Endress M, 1996, NATURE, V379, P701, DOI 10.1038/379701a0; GRIMM RE, 1993, SCIENCE, V259, P653, DOI 10.1126/science.259.5095.653; GROSSMAN L, 1980, ANNU REV EARTH PL SC, V8, P559, DOI 10.1146/annurev.ea.08.050180.003015; Hohenberg CM, 1998, METEORIT PLANET SCI, V33, pA69; Housley R. M., 1983, CHONDRULES THEIR ORI, P145; HUA X, 1988, GEOCHIM COSMOCHIM AC, V52, P1389, DOI 10.1016/0016-7037(88)90210-4; HUA X, 1995, GEOCHIM COSMOCHIM AC, V59, P563, DOI 10.1016/0016-7037(94)00383-W; HUTCHEON ID, 1997, 9702 LUN PLAN I 1, P27; HUTCHEON ID, 1992, LUNAR PLANET SCI, V23, P565; HUTCHEON ID, 1981, LUNAR PLANET SCI, V12, P491; KELLER LP, 1990, GEOCHIM COSMOCHIM AC, V54, P2113, DOI 10.1016/0016-7037(90)90274-O; KELLER LP, 1991, SCIENCE, V252, P946, DOI 10.1126/science.252.5008.946; Kerridge JF., 1988, METEORITES EARLY SOL; KIMUR M, 1997, ANTARCT MET RES, V10, P217; Kojima T, 1996, GEOCHIM COSMOCHIM AC, V60, P2651, DOI 10.1016/0016-7037(96)00116-0; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; Krot AN, 1998, METEORIT PLANET SCI, V33, pA89; KROT AN, 1997, 9702 LPI 1, P34; Lawson WA, 1996, MON NOT R ASTRON SOC, V280, P1071; Lugmair G. W., 1992, LUNAR PLANET SCI, VXXIII, P823; LUGMAIR GW, 1994, METEORITICS, V29, P493; LUGMAIR GW, 1997, LUNAR PLANET SCI, V27, P851; MACDOUGALL JD, 1984, NATURE, V307, P249, DOI 10.1038/307249a0; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MACPHERSON GJ, 1997, 9702 LUN PLAN I 1, P42; MCSWEEN HY, 1977, GEOCHIM COSMOCHIM AC, V41, P1777, DOI 10.1016/0016-7037(77)90210-1; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; PALME H, 1990, EARTH PLANET SC LETT, V101, P180, DOI 10.1016/0012-821X(90)90152-N; PECK JA, 1987, GEOCHIM COSMOCHIM AC, V51, P1503, DOI 10.1016/0016-7037(87)90332-2; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; Richardson S. M., 1978, Meteoritics, V13, P141, DOI 10.1111/j.1945-5100.1978.tb00803.x; Rubin A. E., 1988, METEORITES EARLY SOL, P488; RUSSELL SS, 1997, 9702 LUN PLAN I 1, P54; SHIELDS WR, 1966, J RES NBS A PHYS CH, VA 70, P193, DOI 10.6028/jres.070A.016; SHUKOLYUKOV A, 1998, LUNAR PLANET SCI, V29, P1208; Strom S. E., 1993, PROTOSTARS PLANETS, P837; TOMEOKA K, 1982, NATURE, V299, P327, DOI 10.1038/299327a0; TOMEOKA K, 1997, WORKSH PAR BOD NEB 1, P61; TORNEOKA K, 1990, GEOCHIM COSMOCHIM AC, V54, P1745; WADHWA M, 1998, LUNAR PLANET SCI, V29, P1480; WADHWA M, 1998, LUNAR PLANET SCI, V29, P1484; WEINBRUCH S, 1990, METEORITICS, V25, P115, DOI 10.1111/j.1945-5100.1990.tb00983.x; WEINBRUCH S, 1994, GEOCHIM COSMOCHIM AC, V58, P1019, DOI 10.1016/0016-7037(94)90523-1; Weisberg MK, 1997, METEORIT PLANET SCI, V32, pA138; WEISBERG MK, 1997, METEORIT PLANET SCI, V32, P719; WOOD JA, 1988, ANNU REV EARTH PL SC, V16, P53; WOOD JA, 1993, GEOCHIM COSMOCHIM AC, V57, P2377, DOI 10.1016/0016-7037(93)90575-H; ZOLENSKY ME, 1997, 9702 LUN PLAN I 2; ZOLENSKY ME, 1997, 9702 LUN PLAN I 1; [No title captured]; [No title captured]	58	65	66	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1865	1867		10.1126/science.282.5395.1865	http://dx.doi.org/10.1126/science.282.5395.1865			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836631				2022-12-24	WOS:000077338100041
J	Kramer, MS; Platt, R; Yang, H; Joseph, KS; Wen, SW; Morin, L; Usher, RH				Kramer, MS; Platt, R; Yang, H; Joseph, KS; Wen, SW; Morin, L; Usher, RH			Secular trends in preterm birth - A hospital-based cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFANT-MORTALITY RATES; GESTATIONAL-AGE; WEIGHT; FRANCE	Context.-Canada and the United States have reported a recent increase in the incidence of preterm birth, but the reasons for this increase are unknown. Objective.-To assess secular trends in preterm birth and its potential determinants. Design.-Hospital-based cohort study. Setting.-Canadian tertiary care university teaching hospital, 1978-1996. Participants.-A total of 65 574 nonreferred live births and stillbirths. Main Outcome Measures.-Changes in occurrence of preterm birth, before and after adjustment for changes in method of gestational age assessment, obstetric intervention, registration of births weighing less than 500 g, and sociodemographic, behavioral, and clinical determinants. Results.-A crude secular increase in preterm births was seen for births less than 37, 34, and 32 completed weeks using 3 alternative gestational age estimation methods, Based on an algorithm incorporating both menstrual and early ultrasound gestational age estimates, rates increased from 6.6% to 9.8% for births at less than 37 weeks' gestation, 1.7% to 2.3% at less than 34 weeks, and 1.0% to 1.2% at less than 32 weeks. Exclusion of births weighing less than 500 g and those with induction or preterm cesarean delivery without labor before each of the corresponding gestational age cutoffs eliminated the secular trends for births before 34 and 32 weeks and attenuated the trend for births before 37 weeks. Nearly half of the remaining trend for births before 37 weeks was accounted for by the increasing use of early ultrasound dating. The residual trend was eliminated after controlling for secular increases in unmarried status and the proportion of women aged 35 years or older. These factors, combined with a decrease in alcohol consumption and increases in histological chorioamnionitis and cocaine use, appear to have counteracted a reduction in preterm birth since the mid-1980s that otherwise would have been observed. Conclusions.-This hospital's increase in preterm births since 1978 parallels increases reported in population-based national studies from the United States and Canada. This trend appears largely attributable to the increasing use of early ultrasound dating, preterm induction and preterm cesarean delivery without labor, and changes in sociodemographic and behavioral factors.	McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Fac Med, Dept Obstet & Gynecol, Montreal, PQ H3A 2T5, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Hlth Canada, Lab Ctr Dis Control, Bur Reprod & Child Hlth, Ottawa, ON K1A 0L2, Canada	McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital; Health Canada	Kramer, MS (corresponding author), 1020 Pine Ave, W Montreal, PQ H3A 1A2, Canada.			Joseph, K.S./0000-0003-2317-5607; Platt, Robert/0000-0002-5981-8443				[Anonymous], 1985, PREV LOW BIRTHW; BREART G, 1995, PAEDIATR PERINAT EP, V9, P296, DOI 10.1111/j.1365-3016.1995.tb00146.x; DOLLFUS C, 1990, PEDIATRICS, V86, P176; GOLDENBERG RL, 1989, AM J OBSTET GYNECOL, V160, P462, DOI 10.1016/0002-9378(89)90473-0; Joseph KS, 1997, CAN MED ASSOC J, V157, P535; Joseph KS, 1998, NEW ENGL J MED, V339, P1434, DOI 10.1056/NEJM199811123392004; Joseph KS, 1996, CAN MED ASSOC J, V155, P1047; KLIEGMAN RM, 1995, AM J PUBLIC HEALTH, V85, P909, DOI 10.2105/AJPH.85.7.909; KRAMER M, 1987, B WORLD HEALTH ORGAN, V65, P665; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; LEE KS, 1980, AM J PUBLIC HEALTH, V70, P15, DOI 10.2105/AJPH.70.1.15; Martin J A, 1995, Stat Bull Metrop Insur Co, V76, P10; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MORRISON JC, 1990, OBSTET GYNECOL, V76, P55; *NAT CTR CHRON DIS, 1994, MMWR-MORBID MORTAL W, V43, P335; OLSEN P, 1995, AM J EPIDEMIOL, V142, P1184, DOI 10.1093/oxfordjournals.aje.a117577; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; SMITH LP, 1982, ACTA OBSTET GYNECO S, V109, P49	21	122	124	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1849	1854		10.1001/jama.280.21.1849	http://dx.doi.org/10.1001/jama.280.21.1849			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846780				2022-12-24	WOS:000077176600031
J	Rexrode, KM; Carey, VJ; Hennekens, CH; Walters, EE; Colditz, GA; Stampfer, MJ; Willett, WC; Manson, JAE				Rexrode, KM; Carey, VJ; Hennekens, CH; Walters, EE; Colditz, GA; Stampfer, MJ; Willett, WC; Manson, JAE			Abdominal adiposity and coronary heart disease in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-FAT DISTRIBUTION; CARDIOVASCULAR RISK-FACTORS; POSTMENOPAUSAL WOMEN; PROSPECTIVE COHORT; DIABETES-MELLITUS; NATIONAL-HEALTH; OLDER WOMEN; HIP RATIO; MEN; FOLLOW	Context.-Obesity is a well-established risk factor for coronary heart disease (CHD), but whether regional fat distribution contributes independently to risk remains unclear. Objective.-To compare waist-hip ratio (WHR) and waist circumference in determining risk of CHD in women. Design and Setting.-Prospective cohort study among US female registered nurses participating in the Nurses' Health Study conducted between 1986, when the nurses completed a questionnaire, and follow-up in June 1994. Participants.-A total of 44 702 women aged 40 to 65 years who provided waist and hip circumferences and were free of prior CHD, stroke, or cancer in 1986. Main Outcome Measures.-Incidence of CHD (nonfatal myocardial infarction or CHD death). Results.-During 8 years of follow-up 320 CHD events (251 myocardial infarctions and 69 CHD deaths) were documented. Higher WHR and greater waist circumference were independently associated with a significantly increased age-adjusted risk of CHD. After adjusting for body mass index (BMI) (defined as weight in kilograms divided by the square of height in meters) and other cardiac risk factors, women with a WHR of 0.88 or higher had a relative risk (RR) of 3.25 (95% confidence interval [CI], 1.78-5.95) for CHD compared with women with a WHR of less than 0.72. A waist circumference of 96.5 cm (38 in) or more was associated with an RR of 3.06 (95% CI, 1.54-6.10). The WHR and waist circumference were independently strongly associated with increased risk of CHD also among women with a BMI of 25 kg/m(2) or less. After adjustment for reported hypertension, diabetes, and high cholesterol level, a WHR of 0.76 or higher or waist circumference of 76.2 cm (30 in) or more was associated with more than a 2-fold higher risk of CHD. Conclusions.-The WHR and waist circumference are independently associated with risk of CHD in women.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Rexrode, KM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009; Rexrode, Kathryn M/I-1177-2018	Colditz, Graham/0000-0002-7307-0291; Rexrode, Kathryn/0000-0003-3387-8429	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; CURB JD, 1991, AM J CLIN NUTR, V53, pS1612, DOI 10.1093/ajcn/53.6.1612S; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DONAHUE RP, 1987, LANCET, V1, P821; DUCIMETIERE P, 1986, INT J OBESITY, V10, P229; Duncan Bruce B., 1995, Annals of Epidemiology, V5, P192, DOI 10.1016/1047-2797(94)00106-4; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; FRASER GE, 1992, CIRCULATION, V86, P406, DOI 10.1161/01.CIR.86.2.406; FREEDMAN DS, 1995, AM J EPIDEMIOL, V142, P53, DOI 10.1093/oxfordjournals.aje.a117545; HAFFNER SM, 1991, INT J OBESITY, V15, P471; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; PEIRIS AN, 1987, INT J OBESITY, V11, P581; Prineas R J, 1993, Ann Epidemiol, V3, P35, DOI 10.1016/1047-2797(93)90007-Q; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033; SVENDSEN OL, 1993, AM J MED, V95, P131, DOI 10.1016/0002-9343(93)90253-L; TERRY RB, 1992, INT J OBESITY, V16, P417; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WING RR, 1995, INT J OBESITY, V19, P67; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250	34	802	829	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1843	1848		10.1001/jama.280.21.1843	http://dx.doi.org/10.1001/jama.280.21.1843			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846779	Bronze			2022-12-24	WOS:000077176600030
J	Shao, DL; Rangwala, SM; Bailey, ST; Krakow, SL; Reginato, MJ; Lazar, MA				Shao, DL; Rangwala, SM; Bailey, ST; Krakow, SL; Reginato, MJ; Lazar, MA			Interdomain communication regulating ligand binding by PPAR-gamma	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; ESTROGEN-RECEPTOR; ADIPOCYTE DIFFERENTIATION; PROTEIN-KINASE; PROLIFERATOR; PHOSPHORYLATION; HORMONE; ALPHA; THIAZOLIDINEDIONES; TRANSCRIPTION	Binding to receptors in the cell nucleus is crucial for the action of lipophilic hormones and ligands. PPAR-gamma (for peroxisome proliferator-activated receptor) is a nuclear hormone receptor that mediates adipocyte differentiation(1,2) and modulates insulin sensitivity(3), cell proliferation(4) and inflammatory processes(5,6). PPAR-gamma ligands have been implicated in the development of atherogenic foam cells(7) and as potential cancer treatments(8). Transcriptional activity of PPAR-gamma is induced by binding diverse ligands, including natural fatty acid derivatives(9-11), antidiabetic thiazolidinediones(12), and non-steroidal anti-inflammatory drugs(13). Ligand binding by PPAR-gamma, as well as by the entire nuclear-receptor superfamily, is an independent property of the carboxy-terminal ligand-binding domain (LBD) of the receptor(14,15). Here we show that ligand binding by PPAR-gamma is regulated by intramolecular communication between its amino-terminal A/B domain and its carboxy-terminal LED. Modification of the A/B domain, for example by physiological phosphorylation by MAP kinase, reduces ligand-binding affinity, thus negatively regulating the transcriptional and biological functions of PPAR-gamma. The ability of the A/B domain to regulate ligand binding has important implications for the evaluation and mechanism of action of potentially therapeutic ligands that bind PPAR-gamma and that are likely to extend to other members of the nuclear-receptor superfamily.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Bailey, Shannon/B-8045-2014; Lazar, Mitchell A/AAF-3738-2019; Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAMP HS, 1997, J BIOL CHEM, V272, P13452; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	30	294	308	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					377	380		10.1038/24634	http://dx.doi.org/10.1038/24634			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845075				2022-12-24	WOS:000077204000052
J	Amitai, M				Amitai, M			Hidden models in biopolymers	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; PROFILE ANALYSIS; MARKOV-MODELS; PREDICTION		Compugen Ltd, IL-69512 Tel Aviv, Israel		Amitai, M (corresponding author), Compugen Ltd, Pinchas Rozen 72, IL-69512 Tel Aviv, Israel.	mor@compugen.co.il						BIRNEY E, 1997, P 5 INT C INT SYST M, P56; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Durbin, 1998, BIOL SEQUENCE ANAL P; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; EDDY SR, 1995, P 3 INT C INT SYST M, P114; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; Goldman N, 1996, J MOL BIOL, V263, P196, DOI 10.1006/jmbi.1996.0569; Gribskov M, 1996, METHOD ENZYMOL, V266, P198; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Murzin AG, 1997, PROTEINS, P105; RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schuster-Bockler Benjamin, 2007, Curr Protoc Bioinformatics, VAppendix 3, p3A, DOI [10.1109/MASSP.1986.1165342, 10.1002/0471250953.bia03as18]; Sjolander K, 1996, COMPUT APPL BIOSCI, V12, P327; Slonim D, 1997, J COMPUT BIOL, V4, P487, DOI 10.1089/cmb.1997.4.487; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; [No title captured]	21	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1436	1437						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867651				2022-12-24	WOS:000077110800032
J	Luther, A; Brandsch, R; von Kiedrowski, G				Luther, A; Brandsch, R; von Kiedrowski, G			Surface-promoted replication and exponential amplification of DNA analogues	NATURE			English	Article							PEPTIDE SELF-REPLICATION; CHEMICAL LIGATION; SYSTEM; EVOLUTION; OLIGOMERS; TEMPLATES; GROWTH; LIFE	Self-replicating chemical systems have been designed and studied to identify the minimal requirements for molecular replication(1), to translate the principle into synthetic supramolecular systems(2) and to derive a better understanding of the scope and limitations of self-organization processes(3) that are believed to be relevant to the origin of life on Earth(4). Current implementations make use of oligonucleotide analogues(5-12), peptides(13-17), and other molecules(18-24) as templates and are based either on autocatalytic, cross-catalytic, or collectively catalytic pathways for template formation. A common problem of these systems is product inhibition, leading to parabolic instead of exponential amplification(25). The fatter is the dynamic prerequisite for selection in the darwinian sense(26,27). We here describe an iterative, stepwise procedure for chemical replication which permits an exponential increase in the concentration of oligonucleotide analogues. The procedure employs the surface of a solid support and is called SPREAD (surface-promoted replication and exponential amplification of DNA analogues). Copies are synthesized from precursor fragments by chemical ligation on immobilized templates, and then Liberated and immobilized to become new templates. The process is repeated iteratively. The role of the support is to separate complementary templates which would form stable duplexes in solution. SPREAD combines the advantages of solid-phase chemistry with chemical replication, and can be further developed for the non-enzymatic and enzymatic amplification of RNA, peptides and other templates as well as for studies of in vitro evolution and competition in artificial chemical systems. Similar processes may also have played a role in the origin of life on Earth, because the earliest replication systems may have proliferated by spreading on mineral surfaces(28-33).	Ruhr Univ Bochum, Lehrstuhl Bioorgan Chem, D-44780 Bochum, Germany	Ruhr University Bochum	von Kiedrowski, G (corresponding author), Ruhr Univ Bochum, Lehrstuhl Bioorgan Chem, Univ Str 150 NC 2-173, D-44780 Bochum, Germany.	kiedro@ernie.orch.ruhr-uni-bochum.de						ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; BERNAL JD, 1951, PHYSICAL BASE LIFE; DOLINNAYA NG, 1991, NUCLEIC ACIDS RES, V19, P3073, DOI 10.1093/nar/19.11.3073; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; FENG Q, 1992, SCIENCE, V256, P1179, DOI 10.1126/science.256.5060.1179; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; James KD, 1997, CHEM BIOL, V4, P595, DOI 10.1016/S1074-5521(97)90245-3; Joyce GF., 1994, ORIGINS LIFE CENTRAL; Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112; KUHN H, 1981, ANGEW CHEM INT EDIT, V20, P500, DOI 10.1002/anie.198105001; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; Lee DH, 1997, NATURE, V390, P591, DOI 10.1038/37569; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; MARTIN B, 1997, HELV CHIM ACTA, V80, P1901; Orgel LE, 1998, ORIGINS LIFE EVOL B, V28, P227, DOI 10.1023/A:1006595411403; ORGEL LE, 1995, ACCOUNTS CHEM RES, V28, P109, DOI 10.1021/ar00051a004; PIETERS RJ, 1994, ANGEW CHEM INT EDIT, V33, P1579, DOI 10.1002/anie.199415791; Reinhoudt DN, 1996, J AM CHEM SOC, V118, P6880, DOI 10.1021/ja960324g; Severin K, 1998, ANGEW CHEM INT EDIT, V37, P126, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<126::AID-ANIE126>3.0.CO;2-4; Severin K, 1997, CHEM-EUR J, V3, P1017, DOI 10.1002/chem.19970030706; SIEVERS D, 1994, NATO ADV SCI INST SE, V446, P45; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; Sievers D, 1998, CHEM-EUR J, V4, P629, DOI 10.1002/(SICI)1521-3765(19980416)4:4<629::AID-CHEM629>3.0.CO;2-0; SZATHMARY E, 1989, J THEOR BIOL, V138, P55, DOI 10.1016/S0022-5193(89)80177-8; Szathmary E, 1997, J THEOR BIOL, V187, P555, DOI 10.1006/jtbi.1996.0389; TERFORT A, 1992, ANGEW CHEM INT EDIT, V31, P654, DOI 10.1002/anie.199206541; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; vonKiedrowski G, 1996, NATURE, V381, P20, DOI 10.1038/381020a0; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; Wang B, 1997, CHEM COMMUN, P1495, DOI 10.1039/a701573i; WILLS RW, 1997, 9707065; WILLS RW, IN PRESS B MATH BIOL; WINTNER EA, 1994, ACCOUNTS CHEM RES, V27, P198, DOI 10.1021/ar00043a003; Yao S, 1998, ANGEW CHEM INT EDIT, V37, P478, DOI 10.1002/(SICI)1521-3773(19980302)37:4<478::AID-ANIE478>3.0.CO;2-V; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0; [No title captured]	40	198	219	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1998	396	6708					245	248		10.1038/24343	http://dx.doi.org/10.1038/24343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834031				2022-12-24	WOS:000077110400041
J	Rhee, KH; Morriss, EP; Barber, J; Kuhlbrandt, W				Rhee, KH; Morriss, EP; Barber, J; Kuhlbrandt, W			Three-dimensional structure of the plant photosystem II reaction centre at 8 angstrom resolution	NATURE			English	Article							PHOTOSYNTHETIC REACTION-CENTER; PURPLE MEMBRANE; MODEL; DONOR; POLYPEPTIDES	Photosystem II is a multisubunit enzyme complex involved in plant photosynthesis. It uses solar energy to catalyse the breakdown of water to reducing equivalents and molecular oxygen(1). Native photosystem II comprises more than 25 different subunits, and has a relative molecular mass of more than 600K. Here we report the three-dimensional structure of a photosystem II subcomplex, containing the proteins D1, D2, CP47 and cytochrome b-559, determined by electron crystallography. This CP47 reaction centre, which has a relative molecular mass of 160K, can perform light-mediated energy and electron-transfer reactions but is unable to oxidize water(2). The complex contains 23 transmembrane alpha-helices, of which 16 have been assigned to the D1, D2 and CP47 proteins. The arrangement of these helices is remarkably similar to that of the helices in the reaction centres of purple bacteria and of plant photosystem I, indicating a common evolutionary origin for these assemblies. The map suggests that redox cofactors in the D1-D2 complex are located in positions analogous to those in the bacterial reaction centre, but the distance between the chlorophylls corresponding to the bacterial 'special pair' is significantly larger.	Max Planck Inst Biophys, Abt Strukt Biol, D-60528 Frankfurt, Germany; European Mol Biol Lab, Struct Biol Programme & Biocomp Unit, D-69117 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Max Planck Society; European Molecular Biology Laboratory (EMBL); Imperial College London	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Abt Strukt Biol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.			Kuhlbrandt, Werner/0000-0002-2013-4810				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; Bianchetti M, 1998, J BIOL CHEM, V273, P16128, DOI 10.1074/jbc.273.26.16128; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DURRANT JR, 1995, P NATL ACAD SCI USA, V92, P4798, DOI 10.1073/pnas.92.11.4798; Fromme P, 1996, BBA-BIOENERGETICS, V1275, P76, DOI 10.1016/0005-2728(96)00053-9; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; MATHIS P, 1990, BIOCHIM BIOPHYS ACTA, V1018, P163, DOI 10.1016/0005-2728(90)90240-5; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MOSKALENKO AA, 1992, FEBS LETT, V314, P271, DOI 10.1016/0014-5793(92)81487-7; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Nitschke W., 1998, P285; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; Rutherford A. W., 1996, P143; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122	29	283	296	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					283	286		10.1038/24421	http://dx.doi.org/10.1038/24421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834037				2022-12-24	WOS:000077110400052
J	Nguyen, M; Park, S; Marques, G; Arora, K				Nguyen, M; Park, S; Marques, G; Arora, K			Interpretation of a BMP activity gradient in Drosophila embryos depends on synergistic signaling by two type I receptors, SAX and TKV	CELL			English	Article							SHORT GASTRULATION GENE; DORSAL-VENTRAL PATTERN; DPP RECEPTORS; BETA FAMILY; THICK VEINS; DECAPENTAPLEGIC GENE; CELL FATES; MORPHOGEN; PROTEINS; XENOPUS	Graded activity of the DPP signaling pathway is critical for specification of dorsal embryonic cell fates in Drosophila. We present evidence that a second BMP ligand, SCW, potentiates DPP activity. Using dominant-negative forms of the type I receptors SAX and TKV, we demonstrate that SAX mediates the SCW signal, white TKV is required for both DPP and SCW activity. We find that while DPP/TKV signaling is obligatorily required, SCW/SAX activity is necessary but not sufficient for dorsal patterning. SAX and TKV act synergistically, suggesting a mechanism for integration of the SCW and DPP signals. Further, we show that the extracellular protein SOG can antagonize SCW, thus limiting its ability to augment DPP signaling in a graded manner.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; CSIC, Inst Cajal, E-28002 Madrid, Spain	University of California System; University of California Irvine; University of California System; University of California Irvine; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Arora, K (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM55442] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055442] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Burke R, 1996, DEVELOPMENT, V122, P2261; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GELBART WM, 1989, DEVELOPMENT, V107, P65; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LECUIT T, 1996, NATURE, V381, P1387; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Parkansky N, 1995, SURF COAT TECH, V76, P197, DOI 10.1016/0257-8972(95)02588-X; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; RAFTERY LA, 1995, GENETICS, V139, P241; RAY RP, 1991, DEVELOPMENT, V113, P35; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Singer MA, 1997, DEVELOPMENT, V124, P79; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; TERRACOL R, 1994, GENETICS, V138, P165; WHARTON KA, 1993, DEVELOPMENT, V117, P807; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; Yu K, 1996, DEVELOPMENT, V122, P4033	47	100	104	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					495	506		10.1016/S0092-8674(00)81617-7	http://dx.doi.org/10.1016/S0092-8674(00)81617-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827802	Bronze			2022-12-24	WOS:000077049400008
J	Sen, J; Goltz, JS; Stevens, L; Stein, D				Sen, J; Goltz, JS; Stevens, L; Stein, D			Spatially restricted expression of pipe in the Drosophila egg chamber defines embryonic dorsal-ventral polarity	CELL			English	Article							HEPARAN-SULFATE 2-SULFOTRANSFERASE; TOLL GENE-PRODUCT; FAINT-LITTLE-BALL; TRANSMEMBRANE PROTEIN; DORSOVENTRAL PATTERN; RECEPTOR HOMOLOG; SERINE PROTEASE; ENCODES; LOCALIZATION; MELANOGASTER	Expression of pipe in the somatic tissue of the Drosophila ovary is required for the formation of embryonic dorsal-ventral polarity. pipe, which encodes an enzyme similar to the glycosaminoglycan-modifying enzyme heparan sulfate 2-O-sulfotransferase, is expressed in a spatially restricted domain of follicle cells on the Ventral side of the egg chamber. Mutations that affect follicular polarity correspondingly alter the spatial pattern of pipe expression. Directed expression of pipe in otherwise pipe mutant females restores embryonic lateral and ventral pattern elements and can orient the dorsal-ventral axis of the embryo. Thus, the localized expression of pipe and the spatially restricted modification of carbohydrate chains play pivotal roles in the mechanisms that establish embryonic pattern and integrate follicular and embryonic polarity.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Stein, D (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stein@aecom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBRUNNER M, 1989, DROSOPHILA LAB MANUA; BEMFIELD M, 1992, ANN REV CELL BIOL, V8, P365; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; ENGELS WR, 1986, FOCUS, V8, P6; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEINO TI, 1994, DROS INF SERV, V73, P621; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MOHLER JD, 1977, GENETICS, V85, P259; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Nilson LA, 1998, CELL, V93, P253, DOI 10.1016/S0092-8674(00)81576-7; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; ROTH S, 1993, DEVELOPMENT, V117, P1385; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SAVANTBHONSALE S, 1993, GENE DEV, V7, P2548, DOI 10.1101/gad.7.12b.2548; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRIPOULAS NA, 1994, GENETICS, V137, P1027; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wharton K. A., 1992, DROS INFO SERV, V71, P152; Wieschaus E., 1986, P199; Wieschaus E., 1978, WILHELMS ROUXS ARCH, V184, P74; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443	66	176	179	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					471	481		10.1016/S0092-8674(00)81615-3	http://dx.doi.org/10.1016/S0092-8674(00)81615-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827800	Bronze			2022-12-24	WOS:000077049400006
J	Golden, BL; Gooding, AR; Podell, ER; Cech, TR				Golden, BL; Gooding, AR; Podell, ER; Cech, TR			A preorganized active site in the crystal structure of the Tetrahymena ribozyme	SCIENCE			English	Article							GROUP-I INTRON; SELF-SPLICING INTRONS; BINDING-SITE; CATALYTIC CORE; METAL-ION; ELECTRON-MICROSCOPY; TERTIARY STRUCTURE; DIFFRACTION DATA; GAAA TETRALOOP; RNA CATALYSIS	Group I introns possess a single active site that catalyzes the two sequential reactions of self-splicing. An RNA comprising the two domains of the Tetrahymena thermophila group I intron catalytic core retains activity, and the 5.0 angstrom crystal structure of this 247-nucleotide ribozyme is now described. Close packing of the two domains forms a shallow cleft capable of binding the short helix that contains the 5' splice site. The helix that provides the binding site for the guanosine substrate deviates significantly from A-form geometry, providing a tight binding pocket. The binding pockets for both the 5' splice site helix and guanosine are formed and oriented in the absence of these substrates. Thus, this large ribozyme is largely preorganized for catalysis, much Like a globular protein enzyme.	Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Golden, BL (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Campus Box 215, Boulder, CO 80309 USA.	bgolden@petunia.colorado.edu; Cech@colorado.edu		Golden, Barbara/0000-0002-9741-882X				ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Berens C, 1998, CHEM BIOL, V5, P163, DOI 10.1016/S1074-5521(98)90061-8; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BRUNGER AT, IN PRESS ACTA CRYS D; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; CAPRARA MG, 1994, GENE, V143, P29, DOI 10.1016/0378-1119(94)90600-9; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1993, RNA WORLD, P239; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CHRISTIAN EL, 1992, J MOL BIOL, V228, P743, DOI 10.1016/0022-2836(92)90861-D; Cohen SB, 1997, J AM CHEM SOC, V119, P6259, DOI 10.1021/ja9707421; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; Downs WD, 1996, RNA, V2, P718; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GEWIRTH D, 1994, HKL MANUAL DESCRIPTI; Golden BL, 1997, J MOL BIOL, V270, P711, DOI 10.1006/jmbi.1997.1155; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MCCONNELL T, 1995, THESIS U COLORADO; McKay DB, 1996, RNA, V2, P395; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; NAKAMURA TM, 1995, EMBO J, V14, P4849, DOI 10.1002/j.1460-2075.1995.tb00166.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ortoleva-Donnelly L, 1998, RNA, V4, P498, DOI 10.1017/S1355838298980086; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT, P80; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sclavi B, 1998, SCIENCE, V279, P1940, DOI 10.1126/science.279.5358.1940; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; Szewczak AA, 1997, RNA, V3, P838; Tanner MA, 1997, SCIENCE, V275, P847, DOI 10.1126/science.275.5301.847; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG YH, 1994, J MOL BIOL, V236, P64, DOI 10.1006/jmbi.1994.1118; WARING RB, 1985, CELL, V40, P371, DOI 10.1016/0092-8674(85)90151-5; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	59	279	288	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					259	264		10.1126/science.282.5387.259	http://dx.doi.org/10.1126/science.282.5387.259			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9841391				2022-12-24	WOS:000076370200037
J	Ramanathan, K; Michael, TH; Jiang, GJ; Hiel, H; Fuchs, PA				Ramanathan, K; Michael, TH; Jiang, GJ; Hiel, H; Fuchs, PA			A molecular mechanism for electrical tuning of cochlear hair cells	SCIENCE			English	Article							ACTIVATED POTASSIUM CHANNELS; BETA-SUBUNIT; HUMAN BRAIN; EXPRESSION; CONDUCTANCES; ISOFORMS; CLONING; CHICK; HSLO	Cochlear frequency selectivity in Lower vertebrates arises in part from electrical tuning intrinsic to the sensory hair cells. The resonant frequency is determined largely by the gating kinetics of calcium-activated potassium (BK) channels encoded by the slo gene. Alternative splicing of slo from chick cochlea generated kinetically distinct BK channels. Combination with accessory beta subunits slowed the gating kinetics of alpha splice variants but preserved relative differences between them. In situ hybridization showed that the beta subunit is preferentially expressed by low-frequency (apical) hair cells in the avian cochlea, Interaction of beta with alpha splice variants could provide the kinetic range needed for electrical tuning of cochlear hair cells.	Johns Hopkins Univ, Sch Med, Ctr Hearing Sci, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Hearing Sci, Dept Biomed Engn, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Fuchs, PA (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Hearing Sci, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.	pfuchs@bme.jhu.edu			NIDCD NIH HHS [DC00276] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; ART JJ, 1995, J GEN PHYSIOL, V105, P49, DOI 10.1085/jgp.105.1.49; BERS DM, 1994, METHOD CELL BIOL, V40, P3; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1988, J COMP PHYSIOL A, V164, P151, DOI 10.1007/BF00603947; Hiel H, 1996, BRAIN RES, V738, P347, DOI 10.1016/S0006-8993(96)01046-3; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P237, DOI 10.1113/jphysiol.1988.sp017119; Jiang GJ, 1997, P ROY SOC B-BIOL SCI, V264, P731, DOI 10.1098/rspb.1997.0104; Jones EMC, 1998, P ROY SOC B-BIOL SCI, V265, P685, DOI 10.1098/rspb.1998.0348; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Michael T, 1997, BIOPHYS J, V72, pTHP20; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443	22	152	158	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1999	283	5399					215	217		10.1126/science.283.5399.215	http://dx.doi.org/10.1126/science.283.5399.215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880252				2022-12-24	WOS:000077976700037
J	Hanley, JG; Koulen, P; Bedford, F; Gordon-Weeks, PR; Moss, SJ				Hanley, JG; Koulen, P; Bedford, F; Gordon-Weeks, PR; Moss, SJ			The protein MAP-1B links GABA(c) receptors to the cytoskeleton at retinal synapses	NATURE			English	Article							A RECEPTORS; XENOPUS OOCYTES; EXPRESSION; SUBUNITS; GEPHYRIN; LOCALIZATION; CLONING; DOMAIN; RHO-1; GENE	The ionotropic type-A and type-C receptors for the neurotransmitter gamma-aminobutyric acid (GABA(A) and GABA(C) receptors) are the principal sites of fast synaptic inhibition in the central nervous system(1-3), but it is not known how these receptors are localized at GABA-dependent synapses. GABA(C) receptors, which are composed of rho-subunits(3-6), are expressed almost exclusively in the retina of adult vertebrates, where they are enriched on bipolar cell axon terminals(7-9). Here we show that the microtubule-associated protein 1B (MAP-1B) specifically interacts with the GABA(C) pi subunit but not with GABA(A) receptor subunits. Furthermore, GABA(C) receptors and MAP-1B co-localize at postsynaptic sites on bipolar cell axon terminals. Co-expression of MAP-1B and the pi subunit in COS cells results in a dramatic redistribution of the rho 1 subunit. Our observations suggest a novel mechanism for localizing ionotropic GABA receptors to synaptic sites. This mechanism, which is specific for GABA(C) but not GABA(A) receptors, may allow these receptor subtypes, which have distinct physiological and pharmacological properties, to be differentially localized at inhibitory synapses.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Max Planck Inst Hirnforsch, Neuroanat Abt, D-60528 Frankfurt, Germany; Kings Coll London, Dev Biol Res Ctr, Div Biomed Sci, London WC2R 5LL, England	University of London; University College London; University of London; University College London; Max Planck Society; University of London; King's College London	Moss, SJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	steve.moss@UCL.ac.uk	Gordon-Weeks, Phillip R./C-5328-2009	Gordon-Weeks, Phillip R./0000-0002-4738-4246; Hanley, Jonathan/0000-0003-1704-4707	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBRECHT BE, 1995, NEUROSCI LETT, V189, P155, DOI 10.1016/0304-3940(95)11479-G; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; ENZ R, 1995, EUR J NEUROSCI, V7, P1495, DOI 10.1111/j.1460-9568.1995.tb01144.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJII T, 1993, J BIOCHEM-TOKYO, V114, P827, DOI 10.1093/oxfordjournals.jbchem.a124263; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; HAMMARBACK JA, 1997, BRAIN MICROTUBULE AS, P1; Johnstone M, 1997, J ANAT, V191, P229, DOI 10.1046/j.1469-7580.1997.19120229.x; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Koulen P, 1998, EUR J NEUROSCI, V10, P115, DOI 10.1046/j.1460-9568.1998.00005.x; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIEN LL, 1994, GENOMICS, V22, P273, DOI 10.1006/geno.1994.1384; Lukasiewicz PD, 1996, MOL NEUROBIOL, V12, P181, DOI 10.1007/BF02755587; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA M, 1987, P NATL ACAD SCI USA, V84, P3501, DOI 10.1073/pnas.84.10.3501; ULLOA L, 1997, BRAIN MICROTUBLE ASS, P17; WANG TL, 1994, J NEUROSCI, V14, P6524; Wyszynski M, 1998, J NEUROSCI, V18, P1383	25	110	111	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					66	69		10.1038/16258	http://dx.doi.org/10.1038/16258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892354				2022-12-24	WOS:000077959400048
J	Pelliccia, A; Culasso, F; DiPaolo, FM; Maron, BJ				Pelliccia, A; Culasso, F; DiPaolo, FM; Maron, BJ			Physiologic left ventricular cavity dilatation in elite athletes	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; NON-INVASIVE EVALUATION; ECHOCARDIOGRAPHIC MEASUREMENTS; HYPERTROPHIC CARDIOMYOPATHY; PROGNOSTIC IMPLICATIONS; CARDIAC-HYPERTROPHY; DIASTOLIC FUNCTION; DYNAMIC EXERCISE; DISTANCE RUNNERS; UPPER LIMIT	Background: Absolute left ventricular cavity dimension may be substantially increased in some highly trained athletes. This raises questions about the differential diagnosis between athlete's heart and dilated cardiomyopathy as well as possible disqualification from competitive sports. Objective: To evaluate the morphologic characteristics and physiologic limits of left ventricular cavity enlargement associated with intensive, long-term athletic conditioning. Design: Evaluation of left ventricular cavity dimension in a large sample of highly trained athletes. Setting: institute of Sports Science, Rome, Italy. Participants: 1309 elite Italian athletes (957 men and 352 women), 13 to 59 years of age (mean, 24 years), participating in 38 different sports. Measurements: Echocardiographic assessment of left ventricular cavity dimension and multivariate statistical analysis of the determinants. Results: Left ventricular end-diastolic cavity dimensions varied widely (38 to 66 mm [mean, 48 mm] in women and 43 to 70 mm [mean, 55 mm] in men) and was within generally accepted normal limits for most participants (less than or equal to 54 mm in 725 athletes [55%]). According to an arbitrary clinical cut-point of 60 mm, the left ventricular cavity was substantially enlarged in 185 participants (14%). These athletes had global left ventricular systolic function within normal limits and no regional wall-motion abnormalities; participants remained free of cardiac symptoms and impaired performance over 1 to 12 years (mean, 4.7 years). The major determinants of cavity dimension were greater body surface area and participation in certain endurance sports (cycling, cross-country skiing, and canoeing). Conclusions: In a sample of highly trained athletes, left ventricular cavity dimension varied widely but was strikingly increased to a degree compatible with primary dilated cardiomyopathy in almost 15% of participants. In the absence of systolic dysfunction, this cavity dilatation is most likely an extreme physiologic adaptation to intensive athletic conditioning. The long-term consequences and significance of this marked left Ventricular remodeling of the athlete's heart is not known.	Italian Natl Olymp Comm, Inst Sport Sci, Dept Med, I-00197 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med, I-00298 Rome, Italy; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Sapienza University Rome; Minneapolis Heart Institute Foundation	Pelliccia, A (corresponding author), Italian Natl Olymp Comm, Inst Sport Sci, Dept Med, Via Campi Sportivi 46, I-00197 Rome, Italy.	ISS-Fisiologia@coni.it						ADAMS TD, 1981, CIRCULATION, V64, P958, DOI 10.1161/01.CIR.64.5.958; ARMITAGE P, 1994, STAT METHODS MED RES, P277; BLAIR NL, 1980, AUST NZ J MED, V10, P540, DOI 10.1111/j.1445-5994.1980.tb04973.x; DEMARIA AN, 1978, CIRCULATION, V57, P237, DOI 10.1161/01.CIR.57.2.237; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; DEVEREUX RB, 1986, AM J CARDIOL, V57, P1388, DOI 10.1016/0002-9149(86)90224-9; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DIXON WJ, 1992, BMDP STAT SOFTWARE M, P145; EKBLOM B, 1968, J APPL PHYSIOL, V25, P619, DOI 10.1152/jappl.1968.25.5.619; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; FORD LE, 1976, CIRC RES, V39, P297, DOI 10.1161/01.RES.39.3.297; GANAU A, 1992, J AM COLL CARDIOL, V19, P1550, DOI 10.1016/0735-1097(92)90617-V; GAVAZZI A, 1993, AM HEART J, V125, P410; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; HINDERLITER AL, 1992, AM J CARDIOL, V69, P1196, DOI 10.1016/0002-9149(92)90935-R; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; IKAHEIMO MJ, 1979, AM J CARDIOL, V44, P24, DOI 10.1016/0002-9149(79)90246-7; KEREN A, 1990, CIRCULATION, V81, P506, DOI 10.1161/01.CIR.81.2.506; KEUL J, 1981, CIRC RES, V48, P162; KNUTSEN KM, 1989, J INTERN MED, V225, P111, DOI 10.1111/j.1365-2796.1989.tb00049.x; LAUER MS, 1995, J AM COLL CARDIOL, V26, P1039, DOI 10.1016/0735-1097(95)00275-0; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; LONGHURST JC, 1980, J APPL PHYSIOL, V48, P154, DOI 10.1152/jappl.1980.48.1.154; LONGHURST JC, 1981, CIRC RES, V48, P171; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MARON BJ, 1994, J AM COLL CARDIOL, V24, P848, DOI 10.1016/0735-1097(94)90837-0; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MORGANROTH J, 1975, ANN INTERN MED, V82, P521, DOI 10.7326/0003-4819-82-4-521; NISHIMURA T, 1980, CIRCULATION, V61, P832, DOI 10.1161/01.CIR.61.4.832; PARKER BM, 1978, CHEST, V73, P376, DOI 10.1378/chest.73.3.376; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; Pelliccia A, 1996, JAMA-J AM MED ASSOC, V276, P211, DOI 10.1001/jama.276.3.211; PELLICCIA A, 1993, AM J CARDIOL, V72, P1048, DOI 10.1016/0002-9149(93)90861-6; REDFIELD MM, 1994, AM J CARDIOL, V74, P737, DOI 10.1016/0002-9149(94)90323-9; REGUERO JJR, 1995, EUR J APPL PHYSIOL, V70, P375, DOI 10.1007/BF00618486; ROST R, 1983, INT J SPORTS MED, V4, P147, DOI 10.1055/s-2008-1026028; ROY A, 1988, J APPL PHYSIOL, V64, P2552, DOI 10.1152/jappl.1988.64.6.2552; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SPIRITO P, 1994, AM J CARDIOL, V74, P802, DOI 10.1016/0002-9149(94)90439-1; SPIRITO P, 1988, BRIT HEART J, V59, P672; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; VALDEZ RS, 1979, CIRCULATION, V60, P921, DOI 10.1161/01.CIR.60.4.921; VOOGD PJ, 1984, EUR HEART J, V5, P762, DOI 10.1093/oxfordjournals.eurheartj.a061739	48	384	393	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					23	31		10.7326/0003-4819-130-1-199901050-00005	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890846				2022-12-24	WOS:000077744500004
J	Ganser, BK; Li, S; Klishko, VY; Finch, JT; Sundquist, WI				Ganser, BK; Li, S; Klishko, VY; Finch, JT; Sundquist, WI			Assembly and analysis of conical models for the HIV-1 core	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ROUS-SARCOMA VIRUS; IN-VITRO; VIRION MORPHOGENESIS; CAPSID PROTEINS; TYPE-1; GAG; INFECTIVITY; RETROVIRUS; PARTICLES	The genome of the human immunodeficiency virus (HIV) is packaged within an unusual conical core particle located-at the center of the infectious virion. The core is composed of a complex of the NC (nucleocapsid) protein and genomic RNA, surrounded by a shell of the CA (capsid) protein. A method was developed for assembling cones in vitro using pure recombinant HIV-1 CA-NC fusion proteins and RNA templates. These synthetic cores are capped at both ends and appear similar in size and morphology to authentic viral cores. It is proposed that both viral and synthetic cores are organized on conical hexagonal Lattices, which by Euler's theorem requires quantization of their cane angles. Electron microscopic analyses revealed that the cone angles of synthetic cores were indeed quantized into the five allowed angles. The viral core and most synthetic cones exhibited cone angles of approximately 19 degrees (the narrowest of the allowed angles). These observations suggest that the core of HIV is organized on the principles of a fullerene cone, in analogy to structures recently observed for elemental carbon.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; MRC, Mol Biol Lab, Struct Studies Div, Cambridge CB2 2QH, England	Utah System of Higher Education; University of Utah; MRC Laboratory Molecular Biology	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.			Li, Sam/0000-0002-0210-8192				Accola MA, 1998, J VIROL, V72, P2072, DOI 10.1128/JVI.72.3.2072-2078.1998; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Barklis E, 1998, J BIOL CHEM, V273, P7177, DOI 10.1074/jbc.273.13.7177; Barklis E, 1997, EMBO J, V16, P1199, DOI 10.1093/emboj/16.6.1199; Campbell S, 1997, J VIROL, V71, P4425, DOI 10.1128/JVI.71.6.4425-4435.1997; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; CROWTHER RA, 1976, P 3 J INN S, P15; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; EHRLICH LS, 1992, J VIROL, V66, P4874, DOI 10.1128/JVI.66.8.4874-4883.1992; FINCH JW, UNPUB; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; GE MH, 1994, CHEM PHYS LETT, V220, P192, DOI 10.1016/0009-2614(94)00167-7; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; HOGLUND S, 1992, AIDS RES HUM RETROV, V8, P1, DOI 10.1089/aid.1992.8.1; KELLENBERGER E, 1982, ULTRAMICROSCOPY, V9, P139, DOI 10.1016/0304-3991(82)90236-4; KLISHKO VY, UNPUB; Kong LB, 1998, J VIROL, V72, P4403, DOI 10.1128/JVI.72.5.4403-4407.1998; KRAUSSLICH HG, 1996, CURRENT TOPICS MICRO, V214; Krishnan A, 1997, NATURE, V388, P451, DOI 10.1038/41284; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; SEYMOUR J, 1987, J MICROSC-OXFORD, V148, P195, DOI 10.1111/j.1365-2818.1987.tb02866.x; Swanstrom R., 1997, P263; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; Vogt V. M., 1997, P27; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; VONSCHWEDLER U, UNPUB; Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299	36	498	510	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					80	83		10.1126/science.283.5398.80	http://dx.doi.org/10.1126/science.283.5398.80			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872746				2022-12-24	WOS:000077976600054
J	Matsui, H; Grubb, BR; Tarran, R; Randell, SH; Gatzy, JT; Davis, CW; Boucher, RC				Matsui, H; Grubb, BR; Tarran, R; Randell, SH; Gatzy, JT; Davis, CW; Boucher, RC			Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease	CELL			English	Article							PSEUDOMONAS-AERUGINOSA; ELECTROLYTE TRANSPORT; MUCOCILIARY CLEARANCE; RESPIRATORY MUCOSA; FLUID TRANSPORT; SURFACE FLUID; EPITHELIA; LUNG; MUCUS; BACTERIA	The pathogenesis of cystic fibrosis (CF) airways infection is unknown. Two hypotheses, "hypotonic [low salt]/defensin" and "isotonic volume transport/mucus clearance," attempt to link defects in cystic fibrosis transmembrane conductance regulator-mediated ion transport to CF airways disease. We tested these hypotheses with planar and cylindrical culture models and found no evidence that the liquids lining airway surfaces were hypotonic or that salt concentrations differed between CF and normal cultures. In contrast, CF airway epithelia exhibited abnormally high rates of airway surface liquid absorption, which depleted the periciliary liquid layer and abolished mucus transport. The failure to clear thickened mucus from airway surfaces likely initiates CF airways infection. These data indicate that therapy for CF lung disease should not be directed at modulation of ionic composition, but rather at restoring volume (salt and water) on airway surfaces.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Boucher, RC (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.	rboucher@med.unc.edu			NHLBI NIH HHS [HL42384, P01 HL34322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, P01HL034322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker E, 1998, J CLIN INVEST, V102, P10, DOI 10.1172/JCI1795; BALLARD ST, 1991, J APPL PHYSIOL, V70, P1665, DOI 10.1152/jappl.1991.70.4.1665; BLAKE J, 1975, J BIOMECH, V8, P179, DOI 10.1016/0021-9290(75)90023-8; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVOIS CW, 1998, PEDIATR PULM, V17, P247; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Grubb BR, 1997, AM J PHYSIOL-CELL PH, V273, pC21, DOI 10.1152/ajpcell.1997.273.1.C21; Hull J, 1998, AM J RESP CRIT CARE, V157, P10, DOI 10.1164/ajrccm.157.1.9703045; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JOHNSON JG, 1998, PED PULMONOL S, V17, P241; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; KEREM E, 1997, PEDIATR PULM, V14, P78; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; KOHLER D, 1986, EUR J RESPIR DIS, V69, P319; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; LAM J, 1980, INFECT IMMUN, V28, P546; LEVISON H, 1983, EUR J RESPIR DIS, V64, P102; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; NELSON JW, 1990, INFECT IMMUN, V58, P1489, DOI 10.1128/IAI.58.6.1489-1495.1990; NOONE PG, 1996, AM J RESP CRIT CARE, V153, pA530; Novotny JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1764, DOI 10.1152/ajpcell.1996.270.6.C1764; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; PLOTKOWSKI MC, 1992, MEM I OSWALDO CRUZ, V87, P61, DOI 10.1590/S0074-02761992000900008; PUCHELLE E, 1995, RESPIRATION, V62, P2; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; Rogers D. F., 1997, AIRWAY MUCUS BASIC M, P1; SATIR P, 1990, ANNU REV PHYSIOL, V52, P137, DOI 10.1146/annurev.ph.52.030190.001033; SCHERER PW, 1981, CHEST, V80, P830, DOI 10.1378/chest.80.6.830; Sims DE, 1997, AM J PHYSIOL-LUNG C, V273, pL1036; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; STUTTS MJ, 1998, PEDIATR PULM, V17, P217; TSANG KWT, 1994, EUR RESPIR J, V7, P1746, DOI 10.1183/09031936.94.07101746; Ulrich M, 1998, AM J RESP CELL MOL, V19, P83, DOI 10.1165/ajrcmb.19.1.3137; VISHWANATH S, 1984, INFECT IMMUN, V45, P197, DOI 10.1128/IAI.45.1.197-202.1984; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; ZAHM JM, 1989, BIORHEOLOGY, V26, P747; ZUELZER WW, 1949, PEDIATRICS, V4, P53	48	869	893	0	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					1005	1015		10.1016/S0092-8674(00)81724-9	http://dx.doi.org/10.1016/S0092-8674(00)81724-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875854	Bronze, Green Published			2022-12-24	WOS:000077759100015
J	Racoosin, JA; Whitney, CG; Conover, CS; Diaz, PS				Racoosin, JA; Whitney, CG; Conover, CS; Diaz, PS			Serogroup Y meningococcal disease in Chicago, 1991-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS	Context.-In 1994, surveillance by the Chicago Department of Public Health detected a growing trend in the proportion of invasive meningococcal infections caused by serogroup Y. Objective.-To examine the emergence of serogroup Y meningococcal disease and compare its clinical characteristics with those of other meningococcal serogroups. Design.-Population-based retrospective review of surveillance records; medical record review and cohort analysis of serogroup Y vs non-serogroup Y case patients. Setting.-Chicago, Ill. Participants.-City residents with Neisseria meningitidis isolated from a normally sterile site from January 1, 1991, through December 31, 1997; cohort analysis included those identified through March 31, 1996. Main Outcome Measures.-Serogroup-specific incidence, demographics, and clinical outcomes. Results.-We identified 214 case patients; 53 (25%) had serogroup Y. The attack rate of serogroup Y meningococcal disease increased from 0.04 cases per 100 000 in 1991 to a peak of 0.82 cases per 100 000 in 1995 and subsequently decreased to 0.26 cases per 100 000 and 0.34 cases per 100 000 in 1996 and 1997, respectively. Compared with patients infected by other serogroups, patients with serogroup Y were older (median age, 16 years vs 1 year; P=.001) and more likely to have a chronic underlying illness (prevalence ratio, 2.3; 95% confidence interval, 1.2-4.4). Outcome did not differ significantly between the 2 groups. Multilocus enzyme electrophoresis typing of isolates from 19 case patients identified 5 different types. We found no clustering among the enzyme types by age, race/ethnicity, community area, or time. Conclusions.-Serogroup Y emerged as the most frequent cause of meningococcal disease in Chicago in 1995 and accounted for a substantial proportion of cases in 1996 and 1997. Current data suggest that the magnitude of serogroup Y meningococcal disease is sufficient for vaccine developers to incorporate serogroup Y into new vaccines.	Chicago Dept Publ Hlth, Chicago, IL 60612 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Illinois, Sch Publ Hlth, Chicago, IL USA	Chicago Department of Public Health; Centers for Disease Control & Prevention - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Diaz, PS (corresponding author), Chicago Dept Publ Hlth, 2160 W Ogden Ave, Chicago, IL 60612 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1976, J INFECT DIS, V134, P201, DOI 10.1093/infdis/134.2.201; BIBB WF, 1989, INT J FOOD MICROBIOL, V8, P233, DOI 10.1016/0168-1605(89)90018-4; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P1010; Dean A.G., 1994, EPI INFO VERSION 6 W; GALAID EI, 1980, JAMA-J AM MED ASSOC, V244, P2167, DOI 10.1001/jama.244.19.2167; HEDRICH AW, 1952, PUBLIC HEALTH REP, V67, P411, DOI 10.2307/4588096; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; KOPPES GM, 1977, AM J MED, V62, P661, DOI 10.1016/0002-9343(77)90867-1; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SMILACK JD, 1974, ANN INTERN MED, V81, P740, DOI 10.7326/0003-4819-81-6-740; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; STEPHENS DS, 1995, ANN INTERN MED, V123, P937, DOI 10.7326/0003-4819-123-12-199512150-00007	15	52	55	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2094	2098		10.1001/jama.280.24.2094	http://dx.doi.org/10.1001/jama.280.24.2094			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875877	Bronze			2022-12-24	WOS:000077606100033
J	Winberg, ML; Noordermeer, JN; Tamagnone, L; Comoglio, PM; Spriggs, MK; Tessier-Lavigne, M; Goodman, CS				Winberg, ML; Noordermeer, JN; Tamagnone, L; Comoglio, PM; Spriggs, MK; Tessier-Lavigne, M; Goodman, CS			Plexin A is a neuronal semaphorin receptor that controls axon guidance	CELL			English	Article							GROWTH CONE GUIDANCE; FASCICLIN-II; SYNAPSE FORMATION; GENETIC-ANALYSIS; EXPRESSION; NEUROPILIN; FAMILY; DROSOPHILA; SURFACE; TRANSMEMBRANE	The Semaphorins comprise a large family of secreted and transmembrane proteins, some of which function as repellents during axon guidance. Semaphorins fall into seven subclasses. Neuropilins are neuronal receptors for class III Semaphorins. In the immune system, VESPR, a member of the Plexin family, is a receptor for a viral-encoded Semaphorin. Here, we identify two Drosophila Plexins, both of which are expressed in the developing nervous system. We present evidence that Plexin A is a neuronal receptor for class I Semaphorins (Sema 1a and Sema 1b) and show that Plexin A controls motor and CNS axon guidance. Plexins, which themselves contain complete Semaphorin domains, may be both the ancestors of classical Semaphorins and binding partners for Semaphorins.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Turin, Sch Med, Inst Canc Res, Dept Mol Oncol, I-10060 Turin, Italy; Immunex Corp, Dept Mol Biol, Seattle, WA 98101 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Turin; Immunex Corporation; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goodman, CS (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Tamagnone, Luca/J-8948-2018	Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328	NICHD NIH HHS [HD21294] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021294, R01HD021294] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bagnard D, 1998, DEVELOPMENT, V125, P5043; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; ENSSER A, 1995, J GEN VIROL, V76, P1063, DOI 10.1099/0022-1317-76-4-1063; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herold C, 1996, J IMMUNOL, V157, P5262; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Roberts D. B, 1986, DROSOPHILA PRACTICAL; SATODA M, 1995, J NEUROSCI, V15, P942; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Wong JTW, 1997, DEVELOPMENT, V124, P3597; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X; Yu W, 1997, GENOME RES, V7, P353, DOI 10.1101/gr.7.4.353	42	372	378	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					903	916		10.1016/S0092-8674(00)81715-8	http://dx.doi.org/10.1016/S0092-8674(00)81715-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875845	Bronze			2022-12-24	WOS:000077759100006
J	Smith, GCS; Smith, MFS; McNay, MB; Fleming, JEE				Smith, GCS; Smith, MFS; McNay, MB; Fleming, JEE			First-trimester growth and the risk of low birth weight	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CROWN-RUMP LENGTH; AGE	Background Previous studies have demonstrated a correlation between first-trimester size and birth weight. it is not known, however, whether low birth weight is related to first-trimester growth. We sought to determine whether the risk of low birth weight and birth weight that was low for gestational age is related to the size of the embryo or the fetus in the first trimester. Methods From a data base of ultrasound records of more than 30,000 pregnancies, We identified women who had no important medical problems, a normal menstrual history, and a first-trimester ultrasound scan in which the crown-rump length of the embryo or fetus had been measured. We examined the relation between the outcome of 4229 pregnancies and the difference between the measured and the expected crown-rump length in the first trimester, expressed as equivalent days of growth. Results A first-trimester crown-rump length that was two to six days smaller than expected was associated with an increased risk las compared with a normal or slightly larger than expected crown-rump length) of a birth weight below 2500 g (relative risk, 1.8; 95 percent confidence interval, 1.3 to 2.4), a birth weight below 2500 g at term (relative risk, 2.3; 95 percent confidence interval, 1.4 to 3.8), a birth weight below the fifth percentile for gestational age (relative risk, 3.0; 95 percent confidence interval, 2.0 to 4.4), and delivery between 24 and 32 weeks of gestation (relative risk, 2.1; 95 percent confidence interval, 1.1 to 4.0), but not with delivery between 33 and 36 weeks (relative risk, 1.0; 95 percent confidence interval, 0.7 to 1.5). Conclusions Suboptimal first-trimester growth may be associated with low birth weight, low birthweight percentile, and premature delivery. (N Engl J Med 1998;339:1817-22.) (C) 1998, Massachusetts Medical Society.	Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA; Univ Glasgow, Queen Mothers Hosp, Dept Obstet & Gynaecol, Glasgow, Lanark, Scotland	Cornell University; University of Glasgow	Smith, GCS (corresponding author), Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA.		Smith, Gordon/A-8070-2008	Smith, Gordon/0000-0003-2124-0997	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM AH, 1979, BRIT J OBSTET GYNAEC, V86, P521, DOI 10.1111/j.1471-0528.1979.tb10803.x; Aitken D. A., 1995, P12; Barker DJP, 1992, FETAL INFANT ORIGINS; BUCK GM, 1989, AM J EPIDEMIOL, V129, P874, DOI 10.1093/oxfordjournals.aje.a115221; Campbell S., 1989, RCOG STUD GROUP P FE, P251; DAYA S, 1993, AM J OBSTET GYNECOL, V168, P903, DOI 10.1016/S0002-9378(12)90842-X; DICKEY RP, 1993, HUM REPROD, V8, P331, DOI 10.1093/oxfordjournals.humrep.a138046; EVANS E, 1990, CLIN APPL ULTRASONIC; FORBES JF, 1983, BRIT J OBSTET GYNAEC, V90, P297, DOI 10.1111/j.1471-0528.1983.tb08913.x; GLUCKMAN PD, 1984, FETAL PHYSL MED BASI, V6, P511; HOLST K, 1989, AM J PERINAT, V6, P258, DOI 10.1055/s-2007-999588; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KUSTERMANN A, 1992, BRIT J OBSTET GYNAEC, V99, P38, DOI 10.1111/j.1471-0528.1992.tb14389.x; LENTON EA, 1985, CLIN REPROD ENDOCRIN, P81; Luke B, 1998, PRENAT NEONAT MED, V3, P32; NOVY MJ, 1995, CLIN OBSTET GYNECOL, V38, P790, DOI 10.1097/00003081-199538040-00013; ROBINSON HP, 1975, BRIT J OBSTET GYNAEC, V82, P702, DOI 10.1111/j.1471-0528.1975.tb00710.x; ROSSAVIK IK, 1988, FERTIL STERIL, V49, P1012	18	253	257	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1817	1822		10.1056/NEJM199812173392504	http://dx.doi.org/10.1056/NEJM199812173392504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854117				2022-12-24	WOS:000077545800004
J	Song, HB; Endow, SA				Song, HB; Endow, SA			Decoupling of nucleotide- and microtubule-binding sites in a kinesin mutant	NATURE			English	Article							MOTOR DOMAIN; CRYSTAL-STRUCTURE; MITOTIC SPINDLE; PROTEIN; MYOSIN; KAR3; NCD; PURIFICATION; POLYMERASE	Molecular motors require ATP to move along microtubules or actin filaments. To understand how molecular motors function, it is crucial to know how binding of the motor to its filamentous track stimulates the hydrolysis of ATP by the motor, enabling it to move along the filament. A mechanism for the enhanced ATP hydrolysis has not been elucidated, but it is generally accepted that conformational changes in the motor proteins(1-3) occur when they bind to microtubules or actin filaments, facilitating the release of ADP. Here we report that a mutation in the motor domain of the microtubule motor proteins Kar3 and Ncd uncouples nucleotide- and microtubule-binding by the proteins, preventing activation of the motor ATPase by microtubules. Unlike the wild-type motors, the mutants bind tightly to both ADP and microtubules, indicating that interactions between the nucleotide- and microtubule-binding sites are blocked. The region of the motor that includes the mutated amino arid could transmit or undergo a conformational change required to convert the motor ATPase into a microtubule-stimulated state.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Endow, SA (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.			Endow, Sharyn A./0000-0002-0907-8889	NIGMS NIH HHS [R01 GM046225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BascomSlack CA, 1997, J CELL BIOL, V139, P459, DOI 10.1083/jcb.139.2.459; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYT MA, 1993, GENETICS, V135, P35; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; Song H, 1996, BIOCHEMISTRY-US, V35, P11203, DOI 10.1021/bi960997b; Song H, 1997, BIOTECHNIQUES, V22, P82, DOI 10.2144/97221bm18; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	23	51	52	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					587	590		10.1038/25153	http://dx.doi.org/10.1038/25153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859995				2022-12-24	WOS:000077466800061
J	Polleux, F; Giger, RJ; Ginty, DD; Kolodkin, AL; Ghosh, A				Polleux, F; Giger, RJ; Ginty, DD; Kolodkin, AL; Ghosh, A			Patterning of cortical efferent projections by semaphorin-neuropilin interactions	SCIENCE			English	Article							EXPRESSION; RECEPTOR; GROWTH		Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Ghosh, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Polleux, Franck/H-9948-2014	Polleux, Franck/0000-0003-4313-0481	NINDS NIH HHS [NS534814, NS36176, NS35165] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036176, R01NS035165, R37NS035165] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BOLZ J, 1993, TRENDS NEUROSCI, V16, P310, DOI 10.1016/0166-2236(93)90107-W; Catalano SM, 1998, MOL CELL NEUROSCI, V11, P173, DOI 10.1006/mcne.1998.0687; Chedotal A, 1998, DEVELOPMENT, V125, P4313; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GIGER RJ, UNPUB; GIGER RJ, IN PRESS NEURON; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; POLLEUX F, UNPUB; Skaliora I, 1998, EUR J NEUROSCI, V10, P1215, DOI 10.1046/j.1460-9568.1998.00128.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1	17	207	211	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1904	1906		10.1126/science.282.5395.1904	http://dx.doi.org/10.1126/science.282.5395.1904			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836643				2022-12-24	WOS:000077338100053
J	Caron, E; Hall, A				Caron, E; Hall, A			Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases	SCIENCE			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; COMPLEMENT RECEPTORS; SIGNALING PATHWAY; NADPH OXIDASE; CDC42 GTPASES; MACROPHAGES; ACTIVATION; RAC	The complement and immunoglobulin receptors are the major phagocytic receptors involved during infection. However, only immunoglobulin-dependent uptake results in a respiratory burst and an inflammatory response in macrophages. Rho guanosine triphosphatases (molecular switches that control the organization of the actin cytoskeleton) were found to be essential for-both types of phagocytosis. Two distinct mechanisms of phagocytosis were identified: Type I, used by the immunoglobulin receptor, is mediated by Cdc42 and Rac, and type II, used by the complement receptor, is mediated by Rho. These results suggest a molecular basis for the different biological consequences that are associated with phagocytosis.	UCL, Canc Res Campaign, Oncogene & Signal Transduct Grp, MRC,Lab Mol Cell Biol, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Hall, A (corresponding author), UCL, Canc Res Campaign, Oncogene & Signal Transduct Grp, MRC,Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk						ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADEREM AA, 1985, J EXP MED, V161, P617, DOI 10.1084/jem.161.3.617; Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GREENBERG S, 1991, J IMMUNOL METHODS, V139, P115, DOI 10.1016/0022-1759(91)90358-M; HACKAM DJ, 1998, J BIOL CHEM, V273, P955; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLZER TJ, 1986, INFECT IMMUN, V51, P514, DOI 10.1128/IAI.51.2.514-520.1986; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSSER DM, 1987, NATURE, V327, P329, DOI 10.1038/327329b0; MOSSER DM, 1985, J IMMUNOL, V135, P2785; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; NEWMAN SL, 1991, J IMMUNOL, V146, P967; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESINGER LS, 1990, J CLIN INVEST, V85, P1304, DOI 10.1172/JCI114568; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405	33	778	795	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1717	1721		10.1126/science.282.5394.1717	http://dx.doi.org/10.1126/science.282.5394.1717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831565				2022-12-24	WOS:000077246600050
J	Dorsky, RI; Moon, RT; Raible, DW				Dorsky, RI; Moon, RT; Raible, DW			Control of neural crest cell fate by the Wnt signalling pathway	NATURE			English	Article							XENOPUS EMBRYOS; NERVOUS-SYSTEM; BETA-CATENIN; ZEBRAFISH; EXPRESSION; DIFFERENTIATION; RESTRICTIONS; LINEAGE	Environmental signals are important in the development of neural crest, during which process multipotent progenitor must choose from several fates(1-3). However, the nature of these environmental signals is unknown. A previous fate map of zebrafish cranial neural crest showed that lineage-restricted clones of pigment cells arise hom medial cells near the neural keel, and that clones of neurons arise from lateral cells farther from the neural keel(4), Wnt-1 and Wnt-3a are candidate genes for influencing neural crest fate, as they are expressed next to medial, but not lateral, crest cells. Here we determine the role of Wnt signals in modulating the fate of neural crest by injecting messenger RNAs into single, premigratory neural crest cells of zebrafish, Lineage analysis of injected cells shows that activation of Wnt signalling by injection of mRNA encoding cytoplasmic beta-catenin promotes pigment-cell formation at the expense of neurons and glia. Conversely, inhibition of the Wnt pathway, by injection of mRNAs encoding either a truncated form of the transcription factor Tcf-3 or a dominant-negative Wnt, promotes neuronal fates at the expense of pigment cells. We conclude that endogenous Wnt signalling normality promotes pigment-cell formation by medial crest cells and thereby contributes to the diversity of neural crest cell fates.	Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Dorsky, RI (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.		Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; Raible, David/0000-0002-5342-5841				Appel B, 1995, DEVELOPMENT, V121, P4117; Baker CVH, 1997, DEVELOPMENT, V124, P3077; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang CB, 1998, DEV BIOL, V194, P129, DOI 10.1006/dbio.1997.8820; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; FRASER MB, 1991, DEVELOPMENT S, V2, P17; Henion PD, 1997, DEVELOPMENT, V124, P4351; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; HOPPLER S, 1996, GENE DEV, V10, P3805; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; KRAUSS S, 1992, DEVELOPMENT, V116, P249; LaBonne C, 1998, DEVELOPMENT, V125, P2403; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; Raible DW, 1996, DEVELOPMENT, V122, P501; Reissmann E, 1996, DEVELOPMENT, V122, P2079; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; SCHILLING TF, 1994, DEVELOPMENT, V120, P483; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	26	381	394	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					370	373		10.1038/24620	http://dx.doi.org/10.1038/24620			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845073				2022-12-24	WOS:000077204000050
J	Kinoshita, S; Chen, BK; Kaneshima, H; Nolan, GP				Kinoshita, S; Chen, BK; Kaneshima, H; Nolan, GP			Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOSPORINE-A; TRANSCRIPTION FACTORS; NONDIVIDING CELLS; CYCLOPHILIN-A; DNA-SYNTHESIS; TYPE-1 DNA; KAPPA-B; INFECTION; LYMPHOCYTES	Post HIV-1 entry, productive HIV-1 infection of primary T cells requires overcoming several cellular blocks to provirus establishment and replication. Activation of unknown host intracellular events overcomes such inhibitory steps and is concomitant with HIV-1 replication. We show that the transcription factor NFATc was sufficient as a cellular factor to induce a highly permissive state for HIV-1 replication in primary CD4(+) T cells. NFATc overcame a blockade at reverse transcription and permitted active HIV-1 replication. Pharmacologic blockade of endogenous NFAT activity by FK506 or CsA inhibited synthesis of reverse transcription and also potently blocked HIV-1 replication. T cells therefore can become competent for HIV-1 replication by control of regulated host factors such as the NFATc transcription factor. The host mechanisms regulated by such permissivity factors are potential targets for anti-HIV-1 therapy.	Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Rockefeller Univ, New York, NY 10021 USA; Systemix Inc, Palo Alto, CA 94303 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); Rockefeller University; Novartis	Nolan, GP (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	gnolan@CMGM.stanford.edu	Nolan, Garry/AAE-7903-2019	Chen, Benjamin K/0000-0002-5404-1997; Nolan, Garry/0000-0002-8862-9043	NIAID NIH HHS [P01-AI39646, AI27666] Funding Source: Medline; NIAMS NIH HHS [AR44565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039646, U01AI027666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; Borvak J, 1996, J INFECT DIS, V174, P850, DOI 10.1093/infdis/174.4.850; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GRILLI M, 1993, INT REV CYTOL, V143, P1; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; JAIN JN, 1993, J IMMUNOL, V151, P837; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LI GR, 1993, J VIROL, V67, P3969, DOI 10.1128/JVI.67.7.3969-3977.1993; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sinoussi F. B., 1983, SCIENCE, V220, P868; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THOMSON AW, 1995, ADV EXP MED BIOL, V374, P211; TOBA K, 1995, J IMMUNOL METHODS, V182, P193, DOI 10.1016/0022-1759(95)00050-K; VANDEKERCKHOVE BAE, 1992, J EXP MED, V175, P1033, DOI 10.1084/jem.175.4.1033; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	40	192	195	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					595	604		10.1016/S0092-8674(00)81630-X	http://dx.doi.org/10.1016/S0092-8674(00)81630-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845362	Bronze			2022-12-24	WOS:000077253700007
J	Litvan, I				Litvan, I			Parkinsonian features - When are they Parkinson disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-DIAGNOSIS; ACCURACY		Henry M Jackson Fdn, Def & Vet Head Injury Program, Neuropharmacol Unit, Bethesda, MD USA; NINDS, NIH, Bethesda, MD 20892 USA	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Litvan, I (corresponding author), Fed Bldg,Room 714, Bethesda, MD 20892 USA.	Litvan1@helix.nih.gov	Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445				Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; KOLLER WC, 1992, NEUROLOGY, V42, P6; Litvan I, 1998, ARCH NEUROL-CHICAGO, V55, P969, DOI 10.1001/archneur.55.7.969; MAYEUX R, 1995, AM J EPIDEMIOL, V142, P820, DOI 10.1093/oxfordjournals.aje.a117721; Rajput A H, 1997, Parkinsonism Relat Disord, V3, P159, DOI 10.1016/S1353-8020(97)00030-8; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; Shoulson I, 1998, ANN NEUROL, V43, P318; WARD CD, 1990, ADV NEUROL, V53, P245; Wenning GK, 1998, J NEUROL NEUROSUR PS, V64, P184, DOI 10.1136/jnnp.64.2.184	12	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1654	1655		10.1001/jama.280.19.1654	http://dx.doi.org/10.1001/jama.280.19.1654			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9831984				2022-12-24	WOS:000076980700012
J	Murley, LL; Grindley, NDF				Murley, LL; Grindley, NDF			Architecture of the gamma delta resolvase synaptosome: Oriented heterodimers identify interactions essential for synapsis and recombination	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; TN3 RESOLVASE; CRYSTAL-STRUCTURE; RES SITES; DNA; PROTEIN; CLEAVAGE; RESIDUES; BINDING; COMPLEX	gamma delta resolvase catalyzes recombination within a complex nucleoprotein structure containing at least 12 resolvase subunits bound to two 114 bp res sites. The 2,3' interaction between resolvase dimers is essential for synapsis and recombination. Using oriented resolvase heterodimers, we have identified half sites of res that must be occupied by a 2,3'-proficient protomer. For synapsis, only four of the eight subunits bound to sites II and III, those at II-L and III-L, require a 2,3'-proficient interface. This 2,3' interaction, apparently between protomers bound to adjacent sites, may nucleate assembly of the core synaptic complex. For recombination, 2,3'-proficient subunits are also required at sites I-R and III-R, suggesting an important communication between the crossover site and the core of the synapse.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Grindley, NDF (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028470, R37GM028470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COZZARELLI NR, 1984, COLD SPRING HARB SYM, V49, P383, DOI 10.1101/SQB.1984.049.01.045; GRINDLEY NDF, 1993, SCIENCE, V262, P738, DOI 10.1126/science.8235593; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; HATFULL GF, 1989, J MOL BIOL, V208, P661, DOI 10.1016/0022-2836(89)90156-3; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HUGHES RE, 1992, THESIS YALE U NEW HA; LIU T, 1993, J BIOL CHEM, V268, P16309; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SOULTANAS P, 1995, J MOL BIOL, V245, P208, DOI 10.1006/jmbi.1994.0017; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; Watson MA, 1996, J MOL BIOL, V257, P317, DOI 10.1006/jmbi.1996.0165; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; [No title captured]	29	42	43	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					553	562		10.1016/S0092-8674(00)81622-0	http://dx.doi.org/10.1016/S0092-8674(00)81622-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827807	hybrid			2022-12-24	WOS:000077049400013
J	Sugarman, J; Burk, L				Sugarman, J; Burk, L			Physicians' ethical obligations regarding alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; Duke Univ, Dept Philosophy, Durham, NC USA; Duke Univ, Dept Radiol, Durham, NC 27710 USA; Duke Univ, Off Integrat Med Educ, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University	Sugarman, J (corresponding author), Duke Univ, Med Ctr, Div Gen Internal Med, Box 3040, Durham, NC 27710 USA.			Sugarman, Jeremy/0000-0001-7022-8332				Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Barrett S, 1998, BIOMED ETH, P1; BRATMAN S, 1997, ALTERN THER, V3, P127; CALLAHAN D, 1996, HASTINGS CENT RE NOV, P9; CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Daly D, 1997, J Altern Complement Med, V3, P405, DOI 10.1089/acm.1997.3.405; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 1996, J MED ETHICS, V22, P197, DOI 10.1136/jme.22.4.197; Halperin E C, 1998, N C Med J, V59, P21; Hufford, 1995, Altern Ther Health Med, V1, P94; Hufford D J, 1997, Altern Ther Health Med, V3, P78; JENIKE MA, 1994, J GERIATR PSYCHIA S1, V7, P1; Kahn J. P., 1998, CONSENT SEEKING JUST; KOTTOW MH, 1992, J MED ETHICS, V18, P18, DOI 10.1136/jme.18.1.18; LYNOE N, 1992, SCAND J SOC MED, V20, P217, DOI 10.1177/140349489202000406; MACK RB, 1998, NC MED J, V59, P24; Macklin R, 1998, KENNEDY INST ETHIC J, V8, P1, DOI 10.1353/ken.1998.0005; Milan FB, 1998, J GEN INTERN MED, V13, P562, DOI 10.1046/j.1525-1497.1998.00168.x; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; VONBEHREN D, 1997, ARIZONA HLTH HORIZON, P16; *WORKSH ALT MED, 1995, ALT MED EXP MED HOR	24	37	37	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1623	1625		10.1001/jama.280.18.1623	http://dx.doi.org/10.1001/jama.280.18.1623			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820269				2022-12-24	WOS:000076852000035
J	Duthie, DJR				Duthie, DJR			Heat-related illness	LANCET			English	Editorial Material							HEATSTROKE; HYPERTHERMIA; DANTROLENE; STROKE		Univ Leicester, Glenfield Hosp, Dept Anaesthesia, Leicester L3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Duthie, DJR (corresponding author), Univ Leicester, Glenfield Hosp, Dept Anaesthesia, Leicester L3 9QP, Leics, England.							BOUCHAMA A, 1991, CRIT CARE MED, V19, P176, DOI 10.1097/00003246-199102000-00011; Bouchama A, 1996, CRIT CARE MED, V24, P1173, DOI 10.1097/00003246-199607000-00018; Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001; Epstein Y, 1997, LANCET, V350, P83, DOI 10.1016/S0140-6736(05)61811-9; Farmer JC, 1997, CRIT CARE MED, V25, P1263, DOI 10.1097/00003246-199708000-00003; Hammami MM, 1997, CRIT CARE MED, V25, P1314, DOI 10.1097/00003246-199708000-00017; Hammani MM, 1998, J APPL PHYSIOL, V84, P1615, DOI 10.1152/jappl.1998.84.5.1615; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; LARNER AJ, 1992, LANCET, V339, P182, DOI 10.1016/0140-6736(92)90248-2; Lene B, 1997, JAMA-J AM MED ASSOC, V278, P462; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SIMON HB, 1993, NEW ENGL J MED, V329, P483; 1998, SCORCHING START 1998	13	10	11	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1329	1330		10.1016/S0140-6736(05)60742-8	http://dx.doi.org/10.1016/S0140-6736(05)60742-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802267				2022-12-24	WOS:000076691700007
J	Thiemens, MH				Thiemens, MH			Atmosphere science - Mass-independent isotope effects in planetary atmospheres and the early solar system	SCIENCE			English	Review							STRATOSPHERIC NITROUS-OXIDE; MARS VOLATILE EVOLUTION; HEAVY OZONE; MARTIAN ATMOSPHERE; CARBON-DIOXIDE; TROPOSPHERIC OZONE; GLOBAL PERSPECTIVE; OXYGEN ISOTOPES; FRACTIONATION; SYMMETRY	A class of isotope effects that alters isotope ratios on a mass-independent basis provides a toot for studying a wide range of processes in atmospheres of Earth and other planets as well as early processes in the solar nebula. The mechanism for the effect remains uncertain. Mass-independent isotopic compositions; have been observed in O-3, CO2, N2O, and CO in Earth's atmosphere and in carbonate from a martian meteorite, which suggests a role for mass-independent processes in the atmosphere of Mars. Observed mass-independent meteoritic oxygen and sulfur isotopic compositions may derive from chemical processes in the presolar nebula, and their distributions could provide insight into early solar system evolution.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Thiemens, MH (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	mht@chem.ucsd.edu						ABBAS MM, 1987, J GEOPHYS RES-ATMOS, V92, P13231, DOI 10.1029/JD092iD11p13231; Anderson R.B., 1956, CATALYSIS, VIV, P1; Anderson SM, 1997, J CHEM PHYS, V107, P5385, DOI 10.1063/1.474247; BAINSSAHOTA SK, 1989, J CHEM PHYS, V90, P6099, DOI 10.1063/1.456375; BAKER V, 1998, LUNAR PLANET SCI C, V29, P39; BARTH CA, 1986, PHOTOCHEMISTRY ATMOS, P337; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BHATTACHARYA SK, 1989, Z NATURFORSCH A, V44, P435; BIGELEISEN J, 1947, J CHEM PHYS, V15, P261, DOI 10.1063/1.1746492; BJORAAKER GL, 1989, B AM ASTRON SOC, V29, P991; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; Brenninkmeijer CAM, 1997, J GEOPHYS RES-ATMOS, V102, P25477, DOI 10.1029/97JD02291; Brenninkmeijer CAM, 1995, J GEOPHYS RES-ATMOS, V100, P26163, DOI 10.1029/95JD02528; BRENNINKMEIJER CAM, 1993, J GEOPHYS RES-ATMOS, V98, P10595, DOI 10.1029/93JD00587; CANTRELL CA, 1994, J GEOPHYS RES-ATMOS, V99, P3739, DOI 10.1029/93JD02659; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; CRUTZEN PJ, 1991, TELLUS A, V43, P136, DOI 10.1034/j.1600-0870.1991.00012.x; Farquhar J, 1998, SCIENCE, V280, P1580, DOI 10.1126/science.280.5369.1580; GARNO T, 1989, TELLUS B, V41, P127; Gellene GI, 1996, SCIENCE, V274, P1344, DOI 10.1126/science.274.5291.1344; GELLENE GI, 1996, ADV GAS P I, V2, P161; GOLDMAN A, 1989, J GEOPHYS RES-ATMOS, V94, P8467, DOI 10.1029/JD094iD06p08467; GRIFFITH KS, 1992, J CHEM PHYS, V96, P4403, DOI 10.1063/1.462831; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; HEIDENREICH JE, 1986, J CHEM PHYS, V84, P2129, DOI 10.1063/1.450373; HODDER PS, 1994, US GEOL CIRC, V1107, P73; Houston PL, 1996, J GEOPHYS RES-ATMOS, V101, P18829, DOI 10.1029/96JD01664; Huff AK, 1998, GEOPHYS RES LETT, V25, P3509, DOI 10.1029/98GL02603; HUFF AK, 1996, EOS S            FAL, pF124; HULSTON JR, 1965, J GEOPHYS RES, V70, P3475, DOI 10.1029/JZ070i014p03475; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; HUTCHEON ID, 1994, ASTROPHYS J, V425, pL97, DOI 10.1086/187319; Hutchins KS, 1996, J GEOPHYS RES-PLANET, V101, P14933, DOI 10.1029/96JE00860; Irion FW, 1996, GEOPHYS RES LETT, V23, P2377, DOI 10.1029/96GL01695; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHNSTON JC, 1995, J GEOPHYS RES-ATMOS, V100, P16801, DOI 10.1029/95JD01646; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; KARLSSON KR, 1992, SCIENCE, V255, P1409, DOI 10.1126/science.11537889; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KAYE JA, 1983, J GEOPHYS RES-OCEANS, V88, P8447, DOI 10.1029/JC088iC13p08447; KERRIDGE JF, 1988, LUNAR PLANET SCI, V19, P599; KIM KR, 1993, SCIENCE, V262, P1855, DOI 10.1126/science.262.5141.1855; KIM KR, 1990, NATURE, V347, P58, DOI 10.1038/347058a0; KRANKOWSKY D, 1995, GEOPHYS RES LETT, V22, P1713, DOI 10.1029/95GL01436; KRASNOPOLSKY VA, 1996, ICARUS, V553; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; MAK JE, 1994, J GEOPHYS RES-ATMOS, V99, P22915, DOI 10.1029/94JD01931; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MAUERSBERGER K, 1981, GEOPHYS RES LETT, V8, P935, DOI 10.1029/GL008i008p00935; MCELROY MB, 1976, SCIENCE, V194, P70, DOI 10.1126/science.194.4260.70; MILLER RL, 1994, SCIENCE, V265, P1831, DOI 10.1126/science.265.5180.1831; MINSCHWANER K, 1993, J GEOPHYS RES-ATMOS, V98, P10543, DOI 10.1029/93JD00223; MORTON J, 1989, CHEM PHYS LETT, V154, P143, DOI 10.1016/S0009-2614(89)87276-8; MORTON J, 1990, J GEOPHYS RES-ATMOS, V95, P901, DOI 10.1029/JD095iD01p00901; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; NAVON O, 1985, EARTH PLANET SC LETT, V73, P1, DOI 10.1016/0012-821X(85)90030-5; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; NIER AO, 1976, SCIENCE, V194, P68, DOI 10.1126/science.194.4260.68; NIER AO, 1947, REV SCI INSTRUM, V18, P294, DOI 10.1063/1.1740940; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; NITTLER LR, 1997, AIP C P, V402, P59, DOI DOI 10.1063/1.53320; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; PRASAD JS, 1994, J GEOPHYS RES, V99, P5295; Prasad SS, 1998, GEOPHYS RES LETT, V25, P2173, DOI 10.1029/98GL01610; Prasad SS, 1997, J GEOPHYS RES-ATMOS, V102, P21537, DOI 10.1029/97JD00002; Rahn T, 1997, SCIENCE, V278, P1776, DOI 10.1126/science.278.5344.1776; RINSLAND CP, 1985, J GEOPHYS RES-ATMOS, V90, P10719, DOI 10.1029/JD090iD06p10719; ROBERT F, 1998, EARTH PLANET SCI, V91, P231; Rockmann T, 1998, J GEOPHYS RES-ATMOS, V103, P1463, DOI 10.1029/97JD02929; Rockmann T, 1998, SCIENCE, V281, P544, DOI 10.1126/science.281.5376.544; SCAMBOS TA, 1990, J GEOPHYS RES-SOLID, V95, P14779, DOI 10.1029/JB095iB09p14779; Sehested J, 1998, J GEOPHYS RES-ATMOS, V103, P3545, DOI 10.1029/97JD03124; STEVENS CM, 1972, EARTH PLANET SC LETT, V16, P147, DOI 10.1016/0012-821X(72)90183-5; Thiemen M.H, 1996, CHONDRULES PROTOPLAN, P107; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; THIEMENS MH, 1991, GEOPHYS RES LETT, V18, P669, DOI 10.1029/91GL00121; THIEMENS MH, 1990, GEOPHYS RES LETT, V17, P717, DOI 10.1029/GL017i006p00717; THIEMENS MH, 1995, SCIENCE, V270, P969, DOI 10.1126/science.270.5238.969; UREY HC, 1947, J CHEM SOC, P562, DOI 10.1039/jr9470000562; VALENTINI JJ, 1987, J CHEM PHYS, V86, P6757, DOI 10.1063/1.452375; WAHLEN M, 1985, NATURE, V313, P780, DOI 10.1038/313780a0; WEN J, 1993, J GEOPHYS RES-ATMOS, V98, P12801, DOI 10.1029/93JD00565; WESTON RE, UNPUB CHEM REV; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; *WORLD MET ORG, 1995, 37 WORLD MET ORG, P2; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; Yoo RK, 1996, J CHEM PHYS, V105, P177, DOI 10.1063/1.471855; YOO RK, 1995, J CHEM PHYS, V102, P3227, DOI 10.1063/1.468633; Yoo RK, 1997, J CHEM PHYS, V106, P1294, DOI 10.1063/1.474089; YOSHIDA N, 1988, NATURE, V335, P528, DOI 10.1038/335528a0; YOSHINARI T, 1985, NATURE, V317, P349, DOI 10.1038/317349a0; YUNG YL, 1991, GEOPHYS RES LETT, V18, P13, DOI 10.1029/90GL02478; Yung YL, 1997, J GEOPHYS RES-ATMOS, V102, P10857, DOI 10.1029/97JD00528; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; Yung YL, 1997, SCIENCE, V278, P1778, DOI 10.1126/science.278.5344.1778; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147	104	298	309	7	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					341	345		10.1126/science.283.5400.341	http://dx.doi.org/10.1126/science.283.5400.341			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888843				2022-12-24	WOS:000078067000032
J	Ikonomidou, C; Bosch, F; Miksa, M; Bittigau, P; Vockler, J; Dikranian, K; Tenkova, TI; Stefovska, V; Turski, L; Olney, JW				Ikonomidou, C; Bosch, F; Miksa, M; Bittigau, P; Vockler, J; Dikranian, K; Tenkova, TI; Stefovska, V; Turski, L; Olney, JW			Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain	SCIENCE			English	Article							CEREBELLAR GRANULE NEURONS; AMINO-ACID RECEPTORS; DEVELOPING RAT-BRAIN; CELL-DEATH; CAUTIONARY NOTE; MESSENGER-RNAS; GROWTH SPURT; ETHANOL; EXPRESSION; GLUTAMATE	Programmed cell death (apoptosis) occurs during normal development of the central nervous system. However, the mechanisms that determine which neurons will succumb to apoptosis are poorly understood. Blockade of N-methyl-D-aspartate (NMDA) glutamate receptors for only a few hours during late fetal or early neonatal Life triggered widespread apoptotic neurodegeneration in the developing rat brain, suggesting that the excitatory neurotransmitter glutamate, acting at NMDA receptors, controls neuronal survival. These findings may have relevance to human neurodevelopmental disorders involving prenatal (drug-abusing mothers) or postnatal (pediatric anesthesia) exposure to drugs that block NMDA receptors.	Humboldt Univ, Charite Virchow Clin, Dept Pediat Neurol, D-13353 Berlin, Germany; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; UCL, Eisai London Res Labs, London WC1E 6BT, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Washington University (WUSTL); Eisai Co Ltd; University of London; University College London	Ikonomidou, C (corresponding author), Humboldt Univ, Charite Virchow Clin, Dept Pediat Neurol, Augustenburger Pl 1, D-13353 Berlin, Germany.	hrissanthi.ikonomidou@charite.de			NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER; NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BALAZS R, 1990, INT J DEV NEUROSCI, V8, P347, DOI 10.1016/0736-5748(90)90068-D; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; COLES C D, 1987, Advances in Alcohol and Substance Abuse, V6, P87; CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ishimaru M. J., 1997, Society for Neuroscience Abstracts, V23, P895; IZQUIERDO I, 1990, TRENDS PHARMACOL SCI, V11, P309, DOI 10.1016/0165-6147(90)90229-2; JEVTOVICTODOROV.V, 1998, NAT MED, V4, P450; JONES KL, 1973, LANCET, V2, P999; KAPPELLE AC, 1993, BRIT J PHARMACOL, V108, P780, DOI 10.1111/j.1476-5381.1993.tb12878.x; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KRISTENSEN JD, 1995, BRIT J ANAESTH, V74, P193, DOI 10.1093/bja/74.2.193; LEE HS, 1992, EXP NEUROL, V118, P284, DOI 10.1016/0014-4886(92)90185-S; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; Reynolds JD, 1995, CAN J PHYSIOL PHARM, V73, P1209, DOI 10.1139/y95-173; VALENTINE JL, 1994, J PHARMACOL EXP THER, V269, P1079; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; WHITE PF, 1976, J PHARMACOL EXP THER, V196, P545; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; ZHONG J, 1995, J NEUROCHEM, V64, P531	34	1514	1594	6	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					70	74		10.1126/science.283.5398.70	http://dx.doi.org/10.1126/science.283.5398.70			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872743				2022-12-24	WOS:000077976600051
J	Lee, KM; Chuang, E; Griffin, M; Khattri, R; Hong, DK; Zhang, WG; Straus, D; Samelson, LE; Thompson, CB; Bluestone, JA				Lee, KM; Chuang, E; Griffin, M; Khattri, R; Hong, DK; Zhang, WG; Straus, D; Samelson, LE; Thompson, CB; Bluestone, JA			Molecular basis of T cell inactivation by CTLA-4	SCIENCE			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHORYLATION; RECEPTOR; ACTIVATION; KINASES; ZETA; EXPRESSION; SUBUNIT; COMPLEX; DOMAIN	CTLA-4, a negative regulator of T cell function, was found to associate with the T cell receptor (TCR) complex zeta chain in primary T cells, The association of TCR zeta with CTLA-4, reconstituted in 293 transfectants, was enhanced by p56(lck)- induced tyrosine phosphorylation. Coexpression of the CTLA-4-associated tyrosine phosphatase, SHP-2, resulted in dephosphorylation of TCR zeta bound to CTLA-4 and abolished the p56(lck)-inducible TCR zeta-CTLA-4 interaction. Thus, CTLA-4 inhibits TCR signal transduction by binding to TCR zeta and inhibiting tyrosine phosphorylation after T cell activation. These findings have broad implications for the negative regulation of T cell function and T cell tolerance.	Univ Chicago, Ben May Inst Canc Res, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Pathol & Med, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Chicago	Bluestone, JA (corresponding author), Univ Chicago, Ben May Inst Canc Res, Howard Hughes Med Inst, Chicago, IL 60637 USA.		Griffin, Matthew/A-1688-2009	Griffin, Matthew/0000-0002-8701-8056; Hong, David/0000-0003-3152-0618; Lee, Kyung-Mi/0000-0002-5378-9258	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035294] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI35294-6] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE R, 1995, J IMMUNOL, V154, P985; Blair PJ, 1998, J IMMUNOL, V160, P12; Bluestone JA, 1997, J IMMUNOL, V158, P1989; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Chuang E, 1997, J IMMUNOL, V159, P144; CHUANG E, IN PRESS J IMMUNOL; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GRIFFIN MCA, UNPUB; HOULDEN BA, 1988, J IMMUNOL, V141, P3753; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; KUPFER A, 1988, P NATL ACAD SCI USA, V85, P8216, DOI 10.1073/pnas.85.21.8216; Lee K. T., UNPUB; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALLACE PM, 1994, TRANSPLANTATION, V58, P602, DOI 10.1097/00007890-199409150-00013; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	28	507	530	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2263	2266		10.1126/science.282.5397.2263	http://dx.doi.org/10.1126/science.282.5397.2263			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856951				2022-12-24	WOS:000077645800049
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Plant genomics - Plant genotoxicity	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Peters, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Kovalchuk I, 1998, NAT BIOTECHNOL, V16, P1054, DOI 10.1038/3505; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x	2	0	0	3	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2214	2214		10.1126/science.282.5397.2214	http://dx.doi.org/10.1126/science.282.5397.2214			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890831				2022-12-24	WOS:000077645800034
J	Rougier, GW; Wible, JR; Novacek, MJ				Rougier, GW; Wible, JR; Novacek, MJ			Implications of Deltatheridium specimens for early marsupial history	NATURE			English	Article							MAMMALS; AMERICA; ORIGIN	We describe here two new specimens of the mammal Deltatheridium pretrituberculare from the Late Cretaceous period of Mongolia. These specimens provide information on tooth replacement in basal therian mammals and on lower jaw and basicranial morphology. Deltatheroidans, known previously from isolated teeth, partial rostra and jaws from the late Cretaceous of Asia(1-4) and possibly North America(5,6), have been identified variously as eutherians(1,7,8), as basal metatherians (the stem-based dade formed by marsupials and their extinct relatives)(3,9-11) or as an outgroup to both eutherians and metatherians(2,12-15). Resolution of these conflicting hypotheses and understanding of the early evolution of the therian lineage have been hampered by a sparse fossil record for basal therians. The new evidence supports metatherian affinities for deltatheroidans and allows a comprehensive phylogenetic analysis of basal metatherians and marsupials, The presence of specialized marsupial patterns of tooth replacement and cranial vascularization in Deltatheridium and the basal phylogenetic position of this taxon indicate that these features are characteristic of Metatheria as a whole. Other morphological transformations recognized here secure the previously elusive diagnosis of Metatheria(3,14,15). The new specimens of Deltatheridium illustrate the effectiveness of fairly complete fossil specimens in determining the nature of early evolutionary events.	Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Amer Museum Nat Hist, Dept Vertebrate Paleontol, New York, NY 10024 USA; Carnegie Museum Nat Hist, Sect Mammals, Pittsburgh, PA 15206 USA	University of Louisville; American Museum of Natural History (AMNH)	Rougier, GW (corresponding author), Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.	grougier@louisville.edu						Averianov AO, 1997, ACTA PALAEONTOL POL, V42, P243; BISCOE CHT, 1987, REPROD PHYSL MARSUPI; BUTLER PM, 1973, NATURE, V245, P105, DOI 10.1038/245105a0; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P332; CIFELLI RL, 1993, P NATL ACAD SCI USA, V90, P9413, DOI 10.1073/pnas.90.20.9413; Cifelli RL, 1998, CR ACAD SCI II A, V326, P215, DOI 10.1016/S1251-8050(00)89038-2; Cifelli RL, 1996, NATURE, V379, P715, DOI 10.1038/379715a0; CIFELLI RL, 1993, MAMMAL PHYLOGENY, P205; DASHZEVEG D, 1995, NATURE, V374, P446, DOI 10.1038/374446a0; deMuizon C, 1997, NATURE, V389, P486, DOI 10.1038/39029; FOX RC, 1974, NATURE, V249, P392, DOI 10.1038/249392a0; FOX RC, 1975, CAN J EARTH SCI, V12, P412, DOI 10.1139/e75-037; Gregory WK, 1926, AM MUS NOVIT, V225, P7; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hershkovitz Philip, 1995, Bonner Zoologische Beitraege, V45, P153; Kielan-Jaworowska Z., 1979, P182; KIELAN-JAWOROWSKA Z, 1975, Palaeontologia Polonica, V33, P103; KIELANJAWOROWSKA Z, 1990, LETHAIA, V23, P1, DOI 10.1111/j.1502-3931.1990.tb01776.x; Kirsch JAW, 1997, AUST J ZOOL, V45, P211, DOI 10.1071/ZO96030; LUCKETT WP, 1993, MAMMAL PHYLOGENY, P182; MAIER W, 1993, MAMMAL PHYLOGENY, P165; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x; Martin Thomas, 1997, Journal of Mammalian Evolution, V4, P1, DOI 10.1023/A:1027300726126; MCKENNA M C, 1971, Journal of Paleontology, V45, P441; Sanchez-Villagra Marcelo R., 1997, Journal of Mammalian Evolution, V4, P119, DOI 10.1023/A:1027318213347; SLAUGHTER BH, 1974, J MAMMAL, V55, P115, DOI 10.2307/1379261; Springer Mark S., 1997, P129; Szalay F.S., 1994, EVOLUTIONARY HIST MA; VAN VALEN LEIGH, 1966, BULL AMER MUS NATUR HIST, V132, P1; Wible J.R., 1990, Journal of Vertebrate Paleontology, V10, P183	30	205	216	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					459	463		10.1038/24856	http://dx.doi.org/10.1038/24856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853752				2022-12-24	WOS:000077370100052
J	Nightingale, SL				Nightingale, SL			New FDA web site for health care professionals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-24	WOS:000077176600005
J	Franks, AL; Marks, JS				Franks, AL; Marks, JS			Introduction to supplement on iron overload, public health, and genetics	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEREDITARY HEMOCHROMATOSIS		Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Franks, AL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Mailstop K-24,4770 Buford Highway, Atlanta, GA 30341 USA.	alf1@cdc.gov						BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; Bradley L A, 1996, J Med Screen, V3, P178; Bradley L A, 1996, J Med Screen, V3, P171; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Haddow J E, 1994, J Med Screen, V1, P16; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; SIMON M, 1977, NEW ENGL J MED, V297, P1017, DOI 10.1056/NEJM197711102971901; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2	9	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					923	924		10.7326/0003-4819-129-11_Part_2-199812011-00001	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867743				2022-12-24	WOS:000077239200023
J	Rose, DN				Rose, DN			Short-course prophylaxis against tuberculosis in HIV-infected persons - A decision and cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						tuberculosis; human immunodeficiency virus infections; cost-benefit analysis; isoniazid; rifampin	HUMAN-IMMUNODEFICIENCY-VIRUS; ISONIAZID PREVENTIVE THERAPY; UNITED-STATES; ACTIVE TUBERCULOSIS; DRUG-USERS; RISK; HEPATITIS; PROGRESSION; RIFAMPIN; COHORT	Background: Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality. Recent clinical trials have found that some short-course regimens also effectively prevent tuberculosis. Objective: To compare the benefits, risks, and cost-effectiveness of isoniazid prophylaxis and short-course prophylaxis regimens. Design: Decision and cost-effectiveness analysis. Setting: United States. Patients: Hypothetical patients who are HIV-infected and have CD4 counts of 200 cells/mm(3) or less and positive results on tuberculin skin tests. Interventions: Isoniazid prophylaxis lasting 12 months and six short-course prophylaxis regimens of isoniazid, rifampin, and pyrazinamide alone or in combination. Measurements: 5-year survival rate, life expectancy, lifetime incidence of tuberculosis, and cost per quality-adjusted life-year saved. Results: Compared with no prophylaxis, the 12-month isoniazid regimen increased 5-year survival rates by 9% and life expectancy by 8.7 months, decreased incidence of tuberculosis by 27%, and saved 4 medical care dollars for every 1 spent on prophylaxis. Regimens of isoniazid for 6 months, isoniazid and rifampin for 3 months, and rifampin and pyrazinamide for 2 months had similar results: 6.2- to 8.6-month increases in life expectancy, 19% to 26% reductions in incidence of tuberculosis, and 1 to 7 medical care dollars saved for every 1 spent on prophylaxis. A 3-month regimen of isoniazid, rifampin, and pyrazinamide resulted in fewer clinical benefits and was the only regimen tested that did not save medical care dollars. Conclusions: Prophylaxis decreases the incidence of tuberculosis and increases life expectancy for HIV-infected patients. Some regimens save medical care dollars, and some short-course regimens have clinical and economic benefits similar to those of the 12-month isoniazid regimen. Short-course prophylaxis is a reasonable alternative to the 12-month isoniazid regimen.	Long Isl Jewish Med Ctr, Div Gen Internal Med & Primary Care, New Hyde Pk, NY 11042 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Northwell Health; Yeshiva University; Albert Einstein College of Medicine	Rose, DN (corresponding author), Long Isl Jewish Med Ctr, Div Gen Internal Med & Primary Care, 410 Lakeville Rd,Suite 105, New Hyde Pk, NY 11042 USA.							ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; CHAISSON RE, 1998, 12 WORLD AIDS C GEN; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827; FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; Garrait V, 1997, J IMMUNOL, V159, P2824; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; Goletti D, 1996, J IMMUNOL, V157, P1271; GORDIN F, 1998, C RETROVIR OPPO 0201, P223; Gourevitch MN, 1998, INT J TUBERC LUNG D, V2, P531; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; Holtgrave DR, 1997, J ACQ IMMUN DEF SYND, V16, P54, DOI 10.1097/00042560-199709010-00009; HORWITZ O, 1974, AM J EPIDEMIOL, V99, P333, DOI 10.1093/oxfordjournals.aje.a121618; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; Leroy V, 1997, AM J EPIDEMIOL, V145, P293; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; *MED EC, 1997, RED BOOK; Moreno S, 1997, ARCH INTERN MED, V157, P1729, DOI 10.1001/archinte.157.15.1729; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; MORRIS L, 1998, 5 C RETR OPP INF CHI; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; Rose DN, 1998, JAMA-J AM MED ASSOC, V279, P160, DOI 10.1001/jama.279.2.160; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; SALPETER SR, 1993, WESTERN J MED, V159, P560; Salpeter SR, 1997, ANN INTERN MED, V127, P1051, DOI 10.7326/0003-4819-127-12-199712150-00001; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465; Tacconelli E, 1997, INT J TUBERC LUNG D, V1, P582; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WADHAWAN D, 1993, INT C AIDS 6 11 JUN, V9, P321; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; *WHO, 1993, WKLY EPIDEMIOL REC, V68, P361; 1997, ANN INTERN MED, V127, P922; 1989, MMWR MORB MORTAL WKL, V38, P236; 1989, MMWR MORB MORTAL WKL, V38, P243; 1990, MMWR MORB MORTAL WKL, V39, P9	52	43	44	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					779	+		10.7326/0003-4819-129-10-199811150-00005	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841583				2022-12-24	WOS:000076984800003
J	Feng, GP; Tintrup, H; Kirsch, J; Nichol, MC; Kuhse, J; Betz, H; Sanes, JR				Feng, GP; Tintrup, H; Kirsch, J; Nichol, MC; Kuhse, J; Betz, H; Sanes, JR			Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme activity	SCIENCE			English	Article							RAT SPINAL-CORD; TUBULIN LINKER PROTEIN; SUBUNITS; SYNAPSES; MICE; CYTOSKELETON; BIOSYNTHESIS; DEFICIENCY; MUTATIONS; GENES	Glycine receptors are anchored at inhibitory chemical synapses by a cytoplasmic protein, gephyrin. Molecular cloning revealed the similarity of gephyrin to prokaryotic and invertebrate proteins essential for synthesizing a cofactor required for activity of molybdoenzymes. Gene targeting in mice showed that gephyrin is required both for synaptic clustering of glycine receptors in spinal cord and for molybdoenzyme activity in nonneural tissues. The mutant phenotype resembled that of humans with hereditary molybdenum cofactor deficiency and hyperekplexia (a failure of inhibitory neurotransmission), suggesting that gephyrin function may be impaired in both diseases.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Washington University (WUSTL); Max Planck Society	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.	sanesj@thalamus.wustl.edu	Feng, Guoping/Y-2827-2019; Kuhse, Jochen/T-3864-2019					Andrew M, 1997, BRIT J PSYCHIAT, V170, P106, DOI 10.1192/bjp.170.2.106; Aprison M. H., 1990, GLYCINE NEUROTRANSMI, P1; Bechade C, 1996, SEMIN CELL DEV BIOL, V7, P717, DOI 10.1006/scdb.1996.0088; BRUNE W, 1996, AM J HUM GENET, V58, P959; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON JL, 1991, J INHERIT METAB DIS, V14, P932, DOI 10.1007/BF01800477; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, BRAIN RES, V621, P301, DOI 10.1016/0006-8993(93)90120-C; KIRSCH J, 1995, J NEUROSCI, V15, P4148; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; Nishimaru H, 1996, J PHYSIOL-LONDON, V497, P131, DOI 10.1113/jphysiol.1996.sp021755; PARKS D, 1988, J APPL PHYSIOL, V254, P768; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PFEIFFER F, 1984, P NATL ACAD SCI-BIOL, V81, P7224, DOI 10.1073/pnas.81.22.7224; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Ramming M, 1997, FEBS LETT, V405, P137, DOI 10.1016/S0014-5793(97)00164-6; Rupar CA, 1996, NEUROPEDIATRICS, V27, P299, DOI 10.1055/s-2007-973798; SANES JR, IN PRESS ANN REV NEU; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Simon ES, 1997, MOVEMENT DISORD, V12, P221, DOI 10.1002/mds.870120213; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; TODD AJ, 1995, EUR J NEUROSCI, V7, P1, DOI 10.1111/j.1460-9568.1995.tb01014.x; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; WATTS RWE, 1965, J LAB CLIN MED, V66, P688; WU WI, 1992, J NEUROSCI, V12, P3935; Yoshida A, 1975, Methods Enzymol, V41, P304	36	322	329	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1321	1324		10.1126/science.282.5392.1321	http://dx.doi.org/10.1126/science.282.5392.1321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812897				2022-12-24	WOS:000076982200046
J	Owen, DJ; Evans, PR				Owen, DJ; Evans, PR			A structural explanation for the recognition of tyrosine-based endocytotic signals	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; VESICLE FORMATION; CRYSTAL-STRUCTURE; SORTING SIGNALS; INTERNALIZATION; PROTEINS; DOMAIN; MOTIF; ASSOCIATION; REFINEMENT	Many cell surface proteins are marked for endocytosis by a cytoplasmic sequence motif, tyrosine-X-X-(hydrophobic residue), that is recognized by the mu 2 subunit of AP2 adaptors. Crystal structures of the internalization signal binding domain of mu 2 complexed with the internalization signal peptides of epidermal growth factor receptor and the trans-Golgi network protein TGN38 have been determined at 2.7 angstrom resolution, The signal peptides adopted an extended conformation rather than the expected tight turn, Specificity was conferred by hydrophobic pockets that bind the tyrosine and leucine in the peptide. In the crystal, the protein forms dimers that could increase the strength and specificity of binding to dimeric receptors.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk			Medical Research Council [MC_U105178845] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	451	462	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1998	282	5392					1327	1332		10.1126/science.282.5392.1327	http://dx.doi.org/10.1126/science.282.5392.1327			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812899	Green Accepted			2022-12-24	WOS:000076982200048
J	Thomson, JA; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM				Thomson, JA; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM			Embryonic stem cell lines derived from human blastocysts	SCIENCE			English	Article							TELOMERASE ACTIVITY; MOUSE EMBRYOS; CULTURE; ANTIGEN	Human blastocyst-derived, pluripotent cell lines are described that have normal karyotypes, express high levels of telomerase activity, and express cell surface markers that characterize primate embryonic stem cells but do not characterize other early lineages. After undifferentiated proliferation in vitro for 4 to 5 months, these cells still maintained the developmental potential to form trophoblast and derivatives of all three embryonic germ layers, including gut epithelium (endoderm); cartilage, bone, smooth muscle, and striated muscle (mesoderm); and neural epithelium, embryonic ganglia, and stratified squamous epithelium (ectoderm). These cell lines should be useful in human developmental biology, drug discovery, and transplantation medicine.	Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Technion Israel Inst Technol, Fac Med, Dept Gynecol & Obstet, Rambam Med Ctr, IL-31096 Haifa, Israel; Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53715 USA	University of Wisconsin System; University of Wisconsin Madison; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Wisconsin System; University of Wisconsin Madison	Thomson, JA (corresponding author), Univ Wisconsin, Wisconsin Reg Primate Res Ctr, 1223 Capitol Court, Madison, WI 53715 USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANDREWS PW, 1987, TERATOCARCINOMAS EMB, P207; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gardner DK, 1998, FERTIL STERIL, V69, P84, DOI 10.1016/S0015-0282(97)00438-X; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hayflick L, 1961, EXP CELL RES, V25, P581; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KLUNG MG, 1996, J CLIN INVEST, V98, P216; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; O'Rahilly R., 1987, DEV STAGES HUMAN EMB; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Thomson JA, 1998, CURR TOP DEV BIOL, V38, P133; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; WILES MV, 1991, DEVELOPMENT, V111, P259; Wright WE, 1996, DEV GENET, V18, P173	23	10766	12157	32	1538	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1145	1147		10.1126/science.282.5391.1145	http://dx.doi.org/10.1126/science.282.5391.1145			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804556				2022-12-24	WOS:000076887700056
J	Soignet, SL; Maslak, P; Wang, ZG; Jhanwar, S; Calleja, E; Dardashti, LJ; Corso, D; DeBlasio, A; Gabrilove, J; Scheinberg, DA; Pandolfi, PP; Warrell, RP				Soignet, SL; Maslak, P; Wang, ZG; Jhanwar, S; Calleja, E; Dardashti, LJ; Corso, D; DeBlasio, A; Gabrilove, J; Scheinberg, DA; Pandolfi, PP; Warrell, RP			Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-RETINOIC ACID; POLYMERASE CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; DIFFERENTIATION THERAPY; CASPASE ACTIVATION; INDUCED APOPTOSIS; CELLS; TRANSCRIPTION; EXPRESSION; GENE	Background Two reports from China have suggested that arsenic trioxide can induce complete remissions in patients with acute promyelocytic leukemia (APL). We evaluated this drug in patients with APL in an attempt to elucidate its mechanism of action. Methods Twelve patients with APL who had relapsed after extensive prior therapy were treated with arsenic trioxide at doses ranging from 0.06 to 0.2 mg per kilogram of body weight per day until visible leukemic cells were eliminated from the bone marrow. Bone marrow mononuclear cells were serially monitored by flow cytometry for immunophenotype, fluorescence in situ hybridization, reverse-transcription-polymerase-chain-reaction (RT-PCR) assay for PML-RAR-alpha: fusion transcripts, and Western blot analysis for expression of the apoptosis-associated proteins caspases 1, 2, and 3. Results Of the 12 patients studied, 11 had a complete remission after treatment that lasted from 12 to 39 days (range of cumulative doses, 160 to 515 mg). Adverse effects were relatively mild and included rash, lightheadedness, fatigue, and musculoskeletal pain. Cells that expressed both CD11b and CD33 (antigens characteristic of mature and immature cells, respectively), and which were found by fluorescence in situ hybridization to carry the t(15;17) translocation, increased progressively in number during treatment and persisted in the early phase of complete remission. Eight of 11 patients who initially tested positive for the PML-RAR-alpha fusion transcript by the RT-PCR assay later tested negative; 3 other patients, who persistently tested positive, relapsed early. Arsenic trioxide induced the expression of the proenzymes of caspase 2 and caspase 3 and activation of both caspase 1 and caspase 3. Conclusions Low doses of arsenic trioxide can induce complete remissions in patients with APL who have relapsed. The clinical response is associated with incomplete cytodifferentiation and the induction of apoptosis with caspase activation in leukemic cells. (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Pharm, New York, NY 10021 USA; Cornell Univ Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Warrell, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, 1275 York Ave, New York, NY 10021 USA.		Roszak, Joanna/F-4003-2010	Maslak, Peter/0000-0003-1949-5819	NATIONAL CANCER INSTITUTE [R03CA077136, T32CA009207] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77136, CA-09207] Funding Source: Medline; FDA HHS [FD-R-001364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		Bainbridge WS, 1914, CANC PROBLEM, P271; BIONDI A, 1992, BLOOD, V80, P492; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BURRI C, 1993, CHEMOTHERAPY, V39, P225, DOI 10.1159/000239130; CALLEJA EM, 1998, P AN M AM SOC CLIN, V17, pA218; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, BLOOD, V88, P1052; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; *EUR RET GROUP, 1996, LEUKEMIA, V10, P368; FENAUX P, 1993, BLOOD, V82, P3241; Forkner CE, 1931, J AMER MED ASSOC, V97, P0003, DOI 10.1001/jama.1931.02730010007002; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; Grimwade D, 1996, LEUKEMIA, V10, P61; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Konig A, 1997, BLOOD, V90, P562, DOI 10.1182/blood.V90.2.562.562_562_570; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Mandelli F, 1997, BLOOD, V90, P1014; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MILLER WH, 1993, BLOOD, V82, P1689; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet S, 1997, CANCER CHEMOTH PHARM, V40, pS25, DOI 10.1007/s002800051057; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Tallman MS, 1997, NEW ENGL J MED, V337, P1639; TERSTAPPEN LWMM, 1990, J LEUKOCYTE BIOL, V48, P138, DOI 10.1002/jlb.48.2.138; Thornberry NA, 1997, BRIT MED BULL, V53, P478; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Watson RWG, 1997, FEBS LETT, V412, P603, DOI 10.1016/S0014-5793(97)00779-5; Westervelt P., 1997, Blood, V90, p249B; Yang C. H., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P227; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	44	1044	1119	1	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1341	1348		10.1056/NEJM199811053391901	http://dx.doi.org/10.1056/NEJM199811053391901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801394				2022-12-24	WOS:000076780200001
J	Bloch, KC; Zwerling, L; Pletcher, MJ; Hahn, JA; Gerberding, JL; Ostroff, SM; Vugia, DJ; Reingold, AL				Bloch, KC; Zwerling, L; Pletcher, MJ; Hahn, JA; Gerberding, JL; Ostroff, SM; Vugia, DJ; Reingold, AL			Incidence and clinical implications of isolation of Mycobacterium kansasii: Results of a 5-year, population-based study	ANNALS OF INTERNAL MEDICINE			English	Article						Mycobacterium kansasii; human immunodeficiency virus infections; socioeconomic factors; population surveillance; comorbidity	HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; SAN-FRANCISCO; INFECTION; DISEASE; WATER; AIDS; INTRACELLULARE; TRANSMISSION; EPIDEMIOLOGY	Background: Mycobacterium kansasii, an unusual pathogen in the pre-AIDS era, is increasingly reported to cause infection among patients with HIV infection. Little is known about the epidemiology and clinical implications of M. kansasii infection in the AIDS era. Objective: To compare the incidence, demographic characteristics, and clinical features of M. kansasii infection in HIV-positive and HIV-negative persons. Design: Population-based laboratory surveillance. Setting: Three counties in northern California. Patients: All persons who had a positive culture for M. kansasii between 1 January 1992 and 31 December 1996. Measurements: Cumulative incidence rates were calculated for each year by dividing the number of adult patients by the annual estimated adult population. Demographic and socioeconomic data for a single county were obtained by linkage with the 1990 U.S. Census report. Results: 270 patients (69.3% of whom were HIV positive) were identified, for an incidence of 2.4 cases per 100 000 adults per year (95% Cl, 2.1 to 2.7), 115 cases per 100 000 HIV-positive persons per year (Cl, 99 to 133), and 647 cases per 100 000 persons with AIDS per year (Cl, 554 to 751). Indicators of lower socioeconomic status were common among patients: Median incomes were $32 317 in census tracts in which cases were identified and $38 048 in census tracts without cases (P = 0.001), and 35.7% of patients had unstable housing situations. Ninety-four percent of cases were from respiratory isolates, and 87.5% of patients had evidence of infection. Persons with HIV infection differed from those without HIV infection with respect to mycobacteremia (9.6% compared with 0%; P = 0.001), need for hospitalization (77.4% compared with 51.9%; P < 0.001), and smear positivity (41.7% compared with 20.7%; P = 0.005). Chronic diseases were common among HIV-negative persons; however, 40.3% had no predisposing medical condition. Conclusions: Mycobacterium kansasii isolation is more common in HIV-positive persons, but most patients with M. kansasii infection have clinical and radiologic evidence of infection regardless of HIV status. Persons infected with HIV and M. kansasii have a higher rate of hospitalization and a greater burden of organisms. A possible association with poverty suggests mechanisms of transmission and requires further study.	Univ Calif Berkeley, Berkeley, CA 94720 USA; Calif Dept Hlth Serv, Berkeley, CA 94704 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; California Department of Health Care Services; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Bloch, KC (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, A-3310 MCN, Nashville, TN 37212 USA.		Hahn, Judith/J-5813-2014; Bloch, Karen/AAE-1479-2020	Hahn, Judith/0000-0002-2697-8264; 	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42459, MH 19105] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHN CH, 1982, AM REV RESPIR DIS, V125, P388; AHN CH, 1979, CHEST, V75, P120, DOI 10.1378/chest.75.2.120; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BAMBERGER DR, 1994, CLIN INFECT DIS, V18, P395, DOI 10.1093/clinids/18.3.395; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; BENNETT C, 1986, AM J MED, V80, P891, DOI 10.1016/0002-9343(86)90634-0; Bittner MJ, 1996, CLIN INFECT DIS, V22, P1109, DOI 10.1093/clinids/22.6.1109; Bor D H, 1991, Semin Respir Infect, V6, P194; Campo RE, 1997, CLIN INFECT DIS, V24, P1233, DOI 10.1086/513666; CHAISSON RE, 1991, ANN INTERN MED, V115, P496; *DEP FIN STAT CA, 1993, P3 DEP FIN STAT CAL; ENGEL HWB, 1980, TUBERCLE, V61, P21, DOI 10.1016/0041-3879(80)90055-0; Evans AJ, 1996, THORAX, V51, P1243, DOI 10.1136/thx.51.12.1243; Evans SA, 1996, THORAX, V51, P1248, DOI 10.1136/thx.51.12.1248; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; GOOD RC, 1982, J INFECT DIS, V146, P829, DOI 10.1093/infdis/146.6.829; GOSLEE S, 1976, AM REV RESPIR DIS, V113, P287; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; JOYNSON DHM, 1979, TUBERCLE, V60, P77, DOI 10.1016/0041-3879(79)90039-4; Kubalek I, 1996, EUR J EPIDEMIOL, V12, P471, DOI 10.1007/BF00143998; LEVINE B, 1991, ANN INTERN MED, V114, P861, DOI 10.7326/0003-4819-114-10-861; LILLO M, 1990, REV INFECT DIS, V12, P760; Maniar A C, 1976, Can J Public Health, V67, P59; MCSWIGGAN D A, 1974, Tubercle, V55, P291, DOI 10.1016/0041-3879(74)90038-5; OBRIEN RJ, 1987, AM REV RESPIR DIS, V135, P1007; ONSTAD GD, 1969, AM REV RESPIR DIS, V99, P426; PENNY ME, 1982, TUBERCLE, V63, P129, DOI 10.1016/S0041-3879(82)80050-0; Picardeau M, 1997, J CLIN MICROBIOL, V35, P25, DOI 10.1128/JCM.35.1.25-32.1997; POWELL BL, 1981, J CLIN MICROBIOL, V13, P969, DOI 10.1128/JCM.13.5.969-975.1981; PRINCE DS, 1989, NEW ENGL J MED, V321, P863, DOI 10.1056/NEJM198909283211304; Roberts GD, 1991, MANUAL CLIN MICROBIO, P304; SCHRAUFNAGEL DE, 1986, BRIT J DIS CHEST, V80, P131, DOI 10.1016/0007-0971(86)90033-1; SHAFER RW, 1992, CLIN INFECT DIS, V15, P161, DOI 10.1093/clinids/15.1.161; SINGLETON J, 1995, HIV AIDS UPDATE, P1; Singleton JA, 1996, WESTERN J MED, V164, P122; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; TABNAK F, 1997, HIV AIDS UPDATE, P1; VALAINIS GT, 1991, ANN INTERN MED, V115, P496, DOI 10.7326/0003-4819-115-6-496; WALLACE RJ, 1990, AM REV RESPIR DIS, V142, P940, DOI 10.1164/ajrccm/142.4.940; Wallace RJ, 1997, AM J RESP CRIT CARE, V156, pS1, DOI 10.1164/ajrccm.156.2.atsstatement; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; WITZIG RS, 1995, CLIN INFECT DIS, V21, P77, DOI 10.1093/clinids/21.1.77; WITZIG RS, 1993, ANTIMICROB AGENTS CH, V37, P1997, DOI 10.1128/AAC.37.9.1997; WOLINSKY E, 1992, CLIN INFECT DIS, V15, P1, DOI 10.1093/clinids/15.1.1; WOLINSKY E, 1981, REV INFECT DIS, V3, P1025; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; WOODS GL, 1987, REV INFECT DIS, V9, P275; 1997, MMWR MORB MORTAL WKL, V46, P861; 1997, MMWR MORB MORTAL WKL, V46, P695	52	109	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					698	+		10.7326/0003-4819-129-9-199811010-00004	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841601				2022-12-24	WOS:000076785200003
J	Mayans, O; van der Ven, PFM; Wilm, M; Mues, A; Young, P; Furst, DO; Wilmanns, M; Gautel, M				Mayans, O; van der Ven, PFM; Wilm, M; Mues, A; Young, P; Furst, DO; Wilmanns, M; Gautel, M			Structural basis for activation of the titin kinase domain during myofibrillogenesis	NATURE			English	Article							GIANT PROTEIN-KINASES; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; TYROSINE KINASE; IMMUNOELECTRON MICROSCOPY; MOLLUSCAN TWITCHIN; PEPTIDE SUBSTRATE; PHOSPHORYLATION; EXPRESSION; MUSCLE	The giant muscle protein titin (connectin) is essential in the temporal and spatial control of the assembly of the highly ordered sarcomeres (contractile units) of striated muscle. Here we present the crystal structure of titin's only catalytic: domain, an autoregulated serine kinase (titin kinase). The structure shows how the active site is inhibited by a tyrosine of the kinase domain. We describe a dual mechanism of activation of titin kinase that consists of phosphorylation of this tyrosine and binding of calcium/calmodulin to the regulatory tail. The serine kinase domain of titin is the first known non-arginine-aspartate kinase to be activated by phosphorylation. The phosphorylated tyrosine is not located in the activation segment, as in other kinases, but in the P + 1 loop, indicating that this tyrosine is a binding partner of the titin kinase substrate. Titin kinase phosphorylates the muscle protein telethonin in early differentiating myocytes, indicating that this kinase may act in myofibrillogenesis.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Univ Potsdam, Dept Cell Biol, D-14471 Potsdam, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Potsdam; European Molecular Biology Laboratory (EMBL)	Wilmanns, M (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	Wilmanns@embl-hamburg.de; Gautel@embl-heidelberg.de	Gautel, Mathias/AAB-9860-2019; Fürst, Dieter O./H-8561-2013; Mayans, Olga/A-3954-2008; Young, Paul/A-4874-2015	Fürst, Dieter O./0000-0001-8805-6444; Young, Paul/0000-0002-1307-0249; Wilm, Matthias/0000-0002-5461-6834; Gautel, Mathias/0000-0003-4027-9803; van der Ven, Peter/0000-0002-9750-8913; Mayans, Olga/0000-0001-6876-8532; Wilmanns, Matthias/0000-0002-4643-5435				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chayen NE, 1997, J APPL CRYSTALLOGR, V30, P198, DOI 10.1107/S0021889896013532; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heierhorst J, 1996, EUR J BIOCHEM, V242, P454, DOI 10.1111/j.1432-1033.1996.454rr.x; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KLEYWEGT GJ, 1994, P CCP4 STUD WEEK 1 M, P56; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500; Mues A, 1998, FEBS LETT, V428, P111, DOI 10.1016/S0014-5793(98)00501-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; OTKINOWSKI Z, 1993, P CCP4 STUD WEEK SER, P56; Sebestyen MG, 1996, J MUSCLE RES CELL M, V17, P343; Song XD, 1996, IEEE T IMAGE PROCESS, V5, P16, DOI 10.1109/83.481667; TAN JL, 1991, J BIOL CHEM, V266, P16044; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Trinick J, 1996, CURR BIOL, V6, P258, DOI 10.1016/S0960-9822(02)00472-4; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; Weijland A, 1996, EUR J BIOCHEM, V240, P756, DOI 10.1111/j.1432-1033.1996.0756h.x; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	47	297	307	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					863	869		10.1038/27603	http://dx.doi.org/10.1038/27603			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804419				2022-12-24	WOS:000076713400046
J	Hoddinott, P; Pill, R				Hoddinott, P; Pill, R			Qualitative study of decisions about infant feeding among women in east end of London	BRITISH MEDICAL JOURNAL			English	Article								Objective To improve understanding of how first time mothers who belong to a socioeconomic group with particularly low rates of breast feeding decide whether or not to initiate breast feeding. Design Qualitative semistructured interviews early in pregnancy and 6-10 weeks after birth. Setting Women's homes in east end of London. Subjects 21 white, low income women expecting their first baby were interviewed mostly at home, often with their partner or a relative. Two focus groups were conducted. Results Women who had regularly seen a relative or friend successfully breast feed and described this experience positively were more confident about and committed to breast feeding. They were also more likely to succeed. Exposure to breast feeding, however, could be either a positive or a negative influence on the decision to breast feed, depending on the context Women who had seen breast feeding only by a stranger often described this as a negative influence, particularly if other people were present. All women knew that breast feeding has health benefits. Ownership of this knowledge, however, varied according to the woman's experience of seeing breast feeding. Conclusions The decision to initiate breast feeding is influenced more by embodied knowledge gained from seeing breast feeding than by theoretical knowledge about its benefits. Breast feeding involves performing a practical skill, often with others present The knowledge, confidence, and commitment necessary to breast feed may be more effectively gained through antenatal apprenticeship to a breastfeeding mother than from advice given in consultations or from books.	Macduff Med Practice, Macduff AB44 1PR, Banff, Scotland; Univ Wales, Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales	Cardiff University	Hoddinott, P (corresponding author), Macduff Med Practice, Macduff AB44 1PR, Banff, Scotland.	hoddinott@dial.pipexcom	Sandall, Jane/D-4146-2009; Hoddinott, Pat/F-9090-2011	Sandall, Jane/0000-0003-2000-743X; Hoddinott, Pat/0000-0002-4372-9681				BOND S, 1991, DEV VALIDATION INSTR; Foster K, 1997, INFANT FEEDING 1995; HALLY MR, 1984, ACTA PAEDIATR SCAND, V73, P33, DOI 10.1111/j.1651-2227.1984.tb09894.x; HASTRUP K, 1995, PASSAGE ANTHR EXPERI, P1; Henschel D, 1989, Nurs Stand, V4, P54; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; MACLEAN HM, 1989, HLTH PROMOTION, V3, P355; MANSTEAD ASR, 1983, J PERS SOC PSYCHOL, V44, P657, DOI 10.1037/0022-3514.44.4.657; MCINTOSH J, 1985, MIDWIFERY, V1, P213, DOI DOI 10.1016/S0266-6138(85)80019-X; Miles M., 1994, QUALITATIVE DATA ANA; *NAT BREASTF WORK, 1995, BREASTF GOOD PRACT G; Patton M. Q., 1990, QUALITATIVE EVALUATI; Potter J., 1995, ANAL QUALITATIVE DAT, P47; RENFREW MJ, 1995, COCHRANE LIBRARY; Richie J, 1994, ANAL QUALITATIVE DAT, P173, DOI DOI 10.4324/9780203413081_CHAPTER_9; Strauss A., 1990, BASICS QUALITATIVE R; WHITE AS, 1992, INFANT FEEDING 1990; WHO/UNICEF, 1989, WHO UNICEF JOINT STA; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; WYLIE J, 1994, J HUM NUTR DIET, V7, P115, DOI 10.1111/j.1365-277X.1994.tb00418.x; [No title captured]	24	137	141	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					30	34						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872883	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000078013100026
J	Marcus, GF; Vijayan, S; Rao, SB; Vishton, PM				Marcus, GF; Vijayan, S; Rao, SB; Vishton, PM			Rule learning by seven-month-old infants	SCIENCE			English	Article							LANGUAGE-ACQUISITION; SPEECH; WORDS	A fundamental task of language acquisition is to extract abstract algebraic rules. Three experiments show that 7-month-old infants attend longer to sentences with unfamiliar structures than to sentences with familiar structures. The design of the artificial language task used in these experiments ensured that this discrimination could not be performed by counting, by a system that is sensitive only to transitional probabilities, or by a popular class of simple neural network models. Instead, these results suggest that infants can represent, extract, and generalize abstract algebraic rules.	NYU, Dept Psychol, New York, NY 10003 USA; Amherst Coll, Dept Psychol, Amherst, MA 01002 USA	New York University; Amherst College	Marcus, GF (corresponding author), NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA.							Bates E, 1996, SCIENCE, V274, P1849, DOI 10.1126/science.274.5294.1849; Berent I, 1997, COGNITION, V64, P39, DOI 10.1016/S0010-0277(97)00016-4; BIJELJACBABIC R, 1993, DEV PSYCHOL, V29, P711, DOI 10.1037/0012-1649.29.4.711; Chomsky N, 1980, RULES REPRESENTATION; DIENES Z, 1995, NEURAL COMPUTATION P; ELMAN JL, 1990, COGNITIVE SCI, V14, P179, DOI 10.1207/s15516709cog1402_1; GOMEZ RL, 1997, ANN M PSYCH SOC PHIL; GOMEZ RL, 1997, BOSTON U C LANGUAGE, V21, P194; GOODSITT JV, 1984, CHILD DEV, V55, P903, DOI 10.2307/1130141; Hummel JE, 1997, PSYCHOL REV, V104, P427, DOI 10.1037/0033-295X.104.3.427; JUSCZYK PW, 1995, COGNITIVE PSYCHOL, V29, P1, DOI 10.1006/cogp.1995.1010; MARCUS G, 1999, IN PRESS ALGEBRAIC M; Marcus G. F., 1995, COGNITIVE PSYCHOL, V29, P186; Marcus GF, 1998, COGNITION, V66, P153, DOI 10.1016/S0010-0277(98)00018-3; MARCUS GF, IN PRESS COGN PSYCHO; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; REBER AS, 1969, J EXP PSYCHOL, V81, P115, DOI 10.1037/h0027454; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Seidenberg MS, 1997, SCIENCE, V275, P1599, DOI 10.1126/science.275.5306.1599	20	735	742	4	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					77	80		10.1126/science.283.5398.77	http://dx.doi.org/10.1126/science.283.5398.77			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155ZH	9872745				2022-12-24	WOS:000077976600053
J	Hurtig, AK; Nicoll, A; Carne, C; Lissauer, T; Connor, N; Webster, JP; Ratcliffe, L				Hurtig, AK; Nicoll, A; Carne, C; Lissauer, T; Connor, N; Webster, JP; Ratcliffe, L			Syphilis in pregnant women and their children in the United Kingdom: results from national clinician reporting surveys 1994-7	BRITISH MEDICAL JOURNAL			English	Article								Objective To measure the incidence of syphilis detected in pregnancy and congenital syphilis in the United Kingdom. Design Surveys through consultants in genitourinary medicine and paediatricians with active surveillance. Setting United Kingdom, 1994-7. Subjects Women treated for syphilis in pregnancy, and children with early congenital syphilis born in the United Kingdom. Results Over 3 years 139 women were diagnosed with and treated for syphilis in pregnancy; 121 were detected through antenatal screening. Thirty one had confirmed or probable congenitally transmissible syphilis, putting their pregnancies at risk These were minimum figures but are compatible with the 90 to 100 women newly diagnosed annually as having infectious or early latent syphilis. A universal screening policy would require 18 600 and 55 700 women (maximum numbers) to be screened, respectively, to detect one woman needing treatment and to prevent one case of congenital syphilis. Nine presumptive cases of children with congenital syphilis born in the United Kingdom were reported. Mothers requiring treatment for syphilis were found in almost every health region but were more prevalent in London and the south east Being born abroad and belonging to an ethnic minority group were strong risk factors, but 14% (19 of 121) of cases treated and six of 31 definite or probably transmissible cases occurred in white women born in the United Kingdom. Conclusions Congenitally transmissible syphilis continues to occur among pregnant women in the United Kingdom. Cases would be missed and stillbirths and congenitally infected babies would occur if antenatal screening was abandoned.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, STD Sect, HIV & STD Div, London NW9 5EQ, England; Addenbrookes Hosp, Dept Genitourinary Med, British Cooperat Clin Grp, Cambridge CB2 2QQ, England; St Marys Hosp, Dept Paediat, London W2 1NY, England	Public Health England; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, STD Sect, HIV & STD Div, London NW9 5EQ, England.							[Anonymous], MMWR; Calman K, 1994, J Med Screen, V1, P101; *CDCP, 1998, MMWR, V47; *COMM DIS SURV CTR, 1997, CDR WEEKLY, V7, P192; NICOLL A, 1994, BRIT MED J, V308, P1253, DOI 10.1136/bmj.308.6939.1253; SCHWARTZ DA, 1995, HUM PATHOL, V26, P784, DOI 10.1016/0046-8177(95)90228-7; *STD SECT HIV STD, 1998, REP NAT SCREEN COMM; 1998, CDR WEEKLY, V8, P413; 1998, CDR WEEKLY, V8, P416	9	35	39	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1617	1619		10.1136/bmj.317.7173.1617	http://dx.doi.org/10.1136/bmj.317.7173.1617			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848899	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000077602100022
J	Kaffman, A; Rank, NM; O'Neill, EM; Huang, LS; O'Shea, EK				Kaffman, A; Rank, NM; O'Neill, EM; Huang, LS; O'Shea, EK			The receptor Msn5 exports the phosphorylated transcription factor Pho4 out of the nucleus	NATURE			English	Article							CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEINS; RNA TRANSPORT; SIGNALS; PHO80-PHO85; INHIBITOR; PATHWAY; KINASE; CRM1	The movement of many transcription factors, kinases and replication factors between the nucleus and cytoplasm is important in regulating their activity(1). In some cases, phosphorylation of a protein regulates its entry into the nucleus(2); in others, it causes the protein to be exported to the cytoplasm(3-6). The mechanism by which phosphorylation promotes protein export from the nucleus is poorly understood. Here we investigate how the export of the yeast transcription factor Pho4 is regulated in response to changes in phosphate availability. We show that phosphorylation of Pho4 by a nuclear complex of a cyclin with a cyclin-dependent kinase, Pho80-Pho85, triggers its export from the nucleus. We also find that the shuttling receptor used by Pho4 for nuclear export is the importin-beta-family member Msn5 (refs 7, 8), which is required for nuclear export of Pho4 in vivo and binds only to phosphorylated Pho4 in the presence of the GTP-bound form of yeast Ran in vitro. Our results reveal a simple mechanism by which phosphorylation can control the nuclear export of a protein.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Huang, Linda/C-9903-2014	Huang, Linda/0000-0002-9033-4391	NIGMS NIH HHS [F32 GM017494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CHENEVERT J, 1994, GENETICS, V136, P1287; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OGAWA N, 1995, MOL CELL BIOL, V15, P997; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691	30	275	280	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					482	486		10.1038/24898	http://dx.doi.org/10.1038/24898			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853758				2022-12-24	WOS:000077370100058
J	Nightingale, SL				Nightingale, SL			New professional labeling for aspirin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-24	WOS:000077176600006
J	Wee, CC; Phillips, RS; Aurigemma, G; Erban, S; Kriegel, G; Riley, M; Douglas, PS				Wee, CC; Phillips, RS; Aurigemma, G; Erban, S; Kriegel, G; Riley, M; Douglas, PS			Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication	ANNALS OF INTERNAL MEDICINE			English	Article							MITRAL REGURGITATION; DOPPLER	Background: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market. Objective: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications. Design: Cohort study. Setting: Academic primary care practices. Patients: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy. Measurements: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one deg ree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation). Results: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease. One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation. The second patient developed new moderate aortic insufficiency. Conclusion: Users of diet medications are at risk for valvular heart disease. However, the incidence may be lower than that reported previously.	Beth Israel Deaconess Med Ctr, Div Gen Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Massachusetts, Med Ctr, Div Cardiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Wee, CC (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brookline Ave,Libby 330, Boston, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049	BHP HRSA HHS [5 T32 PE11001] Funding Source: Medline	BHP HRSA HHS		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; Klein A L, 1990, J Am Soc Echocardiogr, V3, P54; *MA MED SOC COMM N, 1996, OB TREATM US DRUG TH; OTTO CM, 1995, TXB CLIN ECHOCARDIOG, P247; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; REDFIELD MM, 1992, ANN INTERN MED, V117, P50, DOI 10.7326/0003-4819-117-1-50; REID CL, 1992, AM HEART J, V124, P657, DOI 10.1016/0002-8703(92)90274-Y; REID CL, 1994, CIRCULATION, V90, P1519; SPAIN MG, 1989, J AM COLL CARDIOL, V13, P585, DOI 10.1016/0735-1097(89)90597-4; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; WEYMAN AE, 1994, PRINCIPLES PRACTICE, P431	16	49	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819			ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					870	874		10.7326/0003-4819-129-11_Part_1-199812010-00005	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867728				2022-12-24	WOS:000077239200004
J	Chen, JJ; Sun, YN; Nabel, GJ				Chen, JJ; Sun, YN; Nabel, GJ			Regulation of the proinflammatory effects of Fas ligand (CD95L)	SCIENCE			English	Article							CONFER IMMUNE PRIVILEGE; INDUCED APOPTOSIS; GROWTH-FACTOR; ACTIVATION; EXPRESSION; CELLS; NEUTROPHILS; PHOSPHORYLATION; REJECTION; MECHANISM	Fas ligand (CD95L) inhibits T cell function in immune-privileged organs such as the eye and testis, yet in most tissues CD95L expression induces potent inflammatory responses. With a stably transfected colon carcinoma cell Line, CT26-CD95L, the molecular basis for these divergent responses was defined. When injected subcutaneously, rejection of CT26-CD95L was caused by neutrophils activated by CD95L. CT26-CD95L survived in the intraocular space because of the presence of transforming growth factor-beta (TGF-beta), which inhibited neutrophil activation. Providing TGF-beta to subcutaneous sites protected against tumor rejection. Thus, these cytokines together generate a microenvironment that promotes immunologic tolerance, which may aid in the amelioration of allograft rejection.	Univ Michigan, Med Ctr, Dept Internal Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Howard Hughes Med Inst, 1150 W Med Ctr Dr,4250 Med Sci Res Bldg 1, Ann Arbor, MI 48109 USA.	gnabel@umich.edu						Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Arai H, 1997, NAT MED, V3, P843, DOI 10.1038/nm0897-843; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Berrou E, 1996, BIOCHEM J, V316, P167, DOI 10.1042/bj3160167; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chen J., UNPUB; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; DAUGHADAY WH, 1991, ENDOCRIN METAB CLIN, V20, P539, DOI 10.1016/S0889-8529(18)30258-5; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HORGAN K, 1998, CURR PROTOC IMMUNOL, V7, P4; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lee M, 1997, AM J PHYSIOL-LUNG C, V273, pL374, DOI 10.1152/ajplung.1997.273.2.L374; LILES WC, 1995, J IMMUNOL, V155, P2175; LUO Y, 1998, CURR PROTOC IMMUNOL, V3, P20; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rose DM, 1997, BIOCHEM BIOPH RES CO, V238, P256, DOI 10.1006/bbrc.1997.7271; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STREILEIN JW, 1992, CURR EYE RES, V11, P41, DOI 10.3109/02713689208999510; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; VARANI J, 1989, AM J PATHOL, V135, P435; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; Zu YL, 1998, J IMMUNOL, V160, P1982	38	307	324	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1714	1717		10.1126/science.282.5394.1714	http://dx.doi.org/10.1126/science.282.5394.1714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831564				2022-12-24	WOS:000077246600049
J	Thiele, TE; Marsh, DJ; Ste Marie, L; Bernstein, IL; Palmiter, RD				Thiele, TE; Marsh, DJ; Ste Marie, L; Bernstein, IL; Palmiter, RD			Ethanol consumption and resistance are inversely related to neuropeptide Y levels	NATURE			English	Article							INBRED MOUSE STRAINS; FOOD-INTAKE; ALCOHOL; RATS; BEHAVIOR; SEIZURES; MICE; SENSITIVITY; INHIBITION; RECEPTORS	Genetic linkage analysis of rats that were selectively bred for alcohol preference identified a chromosomal region that includes the neuropeptide Y (NPY) gene(I). Alcohol-preferring rats have lower levels of NPY in several brain regions compared with alcohol-non-preferring rats(2). We therefore studied alcohol consumption by mice that completely lack NPYas a result of targeted gene disruption(3). Here we report that NPY-deficient mice show increased consumption, compared with wild-type mice, of solutions containing 6%, 10% and 20% (v/v) ethanol. NPY-deficient nice are also less sensitive to the sedative/hypnotic effects of ethanol, as shown by more rapid recovery from ethanol-induced sleep, even though plasma ethanol concentrations do not differ significantly from those of controls, In contrast, transgenic mice that overexpress a marked NPY gene in neurons that usually express it have a lower preference for ethanol and are more sensitive to the sedative/hypnotic effects of this drug than controls. These data are direct evidence that alcohol consumption and resistance are inversely related to NPY levels in the brain.	Univ Washington, Dept Psychol, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Thiele, TE (corresponding author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA.							BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P503, DOI 10.1007/BF02244901; Carr LG, 1998, ALCOHOL CLIN EXP RES, V22, P884, DOI 10.1097/00000374-199806000-00017; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; COLMER WF, 1993, BIOL NEUROPEPTIDE Y; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EHLERS CL, IN PRESS ALCOHOL CLI; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; HEILIG M, 1995, CRIT REV NEUROBIOL, V9, P115; HEILIG M, 1992, REGUL PEPTIDES, V41, P61, DOI 10.1016/0167-0115(92)90514-U; HEILIG M, 1993, NEUROPSYCHOPHARMACOL, V8, P357, DOI 10.1038/npp.1993.35; Kim JJ, 1997, P NATL ACAD SCI USA, V94, P5929, DOI 10.1073/pnas.94.11.5929; Kurtz DL, 1996, PHARMACOL BIOCHEM BE, V53, P585, DOI 10.1016/0091-3057(95)02055-1; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LI TK, 1993, BEHAV GENET, V23, P163, DOI 10.1007/BF01067421; MELO JA, 1996, NAT GENET, V13, P137; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Palmiter RD, 1998, RECENT PROG HORM RES, V53, P163; RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704; Ryabinin AE, 1997, MOL PSYCHIATR, V2, P32, DOI 10.1038/sj.mp.4000206; Self DW, 1998, J NEUROSCI, V18, P1848; STEWART RB, 1993, ALCOHOL, V10, P1, DOI 10.1016/0741-8329(93)90046-Q; Woldbye DPD, 1996, BRAIN RES, V737, P162, DOI 10.1016/0006-8993(96)00730-5; Woldbye DPD, 1997, NAT MED, V3, P761, DOI 10.1038/nm0797-761; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Yamada K, 1996, BRAIN RES, V725, P272, DOI 10.1016/S0006-8993(96)00405-2	30	376	385	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					366	369		10.1038/24614	http://dx.doi.org/10.1038/24614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845072				2022-12-24	WOS:000077204000049
J	Begg, CB; Cramer, LD; Hoskins, WJ; Brennan, MF				Begg, CB; Cramer, LD; Hoskins, WJ; Brennan, MF			Impact of hospital volume on operative mortality for major cancer surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; BREAST-CANCER; PANCREATIC RESECTION; SURVIVAL; CARE; MORBIDITY; PATTERNS; QUALITY	Context.-Hospitals that treat a relatively high volume of patients for selected surgical oncology procedures report lower surgical in-hospital mortality rates than hospitals with a low volume of the procedures, but the reports do not take into account length of stay or adjust for case mix. Objective.-To determine whether hospital volume was inversely associated with 30-day operative mortality, after adjusting for case mix. Design and Setting.-Retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database in which the hypothesis was prospectively specified. Surgeons determined in advance the surgical oncology procedures for which the experience of treating a larger volume of patients was most likely to lead to the knowledge or technical expertise that might offset surgical fatalities. Patients.-All 5013 patients in the SEER registry aged 65 years or older at cancer diagnosis who underwent pancreatectomy, esophagectomy, pneumonectomy, liver resection, or pelvic exenteration, using incident cancers of the pancreas, esophagus, lung, colon, and rectum, and various genitourinary cancers diagnosed between 1984 and 1993. Main Outcome Measure.-Thirty-day mortality in relation to procedure volume, adjusted for comorbidity, patient age, and cancer stage. Results.-Higher volume was linked with lower mortality for pancreatectomy (P=.004), esophagectomy (P<.001), liver resection (P=.04), and pelvic exenteration (P=.04), but not for pneumonectomy (P=.32). The most striking results were for esophagectomy, for which the operative mortality rose to 17.3% in low-volume hospitals, compared with 3.4% in high-volume hospitals, and for pancreatectomy, for which the corresponding rates were 12.9% vs 5.8%. Adjustments for case mix and other patient factors did not change the finding that low volume was strongly associated with excess mortality. Conclusions.-These data support the hypothesis that when complex surgical oncologic procedures are provided by surgical teams in hospitals with specialty expertise, mortality rates are lower.	Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Begg, CB (corresponding author), 1275 York Ave,Box 44, New York, NY 10021 USA.							ANDRENSANDBERG A, 1983, ANN SURG, V198, P605, DOI 10.1097/00000658-198311000-00008; ARMITAGE P, 1994, STAT METHODS MED RES, P464; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choti M A, 1998, J Gastrointest Surg, V2, P11, DOI 10.1016/S1091-255X(98)80098-X; EDGE SB, 1993, CANCER-AM CANCER SOC, V71, P3502, DOI 10.1002/1097-0142(19930601)71:11<3502::AID-CNCR2820711107>3.0.CO;2-N; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; Glasgow RE, 1996, WESTERN J MED, V165, P294; GORDON TA, 1995, ANN SURG, V221, P43, DOI 10.1097/00000658-199501000-00005; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; Janes RH, 1996, ANN SURG, V223, P261, DOI 10.1097/00000658-199603000-00006; KOSARY CL, NIH PUBL; LIEBERMAN MD, 1995, ANN SURG, V222, P638, DOI 10.1097/00000658-199511000-00006; Ma M, 1997, BRIT J CANCER, V75, P1652, DOI 10.1038/bjc.1997.281; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; Nattinger AB, 1997, J CLIN EPIDEMIOL, V50, P939, DOI 10.1016/S0895-4356(97)00099-1; NGUYEN HN, 1993, CANCER, V72, P8663; PELLEGRINI CA, 1989, ARCH SURG-CHICAGO, V124, P778; POTOSKY AL, 1993, MED CARE, V31, P732; ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9	23	1308	1318	0	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1747	1751		10.1001/jama.280.20.1747	http://dx.doi.org/10.1001/jama.280.20.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842949	Bronze			2022-12-24	WOS:000077081400029
J	Drici, MD; Knollmann, BC; Wang, WX; Woosley, RL				Drici, MD; Knollmann, BC; Wang, WX; Woosley, RL			Cardiac actions of erythromycin - Influence of female sex	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORSADES-DE-POINTES; LONG QT SYNDROME; INTERVAL; GENDER; PROLONGATION; HEART; AGE	Context.-Erythromycin is a widely used antibiotic that infrequently causes QT-prolongation and torsades de pointes cardiac arrhythmias. For antiarrhythmic drugs, women are at a higher risk for these cardiac arrhythmias, but few other classes of drugs have been studied. Objectives.-To determine whether female sex is a risk factor for cardiac arrhythmias associated with erythromycin, and if this can be correlated with in vitro measurements of the QT-response to erythromycin in male and female rabbit hearts. Design.-Food and Drug Administration (FDA) MEDWATCH database analysis and in vitro experiment. Main Outcome Measures.-Cardiac arrhythmia reports associated with erythromycin from 1970 until 1996 classified by patient sex and age, and effect: of female sex on erythromycin-induced QT-prolongation in isolated perfused rabbit hearts. Results.-We observed a sex difference in cardiac arrhythmias associated with administration of erythromycin. A total of 346 cases were found in the FDA database: 201 females (58%), 110 males (32%), and 35 unspecified (10%). Forty-nine were life-threatening ventricular arrhythmias and deaths directly related to intravenous erythromycin lactobionate: 33 women (67%) and 16 men (33%) (P = .03). During the same period, no sex imbalance was present in the prescription pattern for intravenous erythromycin lacobionate (men 47%, women 49%, unspecified 4%). Perfusion with erythromycin caused significantly greater QT-prolongation in female rabbit hearts (mean [SD], 11.8% [2.3%]) than in male hearts (6.9% [2.1%]; P = .03). Conclusions.-As has been shown in reports of antiarrhythmic drugs, we found a female predominance in the FDA reports of erythromycin-associated cardiac arrhythmias. Based on in vitro experiments, a sex difference in cardiac repolarization response to erythromycin isa potential contributing factor.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Woosley, RL (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.		Woosley, Raymond/AAE-4874-2020	Woosley, Raymond/0000-0002-2588-328X; Knollmann, Bjorn/0000-0003-4956-9735	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054590] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54590] Funding Source: Medline; NIGMS NIH HHS [GM08386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antzelevitch C, 1996, J AM COLL CARDIOL, V28, P1836, DOI 10.1016/S0735-1097(96)00377-4; AUSTIN KL, 1980, BRIT J CLIN PHARMACO, V10, P273, DOI 10.1111/j.1365-2125.1980.tb01755.x; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Burke JH, 1997, AM J CARDIOL, V79, P178, DOI 10.1016/S0002-9149(96)00707-2; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; FREEDMAN RA, 1987, AM J CARDIOL, V59, P168, DOI 10.1016/S0002-9149(87)80096-6; Lehmann MH, 1997, J AM COLL CARDIOL, V29, P93, DOI 10.1016/S0735-1097(96)00454-8; Lehmann Michael H., 1996, Circulation, V94, P2534; Locati EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MCCOMB JM, 1984, AM J CARDIOL, V54, P922, DOI 10.1016/S0002-9149(84)80237-4; OBERG KC, 1995, PHARMACOTHERAPY, V15, P687; PONSONNAILLE J, 1988, ARCH MAL COEUR VAISS, V81, P1001; RAUTAHARJU PM, 1992, CAN J CARDIOL, V8, P690; Vogt AW, 1997, ANESTH ANALG, V85, P1011, DOI 10.1097/00000539-199711000-00010	15	136	143	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1774	1776		10.1001/jama.280.20.1774	http://dx.doi.org/10.1001/jama.280.20.1774			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842954	Bronze			2022-12-24	WOS:000077081400034
J	Engelgau, MM; Narayan, KMV; Thompson, TJ; Boyle, JP; Williamson, DF; Manninen, DL; Dong, FB; Orians, CE; Dasbach, EJ; Teutsch, SM; Eastman, R; Herman, WH; Songer, TJ				Engelgau, MM; Narayan, KMV; Thompson, TJ; Boyle, JP; Williamson, DF; Manninen, DL; Dong, FB; Orians, CE; Dasbach, EJ; Teutsch, SM; Eastman, R; Herman, WH; Songer, TJ		CDC Diabetes Cost-Effect Study Grp	The cost-effectiveness of screening for type 2 diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-DIAGNOSIS; NIDDM; COMPLICATIONS; MELLITUS; PREVALENCE; ROCHESTER; HEALTH; TRIAL; ONSET; RETINOPATHY	Context.-Type 2 diabetes mellitus is a common and serious disease in the United States, but one third of those affected are unaware they have it. Objective.-To estimate the cost-effectiveness of early detection and treatment of type 2 diabetes. Design.-A Monte Carlo computer simulation model was developed to estimate the lifetime costs and benefits of 1-time opportunistic screening (ie, performed during routine contact with the medical care system) for type 2 diabetes and to compare them with current clinical practice. Cost-effectiveness was estimated for all persons aged 25 years or older, for age-specific subgroups, and for African Americans. Data were obtained from clinical trials, epidemiologic studies, and population surveys, and a single-payer perspective was assumed. Costs and benefits are discounted at 3% and costs are expressed in 1995 US dollars. Setting.-Single-payer health care system. Participants.-Hypothetical cohort of 10000 persons with newly diagnosed diabetes from the general US population. Main Outcome Measures.-Cost per additional life-year gained and cost per quality-adjusted life-year (QALY) gained. Results.-The incremental cost of opportunistic screening among all persons aged 25 years or older is estimated at $236 449 per life-year gained and $56 649 per QALY gained. Screening is more cost-effective among younger people and among African Americans. The benefits of early detection and treatment accrue more from postponement of complications and the resulting improvement in quality of life than from additional life-years. Conclusions.-Early diagnosis and treatment through opportunistic screening of type 2 diabetes may reduce the lifetime incidence of major microvascular complications and result in gains in both life-years and QALYs. Incremental increases in costs attributable to screening and earlier treatment are incurred but may well be in the range of acceptable cost-effectiveness for US health care systems, especially for younger adults and for some subpopulations (eg, minorities) who are at relatively high risk of developing the major complications of type 2 diabetes. Although current recommendations are that screening begin at age 45 years, these results suggest that screening is more cost-effective at younger ages. The selection of appropriate target populations for screening should consider factors in addition to the prevalence of diabetes.	Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Emory Univ, Sch Publ Hlth, Div Epidemiol, Atlanta, GA USA; Ctr Publ Hlth Res, Seattle, WA USA; Merck & Co Inc, Blue Bell, PA USA; Merck & Co Inc, West Point, PA USA; NIDDKD, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA; Univ Michigan, Dept Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	Centers for Disease Control & Prevention - USA; Emory University; Merck & Company; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelgau, MM (corresponding author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-10,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	mxe1@cdc.gov	Narayan, K.M. Venkat/J-9819-2012; Dasbach, Erik/AAP-6801-2021	Narayan, K.M. Venkat/0000-0001-8621-5405; 				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; *AM HEART ASS, 1995, HEART STROK FACTS ST; American Diabetes Association, 1998, DIABETES CARE S1, V12, pS20, DOI DOI 10.2337/DIACARE.21.1.S20; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; [Anonymous], 1995, DIABETES CARE, V18, P1510; [Anonymous], 1995, DIABETES, V44, P968; BALKIN SW, 1995, JAMA-J AM MED ASSOC, V273, P185, DOI 10.1001/jama.1995.03520270019016; BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1013; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; COPPLESON LW, 1976, AM J OBSTET GYNECOL, V125, P153, DOI 10.1016/0002-9378(76)90585-8; DASBACH EJ, 1992, MED DECIS MAKING, V12, P4; DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468; DONG F, 1997, DIABETES S1, V46, pA77; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; EASTMAN R, 1997, AM DIAB ASS ANN M JU; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P721; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; FERTIG BJ, 1995, NIH PUBLICATION; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gold MR, 1996, COST EFFECTIVENESS H; Granata AV, 1998, ANN INTERN MED, V128, P56, DOI 10.7326/0003-4819-128-1-199801010-00009; HARRIS MI, 1994, DIABETES CARE, V17, P440, DOI 10.2337/diacare.17.5.440; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Herman WH, 1995, DIABETIC MED, V12, P1126, DOI 10.1111/j.1464-5491.1995.tb00432.x; *HLTH CAR FIN ADM, 1996, RES REP END STAG REN; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; HUMPHREY LL, 1994, ARCH INTERN MED, V154, P885, DOI 10.1001/archinte.154.8.885; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; KLEIN R, 1995, ARCH INTERN MED, V155, P745, DOI 10.1001/archinte.155.7.745; KLEIN R, 1993, DIABETES CARE, V16, P1325, DOI 10.2337/diacare.16.10.1325; KNOWLER WC, 1994, DIABETES CARE, V17, P445, DOI 10.2337/diacare.17.5.445; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; McDowell A, 1981, Vital Health Stat 1, P1; *MED EC, 1996, RED BOOK; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; NATHAN DM, 1994, NEW ENGL J MED, V330, P642; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; Stern MP, 1997, DIABETES CARE, V20, P1501, DOI 10.2337/diacare.20.10.1501; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533; Thompson TJ, 1996, DIABETIC MED, V13, P337, DOI 10.1002/(SICI)1096-9136(199604)13:4<337::AID-DIA71>3.0.CO;2-A; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; TURNER RC, 1991, DIABETOLOGIA, V34, P877; WEI M, 1997, DIABETES S1, V46, pA137; 1993, NATL HLTH INTERVIEW	54	177	181	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1757	1763						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842951				2022-12-24	WOS:000077081400031
J	Sexton, M; Althuis, MD; Santanello, N; Hyndman, S; Williams, R; Schmeidler, D				Sexton, M; Althuis, MD; Santanello, N; Hyndman, S; Williams, R; Schmeidler, D			Sex differences in the use of asthma drug's: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							YOUNG-ADULTS; PRESCRIPTION DATABASE; POPULATION; MEDICATIONS; PREDICTORS; CARE	Objectives To assess the use of asthma drugs by men and women with asthma and to identify sex specific predictors for the use of oral steroids. Design Cross sectional study Setting Six general practices in East Anglia. Subjects 103 men and 134 women aged 20-54 with asthma. Main outcome measures Self reported use of beta agonists, inhaled steroids, and oral steroids. Results No sex difference was found in use of beta agonists or inhaled steroids. However a strong association existed between sex and oral steroid use. 40 (30%) women reported using oral steroids compared with nine (9%) men. Women were more than five times (odds ratio = 5.5, 95% confidence interval 2.2 to 13.7) more likely to report use of oral steroids than men after asthma symptoms, age, visits to the general practitioner in previous six months, and time since diagnosis of asthma were controlled for. Women who had visited the general practitioner for asthma one or more times in the previous six months were four times (3.9, 1.6 to 9.5) as likely to report use of oral steroids. In addition, more frequent visits to the general practitioner for asthma were related in a dose-response manner to a greater likelihood of using oral steroids among women after asthma symptoms, age, and time since diagnosis were controlled for. This relation was not observed among men. Conclusion Women used oral steroids more than men. The more frequent consultations with a doctor by women may result in more requests for oral steroids or doctors may preferentially prescribe oral steroids to women.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Merck & Co Inc, Merck Res Labs, Epidemiol Res, West Point, PA 19486 USA; Univ Cambridge, Inst Publ Hlth, Dept Community Med, Hlth Serv Res Grp, Cambridge CB2 2SR, England; Univ Leeds, Nuffield Inst Hlth, Leeds LS2 9PL, W Yorkshire, England	University System of Maryland; University of Maryland Baltimore; Merck & Company; University of Cambridge; University of Leeds	Sexton, M (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.	msexton@epl.umaryland.edu						CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; Gaist D, 1996, BRIT J CLIN PHARMACO, V41, P285, DOI 10.1046/j.1365-2125.1996.03154.x; GERSTMAN BB, 1989, J ALLERGY CLIN IMMUN, V83, P1032, DOI 10.1016/0091-6749(89)90444-2; GRABENSTEIN JD, 1995, MIL MED, V160, P571, DOI 10.1093/milmed/160.11.571; HABBICK B, 1995, CAN MED ASSOC J, V153, P1437; HALLAS J, 1993, J INTERN MED, V234, P65, DOI 10.1111/j.1365-2796.1993.tb00706.x; HAY IFC, 1987, LANCET, V2, P609; Lassila HC, 1996, ANN PHARMACOTHER, V30, P589, DOI 10.1177/106002809603000604; LeSon S, 1996, J ASTHMA, V33, P27, DOI 10.3109/02770909609077760; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; Murdoch J C, 1980, J R Coll Gen Pract, V30, P593; OSBORNE ML, 1995, J CLIN EPIDEMIOL, V48, P1393, DOI 10.1016/0895-4356(95)00065-8; Rea HH, 1996, CHEST, V110, P1446, DOI 10.1378/chest.110.6.1446; ROBERTS SJ, 1994, BRIT J CLIN PHARMACO, V38, P489, DOI 10.1111/j.1365-2125.1994.tb04389.x; SIBBALD B, 1989, THORAX, V44, P97, DOI 10.1136/thx.44.2.97; Simon GE, 1996, J CLIN EPIDEMIOL, V49, P1067, DOI 10.1016/0895-4356(96)00139-4; SKEGG DCG, 1977, BRIT MED J, V1, P1561, DOI 10.1136/bmj.1.6076.1561; SLY RM, 1994, ANN ALLERGY, V73, P259	18	13	14	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1998	317	7170					1434	1437		10.1136/bmj.317.7170.1434	http://dx.doi.org/10.1136/bmj.317.7170.1434			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822401	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000077202200026
J	Eskinazi, DP				Eskinazi, DP			Factors that shape alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ Coll Phys & Surg, Rosenthal Ctr Complementary & Alternat Med, New York, NY 10032 USA	Columbia University	Eskinazi, DP (corresponding author), Columbia Univ Coll Phys & Surg, Rosenthal Ctr Complementary & Alternat Med, 630 W 168th St,Box 75, New York, NY 10032 USA.							*ALT MED PROGR ADV, 1994, TRANSCR ALT MED PROG; BENFIELD H, 1991, HEAVEN EARTH GUIDE C, P5; BENVENISTE J, 1988, NATURE, V334, P291, DOI 10.1038/334291a0; BURKHOLTZ H, 1994, FDA FOLLIES, V12, P110; Chez RA, 1997, AM J OBSTET GYNECOL, V177, P1156, DOI 10.1016/S0002-9378(97)70033-4; Donden Y., 1986, HLTH BALANCE INTRO T; EISENBERG DM, 1993, NEW ENGL J MED, V328, P245; ERNST E, 1996, COMPLEMENTARY MED OB; ESKINAZI D, BOTANICALS ROLE US H; ESKINAZI D, 1996, J ALTERN COMPLEM MED, V2, P1; FUGHBERMAN A, 1996, ALTERNATIVE MED WHAT, P50; JONAS W, 1995, M ALT MED PROGR ADV; Merriam-Webster's, 1993, MERRIAM WEBSTERS COL; *MILB MEM FUND, 1998, ENH ACC ALT MED; *NIH, 1995, ALT MED EXP MED HOR; *ROS CTR COMPL ALT, 1998, INF SHEET WHAT IS CO; SCHIFF M., 1995, MEMORY WATER; Sharma H.M., 1996, FUNDAMENTALS COMPLEM; SIEGFRIED JD, 1998, PHARMA NEWSL     JAN; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; WISE TA, 1986, HINDU SYSTEM MED, P1	21	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1621	1623		10.1001/jama.280.18.1621	http://dx.doi.org/10.1001/jama.280.18.1621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820268				2022-12-24	WOS:000076852000034
J	Farzadegan, H; Hoover, DR; Astemborski, J; Lyles, CM; Margolick, JB; Markham, RB; Quinn, TC; Vlahov, D				Farzadegan, H; Hoover, DR; Astemborski, J; Lyles, CM; Margolick, JB; Markham, RB; Quinn, TC; Vlahov, D			Sex differences in HIV-1 viral load and progression to AIDS	LANCET			English	Article							MONONUCLEAR CELL COCULTURES; INFECTION; MARKERS; REPLICATION; THERAPY; GROWTH; RNA	Background Plasma HIV-1 RNA measurements are used for initiation of antiretroviral treatments, Whether the viral-load association with prognosis is similar in women and men is unknown. Methods We studied 812 specimens from 650 injection-drug users (IDUs) participating in a continuous observational study of patients based in a community clinic. HIV-1 load was measured by branched-chain DNA on samples from 527 IDUs from the baseline visit, and by reverse-transcriptase PCR and quantitative microculture on samples from 285 IDUs ai a follow-up visit 3 years later. Findings Women had lower median viral-load measurements than men by branched-chain DNA (3365 vs 8907 copies/mL; p=0.001), reverse-transcriptase PCR (45 416 vs 93 130 copies/mL; p=0.02), and quantitative microculture (5 vs 8 infectious units per million peripheral blood mononuclear cells; p=0.015). This association remained even after adjustment for CD4 cell count, race, and drug use within the previous 6 months. Time to AIDS was statistically similar for men and women in a univariate proportional-hazards model and in a model adjusting for CD4 cell count. Proportional-hazards models showed that women with the same viral load as men had a 1.6-fold higher risk of AIDS (95% CI 1.10-2.32); or, equivalently, that women with half the viral load of men had a similar time to AIDS as men. Interpretation Although a biological mechanism remains unclear, these data suggest that current recommendations for HIV-1 viral-load thresholds to initiate antiretroviral therapy should be revised downwards for women.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Farzadegan, H (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Room E6004, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010		NIDA NIH HHS [DA04334] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R56DA004334, R37DA004334] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Brancato G, 1997, AM J PUBLIC HEALTH, V87, P1654, DOI 10.2105/AJPH.87.10.1654; Bush CE, 1996, J CLIN MICROBIOL, V34, P970, DOI 10.1128/JCM.34.4.970-972.1996; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; Hessol N A, 1996, AIDS, V10 Suppl A, pS69, DOI 10.1097/00002030-199601001-00010; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; MELLORS JW, 1991, J INFECT DIS, V163, P78, DOI 10.1093/infdis/163.1.78; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PETERSON PK, 1991, J IMMUNOL, V146, P81; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; Pezzotti P, 1996, BRIT MED J, V313, P583; SHANKER G, 1994, LYMPHOKINE CYTOK RES, V13, P377; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; VLAHOV D, 1991, J DRUG ISSUES, V21, P767	17	317	322	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1510	1514		10.1016/S0140-6736(98)02372-1	http://dx.doi.org/10.1016/S0140-6736(98)02372-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820299	hybrid			2022-12-24	WOS:000076862300009
J	Jones, VA				Jones, VA			In the same boat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DISEASE		Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA	Columbia University	Jones, VA (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA.							Bouma Hessel, 1989, CHRISTIAN FAITH HLTH; Chen C. P. L.-H, 1997, SMJ, V38, P100; DICKENS BM, 1994, ALZ DIS ASSOC DIS, V8, P94, DOI 10.1097/00002093-199408020-00006; Post SG, 1997, JAMA-J AM MED ASSOC, V277, P832, DOI 10.1001/jama.277.10.832; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1537	1538		10.1001/jama.280.17.1537	http://dx.doi.org/10.1001/jama.280.17.1537			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809740				2022-12-24	WOS:000076757200033
J	Nightingale, SL				Nightingale, SL			Emergency contraception kit approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	34	37	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1472	1472		10.1001/jama.280.17.1472-b	http://dx.doi.org/10.1001/jama.280.17.1472-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809716				2022-12-24	WOS:000076757200003
J	Nichols, J; Zevnik, B; Anastassiadis, K; Niwa, H; Klewe-Nebenius, D; Chambers, I; Scholer, H; Smith, A				Nichols, J; Zevnik, B; Anastassiadis, K; Niwa, H; Klewe-Nebenius, D; Chambers, I; Scholer, H; Smith, A			Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4	CELL			English	Article							MOUSE EGG-CYLINDERS; ES CELLS; GENE-EXPRESSION; DOMAIN; MASS; LINE; DIFFERENTIATION; ESTABLISHMENT; BLASTOCYST; ENHANCER	Oct4 is a mammalian POU transcription factor expressed by early embryo cells and germ cells. We report that the activity of Oct4 is essential for the identity of the pluripotential founder cell population in the mammalian embryo. Oct4-deficient embryos develop to the blastocyst stage, but the inner cell mass cells are not pluripotent. Instead, they are restricted to differentiation along the extraembryonic trophoblast lineage. Furthermore, in the absence of a true inner cell mass, trophoblast proliferation is not maintained in Oct4(-/-) embryos. Expansion of trophoblast precursors is restored, however, by an Oct4 target gene product, fibroblast growth factor-4. Therefore, Oct4 also determines paracrine growth factor signaling from stem cells to the trophectoderm.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Edinburgh; European Molecular Biology Laboratory (EMBL)	Smith, A (corresponding author), Univ Edinburgh, Ctr Genome Res, W Mains Rd,Kings Bldg, Edinburgh EH9 3JQ, Midlothian, Scotland.	Austin.smith@ed.ac.uk	Anastassiadis, Konstantinos/A-8944-2010; Zevnik, Branko/AAB-7853-2020	Anastassiadis, Konstantinos/0000-0002-9814-0559; Zevnik, Branko/0000-0001-7845-9522; Chambers, Ian/0000-0003-2605-1597; Scholer, Hans/0000-0003-2643-5136; Smith, Austin/0000-0002-3029-4682; Nichols, Jennifer/0000-0002-8650-1388				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; ANSELL JD, 1975, J EMBRYOL EXP MORPH, V33, P177; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DIWAN SB, 1976, J NATL CANCER I, V57, P937, DOI 10.1093/jnci/57.4.937; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GARDNER RL, 1983, INT REV EXP PATHOL, V24, P63; GARDNER RL, 1972, J EMBRYOL EXP MORPH, V28, P279; Gardner RLP., 1975, EARLY DEV MAMMALS, P107; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HANDYSIDE AH, 1984, J EXP ZOOL, V231, P429, DOI 10.1002/jez.1402310317; Hogan B, 1994, MANIPULATING MOUSE E; HOLDENER BC, 1994, DEVELOPMENT, V120, P1335; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; Liu LM, 1996, J BIOL CHEM, V271, P16683, DOI 10.1074/jbc.271.28.16683; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; PAPAIOANNOU VE, 1982, J EMBRYOL EXP MORPH, V68, P199; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/bf01666137, DOI 10.1007/BF01666137, 10.1007/BF01666137]; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; SOLTER D, 1970, NATURE, V227, P503, DOI 10.1038/227503a0; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; TARKOWSKI AK, 1967, J EMBRYOL EXP MORPH, V18, P155; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wilder PJ, 1997, DEV BIOL, V192, P614, DOI 10.1006/dbio.1997.8777; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yuan H., 1996, GENE DEV, V9, P2635	61	2538	2710	3	181	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					379	391		10.1016/S0092-8674(00)81769-9	http://dx.doi.org/10.1016/S0092-8674(00)81769-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814708	Green Submitted, Bronze			2022-12-24	WOS:000076789600011
J	Sacco, RL; Elkind, M; Boden-Albala, B; Lin, IF; Kargman, DE; Hauser, WA; Shea, S; Paik, MC				Sacco, RL; Elkind, M; Boden-Albala, B; Lin, IF; Kargman, DE; Hauser, WA; Shea, S; Paik, MC			The protective effect of moderate alcohol consumption on ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	22nd International Joint Conference on Stroke and Cerebral Circulation	FEB 06-08, 1997	ANAHEIM, CALIFORNIA	Natl Inst Neurol Disorders & Stroke, Amer Heart Assoc			HIGH-DENSITY-LIPOPROTEIN; RISK-FACTORS; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; CEREBRAL-HEMORRHAGE; CIGARETTE-SMOKING; DRINKING HABITS; HEART-DISEASE; FOLLOW-UP; QUESTIONNAIRE	Context Moderate alcohol consumption has been shown to be protective for coronary heart disease, but the relationship between moderate alcohol consumption and ischemic stroke is more controversial. Objective To determine the association between alcohol consumption and risk of ischemic stroke. Design Population-based case-control study conducted between July 1993 and June 1997. Setting Multiethnic population in northern Manhattan, New York, NY, aged 40 years or older. Patients and Other Participants Cases (n = 677) had first ischemic stroke and were matched to community controls (n = 1139) derived through random digit dialing by age, sex, and race/ethnicity. Mean +/- SD age of cases was 70.0 +/- 12.7 years; 55.8% were women; 19.5% were white, 28.4% black, and 50.7% Hispanic. Main Outcome Measure First ischemic stroke (fatal or nonfatal). Results Moderate alcohol consumption, up to 2 drinks per day, was significantly protective for ischemic stroke after adjustment for cardiac disease, hypertension, diabetes, current smoking, body mass index, and education (odds ratio [OR], 0.51; 95% confidence interval [CI], 0.39-0.67). This protective effect of alcohol consumption was detected in both younger and older groups, in men and women, and in whites, blacks, and Hispanics. In a quadratic model of stroke risk, increased risk of ischemic stroke was statistically significant among those consuming 7 or more drinks per day (OR, 2.96; 95% CI, 1.05-8.29). Conclusions Moderate alcohol consumption was independently associated with a decreased risk of ischemic stroke in our elderly, multiethnic, urban subjects, while heavy alcohol consumption had deleterious effects. Our data support the National Stroke Association Stroke Prevention Guidelines regarding the beneficial effects of moderate alcohol consumption.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Gen Med, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY USA; Columbia Univ, Sch Publ Hlth, Div Sociomed Sci, New York, NY USA; Columbia Univ, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Sacco, RL (corresponding author), Neurol Inst, 710 W 168th St, New York, NY 10032 USA.		Albala, Bernadette Boden/J-5703-2013; Hauser, W Allen/AAB-5277-2020; Tuluc, Petronel/C-2527-2011; Sacco, Ralph/Y-9278-2019	Albala, Bernadette Boden/0000-0001-5664-2342; Boden-Albala, Bernadette/0000-0002-3752-329X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027517, R01NS029993, T32NS007153] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 29993, R01 NS 27517, T32 NS 07153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUZEID HAH, 1977, STROKE, V8, P106, DOI 10.1161/01.STR.8.1.106; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; Aull S, 1996, AM J MED, V101, P291, DOI 10.1016/S0002-9343(96)00199-4; BEGHI E, 1995, STROKE, V26, P1691, DOI 10.1161/01.STR.26.9.1691; BENSHLOMO Y, 1992, STROKE, V23, P1093, DOI 10.1161/01.STR.23.8.1093; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; Camargo CA, 1996, CLIN CHIM ACTA, V246, P107, DOI 10.1016/0009-8981(96)06231-6; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; Fang J, 1996, NEW ENGL J MED, V335, P1545, DOI 10.1056/NEJM199611213352101; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; Gentry E M, 1985, Am J Prev Med, V1, P9; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GILL JS, 1988, INT J EPIDEMIOL, V17, P542, DOI 10.1093/ije/17.3.542; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; GORELICK P B, 1986, Current Concepts of Cerebrovascular Disease and Stroke, V21, P21; GORELICK PB, 1989, NEUROLOGY, V39, P339, DOI 10.1212/WNL.39.3.339; HANSAGI H, 1995, STROKE, V26, P1768, DOI 10.1161/01.STR.26.10.1768; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; HASELAGER EM, 1977, LANCET, V1, P774; HENRICH JB, 1989, ARCH INTERN MED, V149, P1413, DOI 10.1001/archinte.149.6.1413; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; JAMROZIK K, 1994, STROKE, V25, P51, DOI 10.1161/01.STR.25.1.51; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; KLATSKY AL, 1989, STROKE, V20, P741, DOI 10.1161/01.STR.20.6.741; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KOZAREVIC D, 1983, INT J EPIDEMIOL, V12, P145, DOI 10.1093/ije/12.2.145; Maclure M, 1990, Epidemiology, V1, P441, DOI 10.1097/00001648-199011000-00005; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MarquesVidal P, 1996, AM J EPIDEMIOL, V143, P1089, DOI 10.1093/oxfordjournals.aje.a008683; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; *NAT STROK ASS STR, 1998, J STROKE CEREBROVASC, V7, P162; OKADA H, 1976, STROKE, V7, P599, DOI 10.1161/01.STR.7.6.599; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; Rimm EB, 1996, AM J EPIDEMIOL, V143, P1094; RODGERS H, 1993, STROKE, V24, P1473, DOI 10.1161/01.STR.24.10.1473; ROMELSJO A, 1995, INT J EPIDEMIOL, V24, P929, DOI 10.1093/ije/24.5.929; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380; Sacco RL, 1997, STROKE, V28, P929, DOI 10.1161/01.STR.28.5.929; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEMMERMANN GN, 1984, STROKE, V15, P23, DOI 10.1161/01.STR.15.1.23; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WOLF PA, 1988, ANN NEUROL, V24, P177	63	367	373	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					53	60		10.1001/jama.281.1.53	http://dx.doi.org/10.1001/jama.281.1.53			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892451	Bronze			2022-12-24	WOS:000077829300035
J	Chang, G; Spencer, RH; Lee, AT; Barclay, MT; Rees, DC				Chang, G; Spencer, RH; Lee, AT; Barclay, MT; Rees, DC			Structure of the MscL homolog from Mycobacterium tuberculosis: A gated mechanosensitive ion channel	SCIENCE			English	Article							RESTRAINED MOLECULAR-DYNAMICS; ESCHERICHIA-COLI; ACETYLCHOLINE-RECEPTOR; PROTEIN STRUCTURES; PROGRAM; ARCHITECTURE; MOLSCRIPT; SUBUNITS	Mechanosensitive ion channels play a critical role in transducing physical stresses at the cell membrane into an electrochemical response. The MscL family of Large-conductance mechanosensitive channels is widely distributed among prokaryotes and may participate in the regulation of osmotic pressure changes within the cell. In an effort to better understand the structural basis for the function of these channels, the structure of the MscL homolog from Mycobacterium tuberculosis was determined by x-ray crystallography to 3.5 angstroms resolution. This channel is organized as a homopentamer, with each subunit containing two transmembrane cr helices and a third cytoplasmic alpha helix. From the extracellular side, a water-filled opening approximately 18 angstroms in diameter Leads into a pore Lined with hydrophilic residues which narrows at the cytoplasmic side to an occluded hydrophobic apex that may act as the channel gate. This structure may serve as a model for other mechanosensitive channels, as well as the broader class of pentameric ligand-gated ion channels exemplified by the nicotinic acetylcholine receptor.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Rees, DC (corresponding author), CALTECH, Howard Hughes Med Inst, 147-75CH, Pasadena, CA 91125 USA.	dcrees@caltech.edu			NIGMS NIH HHS [GM18486] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chang G.-H., UNPUB; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GROS P, 1990, SCIENCE, V249, P1149, DOI 10.1126/science.2396108; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; NUMA S, 1989, HARVEY LECT, V83, P121; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Pellegrini M, 1997, PROTEINS, V29, P426, DOI 10.1002/(SICI)1097-0134(199712)29:4<426::AID-PROT3>3.3.CO;2-J; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Saint N, 1998, J BIOL CHEM, V273, P14667, DOI 10.1074/jbc.273.24.14667; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; Sigurdson WJ, 1997, BIOPHYS J, V72, pWP104; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; SPENCER RH, UNPUB; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	40	825	864	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2220	2226		10.1126/science.282.5397.2220	http://dx.doi.org/10.1126/science.282.5397.2220			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856938				2022-12-24	WOS:000077645800036
J	Lloyd-Jones, DM; Martin, DO; Larson, MG; Levy, D				Lloyd-Jones, DM; Martin, DO; Larson, MG; Levy, D			Accuracy of death certificates for coding coronary heart disease as the cause of death	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; death certificates; cause of death; mortality; epidemiologic methods	MORTALITY; AUTOPSY; POPULATION; TRENDS; COMPLETION; STATISTICS; DECLINE; ERRORS; MEN	Background: Death certificates are widely used in epidemiologic and clinical investigations and for national statistics. Objective: To examine the accuracy of death certificates for coding coronary heart disease as the underlying cause of death. Design: Community-based inception cohort followed since 1948. Setting: Framingham, Massachusetts. Patients: 2683 deceased Framingham Heart Study participants. Measurements: Sensitivity, specificity, and predictive values of the death certificate. The reference standard was cause of death adjudicated by a panel of three physicians. Results: Among 2683 decedents, the death certificate coded coronary heart disease as the underlying cause of death for 942; the physician panel assigned coronary heart disease for 758. The death certificate had a sensitivity of 83.8% (95% CI, 81.1% to 86.4%), positive predictive value of 67.4% (CI, 64.4% to 70.4%), specificity of 84.1% (CI, 82.4% to 85.7%1), and negative predictive value of 92.9% (CI, 91.7% to 94.1 %) for coronary heart disease. The death certificate assigned coronary heart disease in 51.2% of 242 deaths (9.0% of total deaths) for which the physician panel could not determine a ca use. Compared with the physician panel, the death certificate attributed 24.3% more deaths to coronary heart disease overall and more than twice as many deaths to coronary heart disease in decedents who were at least 85 years of age. When deaths that were assigned unknown cause by the physician panel were excluded, the death certificate still assigned more deaths to coronary heart disease (7.9% overall and 43.1% in the oldest age group). Conclusions: Coronary heart disease may be overrepresented as a cause of death on death certificates. National mortality statistics, which are based on death certificate data, may overestimate the frequency of coronary heart disease by 7.9% to 24.3% overall and by as much as twofold in older persons.	NHLBI, NIH, Bethesda, MD 20892 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Duke University; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Levy, D (corresponding author), Framingham Heart Dis Epidemiol Study, 5 Thurber St, Framingham, MA 01702 USA.		Lloyd-Jones, Donald M/C-5899-2009; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254; Lloyd-Jones, Donald/0000-0003-0847-6110	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson R, 1995, MONTHLY VITAL STA S2, V45; BATTLE RM, 1987, JAMA-J AM MED ASSOC, V258, P339, DOI 10.1001/jama.258.3.339; BRITTON M, 1974, ACTA MED SCAND, V196, P203; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COUGHLIN SS, 1992, J CLIN EPIDEMIOL, V45, P1, DOI 10.1016/0895-4356(92)90180-U; DAVIS BR, 1987, CONTROL CLIN TRIALS, V8, P110, DOI 10.1016/0197-2456(87)90036-5; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; ENGEL LW, 1980, AM J EPIDEMIOL, V111, P99, DOI 10.1093/oxfordjournals.aje.a112879; Falkeborn M, 1996, EPIDEMIOLOGY, V7, P67, DOI 10.1097/00001648-199601000-00012; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JORDAN JM, 1993, CLIN INVEST MED, V16, P249; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KULLER LH, 1989, CIRCULATION, V80, P261, DOI 10.1161/01.CIR.80.2.261; LINDAHL BIB, 1994, SCAND J SOC MED, V22, P145, DOI 10.1177/140349489402200211; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAUSNER JS, 1974, EPIDEMIOLOGY INTRO T, P245; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MODELMOG D, 1992, CANCER CAUSE CONTROL, V3, P541, DOI 10.1007/BF00052751; *NAT CTR HLTH STAT, 1989, ADV REP FIN MORT STA; *NAT HEART LUNG BL, 1996, MORB MORT; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PARK CB, 1991, J CLIN EPIDEMIOL, V44, P519, DOI 10.1016/0895-4356(91)90215-U; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; SAS Institute, 1996, SAS STAT SOFTW CHANG; SEXTON PT, 1992, AUST NZ J MED, V22, P114, DOI 10.1111/j.1445-5994.1992.tb02788.x; SORLIE PD, 1987, AM J PUBLIC HEALTH, V77, P148, DOI 10.2105/AJPH.77.2.148; STEHBENS WE, 1987, LANCET, V1, P606; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; WHO, 1995, WORLD HLTH STAT ANN; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; ZUMWALT RE, 1987, POSTGRAD MED, V81, P245, DOI 10.1080/00325481.1987.11699876	37	360	365	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1020	+		10.7326/0003-4819-129-12-199812150-00005	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	147DC	9867756				2022-12-24	WOS:000077471900004
J	Martin, MP; Dean, M; Smith, MW; Winkler, C; Gerrard, B; Michael, NL; Lee, B; Doms, RW; Margolick, J; Buchbinder, S; Goedert, JJ; O'Brien, TR; Hilgartner, MW; Vlahov, D; O'Brien, SJ; Carrington, M				Martin, MP; Dean, M; Smith, MW; Winkler, C; Gerrard, B; Michael, NL; Lee, B; Doms, RW; Margolick, J; Buchbinder, S; Goedert, JJ; O'Brien, TR; Hilgartner, MW; Vlahov, D; O'Brien, SJ; Carrington, M			Genetic acceleration of AIDS progression by a promoter variant of CCR5	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR GENE; HIV-1 INFECTION; DISEASE PROGRESSION; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; MIP-1-ALPHA; MIP-1-BETA; RESISTANCE; RANTES	The CCR5 gene encodes a cell surface chemokine receptor molecule that serves as the principal coreceptor, with CD4, for macrophage-tropic (R5) strains of human immunodeficiency virus-type 1 (HIV-1). Genetic association analysis of five cohorts of people with acquired immunodeficiency syndrome (AIDS) revealed that infected individuals homozygous for a multisite haplotype of the CCR5 regulatory region containing the promoter allele, CCR5P1, progress to AIDS more rapidly than those with other CCR5 promoter genotypes, particularly in the early years after infection. Composite genetic epidemiologic analyses of genotypes bearing CCR5P1, CCR5-Delta 32, CCR2-641, and SDF1-3'A affirmed distinct regulatory influences for each gene on AIDS progression. An estimated 10 to 17 percent of patients who develop AIDS within 3.5 years of HIV-1 infection do so because they are homozygous for CCR5P1/P1, and 7 to 13 percent of all people carry this susceptible genotype. The cumulative and interactive influence of these AIDS restriction genes illustrates the multigenic nature of host factors Limiting AIDS disease progression.	NCI, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Sci Applicat Int Corp, Frederick, MD 21702 USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA; NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA; Cornell Univ, Med Ctr, New York Hosp, Div Pediat Hematol & Oncol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Pennsylvania; Johns Hopkins University; San Francisco Department of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; NewYork-Presbyterian Hospital	O'Brien, TR (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.	obrien@ncifcrf.gov	Smith, Michael/B-5341-2012; Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019; OBRIEN, STEPHEN/ABD-1346-2020	Dean, Michael C/0000-0003-2234-0631; OBRIEN, STEPHEN/0000-0001-7857-0757	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Allison PD, 1995, SURVIVAL ANAL USING, P155; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CARRINGTON M, UNPUB; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, PROPORTIONAL HAZARD; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Donefield SM, 1998, SCIENCE, V280, P1819, DOI 10.1126/science.280.5371.1815f; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HILGARTNER MW, 1993, AM J PEDIAT HEMATOL, V15, P208; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Ioannidis JPA, 1998, NAT MED, V4, P536, DOI 10.1038/nm0598-536; Khoury M, 1993, FUNDAMENTALS GENETIC; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rizzardi GP, 1998, NAT MED, V4, P252, DOI 10.1038/nm0398-252; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHWEDER T, 1982, BIOMETRIKA, V69, P493; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1998, SCIENCE, V280, P1820; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; *US CDC, 1987, MORB MORTAL WKLY S1, V36; *US CDCP, 1992, MMWR-MORBID MORTAL W, V41, P1; van Rij RP, 1998, AIDS, V12, pF85, DOI 10.1097/00002030-199809000-00001; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; Weir BS, 1990, GENETIC DATA ANAL; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	48	369	383	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1907	1911		10.1126/science.282.5395.1907	http://dx.doi.org/10.1126/science.282.5395.1907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836644				2022-12-24	WOS:000077338100054
J	Williams, DM; Kasting, JF; Frakes, LA				Williams, DM; Kasting, JF; Frakes, LA			Low-latitude glaciation and rapid changes in the Earth's obliquity explained by obliquity-oblateness feedback	NATURE			English	Article							CLIMATE FRICTION; SOUTH-AUSTRALIA; SNOWBALL EARTH; ICE-AGE; PALEOLATITUDE; DEPOSITION; INSOLATION; INTERVALS; EVOLUTION; MARS	Palaeomagnetic data suggest that the Earth was glaciated at low latitudes during the Palaeoproterozoic(1,2) (about 2.4-2.2 Gyr ago) and Neoproterozoic(3-8) (about 820-550 Myr ago) eras, although some of the Neoproterozoic data are disputed(9,10). If the Earth's magnetic field was aligned more or less with its spin axis, as it is today, then either the polar ice caps must have extended well down into the tropics-the 'snowball Earth' hypothesis(8)-or the present zonation of climate with respect to latitude must have been reversed. Williams(11) has suggested that the Earth's obliquity may have been greater than 54 degrees during most of its history, which would have made the Equator the coldest part of the planet(12). But this would require a mechanism to bring the obliquity down to its present value of 23.5 degrees. Here we propose that obliquity-oblateness feedback(13) could have reduced the Earth's obliquity by tens of degrees in less than 100 Myr if the continents were situated so as to promote the formation of large polar ice sheets. A high obliquity for the early Earth may also provide a natural explanation for the present inclination of the lunar orbit with respect to the ecliptic (5 degrees), which is otherwise difficult to explain.	Penn State Univ, Behrend Coll, Sch Sci, Erie, PA 16563 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Univ Adelaide, Dept Geol & Geophys, Adelaide, SA 5005, Australia	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Adelaide	Williams, DM (corresponding author), Penn State Univ, Behrend Coll, Sch Sci, Stn Rd, Erie, PA 16563 USA.		Kasting, James/AAF-6851-2020					AWRAMIK SM, 1986, SCIENCE, V231, P1279, DOI 10.1126/science.231.4743.1279; BILLS BG, 1994, GEOPHYS RES LETT, V21, P177, DOI 10.1029/93GL02024; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; EMBLETON BJJ, 1986, EARTH PLANET SC LETT, V79, P419, DOI 10.1016/0012-821X(86)90197-4; Evans DA, 1997, NATURE, V386, P262, DOI 10.1038/386262a0; Frakes L. A., 1979, CLIMATES THROUGHOUT; GOLDREIC.P, 1966, REV GEOPHYS, V4, P411, DOI 10.1029/RG004i004p00411; HECHT J, 1997, AGES EARTH; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Ida S, 1997, NATURE, V389, P353, DOI 10.1038/38669; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; ITO T, 1995, J GEOPHYS RES-SOL EA, V100, P15147, DOI 10.1029/95JB01061; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; MEERT JG, 1994, EARTH PLANET SC LETT, V123, P1, DOI 10.1016/0012-821X(94)90253-4; Park JK, 1997, CAN J EARTH SCI, V34, P34, DOI 10.1139/e17-003; PELTIER WR, 1994, GEOPHYS RES LETT, V21, P2299, DOI 10.1029/94GL02058; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; ROCHESTER MG, 1976, GEOPHYS J ROY ASTR S, V46, P109, DOI 10.1111/j.1365-246X.1976.tb01635.x; RUBINCAM DP, 1975, J GEOPHYS RES, V80, P1537, DOI 10.1029/JB080i011p01537; RUBINCAM DP, 1993, J GEOPHYS RES-PLANET, V98, P10827, DOI 10.1029/93JE00999; RUBINCAM DP, 1995, PALEOCEANOGRAPHY, V10, P365, DOI 10.1029/95PA00578; SCHMIDT PW, 1995, EARTH PLANET SC LETT, V134, P107, DOI 10.1016/0012-821X(95)00106-M; TOUMA J, 1994, ASTRON J, V108, P1943, DOI 10.1086/117209; Touma J, 1998, ASTRON J, V115, P1653, DOI 10.1086/300312; VANYO JP, 1982, GEOPHYS RES LETT, V9, P1125, DOI 10.1029/GL009i010p01125; WALKER JCG, 1986, NATURE, V320, P600, DOI 10.1038/320600a0; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; WILLIAMS DM, 1998, STABILITY HABITABLE; WILLIAMS GE, 1993, EARTH-SCI REV, V34, P1, DOI 10.1016/0012-8252(93)90004-Q; WILLIAMS GE, 1995, EARTH PLANET SC LETT, V131, P115, DOI 10.1016/0012-821X(95)00004-V; Williams GE, 1997, EARTH PLANET SC LETT, V153, P157, DOI 10.1016/S0012-821X(97)00181-7; ZHANG HM, 1985, PRECAMBRIAN RES, V29, P65, DOI 10.1016/0301-9268(85)90060-9	33	72	78	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					453	455		10.1038/24845	http://dx.doi.org/10.1038/24845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853751				2022-12-24	WOS:000077370100050
J	Takei, K; Shin, RM; Inoue, T; Kato, K; Mikoshiba, K				Takei, K; Shin, RM; Inoue, T; Kato, K; Mikoshiba, K			Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones	SCIENCE			English	Article							ASSISTED LASER INACTIVATION; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; EXPRESSION; CALCIUM; EXTENSION; MOTILITY; PROTEINS	The inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) acts as a Ca2+ release channel on internal Ca2+ stores. Type 1 IP3R(IP(3)R1) is enriched in growth cones of neurons in chick dorsal root ganglia. Depletion of internal Ca2+ stores and inhibition of IP3 signaling with drugs inhibited neurite extension. Microinjection of. heparin, a competitive IP3R blocker, induced neurite retraction. Acute Localized Loss of function of IP(3)R1 in the growth cone induced by chromophore-assisted Laser inactivation resulted in growth arrest and neurite retraction. IP3-induced Ca2+ release in growth cones appears to have a crucial role in control of nerve growth.	Japan Sci & Technol Corp, ERATO, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1080071, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Takei, K (corresponding author), Japan Sci & Technol Corp, ERATO, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan.		Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015	Inoue, Takafumi/0000-0002-2728-0060; 				AIHARA Y, UNPUB; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CYPHER C, 1992, Current Opinion in Cell Biology, V4, P4, DOI 10.1016/0955-0674(92)90051-D; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; KATER SB, 1991, J NEUROSCI, V11, P891; Kuhn TB, 1998, J NEUROSCI, V18, P184; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; TAKEI K, UNPUB; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VANBERKUM MFA, 1995, NEURON, V14, P43, DOI 10.1016/0896-6273(95)90239-2; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	26	154	157	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1705	1708		10.1126/science.282.5394.1705	http://dx.doi.org/10.1126/science.282.5394.1705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831561				2022-12-24	WOS:000077246600046
J	Cabral, JHM; Lee, A; Cohen, SL; Chait, BT; Li, M; Mackinnon, R				Cabral, JHM; Lee, A; Cohen, SL; Chait, BT; Li, M; Mackinnon, R			Crystal structure and functional analysis of the HERG potassium channel N terminus: A eukaryotic PAS domain	CELL			English	Article							HUMAN INWARD RECTIFIER; CARDIAC-ARRHYTHMIA; ESCHERICHIA-COLI; PROTEIN; FAMILY; EAG; RECTIFICATION; INACTIVATION; DROSOPHILA; OXYGEN	The HERG voltage-dependent K+ channel plays a role in cardiac electrical excitability, and when defective, it underlies one form of the long QT syndrome. We have determined the crystal structure of the HERG K+ channel N-terminal domain and studied its role as a modifier of gating using electrophysiological methods. The domain is similar in structure to a bacterial light sensor photoactive yellow protein and provides the first three-dimensional model of a eukaryotic PAS domain. Scanning mutagenesis of the domain surface has allowed the identification of a hydrophobic "hot spot" forming a putative interface with the body of the K+ channel to which it tightly binds. The presence, of the domain attached to the channel slows the rate of deactivation. Given the roles of PAS domains in biology, we propose that the HERG N-terminal domain has a regulatory function.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Johns Hopkins University	Mackinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu	Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716	NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM47400] Funding Source: Medline; NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033324, R55NS033324] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; BRUNGER AT, 1996, XPLOR VERSION 3 851; CHAIT BT, 1994, STRUCTURE, V2, P465, DOI 10.1016/S0969-2126(00)00047-2; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; REPPERT SM, 1998, CELL, V21, P1; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	33	359	368	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					649	655		10.1016/S0092-8674(00)81635-9	http://dx.doi.org/10.1016/S0092-8674(00)81635-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845367	Bronze			2022-12-24	WOS:000077253700012
J	Huang, Z; Shilo, BZ; Kunes, S				Huang, Z; Shilo, BZ; Kunes, S			A retinal axon fascicle uses spitz, an EGF receptor ligand, to construct a synaptic cartridge in the brain of Drosophila	CELL			English	Article							CHICK OPTIC TECTUM; FAINT-LITTLE-BALL; VISUAL-SYSTEM; VENTRAL ECTODERM; SECRETED PROTEIN; GENE ENCODES; CELL FATE; EYE; HEDGEHOG; HOMOLOG	Photoreceptor axons arriving in the Drosophila brain organize their postsynaptic target field into a precise array of five neuron "cartridge" ensembles. Here we show that Hedgehog, an initial inductive; signal transported along retinal axons from the developing eye, induces postsynaptic precursor cells to express the Drosophila homolog of the epidermal growth factor receptor (EGFR). The EGFR ligand Spitz, a signal for ommatidial assembly in the compound eye, is transported to retinal axon termini in the brain where it acts as a local cue for the recruitment of five cells into a cartridge ensemble. Hedgehog and Spitz thus bring about the concerted assembly of ommatidial and synaptic cartridge units, imposing the "neurocrystalline" order of the compound eye on the postsynaptic target field.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Harvard University; Weizmann Institute of Science	Kunes, S (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			Shilo, Ben Zion/0000-0003-4903-8889	NATIONAL EYE INSTITUTE [R01EY010112] Funding Source: NIH RePORTER; NEI NIH HHS [EY10112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAITENBERG V, 1967, EXP BRAIN RES, V3, P271; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; CONTAMINE D, 1989, GENETICS, V123, P525; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GRAZIADEI PPC, 1992, NEUROSCIENCE, V46, P617, DOI 10.1016/0306-4522(92)90149-V; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; Huang Z, 1998, DEVELOPMENT, V125, P3753; JONES B, 1993, DEVELOPMENT, V117, P793; KAMMERMEYER KL, 1987, DEVELOPMENT, V100, P201; KELLY JP, 1972, BRAIN RES, V42, P263, DOI 10.1016/0006-8993(72)90530-6; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; KUNES S, 1993, J NEUROSCI, V13, P752; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACAGNO ER, 1979, DEV BIOL, V73, P206, DOI 10.1016/0012-1606(79)90064-2; MARDON G, 1994, DEVELOPMENT, V120, P3473; Meinertzhagen Ian A., 1993, P1363; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; OLAND LA, 1987, J COMP NEUROL, V255, P196, DOI 10.1002/cne.902550204; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Pignoni F, 1997, DEVELOPMENT, V124, P271; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SELLECK SB, 1992, NATURE, V355, P253, DOI 10.1038/355253a0; Tio M, 1997, DEVELOPMENT, V124, P343; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TRUJILLOCENOZ O, 1973, J ULTRA MOL STRUCT R, V42, P554, DOI 10.1016/S0022-5320(73)80027-9; XU T, 1993, DEVELOPMENT, V117, P1223; YAMAGATA M, 1995, J NEUROSCI, V15, P4556; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V; ZECCA M, 1995, DEVELOPMENT, V121, P2265	48	99	99	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					693	703		10.1016/S0092-8674(00)81639-6	http://dx.doi.org/10.1016/S0092-8674(00)81639-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845371	Bronze			2022-12-24	WOS:000077253700016
J	Melhus, H; Michaelsson, K; Kindmark, A; Bergstrom, R; Holmberg, L; Mallmin, H; Wolk, A; Ljunghall, S				Melhus, H; Michaelsson, K; Kindmark, A; Bergstrom, R; Holmberg, L; Mallmin, H; Wolk, A; Ljunghall, S			Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture	ANNALS OF INTERNAL MEDICINE			English	Article						hip fracture; bone density; vitamin A; hypervitaminosis A; osteoporosis	GREEN LEAFY VEGETABLES; RETINOIC ACID; BREAST-CANCER; A STATUS; RESORPTION; NORWAY; 9-CIS	Background: The highest incidence of osteoporotic fractures is found in northern Europe, where dietary intake of vitamin A (retinol) is unusually high. In animals, the most common adverse effect of toxic doses of retinol is spontaneous fracture. Objective: To investigate whether excessive dietary intake of vitamin A is associated with decreased bone mineral density and increased risk for hip fracture. Design: A cross-sectional study and a nested case-control study. Setting: Two counties in central Sweden. Participants: For the cross-sectional study, 175 women 28 to 74 years of age were randomly selected. For the nested case-control study, 247 women who had a first hip fracture within 2 to 64 months after enrollment and 873 age-matched controls were selected from a mammography study cohort of 66 651 women 40 to 76 years of age. Measurements: Retinol intake was estimated from dietary records and a food-frequency questionnaire. Bone mineral density was measured with dual-energy x-ray absorptiometry. Hip fracture was identified by using hospital discharge records and was confirmed by record review. Results: In multivariate analysis, retinol intake was negatively associated with bone mineral density. For every l-mg increase in daily intake of retinol, risk for hip fracture increased by 68% (95% CI, 18% to 140%; P for trend, 0.006). For intake greater than 1.5 mg/d compared with intake less than 0.5 mg/d, bone mineral density was reduced by 10% at the femoral neck (P = 0.05), 14% at the lumbar spine (P = 0.001), and 6% for the total body (P = 0.009) and risk for hip fracture was doubled (odds ratio, 2.1 [CI, 1.1 to 4.0]). Conclusion: High dietary intake of retinol seems to be associated with osteoporosis.	Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Univ Uppsala Hosp, Dept Surg, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Karolinska Institutet; Uppsala University; Uppsala University Hospital	Melhus, H (corresponding author), Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden.	Hakan.Melhus@medicin.uu.se	Michaelsson, Karl/AAM-9094-2021	Michaelsson, Karl/0000-0003-2815-1217				Ariens E., 1982, NUTR TOXICOL, V1, P17; ARMSTRONG R, 1994, RETINOIDS, V1, P545; BECKER W, 1989, FOOD HABITS NUTR INT; Belsley D., 1980, REGRESSION DIAGNOSIS; BLAND M, 1993, INTRO MED STAT; Bloch CE, 1924, AM J DIS CHILD, V28, P659; CRUZ JAA, 1991, EUR J CLIN NUTR, V45, P121; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; dePee S, 1996, EUR J CLIN NUTR, V50, pS38; DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7; DEQUEKER J, 1991, CLIN RHEUMATOL, V10, P49, DOI 10.1007/BF02208033; DIGIOVANNA JJ, 1995, ARCH DERMATOL, V131, P1263, DOI 10.1001/archderm.131.11.1263; FALCH JA, 1985, ACTA ORTHOP SCAND, V56, P12, DOI 10.3109/17453678508992970; FALCH JA, 1993, BONE, V14, P643, DOI 10.1016/8756-3282(93)90086-P; *FAO, 1988, FAO FOOD NUTR SER, V23, P85; FELL HB, 1952, J PHYSIOL-LONDON, V116, P320, DOI 10.1113/jphysiol.1952.sp004708; FRISTEDT R, 1873, TELEOSTEI GADIDAE TX, P595; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; Hills, 1993, STAT MODELS EPIDEMIO; HOLMBERG L, 1994, ARCH INTERN MED, V154, P1805, DOI 10.1001/archinte.154.16.1805; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; *INT DAIR FED, 1995, ANN B INT DAIR FED, P14; Johansson L., 1997, Scandinavian Journal of Nutrition/Naringsforskning, V41, P63; JOHNELL O, 1992, OSTEOPOROSIS INT, V2, P298, DOI 10.1007/BF01623186; KAMM JJ, 1984, RETINOIDS, V2, P287; KINDMARK A, 1995, CALCIFIED TISSUE INT, V57, P242, DOI 10.1007/BF00310266; KINDMARK A, 1993, BIOCHEM BIOPH RES CO, V192, P1367, DOI 10.1006/bbrc.1993.1567; Maddala G.S., 1988, INTRO ECONOMETRICS; MATHEWSROTH MM, 1988, TOXICOL LETT, V41, P185, DOI 10.1016/0378-4274(88)90053-7; MCCOLLUM EV, 1957, HIST NUTR SEQUENCE I, P266; MELLANBY E, 1947, J PHYSIOL-LONDON, V105, P382, DOI 10.1113/jphysiol.1947.sp004178; Melton L III, 1995, OSTEOPOROSIS ETIOLOG, P225; MICHAELSSON K, 1995, CALCIFIED TISSUE INT, V57, P86, DOI 10.1007/BF00298425; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; MOORE T, 1945, BIOCHEM J, V39, P222, DOI 10.1042/bj0390222; NIEMAN C, 1954, VITAM HORM, V12, P69; Okada Natsuko, 1994, Journal of Dermatology (Tokyo), V21, P308; Olson JA, 1990, PRESENT KNOWLEDGE NU, V6th, P96; REDDY V, 1995, LANCET, V346, P1634, DOI 10.1016/S0140-6736(95)91973-2; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; SANESHIGE S, 1995, BIOCHEM J, V309, P721, DOI 10.1042/bj3090721; SCHEVEN BAA, 1990, BONE, V11, P53, DOI 10.1016/8756-3282(90)90072-7; TOGARI A, 1991, GEN PHARMACOL, V22, P287, DOI 10.1016/0306-3623(91)90450-K; [No title captured]	46	253	262	2	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					770	+		10.7326/0003-4819-129-10-199811150-00003	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841582				2022-12-24	WOS:000076984800002
J	Andersson, SGE; Zomorodipour, A; Andersson, JO; Sicheritz-Ponten, T; Alsmark, UCM; Podowski, RM; Naslund, AK; Eriksson, AS; Winkler, HH; Kurland, CG				Andersson, SGE; Zomorodipour, A; Andersson, JO; Sicheritz-Ponten, T; Alsmark, UCM; Podowski, RM; Naslund, AK; Eriksson, AS; Winkler, HH; Kurland, CG			The genome sequence of Rickettsia prowazekii and the origin of mitochondria	NATURE			English	Article							STAPHYLOCOCCUS-AUREUS; EVOLUTION; ALIGNMENT; RNA; SYSTEM; GENES	We describe here the complete genome sequence (1,111,523 base pairs) of the obligate intracellular parasite Rickettsia prowarekii, the causative agent of epidemic typhus, This genome contains 834 protein-ooding genes. The functional profiles of these genes show similarities to those of mitochondrial genes: no genes required for anaerobic glycolysis are found in either R. prowazekii or mitochondrial genomes, but a complete set of genes encoding components of the tricarboxyilc acid cycle and the respiratory-chain complex is found in R. prowarekii, In effect, ATP production In Rickettsia Is the same as that in mitochondria. Many genes involved in the biosynthesis and regulation of biosynthesis of amino acids and nucleosides in free-living bacteria are absent front R. prowazekii and mitochondria, Such genes seem to have been replaced by homologues in the nuclear (host) genome, the R. prowarekii genome contains the highest proportion of non-coding DNA (24%) detected so far in a microbial genome, Such non-coding sequences may be degraded remnants of 'neutralized' genes that await elimination from the genome, Phylogenetic analyses Indicate that R. prowazekii is more closely related to mitochondria than is any other microbe studied so far.	Uppsala Univ, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ S Alabama, Dept Microbiol & Immunol, Mobile, AL 36688 USA	Uppsala University; University of South Alabama	Kurland, CG (corresponding author), Uppsala Univ, Dept Mol Biol, S-75124 Uppsala, Sweden.	chuck@xray.bmc.uu.se	Alsmark, Cecilia/AAO-1330-2021; Zomorodipour, Alireza/AAA-9003-2022; Sicheritz-Ponten, Thomas/A-4325-2017	Zomorodipour, Alireza/0000-0003-0671-4779; Sicheritz-Ponten, Thomas/0000-0001-6615-1141; Podowski, Raf/0000-0001-5500-8913				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Andersson JO, 1997, MICROBIOL-SGM, V143, P2783, DOI 10.1099/00221287-143-8-2783; ANDERSSON SGE, 1995, J BACTERIOL, V177, P4171, DOI 10.1128/jb.177.14.4171-4175.1995; Andersson SGE, 1995, BIOCHEM CELL BIOL, V73, P775, DOI 10.1139/o95-086; Andersson SGE, 1996, J MOL EVOL, V42, P525, DOI 10.1007/BF02352282; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; EBELING S, 1991, J BACTERIOL, V173, P6373, DOI 10.1128/jb.173.20.6373-6382.1991; Felsenstein J., 1974, GENETICS, V78, P157; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GRAY MW, 1989, P NATL ACAD SCI USA, V86, P2267, DOI 10.1073/pnas.86.7.2267; GRAY MW, 1996, EVOLUTION MICROBIAL, P00109; Gross L, 1996, P NATL ACAD SCI USA, V93, P10539, DOI 10.1073/pnas.93.20.10539; HIMMELREICH R, 1996, NUCLEIC ACIDS RES, V3, P109; Koonin EV, 1998, CURR BIOL, V8, pR266, DOI 10.1016/S0960-9822(98)70169-1; KURLAND CG, 1992, BIOESSAYS, V14, P709, DOI 10.1002/bies.950141013; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MARGULIS L, 1970, P349; MELLY MA, 1974, INFECT IMMUN, V10, P389, DOI 10.1128/IAI.10.2.389-397.1974; Ohta T, 1972, J Mol Evol, V1, P150, DOI 10.1007/BF01659161; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ota T, 1971, J Mol Evol, V1, P18, DOI 10.1007/BF01659391; PETERSON PK, 1978, INFECT IMMUN, V19, P943, DOI 10.1128/IAI.19.3.943-949.1978; Sicheritz-Ponten T, 1998, BBA-BIOENERGETICS, V1365, P545, DOI 10.1016/S0005-2728(98)00099-1; Sicheritz-Ponten T, 1997, COMPUT APPL BIOSCI, V13, P621; Sicheritz-Ponten T, 1997, Microb Comp Genomics, V2, P123, DOI 10.1089/omi.1.1997.2.123; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VIALE AM, 1994, FEBS LETT, V341, P146, DOI 10.1016/0014-5793(94)80446-X; WEISBURG WG, 1989, J BACTERIOL, V171, P4202, DOI 10.1128/JB.171.8.4202-4206.1989; WEISBURG WG, 1985, SCIENCE, V230, P556, DOI 10.1126/science.3931222; WINKLER HH, 1976, J BIOL CHEM, V251, P389; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	47	1266	1897	5	152	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					133	140		10.1038/24094	http://dx.doi.org/10.1038/24094			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823893	Bronze			2022-12-24	WOS:000077013300041
J	Oancea, E; Meyer, T				Oancea, E; Meyer, T			Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals	CELL			English	Article							FLUORESCENT INDICATORS; ACIDIC LIPIDS; CALMODULIN; CELLS; OSCILLATIONS; ACTIVATION; MEMBRANES; BINDING	The specificity of many signal transduction pathways relies on the temporal coordination of different second messenger signals. Here we found a molecular mechanism which guarantees that conventional protein kinase C (PKC) isoforms are sequentially activated by calcium and diacylglycerol signals. Receptor stimuli that triggered repetitive calcium spikes induced a parallel repetitive translocation of GFP-tagged PKC gamma to the plasma membrane. While calcium acted rapidly, diacylglycerol binding to PKC gamma was initially prevented by a pseudosubstrate clamp, which kept the diacylglycerol-binding site inaccessible and delayed calcium- and diacylglycerol-mediated kinase activation. After termination of calcium signals, bound diacylglycerol prolonged kinase activity. The properties of this molecular decoding machine make PKC gamma responsive to persistent diacylglycerol increases combined with high- but not low-frequency calcium spikes.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Meyer, T (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	tobias@cellbio.duke.edu		Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM-51457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONI LT, 1985, J BIOL CHEM, V260, P819; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; KONTOS CD, 1998, IN PRESS MOL CELL BI; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PEARS CJ, 1991, J CELL SCI, V100, P683; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; Srinivasan N, 1996, PROTEINS, V26, P217; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Teruel MN, 1997, BIOPHYS J, V73, P1785, DOI 10.1016/S0006-3495(97)78209-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	31	517	526	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					307	318		10.1016/S0092-8674(00)81763-8	http://dx.doi.org/10.1016/S0092-8674(00)81763-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814702	Bronze			2022-12-24	WOS:000076789600005
J	Bhalla, US; Iyengar, R				Bhalla, US; Iyengar, R			Emergent properties of networks of biological signaling pathways	SCIENCE			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; INOSITOL TRISPHOSPHATE; CATALYTIC ACTIVITY; ADENYLYL CYCLASES; ACTIVATES RAF-1; CYCLIC-AMP; AREA CA1; CALCIUM; PHOSPHORYLATION	Many distinct signaling pathways allow the cell to receive, process, and respond to information. Often, components of different pathways interact, resulting in signaling networks. Biochemical signaling networks were constructed with experimentally obtained constants and analyzed by computational methods to understand their role in complex biological processes. These ner:works exhibit emergent properties such as integration of signals across multiple time scales, generation of distinct outputs depending on input strength and duration, and self-sustaining feedback Loops. Feedback can result in bistable behavior with discrete steady-state activities, well-defined input thresholds for transition between states and prolonged signal output, and signal modulation in response to transient stimuli. These properties of signaling networks raise the possibility that information for "learned behavior" of biological systems may be stored within intracellular biochemical reactions that comprise signaling pathways.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Natl Ctr Biol Sci, Bangalore 560012, Karnataka, India	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BHALLA US, 1998, BOOK GENESIS EXPLORI, pCH10; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DESCHUTTER E, 1993, NEURAL COMPUT, V5, P681, DOI 10.1162/neco.1993.5.5.681; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HESTRIN S, 1990, J PHYSL, V422, P302; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KREBS EG, 1956, J BIOL CHEM, V218, P483; LAI CY, 1980, CRC CR REV BIOCH MOL, V9, P171, DOI 10.3109/10409238009105434; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; PUEFFER T, 1977, J BIOL CHEM, V252, P7244; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schuman EM, 1997, NEURON, V18, P339, DOI 10.1016/S0896-6273(00)81234-9; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Staubli U, 1996, J NEUROSCI, V16, P853; SUTHERLAND EW, 1955, NATURE, V175, P169, DOI 10.1038/175169a0; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TRAUB RD, 1991, J NEUROPHYSIOL, V66, P635, DOI 10.1152/jn.1991.66.2.635; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	57	1156	1205	3	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					381	387		10.1126/science.283.5400.381	http://dx.doi.org/10.1126/science.283.5400.381			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888852				2022-12-24	WOS:000078067000046
J	Scalf, M; Westphall, MS; Krause, J; Kaufman, SL; Smith, LM				Scalf, M; Westphall, MS; Krause, J; Kaufman, SL; Smith, LM			Controlling charge states of large ions	SCIENCE			English	Article							PROTON-TRANSFER REACTIONS; IONIZATION MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; GAS-PHASE; PROTEINS; REDUCTION; OLIGONUCLEOTIDES; EVAPORATION; MOBILITY; ANIONS	The charge state of ions produced in electrospray ionization (ESI) was reduced in a controlled manner to yield predominantly singly charged species by exposure of the aerosol to a bipolar ionizing gas. Analysis of the resulting ions on an orthogonal time-of-flight mass spectrometer yielded mass spectra greatly simplified compared with conventional ESI spectra, The decreased spectral complexity afforded by the charge reduction facilitates the analysis of mixtures by ESI mass spectrometry.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Smith, LM (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000321, R01HG001808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01HG001808, R01HG00321] Funding Source: Medline; NIGMS NIH HHS [5T32GMO8349] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apffel A, 1997, ANAL CHEM, V69, P1320, DOI 10.1021/ac960916h; BOYLE JG, 1992, ANAL CHEM, V64, P2084, DOI 10.1021/ac00042a011; CHEN DR, 1995, J AEROSOL SCI, V26, P963, DOI 10.1016/0021-8502(95)00027-A; CHEN RD, 1995, ANAL CHEM, V67, P1159, DOI 10.1021/ac00103a004; CHENG XH, 1995, ANAL CHEM, V67, P586, DOI 10.1021/ac00099a016; COOPER DW, 1973, J COLLOID INTERF SCI, V45, P17, DOI 10.1016/0021-9797(73)90239-7; Dawson J.H.J., 1989, RAPID COMMUN MASS SP, V3, P155, DOI [DOI 10.1002/RCM.1290030511, 10.1002/rcm.1290030511]; DOLE M, 1968, J CHEM PHYS, V49, P2240, DOI 10.1063/1.1670391; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fuchs N., 1963, GEOFIS PURA APPL, V56, P185, DOI [10.1007/BF01993343, DOI 10.1007/BF01993343]; IKONOMOU MG, 1991, J AM SOC MASS SPECTR, V2, P497, DOI 10.1016/1044-0305(91)80038-9; IRIBARNE JV, 1976, J CHEM PHYS, V64, P2287, DOI 10.1063/1.432536; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KAUFMAN S, UNPUB; Kaufman SL, 1996, ANAL CHEM, V68, P1895, DOI 10.1021/ac951128f; KAUFMAN SL, 1993, Patent No. 5247842; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; LEWIS KC, 1994, ANAL CHEM, V66, P2285, DOI 10.1021/ac00086a014; LIU BYH, 1974, J COLLOID INTERF SCI, V49, P305, DOI 10.1016/0021-9797(74)90366-X; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; MIRGORODSKAYA OA, 1994, ANAL CHEM, V66, P99, DOI 10.1021/ac00073a018; MIRZA UA, 1994, ANAL CHEM, V66, P2898, DOI 10.1021/ac00090a017; Mouradian S, 1997, ANAL CHEM, V69, P919, DOI 10.1021/ac960785k; Muddiman DC, 1996, J AM SOC MASS SPECTR, V7, P697, DOI 10.1016/1044-0305(96)80516-2; OGORZALEKLOO RR, 1991, J PHYS CHEM-US, V95, P6412; ROLLGEN FW, 1987, J PHYS-PARIS, V48, P253; SCHMELZEISENREDEKER G, 1989, INT J MASS SPECTROM, V90, P139, DOI 10.1016/0168-1176(89)85004-9; SMITH RD, 1990, J AM SOC MASS SPECTR, V1, P53, DOI 10.1016/1044-0305(90)80006-9; Stephenson JL, 1998, J AM SOC MASS SPECTR, V9, P585, DOI 10.1016/S1044-0305(98)00025-7; Stephenson JL, 1998, J MASS SPECTROM, V33, P664, DOI 10.1002/(SICI)1096-9888(199807)33:7<664::AID-JMS663>3.3.CO;2-G; Stephenson JL, 1996, ANAL CHEM, V68, P4026, DOI 10.1021/ac9605657; Stephenson JL, 1996, J AM CHEM SOC, V118, P7390, DOI 10.1021/ja9611755; Stephenson JL, 1997, J AM SOC MASS SPECTR, V8, P637, DOI 10.1016/S1044-0305(97)00023-8; Stephenson JL, 1997, RAPID COMMUN MASS SP, V11, P875, DOI 10.1002/(SICI)1097-0231(199705)11:8<875::AID-RCM934>3.0.CO;2-K; Stephenson JL, 1997, INT J MASS SPECTROM, V165, P419, DOI 10.1016/S0168-1176(97)00176-6; Stephenson JL, 1998, J AM SOC MASS SPECTR, V9, P957, DOI 10.1016/S1044-0305(98)00066-X; Stephenson JL, 1998, ANAL CHEM, V70, P3533, DOI 10.1021/ac9802832; STEPHENSON JL, 1998, RAPID COMMUN MASS SP, V70, P1198; THOMSON BA, 1979, J CHEM PHYS, V71, P4451, DOI 10.1063/1.438198; VERENTCHIKOV AN, 1994, ANAL CHEM, V66, P126, DOI 10.1021/ac00073a022; ZARRIN F, 1991, Patent No. 5076097; ZELENY J, 1915, P CAMB PHILOS SOC, V18, P71	43	143	156	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					194	197		10.1126/science.283.5399.194	http://dx.doi.org/10.1126/science.283.5399.194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880246				2022-12-24	WOS:000077976700031
J	Schofield, L; McConville, MJ; Hansen, D; Campbell, AS; Fraser-Reid, B; Grusby, MJ; Tachado, SD				Schofield, L; McConville, MJ; Hansen, D; Campbell, AS; Fraser-Reid, B; Grusby, MJ; Tachado, SD			CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells	SCIENCE			English	Article							PROMPTLY PRODUCE INTERLEUKIN-4; II-DEFICIENT MICE; NK1.1(+) T-CELLS; SIGNAL-TRANSDUCTION; ALPHA-CHAIN; ACTIVATION; CD4(+); CD1; RECOGNITION; LEISHMANIA	Immunoglobulin G (IgG) responses require major histocompatibility complex (MHC)-restricted recognition of peptide fragments by conventional CD4(+) helper T cells. Immunoglobulin G responses to glycosylphosphatidylinositol (GPI)-anchored protein antigens, however, were found to be regulated in part through CD1d-restricted recognition of the GPI moiety by thymus-dependent, interleukin-4-producing CD4(+), natural killer cell antigen 1.1 [(NK1.1)(+)] helper T cells. The CD1-NKT cell pathway regulated immunogobulin G responses to the GPI-anchored surface antigens of Plasmodium and Trypanosoma and may be a general mechanism for rapid, MHC-unrestricted antibody responses to diverse pathogens.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; INSMED Pharmaceut, Richmond, VA 23219 USA; Nat Prod & Glycotechnol, Durham, NC 27707 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Schofield, L (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	schofield@wehi.edu.au		Campbell, Anthony/0000-0001-5094-9714; Tachado, Souvenir/0000-0002-8368-6102	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040171, R21AI040171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041071] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40171] Funding Source: Medline; NIGMS NIH HHS [GM 41071] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, J EXP MED, V182, P2091, DOI 10.1084/jem.182.6.2091; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; Brossay L, 1998, J IMMUNOL, V160, P3681; Brossay L, 1997, J IMMUNOL, V159, P1216; Brossay L, 1998, J IMMUNOL, V161, P5124; CAMPBELL AS, 1995, J AM CHEM SOC, V117, P10387, DOI 10.1021/ja00146a026; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Chen HJ, 1997, J IMMUNOL, V158, P5112; Chen HJ, 1997, J IMMUNOL, V159, P2240; CLARKE MW, 1985, MOL BIOCHEM PARASIT, V17, P19, DOI 10.1016/0166-6851(85)90125-2; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; JOYCE S, 1998, J IMMUNOL, V279, P1541; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Park SH, 1998, J IMMUNOL, V160, P3128; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; ROMERO PJ, 1988, EUR J IMMUNOL, V18, P1951, DOI 10.1002/eji.1830181213; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; WEISS WR, 1993, J IMMUNOL, V151, P2690; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	41	337	349	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					225	229		10.1126/science.283.5399.225	http://dx.doi.org/10.1126/science.283.5399.225			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880256				2022-12-24	WOS:000077976700041
J	Levenstein, S; Ackerman, S; Kiecolt-Glaser, JK; Dubois, A				Levenstein, S; Ackerman, S; Kiecolt-Glaser, JK; Dubois, A			Stress and peptic ulcer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GASTRIC-ACID SECRETION; DUODENAL-ULCER; SERUM GASTRIN; PREDICTORS; ADULTS; RISK		Nuovo Regina Margherita Hosp, Dept Gastroenterol, Rome, Italy; St Lukes Roosevelt Hosp Ctr, Dept Psychiat, New York, NY USA; Ohio State Univ, Coll Med, Dept Psychiat, Columbus, OH 43210 USA; Uniformed Serv Univ Hlth Sci, Div Digest Dis, Bethesda, MD 20814 USA	Poliambulatorio Nuovo Regina Margherita; Mount Sinai St. Luke's; Mount Sinai West; University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA	Levenstein, S (corresponding author), Via Templo 1A, I-00186 Rome, Italy.	slevenstein@compuserve.com	Kiecolt-Glaser, Janice K/A-3236-2009	Kiecolt-Glaser, Janice K/0000-0003-4900-9578				ACKERMAN SH, 1975, PSYCHOSOM MED, V37, P180, DOI 10.1097/00006842-197503000-00007; ANDA RF, 1992, ARCH INTERN MED, V152, P829, DOI 10.1001/archinte.152.4.829; Aoyama N, 1998, AM J GASTROENTEROL, V93, P311, DOI 10.1111/j.1572-0241.1998.00311.x; ARMSTRONG D, 1994, DIGEST DIS SCI, V39, P1425, DOI 10.1007/BF02088044; BRESNICK WH, 1993, J CLIN GASTROENTEROL, V17, P117, DOI 10.1097/00004836-199309000-00006; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P985; DUBOIS A, 1981, DIGEST DIS SCI, V26, P292, DOI 10.1007/BF01308367; FELDMAN M, 1992, GASTROENTEROLOGY, V102, P175, DOI 10.1016/0016-5085(92)91798-9; Graham DY, 1997, GASTROENTEROLOGY, V113, P1983, DOI 10.1016/S0016-5085(97)70019-2; HOJGAARD L, 1989, GUT, V30, P782, DOI 10.1136/gut.30.6.782; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; LAM SK, 1995, J GASTROEN HEPATOL, V10, P570, DOI 10.1111/j.1440-1746.1995.tb01348.x; LEVENSTEIN S, 1995, J CLIN GASTROENTEROL, V21, P185, DOI 10.1097/00004836-199510000-00004; Levenstein S, 1996, J CLIN GASTROENTEROL, V22, P84, DOI 10.1097/00004836-199603000-00002; Levenstein S, 1997, J CLIN GASTROENTEROL, V24, P140, DOI 10.1097/00004836-199704000-00004; Levenstein S, 1998, BRIT MED J, V316, P538, DOI 10.1136/bmj.316.7130.538; Marucha PT, 1998, PSYCHOSOM MED, V60, P362, DOI 10.1097/00006842-199805000-00025; MIRSKY IA, 1958, AM J DIG DIS, V3, P285, DOI 10.1007/BF02232411; NATELSON BH, 1977, AM J DIG DIS, V22, P888, DOI 10.1007/BF01076165; Nice DS, 1996, JAMA-J AM MED ASSOC, V276, P375, DOI 10.1001/jama.276.5.375; Padgett DA, 1998, BRAIN BEHAV IMMUN, V12, P64, DOI 10.1006/brbi.1997.0512; PETERS MN, 1983, GASTROENTEROLOGY, V84, P114; PETERSON WL, 1997, GASTROINTESTINAL LIV, P604; POMAKOV P, 1993, J RADIOL, V74, P265; Spicer CC, 1944, LANCET, V1, P14; VELDHUIS JD, 1996, SLEEP S, V19, P5221; WEISS JM, 1971, J COMP PHYSIOL PSYCH, V77, P22, DOI 10.1037/h0031581	28	61	63	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					10	11		10.1001/jama.281.1.10	http://dx.doi.org/10.1001/jama.281.1.10			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892430				2022-12-24	WOS:000077829300002
J	Lee, IM; Paffenbarger, RS				Lee, IM; Paffenbarger, RS			Life is sweet: candy consumption and longevity	BRITISH MEDICAL JOURNAL			English	Article							CHOCOLATE		Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Lee, IM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.				NCI NIH HHS [CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doll R, 1997, BRIT MED J, V315, P1664, DOI 10.1136/bmj.315.7123.1664; Krummel DA, 1996, CRIT REV FOOD SCI, V36, P31, DOI 10.1080/10408399609527717; *NAT CONF ASS, CHOC MAN ASS; Sanbongi C, 1997, CELL IMMUNOL, V177, P129, DOI 10.1006/cimm.1997.1109; Waterhouse AL, 1996, LANCET, V348, P834, DOI 10.1016/S0140-6736(05)65262-2	5	25	26	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1683	1684		10.1136/bmj.317.7174.1683	http://dx.doi.org/10.1136/bmj.317.7174.1683			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857124	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000077742300010
J	Hudson, PJ; Dobson, AP; Newborn, D				Hudson, PJ; Dobson, AP; Newborn, D			Prevention of population cycles by parasite removal	SCIENCE			English	Article							RED GROUSE	The regular cyclic fluctuations in vertebrate numbers have intrigued scientists for more than 70 years, and yet the cause of such cycles has not been clearly demonstrated. Red grouse populations in Britain exhibit cyclic fluctuations in abundance, with periodic crashes. The hypothesis that these fluctuations are caused by the impact of a nematode parasite on host fecundity was tested by experimentally reducing parasite burdens in grouse. Treatment of the grouse population prevented population crashes, demonstrating that parasites were the cause of the cyclic fluctuations.	Univ Stirling, Inst Biol Sci, Stirling FK9 4LA, Scotland; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Game Conservancy Trust, Swaledale DL8 3HG, N Yorkshire, England	University of Stirling; Princeton University	Hudson, PJ (corresponding author), Univ Stirling, Inst Biol Sci, Stirling FK9 4LA, Scotland.		Hudson, Peter/AAB-8080-2020	Hudson, Peter/0000-0003-0468-3403				DOBSON AP, 1992, J ANIM ECOL, V61, P487, DOI 10.2307/5339; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; Hudson P. J., 1985, Ecology and genetics of host-parasite interactions. International symposium, Keele University, 12-13 July 1984, P77; Hudson P.J., 1992, GROUSE SPACE TIME; HUDSON PJ, 1986, J ANIM ECOL, V55, P85, DOI 10.2307/4694; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; May, 1973, COMPLEXITY STABILITY; MOSS R, 1991, IBIS, V133, P113, DOI 10.1111/j.1474-919X.1991.tb07674.x; POTTS GR, 1986, J ANIM ECOL, V55, P21	9	650	675	0	263	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2256	2258		10.1126/science.282.5397.2256	http://dx.doi.org/10.1126/science.282.5397.2256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856948				2022-12-24	WOS:000077645800046
J	Shimada, M; Tritos, NA; Lowell, BB; Flier, JS; Maratos-Flier, E				Shimada, M; Tritos, NA; Lowell, BB; Flier, JS; Maratos-Flier, E			Mice lacking melanin-concentrating hormone are hypophagic and lean	NATURE			English	Article							TARGETED DISRUPTION; NEUROPEPTIDE-Y; MESSENGER-RNA; OBESE GENE; LEPTIN; AGOUTI; PROTEIN; WEIGHT	Feeding is influenced by hypothalamic neuropeptides that promote (orexigenic peptides) or inhibit feeding(1). Of these, neuropeptide Y (NPY) in the arcuate nucleus' and melanin-concentrating hormone (MCH)(3) and orexins/hypocretins(4,5) in the lateral hypothalamus have received attention because their expression is increased during fasting and because they promote feeding when administered centrally. Surprisingly, absence of the orexigenic neuropeptide NPY fails to alter feeding or body weight in normal mice(6). As deficiency of a single component of the pathway that limits food intake (such as leptin or receptors for melanocortin-4)(7,8) causes obesity, it has been suggested that orexigenic signals are more redundant than those limiting food intake(7,8). To define further the physiological role of MCH and to test the redundancy of orexigenic signals, we generated mice carrying a targeted deletion of the MCH gene. MCH-deficient mice have reduced body weight and leanness due to hypophagia (reduced feeding) and an inappropriately increased metabolic rate, despite their reduced amounts of both leptin and arcuate nucleus pro-opiomelanocortin messenger RNA. Our results show that MCH is a critical regulator of feeding and energy balance which acts downstream of leptin and the melanocortin system, and that deletion of a gene encoding a single orexigenic peptide can result in leanness.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center	Maratos-Flier, E (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	emarat@joslab.harvard.edu	Tritos, Nicholas/W-1594-2019; Flier, jeffrey/AAG-6223-2019	Tritos, Nicholas/0000-0001-8867-607X; 				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; BITTENCOURT JC, 1993, ANN NY ACAD SCI, V680, P462, DOI 10.1111/j.1749-6632.1993.tb19708.x; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DRYDEN S, 1994, EUR J CLIN INVEST, V24, P293, DOI 10.1111/j.1365-2362.1994.tb01089.x; ELIAS CF, IN PRESS J COMP NEUR; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MARKS DL, 1992, MOL CELL NEUROSCI, V3, P395, DOI 10.1016/1044-7431(92)90051-3; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; TSUJII S, 1989, BRAIN RES BULL, V23, P165, DOI 10.1016/0361-9230(89)90142-1; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	904	949	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					670	674		10.1038/25341	http://dx.doi.org/10.1038/25341			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872314				2022-12-24	WOS:000077694200052
J	Clouse, WD; Hallett, JW; Schaff, HV				Clouse, WD; Hallett, JW; Schaff, HV			Improved prognosis of thoracic aortic aneurysms - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARFANS-SYNDROME; NATURAL-HISTORY; SIZE	Context.-Managing thoracic aortic aneurysms identified incidentally by increased use of computed tomography, echocardiography, and magnetic resonance imaging is problematic, especially in the elderly. Objective.-To ascertain whether the previously reported poor prognosis for individuals with thoracic aortic aneurysms has changed with better medical therapies and improved surgical techniques that can now be applied to aneurysm management. Design.-Population-based cohort study. Setting and Patients.-All 133 patients with the diagnosis of degenerative thoracic aortic aneurysms among Olmsted County, Minnesota, residents between 1980 and 1994 compared with a previously reported cohort of similar patients between 1951 and 1980. Main Outcome Measures.-The primary clinical end points were incidence, cumulative rupture risk, rupture risk as a function of aneurysm size, and survival. Results.-In contrast to abdominal aortic aneurysms, for which men are affected predominately, 51% of thoracic aortic aneurysms were identified in women who were considerably older at recognition than men (mean age, 75.9 vs 62.8 years, respectively; P = .01). The overall incidence rate of 10.4 per 100 000 person-years (95% confidence interval [CI], 8.6-12.2) between 1980 and 1994 was more than 3-fold higher than the rate from 1951 to 1980. The cumulative risk of rupture was 20% after 5 years. Seventy-nine percent of ruptures occurred in women (P = .01). The 5-year risk of rupture as a function of aneurysm size at recognition was 0% for aneurysms less than 4 cm in diameter, 16% (95% CI, 4%-28%) fd those 4 to 5.9 cm, and 31% (95% CI, 5%-56%) for aneurysms 6 cm or more. Overall 5-year survival improved to 56% (95% CI, 48%-66%) between 1980 and 1994 compared with only 19% between 1951 and 1980 (P < .01). Conclusions.-In this population, elderly women represent an increasing portion of all patients with clinically recognized thoracic aortic aneurysms and constitute the majority of patients whose aneurysm eventually ruptures. Overall survival for thoracic aortic aneurysms has improved significantly in the past 15 years.	Mayo Clin & Mayo Fdn, Div Vasc Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Epidemiol Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Hallett, JW (corresponding author), Mayo Clin & Mayo Fdn, Div Vasc Res, 200 1st St SW, Rochester, MN 55905 USA.			Schaff, Hartzell/0000-0003-0994-027X	NIAMS NIH HHS [AR 30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERSTRALH EJ, 1992, MAYO CLIN TECHNICAL, V49; BICKERSTAFF L, 1986, SURGERY, V92, P1103; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Coady MA, 1997, J THORAC CARDIOV SUR, V113, P476, DOI 10.1016/S0022-5223(97)70360-X; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD ES, 1991, ANN SURG, V213, P417, DOI 10.1097/00000658-199105000-00006; CRAWFORD ES, 1989, J THORAC CARDIOV SUR, V98, P659; CRONENWETT JL, 1985, SURGERY, V98, P472; DAPUNT OE, 1994, J THORAC CARDIOV SUR, V107, P1323, DOI 10.1016/S0022-5223(94)70054-0; ERNST CB, 1993, NEW ENGL J MED, V328, P1167; HALLETT JW, 1993, J VASC SURG, V18, P684, DOI 10.1016/0741-5214(93)90078-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; MCNAMARA JJ, 1978, ANN THORAC SURG, V26, P468, DOI 10.1016/S0003-4975(10)62927-X; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PERKO MJ, 1995, ANN THORAC SURG, V59, P1204, DOI 10.1016/0003-4975(95)00132-5; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SVENSSON LG, 1993, CHEST, V104, P1248, DOI 10.1378/chest.104.4.1248; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H; TAHERNIA AC, 1993, SOUTH MED J, V86, P305, DOI 10.1097/00007611-199303000-00012	21	330	351	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1926	1929		10.1001/jama.280.22.1926	http://dx.doi.org/10.1001/jama.280.22.1926			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851478	Bronze			2022-12-24	WOS:000077364500037
J	LeRoy, G; Orphanides, G; Lane, WS; Reinberg, D				LeRoy, G; Orphanides, G; Lane, WS; Reinberg, D			Requirement of RSF and FACT for transcription of chromatin templates in vitro	SCIENCE			English	Article							RNA-POLYMERASE-II; REMODELING FACTOR; NUCLEOSOMAL DNA; PURIFICATION; BINDING; SEQUENCES; PROTEINS; COMPLEX; ISWI	Transcription of naked DNA in vitro requires the general transcription factors and RNA polymerase II. However, this minimal set of factors is not sufficient for transcription when the DNA template is packaged into chromatin. Here, a factor that facilitates activator-dependent transcription initiation on chromatin templates was purified. This factor, remodeling and spacing factor (RSF), has adenosine triphosphate-dependent nucleosome-remodeling and spacing activities. Polymerases that initiate transcription with RSF can only extend their transcripts in the presence of FACT (facilitates chromatin transcription). Thus, the minimal factor requirements for activator-dependent transcription on chromatin templates in vitro have been defined.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucleic Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucleic Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbdf@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIHARA T, AB010882 DNA DAT BAN; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bulger M., 1994, METH MOL G, V5, P241; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; ORPHANIDES G, UNPUB; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587	25	249	259	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1900	1904		10.1126/science.282.5395.1900	http://dx.doi.org/10.1126/science.282.5395.1900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836642				2022-12-24	WOS:000077338100052
J	Yu, XM; Salter, MW				Yu, XM; Salter, MW			Gain control of NMDA-receptor currents by intracellular sodium	NATURE			English	Article							HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; CHANNEL ACTIVITY; CALCIUM; NA+; KINASE; INACTIVATION; PHOSPHATASES; ACTIVATION; TRANSPORT	The influx of Na+ is fundamental to electrical signalling in the nervous system and is essential for such basic signals as action potentials and excitatory postsynaptic potentials(1). During periods of bursting or high levels of discharge activity, large increases in intracellular Na+ concentration ([Na+](i)) are produced in neuronal soma and dendrites(2-4). However, the intracellular signalling function of raised postsynaptic: [Na+](i) is unknown. Here we show that [Na+](i) regulates the function of NMDA (N-methyl-D-aspartate) receptors, a principal subtype of glutamate receptor(5). NMDA-receptor-mediated whole-cell currents and NMDA-receptor single-channel activity were increased by raising [Na+](i) and channel activity decreased upon lowering [Na+](i); therefore. the activity of NMDA channels tracks changes in [Na+](i). We found that the sensitivity of the channel to Na+ was set by a Src kinase that is associated with the channel. Raising [Na+](i) selectively increased synaptic responses mediated by NMDA receptors, but not by non-NMDA receptors. Thus, the change in postsynaptic [Na+](i) that occurs during neuronal activity is a signal for controlling the gain of excitatory synaptic transmission. This mechanism may be important for NMDA-receptor-dependent plasticity and toxicity in the central nervous system.	Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Oral Physiol, Toronto, ON M5G 1G6, Canada; Clarke Inst Psychiat, Mol Neurobiol Sect, Toronto, ON M5T 1R8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Salter, MW (corresponding author), Hosp Sick Children, Programme Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; Callaway JC, 1997, J NEUROPHYSIOL, V77, P145, DOI 10.1152/jn.1997.77.1.145; Chidekel AS, 1997, EXP NEUROL, V146, P403, DOI 10.1006/exnr.1997.6544; Congar P, 1997, J NEUROSCI, V17, P5366; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.ph.58.030196.002025; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; Hille B., 1992, IONIC CHANNELS EXCIT; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; Medina I, 1996, J PHYSIOL-LONDON, V495, P411, DOI 10.1113/jphysiol.1996.sp021603; NOWAK LM, 1992, NEURON, V8, P181, DOI 10.1016/0896-6273(92)90119-X; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Parri HR, 1998, J NEUROSCI, V18, P854; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SANDEAUX R, 1982, BIOCHIM BIOPHYS ACTA, V684, P127, DOI 10.1016/0005-2736(82)90056-6; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	30	126	132	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					469	474		10.1038/24877	http://dx.doi.org/10.1038/24877			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853755				2022-12-24	WOS:000077370100055
J	Brittenham, GM; Franks, AL; Rickles, FR				Brittenham, GM; Franks, AL; Rickles, FR			Research priorities in hereditary hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article							GENE	The Working Group on Research Priorities used a formal nominal group technique to identify and prioritize the specific aims of applied research needed to provide the scientific basis for population screening for iron overload disorders. The most important applied research goal was characterization of the natural history of the relation between genotype and phenotype in hereditary hemochromatosis and other iron overload disorders. Three other important research objectives were development of an optimal approach to screening for iron overload; analyses of the cost-effectiveness of screening; and assessment of the ethical, legal, and social implications of screening. To achieve these specific aims, two research studies were recommended as being of the highest priority: a multicenter, cross-sectional, population-based study of the natural history of iron overload and a multicenter, case-control study of patients with disease manifestations potentially attributable to hereditary hemochromatosis in primary care and subspecialty clinics.	Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, TB Lab Res, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Atlanta, GA 30341 USA	Columbia University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Brittenham, GM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, Harkness Pavil Room HP 550,630 W 168th St, New York, NY 10032 USA.							Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; Bradley L A, 1996, J Med Screen, V3, P178; *CDCP, 1996, CDC GUID IMPR QUAL; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Reinke W, 1988, HLTH PLANNING EFFECT, P203; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	9	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					993	996		10.7326/0003-4819-129-11_Part_2-199812011-00011	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867753				2022-12-24	WOS:000077239200033
J	Edwards, G; Dora, KA; Gardener, MJ; Garland, CJ; Weston, AH				Edwards, G; Dora, KA; Gardener, MJ; Garland, CJ; Weston, AH			K+ is an endothelium-derived hyperpolarizing factor in rat arteries	NATURE			English	Article							SMOOTH-MUSCLE; POTASSIUM CHANNELS; DEPENDENT HYPERPOLARIZATION; MESENTERIC-ARTERY; CEREBRAL-ARTERIES; NITRIC-OXIDE; CORONARY; CELLS; RELAXATION; MECHANISMS	In arteries, muscarinic agonists such as acetylcholine release an unidentified, endothelium-derived hyperpolarizing factor (EDHF) which is neither prostacyclin nor nitric oxide(1-3). Here we show that EDHF-induced hyperpolarization of smooth muscle and relaxation of small resistance arteries are inhibited by ouabain plus Ba2+; ouabain is a blocker of Na+/K+ ATPase(4) and Ba2+ blocks inwardly rectifying K+ channels(5). Small increases in the amount of extracellular K+ mimic these effects of EDHF in a ouabain- and Ba2+-sensitive, but endothelium-independent, manner. Acetylcholine hyperpolarizes endothelial tells and increases the K+ concentration in the myoendothelial space; these effects are abolished by charybdotoxin plus apamin. Hyperpolarization of smooth muscle by EDHF is also abolished by this toxin combination, but these toxins do not affect the hyperpolarization of smooth muscle by added K+. These data show that EDHF is K+ that effluxes through charybdotoxin- and apamin-sensitive K+ channels on endothelial cells. The resulting increase in myoendothelial K+ concentration hyperpolarizes and relaxes adjacent smooth-muscle cells by activating Ba2+-sensitive K+ channels and Na+/K+ ATPase, These results show that fluctuations in K+ levels originating within the blood vessel itself are important in regulating mammalian blood pressure and flow.	Univ Manchester, Sch Biol Sci, Div Physiol Pharmacol & Toxicol, Manchester M13 9PT, Lancs, England; Univ Bristol, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Manchester; University of Bristol	Weston, AH (corresponding author), Univ Manchester, Sch Biol Sci, Div Physiol Pharmacol & Toxicol, G38 Stopford Bldg, Manchester M13 9PT, Lancs, England.	aweston@man.ac.uk	Garland, Christopher/O-1254-2015	Garland, Christopher/0000-0003-0848-6044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BOLTON TB, 1984, J PHYSIOL-LONDON, V351, P549, DOI 10.1113/jphysiol.1984.sp015262; BUENGER R, 1976, Pfluegers Archiv European Journal of Physiology, V363, P27; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chataigneau T, 1998, BRIT J PHARMACOL, V123, P574, DOI 10.1038/sj.bjp.0701629; Chaytor AT, 1998, J PHYSIOL-LONDON, V508, P561, DOI 10.1111/j.1469-7793.1998.561bq.x; Danker T, 1996, PFLUG ARCH EUR J PHY, V433, P71, DOI 10.1007/s004240050250; Dora KA, 1997, P NATL ACAD SCI USA, V94, P6529, DOI 10.1073/pnas.94.12.6529; EDWARDS FR, 1988, J PHYSIOL-LONDON, V404, P437, DOI 10.1113/jphysiol.1988.sp017298; Edwards G, 1997, Prog Drug Res, V49, P93; Edwards G, 1998, PROG DRUG RES, V50, P107; FEELISCH M, 1987, EUR J PHARMACOL, V142, P465, DOI 10.1016/0014-2999(87)90090-2; FELETOU M, 1988, BRIT J PHARMACOL, V93, P515, DOI 10.1111/j.1476-5381.1988.tb10306.x; GARCIA ML, 1995, AM J PHYSIOL-CELL PH, V269, pC1, DOI 10.1152/ajpcell.1995.269.1.C1; GARLAND CJ, 1992, BRIT J PHARMACOL, V105, P429, DOI 10.1111/j.1476-5381.1992.tb14270.x; GARLAND CJ, 1995, TRENDS PHARMACOL SCI, V16, P23, DOI 10.1016/S0165-6147(00)88969-5; GORDON JL, 1983, BRIT J PHARMACOL, V79, P531, DOI 10.1111/j.1476-5381.1983.tb11028.x; HOEFFNER U, 1989, AM J PHYSIOL, V257, pH330, DOI 10.1152/ajpheart.1989.257.1.H330; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KUSCHINSKY W, 1972, CIRC RES, V31, P240, DOI 10.1161/01.RES.31.2.240; Marchenko SM, 1996, J PHYSIOL-LONDON, V492, P53, DOI 10.1113/jphysiol.1996.sp021288; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902, DOI 10.1152/ajpheart.1990.259.3.H902; NEWBY AC, 1990, ANNU REV PHYSIOL, V52, P661; Paterson DJ, 1996, ACTA PHYSIOL SCAND, V156, P287, DOI 10.1046/j.1365-201X.1996.190000.x; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; Prior HM, 1998, CARDIOVASC RES, V37, P780, DOI 10.1016/S0008-6363(97)00237-X; WALDRON GJ, 1994, CAN J PHYSL PHARM S1, V72, P11; Wellman GC, 1996, PFLUG ARCH EUR J PHY, V432, P355, DOI 10.1007/s004240050144; Zygmunt PM, 1996, BRIT J PHARMACOL, V117, P1600, DOI 10.1111/j.1476-5381.1996.tb15327.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V122, P1679, DOI 10.1038/sj.bjp.0701601	30	910	930	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					269	272		10.1038/24388	http://dx.doi.org/10.1038/24388			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834033				2022-12-24	WOS:000077110400048
J	Merabet, L; Desautels, A; Minville, K; Casanova, C				Merabet, L; Desautels, A; Minville, K; Casanova, C			Motion integration in a thalamic visual nucleus	NATURE			English	Article							ANTERIOR ECTOSYLVIAN SULCUS; AREA MT; CAT; PULVINAR; STRIATE; ORGANIZATION; ORIENTATION; SELECTIVITY; DIRECTION; NEURONS	Thalamic nuclei have long been regarded as passive relay stations for sensory information en route to higher level processing in the cerebral cortex. Recently, physiological and theoretical studies have reassessed the role of the thalamus and it has been proposed that thalamic nuclei may actively participate with cortical areas in processing specific information(1-4). In support of this idea, we now show that a subset of neurons in an extrageniculate visual nucleus, the lateral-posterior pulvinar complex, can signal the true direction of motion of a plaid pattern, indicating that thalamic cells can integrate different motion signals into a coherent moving percept(5-8). This is the first time that these computations have been found to occur outside the higher-order cortical areas(5,6,9,10). Our fi(n)dings implicate extrageniculate cortico-thalamo-cortical loops in the dynamic processing of image motion, and, more generally, as basic computational modules involved in analysing specific features of complex visual scenes.	Univ Montreal, Sch Optometry, Visual Neurosci Lab, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Casanova, C (corresponding author), Univ Montreal, Sch Optometry, Visual Neurosci Lab, CP 6128,Succ Centreville, Montreal, PQ H3C 3J7, Canada.	casanovc@ere.umontreal.ca	Merabet, Lotfi B./V-2735-2017; merabet, lotfi/AAU-8259-2020	Merabet, Lotfi B./0000-0002-8094-9536; merabet, lotfi/0000-0002-8094-9536				ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; Bazhenov M, 1998, J NEUROSCI, V18, P6444; Casanova C, 1996, NEUROSCIENCE, V70, P439, DOI 10.1016/0306-4522(95)00359-2; CHALUPA LM, 1976, J NEUROPHYSIOL, V39, P354, DOI 10.1152/jn.1976.39.2.354; CHALUPA LM, 1991, VISION VISUAL DYSFUN, V4, P140; CREUTZFELDT OD, 1988, PROG BRAIN RES, V75, P307; Crick F, 1998, NATURE, V391, P245, DOI 10.1038/34584; CUSICK CG, 1993, J COMP NEUROL, V336, P1, DOI 10.1002/cne.903360102; FABRETHORPE M, 1986, EXP BRAIN RES, V62, P596; GIZZI MS, 1990, J NEUROPHYSIOL, V63, P1529, DOI 10.1152/jn.1990.63.6.1529; Guillery RW, 1995, J ANAT, V187, P583; HARTH E, 1987, SCIENCE, V237, P184, DOI 10.1126/science.3603015; MILLER R, 1996, BIOL CYBERN, V75, P623; Minville K, 1998, NEUROSCIENCE, V84, P699, DOI 10.1016/S0306-4522(97)00525-3; Movshon Adelson, 1985, PATTERN RECOGNITION, V54, P117, DOI 10.1098/rstb.1998.0333; MUCKE L, 1982, EXP BRAIN RES, V46, P1; MUMFORD D, 1991, BIOL CYBERN, V65, P135, DOI 10.1007/BF00202389; MUMFORD D, 1994, LARGE SCALE NEURONAL, P125; NOWLAN SJ, 1995, J NEUROSCI, V15, P1195; PALMER LA, 1978, J COMP NEUROL, V177, P237, DOI 10.1002/cne.901770205; PAYNE BR, 1993, CEREB CORTEX, V3, P1, DOI 10.1093/cercor/3.1.1; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; Scannell J. W., 1997, Society for Neuroscience Abstracts, V23, P1306; Scannell JW, 1996, J NEUROPHYSIOL, V76, P895, DOI 10.1152/jn.1996.76.2.895; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SINGER W, 1994, NATURE, V369, P444, DOI 10.1038/369444a0; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; STONER GR, 1994, VISUAL DETECTION MOT, P253	29	80	81	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1998	396	6708					265	268		10.1038/24382	http://dx.doi.org/10.1038/24382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834032				2022-12-24	WOS:000077110400047
J	Syngal, S; Weeks, JC; Schrag, D; Garber, JE; Kuntz, KM				Syngal, S; Weeks, JC; Schrag, D; Garber, JE; Kuntz, KM			Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations	ANNALS OF INTERNAL MEDICINE			English	Article						colonoscopy; colectomy; colorectal neoplasms, hereditary, nonpolyposis; quality of life; life expectancy	FAMILIAL ADENOMATOUS POLYPOSIS; POUCH-ANAL ANASTOMOSIS; QUALITY-OF-LIFE; COLON-CANCER; ILEORECTAL ANASTOMOSIS; ULCERATIVE-COLITIS; COST-EFFECTIVENESS; PULL-THROUGH; RISK; CARCINOMA	Background: Predisposition genetic testing is now possible for many hereditary cancer syndromes, including hereditary nonpolyposis colorectal cancer. The optimal management of the elevated risk for cancer in carriers of mutations for hereditary nonpolyposis colorectal cancer is unclear. Objective: To assess the life expectancy and quality-adjusted life expectancy benefits derived from endoscopic surveillance and prophylactic colectomy for persons who carry a mutation associated with hereditary nonpolyposis colorectal cancer. Design: Decision analysis model. Lifetime risk for colorectal cancer, efficacy of surveillance and colectomy, stage-specific colorectal cancer mortality, and quality of life were included in the model. Setting: Decision about a cancer prevention strategy at the time of a positive result on genetic testing. Patients: Carriers of a mutation for hereditary nonpolyposis colorectal cancer who were 25 years of age. Interventions: Immediate prophylactic colectomy; delayed colectomy on the basis of age, adenoma, or diagnosis of colorectal cancer; and endoscopic surveillance. Prophylactic surgical options were proctocolectomy with ileoanal anastomosis and subtotal colectomy with ileorectal anastomosis. Measurements: Life expectancy and quality-adjusted life expectancy. Results: All risk-reduction strategies led to large gains in life expectancy for carriers of a mutation for hereditary nonpolyposis colorectal cancer, with benefits ranging from 13.5 years for surveillance to 15.6 years for prophylactic proctocolectomy at 25 years of age compared with no intervention. The benefits of colectomy compared with surveillance decreased with increasing age and were minimal if colectomy was performed at the time of colorectal cancer diagnosis. When health-related quality of life was considered, surveillance led to the greatest quality-adjusted life expectancy benefit (3.2 years compared with proctocolectomy and 0.3 years compared with subtotal colectomy). Conclusions: Colonoscopic surveillance is an effective method of reducing risk far cancer in carriers of a mutation for hereditary nonpolyposis colorectal cancer. The individual patient's choice between prophylactic surgery and surveillance is a complex decision in which personal preferences weigh heavily.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Sch Hlth, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Anal, 718 Huntington Ave,2nd Floor, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R25CA057711] Funding Source: NIH RePORTER; NCI NIH HHS [5R25CA57711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; AMBROZE WL, 1992, DIS COLON RECTUM, V35, P12, DOI 10.1007/BF02053332; BESS MA, 1980, ARCH SURG-CHICAGO, V115, P460; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; CORAN AG, 1990, ANN SURG, V212, P242, DOI 10.1097/00000658-199009000-00002; DECOSSE JJ, 1992, BRIT J SURG, V79, P1372, DOI 10.1002/bjs.1800791245; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FITZGIBBONS RJ, 1987, ANN SURG, V206, P289, DOI 10.1097/00000658-198709000-00007; FRUHMORGEN P, 1979, ENDOSCOPY, V11, P146; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; HOEHNER JC, 1994, DIS COLON RECTUM, V37, P824, DOI 10.1007/BF02050149; IWAMA T, 1994, DIS COLON RECTUM, V37, P1024, DOI 10.1007/BF02049317; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; JASS JR, 1992, EUR J GASTROEN HEPAT, V4, P523; KOHLER LW, 1991, GASTROENTEROLOGY, V101, P679; Kollmorgen CF, 1996, DIS COLON RECTUM, V39, P525, DOI 10.1007/BF02058705; LANSPA SJ, 1990, GASTROENTEROLOGY, V98, P1117, DOI 10.1016/0016-5085(90)90323-S; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIJONMARCK CE, 1990, DIS COLON RECTUM, V33, P195, DOI 10.1007/BF02134178; LOVE RR, 1986, SURG GYNECOL OBSTET, V162, P8; LYNCH HT, 1981, MED HYPOTHESES, V7, P1201, DOI 10.1016/0306-9877(81)90063-3; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P849, DOI 10.1007/BF02555362; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P160, DOI 10.1007/BF02555012; *NAT CTR HLTH STAT, 1990, MON VITAL STAT REP, P39; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; *NIH, 1994, NIH PUBL; NUGENT KP, 1993, DIS COLON RECTUM, V36, P1059, DOI 10.1007/BF02047300; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEDERSEN T, 1990, ACTA ANAESTH SCAND, V34, P176, DOI 10.1111/j.1399-6576.1990.tb03066.x; PENNA C, 1994, DIS COLON RECTUM, V37, P157, DOI 10.1007/BF02047539; Provenzale D, 1997, GASTROENTEROLOGY, V113, P7, DOI 10.1016/S0016-5085(97)70074-X; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; ROUFFET F, 1994, DIS COLON RECTUM, V37, P651, DOI 10.1007/BF02054407; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; SettiCarraro P, 1996, BRIT J SURG, V83, P885, DOI 10.1002/bjs.1800830704; SITZMANN JV, 1995, SURGERY, V118, P797, DOI 10.1016/S0039-6060(05)80267-3; STELZNER M, 1989, SURG GYNECOL OBSTET, V169, P187; STEVENSON G, 1989, P PROF C SPONS ACR C; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; von Neumann J., 1953, THEORY GAMES EC BEHA; Wagner JL, 1996, PREVENTION EARLY DET, P321; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Weinstein MC, 1980, CLIN DECISION ANAL; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	54	136	146	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					787	+		10.7326/0003-4819-129-10-199811150-00007	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841584				2022-12-24	WOS:000076984800004
J	ter Haar, E; Musacchio, A; Harrison, SC; Kirchhausen, T				ter Haar, E; Musacchio, A; Harrison, SC; Kirchhausen, T			Atomic structure of clathrin: A beta propeller terminal domain joins an alpha zigzag linker	CELL			English	Article							COUPLED RECEPTOR KINASES; COATED VESICLES; HEAVY-CHAIN; G-PROTEIN; LIGHT-CHAINS; ARRESTIN/CLATHRIN INTERACTION; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; SORTING SIGNALS; AP-2 COMPLEXES	Clathrin triskelions form the lattice that organizes recruitment of proteins to coated pits and helps drive Vesiculation of the lipid bilayer. We report the crystal structure at 2.6 Angstrom resolution of a 55 kDa N-terminal fragment from the 190 kDa clathrin heavy chain. The structure comprises the globular "terminal domain" and the linker that joins it to the end of a triskelion leg. The terminal domain is a seven-blade beta propeller, a structure well adapted to interaction with multiple partners, such as the AP-1 and AP-2 sorting adaptor complexes and the nonvisual arrestins. The linker is an alpha-helical zigzag emanating from the propeller domain. We propose that this simple motif may extend into the rest of the clathrin leg.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	kirchhausen@crystal.harvard.edu		Musacchio, Andrea/0000-0003-2362-8784	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36548, R01 GM036548] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clairmont KB, 1997, CELL MOL LIFE SCI, V53, P611, DOI 10.1007/s000180050080; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CROWTHER RA, 1981, J CELL BIOL, V91, P790, DOI 10.1083/jcb.91.3.790; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; Diviani D, 1996, J BIOL CHEM, V271, P5049; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; Huang KM, 1997, J CELL SCI, V110, P899; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Saxena K, 1996, BIOCHEMISTRY-US, V35, P15215, DOI 10.1021/bi961616x; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SPRINGER TA, 1998, IN PRESS J MOL BIOL; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; UNGEWICKELL E, 1981, COLD SPRING HARB SYM, V46, P723, DOI 10.1101/SQB.1982.046.01.069; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	75	181	186	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					563	573		10.1016/S0092-8674(00)81623-2	http://dx.doi.org/10.1016/S0092-8674(00)81623-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827808	Green Accepted, Bronze			2022-12-24	WOS:000077049400014
J	Etienne, AS; Maurer, R; Berlie, J; Reverdin, B; Rowe, T; Georgakopoulos, J; Seguinot, V				Etienne, AS; Maurer, R; Berlie, J; Reverdin, B; Rowe, T; Georgakopoulos, J; Seguinot, V			Navigation through vector addition	NATURE			English	Article							PATH INTEGRATION; HOUSE MOUSE; DISTANCE	During short foraging excursions away from their home, central place foragers update their position relative to their point of departure by processing signals generated by locomotion. They therefore can home along a self-generated vector without using learned references, In rodents(1-5) and other mammals(6,7), this path integration process (dead reckoning) can occur on the basis of purely internal signals, such as vestibular(8) or proprioceptive (re)afferences(6). We report here that hamsters are also capable of proceeding to a previously learned feeding site through vector information from locomotion only. The subjects compute(9) the direction and distance to the goal by subtracting their current-position vector from the stored nest-to-goal vector. This computation pertains to locations per se and therefore occurs in absolute space, independently of landmark objects. If available, prominent visual cues merely serve to confirm the path planned through the addition of self-generated vectors, whereas visual as well as nonvisual references confirm that the subject has arrived at the goal site.	Univ Geneva, FPSE, Ethol Lab, CH-1227 Carouge, Switzerland	University of Geneva	Etienne, AS (corresponding author), Univ Geneva, FPSE, Ethol Lab, 54 Route Acacias, CH-1227 Carouge, Switzerland.	Ariane.Etienne@pse.unige.ch; Roland.Maurer@pse.unige.ch						ALYAN S, 1994, ANIM BEHAV, V48, P285, DOI 10.1006/anbe.1994.1242; Alyan SH, 1997, BEHAV PROCESS, V41, P245, DOI 10.1016/S0376-6357(97)00051-X; Benhamou S, 1997, ANIM BEHAV, V54, P321, DOI 10.1006/anbe.1996.0464; CHENG K, 1989, J EXP PSYCHOL ANIM B, V15, P366, DOI 10.1037/0097-7403.15.4.366; COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; Etienne AS, 1996, J EXP BIOL, V199, P201; ETIENNE AS, 1988, BEHAVIOUR, V106, P81, DOI 10.1163/156853988X00106; ETIENNE AS, 1982, EXPERIENTIA, V38, P553, DOI 10.1007/BF02327044; Etienne AS, 1992, CURRENT DIRECTIONS P, V1, P48, DOI DOI 10.1111/1467-; Gallistel C. R., 1990, ORG LEARNING; MAURER R, 1995, J THEOR BIOL, V175, P457, DOI 10.1006/jtbi.1995.0154; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; Mittelstaedt H., 1982, P290; POTEGAL M, 1987, COGNITIVE PROCESS, V2, P28; Seguinot V, 1998, ANIM BEHAV, V55, P787, DOI 10.1006/anbe.1997.0662; SEGUINOT V, 1993, J COMP PHYSIOL A, V173, P103; Wiener SI, 1993, MULTISENSORY CONTROL, P427, DOI [10.1093/acprof:oso/9780198547853.003.0208, DOI 10.1093/ACPROF:OSO/9780198547853.003.0208]	17	89	91	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					161	164		10.1038/24151	http://dx.doi.org/10.1038/24151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	139DU	9823894				2022-12-24	WOS:000077013300050
J	Cook, KA; Dobbs, TE; Hlady, G; Wells, JG; Barrett, TJ; Puhr, ND; Lancette, GA; Bodager, DW; Toth, BL; Genese, CA; Highsmith, AK; Pilot, KE; Finelli, L; Swerdlow, DL				Cook, KA; Dobbs, TE; Hlady, G; Wells, JG; Barrett, TJ; Puhr, ND; Lancette, GA; Bodager, DW; Toth, BL; Genese, CA; Highsmith, AK; Pilot, KE; Finelli, L; Swerdlow, DL			Outbreak of Salmonella serotype hartford infections associated with unpasteurized orange juice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC UREMIC SYNDROME; ESCHERICHIA-COLI O157-H7; PRESSED APPLE CIDER; ODDS RATIO; FRESH	Context.-Acidic foods such as orange juice have been thought to be unlikely vehicles of foodborne illness. Objective.-To investigate an outbreak of Salmonella enterica serotype Hartford (Salmonella Hartford) infections among persons visiting a theme park in Orlando, Fla, in 1995, Design.-Review of surveillance data, matched case-control study, laboratory investigation, and environmental studies. Setting.-General community, Participants.-The surveillance case definition was Salmonella Harfford or Salmonella serogroup C-1 infection in a resident of or a visitor to Orlando in May or June 1995. In the case-control study, case patients were limited to theme park hotel visitors and controls were matched to case patients by age group and hotel check-in date. Main Outcome Measures.-Risk factors for infection and source of implicated food. Results.-Sixty-two case patients from 21 states were identified, Both Salmonella Harfford and Salmonella enterica serotype Gaminara (Salmonella Gaminara) were isolated from stool samples of 1 ill person. Thirty-two case patients and 83 controls were enrolled in the case-control study, Ninety-seven percent of case patients had drunk orange juice in the theme park vs 54% of controls (matched odds ratio, undefined; 95% confidence interval, 5.2 to undefined). The orange juice was unpasteurized and locally produced. Salmonella Gaminara was isolated from 10 of 12 containers of orange juice produced during May and July, indicating ongoing contamination of juice probably because of inadequately sanitized processing equipment. Conclusions.-Unpasteurized orange juice caused an outbreak of salmonellosis in a large Florida theme park. All orange juice was recalled and the processing plant closed, Pasteurization or other equally effective risk-management strategies should be used in the production of all juices.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; US FDA, SE Reg Lab, Atlanta, GA USA; Florida Dept Hlth, Tallahassee, FL USA; Orange Cty Publ Hlth Unit, Orlando, FL USA; New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); Florida Department of Health; New Jersey Department of Health & Senior Services	Cook, KA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30333 USA.		Finelli, Lyn/AAK-2360-2020	Dobbs, Thomas/0000-0001-6199-5337				Altekruse SF, 1997, EMERG INFECT DIS, V3, P285, DOI 10.3201/eid0303.970304; American Public Health Association AWWA, 1992, STAND METH EX WAT WA; Angulo FJ, 1997, AM J PUBLIC HEALTH, V87, P580, DOI 10.2105/AJPH.87.4.580; Attaway J. A., 1972, Proceedings of the Florida State Horticultural Society, V85, P192; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BIRKHEAD GS, 1993, J INFECT DIS, V167, P1228, DOI 10.1093/infdis/167.5.1228; *CDCP, 1995, SALM SURV REP 1993 1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P4; *CDCP, 1975, MMWR-MORBID MORTAL W, V24, P87; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P975; CHALKER RB, 1988, REV INFECT DIS, V10, P111; Dean A.G., 1994, EPI INFO VERSION 6 W; DUNCAN TG, 1946, AM J PUBLIC HEALTH, V36, P34, DOI 10.2105/AJPH.36.1.34; EISENSTEIN AB, 1963, JAMA-J AM MED ASSOC, V185, P171, DOI 10.1001/jama.1963.03060030029020; Ewing W.H., 1986, EDWARDS EWINGS IDENT; *FL DEP CITR, 1996, STAD PROC CITR PROD; HEDBERG CW, 1996, AM J MED SCI, V311, P23; MALLINSON ET, 1989, AVIAN DIS, V33, P684, DOI 10.2307/1591145; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; Mitscherlich E., 1984, MICROBIAL SURVIVAL E; *NAT COMM CLIN LAB, 1995, PERF STAND ANT DISK; Parish ME, 1998, J FOOD PROTECT, V61, P280, DOI 10.4315/0362-028X-61.3.280; Parish ME, 1997, J FOOD SAFETY, V17, P273, DOI 10.1111/j.1745-4565.1997.tb00194.x; PAVIA AT, 1991, BACTERIAL INFECT HUM, P573; PUTNAM JJ, 1997, FOOD CONSUMPTION PRI; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCHMELZER LL, 1967, ARCH ENVIRON HEALTH, V15, P78, DOI 10.1080/00039896.1967.10664879; SINGH BR, 1996, J FOOD SCI TECHNOL I, V32, P504; STEELE BT, 1982, J PEDIATR-US, V101, P963, DOI 10.1016/S0022-3476(82)80021-8; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P97, DOI 10.1001/jama.277.2.97; TABERSHAW IR, 1967, ARCH ENVIRON HEALTH, V15, P72, DOI 10.1080/00039896.1967.10664878; U. S. Environmental Protection Agency (USEPA) U. S. Department of Agriculture Department of Health and Human Services, 1997, FOOD SAF FARM TABL N; *US FDA, 1997, FOOD COD 1997 REC US; WELLS JG, 1997, 97 GEN M AM SOC MICR; WILLIAMS R, 1998, FED REGISTER, V63, P24253; 1988, FED REG, V63, P20449	38	116	121	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1504	1509		10.1001/jama.280.17.1504	http://dx.doi.org/10.1001/jama.280.17.1504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809731				2022-12-24	WOS:000076757200024
J	Kiomento, H				Kiomento, H			The intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1477	1477		10.1001/jama.280.17.1477	http://dx.doi.org/10.1001/jama.280.17.1477			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809719				2022-12-24	WOS:000076757200007
J	Lou, HC				Lou, HC			Autoregulation of cerebral blood flow and brain lesions in newborn infants	LANCET			English	Editorial Material							INTRAVENTRICULAR HEMORRHAGE; PRETERM INFANTS; AUTO-REGULATION		John F Kennedy Inst, Dept Dev Neurol, DK-2600 Glostrup, Denmark		Lou, HC (corresponding author), John F Kennedy Inst, Dept Dev Neurol, DK-2600 Glostrup, Denmark.							ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; COURVILLE CB, 1959, J NEUROPATH EXP NEUR, V18, P115, DOI 10.1097/00005072-195901000-00008; DEREUCK J, 1972, ARCH NEUROL-CHICAGO, V27, P229, DOI 10.1001/archneur.1972.00490150037007; FUNATO M, 1992, J PEDIATR-US, V121, P614, DOI 10.1016/S0022-3476(05)81157-6; GUZETTA F, 1986, PEDIATRICS, V78, P995; HAMBLETON G, 1976, ARCH DIS CHILD, V51, P651, DOI 10.1136/adc.51.9.651; LOU HC, 1977, ACTA NEUROL SCAND, V56, P34; MILLIGAN DWA, 1980, LANCET, V1, P896; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PRYDS O, 1989, J PEDIATR-US, V115, P638, DOI 10.1016/S0022-3476(89)80301-4; SKOV L, 1990, Ugeskrift for Laeger, V152, P1646; TSZYCZUK L, 1998, PEDITRICS, V102, P337; TWEED WA, 1983, PEDIATR RES, V17, P246, DOI 10.1203/00006450-198304000-00002; TWEED WA, 1986, PEDIATR RES, V6, P516; Volpe JJ, 1998, ARCH NEUROL-CHICAGO, V55, P297, DOI 10.1001/archneur.55.3.297	15	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1406	1406		10.1016/S0140-6736(05)61260-3	http://dx.doi.org/10.1016/S0140-6736(05)61260-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807985				2022-12-24	WOS:000076719500005
J	Kurada, P; White, K				Kurada, P; White, K			Ras promotes cell survival in Drosophila by downregulating hid expression	CELL			English	Article							PROTEIN TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; EGF RECEPTOR; FATE DETERMINATION; SIGNALING PATHWAY; ACTS DOWNSTREAM; DEATH; GENE; APOPTOSIS; MIDLINE		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	White, K (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.	kwhite@cbrc.mgh.harvard.edu	White, Kristin/D-7936-2013		NIGMS NIH HHS [GM55568, R01 GM055568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055568] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard JD, 1996, DEVELOPMENT, V122, P1137; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLIFFORD RJ, 1989, GENETICS, V123, P771; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Dong R, 1997, DEV BIOL, V190, P165, DOI 10.1006/dbio.1997.8688; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GEYER PK, 1993, GENETICS, V133, P265; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Karim FD, 1998, DEVELOPMENT, V125, P1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Miller DT, 1998, DEVELOPMENT, V125, P2327; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PERRIMON N, 1984, GENETICS, V108, P559; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; Scholz H, 1997, MECH DEVELOP, V64, P137; Sieff C A, 1994, Curr Opin Hematol, V1, P310; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stemerdink C, 1997, DEVELOPMENT, V124, P3787; Tio M, 1997, DEVELOPMENT, V124, P343; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	51	321	320	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					319	329		10.1016/S0092-8674(00)81764-X	http://dx.doi.org/10.1016/S0092-8674(00)81764-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814703	Bronze			2022-12-24	WOS:000076789600006
J	Teixeira, JMA; Fisk, NM; Glover, V				Teixeira, JMA; Fisk, NM; Glover, V			Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study	BRITISH MEDICAL JOURNAL			English	Article							DOPPLER ULTRASOUND; FETAL ORIGINS; STRESS; PREECLAMPSIA; PREDICTION; GESTATION; BEHAVIOR; DELIVERY; DISEASE	Objective To investigate whether maternal anxiety in the third trimester is associated with an increased uterine artery resistance index. Design Cohort based study. Subjects 100 pregnant women, with a mean gestation of 32 weeks. Outcome measures Self rating Spielberger questionnaire for state anxiety and trait anxiety, and uterine blood now waveform patterns as assessed by colour Doppler ultrasound. Results A significant association was found between uterine artery resistance index and scores for both Spielberger state anxiety and trait anxiety (r(s) = 0.31, P < 0.002 and 0.28 P < 0.005 respectively). Women with state anxiety scores > 40 (n = 15) had a higher mean uterine resistance index than those with scores less than or equal to 40 (mean difference with mean resistance index 24%, 95% confidence interval 12% to 38%; P < 0.0001), Similarly, women with trait anxiety scores >40 (n=32) had a higher mean resistance index than those with scores less than or equal to 40, although to a lesser extent. The presence of notches in the waveform pattern produced by uterine artery blood now was found in 4/15 (27%) women with high state anxiety scores compared with 4/85 (5%) with low anxiety scores (P < 0.02). Conclusions This study shows an association between maternal anxiety in pregnancy and increased uterine artery resistance index. It suggests a mechanism by which the psychological state of the mother may affect fetal development, and may explain epidemiological associations between maternal anxiety and low birth weight The influence of maternal anxiety may be one mechanism by which the intrauterine environment contributes to later disease in offspring.	Queen Charlottes & Chelsea Hosp, Div Paediat Obstet & Gynaecol, Ctr Fetal Care, London W6 0XG, England	Imperial College London	Glover, V (corresponding author), Queen Charlottes & Chelsea Hosp, Div Paediat Obstet & Gynaecol, Ctr Fetal Care, London W6 0XG, England.	vglover@rpms.ac.uk	Fisk, Nicholas M/B-2126-2009; Glover, Vivette/M-2711-2016	Fisk, Nicholas M/0000-0003-0031-7975; Glover, Vivette/0000-0001-6543-1651				BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1995, P ROY SOC B-BIOL SCI, V262, P37, DOI 10.1098/rspb.1995.0173; BOWER S, 1993, BRIT J OBSTET GYNAEC, V100, P989, DOI 10.1111/j.1471-0528.1993.tb15139.x; BOWER SJ, 1995, AM J OBSTET GYNECOL, V173, P502, DOI 10.1016/0002-9378(95)90273-2; Clarke AS, 1996, INFANT BEHAV DEV, V19, P451, DOI 10.1016/S0163-6383(96)90006-5; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; Ferber S.G., 2006, DEV PSYCHOPATHOL, V93, P117, DOI DOI 10.1017/S0954579400005290; FERREIRA AJ, 1965, J NERV MENT DIS, V141, P108, DOI 10.1097/00005053-196507000-00011; FRIED G, 1990, REGUL PEPTIDES, V28, P1, DOI 10.1016/0167-0115(90)90059-6; Frusca T, 1997, EARLY HUM DEV, V48, P177, DOI 10.1016/S0378-3782(96)01854-3; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Groome LJ, 1995, J DEV BEHAV PEDIATR, V16, P391; HACKETT GA, 1992, OBSTET GYNECOL, V79, P919; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; Harrington K, 1996, ULTRASOUND OBST GYN, V7, P182, DOI 10.1046/j.1469-0705.1996.07030182.x; HARRINGTON K, 1995, COLOUR ATLAS DOPPLER; Hedegaard M, 1996, EPIDEMIOLOGY, V7, P339, DOI 10.1097/00001648-199607000-00001; HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; IANNIRUBERTO A, 1981, SEMIN PERINATOL, V5, P175; Lees C, 1996, OBSTET GYNECOL, V88, P14, DOI 10.1016/0029-7844(96)00070-1; LOU HC, 1994, DEV MED CHILD NEUROL, V36, P826; MORISHIMA HO, 1978, AM J OBSTET GYNECOL, V131, P286, DOI 10.1016/0002-9378(78)90602-6; PERKIN MR, 1993, BRIT J OBSTET GYNAEC, V100, P629, DOI 10.1111/j.1471-0528.1993.tb14228.x; ROSENFIELD CR, 1976, AM J OBSTET GYNECOL, V127, P376; Spielberger C., 1983, STAI MANUAL; Spielberger CD., 1983, STATE TRAIT ANXIETY; STARKMAN MN, 1990, PSYCHOSOM MED, V52, P129, DOI 10.1097/00006842-199003000-00001; WADWA PD, 1993, AM J OBSTET GYNECOL, V169, P858; WADWA PD, 1996, PSYCHOSOM MED, V58, P432; WEINSTEIN AM, 1995, BIOL PSYCHIAT, V37, P847, DOI 10.1016/0006-3223(94)00249-3; WOLF F, 1986, BRIT J OBSTET GYNAEC, V93, P1049	31	347	354	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					153	157		10.1136/bmj.318.7177.153	http://dx.doi.org/10.1136/bmj.318.7177.153			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888905	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000078175100023
J	Birger, Y; Shemer, R; Perk, J; Razin, A				Birger, Y; Shemer, R; Perk, J; Razin, A			The imprinting box of the mouse Igf2r gene	NATURE			English	Article							DNA METHYLATION; MECHANISMS; EXPRESSION; PATTERN; EMBRYO; ISLAND	Genomic imprinting is a phenomenon characterized by parent-of-origin-specific expression. The imprint is a mark established during germ-cell development to distinguish between the paternal and maternal copies of the imprinted genes. This imprint is maintained throughout embryo development and erased in the embryonic gonads to set the stage for a new imprint(1). DNA methylation is essential in this process as shown by the presence of differentially methylated regions (DMRs) in all imprinted genes(2) and by the loss of imprinting in mice that are deficient in DNA. methylation(3) or upon deletion of DMRs(4-6). Here we show that a DMR in the imprinted Igf2r gene (which encodes the receptor for insulin-like growth factor type-2) that has been shown to be necessary for imprinting(5) includes a 113-base-pair sequence that constitutes a methylation imprinting box. We identify two new cis-acting elements in this box that bind specific proteins: a de novo methylation signal and an allele-discrimination signal. We propose that this regulatory system, which we show to be involved in the establishment of differential methylation in the Igf2r DMR, represents a critical element in the imprinting process.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Razin, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, POB 12272, IL-91120 Jerusalem, Israel.							Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	17	106	109	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					84	88		10.1038/16291	http://dx.doi.org/10.1038/16291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892358				2022-12-24	WOS:000077959400053
J	Bonfanti, L; Mironov, AA; Martinez-Menarguez, JA; Martella, O; Fusella, A; Baldassarre, M; Buccione, R; Geuze, HJ; Mironov, AA; Luini, A				Bonfanti, L; Mironov, AA; Martinez-Menarguez, JA; Martella, O; Fusella, A; Baldassarre, M; Buccione, R; Geuze, HJ; Mironov, AA; Luini, A			Procollagen traverses the Golgi stack without leaving the lumen of Cisternae: Evidence for cisternal maturation	CELL			English	Article							COLLAGEN TRIPLE-HELIX; ELECTRON-MICROSCOPY; I COLLAGEN; TRANSPORT; CELLS; MEMBRANE; SECRETION; VESICLES; COMPLEX; ORGANIZATION	Newly synthesized procollagen type I (PC) assembles into 300 nm rigid, rod-like triple helices in the lumen of the endoplasmic reticulum. This oligomeric complex moves to the Golgi and forms large electron-dense aggregates. We have monitored the transport of PC along the secretory pathway. We show that PC moves across the Golgi stacks without ever leaving the lumen of the Golgi cisternae. During transport from the endoplasmic reticulum to the Golgi, PC is found within tubular-saccular structures greater than 300 nm in length. Thus, supermolecular cargoes such as PC do not utilize the conventional vesicle-mediated transport to traverse the Golgi stacks. Our results imply that PC moves in the anterograde direction across the Golgi complex by a process involving progressive maturation of Golgi cisternae.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Morphol, I-66030 Chieti, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Mol Neurobiol Lab, I-66030 Chieti, Italy; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Utrecht University; Utrecht University	Luini, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy.	mironov@cmns.mnegri.it; luini@cmns.mnegri.it	Baldassarre, Massimiliano/AAI-6581-2021; Baldassarre, Massimiliano/E-6236-2011; Luini, Alberto/L-1372-2013	Baldassarre, Massimiliano/0000-0002-2498-4767; Baldassarre, Massimiliano/0000-0002-2498-4767; Luini, Alberto/0000-0002-8729-2549; Buccione, Roberto/0000-0001-9210-5261; Mironov, Aleksandr/0000-0002-1497-328X				AYALA J, 1994, J CELL SCI, V107, P753; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Beck K, 1996, J BIOL CHEM, V271, P21566, DOI 10.1074/jbc.271.35.21566; BECKER B, 1995, TRENDS CELL BIOL, V5, P305, DOI 10.1016/S0962-8924(00)89047-9; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Buccione R, 1996, J BIOL CHEM, V271, P3523; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FOELLMER HG, 1983, EUR J BIOCHEM, V134, P183, DOI 10.1111/j.1432-1033.1983.tb07549.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; HARWOOD R, 1976, BIOCHEM J, V156, P81, DOI 10.1042/bj1560081; Jantti J, 1997, EUR J CELL BIOL, V74, P150; KAO WWY, 1977, J BIOL CHEM, V252, P8391; Kim YR, 1997, J CELL BIOCHEM, V67, P338, DOI 10.1002/(SICI)1097-4644(19971201)67:3<338::AID-JCB6>3.0.CO;2-X; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; OHTANI H, 1992, J HISTOCHEM CYTOCHEM, V40, P1139, DOI 10.1177/40.8.1619278; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARRAS MP, 1991, DEV BIOL, V148, P495, DOI 10.1016/0012-1606(91)90267-7; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; TRELSTAD RL, 1979, DEV BIOL, V71, P228, DOI 10.1016/0012-1606(79)90166-0; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	33	300	309	1	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					993	1003		10.1016/S0092-8674(00)81723-7	http://dx.doi.org/10.1016/S0092-8674(00)81723-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875853	Bronze			2022-12-24	WOS:000077759100014
J	Britton, BJ; Evans, JG; Potter, JM				Britton, BJ; Evans, JG; Potter, JM		CRACKPOT Investigators	Does the fly matter? The CRACKPOT study in evidence based trout fishing	BRITISH MEDICAL JOURNAL			English	Article								Objective To investigate the importance of the type of dry fly (artificial floating fly) in catching trout (brown and rainbow) in an English chalkstream. Setting River Kennet, Berkshire. Design Five anglers on five separate occasions spent live hours using a randomly allocated ny from a sample of five types. Participants Five anglers of considerable but varying experience, determination, and opinion. Main outcome measures Number, weight and species of trout caught. Results One ny (Black Gnat) performed significantly worse than the others. The ny most successful in catching brown trout was the Cinnamon Sedge. Conclusion The possible prolongation of doctors' leisure time consequent on the use of unproductive trout flies has resource implications for the NHS. Urgent funding of a definitive, large multiriver trial is needed.	Radcliffe Infirm, Dept Clin Gerontol, Oxford OX2 6HE, England; John Radcliffe Hosp, Oxford OX3 9DU, England; Univ Oxford Wadham Coll, Oxford OX1 3PN, England	Radcliffe Infirmary; University of Oxford; University of Oxford	Evans, JG (corresponding author), Radcliffe Infirm, Dept Clin Gerontol, Oxford OX2 6HE, England.							AELIAN C, 1959, ANIMALIUM NATURA; BERNERS J, 1880, BOKE ST ALBANS; BUCKLAND J, 1986, POCKET GUIDE TROUT S; Frost WE., 1967, TROUT; Halford Frederic, 1886, FLOATING FLIES DRESS; RONALDS A, 1836, FLYFISHERS ENTOMOLOG; Walton Izaak, 1653, COMPLEAT ANGLER	7	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1678	1680		10.1136/bmj.317.7174.1678	http://dx.doi.org/10.1136/bmj.317.7174.1678			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857122	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000077742300008
J	Wang, HS; Pan, ZM; Shi, WM; Brown, BS; Wymore, RS; Cohen, IS; Dixon, JE; McKinnon, D				Wang, HS; Pan, ZM; Shi, WM; Brown, BS; Wymore, RS; Cohen, IS; Dixon, JE; McKinnon, D			KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel	SCIENCE			English	Article							PARAVERTEBRAL SYMPATHETIC NEURONS; LINOPIRDINE DUP-996; K+ CHANNELS; M-CURRENTS; CONDUCTANCE; BLOCKADE; ENHANCER; GENE; ION	The M-current regulates the subthreshold electrical excitability of many neurons, determining their firing properties and responsiveness to synaptic input. To date, however, the genes that encode subunits of this important channel have not been identified. The biophysical properties, sensitivity to pharmacological blockade, and expression pattern of the KCNQ2 and KCNQ3 potassium channels were determined. It is concluded that both these subunits contribute to the native M-current.	SUNY Stony Brook, Dept Physiol & Biophys, Inst Mol Cardiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; Dupont Co, Pharmaceut, CNS Dis Res, Wilmington, DE 19880 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; DuPont	Dixon, JE (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Inst Mol Cardiol, Stony Brook, NY 11794 USA.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				AIKEN SP, 1995, BRIT J PHARMACOL, V115, P1163, DOI 10.1111/j.1476-5381.1995.tb15019.x; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; BROWN DA, 1988, ION CHANNELS, P55; CASSELL JF, 1987, BRIT J PHARMACOL, V91, P259, DOI 10.1111/j.1476-5381.1987.tb10279.x; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; CONSTANTI A, 1987, J PHYSIOL-LONDON, V387, P173, DOI 10.1113/jphysiol.1987.sp016569; CONSTANTI A, 1981, NEUROSCI LETT, V24, P289, DOI 10.1016/0304-3940(81)90173-7; Costa AMN, 1997, NEUROPHARMACOLOGY, V36, P1747, DOI 10.1016/S0028-3908(97)00155-X; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Dixon JE, 1996, EUR J NEUROSCI, V8, P183, DOI 10.1111/j.1460-9568.1996.tb01179.x; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Lamas JA, 1997, EUR J NEUROSCI, V9, P605, DOI 10.1111/j.1460-9568.1997.tb01637.x; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MARRION NV, 1992, P ROY SOC B-BIOL SCI, V248, P207, DOI 10.1098/rspb.1992.0063; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Shi WM, 1997, J NEUROSCI, V17, P9423; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Stansfeld C, 1997, TRENDS NEUROSCI, V20, P13, DOI 10.1016/S0166-2236(96)20058-X; STEINLEIN O, 1995, HUM GENET, V95, P411; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; WANG HS, 1995, J PHYSIOL-LONDON, V485, P319, DOI 10.1113/jphysiol.1995.sp020732; WANG HS, KNCQ2 KNCQ3 M1 MUSCA; WANG HS, RIBONUCLEASE RNASE P; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WOMBLE MD, 1992, J PHYSIOL-LONDON, V457, P93, DOI 10.1113/jphysiol.1992.sp019366; Yamada WM, 1989, METHODS NEURONAL MOD, P97; YANG, 1998, J BIOL SCI, V273, P19419; Zaczek R, 1998, J PHARMACOL EXP THER, V285, P724	30	981	1036	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1890	1893		10.1126/science.282.5395.1890	http://dx.doi.org/10.1126/science.282.5395.1890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836639				2022-12-24	WOS:000077338100049
J	Bradbury, J				Bradbury, J			Bad news for the young in AIDS epidemic update	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1760	1760		10.1016/S0140-6736(05)79835-4	http://dx.doi.org/10.1016/S0140-6736(05)79835-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848364				2022-12-24	WOS:000077246500027
J	Lamme, VAF; Spekreijse, H				Lamme, VAF; Spekreijse, H			Neuronal synchrony does not represent texture segregation	NATURE			English	Article							CAT VISUAL-CORTEX; MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC CONNECTIONS; MACAQUE MONKEY; RESPONSES; OSCILLATIONS; INTEGRATION	The visual environment is perceived as an organized whole of objects and their surroundings. In many visual cortical areas, however, neurons are typically activated when a stimulus is presented over a very limited portion of the visual field, the receptive field of that neuron(1-4). To bridge the gap between this piecewise neuronal analysis and our global visual percepts, it has been postulated that neurons representing elements of the same object fire in synchrony to represent the perceptual organization of a scene(5-10). Experiments with stimuli such as moving bars or gratings have provided evidence for this hypothesis(11-16). We have further tested this by presenting monkeys with various textured scenes consisting of a figure on a background, and recorded neuronal activity in the primary visual cortex (area V1). Our results show no systematic relationship between the synchrony of firing of pairs of neurons and the perceptual organization of the scene. Instead, pairs of recording sites representing elements of the same figure most commonly showed equal amounts of synchrony between them as did pairs of which one site represented the figure and the other the background. We conclude that synchrony in V1 does not reflect the binding of features that leads to texture segregation.	Univ Amsterdam, AMC, Dept Phys Med, Grad Sch Neurosci, NL-1100 AC Amsterdam, Netherlands; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Lamme, VAF (corresponding author), Univ Amsterdam, AMC, Dept Phys Med, Grad Sch Neurosci, POB 12141, NL-1100 AC Amsterdam, Netherlands.	v.lamme@amc.uva.nl						BOUR LJ, 1984, IEEE T BIO-MED ENG, V31, P419, DOI 10.1109/TBME.1984.325281; Brosch M, 1997, CEREB CORTEX, V7, P70, DOI 10.1093/cercor/7.1.70; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; Freiwald WA, 1995, NEUROREPORT, V6, P2348, DOI 10.1097/00001756-199511270-00018; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; KONIG P, 1995, NEURAL COMPUT, V7, P469, DOI 10.1162/neco.1995.7.3.469; Kreiter AK, 1996, J NEUROSCI, V16, P2381; KRUGER J, 1989, BRAIN RES, V477, P57, DOI 10.1016/0006-8993(89)91394-2; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Lamme VAF, 1998, P NATL ACAD SCI USA, V95, P3263, DOI 10.1073/pnas.95.6.3263; Livingstone MS, 1996, J NEUROPHYSIOL, V75, P2467, DOI 10.1152/jn.1996.75.6.2467; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; SCHILLER PH, 1976, J NEUROPHYSIOL, V39, P1288, DOI 10.1152/jn.1976.39.6.1288; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; TSO DY, 1986, J NEUROSCI, V6, P1160; van der Togt C, 1998, EUR J NEUROSCI, V10, P1490, DOI 10.1046/j.1460-9568.1998.00200.x; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113	29	102	103	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					362	366		10.1038/24608	http://dx.doi.org/10.1038/24608			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845071				2022-12-24	WOS:000077204000048
J	Handsfield, HH				Handsfield, HH			Screening asymptomatic women for Chlamydia trachomatis - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INFECTION; CRITERIA		Seattle King Cty Dept Publ Hlth, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Handsfield, HH (corresponding author), Seattle King Cty Dept Publ Hlth, Seattle, WA 98104 USA.							GENE M, 1996, ANN INTERN MED, V124, P1; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HANDSFIELD HH, 1997, SCREENING DIAGNOSING, P1; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840	7	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1800	1801		10.1001/jama.280.20.1800	http://dx.doi.org/10.1001/jama.280.20.1800			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842959				2022-12-24	WOS:000077081400040
J	Defesche, JC; Kastelein, JJP				Defesche, JC; Kastelein, JJP			Molecular epidemiology of familial hypercholesterolaemia	LANCET			English	Editorial Material							RECEPTOR GENE; MUTATIONS		Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Defesche, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands.		Kastelein, John/AAF-7950-2020					AALTOSETALA K, 1992, J INTERN MED, V231, P22; Lee WK, 1998, J MED GENET, V35, P573, DOI 10.1136/jmg.35.7.573; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; Varret M, 1997, NUCLEIC ACIDS RES, V25, P172, DOI 10.1093/nar/25.1.172; Vohl MC, 1997, CLIN GENET, V52, P1, DOI 10.1111/j.1399-0004.1997.tb02506.x	5	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1643	1644		10.1016/S0140-6736(05)61443-2	http://dx.doi.org/10.1016/S0140-6736(05)61443-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853432				2022-12-24	WOS:000077110300004
J	Jonsson, JS; Gislason, T; Gislason, D; Sigurdsson, JA				Jonsson, JS; Gislason, T; Gislason, D; Sigurdsson, JA			Acute bronchitis and clinical outcome three years later: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTICS; ETIOLOGY		Gardabaer Hlth Ctr, IS-210 Gardabaer, Iceland; Vifilsstadir, Dept Pulm, IS-210 Gardabaer, Iceland; Solvangur Hlth Ctr, Dept Family Med, IS-220 Hafnarfjordur, Iceland		Jonsson, JS (corresponding author), Gardabaer Hlth Ctr, Gardatorg 7, IS-210 Gardabaer, Iceland.			Sigurdsson, Johann Agust/0000-0002-5646-6411				Gislason T, 1997, Laeknabladid, V83, P211; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Jonsson JS, 1997, SCAND J PRIM HEALTH, V15, P156, DOI 10.3109/02813439709018507; ORR PH, 1993, J FAM PRACTICE, V36, P507; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66	5	18	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1998	317	7170					1433	1433		10.1136/bmj.317.7170.1433	http://dx.doi.org/10.1136/bmj.317.7170.1433			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142LP	9822398	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000077202200025
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Molecular barbells	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Peters, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1439	1439		10.1126/science.282.5393.1439	http://dx.doi.org/10.1126/science.282.5393.1439			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867653				2022-12-24	WOS:000077110800035
J	Bader, BL; Rayburn, H; Crowley, D; Hynes, RO				Bader, BL; Rayburn, H; Crowley, D; Hynes, RO			Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-ADHESION; HUMAN CYTOTROPHOBLASTS; ENDOVASCULAR INVASION; VASCULAR DEVELOPMENT; MESODERMAL DEFECTS; TARGETED MUTATIONS; DEFICIENT MICE; BLOOD-VESSELS; ALPHA(V)BETA(3)	alpha v integrins have been implicated in many developmental processes and are therapeutic targets for inhibition of angiogenesis and osteoporosis. Surprisingly, ablation of the gene for the alpha v integrin subunit, eliminating all five alpha v integrins, although causing lethality, allows considerable development and organogenesis including, most notably, extensive vasculogenesis and angiogenesis. Eighty percent of embryos die in midgestation, probably because of placental defects, but all embryos develop normally to E9.5, and 20% are born alive. These liveborn alpha v-null mice consistently exhibit intracerebral and intestinal hemorrhages and cleft palates. These results necessitate reevaluation of the primacy of alpha v integrins in many functions including vascular development, despite reports that blockade of these integrins with antibodies or peptides prevents angiogenesis.	MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hynes, RO (corresponding author), MIT, Howard Hughes Med Inst, Ctr Canc Res, Cambridge, MA 02139 USA.	rohynes@mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALFANDARI D, 1995, DEV BIOL, V170, P249, DOI 10.1006/dbio.1995.1212; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAMSKY C, 1993, FASEB J, V7, P1320, DOI 10.1096/fasebj.7.14.8224605; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; George EL, 1997, BLOOD, V90, P3073, DOI 10.1182/blood.V90.8.3073; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GeorgesLabouesse EN, 1996, DEV DYNAM, V207, P145, DOI 10.1002/(SICI)1097-0177(199610)207:2<145::AID-AJA3>3.0.CO;2-H; Gerber DJ, 1996, P NATL ACAD SCI USA, V93, P14698, DOI 10.1073/pnas.93.25.14698; Goh KL, 1997, DEVELOPMENT, V124, P4309; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HIRSCH E, 1994, DEV DYNAM, V201, P108, DOI 10.1002/aja.1002010203; HodivalaDilke KM, 1997, BLOOD, V90, P2550; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARINPADILLA M, 1985, J COMP NEUROL, V241, P237, DOI 10.1002/cne.902410210; Martin PT, 1997, DEVELOPMENT, V124, P3909; MCDONALD KA, 1995, J CELL SCI, V108, P2573; MILNER R, 1994, DEVELOPMENT, V120, P3497; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamada S, 1995, CELL ADHES COMMUN, V3, P311, DOI 10.3109/15419069509081016; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; YANG JT, 1995, DEVELOPMENT, V121, P549; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yang JT, 1996, MOL BIOL CELL, V7, P1737, DOI 10.1091/mbc.7.11.1737; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388	61	510	535	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					507	519		10.1016/S0092-8674(00)81618-9	http://dx.doi.org/10.1016/S0092-8674(00)81618-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827803	Bronze			2022-12-24	WOS:000077049400009
J	Cottaris, NP; De Valois, RL				Cottaris, NP; De Valois, RL			Temporal dynamics of chromatic tuning in macaque primary visual cortex	NATURE			English	Article							STRIATE CORTEX; SIMPLE CELLS; MECHANISMS; RETINA; PATHWAY; NEURONS; MONKEY	The ability to distinguish colour from intensity variations is a difficult computational problem for the visual system because each of the three cone photoreceptor types absorb all wavelengths of light, although their peak sensitivities are at relatively short (S cones), medium (M cones), or long (L cones) wavelengths. The first stage in colour processing is the comparison of the outputs of different cone types by spectrally opponent neurons in the retina and upstream in the lateral geniculate nucleus(1-3). Some neurons receive opponent inputs from L and M cones, whereas others receive input from S cones opposed by combined signals from L and M cones. Here we report how the outputs of the L/M- and S-opponent geniculate cell types are combined in time at the next stage of colour processing, in the macaque primary visual cortex (V1). Some V1 neurons respond to a single chromatic region, with either a short (68-95 ms) or a longer (96-135 ms) latency, whereas others respond to two chromatic regions with a difference in latency of 20-30 ms. Across all types, short latency responses are mostly evoked by L/M-opponent inputs whereas longer latency responses are evoked mostly by S-opponent inputs. Furthermore, neurons with late S-cone inputs exhibit dynamic changes in the sharpness of their chromatic tuning over time. We propose that the sparse, S-opponent signal in the lateral geniculate nucleus is amplified in area V1, possibly through recurrent excitatory networks. This results in a delayed, sluggish cortical S-cone signal which is then integrated with L/M-opponent signals to rotate the lateral geniculate nucleus chromatic axes(4-5).	Univ Calif Berkeley, Program Vis Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Cottaris, NP (corresponding author), Univ Calif Berkeley, Program Vis Sci, 3210 Tolman Hall, Berkeley, CA 94720 USA.	nicolas@valois.berkeley.edu						ALBRECHT DG, 1991, VISUAL NEUROSCI, V7, P531, DOI 10.1017/S0952523800010336; Calkins DJ, 1998, J NEUROSCI, V18, P3373; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; Dacey DM, 1996, P NATL ACAD SCI USA, V93, P582, DOI 10.1073/pnas.93.2.582; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DEMONASTERIO FM, 1981, SCIENCE, V213, P1278, DOI 10.1126/science.7268439; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DEVALOIS RL, 1966, J OPT SOC AM, V56, P966, DOI 10.1364/JOSA.56.000966; DEVALOIS RL, 1993, VISION RES, V33, P1053, DOI 10.1016/0042-6989(93)90240-W; DEVALOIS RL, UNPUB VISION RES; GEGENFURTNER KR, 1995, VISION RES, V35, P1547, DOI 10.1016/0042-6989(94)00264-M; GIELEN CCAM, 1982, BIOL CYBERN, V44, P211, DOI 10.1007/BF00344277; Hartline HK, 1940, AM J PHYSIOL, V130, P0690, DOI 10.1152/ajplegacy.1940.130.4.690; HAWKEN MJ, 1988, J NEUROSCI, V8, P3541; LENNIE P, 1990, J NEUROSCI, V10, P649; LENNIE P, 1988, CRIT REV NEUROBIOL, V3, P333; LENNIE P, 1984, TRENDS NEUROSCI, V7, P243, DOI 10.1016/S0166-2236(84)80216-7; MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183; MALPELI JG, 1978, BRAIN RES, V141, P385, DOI 10.1016/0006-8993(78)90211-1; Martin PR, 1997, EUR J NEUROSCI, V9, P1536, DOI 10.1111/j.1460-9568.1997.tb01509.x; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; PUGH M, 1997, SOC NEUR ABSTR, V23, P603; RABIN J, 1994, VISION RES, V34, P2657, DOI 10.1016/0042-6989(94)90222-4; Reid RC, 1997, VISUAL NEUROSCI, V14, P1015, DOI 10.1017/S0952523800011743; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; STOCKMAN A, 1991, VISION RES, V31, P189, DOI 10.1016/0042-6989(91)90111-H; Tolhurst DJ, 1997, VISUAL NEUROSCI, V14, P293, DOI 10.1017/S0952523800011433	27	144	144	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					896	900		10.1038/27666	http://dx.doi.org/10.1038/27666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804422				2022-12-24	WOS:000076713400056
J	Ledent, C; Valverde, O; Cossu, C; Petitet, F; Aubert, LF; Beslot, F; Bohme, GA; Imperato, A; Pedrazzini, T; Roques, BP; Vassart, G; Fratta, W; Parmentier, M				Ledent, C; Valverde, O; Cossu, C; Petitet, F; Aubert, LF; Beslot, F; Bohme, GA; Imperato, A; Pedrazzini, T; Roques, BP; Vassart, G; Fratta, W; Parmentier, M			Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice	SCIENCE			English	Article							MORPHINE; ACTIVATION; WITHDRAWAL; LACKING; GENE	The function of the central cannabinoid receptor (CB1) was investigated by invalidating its gene. Mutant mice did not respond to cannabinoid drugs, demonstrating the exclusive role of the CB1 receptor in mediating analgesia, reinforcement, hypothermia, hypolocomotion, and hypotension, The acute effects of opiates were unaffected, but the reinforcing properties of morphine and the severity of the withdrawal syndrome were strongly reduced. These observations suggest that the CB1 receptor is involved in the motivational properties of opiates and in the development of physical dependence and extend the concept of an interconnected role of CB1 and opiate receptors in the brain areas mediating addictive behavior.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Univ Paris 05, Dept Pharmacochim Mol & Struct, CNRS,URA D1500, INSERM,U266, F-75270 Paris, France; Univ Cagliari, Bernard B Brodie Dept Neurosci, I-09124 Cagliari, Italy; Rhone Poulenc Rorer SA, Ctr Rech Vitry Alfortville, F-94403 Vitry, France; Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cagliari; Sanofi-Aventis; University of Lausanne; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium.	mparment@ulb.ac.be	Valverde, Olga/D-8654-2012	Valverde, Olga/0000-0003-2264-7852; Parmentier, Marc/0000-0001-8081-4685				Abood ME, 1996, INT REV NEUROBIOL, V39, P197, DOI 10.1016/S0074-7742(08)60667-4; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Hutcheson DM, 1998, BRIT J PHARMACOL, V125, P1567, DOI 10.1038/sj.bjp.0702228; KUSTER JE, 1993, J PHARMACOL EXP THER, V264, P1352; KUZMIN A, 1992, PHARMACOL BIOCHEM BE, V41, P497, DOI 10.1016/0091-3057(92)90363-K; LAHTI RA, 1982, LIFE SCI, V31, P2257, DOI 10.1016/0024-3205(82)90132-1; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; Martellotta MC, 1998, NEUROSCIENCE, V85, P327, DOI 10.1016/S0306-4522(98)00052-9; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; SMITH PB, 1994, J PHARMACOL EXP THER, V268, P1381; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; WAY EL, 1993, OPIOIDS, V2, P573; WELCH SP, 1992, J PHARMACOL EXP THER, V262, P10	24	1017	1044	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					401	404		10.1126/science.283.5400.401	http://dx.doi.org/10.1126/science.283.5400.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888857				2022-12-24	WOS:000078067000051
J	Beral, V; Hermon, C; Kay, C; Hannaford, P; Darby, SA; Reeves, G				Beral, V; Hermon, C; Kay, C; Hannaford, P; Darby, SA; Reeves, G			Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study	BRITISH MEDICAL JOURNAL			English	Article								Objective To describe the long term effects of the use of oral contraceptives on mortality Design Cohort study with 25 year follow up. Details of oral contraceptive use and of morbidity and mortality were reported six monthly by general practitioners. 75% of the original cohort was "flagged" on the NHS central registers. Setting 1400 general practices throughout Britain. Subjects 46 000 women, half of whom were using oral contraceptives at recruitment in 1968-9. Median age at end of follow up was 49 years. Main outcome measures Relative risks of death adjusted for age, parity, social class, and smoking. Results Over the 25 year follow up 1599 deaths were Research reported. Over the entire period of follow up the risk of death from all causes was similar in ever users and never users of oral contraceptives (relative risk = 1.0, 95% confidence interval 0.9 to 1.1; P = 0.7) and the risk of death for most specific causes did not differ significantly in the two groups, However, among current and recent (within 10 years) users the relative risk of death from ovarian cancer was 0.2 (0.1 to 0.8; P = 0.01), from cervical cancer 2.5 (1.1 to 6.1; P = 0.04), and from cerebrovascular disease 1.9 (1.2 to 3.1, P = 0.009). By contrast, for women who had stopped use greater than or equal to 10 years previously there were no significant excesses or deficits either overall or for any specific cause of death. Conclusion Oral contraceptives seem to have their main effect on mortality while they are being used and in the 10 years after use ceases. Ten or more years after use ceases mortality in past users is similar to that in never users.	Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England; Royal Coll Gen Practitioners, Manchester Res Unit, Manchester M22 4DB, Lancs, England	Radcliffe Infirmary; University of Oxford	Beral, V (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England.	beral@icrf.icnet.uk	Hannaford, Philip C/B-7867-2012					Beral V, 1996, EVIDENCE GUIDED PRES, P327; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; COLDITZ GA, 1994, ANN INTERN MED, V120, P821, DOI 10.7326/0003-4819-120-10-199405150-00002; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; OWENSMITH V, IN PRESS J EPIDEMIOL; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; PRESTON D. L., 1993, EPICURE USERS GUIDE; *ROYAL COLL GEN PR, 1974, OR CONTR HLTH; *ROYAL COLL GEN PR, 1983, J R COLL GEN PRACT, V33, P75; VESSEY M, 1976, Journal of Biosocial Science, V8, P373; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P1221; *WHO SCI GROUP, 1998, WHO TECH REP SER, V877; WINGRAVE SJ, 1981, J EPIDEMIOL COMMUN H, V35, P51, DOI 10.1136/jech.35.1.51; World Health Organization, 1967, INT CLASS DIS INJ CA	16	164	174	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					96	100		10.1136/bmj.318.7176.96	http://dx.doi.org/10.1136/bmj.318.7176.96			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880284	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000078087500027
J	Gao, YJ; Sun, Y; Frank, KM; Dikkes, P; Fujiwara, Y; Seidl, KJ; Sekiguchi, JM; Rathbun, GA; Swat, W; Wang, JY; Bronson, RT; Malynn, BA; Bryans, M; Zhu, CM; Chaudhuri, J; Davidson, L; Ferrini, R; Stamato, T; Orkin, SH; Greenberg, ME; Alt, FW				Gao, YJ; Sun, Y; Frank, KM; Dikkes, P; Fujiwara, Y; Seidl, KJ; Sekiguchi, JM; Rathbun, GA; Swat, W; Wang, JY; Bronson, RT; Malynn, BA; Bryans, M; Zhu, CM; Chaudhuri, J; Davidson, L; Ferrini, R; Stamato, T; Orkin, SH; Greenberg, ME; Alt, FW			A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis	CELL			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; LIGASE-IV; GENE RECOMBINATION; MAMMALIAN-CELLS; NERVOUS-SYSTEM; DEFICIENT MICE; IN-VIVO; BCL-X; REARRANGEMENT	XRCC4 was identified via a complementation cloning method that employed an ionizing radiation (IR)-sensitive hamster cell line. By gene-targeted mutation, we show that XRCC4 deficiency in primary murine cells causes growth defects, premature senescence, IR sensitivity, and inability to support V(D)J recombination. In mice, XRCC4 deficiency causes late embryonic lethality accompanied by defective lymphogenesis and defective neurogenesis manifested by extensive apoptotic death of newly generated postmitotic neuronal cells. We find similar neuronal developmental defects in embryos that lack DNA ligase IV, an XRCC4-associated protein. Our findings demonstrate that differentiating lymphocytes and neurons strictly require the XRCC4 and DNA ligase IV end-joining proteins and point to the general stage of neuronal development in which these proteins are necessary.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Dept Pediat, Boston, MA 02115 USA; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 812, Japan; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Lankenau Med Res Ctr, Wynnewood, PA 19096 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Kyushu University; Tufts University; Tufts University; Lankenau Medical Center; Lankenau Institute for Medical Research	Alt, FW (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Ctr Blood Res, Boston, MA 02115 USA.			Sekiguchi, JoAnn/0000-0002-7178-4258	NIAID NIH HHS [AI35714, AI01428, AI20047] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047, P01AI035714, K08AI001428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayer S.A., 1991, NEOCORTICAL DEV; Behrens TW, 1997, IMMUNOL RES, V16, P149, DOI 10.1007/BF02786359; Blaschke AJ, 1998, J COMP NEUROL, V396, P39, DOI 10.1002/(SICI)1096-9861(19980622)396:1<39::AID-CNE4>3.0.CO;2-J; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; CHANG Y, 1995, IMMUNITY, V2, P607, DOI 10.1016/1074-7613(95)90005-5; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; CHUN JJ, 1993, NEURONAL CELL DEATH, P283; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DATTA SR, 1998, HORMONES SIGNALING, V1, P94; Errami A, 1996, MOL CELL BIOL, V16, P1519; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NORNES HO, 1978, BRAIN RES, V159, P1, DOI 10.1016/0006-8993(78)90105-1; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shortman K, 1990, Semin Immunol, V2, P3; STAMATO T, 1993, RADIAT RES, V133, P60, DOI 10.2307/3578257; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tourigny MR, 1997, J EXP MED, V185, P1549, DOI 10.1084/jem.185.9.1549; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	46	554	565	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					891	902		10.1016/S0092-8674(00)81714-6	http://dx.doi.org/10.1016/S0092-8674(00)81714-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875844	Bronze			2022-12-24	WOS:000077759100005
J	Gale, C; Martyn, C				Gale, C; Martyn, C			Larks and owls and health, wealth, and wisdom	BRITISH MEDICAL JOURNAL			English	Article								Objective To test the validity of Benjamin Franklin's maxim "early to bed and early to rise makes a man healthy, wealthy, and wise." Design Cross sectional analysis of sleeping patterns in a nationally representative group of elderly people, and longitudinal investigation of mortality. Setting Eight areas in Britain (five in England, two in Scotland, and one in Wales). Subjects 1229 men and women aged 65 and over who in 1973-4 had taken part in a survey funded by the Department of Health and Social Security and for whom data on sleeping patterns, health, socioeconomic circumstances, and cognitive function had been recorded Main outcome measures Self reported income, access to a car, standard of accommodation, performance on a test of cognitive function, state of health and mortality during 23 years of follow up. Results 356 people (29%) were defined as larks (to bed before 11 pm and up before 8 am) and 318 (26%) were defined as owls (to bed at or after 11 pm and up at or after 8 am). There was no indication that larks were richer than those with other sleeping patterns. On the contrary, owls had the largest mean income and were more likely to have access to a car. There was also no evidence that larks were superior to those with other sleeping patterns with regard to their cognitive performance or their state of health. Both larks and owls had a slightly reduced risk of death compared with the rest of the study sample, but this was accounted for by the fact that they spent less time in bed at night. In the study sample as a whole, longer periods of time in bed were associated with increased mortality. After adjustment for age, sex, the presence of illness, and other risk factors, people who spent 12 or more hours in bed had a relative risk of death of 1.7 (1.2 to 2.5) compared with those who were in bed for 9 hours. The lowest risk occurred in people who spent 8 hours in bed (adjusted relative risk 0.8; 0.7 to 1.0). Conclusion These findings do not support Franklin's claim. A "late to bed and late to rise" lifestyle does not seem to lead to socioeconomic, cognitive, or health disadvantage, but a longer time spent in bed may be associated with increased mortality.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Martyn, C (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							BOSWELL J, 1934, LIFE JOHNSON, V5, P299; EDISON TA, 1948, PHILOS LIBR, V52, P178; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Minors D, 1998, AGE AGEING, V27, P67, DOI 10.1093/ageing/27.1.67; Qureshi AI, 1997, NEUROLOGY, V48, P904, DOI 10.1212/WNL.48.4.904; RUIGOMEZ A, 1995, AGE AGEING, V24, P113, DOI 10.1093/ageing/24.2.113; SMITH CS, 1989, J APPL PSYCHOL, V74, P728, DOI 10.1037/0021-9010.74.5.728; WINGARD DL, 1982, AM J EPIDEMIOL, V116, P765, DOI 10.1093/oxfordjournals.aje.a113466	8	59	60	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1675	1677		10.1136/bmj.317.7174.1675	http://dx.doi.org/10.1136/bmj.317.7174.1675			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857121	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000077742300007
J	Labauge, P; Laberge, S; Brunereau, L; Levy, C; Tournier-Lasserve, E				Labauge, P; Laberge, S; Brunereau, L; Levy, C; Tournier-Lasserve, E		Soc Francaise Neurochirurg	Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families	LANCET			English	Article							CHROMOSOME 7Q; NATURAL-HISTORY; MALFORMATIONS; LOCUS; INTERVAL; BRAIN; MAPS; CCM1	Background Cavernous angiomas, which are vascular malformations mostly located in the central nervous system, may be inherited as an autosomal dominant disorder known as familiar cerebral cavernoma (FCC). FCC has been studied in Hispanoamerican families, in which a strong founder effect was shown. We studied the families of 57 non-Hispanic patients with cavernous angiomas. Methods All 28 neurosurgery centres in France collaborated in the study. Inclusion criteria were: families of index patients known to have at least one clinically affected relative, and families of index patients with multiple cavernous angiomas who initially presented as sporadic cases. Clinical and cerebral magnetic resonance imaging (MRI) investigations were done in all patients and in other at-risk individuals who consented to take part. Findings On MRI, 16 of 22 sporadic index patients had relatives with cavernous angiomas. 51 multiple-case families, including 100 patients with symptoms and 164 symptom-free individuals had MRI lesions. Most FCC patients had multiple lesions and there was a strong correlation between number of lesions and age (p<0.01). The sensitivity of gradient-echo sequences was higher than that of standard MRI for detection of small cavernous angiomas. Pattern of inheritance was autosomal dominant, with incomplete clinical penetrance. The occurence of denovo mutations was strongly suggested in some families. Interpretation Neuroimaging penetrance of FCC is much higher than clinical penetrance. 75% of sporadic cases with multiple lesions are in fact familial cases. The proportion of patients developing clinical symptoms is higher in the hereditary form than in the sporadic form of the disorder.	Fac Med Necker Enfants Malad, INSERM, U25, F-75730 Paris, France; Hop Lariboisiere, F-75475 Paris, France; CHU Bretonneau, Serv Neuroradiol, F-37044 Tours, France; CHU St Antoine, Serv Radiol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Tournier-Lasserve, E (corresponding author), Fac Med Necker Enfants Malad, INSERM, U25, 156 Rue Vangirard, F-75730 Paris, France.	tournier@necker.fr	Tournier-Lasserve, Elisabeth/N-7134-2017; Laberge, Sophie/ABD-7353-2020	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Laberge, Sophie/0000-0003-4722-0361				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; GilNagel A, 1996, ANN NEUROL, V39, P807, DOI 10.1002/ana.410390619; Gunel M, 1996, NEW ENGL J MED, V334, P946, DOI 10.1056/NEJM199604113341503; GUNEL M, 1995, P NATL ACAD SCI USA, V92, P6620, DOI 10.1073/pnas.92.14.6620; Gunel M, 1996, NEUROSURGERY, V38, P1265; Headache Classification Committee of the International Headache Society, 1998, CEPHALALGIA S7, V8, P19; HSU FPK, 1993, CAVERNOUS MALFORMATI, P13; JOHNSON EW, 1995, GENOME RES, V5, P368, DOI 10.1101/gr.5.4.368; KATTAPONG VJ, 1995, NEUROLOGY, V45, P492, DOI 10.1212/WNL.45.3.492; KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820; LEJEUNE JP, 1989, NEUROCHIRURGIE, V35, P11; MALIK S, 1992, ARCH NEUROL-CHICAGO, V49, P170, DOI 10.1001/archneur.1992.00530260072023; MARCHUK DA, 1995, GENOMICS, V28, P311, DOI 10.1006/geno.1995.1147; Notelet L, 1997, J NEUROL NEUROSUR PS, V63, P40, DOI 10.1136/jnnp.63.1.40; OFTEN P, 1989, NEUROCHIRURGIE, V35, P82; Polymeropoulos MH, 1997, NEUROLOGY, V48, P752, DOI 10.1212/WNL.48.3.752; Pozzati E, 1996, NEUROSURGERY, V38, P662, DOI 10.1227/00006123-199604000-00006; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; ROBINSON JR, 1993, NEUROSURGERY, V32, P730, DOI 10.1227/00006123-199305000-00005; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; SIMARD JM, 1986, NEUROSURGERY, V18, P162; ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422	25	187	190	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1998	352	9144					1892	1897		10.1016/S0140-6736(98)03011-6	http://dx.doi.org/10.1016/S0140-6736(98)03011-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863787				2022-12-24	WOS:000077544600010
J	Henry, MD; Campbell, KP				Henry, MD; Campbell, KP			A role for dystroglycan in basement membrane assembly	CELL			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; EMBRYONIC STEM-CELLS; BETA-1 INTEGRIN; EPITHELIAL MORPHOGENESIS; NEUROMUSCULAR-JUNCTION; FIBRONECTIN MATRIX; AGRIN RECEPTOR; LAMININ; EXPRESSION; COLLAGEN	Basement membranes are composed of ordered arrays of characteristic extracellular matrix proteins, but little is known about the assembly of these structures in vivo. We have investigated the function of dystroglycan, a cell-surface laminin receptor expressed by cells contacting basement membranes in developing and adult tissues. We find that dystroglycan is required for the formation of a basement membrane in embryoid bodies. Our results further indicate that dystroglycan-laminin interactions are prerequisite for the deposition of other basement membrane proteins. Dystroglycan may exert its influence on basement membrane assembly by binding soluble laminin and organizing it on the cell surface. These data establish a role for dystroglycan in the assembly of basement membranes and suggest fundamental mechanisms underlying this process.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Neurol, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	Kevin-campbell@uiowa.edu		Campbell, Kevin/0000-0003-2066-5889; Henry, Michael/0000-0002-7871-245X	NHLBI NIH HHS [HL07121] Funding Source: Medline; NIDDK NIH HHS [DK09712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; DARRIBERE T, 1986, CELL TISSUE RES, V246, P45, DOI 10.1007/BF00218997; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; Durbeej M, 1996, MATRIX BIOL, V15, P397, DOI 10.1016/S0945-053X(96)90159-6; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; EKBLOM P, 1994, DEVELOPMENT, V120, P2003; EKBLOM P, 1996, LAMININS, P185; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Fleischmajer R, 1998, J CELL SCI, V111, P1929; FORM DM, 1986, LAB INVEST, V55, P521; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; Montanaro F, 1998, J NEUROSCI, V18, P1250; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Sasaki T, 1998, EXP CELL RES, V238, P70, DOI 10.1006/excr.1997.3837; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; THOMAS T, 1993, EXP CELL RES, V208, P54, DOI 10.1006/excr.1993.1222; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VRACKO R, 1974, AM J PATHOL, V77, P314; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; Yurchenco PD., 1994, EXTRACELLULAR MATRIX, P351; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	54	324	330	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					859	870		10.1016/S0092-8674(00)81708-0	http://dx.doi.org/10.1016/S0092-8674(00)81708-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865703	Bronze			2022-12-24	WOS:000077498800015
J	Waxman, R; Tennant, A; Helliwell, P				Waxman, R; Tennant, A; Helliwell, P			Community survey of factors associated with consultation for low back pain	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; MODEL; DEPRESSION; PREVALENCE; DISABILITY; SEEKING; BELIEFS	Objective To investigate the psychosocial factors associated with consultation for low back pain. Design Two phase cross sectional postal survey. Setting Bradford Metropolitan Health District. Subjects 1813 adults responding to the phase 1 questionnaire. 540 of the 782 with an episode of low back pain in the past 12 months completed the second questionnaire. Main outcome measures Six psychosocial constructs. Results 406 (52%) of the respondents reporting back pain in the past 12 months had not consulted a health professional. Logistic regression showed that consultation was associated with externalised beliefs regarding pain management (odds ratio 3.6; 95% confidence interval 2.1 to 6.0). Duration of pain affected the factors associated with consultation Consultation for episodes lasting less than two weeks (n = 290) was associated with greater than median pain (3.0; 1.7 to 5.5), consultation for episodes over two weeks (n = 243) was associated with increased disability (3.7; 1.5 to 9.0), and consultation for episodes over three months (n = 143) with increased depression (3.9; 1.3 to 11.8). Conclusions The results support a role for psychosocial factors in consultation for low back pain and suggest that the reasons for consultation vary with duration of pain. Duration of the episode may be a useful guide to management of non-specific low back pain.	Univ Leeds, Res Sch Med, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Waxman, R (corresponding author), Univ Leeds, Res Sch Med, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England.							ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; Balint M., 1986, DOCTOR HIS PATIENT I; CAREY TS, 1995, SPINE, V20, P312, DOI 10.1097/00007632-199502000-00009; Carey TS, 1996, SPINE, V21, P339, DOI 10.1097/00007632-199602010-00018; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DODD T, 1997, PREVALENCE BACK PAIN; Hillman M, 1996, J EPIDEMIOL COMMUN H, V50, P347, DOI 10.1136/jech.50.3.347; Horal J, 1969, Acta Orthop Scand Suppl, V118, P1; MAIN CJ, 1991, PAIN, V46, P287, DOI 10.1016/0304-3959(91)90112-B; MAIN CJ, 1983, J PSYCHOSOM RES, V27, P503, DOI 10.1016/0022-3999(83)90040-5; Main CJ, 1984, CURR CONCEPTS PAIN, V2, P10; REKOLA KE, 1993, J EPIDEMIOL COMMUN H, V47, P153, DOI 10.1136/jech.47.2.153; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; RUDY TE, 1988, PAIN, V35, P129, DOI 10.1016/0304-3959(88)90220-5; SCHEMPER M, 1997, CONTROL CLIN TRIALS, V18, pS61; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; SZPALSKI M, 1995, SPINE, V20, P431, DOI 10.1097/00007632-199502001-00005; *U YORK NHS CTR RE, 1993, EFFECTIVE HLTH CARE, V5, P1; VONKORFF M, 1996, BRIT J PSYCHIAT, V168, pS101; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WRIGHT D, 1995, BRIT J RHEUMATOL, V34, P156; Zimmermann C, 1996, J PSYCHOSOM RES, V40, P351, DOI 10.1016/0022-3999(95)00536-6	26	58	58	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1564	1567		10.1136/bmj.317.7172.1564	http://dx.doi.org/10.1136/bmj.317.7172.1564			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146VC	9836660	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000077451700027
J	French, AL; Welbel, SF; Dietrich, SE; Mosher, LB; Breall, PS; Paul, WS; Kocka, FE; Weinstein, RA				French, AL; Welbel, SF; Dietrich, SE; Mosher, LB; Breall, PS; Paul, WS; Kocka, FE; Weinstein, RA			Use of DNA fingerprinting to assess tuberculosis infection control	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIDRUG-RESISTANT TUBERCULOSIS; CDC TB SURVEY; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; MEMBER HOSPITALS; CONTROL PROGRAMS; EPIDEMIOLOGY; OUTBREAK; POPULATION; CULTURES	Background: DNA fingerprinting establishes the genetic relatedness of Mycobacterium tuberculosis isolates and has become a powerful tool in tuberculosis epidemiology. Objective: To use DNA fingerprinting to assess the efficacy of current tuberculosis infection-control practices. Design: Retrospective molecular and descriptive epidemiologic study. Setting: A 700-bed urban public hospital that follows the Centers for Disease Control and Prevention (CDC) guidelines for tuberculosis infection control. Patients: 183 patients who had positive cultures for M. tuberculosis from 1 April 1995 to 31 March 1996. Results: 173 of 183 M. tuberculosis isolates from the study period underwent DNA fingerprinting. Fingerprinting revealed that five isolates represented false-positive cultures and that 91 (54%) of the remaining 168 isolates were in 15 DNA fingerprinting clusters, which ranged in size from 2 to 29 isolates. Risk factors for clustering were birth in the United States, African-American ethnicity, homelessness, substance abuse, and male sex. Retrospective epidemiologic analysis of inpatient and outpatient visits by the 91 patients who had clustered isolates revealed only one possible instance of patient-to-patient transmission. Conclusions: The DNA fingerprinting of all M. tuberculosis isolates from a 1-year period revealed one possible instance of nosocomial transmission and five false-positive M. tuberculosis cultures. However, these results did not lead to changes in infection-control practices or in clinical care. The study findings do not support the use of DNA fingerprinting for nosocomial tuberculosis surveillance, but they suggest that compliance with the CDC tuberculosis infection-control guidelines may control patient-to-patient transmission in high-risk urban hospitals.	Cook Cty Hosp, Div Infect Dis, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA; Chicago Dept Publ Hlth, Chicago, IL 60612 USA; Michigan Dept Community Hlth, Div Lab Serv, Lansing, MI 48909 USA	John H Stroger Junior Hospital Cook County; Rush University; Chicago Department of Public Health; MDHHS - Michigan Department of Health & Human Services	French, AL (corresponding author), Cook Cty Hosp, Div Infect Dis, Durand 115,1835 W Harrison St, Chicago, IL 60612 USA.			French, Audrey/0000-0002-9776-8934				ABRUTYN E, 1998, SHEAS RESPONSE OSHA; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1997, FED REG, V62, P54160; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; Braden CR, 1997, CLIN INFECT DIS, V24, P35, DOI 10.1093/clinids/24.1.35; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P321, DOI 10.1164/ajrccm.155.1.9001331; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WELBEL SF, 1996, 34 ANN M INF DIS SOC; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; 1994, MMWR MORB MORTAL WKL, V44	24	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					856	861		10.7326/0003-4819-129-11_Part_1-199812010-00003	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867726				2022-12-24	WOS:000077239200002
J	Zhao, KJ; Wang, WD; Rando, OJ; Xue, YT; Swiderek, K; Kuo, A; Crabtree, GR				Zhao, KJ; Wang, WD; Rando, OJ; Xue, YT; Swiderek, K; Kuo, A; Crabtree, GR			Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling	CELL			English	Article							REMODELING FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; NUCLEAR MATRIX; HUMAN HOMOLOG; ACTIN; YEAST	Lymphocyte activation is accompanied by visible changes in chromatin structure. We find that antigen receptor signaling induces the rapid association of the BAF complex with chromatin. PIP2, which is regulated by activation stimuli, is sufficient in vitro to target the BAF complex to chromatin, but it has no effect on related chromatin remodeling complexes containing SNF2L or hISWI. Purification and peptide sequencing of the subunits of the complex revealed beta-actin as well as a novel actin-related protein, BAF53. beta-actin and BAF53 are required for maximal ATPase activity of BRG1 and are also required with BRG1 fair association of the complex with chromatin/matrix. This work indicates that membrane signals control the activity of the mammalian SWI/SNF or BAF complex and demonstrates a direct interface between signaling and chromatin regulation.	Stanford Univ, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	Howard Hughes Medical Institute; Stanford University; City of Hope; Beckman Research Institute of City of Hope	Crabtree, GR (corresponding author), Stanford Univ, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Rando, Oliver/0000-0003-1516-9397				BILLI AM, 1993, BIOCHEM BIOPH RES CO, V195, P8, DOI 10.1006/bbrc.1993.2001; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; CRABTREE GR, 1989, SCIENCE, V243, P255; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MAZZOTTI G, 1995, J HISTOCHEM CYTOCHEM, V43, P181, DOI 10.1177/43.2.7822774; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	40	607	630	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					625	636		10.1016/S0092-8674(00)81633-5	http://dx.doi.org/10.1016/S0092-8674(00)81633-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845365	Bronze			2022-12-24	WOS:000077253700010
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Treating with HIV	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998	2	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1438	1438						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867652				2022-12-24	WOS:000077110800033
J	Branson, BM				Branson, BM			Home sample collection tests for HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Home sample collection (HSC) tests allow persons to test themselves for human immunodeficiency virus (HIV) infection at home without medical supervision. Characterizing the use of such tests can help assess their potential effect on public health efforts to prevent and control HIV. Objective.-To describe use of HIV HSC tests. Design.-Retrospective descriptive analysis from data collected by test manufacturers during 1996 and 1997. Setting.-United States. Participants.-Volunteer sample of consumers who used either of 2 HSC tests. Main Outcome Measures.-Demographic and behavioral aspects of users. Results.-During the first year of availability, 174316 HIV HSC tests were submitted to the manufacturers for analysis; 0.9% of the results were positive for HIV, and 97% of all users called to learn test results. Survey responses from 70 620 HIV-negative and 865 HIV-positive users revealed that most were men, white, and aged 25 to 34 years; HIV prevalence was highest among nonwhites, aged 35 to 44 years, men who have sex with men, and injection drug users. Bisexual men accounted for a large proportion of HIV-positive users. Nearly 60% of all users and 49% of those who tested HIV positive had never been tested before. Telephone counselors found that 23% of HIV-positive users already had a source of follow-up care, 65% accepted referrals, and 12% had tested themselves to evaluate the effects of antiretroviral therapy. Conclusions.-Home sample collection tests for HIV were used by persons who were at risk for HIV and by persons who did not use other testing. Most HIV-positive users either had a source of medical care or received referrals.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Branson, BM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Mailstop E-06, Atlanta, GA 30333 USA.							BAYER R, 1995, NEW ENGL J MED, V332, P1296, DOI 10.1056/NEJM199505113321911; *CDCP, 1997, HIV COUNS TEST PUBL; COLFAX GJ, 1997, SOC GEN INT MED 20 A; HOXIE NJ, 1992, AM J PUBLIC HEALTH, V82, P1370, DOI 10.2105/AJPH.82.10.1370; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Kassler WJ, 1997, AIDS EDUC PREV, V9, P27; MALOR CJ, 1991, J INFECT DIS, V163, P699; SCHOPPER D, 1996, AIDS, V10, P1255; SCHULTZ WB, 1996, ADVISORY OPINION	9	49	51	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1699	1701		10.1001/jama.280.19.1699	http://dx.doi.org/10.1001/jama.280.19.1699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138PD	9832003				2022-12-24	WOS:000076980700037
J	Ezzo, J; Berman, BM; Vickers, AJ; Linde, K				Ezzo, J; Berman, BM; Vickers, AJ; Linde, K			Complementary medicine and the Cochrane Collaboration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYSTEMATIC REVIEWS; CONTROLLED TRIALS; CEREBRAL INSUFFICIENCY; ALTERNATIVE MEDICINE; GINKGO-BILOBA; METAANALYSES; PREVALENCE; ENGLISH; QUALITY; BIAS		Univ Maryland, Sch Med, Complementary Med Program, Baltimore, MD 21207 USA; Res Council Complementary Med, London, England; Tech Univ, Ctr Complementary Med Res, Munich, Germany	University System of Maryland; University of Maryland Baltimore; Technical University of Munich	Ezzo, J (corresponding author), Univ Maryland, Sch Med, Complementary Med Program, Kernan Hosp Mans,2200 Kernan Dr, Baltimore, MD 21207 USA.	jezzo@compmed.ummc.ab.umd.edu		Linde, Klaus/0000-0002-2902-970X				BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; *COMPL MED FIELD M, 1998, COCHR LIBR; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Dickersin K, 1998, CLIN OBSTET GYNECOL, V41, P315, DOI 10.1097/00003081-199806000-00012; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1997, SYSTEMATATIC REV, P17; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FISHBAIN DA, 1995, NIH TECHN ASS INT BE; FULDER SJ, 1985, LANCET, V2, P542; HOFMANS EA, 1990, LANCET, V336, P57, DOI 10.1016/0140-6736(90)91574-T; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; Kiley R, 1997, J ROY SOC MED, V90, P610, DOI 10.1177/014107689709001105; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KNIPSCHILD P, 1993, LANCET, V341, P1135, DOI 10.1016/0140-6736(93)93140-V; LEHMANN HP, 1995, MED DECIS MAKING, V15, P424; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; WOOTTON JC, 1997, J ALTERN COMPLEM MED, V2, P261; 1998, COCHRANE LIBR	30	34	35	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1628	1630		10.1001/jama.280.18.1628	http://dx.doi.org/10.1001/jama.280.18.1628			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820271				2022-12-24	WOS:000076852000037
J	Argiles, A; Mourad, G; Mion, C				Argiles, A; Mourad, G; Mion, C			Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GEOGRAPHIC VARIATIONS; ENVIRONMENTAL-TEMPERATURE; HYPERTENSION; MORTALITY; SURVIVAL	Background Many factors contribute to the regulation of blood pressure. The role of climate has received relatively little attention. Methods During a four-year period, we determined the influence of climate on blood pressure in 53 patients with end-stage renal disease treated with hemodialysis. For each patient, blood pressure was measured before each of three dialysis treatments per week for an average of 31 months. The dose of dialysis (urea clearance multiplied by the length of dialysis and divided by the distribution volume of urea) and protein catabolism rate were assessed monthly. We then analyzed the monthly mean values for blood pressure, pulse, and body weight in relation to the monthly values for temperature, relative humidity, and atmospheric pressure recorded in Montpellier, France. Results The maximal monthly temperature varied from 10 degrees C in the winter to 31 degrees C in the summer, and the minimal monthly temperature from 1 to 20 degrees C. The mean (+/-SE) systolic and diastolic blood pressure was highest during the winter (153 +/- 3/82 +/- 2 mm Hg) and lowest during the summer (141 +/- 3/75 +/- 2 mm Hg). The seasonal pattern was evident throughout the four-year period. Blood pressure was correlated inversely with monthly maximal temperature (r = -0.65 and P < 0.001 for systolic pressure; r = -0.71 and P < 0.001 for diastolic pressure) and directly with minimal humidity (r = 0.45 and P = 0.002 for systolic pressure; r = 0.43 and P = 0.003 for diastolic pres sure). Changes in protein catabolic rate, weight gain between dialysis sessions, and dialysis dose were not related to changes in blood pressure. Conclusions In patients with end-stage renal disease treated with hemodialysis, blood pressure varies seasonally, with higher values in the winter and lower values in the summer. (C) 1998, Massachusetts Medical Society.	Installat Domicile Epurat Renales, 746 Rue Croix Lavit, F-34192 Montpellier 5, France; Univ Hosp Lapeyronie, Dept Nephrol, Montpellier, France; Inst Genet Humaine, Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier	Argiles, A (corresponding author), Installat Domicile Epurat Renales, 746 Rue Croix Lavit, F-34192 Montpellier 5, France.			Argiles, Angel/0000-0001-7029-4532				BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; BRUCE N, 1991, J HYPERTENS, V9, P851, DOI 10.1097/00004872-199109000-00013; CHARRA B, 1983, NEPHRON, V33, P96, DOI 10.1159/000182920; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; CHESTER AC, 1978, T AM SOC ART INT ORG, V24, P36; Cocchi A, 1984, Contrib Nephrol, V41, P288; de Swiet M, 1984, J Hypertens, V2, P501; Degoulet P, 1980, Proc Eur Dial Transplant Assoc, V17, P149; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; European Dialysis and Transplantation Association, 1992, NEPHROL DIAL TRANSPL, V7, pS20; HUTING J, 1988, NEPHRON, V49, P284, DOI 10.1159/000185077; JENNER DA, 1987, J HYPERTENS, V5, P683; KERR PB, 1992, KIDNEY INT, V41, P1035, DOI 10.1038/ki.1992.157; Kiefe CI, 1997, CIRCULATION, V96, P1082, DOI 10.1161/01.CIR.96.4.1082; Kotchen TA, 1997, CIRCULATION, V96, P1071, DOI 10.1161/01.CIR.96.4.1071; LAZARUS JM, 1975, KIDNEY INT, V7, pS167; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; Luik AJ, 1997, NEPHROL DIAL TRANSPL, V12, P1557; MA KW, 1992, AM J KIDNEY DIS, V19, P505, DOI 10.1016/S0272-6386(12)80827-4; POCOCK SJ, 1980, BRIT MED J, V280, P1243, DOI 10.1136/bmj.280.6226.1243; PRINEAS RJ, 1980, HYPERTENSION, V2, pI18, DOI 10.1161/01.HYP.2.4_Pt_2.I18; Scribner BH, 1997, SEMIN DIALYSIS, V10, P250, DOI 10.1111/j.1525-139X.1997.tb00505.x; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; *USRDS, 1996, AM J KIDNEY DIS S, V28, pS93; VINCENTI F, 1980, AM J MED, V68, P363, DOI 10.1016/0002-9343(80)90104-7	25	113	117	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1364	1370		10.1056/NEJM199811053391904	http://dx.doi.org/10.1056/NEJM199811053391904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801397	Bronze			2022-12-24	WOS:000076780200004
J	Pearce, JM; Roberts, ADL; Good, M				Pearce, JM; Roberts, ADL; Good, M			Hippocampal lesions disrupt navigation based on cognitive maps but not heading vectors	NATURE			English	Article								Animals can find a hidden goal in several ways. They might use a cognitive map that encodes information about the geometric relationship between the goal and two or more landmarks(1), Alternatively, they might use a heading vector that specifies the direction and distance of the goal from a single landmark(2). Rats with damage to the hippocampus have difficulty in finding a hidden goal(3). Here we determine which of the above strategies is affected by such damage. Rats were required to swim in a water maze to a submerged platform, which was always at the same distance and direction from a landmark The platform and landmark remained in the same place for the four trials of each session, but they were moved to a new position at the start of a session(4). Rats with damage to the hippocampus found the platform more efficiently than did normal rats in the first trial of a session but, in contrast to normal rats, their performance did not improve during a session. Our results indicate that hippocampally damaged rats are able to navigate by means of heading vectors but not cognitive maps.	Cardiff Univ, Sch Psychol, Cardiff CF1 3YG, S Glam, Wales	Cardiff University	Pearce, JM (corresponding author), Cardiff Univ, Sch Psychol, Cardiff CF1 3YG, S Glam, Wales.		Pearce, John/A-1783-2010	Roberts, Amanda/0000-0002-2889-9551				COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; GALISTEL CR, 1990, ORG LEARNING; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Rescorla RA, 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Roberts ADL, 1998, J EXP PSYCHOL ANIM B, V24, P172, DOI 10.1037/0097-7403.24.2.172	8	187	191	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					75	77		10.1038/23941	http://dx.doi.org/10.1038/23941			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	136HE	9817202				2022-12-24	WOS:000076852700056
J	Cobey, JC				Cobey, JC			Monitoring of the landmine treaty	LANCET			English	Editorial Material									Surg Off, Washington, DC 20006 USA		Cobey, JC (corresponding author), Surg Off, 2029 K St NW, Washington, DC 20006 USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1468	1468		10.1016/S0140-6736(05)61291-3	http://dx.doi.org/10.1016/S0140-6736(05)61291-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9808011				2022-12-24	WOS:000076719500045
J	Marrion, NV; Tavalin, SJ				Marrion, NV; Tavalin, SJ			Selective activation of Ca2+-activated K+ channels by co-localized Ca2+ channels in hippocampal neurons	NATURE			English	Article							CALCIUM-CHANNEL; PYRAMIDAL NEURONS; POTASSIUM CHANNELS; AFTERHYPERPOLARIZATION; DIFFUSION; BRAIN	Calcium entry through voltage-gated calcium channels can activate either large- (BK) or small- (SK) conductance calcium-activated potassium channels. In hippocampal neurons, activation of BK channels underlies the falling phase of an action potential and generation of the fast afterhyperpolarization (AHP)(1,2). In contrast, SK channel activation underlies generation of the slow AHP after a burst of action potentials(3). The source of calcium for BK channel activation is unknown, but the slow AHP is blocked by dihydropyridine antagonists(4,5), indicating that L-type calcium channels provide the calcium for activation of SK channels. It is not understood how this specialized coupling between calcium and potassium channels is achieved, Here we study channel activity in cell-attached patches from hippocampal neurons and report a unique specificity of coupling. L-type channels activate SK channels only, without activating BK channels present in the same patch. The delay between the opening of L-type channels and SK channels indicates that these channels are 50-150 nm apart. In contrast, N-type calcium channels activate BK channels only, with opening of the two channel types being nearly coincident. This temporal association indicates that N and BK channels are very close. Finally, P/Q-type calcium channels do not couple to either SK or BK channels. These data indicate an absolute segregation of coupling between channels, and illustrate the functional importance of submembrane calcium microdomains.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	Oregon Health & Science University; University of Bristol	Marrion, NV (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	N.V.Marrion@bris.ac.uk			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010202] Funding Source: NIH RePORTER; NINDS NIH HHS [F32 NS010202] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; Cloues RK, 1997, J NEUROSCI, V17, P6493; Davies PJ, 1996, J PHYSIOL-LONDON, V495, P353, DOI 10.1113/jphysiol.1996.sp021599; ELLIOTT EM, 1995, J NEUROSCI, V15, P6433; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; HORN R, 1983, BIOPHYS J, V43, P207, DOI 10.1016/S0006-3495(83)84341-0; IMREDY JP, 1992, NEURON, V9, P197, DOI 10.1016/0896-6273(92)90159-B; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LANCASTER B, 1991, J NEUROSCI, V11, P23; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; McDonough SI, 1996, J NEUROSCI, V16, P2612; MILLS LR, 1994, J NEUROSCI, V14, P6815; MOYER JR, 1992, J NEUROPHYSIOL, V68, P2100, DOI 10.1152/jn.1992.68.6.2100; Naraghi M, 1997, J NEUROSCI, V17, P6961; Pineda JC, 1998, J NEUROPHYSIOL, V79, P2522, DOI 10.1152/jn.1998.79.5.2522; RASCOL O, 1991, FUNDAM CLIN PHARM, V5, P299, DOI 10.1111/j.1472-8206.1991.tb00725.x; SAH P, 1995, NEURON, V15, P435, DOI 10.1016/0896-6273(95)90047-0; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; Valiante TA, 1997, J PHYSIOL-LONDON, V499, P121, DOI 10.1113/jphysiol.1997.sp021915; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745; Zhang L, 1995, J NEUROPHYSIOL, V74, P2225, DOI 10.1152/jn.1995.74.6.2225	26	454	462	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					900	905		10.1038/27674	http://dx.doi.org/10.1038/27674			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804423				2022-12-24	WOS:000076713400057
J	Moss, PJ; Beeching, NJ				Moss, PJ; Beeching, NJ			Provision of health advice for UK medical students planning to travel overseas for their elective study period: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Beeching, NJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.		Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				ELLIS CJ, 1993, BRIT MED J, V307, P1008, DOI 10.1136/bmj.307.6910.1008-c; *EXP ADV GROUP AID, 1997, GUID POST PROPH HLTH; Gilks CF, 1998, BRIT MED J, V316, P1158, DOI 10.1136/bmj.316.7138.1158; *UNAIDS, 1998, REP GLOB HIV AIDS EP, P63	4	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					161	162		10.1136/bmj.318.7177.161	http://dx.doi.org/10.1136/bmj.318.7177.161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888909	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000078175100026
J	Westendorp, RGJ; Kirkwood, TBL				Westendorp, RGJ; Kirkwood, TBL			Human longevity at the cost of reproductive success	NATURE			English	Article							DROSOPHILA-MELANOGASTER; SENESCENCE; EVOLUTION	The disposable soma theory on the evolution of ageing states that longevity requires investments in somatic maintenance that reduce the resources available for reproduction(1,2), Experiments in Drosophila melanogaster indicate that trade-offs of this kind exist in non-human species(3-7). We have determined the interrelationship between longevity and reproductive success in Homo sapiens using a historical data set from the British aristocracy. The number of progeny was small when women died at an early age, increased with the age of death, reaching a plateau through the sixth, seventh and eighth decades of life, but decreased again in women who died at an age of 80 years or over. Age at first childbirth was lowest in women who died early and highest for women who died at the oldest ages. When account was taken only of women who had reached menopause, who were aged 60 years and over, female longevity was negatively correlated with number of progeny and positively correlated with age at first childbirth. The findings show that human life histories involve a trade-off between longevity and reproduction.	Leiden Univ, Med Ctr CO P, Dept Gen Internal Med & Clin Epidemiol, Sect Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Dept Geriatr Med, Biol Gerontol Grp, Manchester M13 9PT, Lancs, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Manchester; University of Manchester	Westendorp, RGJ (corresponding author), Leiden Univ, Med Ctr CO P, Dept Gen Internal Med & Clin Epidemiol, Sect Gerontol & Geriatr, POB 9600, NL-2300 RC Leiden, Netherlands.	RudiWestendorp@compuserv.ecom						CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Finch CE, 1990, LONGEVITY SENESCENCE; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; Gavrilova NS, 1998, HUM BIOL, V70, P799; GIBBS V, 1910, COMPLETE PEERAGE ENG; GIBBS V, 1910, COMPLETE PEERAGE BAR; HOLLINGWOOD TH, 1977, POPULATION S, V18, P323; Khoury M, 1993, FUNDAMENTALS GENETIC; KIDD C, 1994, DEBRETTS PEERAGE BAR; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; Medawar P., 1952, UNSOLVED PROBLEM BIO; MONCREIFFE I, 1982, ROYAL HIGHNESS ANCES; MORBY JE, 1994, WORDSWORTH HDB KINGS; PAGET G, 1977, LINEAGE ANCESTRY HRH; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; Perls TT, 1997, NATURE, V389, P133, DOI 10.1038/38148; Prowse N, 1997, J INSECT PHYSIOL, V43, P501, DOI 10.1016/S0022-1910(97)00014-0; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; TOWNSEND P, 1963, BURKES GENEALOGICAL; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI 10.1111/j.1558-5646.1995.tb02301.x; 1996, WHITTAKERS ALMANACK	25	359	363	3	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 31	1998	396	6713					743	746		10.1038/25519	http://dx.doi.org/10.1038/25519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874369				2022-12-24	WOS:000077742800030
J	Anderson, DG; Kowalczykowski, SC				Anderson, DG; Kowalczykowski, SC			Reconstitution of an SOS response pathway: Derepression of transcription in response to DNA breaks	CELL			English	Article							COLI RECA PROTEIN; HOT-SPOT-CHI; ESCHERICHIA-COLI; RECBCD ENZYME; PAIRING SEQUENCES; LEXA REPRESSOR; RECOMBINATION; MECHANISM; INDUCTION; CLEAVAGE	E. coli responds to DNA damage by derepressing the transcription of about 20 genes that make up the SOS pathway. Genetic analyses have shown that SOS induction in response to double-stranded DNA (dsDNA) breaks requires LexA repressor, and the RecA and RecBCD enzymes - proteins best known for their role as initiators of dsDNA break repair and homologous recombination. Here we demonstrate that purified RecA protein, RecBCD enzyme, single-stranded DNA-binding (SSB) protein, and LexA repressor respond to dsDNA breaks in vitro by derepressing transcription from an SOS promoter. Interestingly, derepression is more rapid if the DNA containing the dsDNA break has a chi recombination hot spot (5'-GCTGGTGG-3'), suggesting a novel regulatory role for one of the most overrepresented octamers in the E. coli genome.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.				NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; Eggleston AK, 1997, CURR BIOL, V7, pR745, DOI 10.1016/S0960-9822(06)00394-0; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890; Tracy RB, 1997, CELL, V90, P205, DOI 10.1016/S0092-8674(00)80328-1; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4	25	43	43	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1998	95	7					975	979		10.1016/S0092-8674(00)81721-3	http://dx.doi.org/10.1016/S0092-8674(00)81721-3			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875851	Bronze			2022-12-24	WOS:000077759100012
J	Low, L; King, S; Wilkie, T				Low, L; King, S; Wilkie, T			Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article								Objectives To gather empirical evidence on any discrimination based on genetic information shown by the insurance industry in the United Kingdom and to assess how society is likely to handle future genetic information from tests for polygenic multifactorial conditions. Design Postal questionnaire survey Subjects Sample (n = 7000) of members from seven British support groups for families with genetic disorders and a representative sample (n = 1033) of the general public who answered questions on applying for life insurance as part of an omnibus survey Main outcome measures Subjects were asked about their experiences with insurers, the medical profession, employers, and social services. Experiences with insurers are reported here. Results Altogether 33.4% of the study group had problems when applying for life insurance compared with 5% of applicants in the omnibus survey Thirteen per cent of Study respondents from subgroups who represented no adverse actuarial risk on genetic grounds reported that their treatment by insurers seemed to represent unjustified genetic discrimination. Conclusions Life insurers may not be operating a consistent policy for assessing genetic information or acting in accord with the actuarial risks brought to them. The inconsistency suggests error rather than a corporate policy of discrimination based on genetic characteristics. Any future proposals for genetic testing for common or multifactorial disorders should be examined carefully.	Wellcome Trust, Unit Policy Res Sci & Med, London NW1 2BE, England	University of London; University College London	Wilkie, T (corresponding author), Wellcome Trust, Unit Policy Res Sci & Med, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ASS BRIT INS, 1997, GEN TEST ABI COD PRA; *ASS BRIT INS, 1997, INS FACTS FIG TRENDS; *ASS BRIT INS, 1997, LIF INS GEN POL STAT; BERDIE D, 1989, MARKETING RES    SEP, P52; *DEP EMPL, 1996, DIS DISCR SERV PREM; *EC INT UN, 1997, HEALTHC INT 2 QUART; Geller Lisa N, 1996, Sci Eng Ethics, V2, P71, DOI 10.1007/BF02639319; GOYDER J, 1985, SOCIOLOGY, V19, P55, DOI 10.1177/0038038585019001006; *HOUS COMM SCI TEC, 1995, HC41 SCI TECHN COMM; *HUM GEN ADV COMM, 1997, IMPL GEN TEST INS; Leslie L.L., 1972, SOC SCI RES, V1, P323, DOI [DOI 10.1016/0049-089X(72)90080-4, 10.1016/0049-089X(72)90080-4]; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MCEWEN JE, 1993, AM J HUM GENET, V53, P33; SHAPIRO D, 1997, FINANCIAL TIMES 0321, P16; Wilkie T, 1998, NAT GENET, V20, P119, DOI 10.1038/2416; WYNBRANDT J, 1991, ENCY GENETIC DISORDE	16	77	77	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1632	1635		10.1136/bmj.317.7173.1632	http://dx.doi.org/10.1136/bmj.317.7173.1632			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	149JW	9848905	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000077602100028
J	Xong, HV; Vanhamme, L; Chamekh, M; Chimfwembe, CE; Van Den Abbeele, J; Pays, A; Van Meirvenne, N; Hamers, R; De Baetselier, P; Pays, E				Xong, HV; Vanhamme, L; Chamekh, M; Chimfwembe, CE; Van Den Abbeele, J; Pays, A; Van Meirvenne, N; Hamers, R; De Baetselier, P; Pays, E			A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense	CELL			English	Article							SURFACE GLYCOPROTEIN GENES; AFRICAN TRYPANOSOMES; BRUCEI-RHODESIENSE; ANTIGEN GENE; T-BRUCEI; TRANSCRIPTION; DISRUPTION; PROTEIN; FAMILY; CLONES	Infectivity of Trypanosoma brucei rhodesiense to humans is due to its resistance to a lytic factor present in human serum. In the ETat 1 strain this character was associated with antigenic variation, since expression of the ETat 1.10 variant surface glycoprotein was required to generate resistant (R) clones. In addition, in this strain transcription of a gene termed SRA was detected in R clones only. We show that the ETat 1.10 expression site is the one selectively transcribed in R variants. This expression site contains SRA as an expression site-associated gene (ESAG) and is characterized by the deletion of several ESAGs. Transfection of SRA into T.b. brucei was sufficient to confer resistance to human serum, identifying this gene as one of those responsible for T.b. rhodesiense adaptation to humans.	Free Univ Brussels, Mol Parasitol Lab, B-1640 Rhode St Genese, Belgium; Free Univ Brussels VIB, Cellular Immunol Lab, B-1640 Rhode St Genese, Belgium; Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Institute of Tropical Medicine (ITM)	Pays, E (corresponding author), Free Univ Brussels, Mol Parasitol Lab, 67 Rue Chevaux, B-1640 Rhode St Genese, Belgium.	epays@dbm.uib.ac.be	De Baetselier, Patrick/D-3866-2014	Van Den Abbeele, Jan/0000-0002-4533-4480				BERNARDS A, 1985, MOL CELL BIOL, V5, P545, DOI 10.1128/MCB.5.3.545; Borst P, 1998, MOL BIOCHEM PARASIT, V91, P67, DOI 10.1016/S0166-6851(97)00184-9; Carruthers VB, 1996, MOL BIOCHEM PARASIT, V81, P65, DOI 10.1016/0166-6851(96)02672-2; CROSS GAM, 1978, PROC R SOC SER B-BIO, V202, P55, DOI 10.1098/rspb.1978.0057; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; DOTHI CD, 1991, MOL BIOCHEM PARASIT, V48, P199; Hager KM, 1997, NATURE, V385, P823, DOI 10.1038/385823a0; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MURPHY NB, 1987, J MOL BIOL, V195, P855, DOI 10.1016/0022-2836(87)90490-6; Navarro M, 1996, MOL CELL BIOL, V16, P3615; PAYS E, 1983, NUCLEIC ACIDS RES, V11, P8137, DOI 10.1093/nar/11.23.8137; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PAYS E, 1981, NATURE, V292, P265, DOI 10.1038/292265a0; RIFKIN MR, 1994, MOL BIOCHEM PARASIT, V66, P211, DOI 10.1016/0166-6851(94)90148-1; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Tomlinson S, 1998, PARASITOL TODAY, V14, P354, DOI 10.1016/S0169-4758(98)01295-2; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VANMEIRVENNE N, 1976, ANN SOC BELG MED TR, V56, P55; Webb H, 1997, J CELL BIOL, V139, P103, DOI 10.1083/jcb.139.1.103	27	279	283	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					839	846						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865701	Bronze			2022-12-24	WOS:000077498800013
J	Peters, C; Mayer, A				Peters, C; Mayer, A			Ca2+/calmodulin signals the completion docking and triggers a late step of vacuole fusion	NATURE			English	Article							ADRENAL CHROMAFFIN CELLS; SACCHAROMYCES-CEREVISIAE; IN-VITRO; YEAST VACUOLES; GTPASE YPT7P; CALMODULIN; INHERITANCE; EXOCYTOSIS; CALCIUM; ENDOCYTOSIS	The basic reaction mechanisms for membrane fusion in the trafficking of intracellular membranes and in exocytosis are probably identical(5). But in contrast to regulated exocytosis, intracellular fusion reactions are referred to as 'constitutive' as no final Ca2+-dependent triggering step has been observed. Although transport from the endoplasmic reticulum to the Golgi apparatus in the cell depends on Ca2+ (ref. 6), as does endosome fusion(7) and assembly of the nuclear envelopes, it is unclear whether Ca2+ triggers these events. Membrane fusion involves several subreactions: priming, tethering and docking. Proteins that are needed for fusion include p115, SNAPs, NSF, SNAREs and small GTPases, which operate in these early reactions(1-3), but the machinery that catalyses the final mixing of biological membranes is still unknown. Here we show that Ca2+ is released from the vacuolar lumen following completion of the docking step. We have identified calmodulin as the putative Ca2+ sensor and as the fir component required in the post-docking phase of vacuole fusion. Calmodulin binds tightly to vacuoles upon Ca2+ release. Unlike synaptotagmin or syncollin in exocytosis(4), calmodulin does not act as a fusion damp but actively promotes bilayer mixing. Hence, activation of SNAREs is not sufficient to drive bilayer mixing between physiological membranes. We propose that Ca2+ control of the latest phase of membrane fusion maybe a conserved feature, relevant not only for exocytosis, but also for intracellular, 'constitutive' fusion reactions. However, the origin of the Ca2+ signal, its receptor and its mode of processing differ.	Max Planck Gesell, Friedrich Miescher Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Mayer, A (corresponding author), Max Planck Gesell, Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.		Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				APODACA G, 1994, J BIOL CHEM, V269, P19005; Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Edwardson JM, 1997, CELL, V90, P325, DOI 10.1016/S0092-8674(00)80340-2; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; KIBBLE VA, 1996, EUR J PHYSL, V431, P464; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WADA Y, 1992, J BIOL CHEM, V267, P18665; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	30	321	328	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					575	580		10.1038/25133	http://dx.doi.org/10.1038/25133			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859992				2022-12-24	WOS:000077466800058
J	Hackett, PH; Yarnell, PR; Hill, R; Reynard, K				Hackett, PH; Yarnell, PR; Hill, R; Reynard, K			High-altitude cerebral edema evaluated with magnetic resonance imaging - Clinical correlation and pathophysiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MOUNTAIN-SICKNESS; PULMONARY-EDEMA; BRAIN EDEMA; DEXAMETHASONE; HYPOTHESIS; FEATURES; LESIONS; ILLNESS; HYPOXIA	Context.-Because of its onset in generally remote environments, high-altitude cerebral edema (HACE) has received little scientific attention. Understanding the pathophysiology might have implications for prevention and treatment of both this disorder and the much more common acute mountain sickness. Objectives.-To identify a clinical imaging correlate for HACE and determine whether the edema is primarily vasogenic or cytotoxic. Design,Case-comparison study. Setting,Community hospitals accessed by helicopter from mountains in Colorado and Alaska, Patients.-A consecutive sample of 9 men with MACE, between 18 and 35 years old, 8 of whom also had pulmonary edema, were studied after evacuation from high-altitude locations; 5 were mountain climbers and 4 were skiers. The control group, matched for age, sex, and altitude exposure, consisted of 3 subjects with high-altitude pulmonary edema only and 3 who had been entirely well at altitude. Four patients with HACE were available for follow-up imaging after complete recovery. Main Outcome Measures.-Magnetic resonance imaging (MRI) of the brain during acute, convalescent, and recovered phases of HACE, and once in controls, immediately after altitude exposure. Results.-Seven of the 9 patients with HACE showed intense T-2 Signal in white matter areas, especially the splenium of the corpus callosum, and no gray matter abnormalities. Control subjects demonstrated no such abnormalities. All patients completely recovered; in the 4 available for follow-up MRI, the changes had resolved entirely. Conclusions.-We conclude that HACE is characterized on MRI by reversible white matter edema, with a predilection for the splenium of the corpus callosum. This finding provides a clinical imaging correlate useful for diagnosis. It also suggests that the predominant mechanism is vasogenic (movement of fluid and protein out of the vascular compartment) and, thus, that the blood-brain barrier may be important in MACE.	Univ Alaska, Sch Hlth Profess, Anchorage, AK USA; Alaska Reg Hosp, Dept Emergency Med, Anchorage, AK USA; Alaska Reg Hosp, Dept Radiol, Anchorage, AK USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; St Anthony Hosp, Denver, CO USA; Univ Colorado, Sch Med, Dept Med, Denver, CO USA	University of Alaska System; University of Alaska Anchorage; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hackett, PH (corresponding author), St Marys Hosp & Med Ctr, Dept Emergency Med, 2635 N 7th Ave, Grand Junct, CO 81502 USA.	phack@ruralhealth.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL040476] Funding Source: NIH RePORTER; NHLBI NIH HHS [R15 HL40476-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTSCH P, 1988, J APPL PHYSIOL, V65, P1929, DOI 10.1152/jappl.1988.65.5.1929; BAUMGARTNER RW, IN PRESS J APPL PHYS; BRADLEY WG, 1987, MAGNETIC RESONANCE I, P29; Cordoliani YS, 1998, AM J NEURORADIOL, V19, P871; DICKINSON J, 1983, THORAX, V38, P646, DOI 10.1136/thx.38.9.646; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; GARRIDO E, 1993, INT J SPORTS MED, V14, P232, DOI 10.1055/s-2007-1021169; GARRIDO E, 1995, EUR J APPL PHYSL, V70, P447; GREENWOOD J, 1995, NEW CONCEPTS BLOOD B; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950; Hackett PH, 1995, WILDERNESS MED, P1; HANSEN JE, 1970, ARCH ENVIRON HEALTH, V21, P666; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; HOUSTON CS, 1975, LANCET, V2, P758; ITO T, 1995, AM J NEURORADIOL, V16, P1344; JOO F, 1989, Neurological Research, V11, P67; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KOBAYASHI T, 1987, CHEST, V92, P814, DOI 10.1378/chest.92.5.814; KRASNEY J, 1997, HYPOXIA WOMEN ALTITU, P254; KRASNEY JA, 1994, MED SCI SPORT EXER, V26, P195, DOI 10.1249/00005768-199402000-00010; KRASNEY JA, 1997, KIDNEY INT S59, V51, pS69; LASSEN NA, 1975, LANCET, V2, P1154; LEBIHAN D, 1992, MAGNETIC RESONANCE I, P335; LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504; Matsuzawa Y, 1992, HIGH ALTITUDE MED, P300; MOODY DM, 1988, AM J NEURORADIOL, V9, P1051; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546; PLATEEL M, 1995, J NEUROCHEM, V65, P2133; RAROQUE HG, 1990, NEUROLOGY, V40, P167, DOI 10.1212/WNL.40.1.167; RICHALET JP, 1991, RESP PHYSIOL, V85, P205, DOI 10.1016/0034-5687(91)90062-N; ROACH RC, 1998, HYPOXIA MOL MED, P272; SEVERINGHAUS JW, 1995, J APPL PHYSIOL, V79, P375, DOI 10.1152/jappl.1995.79.2.375; Simonson T. M., 1996, CLIN MAGNETIC RESONA, P767; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; SUTTON JR, 1979, B EUR PHYSIOPATH RES, V15, P1045; WOHNS RNW, 1981, CRIT CARE MED, V9, P880, DOI 10.1097/00003246-198112000-00017; YAFFE K, 1995, NEUROLOGY, V45, P104, DOI 10.1212/WNL.45.1.104; YAMAGUCHI S, 1992, HIGH ALTITUDE MED, P305; ZAVASKY D, 1995, WILD ENVIRON MED, V6, P229	43	205	220	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1920	1925		10.1001/jama.280.22.1920	http://dx.doi.org/10.1001/jama.280.22.1920			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851477	Bronze			2022-12-24	WOS:000077364500036
J	Showalter, MR				Showalter, MR			Detection of centimeter-sized meteoroid impact events in Saturn's F ring	SCIENCE			English	Article							B-RING; SPOKES; PLANETARY; EVOLUTION; SATELLITES	Voyager images reveal that three prominent clumps in Saturn's F ring were short-lived, appearing rapidly and then spreading and decaying in brightness over periods of similar to 2 weeks. These features arise from hypervelocity impacts by similar to 10-centimeter meteoroids into F ring bodies. Future ring observations of these impact events could constrain the centimeter-sized component of the meteoroid population, which is otherwise unmeasurable but plays an import ant role in the evolution of rings and surfaces in the outer solar system. The F ring's numerous other trumps are much longer lived and appear to be unrelated to impacts.	Stanford Univ, Space Telecommun & Radiosci Lab, Stanford, CA 94305 USA	Stanford University	Showalter, MR (corresponding author), NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.							Bosh AS, 1996, SCIENCE, V272, P518, DOI 10.1126/science.272.5261.518; Burns J.A., 1984, IAU COLLO Q 75 PLANE, P200; Cuzzi JN, 1998, ICARUS, V132, P1, DOI 10.1006/icar.1997.5863; CUZZI JN, 1988, ICARUS, V74, P284, DOI 10.1016/0019-1035(88)90043-7; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; DERMOTT SF, 1981, NATURE, V290, P454, DOI 10.1038/290454a0; DOYLE LR, 1989, ICARUS, V80, P104, DOI 10.1016/0019-1035(89)90163-2; Durisen RH, 1996, ICARUS, V124, P220, DOI 10.1006/icar.1996.0200; GEHRELS T, 1980, SCIENCE, V207, P434, DOI 10.1126/science.207.4429.434; GOERTZ CK, 1983, ICARUS, V53, P219, DOI 10.1016/0019-1035(83)90143-4; GRUN E, 1983, ICARUS, V54, P227, DOI 10.1016/0019-1035(83)90194-X; Grun E., 1984, ADV SPACE RES, V4, P143, DOI [10.1016/0273-1177(84)90019-X, DOI 10.1016/0273-1177(84)90019-X]; Hall DT, 1996, SCIENCE, V272, P516, DOI 10.1126/science.272.5261.516; HILL JR, 1982, J GEOPHYS RES-SPACE, V87, P7413, DOI 10.1029/JA087iA09p07413; HUMES DH, 1980, J GEOPHYS RES-SPACE, V85, P5841, DOI 10.1029/JA085iA11p05841; KOLVOORD RA, 1990, NATURE, V345, P695, DOI 10.1038/345695a0; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MORFILL GE, 1983, ICARUS, V53, P230, DOI 10.1016/0019-1035(83)90144-6; POLLACK JB, 1980, J ATMOS SCI, V37, P868, DOI 10.1175/1520-0469(1980)037<0868:SBNPOS>2.0.CO;2; POULET F, 1997, B AM ASTRON SOC, V29, P1001; RODDIER C, 1996, 6515 IAU; SHOWALTER MR, 1992, ICARUS, V100, P394, DOI 10.1016/0019-1035(92)90107-I; SHOWALTER MR, 1982, ICARUS, V52, P526, DOI 10.1016/0019-1035(82)90013-6; SHOWALTER MR, 1997, B AM ASTRON SOC, V29, P999; SHOWALTER MR, 1994, B AM ASTRON SOC, V26, P1150; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; SYNNOTT SP, 1983, ICARUS, V53, P156, DOI 10.1016/0019-1035(83)90029-5; TAGGER M, 1991, ICARUS, V91, P297, DOI 10.1016/0019-1035(91)90026-P	29	41	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1099	1102		10.1126/science.282.5391.1099	http://dx.doi.org/10.1126/science.282.5391.1099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804543				2022-12-24	WOS:000076887700043
J	de Visser, JAGM; Zeyl, CW; Gerrish, PJ; Blanchard, JL; Lenski, RE				de Visser, JAGM; Zeyl, CW; Gerrish, PJ; Blanchard, JL; Lenski, RE			Diminishing returns from mutation supply rate in asexual populations	SCIENCE			English	Article							TERM EXPERIMENTAL EVOLUTION; ESCHERICHIA-COLI; ADAPTIVE EVOLUTION; MISMATCH REPAIR; ADAPTATION; SELECTION; BACTERIA	Mutator genotypes with increased mutation rates may be especially important in microbial-evolution if genetic adaptation is generally Limited by the supply of mutations. In experimental populations of the bacterium Escherichia coli, the rate of evolutionary adaptation was proportional to the mutation supply rate only in particular circumstances of small or initially well-adapted populations. These experiments also demonstrate a "speed limit" on adaptive evolution in asexual populations, one that is independent of the mutation supply rate.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Wake Forest Univ, Dept Biol, Winston Salem, NC 27109 USA; Univ Oregon, Dept Biol, Eugene, OR 97403 USA; Ctr Dis Control, Atlanta, GA 30333 USA	Michigan State University; Wake Forest University; University of Oregon; Centers for Disease Control & Prevention - USA	de Visser, JAGM (corresponding author), Wageningen Univ Agr, Microbiol Lab, Wageningen, Netherlands.		Gerrish, Philip/AAE-7346-2019; Blanchard, Jeffrey/AAA-5173-2020; de Visser, Arjan/GLU-3870-2022	Blanchard, Jeffrey/0000-0002-7310-9678; Lenski, Richard/0000-0002-1064-8375; Gerrish, Philip/0000-0001-6393-0553; de Visser, Arjan/0000-0002-5098-6686				BURCH C, IN PRESS GENETICS; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; KONDRASHOV AS, 1995, GENET RES, V66, P53, DOI 10.1017/S001667230003439X; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; MALMBERG RL, 1977, GENETICS, V86, P607; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MODRICH P, 1995, PHILOS T ROY SOC B, V347, P89, DOI 10.1098/rstb.1995.0014; MOXON ER, 1978, P NATL ACAD SCI USA, V75, P1534, DOI 10.1073/pnas.75.3.1534; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Otto SP, 1997, GENETICS, V147, P879; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; ZYSKIND J, 1989, RECOMBINANT DNA LAB	23	278	281	4	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					404	406		10.1126/science.283.5400.404	http://dx.doi.org/10.1126/science.283.5400.404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888858				2022-12-24	WOS:000078067000052
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Cell biology - Gentle slam	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Peters, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Laffafian I, 1998, BIOPHYS J, V75, P2558, DOI 10.1016/S0006-3495(98)77700-8	1	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2213	2214		10.1126/science.282.5397.2213b	http://dx.doi.org/10.1126/science.282.5397.2213b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9890830				2022-12-24	WOS:000077645800033
J	Cheung, BMY; Kumana, CR				Cheung, BMY; Kumana, CR			Natriuretic peptides - Relevance in cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; CHRONIC HEART-FAILURE; PLASMA-LEVELS; ATRIAL; SYSTEM; HYPERTENSION; ENDOCRINE; INFUSION		Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China	University of Hong Kong	Cheung, BMY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.		/E-9829-2010	/0000-0001-9106-7363				ARAKAWA N, 1994, CARDIOLOGY, V85, P334, DOI 10.1159/000176706; BEVAN EG, 1992, J HYPERTENS, V10, P607; Cheung BMY, 1997, CLIN EXP PHARMACOL P, V24, P966, DOI 10.1111/j.1440-1681.1997.tb02729.x; CHEUNG BMY, 1994, CLIN SCI, V86, P723, DOI 10.1042/cs0860723; CHOY AMJ, 1994, BRIT HEART J, V72, P16; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; deBold AJ, 1996, CARDIOVASC RES, V31, P7, DOI 10.1016/S0008-6363(95)00121-2; HOLMES SJ, 1993, J CLIN ENDOCR METAB, V76, P91, DOI 10.1210/jc.76.1.91; LANG CC, 1992, CLIN SCI, V83, P519, DOI 10.1042/cs0830519; LAVILLA G, 1994, PACE, V17, P953; Levin ER, 1998, NEW ENGL J MED, V339, P321; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Marcus LS, 1996, CIRCULATION, V94, P3184, DOI 10.1161/01.CIR.94.12.3184; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; NAKAO K, 1992, J HYPERTENS, V10, P907; NORTHRIDGE DB, 1990, AM J HYPERTENS, V3, P682, DOI 10.1093/ajh/3.9.682; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Tsutamoto T, 1997, CIRCULATION, V96, P509; TUNNY TJ, 1993, J HYPERTENS, V11, pS222; Wallen T, 1997, HEART, V77, P264, DOI 10.1136/hrt.77.3.264; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988	23	117	133	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					1983	1984		10.1001/jama.280.23.1983	http://dx.doi.org/10.1001/jama.280.23.1983			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863839				2022-12-24	WOS:000077462300011
J	Goldenberg, RL; Vermund, SH; Goepfert, AR; Andrews, WW				Goldenberg, RL; Vermund, SH; Goepfert, AR; Andrews, WW			Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED TRIAL; BACTERIAL VAGINOSIS; INFECTION; METRONIDAZOLE; ZIDOVUDINE; REDUCTION; MEMBRANES; OUTCOMES; TYPE-1	The obstetric risk factors for perinatal transmission of HIV-1 include preterm birth, prolonged rupture of the chorioamniotic membranes, and clinical and histological bacterial chorioamnionitis. A chronic chorioamnionitis precedes many cases of preterm labour and spontaneous rupture of membranes, whereas an acute chorioamnionitis is more common after rupture of the membranes at term. Amniotic fluid cytokines are raised in the presence of term and preterm intrauterine bacterial infections, and various cytokines seem able to attract HIV-1-infected leucocytes into the amniotic cavity and to increase replication of HIV-1. We postulate that the association of preterm birth and prolonged rupture of membranes with perinatal transmission of HIV-1 may result from an associated chronic or acute bacterial chorioamnionitis marked by the migration of HIV-1-infected maternal leucocytes into the amniotic cavity. Antibiotic treatment could prevent this sequence of events.	Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Goldenberg, RL (corresponding author), Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA.		Vermund, Sten/AAD-3592-2020	Vermund, Sten/0000-0001-7289-8698	PHS HHS [290-92-0055] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREWS G, 1995, BEHAV HEALTHC TOM, V4, P19; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; Fiscella K, 1996, PUBLIC HEALTH REP, V111, P104; GIAQUINTO C, 1992, LANCET, V339, P1007; Goldenberg RL, 1997, CLIN PERINATOL, V24, P23, DOI 10.1016/S0095-5108(18)30182-9; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P656, DOI 10.1016/0029-7844(96)00034-S; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; MANDELBROT L, PREINATAL HIV 1 TRAN; Mansergh G, 1996, JAMA-J AM MED ASSOC, V276, P139, DOI 10.1001/jama.276.2.139; Melendez-Guerrero LM, 1994, TROPHOBLAST RES, V8, P33; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; MINKOFF H, 1995, AM J OBSTET GYNECOL, V173, P585, DOI 10.1016/0002-9378(95)90286-4; MOFENSONLM, 1997, ACTA PAEDIAT S, V491, P1; MUNDY DC, 1987, LANCET, V2, P549; NORMAN K, 1994, BRIT J OBSTET GYNAEC, V101, P404, DOI 10.1111/j.1471-0528.1994.tb11912.x; NYONGO A, 1909, INT C AIDS, V8, pB165; POPEK EJ, 1997, 4 C RETR OPP INF, P158; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; SCHAEFER A, 1998, 12 WORLD AIDS C GEN; SCHAFER AP, 1993, INT C AIDS, V9, P91; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TAHA TF, 1998, 11 WORLD AIDS C GEN; Vuthipongse P, 1998, JAMA-J AM MED ASSOC, V279, P1061	25	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1927	1930		10.1016/S0140-6736(98)04453-5	http://dx.doi.org/10.1016/S0140-6736(98)04453-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863804				2022-12-24	WOS:000077544600045
J	Kehle, J; Beuchle, D; Treuheit, S; Christen, B; Kennison, JA; Bienz, M; Muller, J				Kehle, J; Beuchle, D; Treuheit, S; Christen, B; Kennison, JA; Bienz, M; Muller, J			dMi-2, a hunchback-interacting protein that functions in Polycomb repression	SCIENCE			English	Article							HOMEOTIC GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; SEGMENTAL DETERMINATION; SPATIAL EXPRESSION; BITHORAX COMPLEX; MI-2 AUTOANTIGEN; ULTRABITHORAX; EMBRYOS; DOMAIN; REGION	Early in Drosophila embryogenesis, gap gene products directly repress transcription of homeotic (HOX) genes and thereby delimit HOX expression domains. Subsequently, Polycomb-group proteins maintain this repression. Currently, there is no known molecular Link between gap and Polycomb-group proteins. Here, dMi-2 is identified as a protein that binds to a domain in the gap protein Hunchback that is specifically required for the repression of HOX genes. Genetic analyses show that dMi-2 participates in both Hunchback and Polycomb repression in vivo. Hence, recruitment of dMi-2 may serve as a link between repression of HOX genes by Hunchback and Polycomb proteins.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	Max Planck Society; MRC Laboratory Molecular Biology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Muller, J (corresponding author), Max Planck Inst Entwicklungsbiol, Spemannstr 35-3, D-72076 Tubingen, Germany.	juerg.mueller@tuebingen.mpg.de						AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BREEN TR, 1986, DEV BIOL, V118, P442, DOI 10.1016/0012-1606(86)90015-1; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HULSKAMP M, 1994, GENETICS, V138, P125; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LONIE A, 1994, DEVELOPMENT, V120, P2629; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOAZED D, 1992, DEVELOPMENT, V116, P805; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; MULLER J, 1995, DEVELOPMENT, V121, P2847; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PATTATUCCI AM, 1991, GENETICS, V129, P443; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SOMMER R, 1992, THESIS U MUNICH; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	39	297	302	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1897	1900		10.1126/science.282.5395.1897	http://dx.doi.org/10.1126/science.282.5395.1897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836641				2022-12-24	WOS:000077338100051
J	Amores, A; Force, A; Yan, YL; Joly, L; Amemiya, C; Fritz, A; Ho, RK; Langeland, J; Prince, V; Wang, YL; Westerfield, M; Ekker, M; Postlethwait, JH				Amores, A; Force, A; Yan, YL; Joly, L; Amemiya, C; Fritz, A; Ho, RK; Langeland, J; Prince, V; Wang, YL; Westerfield, M; Ekker, M; Postlethwait, JH			Zebrafish hox clusters and vertebrate genome evolution	SCIENCE			English	Article							FUNCTIONAL EVOLUTION; GENE; ORGANIZATION; EXPRESSION; TRANSCRIPTION; DROSOPHILA; TETRAPODS; COMPLEX	HOX genes specify cell fate in the anterior-posterior axis of animal embryos. Invertebrate chordates have one HOX cluster, but mammals have four, suggesting that cluster duplication facilitated the evolution of vertebrate body Plans. This report shows that zebrafish have seven hox clusters. Phylogenetic analysis and genetic mapping suggest a chromosome doubling event, probably by whole genome duplication, after the divergence of ray-finned and lobe-finned fishes but before the teleost radiation. Thus, teleosts, the most species-rich group of vertebrates, appear to have more copies of;these developmental regulatory genes than do mammals, despite Less complexity in the anterior-posterior axis.	Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; Boston Univ, Sch Med, Ctr Human Genet, Boston, MA 02118 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Chicago, Chicago, IL 60637 USA; Kalamazoo Coll, Dept Biol, Kalamazoo, MI 49006 USA	University of Oregon; University of Ottawa; Ottawa Hospital Research Institute; Boston University; Emory University; Princeton University; University of Chicago; Kalamazoo College	Ekker, M (corresponding author), Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.		Yan, Yi/GSO-3046-2022	Prince, Victoria/0000-0001-5810-7300; Amores, Angel/0000-0002-9307-3609	NCRR NIH HHS [R01RR10715] Funding Source: Medline; NICHD NIH HHS [P01HD22486] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR010715] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; Allendorf F.W., 1984, P1; AMEMIYA C, UNPUB; Aparicio S, 1997, NAT GENET, V16, P79, DOI 10.1038/ng0597-79; Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825; BUTH DG, 1991, CYPRINID FISHES SYST, P00083; CANTATORE P, 1994, J MOL EVOL, V39, P589, DOI 10.1007/BF00160404; Dickman S, 1997, SCIENCE, V275, P1568, DOI 10.1126/science.275.5306.1568; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EIKEN HG, 1987, BIOCHEM BIOPH RES CO, V149, P1165, DOI 10.1016/0006-291X(87)90530-4; FERRIS SD, 1979, J MOL EVOL, V12, P267, DOI 10.1007/BF01732026; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kmita-Cunisse M, 1998, P NATL ACAD SCI USA, V95, P3030, DOI 10.1073/pnas.95.6.3030; Kourakis MJ, 1997, DEV BIOL, V190, P284, DOI 10.1006/dbio.1997.8689; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Misof BY, 1996, MOL PHYLOGENET EVOL, V5, P309, DOI 10.1006/mpev.1996.0026; Misof BY, 1996, J EXP ZOOL, V274, P193, DOI 10.1002/(SICI)1097-010X(19960215)274:3&lt;193::AID-JEZ6&gt;3.0.CO;2-J; NJOLSTAD P R, 1989, Gene (Amsterdam), V73, P33; NJOLSTAD PR, 1988, NUCLEIC ACIDS RES, V16, P9097, DOI 10.1093/nar/16.19.9097; NJOLSTAD PR, 1990, EMBO J, V9, P515, DOI 10.1002/j.1460-2075.1990.tb08138.x; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; PRINCE V, 1997, DEVELOPMENT, V125, P393; Prince VE, 1998, DEVELOPMENT, V125, P407; RUNSTADLER JA, 1991, NUCLEIC ACIDS RES, V19, P5434, DOI 10.1093/nar/19.19.5434; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sordino P, 1996, MECH DEVELOP, V59, P165, DOI 10.1016/0925-4773(96)00587-4; vanderHoeven F, 1996, MECH DEVELOP, V54, P9, DOI 10.1016/0925-4773(95)00455-6; Zhang JZ, 1996, GENETICS, V142, P295	30	1417	1485	4	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1711	1714		10.1126/science.282.5394.1711	http://dx.doi.org/10.1126/science.282.5394.1711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831563				2022-12-24	WOS:000077246600048
J	Stanewsky, R; Kaneko, M; Emery, P; Beretta, B; Wager-Smith, K; Kay, SA; Rosbash, M; Hall, JC				Stanewsky, R; Kaneko, M; Emery, P; Beretta, B; Wager-Smith, K; Kay, SA; Rosbash, M; Hall, JC			The cry(b) mutation identifies cryptochrome as a circadian photoreceptor in Drosophila	CELL			English	Article							CLOCK GENE; PERIOD LOCUS; DARK CYCLES; LIGHT; MELANOGASTER; MUTANTS; EXPRESSION; TIMELESS; TRANSCRIPTION; BEHAVIOR	A new rhythm mutation was isolated based on its elimination of per-controlled luciferase cycling. Levels of period or timeless clock gene products in the mutant are flat in daily light-dark cycles or constant darkness (although PER and TIM oscillate normally in temperature cycles). Consistent with the fact that light normally suppresses TIM, cry(b) is an apparent null mutation in a gene encoding Drosophila's version of the blue light receptor cryptochrome. Behaviorally cry(b) exhibits poor synchronization to light-dark cycles in genetic backgrounds that cause external blindness or demand several hours of daily rhythm resets, and it shows no response to brief light pulses. cry(b) flies are rhythmic in constant darkness, correlating with robust PER and TIM cycling in certain pacemaker neurons.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Natl Sci Fdn, Ctr Biol Timing, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Scripps Res Inst, La Jolla, CA 92037 USA; NSF, Ctr Biol Timing, La Jolla, CA 92037 USA	Brandeis University; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing; Brandeis University; Howard Hughes Medical Institute; Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing	Hall, JC (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02454 USA.	hall@brandeis.edu	Stanewsky, Ralf/ABB-9193-2021; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; Stanewsky, Ralf/0000-0001-8238-6864; Kaneko, Maki/0000-0002-2489-6185	NIGMS NIH HHS [GM-33205] Funding Source: Medline; NIMH NIH HHS [MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; Cashmore AR, 1998, J PLANT RES, V111, P267, DOI 10.1007/BF02512182; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DOWSE HB, 1993, MOL GENETICS BIOL RH, P195; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HELFRICHFORSTER C, 1997, BIOL RHYTHM RES S, V28, P119; HOFBAUER A, 1989, NATURWISSENSCHAFTEN, V76, P335, DOI 10.1007/BF00368438; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 1998, CURR OPIN NEUROBIOL, V8, P652, DOI 10.1016/S0959-4388(98)80095-0; KLEMM E, 1976, PHOTOCHEM PHOTOBIOL, V24, P369, DOI 10.1111/j.1751-1097.1976.tb06838.x; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LINDSLEY DL, 1992, GENETIC VARIATIONS D; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Ohata K, 1998, INT CONGR SER, V1152, P167; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PAGE TL, 1982, EXPERIENTIA, V38, P1007, DOI 10.1007/BF01955344; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pearn MT, 1996, J BIOL CHEM, V271, P4937; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RAGOVOY J, 1971, CRY BABY PEARL ALBUM; ROBERTSON HM, 1988, GENETICS, V118, P461; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; RUTILA JE, 1998, IN PRESS J BIOL RHYT; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SCIENCE, V270, P801; SMITH H, 1982, ANNU REV PLANT PHYS, V33, P481, DOI 10.1146/annurev.pp.33.060182.002405; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Stanewsky R, 1997, J NEUROSCI, V17, P676; Stanewsky R, 1996, GENETICS, V143, P259; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; Yoshikawa T, 1998, COMP BIOCHEM PHYS B, V119, P65, DOI 10.1016/S0305-0491(97)00290-3; Yoshimura T, 1998, BRAIN RES, V779, P188, DOI 10.1016/S0006-8993(97)01122-0; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZERR DM, 1990, J NEUROSCI, V10, P2749; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZIMMERMAN WF, 1971, SCIENCE, V171, P1167, DOI 10.1126/science.171.3976.1167; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	61	745	766	4	96	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					681	692		10.1016/S0092-8674(00)81638-4	http://dx.doi.org/10.1016/S0092-8674(00)81638-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845370	Bronze			2022-12-24	WOS:000077253700015
J	Hu, FB; Stampfer, MJ; Manson, JE; Rimm, EB; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Manson, JE; Rimm, EB; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH; Willett, WC			Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT; PLASMA-CHOLESTEROL; HEALTH; ATHEROSCLEROSIS; LIPOPROTEINS; ALMONDS; WALNUTS; ACIDS; MEN	Objective To examine the relation between nut consumption and risk of coronary heart disease in a cohort of women from the Nurses' Health Study. Design Prospective cohort study Setting Nurses' Health Study. Subjects 86 016 women from 34 to 59 years of age without previously diagnosed coronary heart disease, stroke, or cancer at baseline in 1980. Main outcome measures Major coronary heart disease including non-fatal myocardial infarction and fatal coronary heart disease. Results 1255 major coronary disease events (861 cases of non-fatal myocardial infarction and 394 cases of fatal coronary heart disease) occurred during 14 years of follow up. After adjusting far age, smoking, and other known risk factors for coronary heart disease, women who ate more than five units of nuts tone unit equivalent to 1 oz of nuts) a week (frequent consumption) had a significantly lower risk of total coronary heart disease (relative risk 0.65, 95% confidence interval 0.47 to 0.89, P for trend = 0.0009) than women who never ate nuts or who ate less than one unit a month (rare consumption). The magnitude of risk reduction was similar for both fatal coronary heart disease (0.61, 0.35 to 1.05, P for trend = 0.007) and non-fatal myocardial infarction (0.68, 0.47 to 1.00, P for trend = 0.04), Further adjustment for intakes of dietary fats, fibre, vegetables, and fruits did not alter these results. The inverse association persisted in subgroups stratified by levels of smoking, use of alcohol, use of multivitamin and vitamin E supplements, body mass index, exercise, and intake of vegetables or fruits. Conclusions Frequent nut consumption was associated with a reduced risk of both fatal coronary heart disease and non-fatal myocardial infarction. These data, and these from other epidemiological and clinical studies, support a role for nuts in reducing the risk of coronary heart disease.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.	Frank.Hu@channing.harvard.edu	Colditz, Graham/A-3963-2009; Hu, Frank/C-1919-2013	Colditz, Graham/0000-0002-7307-0291; 	NCI NIH HHS [CA40356, R01 CA040356] Funding Source: Medline; NHLBI NIH HHS [R01 HL034594, HL24074, HL34594] Funding Source: Medline; NIDDK NIH HHS [T32 DK007703, P30 DK046200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007703, P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBEY M, 1994, AM J CLIN NUTR, V59, P995, DOI 10.1093/ajcn/59.5.995; ALDERSON LM, 1986, ARTERIOSCLEROSIS, V6, P465, DOI 10.1161/01.ATV.6.5.465; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; COOKE JP, 1993, ARCH INTERN MED, V153, P896, DOI 10.1001/archinte.1993.00410070076013; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; Dreher ML, 1996, NUTR REV, V54, P241, DOI 10.1111/j.1753-4887.1996.tb03941.x; FRASER GE, 1994, AM J CLIN NUTR, V59, p1117S, DOI 10.1093/ajcn/59.5.1117S; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GABH Rose, 1982, WHO MONOGRAPH SERIES; GRUNDY SM, 1990, J LIPID RES, V31, P1149; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; KRITCHEVSKY D, 1991, INT J TISSUE REACT, V13, P59; OByrne DJ, 1997, LIPIDS, V32, P687, DOI 10.1007/s11745-997-0088-y; PRINEAS RJ, 1993, NEW ENGL J MED, V329, P359; SABATE J, 1993, NEW ENGL J MED, V328, P603, DOI 10.1056/NEJM199303043280902; SABATE J, 1993, EUR J CLIN NUTR, V47, pS71; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SPILLER GA, 1992, J AM COLL NUTR, V11, P126; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; *USDA, 1989, AGR HDB, V8; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011	24	389	404	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1998	317	7169					1341	1345		10.1136/bmj.317.7169.1341	http://dx.doi.org/10.1136/bmj.317.7169.1341			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812929	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000077081600017
J	Ban, C; Yang, W				Ban, C; Yang, W			Crystal structure and ATPase activity of MutL: Implications for DNA repair and mutagenesis	CELL			English	Article							DIRECTED MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; PROTEIN; MUTATIONS; CHAPERONE; RECOMBINATION; REPLICATION	MutL and its homologs are essential for DNA mismatch repair. Mutations in genes encoding human homologs of MutL cause multiorgan cancer susceptibility. We have determined the crystal structure of a 40 kDa N-terminal fragment of E. coli MutL that retains all of the conserved residues in the MutL family. The structure of MutL is homologous to that of an ATPase-containing fragment of DNA gyrase. We have demonstrated that MutL binds and hydrolyzes ATP to ADP and Pi. Mutations in the MutL family that cause deficiencies in DNA mismatch repair and a predisposition to cancer mainly occur in the putative ATP-binding site. We provide evidence that the flexible, yet conserved, loops surrounding this ATP-binding site undergo conformational changes upon ATP hydrolysis thereby modulating interactions between MutL and other components of the repair machinery.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Ban, Changill/F-5426-2013; Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195				Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COOPER DL, 1993, J BIOL CHEM, V268, P11823; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Evarsson A., 1994, EMBO J, V13, P3669; FENG G, 1995, BIOTECHNIQUES, V19, P956; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, COLLABORATIVE COMPUT, V4, P59; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LOEB LA, 1974, CANCER RES, V34, P2311; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stams T, 1998, SCIENCE, V280, P752, DOI 10.1126/science.280.5364.752; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	44	319	322	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					541	552		10.1016/S0092-8674(00)81621-9	http://dx.doi.org/10.1016/S0092-8674(00)81621-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827806	Bronze			2022-12-24	WOS:000077049400012
J	Worgotter, F; Suder, K; Zhao, YQ; Kerscher, N; Eysel, UT; Funke, K				Worgotter, F; Suder, K; Zhao, YQ; Kerscher, N; Eysel, UT; Funke, K			State-dependent receptive-field restructuring in the visual cortex	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; RELAY CELLS; CATS; MODULATION; ORGANIZATION; MECHANISMS; RESPONSES; DYNAMICS; NEURONS	To extract important information from the environment on a useful timescale, the visual system must be able to adapt rapidly to constantly changing scenes. This requires dynamic control of visual resolution possibly at the level of the responses of single neurons. Individual cells in the visual cortex respond to Light stimuli on particular locations (receptive fields) on the retina, and the structure of these receptive fields can change in different contexts(1-4). Here we show experimentally that the shape of receptive fields in the primary visual cortex of anaesthetized cats undergoes significant modifications, which are correlated with the general state of the brain as assessed by electroencephalography: receptive fields are wider during synchronized states and smaller during non-synchronized states. We also show that cortical receptive fields shrink over time when stimulated with hashing light spots. Finally, by using a network model we account for the changing size of the cortical receptive fields by dynamically rescaling the levels of excitation and inhibition in the visual thalamus and cortex. The observed dynamic changes in the sizes of the cortical receptive field could be a reflection of a process that adapts the spatial resolution within the primary visual pathway to different states of excitability.	Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany	Ruhr University Bochum	Worgotter, F (corresponding author), Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany.			Eysel, Ulf/0000-0001-6087-957X; Funke, Klaus/0000-0003-2359-8917				AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHLSEN G, 1985, EXP BRAIN RES, V58, P134; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1091, DOI 10.1152/jn.1993.69.4.1091; ECKHORN R, 1993, BIOL CYBERN, V69, P37, DOI 10.1007/BF00201407; Funke K, 1998, VISUAL NEUROSCI, V15, P711, DOI 10.1017/S0952523898154111; FUNKE K, 1992, BRAIN RES, V573, P217, DOI 10.1016/0006-8993(92)90766-3; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LO FS, 1991, EXP BRAIN RES, V83, P317; MCCARLEY RW, 1983, J NEUROPHYSIOL, V50, P7980; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; SAWAI H, 1988, BRAIN RES, V455, P394, DOI 10.1016/0006-8993(88)90102-3; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Timofeev I, 1996, J NEUROPHYSIOL, V76, P4152, DOI 10.1152/jn.1996.76.6.4152; ULRICH DJ, 1991, J NEUROPHYSIOL, V65, P1528; Worgotter F, 1998, J PHYSIOL-LONDON, V509, P797, DOI 10.1111/j.1469-7793.1998.797bm.x; Zipser K, 1996, J NEUROSCI, V16, P7376	23	137	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					165	168		10.1038/24157	http://dx.doi.org/10.1038/24157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823895				2022-12-24	WOS:000077013300051
J	Zaman, MM; Yoshiike, N; Rouf, MA; Haque, S; Chowdhury, AH; Nakayama, T; Tanaka, H				Zaman, MM; Yoshiike, N; Rouf, MA; Haque, S; Chowdhury, AH; Nakayama, T; Tanaka, H			Association of rheumatic fever with serum albumin concentration and body iron stores in Bangladeshi children: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Tokyo Med & Dent Univ, Med Res Inst, Dept Epidemiol, Tokyo 101, Japan; Natl Inst Hlth & Nutr, Div Adult Hlth Sci, Tokyo 162, Japan; Natl Ctr Control Rheumat Fever & Heart Dis, Dhaka 1207, Bangladesh	Tokyo Medical & Dental University (TMDU); National Institute of Health & Nutrition - Japan	Zaman, MM (corresponding author), Natl Ctr Control Rheumat Fever & Heart Dis, Sher e Bangla Nagar, Dhaka 1207, Bangladesh.		NAKAYAMA, Takeo/HCH-0537-2022; Zaman, M Mostafa/H-4163-2019	Zaman, M Mostafa/0000-0002-1736-1342; Nakayama, Takeo/0000-0002-7918-6252				ARYANPURKASHANI I, 1980, AM HEART J, V100, P942, DOI 10.1016/0002-8703(80)90088-5; COBURN AF, 1960, AM J MED SCI, V240, P687; COOPER WC, 1974, AM J CLIN NUTR, V27, P647, DOI 10.1093/ajcn/27.6.647; GIBSON R, 1990, PRINCIPLE NUTR ASSES; Zaman MM, 1998, J TROP PEDIATRICS, V44, P142, DOI 10.1093/tropej/44.3.142	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1287	1288		10.1136/bmj.317.7168.1287	http://dx.doi.org/10.1136/bmj.317.7168.1287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804715	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000076963800024
J	Rosenthal, PB; Zhang, XD; Formanowski, F; Fitz, W; Wong, CH; Meier-Ewert, H; Skehel, JJ; Wiley, DC				Rosenthal, PB; Zhang, XD; Formanowski, F; Fitz, W; Wong, CH; Meier-Ewert, H; Skehel, JJ; Wiley, DC			Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus	NATURE			English	Article							GP41 TRANSMEMBRANE GLYCOPROTEIN; GP120 ENVELOPE GLYCOPROTEIN; X-RAY-DIFFRACTION; SIALIC-ACID; RECEPTOR DETERMINANT; MEMBRANE-FUSION; HIGH-AFFINITY; HEMAGGLUTININ; PROTEIN; BINDING	The spike glycoproteins of the lipid-enveloped orthomyxoviruses I and paramyxoviruses have three functions: to recognize the receptor on the cell surface, to mediate viral fusion with the cell membrane. and to destroy the receptor. In influenza C virus, a single glycoprotein, the haemagglutinin-esterase-fusion (HEF) protein, possesses all three functions (reviewed in ref, 1). In influenza A and B, the first two activities are mediated by haemagglutinin and the third by a second glycoprotein, neuraminidase. Here we report the crystal structure of the HEF envelope glycoprotein of influenza C virus. We have identified the receptor-binding site and the receptor-destroying enzyme (9-O-acetylesterase) sites, by using receptor analogues. The receptor-binding domain is structurally similar to the sialic acid-binding domain of influenza A haemagglutinin, but binds 9-O-acetylsialic acid. The esterase domain has a structure similar to the esterase from Streptomyces scabies and a brain acetylhydrolase(2,3). The receptor domain is inserted into a surface loop of the esterase domain and the esterase domain is inserted into a surface loop of the stem. The stem domain is similar to that of influenza A haemagglutinin, except that the triple-stranded, alpha-helical bundle diverges at both of its ends, and the amino terminus of HEF2 the fusion peptide, is partially exposed. The segregation of HEF's three functions into structurally distinct domains suggests that the entire stem region, including sequences at the amino and carboxy termini of HEF1 which precede the post-translational cleavage site between HEF1 and HEF2 forms an independent fusion domain which is probably derived from an ancestral membrane fusion protein.	Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Tech Univ Munich, Abt Virol, D-80802 Munich 40, Germany; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Natl Inst Med Res, London NW7 1AA, England	Harvard University; Howard Hughes Medical Institute; Harvard University; Technical University of Munich; Scripps Research Institute; MRC National Institute for Medical Research	Wiley, DC (corresponding author), Harvard Univ, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.			Zhang, Xiaodong/0000-0001-9786-7038				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Eisen MB, 1997, VIROLOGY, V232, P19, DOI 10.1006/viro.1997.8526; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fitz W, 1996, BIOORGAN MED CHEM, V4, P1349, DOI 10.1016/0968-0896(96)00123-X; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HERRLER G, 1991, ADV VIRUS RES, V40, P213; HERRLER G, 1992, J BIOL CHEM, V267, P12501; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenthal PB, 1996, ACTA CRYSTALLOGR D, V52, P1041, DOI 10.1107/S0907444996005021; ROSENTHAL PB, 1996, THESIS HARVARD U; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997	30	182	190	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1998	396	6706					92	96		10.1038/23974	http://dx.doi.org/10.1038/23974			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817207	Green Published			2022-12-24	WOS:000076852700061
J	Tanaka, T; Saha, SK; Tomomori, C; Ishima, R; Liu, DJ; Tong, KI; Park, H; Dutta, R; Qin, L; Swindells, MB; Yamazaki, T; Ono, AM; Kainosho, M; Inouye, M; Ikura, M				Tanaka, T; Saha, SK; Tomomori, C; Ishima, R; Liu, DJ; Tong, KI; Park, H; Dutta, R; Qin, L; Swindells, MB; Yamazaki, T; Ono, AM; Kainosho, M; Inouye, M; Ikura, M			NMR structure of the histidine kinase domain of the E-coli osmosensor EnvZ	NATURE			English	Article							SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; DNA GYRASE; PROTEIN; BINDING; PROGRAM; MUTANT	Bacteria live in capricious environments, in which they must continuously sense external conditions in order to adjust their shape, motility and physiology(1). The histidine-aspartate phosphorelay signal-transduction system (also known as the two-component system) is important in cellular adaptation to environmental changes in both prokaryotes and lower eukaryotes(2,3). In this system, protein histidine kinases function as sensors and signal transducers, The Escherichia coli osmosensor, EnvZ, is a transmembrane protein with histidine kinase activity in its cytoplasmic region(2). The cytoplasmic region contains two functional domains(4): domain A (residues 223-289) contains the conserved histidine residue (H243), a site of autophosphorylation as well as transphosphorylation to the conserved D55 residue of response regulator OmpR, whereas domain B (residues 290-450) encloses several highly conserved regions (G1, G2, F and N boxes) and is able to phosphorylate H243. Here we present the solution structure of domain B, the catalytic core of EnvZ. This core has a novel protein kinase structure, distinct from the serine/threonine/tyrosine kinase fold, with unanticipated similarities to both heat-shock protein 90 and DNA gyrase B.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Helix Res Inst Inc, Kisarazu 2920812, Japan; Natl Inst Agrobiol Resources, Tsukuba, Ibaraki 3050856, Japan; Tokyo Metropolitan Univ, Dept Chem, Hachioji, Tokyo 1920397, Japan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institute of Agrobiological Sciences - Japan; Tokyo Metropolitan University	Ikura, M (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	mikura@oci.utor-onto.ca	Qin, Ling/B-3147-2012	Ikura, Mitsuhiko/0000-0002-9524-1303				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrett JF, 1998, P NATL ACAD SCI USA, V95, P5317, DOI 10.1073/pnas.95.9.5317; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; OTA IM, 1993, SCIENCE, V262, P366; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WIRGLERMURPHY SM, 1997, TRENDS BIOCHEM SCI, V22, P172; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286	23	208	213	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					88	92		10.1038/23968	http://dx.doi.org/10.1038/23968			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817206				2022-12-24	WOS:000076852700060
J	Kuner, R; Kohr, G; Grunewald, S; Eisenhardt, G; Bach, A; Kornau, HC				Kuner, R; Kohr, G; Grunewald, S; Eisenhardt, G; Bach, A; Kornau, HC			Role of heteromer formation in GABA(B) receptor function	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN SLICES; PHYSIOLOGICAL-ROLE; ABSENCE SEIZURES; BASIC MECHANISMS; K+ CHANNELS; PROTEIN; MODULATION; EXPRESSION; CLONING	Recently, GBR1, a seven-transmembrene domain protein with high affinity for gamma-aminobutyric acid (GABA)(B) receptor antagonists, was identified. Here, a GBR1-related protein, GBR2, was shown to be coexpressed with GBR1 in many brain regions and to interact with it through a short domain in the carboxyl-terminal cytoplasmic tail. Heterologously expressed GBR2 mediated inhibition of adenylyl cyclase; however, inwardly rectifying potassium channels were activated by GABA(B) receptor agonists only upon coexpression with GBR1 and GBR2, Thus, the interaction of these receptors appears to be crucial for important physiological effects of GABA and provides a mechanism in receptor signaling pathways that involve a heterotrimeric GTP-binding protein.	BASF LYNX Biosci AG, Dept Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany	BASF; Max Planck Society	Kornau, HC (corresponding author), BASF LYNX Biosci AG, Dept Neurosci, Neuenheimer Feld 515, D-69120 Heidelberg, Germany.	kornau@basf-lynx.de	Kuner, Rohini/AGU-0204-2022					ALGER BE, 1979, NATURE, V281, P315, DOI 10.1038/281315a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BONANNO G, 1993, TRENDS PHARMACOL SCI, V14, P259, DOI 10.1016/0165-6147(93)90124-3; BOWERY NG, 1987, NEUROSCIENCE, V20, P365, DOI 10.1016/0306-4522(87)90098-4; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; Caddick SJ, 1996, MOL NEUROBIOL, V13, P23, DOI 10.1007/BF02740750; CHU DCM, 1990, NEUROSCIENCE, V34, P341, DOI 10.1016/0306-4522(90)90144-S; Dichter MA, 1997, EPILEPSIA, V38, pS2, DOI 10.1111/j.1528-1157.1997.tb05200.x; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HILL DR, 1985, BRIT J PHARMACOL, V84, P249; Jarolimek W, 1998, J NEUROSCI, V18, P4001; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Knight AR, 1996, NEUROPHARMACOLOGY, V35, P703, DOI 10.1016/0028-3908(96)84642-9; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNER R, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; STOFFEL M, 1995, BIOCHEM BIOPH RES CO, V212, P894, DOI 10.1006/bbrc.1995.2053; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOICIK WJ, 1984, MOL PHARMACOL, V25, P24	35	471	505	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					74	77		10.1126/science.283.5398.74	http://dx.doi.org/10.1126/science.283.5398.74			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872744				2022-12-24	WOS:000077976600052
J	Ye, XH; Rivera, VM; Zoltick, P; Cerasoli, F; Schnell, MA; Gao, GP; Hughes, JV; Gilman, M; Wilson, JM				Ye, XH; Rivera, VM; Zoltick, P; Cerasoli, F; Schnell, MA; Gao, GP; Hughes, JV; Gilman, M; Wilson, JM			Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer	SCIENCE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; SUSTAINED EXPRESSION; IMMUNOCOMPETENT MICE; SKELETAL-MUSCLE; ERYTHROPOIETIN; TRANSDUCTION; SECRETION; EFFICIENT; PLASMID; SYSTEM	Stable delivery of a therapeutic protein under pharmacologic control was achieved through in vivo somatic gene transfer. This system was based on the expression of two chimeric, human-derived proteins that were reconstituted by rapamycin into a transcription factor complex. A mixture of two adeno-associated virus vectors, one expressing the transcription factor chimeras and one containing erythropoietin (Epo) under the control of a promoter responsive to the transcription factor, was injected into skeletal muscle of immune-competent mice. Administration of rapamycin resulted in 200-fold induction of plasma Epo, Stable engraftment of this humanized system in immune-competent mice was achieved for 6 months with similar results for at least 3 months in a rhesus monkey.	Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA; Univ Penn, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Wistar Inst, Philadelphia, PA 19104 USA; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; The Wistar Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Wilson, JM (corresponding author), Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA.	wilsonjm@mail.med.upenn.edu	Wilson, James M/F-9220-2011; Wilson, Matthew H/K-3193-2013	Wilson, James M/0000-0002-9630-3131; Rivera, Victor/0000-0002-7258-3001	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR/NS43648-03] Funding Source: Medline; NIDDK NIH HHS [P30 DK47757-05] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohl D, 1997, HUM GENE THER, V8, P195, DOI 10.1089/hum.1997.8.2-195; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Gao GP, 1998, HUM GENE THER, V9, P2353, DOI 10.1089/hum.1998.9.16-2353; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Naffakh N, 1996, HUM GENE THER, V7, P11, DOI 10.1089/hum.1996.7.1-11; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Ye X., UNPUB; Ye XH, 1996, J BIOL CHEM, V271, P3639	25	258	294	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					88	91		10.1126/science.283.5398.88	http://dx.doi.org/10.1126/science.283.5398.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872748				2022-12-24	WOS:000077976600056
J	Moloo, J; Jackson, KL; Waller, JL; McKeown, RE; Addy, CL; Cuffe, SP; Garrison, CZ				Moloo, J; Jackson, KL; Waller, JL; McKeown, RE; Addy, CL; Cuffe, SP; Garrison, CZ			Xenotransmission of the socioeconomic gradient in health? A population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ S Carolina, Sch Med, Dept Med, Columbia, SC 29203 USA; Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Dept Neuropsychiat & Behav Sci, Columbia, SC 29203 USA; Univ Louisville, Off Provost, Louisville, KY 40202 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Louisville	Moloo, J (corresponding author), Univ S Carolina, Sch Med, Dept Med, 2 Med Pk,Room 506, Columbia, SC 29203 USA.			McKeown, Robert/0000-0002-8829-5784	NIMH NIH HHS [MH40363] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM PET PROD MAN A, 1997, 1996 1997 APPMA NAT; Black D., 1982, BLACK REPORT; EVANS RG, 1994, ARE SOME PEOPLE HLTH, P3; HAMM TE, 1983, ATHEROSCLEROSIS, V48, P221, DOI 10.1016/0021-9150(83)90040-0; SMITH GD, 1992, BRIT MED J, V305, P1554, DOI 10.1136/bmj.305.6868.1554	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1686	1686		10.1136/bmj.317.7174.1686	http://dx.doi.org/10.1136/bmj.317.7174.1686			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857126	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000077742300013
J	White, JH; Wise, A; Main, MJ; Green, A; Fraser, NJ; Disney, GH; Barnes, AA; Emson, P; Foord, SM; Marshall, FH				White, JH; Wise, A; Main, MJ; Green, A; Fraser, NJ; Disney, GH; Barnes, AA; Emson, P; Foord, SM; Marshall, FH			Heterodimerization is required for the formation of a functional GABA(B) receptor	NATURE			English	Article							DIMERIZATION; EXPRESSION; CLONING	GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter in the mammalian central nervous system, where it exerts its effects through ionotropic (GABA(A/C)) receptors to produce fast synaptic inhibition and metabotropic (GABA(B)) receptors to produce slow prolonged inhibitory signals. The gene encoding a GABA(B) receptor (GABA(B)R1) has been cloned(1); however, when expressed in mammalian cells this receptor is retained as an immature glycoprotein on intracellular membranes(2) and exhibits low affinity for agonists compared with the endogenous receptor on brain membranes. Here we report the cloning of a complementary DNA encoding a new subtype of the GABA(B) receptor (GABA(B)R2), which we identified by mining expressed-sequence-tag databases. Yeast two-hybrid screening showed that this new GABA(B)R2-receptor subtype forms heterodimers with GABA(B)R1 through an interaction at their intracellular carboxy-terminal tails. Upon expression with GABA(B)R2 in HEK293T cells, GABA(B)R1 is terminally glycosylated and expressed at the cell surface. Go-expression of the two receptors produces a fully functional GABA(B) receptor at the cell surface; this receptor binds GABA with a high affinity equivalent to that of the endogenous brain receptor. These results indicate that, in vivo, functional brain GABA(B) receptors may be heterodimers composed of GABA(B)R1 and GABA(B)R2.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Receptor Syst, Stevenage SG1 2NY, Herts, England; Babraham Inst, Dept Neurobiol, Cambridge CB2 4AT, England	GlaxoSmithKline; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Marshall, FH (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Receptor Syst, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	fhm27375@glaxowellcome.co.uk	Marshall, Fiona/AAZ-9626-2020	Marshall, Fiona/0000-0002-8681-005X				BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; Bittiger H, 1992, PHARM COMMUN, V2, P23; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; HARPUR LL, 1995, EXP AGING RES, V21, P1, DOI 10.1080/03610739508254264; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SIMMONS D, 1988, J IMMUNOL, V141, P2797; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; WIELAND T, 1994, METHOD ENZYMOL, V237, P3	18	954	1027	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					679	682		10.1038/25354	http://dx.doi.org/10.1038/25354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872316				2022-12-24	WOS:000077694200054
J	Cheng, AM; Saxton, TM; Sakai, R; Kulkarni, S; Mbamalu, G; Vogel, W; Tortorice, CG; Cardiff, RD; Cross, JC; Muller, WJ; Pawson, T				Cheng, AM; Saxton, TM; Sakai, R; Kulkarni, S; Mbamalu, G; Vogel, W; Tortorice, CG; Cardiff, RD; Cross, JC; Muller, WJ; Pawson, T			Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; MIDDLE T-ANTIGEN; ADAPTER PROTEIN; SH3 DOMAINS; RAS PATHWAY; SIGNAL-TRANSDUCTION; SH3-SH2-SH3 PROTEIN; BINDING-DOMAIN	Proteins with SH2 and SH3 domains link tyrosine kinases to intracellular pathways. To investigate the biological functions of a mammalian SH2/SH3 adaptor, we have introduced a null mutation into the mouse gene for Grb2. Analysis of mutant embryonic stem cells, embryos, and chimeras reveals that Grb2 is required during embyrogenesis for the differentiation of endodermal cells and formation of the epiblast. Grb2 acts physiologically as an adaptor, since replacing the C terminus of the Ras activator Sos1 with the Grb2 SH2 domain yields a fusion protein that largely rescues the defects caused by the Grb2 mutation. Furthermore, Grb2 is rate limiting for mammary carcinomas induced by polyomavirus middle T antigen. These data provide genetic evidence for a mammalian Grb2-Ras signaling pathway, mediated by SH2/SH3 domain interactions, that has multiple functions in embryogenesis and cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; McMaster University; University of California System; University of California Davis	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Cross, James/F-4814-2011; Pawson, Tony J/E-4578-2013; Cross, James/AAU-2973-2020	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378; Sakai, Ryuichi/0000-0001-6833-1103				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BHATNAGAR P, 1995, DEVELOPMENT, V121, P1333; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Byrne JL, 1996, ONCOGENE, V13, P2055; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSHIMA RG, 1983, DEV BIOL, V99, P447, DOI 10.1016/0012-1606(83)90294-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	288	299	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					793	803		10.1016/S0092-8674(00)81702-X	http://dx.doi.org/10.1016/S0092-8674(00)81702-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865697	Bronze			2022-12-24	WOS:000077498800009
J	Griffith, CA; Yelle, RV; Marley, MS				Griffith, CA; Yelle, RV; Marley, MS			The dusty atmosphere of the brown dwarf Gliese 229B	SCIENCE			English	Article							INFRARED-ABSORPTION; SOLAR-SYSTEM; DARK-MATTER; SPECTRA; MODELS; TITAN; BAND; STAR; TEMPERATURES; ULTRAVIOLET	The brown dwarf Gliese 229B has an observable atmosphere too warm to contain ice clouds Like those on Jupiter and too cool to contain silicate clouds Like those on Low-mass stars. These unique conditions permit visibility to higher pressures than possible in cool stars or planets. Gliese 229B's 0.85- to 1.0- micrometer spectrum indicates particulates deep in the atmosphere (10 to 50 bars) having optical properties of neither ice nor silicates. Their reddish color suggests an organic composition characteristic of aerosols in planetary stratospheres. The particles' mass fraction (10(-7)) agrees with a photochemical origin caused by incident radiation from the primary star and suggests the occurrence of processes native to planetary stratospheres.	No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA; Boston Univ, Ctr Space Phys, Boston, MA 02215 USA; New Mexico State Univ, Dept Astron, Las Cruces, NM 88003 USA	Northern Arizona University; Boston University; New Mexico State University	Griffith, CA (corresponding author), No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA.		Marley, Mark S/I-4704-2013					Allard F, 1996, ASTROPHYS J, V465, pL123, DOI 10.1086/310143; [Anonymous], 1987, ADSPR, DOI [DOI 10.1016/0273-1177(87)90362-0, 10.1016/0273-1177(87)90362-0]; BORYSOW A, 1990, ASTROPHYS J, V348, pL41, DOI 10.1086/185626; BYRNE PB, 1985, MON NOT R ASTRON SOC, V214, P119, DOI 10.1093/mnras/214.2.119; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CHAMBERLAIN JW, 1987, THEORY PLAENTARY ATM; Clarke DW, 1997, ICARUS, V127, P158, DOI 10.1006/icar.1996.5667; COLL P, 1995, ADV SPACE RES, V16, P93, DOI 10.1016/0273-1177(95)00197-M; CONRATH BJ, 1984, ICARUS, V57, P184, DOI 10.1016/0019-1035(84)90065-4; Cronin J.R., 1988, METEORITES EARLY SOL, P819; CRUIKSHANK DP, 1989, ADV SPACE RES, V9, P65; FEGLEY B, 1994, ICARUS, V110, P117, DOI 10.1006/icar.1994.1111; Fegley B, 1996, ASTROPHYS J, V472, pL37, DOI 10.1086/310356; FRENKLACH M, 1989, ASTROPHYS J, V341, P372, DOI 10.1086/167501; Geballe TR, 1996, ASTROPHYS J, V467, pL101, DOI 10.1086/310203; GIARMPAPA MS, 1989, ASTROPHYS J, V345, P53; GUILLOT T, 1997, ASTRONOMICAL BIOCH O, P343; HOLTON JR, 1986, J GEOPHYS RES-ATMOS, V91, P2681, DOI 10.1029/JD091iD02p02681; Houdebine ER, 1996, ASTRON ASTROPHYS, V305, P209; HOUDEBINE ER, 1990, THESIS U ORSAY PARIS; JONES JRA, 1996, ASTRON ASTROPHYS, V480, pL39; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; KOIKE C, 1995, ICARUS, V114, P203, DOI 10.1006/icar.1995.1055; LEWIS JS, 1984, SPACE SCI REV, V39, P163, DOI 10.1007/BF00173673; MARCY GW, 1995, 6251 IAU; Marley MS, 1996, SCIENCE, V272, P1919, DOI 10.1126/science.272.5270.1919; MATTHEWS CN, 1992, ORIGINS LIFE EVOL B, V21, P421; Matthews K, 1996, ASTRON J, V112, P1678, DOI 10.1086/118133; MAYOR M, 1995, NATURE, V378, P355, DOI 10.1038/378355a0; MCDONALD GD, 1994, ICARUS, V108, P137, DOI 10.1006/icar.1994.1046; McKay CP, 1996, PLANET SPACE SCI, V44, P741, DOI 10.1016/0032-0633(96)00009-8; MOULD J, 1987, ASTROPHYS J, V226, P923; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; Noll KS, 1997, ASTROPHYS J, V489, pL87, DOI 10.1086/310954; Oppenheimer BR, 1998, ASTROPHYS J, V502, P932, DOI 10.1086/305928; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; OSSENKOPF V, 1992, ASTRON ASTROPHYS, V261, P567; OWEN T, 1995, ADV SPACE RES-SERIES, V16, P41, DOI 10.1016/0273-1177(95)00192-H; Palik E D, 1985, HDB OPTICAL CONSTANT; PANAGI PM, 1993, ASTRON ASTROPHYS SUP, V100, P343; Partridge H, 1997, J CHEM PHYS, V106, P4618, DOI 10.1063/1.473987; Ragent B, 1998, J GEOPHYS RES-PLANET, V103, P22891, DOI 10.1029/98JE00353; Schiavon RP, 1997, ASTROPHYS J, V484, P499, DOI 10.1086/304332; Schultz AB, 1998, ASTROPHYS J, V492, pL181, DOI 10.1086/311103; Scott A, 1996, ASTROPHYS J SUPPL S, V105, P401, DOI 10.1086/192321; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; TOON OB, 1989, J GEOPHYS RES-ATMOS, V94, P16287, DOI 10.1029/JD094iD13p16287; Tsuji T, 1996, ASTRON ASTROPHYS, V308, pL29; TSUJI T, 1996, ASTRON ASTROPHYS, V305, P91; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963; ZHENG C, 1995, ICARUS, V113, P84, DOI 10.1006/icar.1995.1006	52	49	49	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2063	2067		10.1126/science.282.5396.2063	http://dx.doi.org/10.1126/science.282.5396.2063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851924				2022-12-24	WOS:000077467100042
J	Yaron, A; Hatzubai, A; Davis, M; Lavon, I; Amit, S; Manning, AM; Andersen, JS; Mann, M; Mercurio, F; Ben-Neriah, Y				Yaron, A; Hatzubai, A; Davis, M; Lavon, I; Amit, S; Manning, AM; Andersen, JS; Mann, M; Mercurio, F; Ben-Neriah, Y			Identification of the receptor component of the I kappa B alpha-ubiquitin ligase	NATURE			English	Article							PROTEASOME PATHWAY; PHOSPHORYLATION; COMPLEX; KINASE; DEGRADATION; PROTEINS; ACTIVATION; INHIBITOR; BETA	NF-kappa B, a ubiquitous, inducible transcription factor involved in immune, inflammatory, stress and developmental processes, is retained in a latent form in the cytoplasm of non-stimulated cells by inhibitory molecules, I kappa Bs(1-3). It, activation is a paradigm for a signal-transduction cascade that integrates an inducible kinase and the ubiquitin-proteasome system to eliminate inhibitory regulators. Here we isolate the pI kappa B alpha-ubiquitin ligase (pI kappa B alpha-E3) that attaches ubiquitin, a small protein which marks other proteins for degradation by the proteasome system, to the phosphorylated NF-kappa B inhibitor pI kappa B alpha. Taking advantage of its high affinity to pI kappa B alpha, we isolate this ligase from HeLa cells by single-step immunoaffinity purification. Using nanoelectrospray mass spectrometry, we identify the specific component of the ligase that recognizes the pI kappa B alpha degradation motif as an F-box/WD-domain protein belonging to a recently distinguished family of beta-TrCP/Slimb proteins. This component, which we denote E3RS(I kappa B) (pI kappa B alpha-E3 receptor subunit), binds specifically to pI kappa B alpha and promotes its in vitro ubiquitination in the presence of two other ubiquitin-system enzymes, El and UBC5C, one of many known E2 enzymes. An F-box-deletion mutant of E3RS(I kappa B), which tightly binds pI kappa B alpha but does not support its ubiquitination, acts in vivo as a dominant-negative molecule, inhibiting the degradation of pI kappa B alpha and consequently NF-kappa B activation. E3RS(I kappa B) represents a family of receptor proteins that are core components of a class of ubiquitin ligases. When these receptor components recognize their specific ligand, which is a conserved, phosphorylation-based sequence motif, they target regulatory proteins containing this motif for proteasomal degradation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; Signal Pharmaceut Inc, San Diego, CA 92121 USA; Protana AS, DK-5230 Odense M, Denmark	Hebrew University of Jerusalem	Ben-Neriah, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel.	yinon@cc.huji.ac.il	Lavon, Iris/ABE-6651-2021; Ben-Neriah, Yinon/L-6285-2019; Mann, Matthias/A-3454-2013; Andersen, Jens S/L-2100-2015	Mann, Matthias/0000-0003-1292-4799; Andersen, Jens S/0000-0002-6091-140X				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Paul M, 1997, VIROLOGY, V232, P207, DOI 10.1006/viro.1997.8541; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	26	549	578	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					590	594		10.1038/25159	http://dx.doi.org/10.1038/25159			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859996				2022-12-24	WOS:000077466800062
J	Stern, DL				Stern, DL			A role of Ultrabithorax in morphological differences between Drosophila species	NATURE			English	Article							BITHORAX COMPLEX; GENE ULTRABITHORAX; BODY PLANS; HOX GENES; EVOLUTION; MELANOGASTER; EXPRESSION; PRODUCTS; PROTEINS	The mechanisms underlying the evolution of morphology are poorly understood(1,2). Distantly related taxa sometimes exhibit correlations between morphological differences and patterns of gene expression(3-8), but such comparisons cannot establish how mechanisms evolve to generate diverse morphologies. Answers to these questions require resolution of the nature of developmental evolution within and between closely related species. Here I show how the detailed regulation of the Hox gene Ultrabithorax patterns trichomes on the posterior femur of the second leg in Drosophila melanogaster, and that evolution of Ultrabithorax has contributed to divergence of this feature among closely related species, The cis-regulatory regions of Ultrabithorax, and not the protein itself, appear to have evolved. This study provides experimental evidence that cis-regulatory evolution is one way in which conserved proteins have promoted morphological diversity(1).	Wellcome CRC Inst, Cambridge CB2 1QR, England		Stern, DL (corresponding author), Univ Cambridge, Museum Zool, Lab Dev & Evolut, Downing St, Cambridge CB2 3EJ, England.			Stern, David/0000-0002-1847-6483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063622] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063622-01, R01 GM063622] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; Akam M, 1998, INT J DEV BIOL, V42, P445; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Castelli-Gair J, 1998, INT J DEV BIOL, V42, P437; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; Davis AW, 1996, NATURE, V380, P157, DOI 10.1038/380157a0; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Grenier JK, 1997, CURR BIOL, V7, P547, DOI 10.1016/S0960-9822(06)00253-3; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lowe CJ, 1997, NATURE, V389, P718, DOI 10.1038/39580; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MORATA G, 1981, NATURE, V290, P778, DOI 10.1038/290778a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; SANCHEZHERRERO E, 1985, COLD SPRING HARB SYM, V50, P165, DOI 10.1101/SQB.1985.050.01.022; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2	21	191	198	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					463	466		10.1038/24863	http://dx.doi.org/10.1038/24863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853753	Green Accepted			2022-12-24	WOS:000077370100053
J	Morell, RJ; Kim, HJ; Hood, LJ; Goforth, L; Friderici, K; Fisher, R; Van Camp, G; Berlin, CI; Oddoux, C; Ostrer, H; Keats, B; Friedman, TB				Morell, RJ; Kim, HJ; Hood, LJ; Goforth, L; Friderici, K; Fisher, R; Van Camp, G; Berlin, CI; Oddoux, C; Ostrer, H; Keats, B; Friedman, TB			Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JEWISH POPULATION; HEARING IMPAIRMENT; PREVALENCE; EMISSIONS; FREQUENCY	Background Mutations in the GJB2 gene cause one form of nonsyndromic recessive deafness. Among Mediterranean Europeans, more than 80 percent of cases of nonsyndromic recessive deafness result from inheritance of the 30delG mutant allele of GJB2. We assessed the contribution of mutations in GJB2 to the prevalence of the condition among Ashkenazi Jews. Methods We tested for mutations in GJB2 in DNA samples from three Ashkenazi Jewish families with nonsyndromic recessive deafness, from Ashkenazi Jewish persons seeking carrier testing for other conditions, and from members of other ethnic groups. The hearing of persons who were heterozygous for mutations in GJB2 was assessed by means of pure-tone audiometry, measurement of middle-ear immittance, and recording of otoacoustic emissions. Results Two frame-shift mutations in GJB2, 167delT and 30delG, were observed in the families with nonsyndromic recessive deafness. In the Ashkenazi Jewish population the prevalence of heterozygosity for 167delT, which is rare in the general population, was 4.03 percent (95 percent confidence interval, 2.5 to 6.0 percent), and for 30delG the prevalence was 0.73 percent (95 percent confidence interval, 0.2 to 1.8 percent). Genetic-linkage analysis showed conservation of the haplotype for 167delT but the existence of several haplotypes for 30delG. Audiologic examination of carriers of the mutant alleles who had normal hearing revealed subtle differences in their otoacoustic emissions, suggesting that the expression of mutations in GJB2 may be semidominant. Conclusions The high frequency of carriers of mutations in GJB2(4.76 percent) predicts a prevalence of 1 deaf person among 1765 people, which may account for the majority of cases of nonsyndromic recessive deafness in the Ashkenazi Jewish population. Conservation of the haplotype flanking the 167delT mutation suggests that this allele has a single origin, whereas the multiple haplotypes with the 30delG mutation suggest that this site is a hot spot for recurrent mutations. (N Engl J Med 1998;339:1500-5.) (C) 1998, Massachusetts Medical Society.	NIDCD, Genet Mol Lab, NIH, Rockville, MD 20850 USA; Louisiana State Univ, Med Ctr, Dept Otorhinolaryngol & Biocommun, Kresge Hearing Res Lab, New Orleans, LA USA; Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, E Lansing, MI 48824 USA; Univ Antwerp, Dept Med Genet, Antwerp, Belgium; NYU Med Ctr, Dept Pediat, Human Genet Program, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Louisiana State University System; Michigan State University; Michigan State University College of Human Medicine; University of Antwerp; New York University	Morell, RJ (corresponding author), NIDCD, Genet Mol Lab, NIH, 5 Res Ctr,Rm 2A19, Rockville, MD 20850 USA.		Van Camp, Guy/F-3386-2013; Morell, Robert James/Q-2042-2019	Van Camp, Guy/0000-0001-5105-9000; Morell, Robert/0000-0003-1537-7356	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000039] Funding Source: NIH RePORTER; NIDCD NIH HHS [Z01 DC 00039-01] Funding Source: Medline; PHS HHS [P0100379] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson H, 1968, Acta Otolaryngol, V65, P535; BERLIN CI, 1995, HEARING RES, V87, P96, DOI 10.1016/0378-5955(95)00082-F; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; BROWNSTEIN Z, 1991, AM J MED GENET, V41, P306, DOI 10.1002/ajmg.1320410309; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; CHUNG C S, 1970, American Journal of Human Genetics, V22, P630; COLLET L, 1990, HEARING RES, V43, P251, DOI 10.1016/0378-5955(90)90232-E; COSTEFF H, 1980, AM J HUM GENET, V32, P64; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; FEINMESSER M, 1990, J LARYNGOL OTOL, V104, P675, DOI 10.1017/S0022215100113593; Fraser G R, 1971, Otolaryngol Clin North Am, V4, P227; HOOD LJ, 1998, OTOACOUSTIC EMISSION, P137; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; Konigsmark B.W., 1976, GENETIC METABOLIC DE; Kronn D, 1998, ARCH INTERN MED, V158, P777, DOI 10.1001/archinte.158.7.777; KRONN D, 1995, AM J HUM GENET, V57, P1250; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Liu XZ, 1997, ANN OTO RHINOL LARYN, V106, P220, DOI 10.1177/000348949710600307; MEREDITH R, 1992, J AUDIOL MED, V1, P11; MEULENBELT I, 1995, AM J HUM GENET, V57, P1252; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; MOTULSKY AG, 1995, NAT GENET, V9, P99, DOI 10.1038/ng0295-99; Nance W E, 1980, Birth Defects Orig Artic Ser, V16, P263; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI, P188; VanCamp G, 1997, AM J HUM GENET, V60, P758; VANCAMP G, 1998, HEREDITARY HEARING L; Zbar RIS, 1998, OTOLARYNG HEAD NECK, V118, P333, DOI 10.1016/S0194-5998(98)70311-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	32	411	450	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1500	1505		10.1056/NEJM199811193392103	http://dx.doi.org/10.1056/NEJM199811193392103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819448				2022-12-24	WOS:000077051800003
J	Ait-Si-Ali, S; Ramirez, S; Barre, FX; Dkhissi, F; Magnaghi-Jaulin, L; Girault, JA; Robin, P; Knibiehler, M; Pritchard, LL; Ducommun, B; Trouche, D; Harel-Bellan, A				Ait-Si-Ali, S; Ramirez, S; Barre, FX; Dkhissi, F; Magnaghi-Jaulin, L; Girault, JA; Robin, P; Knibiehler, M; Pritchard, LL; Ducommun, B; Trouche, D; Harel-Bellan, A			Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A	NATURE			English	Article							CREB-BINDING-PROTEIN; TRANSCRIPTION FACTOR; COACTIVATOR; P300; DIFFERENTIATION; PRODUCT	Transforming viral proteins such as E1A force cells through the restriction point of the cell cycle into S phase by forming complexes with two cellular proteins(1-3): the retinoblastoma protein (Rb)(4) a transcriptional co-repressor(5), and CBP/p300 (ref. 6), a transcriptional co-activator(7-9). These two proteins locally influence chromatin structure: Rb recruits a histone deacetylase(10-12) whereas CBP is a histone acetyltransferase(13,14). Progression through the restriction point is triggered by phosphorylation of Rb, leading to disruption of Rb-associated repressive complexes and allowing the activation of S-phase genes(15). Here we show that CBP, like Rb, is controlled by phosphorylation at the G1/S boundary, increasing its histone acetyltransferase activity. This enzymatic activation is mimicked by E1A.	CNRS, UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, F-94801 Villejuif, France; Coll France, INSERM, U114, F-75005 Paris, France; Univ Toulouse 3, CNRS, UPR 9062, IPBS, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Harel-Bellan, A (corresponding author), CNRS, UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, IFC-01, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	DUCOMMUN, Bernard/B-3208-2008; Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015; Barre, François-Xavier/F-6767-2019; Girault, Jean-Antoine/F-7518-2013; Ramirez-Clavijo, Sandra/G-5268-2016	Girault, Jean-Antoine/0000-0002-7900-1705; Harel-Bellan, Annick/0000-0002-2339-153X; Trouche, Didier/0000-0003-1398-6481; DUCOMMUN, Bernard/0000-0002-7126-8368; Ramirez-Clavijo, Sandra/0000-0003-0336-5614				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DYSON N, 1992, CANCER SURV, V12, P161; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Groisman R, 1996, J BIOL CHEM, V271, P5258; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	30	256	261	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					184	186		10.1038/24190	http://dx.doi.org/10.1038/24190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823900				2022-12-24	WOS:000077013300056
J	Shukla, VK; Prakash, A; Tripathi, BD; Reddy, DCS; Singh, S				Shukla, VK; Prakash, A; Tripathi, BD; Reddy, DCS; Singh, S			Biliary heavy metal concentrations in carcinoma of the gall bladder: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Banaras Hindu Univ, Inst Med Sci, Dept Surg, Varanasi 221005, Uttar Pradesh, India; Banaras Hindu Univ, Inst Med Sci, Dept Community Med, Varanasi 221005, Uttar Pradesh, India; Banaras Hindu Univ, Fac Sci, Dept Bot, Varanasi 221005, Uttar Pradesh, India	Banaras Hindu University (BHU); Banaras Hindu University (BHU); Banaras Hindu University (BHU)	Shukla, VK (corresponding author), Banaras Hindu Univ, Inst Med Sci, Dept Surg, Varanasi 221005, Uttar Pradesh, India.			Tripathi, Brahma Dutt/0000-0002-3888-0379; Shukla, Vijay/0000-0002-2585-3478				KJELLSTROM T, 1979, ENVIRON HEALTH PERSP, V28, P199, DOI 10.2307/3428921; KRISHNAMURTI CR, 1990, TOXIC METALS INDIAN, P75; Leonard A., 1983, P INT C HEAV MET ENV, P700; *ROYAL COMM ENV PO, 1983, COMM8852; SHUKLA VK, 1985, J SURG ONCOL, V28, P32, DOI 10.1002/jso.2930280109	5	37	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1288	1289		10.1136/bmj.317.7168.1288	http://dx.doi.org/10.1136/bmj.317.7168.1288			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804716	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000076963800025
J	Shyng, SL; Nichols, CG				Shyng, SL; Nichols, CG			Membrane phospholipid control of nucleotide sensitivity of K-ATP channels	SCIENCE			English	Article							POTASSIUM CHANNELS; SULFONYLUREA RECEPTOR; STOICHIOMETRY; SUBUNIT; MUSCLE	Adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels couple cell metabolism to electrical activity. Phosphatidylinositol phosphates (PIPs) profoundly antagonized ATP inhibition of K-ATP channels when applied to inside-out membrane patches. It is proposed that membrane-incorporated pips can bind to positive charges in the cytoplasmic region of the channel's K(ir)6.2 subunit, stabilizing the open state of the channel and antagonizing the inhibitory effect of ATP. The tremendous effect of pips on ATP sensitivity suggests that in vivo alterations of membrane PIP levels will have substantial effects on K-ATP channel activity and hence on the gain of metabolism-excitation coupling.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	cnichols@cellbio.wustl.edu	Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; CANNELL MB, 1991, BIOPHYS J, V60, P1156, DOI 10.1016/S0006-3495(91)82151-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1991, FEBS LETT, V279, P95, DOI 10.1016/0014-5793(91)80259-6; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0	16	482	483	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1138	1141		10.1126/science.282.5391.1138	http://dx.doi.org/10.1126/science.282.5391.1138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804554				2022-12-24	WOS:000076887700054
J	Hiraoka, N; Allen, E; Apel, IJ; Gyetko, MR; Weiss, SJ				Hiraoka, N; Allen, E; Apel, IJ; Gyetko, MR; Weiss, SJ			Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins	CELL			English	Article							PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; HUMAN STROMELYSIN-3; PROGELATINASE-A; SNAKE-VENOM; TNF-ALPHA; ANGIOGENESIS; MIGRATION; MICE	During angiogenesis, endothelial cells penetrate fibrin barriers via undefined proteolytic mechanisms. We demonstrate that the fibrinolytic plasminogen activator (PA)-plasminogen system is not required for this process, since tissues isolated from PA- or plasminogen-deficient mice successfully neovascularize fibrin gels. By contrast, neovessel formation, in vitro and in vivo, is dependent on fibrinolytic, endothelial cell-derived matrix metalloproteinases (MMP). MMPs directly regulate this process as invasion-incompetent cells penetrate fibrin barriers when transfected with the most potent fibrinolytic metalloproteinase identified in endothelium, membrane type-1 MMP (MT1-MMP). Membrane display of MT1-MMP is required, as invasion-incompetent cells expressing a fibrinolytically active, transmembrane-deleted form of MT1-MMP remain noninvasive. These observations identify a PA-independent fibrinolytic pathway wherein tethered MMPs function as pericellular fibrinolysins during the neovascularization process.	Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Dept Internal Med, Div Pulm Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Weiss, SJ (corresponding author), Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.	sjweiss@umich.edu			NCI NIH HHS [CA71699] Funding Source: Medline; NHLBI NIH HHS [HL54216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071699] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Botos I, 1996, P NATL ACAD SCI USA, V93, P2749, DOI 10.1073/pnas.93.7.2749; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN LF, 1993, AM J PATHOL, V142, P273; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Bugge TH, 1997, BLOOD, V90, P4522; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; NOMURA H, 1995, CANCER RES, V55, P3263; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PLOPLIS V, 1995, CIRCULATION, V92, P2582; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Senger DR, 1996, AM J PATHOL, V149, P1; Ueno H, 1997, CANCER RES, V57, P2055; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	58	615	642	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					365	377		10.1016/S0092-8674(00)81768-7	http://dx.doi.org/10.1016/S0092-8674(00)81768-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814707	Bronze			2022-12-24	WOS:000076789600010
J	Hayashi, T; Umemori, H; Mishina, M; Yamamoto, T				Hayashi, T; Umemori, H; Mishina, M; Yamamoto, T			The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn	NATURE			English	Article							CEREBELLAR GRANULE CELLS; LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; PURKINJE-CELLS; SRC; EXPRESSION; HIPPOCAMPUS; FYN; ASSOCIATION; ACTIVATION	Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. The ionotropic glutamate receptors are classified into two groups, NMDA (N-methyl-D-aspartate) receptors and AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, The AMPA receptor is a ligand-gated postsynaptic currents in the central nervous system(1,2). Here we report that AMPA receptors function not only as ion channels but also as cell-surface signal transducers by means of their interaction with the Src-family non-receptor protein tyrosine kinase Lyn. In the cerebellum, Lyn is physically associated with the AMPA receptor and is rapidly activated following stimulation of the receptor. Activation of Lyn is independent of Ca2+ and Na+ influx through AMPA receptors. As a result of activation of Lyn, the mitogen-activated protein kinase (MAPK) signalling pathway is activated, and the expression of brain-derived neurotrophic factor (BDNF) messenger RNA is increased in a Lyn-kinase-dependent manner. Thus, AMPA receptors generate intracellular signals from the cell surface to the nucleus through the Lyn-MAPK pathway, which may contribute to synaptic plasticity by regulating the expression of BDNF.	Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan; Univ Tokyo, Sch Med, Dept Mol Neurobiol & Pharmacol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan.			Hayashi, Takashi/0000-0003-3591-2109; Umemori, Hisashi/0000-0001-7198-2062				BESSHO Y, 1993, MOL BRAIN RES, V18, P201, DOI 10.1016/0169-328X(93)90190-Z; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; Chen S, 1996, DEV BRAIN RES, V92, P140, DOI 10.1016/0165-3806(95)00208-1; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HIRANO T, 1986, P NATL ACAD SCI USA, V83, P4957, DOI 10.1073/pnas.83.13.4957; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUDOL M, 1988, ONCOGENE RES, V2, P345; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; Wang YZ, 1997, NATURE, V389, P502, DOI 10.1038/39062; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMASHITA H, 1992, ANAL SCI, V8, P251, DOI 10.2116/analsci.8.251; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	28	239	248	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					72	76		10.1038/16269	http://dx.doi.org/10.1038/16269			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892356				2022-12-24	WOS:000077959400050
J	Cleeman, JI; Lenfant, C				Cleeman, JI; Lenfant, C			The National Cholesterol Education Program - Progress and prospects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; MYOCARDIAL-INFARCTION; MEN; PRAVASTATIN; PREVALENCE; PREVENTION; MORTALITY; STROKE	The National Cholesterol Education Program (NCEP) is a prime example of the role the National Heart, Lung, and Blood institute has played, in its 50 years; of existence, as a catalyst for translating research advances into improved clinical and public health practices. Since its inception in 1985, the NCEP has adhered to 2 principles in mounting educational campaigns for professionals and the public: building on a strong science base and working in partnership with other organizations. In slightly more than a decade, the NCEP has made significant progress toward its goal of reducing the prevalence of high blood cholesterol. The impact of cholesterol education is clearly visible in 4 major trends: increasing professional and public cholesterol awareness; declining dietary intakes of saturated fat, total fat, and cholesterol; falling serum cholesterol levels; and a continuing decline in coronary heart disease (CHD) mortality rates. Nevertheless, cholesterol levels are still being undertreated, especially in patients with CHD, and substantial scientific and educational challenges remain. bs it looks forward to the 21st century, the NCEP plans to make continued progress by using emerging scientific developments and pursuing the powerful combination of cholesterol lowering in CHD patients and in primary prevention.	NHLBI, Natl Cholesterol Educ Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cleeman, JI (corresponding author), NHLBI, Natl Cholesterol Educ Program, 31 Ctr Dr,Bldg 31,Room 4A16, Bethesda, MD 20892 USA.	cleemanj@gwgate.nhlbi.nih.gov						BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; *DHHS, 1997, DHHS PUBL PHS, P191; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Ernst ND, 1997, AM J CLIN NUTR, V66, P965; Ernst ND, 1997, J AM DIET ASSOC, V97, pS47, DOI 10.1016/S0002-8223(97)00729-3; Expert Panel on Detection, 1994, CIRCULATION, V89, P1329; *FED AM SOC EXP BI, 1995, 3 REP NUTR MON US, V1; *FED AM SOC EXP BI, 1995, 3 REP NUTR MON US, V2; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HICKMAN TB, IN PRESS PREV MED; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Kuller LH, 1998, CIRCULATION, V98, P196, DOI 10.1161/01.CIR.98.3.196; KULLER LH, 1991, NIH PUBL; LAROSA JC, 1992, CIRCULATION, V85, P1229, DOI 10.1161/01.CIR.85.3.1229; MCDOWELL MA, 1994, NATL CTR HLTH STAT P, V255; Nachman RL, 1997, CIRCULATION, V96, P2485; *NAT CHOL ED PROGR, 1995, NIH PUBL; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; *NAT CHOL ED PROGR, 1990, NIH PUBL; *NAT HEART LUNG BL, 1996, MORD MORT 1996 CHART; *NAT HEART LUNG BL, 1990, NIH PUBL; *NAT HEART LUNG BL, 1995, CHOL AW SURV; National Cholesterol Education Program, 1993, NIH PUBL; National Heart Lung and Blood Institute, 1998, NAT HEART LUNG BLOOD; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259	44	99	99	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2099	2104		10.1001/jama.280.24.2099	http://dx.doi.org/10.1001/jama.280.24.2099			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875878	Green Published			2022-12-24	WOS:000077606100034
J	Sun, PQ; Dong, P; Dai, K; Hannon, GJ; Beach, D				Sun, PQ; Dong, P; Dai, K; Hannon, GJ; Beach, D			p53-independent role of MDM2 in TGF-beta 1 resistance	SCIENCE			English	Article							GROWTH-FACTOR-BETA; P53 GENE-MUTATIONS; RETINOBLASTOMA PROTEIN; BREAST-CARCINOMA; IN-VITRO; EXPRESSION; CELLS; OVEREXPRESSION; ONCOPROTEIN; INHIBITION	Transforming growth factor-beta (TGF-beta) inhibits cell proliferation, and acquisition of TGF-beta resistance has been Linked to tumorigenesis, A genetic screen was performed to identify complementary DNAs that abrogated TGF-beta sensitivity in mink lung epithelial cells, Ectopic expression of murine double minute 2 rescued TGF-beta-induced growth arrest in a p53-independent manner by interference with retinoblastoma susceptibility gene product (Rb)/E2F function. In human breast tumor cells, increased MDM2 expression Levels correlated with TGF-beta resistance. Thus, MDM2 may confer TGF-beta resistance in a subset of tumors and may promote tumorigenesis by interference with two independent tumor suppressors, p53 and Rb.	Inst Child Hlth, London WC1N, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Beach, D (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N, England.		Hannon, Gregory/AAB-3568-2019					ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Boyer SN, 1996, CANCER RES, V56, P4620; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRASAGAKIS K, 1994, ANTICANCER RES, V14, P2565; Kulkarni S, 1996, CELL GROWTH DIFFER, V7, P501; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nowell PC, 1998, IMMUNOL RES, V17, P171, DOI 10.1007/BF02786442; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POREMBA C, 1995, ONCOL RES, V7, P331; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; SUN P, UNPUB; Teti A, 1997, INT J CANCER, V72, P1013; Wagner SN, 1998, BRIT J DERMATOL, V138, P13; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	32	190	191	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2270	2272		10.1126/science.282.5397.2270	http://dx.doi.org/10.1126/science.282.5397.2270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856953				2022-12-24	WOS:000077645800051
J	Dye, C; Garnett, GP; Sleeman, A; Williams, BG				Dye, C; Garnett, GP; Sleeman, A; Williams, BG			Prospects for worldwide tuberculosis control under the WHO DOTS strategy	LANCET			English	Article							TRANSMISSION; HISTORY; DISEASE; MODELS; AGE	Background WHO advocates the use of directly observed treatment with a short-course drug regimen as part of the DOTS strategy, but the potential effect of this strategy worldwide has not been investigated. Methods We developed an age-structured mathematical model to explore the characteristics of tuberculosis control under DOTS, and to forecast the effect of improved case finding and cure on tuberculosis epidemics for each of the six WHO regions. Findings In countries where the incidence of tuberculosis is stable and HIV-1 absent, a control programme that reaches the WHO targets of 70% case detection and 85% cure would reduce the incidence rate by 11% (range 8-12) per year and the death rate by 12% (9-13) per year. If tuberculosis has been in decline for some years, the same case detection and cure rates would have a smaller effect on incidence. DOTS saves a greater proportion of deaths than cases, and this difference is bigger in the presence of HIV-1. HIV-1 epidemics cause an increase in tuberculosis incidence, but do not substantially reduce the preventable proportion of cases and deaths. Without greater effort to control tuberculosis, the annual incidence of the disease is expected to increase by 41% (21-61) between 1998 and 2020 (from 7.4 million to 10.6 million cases per year). Achievement of WHO targets by 2010 would prevent 23% (15-30) or 48 million cases by 2020. Interpretation The potential effect of chemotherapy (delivered as DOTS) on tuberculosis is greater in many developing countries now than it was in developed countries 50 years ago. To exploit this potential, case detection and cure rates urgently need to be improved in the main endemic areas.	WHO, Global TB Programme, CH-1211 Geneva 27, Switzerland; Ctr Epidemiol & Infect Dis, Oxford, England; Epidemiol Res Unit, Johannesburg, South Africa	World Health Organization; University of Oxford	Dye, C (corresponding author), WHO, Global TB Programme, CH-1211 Geneva 27, Switzerland.		Dye, Christopher/AIC-4659-2022; Garnett, Geoffrey P/A-9312-2008	Dye, Christopher/0000-0002-2957-1793; Williams, Brian/0000-0002-3174-4876				BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; CAUTHEN G, 1998, WHOTB88154; Comstock GW, 1993, TUBERCULOSIS COMPREH, P23; FOX W, 1975, AM REV RESPIR DIS, V111, P325; GARNETT GP, 1994, IMA J MATH APPL MED, V11, P161; Harries AD, 1997, PHARMACOL THERAPEUT, V73, P1, DOI 10.1016/S0163-7258(96)00115-5; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; OBRIEN RJ, 1994, TUBERCULOSIS BACK FU, P151; Organization WH, 1997, WHOTB97229; Raviglione M C, 1997, AIDS, V11 Suppl B, pS115; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; Rieder HL, 1993, TUBERCULOSIS COMPREH, P167; Styblo K, 1991, TUBERCULOSIS SURVEIL, V2, P60; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; *UNAIDS, 1997, REP GLOB HIV AIDS EP; *UNPD, 1996, WORLD POP PROSP; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; VYNNYCKY E, 1996, THESIS U LONDON LOND; *WHO, 1996, INV HLTH RES DEV, P35; *WHO, 1998, WHOTB98237; World Health Organization, 1994, FRAM EFF TUB CONTR	24	353	359	1	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1886	1891		10.1016/S0140-6736(98)03199-7	http://dx.doi.org/10.1016/S0140-6736(98)03199-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863786				2022-12-24	WOS:000077544600009
J	Mayer, KFX; Schoof, H; Haecker, A; Lenhard, M; Jurgens, G; Laux, T				Mayer, KFX; Schoof, H; Haecker, A; Lenhard, M; Jurgens, G; Laux, T			Role of WUSCHEL in regulating stem cell fate in the Arabidopsis shoot meristem	CELL			English	Article							PROTEIN PHOSPHATASE; SEQUENCE-ANALYSIS; ANALYSIS SOFTWARE; HOMEOBOX GENES; C-ELEGANS; THALIANA; CLAVATA1; EMBRYOGENESIS; HOMEODOMAIN; EMBRYO	The shoot meristem gives rise to the aerial parts of higher plants by continuously initiating new organs. The basis of this activity is its ability to maintain a pool of pluripotent stem cells, which are the ultimate source of all tissues of the shoot. In Arabidopsis plants mutant for the WUSCHEL (WUS) gene, the stem cells are misspecified and appear to undergo differentiation. Here, we show that WUS encodes a novel homeodomain protein which presumably acts as a transcriptional regulator. The pattern of WUS expression suggests that stem cells in the shoot meristem are specified by an underlying cell group which is established in the 16-cell embryo and becomes localized to its prospective domain of function by asymmetric cell divisions.	Univ Tubingen, Lehrstuhl Entwicklungsgenet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Laux, T (corresponding author), Univ Tubingen, Lehrstuhl Entwicklungsgenet, Auf Morgenstelle 1, D-72076 Tubingen, Germany.	thomas.laux@uni-tuebingen.de	Schoof, Heiko/Y-7073-2018; Mayer, Klaus FX/M-7941-2015; Lenhard, Michael/J-1554-2015	Schoof, Heiko/0000-0002-1527-3752; Mayer, Klaus FX/0000-0001-6484-1077; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barlow PW, 1978, STEM CELLS TISSUE HO, P87; BARTON MK, 1993, DEVELOPMENT, V119, P823; BOEHM U, 1995, PLANT J, V7, P441, DOI 10.1046/j.1365-313X.1995.7030441.x; BOWMAN J, 1994, ARABIDOPSIS ATLAS MI; Brown JWS, 1996, PLANT J, V10, P771, DOI 10.1046/j.1365-313X.1996.10050771.x; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; Clark SE, 1997, PLANT CELL, V9, P1067, DOI 10.1105/tpc.9.7.1067; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P327, DOI 10.1093/nar/14.1.327; HAKE S, 1995, PHILOS T R SOC B, V350, P45, DOI 10.1098/rstb.1995.0136; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Jackson D., 1991, MOL PLANT PATHOLOGY, P163; JURGENS G, 1994, COLOUR ATLAS DEV EMB, P7; Kaplan DR, 1997, PLANT CELL, V9, P1903, DOI 10.1105/tpc.9.11.1903; KAPLAN DR, 1969, PHYTOMORPHOLOGY, V19, P253; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Laux T, 1998, SEMIN CELL DEV BIOL, V9, P195, DOI 10.1006/scdb.1997.0208; Laux T, 1997, TRENDS PLANT SCI, V2, P325, DOI 10.1016/S1360-1385(97)84613-4; Laux T, 1996, DEVELOPMENT, V122, P87; Laux T, 1997, PLANT CELL, V9, P989, DOI 10.1105/tpc.9.7.989; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Long JA, 1998, DEVELOPMENT, V125, P3027; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Matallana E., 1992, Methods in Arabidopsis research., P144; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; NEWMAN I. V., 1965, J LINN SOC LONDON BOT, V59, P185; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUTH J, 1985, AM J BOT, V72, P1127, DOI 10.2307/2443459; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; SPURR AR, 1949, AM J BOT, V36, P629, DOI 10.2307/2437856; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEWART RN, 1970, AM J BOT, V57, P816, DOI 10.2307/2441339; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Williams RW, 1997, P NATL ACAD SCI USA, V94, P10467, DOI 10.1073/pnas.94.19.10467; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; WU L, 1995, PLANT J, V8, P323, DOI 10.1046/j.1365-313X.1995.08030323.x	56	1198	1305	11	244	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					805	815		10.1016/S0092-8674(00)81703-1	http://dx.doi.org/10.1016/S0092-8674(00)81703-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865698	Bronze			2022-12-24	WOS:000077498800010
J	Zuber, MT; Smith, DE; Solomon, SC; Abshire, JB; Afzal, RS; Aharonson, O; Fishbaugh, K; Ford, PG; Frey, HV; Garvin, JB; Head, JW; Ivanov, AB; Johnson, CL; Muhleman, DO; Neumann, GA; Pettengill, GH; Phillips, RJ; Sun, ZL; Zwally, HJ; Banerdt, WB; Duxbury, TC				Zuber, MT; Smith, DE; Solomon, SC; Abshire, JB; Afzal, RS; Aharonson, O; Fishbaugh, K; Ford, PG; Frey, HV; Garvin, JB; Head, JW; Ivanov, AB; Johnson, CL; Muhleman, DO; Neumann, GA; Pettengill, GH; Phillips, RJ; Sun, ZL; Zwally, HJ; Banerdt, WB; Duxbury, TC			Observations of the north polar region of Mars from the Mars Orbiter Laser Altimeter	SCIENCE			English	Article							PLANETARY CONDITIONS; WATER-VAPOR; ICE; BEHAVIOR; MODEL	Elevations from the Mars Orbiter Laser Altimeter (MOLA) have been used to construct a precise topographic map of the martian north polar region. The northern ice cap has a maximum elevation of 3 kilometers above its surroundings but Lies within a 5-kilometer-deep hemispheric depression that is contiguous with the area into which most outflow channels emptied, Polar cap topography displays evidence of modification by ablation, flow, and wind and is consistent with a primarily H2O composition. Correlation of topography with images suggests that the cap was more spatially extensive in the past. The cap volume of 1.2 x 10(6) to 1.7 x 10(6) cubic kilometers is about half that of the Greenland ice cap. Clouds observed over the polar cap are Likely composed of CO2 that condensed out of the atmosphere during northern hemisphere winter. Many clouds exhibit dynamical structure Likely caused by the interaction of propagating wave fronts with surface topography.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; CALTECH, Pasadena, CA 91125 USA; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Massachusetts Institute of Technology (MIT); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Brown University; California Institute of Technology; Washington University (WUSTL); Carnegie Institution for Science; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Zuber, MT (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	zuber@tharsis.gsfc.nasa.gov	Abshire, James/I-2800-2013; Sun, Xiaoli/B-5120-2013; Neumann, Gregory A/I-5591-2013; Banerdt, William/Q-7324-2019	Neumann, Gregory A/0000-0003-0644-9944; Banerdt, William/0000-0003-3125-1542; Aharonson, Oded/0000-0001-9930-2495				ABSHIRE JB, UNPUB; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; BLASIUS KR, 1982, ICARUS, V50, P140, DOI 10.1016/0019-1035(82)90122-1; BUDD WF, 1970, J GLACIOL, V9, P29; CLARK BR, 1976, ICARUS, V27, P215, DOI 10.1016/0019-1035(76)90005-1; CLIFFORD SM, 1987, J GEOPHYS RES-SOLID, V92, P9135, DOI 10.1029/JB092iB09p09135; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; Davies ME, 1995, CELEST MECH DYN ASTR, V63, P127, DOI 10.1007/BF00693410; Drewry D. J., 1982, ANN GLACIOL, V3, P83, DOI DOI 10.1017/S0260305500002573; Durham WB, 1997, J GEOPHYS RES-PLANET, V102, P16293, DOI 10.1029/97JE00916; DURHAM WB, 1992, J GEOPHYS RES-PLANET, V97, P20883, DOI 10.1029/92JE02326; DURHAM WB, 1998, 1 INT C MARS POL SCI, P8; DZURISIN D, 1975, J GEOPHYS RES, V80, P3286, DOI 10.1029/JB080i023p03286; Fanale F.P., 1992, MARS, P1135; FANALE FP, 1986, ICARUS, V67, P1, DOI 10.1016/0019-1035(86)90170-3; FARMER CB, 1979, J GEOPHYS RES, V84, P2881, DOI 10.1029/JB084iB06p02881; FISHER DA, 1993, ICARUS, V105, P501, DOI 10.1006/icar.1993.1144; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GARVIN JB, IN PRESS GEOPHYS RES; Greeley R., 1992, MARS, P730; Haefeli R., 1961, J GLACIOL, V3; HEAD JW, INPRESS GEOPHYS RES; Holton J. R., 1992, INTRO DYNAMIC METEOR; HOWARD A, 1980, 82385 TM; HOWARD AD, 1982, ICARUS, V50, P161, DOI 10.1016/0019-1035(82)90123-3; Jakosky B. M., 1992, MARS, P969; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LANCASTER N, 1990, J GEOPHYS RES-SOLID, V95, P10921, DOI 10.1029/JB095iB07p10921; LEOVY CB, 1982, ADV SPACE RES, V2, P19, DOI DOI 10.1016/0273-1177(82)90103-X; MALIN MC, UNPUB; MUHLEMAN DO, 1998, 1 INT C MARS POL SCI, P28; ROWLANDS DD, 1993, GEODYN 2 SYSTEM DESC; ROWLANDS DQ, UNPUB; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SMITH WHF, 1990, GEOPHYSICS, V55, P293, DOI 10.1190/1.1442837; Thomas P., 1992, MARS, P767; TILLMAN JE, 1988, J GEOPHYS RES-ATMOS, V93, P9433, DOI 10.1029/JD093iD08p09433; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; TSOAR H, 1979, J GEOPHYS RES, V84, P8167, DOI 10.1029/JB084iB14p08167; Wessel P, 1991, EOS T AM GEOPHYS UN, V72, P445, DOI [10.1029/90EO00319, DOI 10.1029/90EO00319, DOI 10.1029/90E000319]; Zuber M., 1998, 1 INT C MARS POL SCI, P45; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; ZUBER MT, IN PRESS GEOPHYS RES; ZUBER MT, 1998, EOS, V79, pF486; ZWALLY HJ, 1989, SCIENCE, V246, P1587, DOI 10.1126/science.246.4937.1587	49	211	212	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2053	2060		10.1126/science.282.5396.2053	http://dx.doi.org/10.1126/science.282.5396.2053			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851922				2022-12-24	WOS:000077467100040
J	Tsai, HM; Lian, ECY				Tsai, HM; Lian, ECY			Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; NORMAL PLASMA; SHEAR-STRESS; FACTOR-VIII; CLEAVAGE; PROTEOLYSIS; PLATELETS	Background Thrombotic thrombocytopenic purpura is a potentially fatal disease characterized by widespread platelet thrombi in the microcirculation. In the normal circulation, von Willebrand factor is cleaved by a plasma protease. We explored the hypothesis that a deficiency of this protease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombosis. Methods We studied the activity of von Willebrand factor-cleaving protease and sought inhibitors of this protease in plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other diseases, and normal control subjects. We also investigated the effect of shear stress on the ristocetin cofactor activity of purified von Willebrand factor in the cryosupernatant fraction of the plasma samples. Results Thirty-nine samples of plasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficiency of von Willebrand factor-cleaving protease. No deficiency was detected in 16 samples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 74 plasma samples from normal subjects, randomly selected hospitalized patients or outpatients, or patients with hemolysis, thrombocytopenia, or thrombosis from other causes. Inhibitory activity against the protease was detected in 26 of the 39 plasma samples (67 percent) obtained during the acute phase of the disease. The inhibitors were IgG antibodies. Shear stress increased the ristocetin cofactor activity of von Willebrand factor in the cryosupernatant of plasma samples obtained during the acute phase, but decreased the activity in cryosupernatant of plasma from normal subjects. Conclusions Inhibitory antibodies against von Willebrand factor-cleaving protease occur in patients with acute thrombotic thrombocytopenic purpura, A deficiency of this protease is likely to have a critical role in the pathogenesis of platelet thrombosis in this disease. (N Engl J Med 1998;339:1585-94.) (C)1998, Massachusetts Medical Society.	Montefiore Med Ctr, Div Hematol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Miami, Ctr Thrombosis & Hemostasis, Miami, FL 33152 USA; Univ Miami, Sylvester Canc Ctr, Miami, FL 33152 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tsai, HM (corresponding author), Montefiore Med Ctr, Div Hematol, 111 E 210th St, Bronx, NY 10467 USA.				NHLBI NIH HHS [R01 HL062136-01, R01 HL062136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASADA Y, 1985, THROMB RES, V38, P469, DOI 10.1016/0049-3848(85)90180-X; BAEHR G, 1936, T ASSOC AM PHYSICIAN, V51, P43; Bell WR, 1997, SEMIN HEMATOL, V34, P134; BURNS ER, 1982, BLOOD, V60, P1030; Chow TW, 1998, AM J HEMATOL, V57, P293, DOI 10.1002/(SICI)1096-8652(199804)57:4<293::AID-AJH5>3.3.CO;2-R; CONSONNI R, 1994, BRIT J HAEMATOL, V87, P321, DOI 10.1111/j.1365-2141.1994.tb04916.x; DENT JA, 1990, P NATL ACAD SCI USA, V87, P9508; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Furlan M, 1997, BLOOD, V89, P3097, DOI 10.1182/blood.V89.9.3097; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Hymes KB, 1997, SEMIN HEMATOL, V34, P117; JOSEPH G, 1994, AM J HEMATOL, V47, P189, DOI 10.1002/ajh.2830470308; KELTON JG, 1992, BLOOD, V80, P2246; Kroll MH, 1996, BLOOD, V88, P1525; Kwaan HC, 1997, SEMIN HEMATOL, V34, P159; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; MIURA M, 1984, AM J HEMATOL, V17, P307, DOI 10.1002/ajh.2830170311; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOAKE JL, 1989, AM J MED, V87, P9; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; NEAME PB, 1980, SEMIN THROMB HEMOST, V6, P416, DOI 10.1055/s-2007-1005113; Nichols W C, 1995, Blood, V86, P2461; NICHOLS WC, 1994, BLOOD, V83, P3225; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; SIDDIQUI FA, 1985, J CLIN INVEST, V76, P1330, DOI 10.1172/JCI112107; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; TANDON NN, 1994, BRIT J HAEMATOL, V88, P816, DOI 10.1111/j.1365-2141.1994.tb05122.x; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Tsai HM, 1997, BLOOD, V89, P1954, DOI 10.1182/blood.V89.6.1954; TSAI HM, 1989, BLOOD, V73, P2074; TSAI HM, 1994, BLOOD, V83, P2171; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235	33	1300	1356	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1585	1594		10.1056/NEJM199811263392203	http://dx.doi.org/10.1056/NEJM199811263392203			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828246	Green Accepted, Bronze			2022-12-24	WOS:000077176100003
J	Kasschau, KD; Carrington, JC				Kasschau, KD; Carrington, JC			A counterdefensive strategy of plant viruses: Suppression of posttranscriptional gene silencing	CELL			English	Article							TOBACCO ETCH POTYVIRUS; HELPER COMPONENT-PROTEINASE; LONG-DISTANCE MOVEMENT; PATHOGEN-DERIVED RESISTANCE; TO-CELL MOVEMENT; TRANSGENIC PLANTS; GENOME AMPLIFICATION; PROTEOLYTIC ACTIVITIES; RNA DEGRADATION; X RNA	Posttranscriptional gene silencing (PTGS) in plants inactivates some aberrant or highly expressed RNAs in a sequence-specific manner in the cytoplasm. A silencing mechanism similar to PTGS appears to function as an adaptive antiviral response. We demonstrate that the P1/HC-Pro polyprotein encoded by tobacco etch virus functions as a suppressor of PTGS. A locus comprised of a highly expressed P-glucuronidase (GUS) transgene was shown to exhibit PTGS. Genetic crosses and segregation analyses revealed that a P1/HC-Pro transgene suppressed PIGS of the GUS sequence. Nuclear transcription assays indicated that the silencing suppression activity of P1/HC-Pro was at the posttranscriptional level. These data reveal that plant viruses can condition enhanced susceptibility within a host through interdiction of a potent defense response.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Carrington, JC (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	carrington@wsu.edu	Carrington, James C/A-4656-2012	Carrington, James C/0000-0003-3572-129X	NIAID NIH HHS [AI27832, AI43288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027832, R01AI027832, R01AI043288, R21AI043288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113; Angell SM, 1997, EMBO J, V16, P3675, DOI 10.1093/emboj/16.12.3675; Baulcombe DC, 1996, PLANT CELL, V8, P1833, DOI 10.1105/tpc.8.10.1833; BRIGNETI G, 1998, IN PRESS EMBO J, V17; CARRINGTON JC, 1990, EMBO J, V9, P1347, DOI 10.1002/j.1460-2075.1990.tb08249.x; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CARRINGTON JC, 1993, J VIROL, V67, P6995, DOI 10.1128/JVI.67.12.6995-7000.1993; COX KH, 1988, PLANT MOL BIOL PRACT, P1; CRONIN S, 1995, PLANT CELL, V7, P549, DOI 10.1105/tpc.7.5.549; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; DING SW, 1995, EMBO J, V14, P5762, DOI 10.1002/j.1460-2075.1995.tb00265.x; DOLJA VV, 1992, P NATL ACAD SCI USA, V89, P10208, DOI 10.1073/pnas.89.21.10208; DOUGHERTY WG, 1994, MOL PLANT MICROBE IN, V7, P544, DOI 10.1094/MPMI-7-0554; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; FEINBERG AP, 1983, ANAL BIOCHEM, V257, P8569; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; HEHL R, 1990, PLANT CELL, V2, P709, DOI 10.1105/tpc.2.8.709; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KASSCHAU KD, 1995, VIROLOGY, V209, P268, DOI 10.1006/viro.1995.1254; Kasschau KD, 1997, VIROLOGY, V228, P251, DOI 10.1006/viro.1996.8368; KJERTRUP S, 1998, PLANT J, V14, P91; KLEIN PG, 1994, VIROLOGY, V204, P759, DOI 10.1006/viro.1994.1591; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDBO JA, 1992, MOL PLANT MICROBE IN, V5, P144, DOI 10.1094/MPMI-5-144; LINDBO JA, 1992, VIROLOGY, V189, P725, DOI 10.1016/0042-6822(92)90595-G; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Matthews REF., 2002, PLANT VIROLOGY; MEINS F, 1995, CURR TOP MICROBIOL, V197, P105; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Pruss G, 1997, PLANT CELL, V9, P859, DOI 10.1105/tpc.9.6.859; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Schaad MC, 1997, J VIROL, V71, P8624, DOI 10.1128/JVI.71.11.8624-8631.1997; Schob H, 1997, MOL GEN GENET, V256, P581, DOI 10.1007/s004380050604; SCHOLTHOF HB, 1995, VIROLOGY, V213, P425, DOI 10.1006/viro.1995.0015; Shi XM, 1997, VIROLOGY, V231, P35, DOI 10.1006/viro.1997.8488; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; Tanzer MM, 1997, PLANT CELL, V9, P1411, DOI 10.1105/tpc.9.8.1411; VANCE VB, 1991, VIROLOGY, V182, P486, DOI 10.1016/0042-6822(91)90589-4; VERCHOT J, 1995, J VIROL, V69, P3668, DOI 10.1128/JVI.69.6.3668-3674.1995; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438	52	629	699	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1998	95	4					461	470		10.1016/S0092-8674(00)81614-1	http://dx.doi.org/10.1016/S0092-8674(00)81614-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827799	Bronze			2022-12-24	WOS:000077049400005
J	King, AJ; Sun, HY; Diaz, B; Barnard, D; Miao, WY; Bagrodia, S; Marshall, MS				King, AJ; Sun, HY; Diaz, B; Barnard, D; Miao, WY; Bagrodia, S; Marshall, MS			The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338	NATURE			English	Article							SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; ACTIVATION; RAS; CASCADE; ERK	The pathway involving the signalling: protein p21(Ras) propagates a range of extracellular signals from receptors on the cell membrane to the cytoplasm and nucleus(1). The Ras proteins regulate many effecters, including members of the Raf family of protein kinases. Ras-dependent activation of Raf-1 at the plasma membrane involves phosphorylation events, protein-protein interactions and structural changes(2-8). Phosphorylation of serine residues 338 or 339 in the catalytic domain of Raf-1 regulates its activation in response to Ras, Src and epidermal growth factor(9,10). Here we show that the p21-activated protein kinase Pak3 phosphorylates Raf-1 on serine 338 in vitro and in vivo. The p21-activated protein kinases are regulated by the Rho-family GTPases Rac and Cdc42 (ref, 11). Our results indicate that signal transduction through Raf-1 depends on both Ras and the activation of the Pak pathway. As guanine-nucleotide-exchange activity on Rac can be stimulated by a Ras-dependent phosphatidylinositol-3-OH kinase(12,13), a mechanism could exist through which one Ras effector pathway can be influenced by another.	Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Cornell Univ, Dept Pharmacol, Sect Mol & Cell Biol, Ithaca, NY 14853 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Cornell University	Marshall, MS (corresponding author), Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Bloomington, IN 47405 USA.	mmarsha@.iupui.edu						BADRODIA S, 1995, J BIOL CHEM, V270, P22731; BARNARD D, IN PRESS ONCOGENE; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; ESCHENBRUCH M, 1982, ANAL BIOCHEM, V125, P96, DOI 10.1016/0003-2697(82)90387-6; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454	22	365	375	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					180	183		10.1038/24184	http://dx.doi.org/10.1038/24184			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823899				2022-12-24	WOS:000077013300055
J	Stevenson, JC				Stevenson, JC			Management of corticosteroid-induced osteoporosis	LANCET			English	Editorial Material							BONE LOSS; FRACTURES; THERAPY; ASTHMA		St Marys Hosp, Imperial Coll, Sch Med, Wynn Inst Endocrinol & Metab Med,Rosen Labs, London W2 1PG, England	Imperial College London	Stevenson, JC (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Wynn Inst Endocrinol & Metab Med,Rosen Labs, Praed St, London W2 1PG, England.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069; Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365-2796.1998.00408.x; Gonnelli S, 1997, CALCIFIED TISSUE INT, V61, P382, DOI 10.1007/s002239900352; HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; REID IR, 1996, ARCH INTERN MED, V156, P1373; Roux C, 1998, J CLIN ENDOCR METAB, V83, P1128, DOI 10.1210/jc.83.4.1128; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SAITO JK, 1995, CALCIFIED TISSUE INT, V57, P115, DOI 10.1007/BF00298431; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211	12	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1327	1328		10.1016/S0140-6736(05)60740-4	http://dx.doi.org/10.1016/S0140-6736(05)60740-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802265				2022-12-24	WOS:000076691700005
J	Gamester, CF; Tilzey, AJ; Banatvala, JE				Gamester, CF; Tilzey, AJ; Banatvala, JE			Medical students' risk of infection with bloodborne viruses at home and abroad: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine risks of exposure to and prevention of bloodborne virus infections among medical students during their elective period. Design Questionnaire study of students returning from their electives in 1997-8. Setting Urban teaching hospital. Subjects 220 final year medical students. Results 148 students (67%) returned questionnaires; all had been vaccinated against hepatitis B. 65 respondents (44%) had visited areas of relatively high endemicity for HIV, although 27 (42%) of these, all of whom had visited areas other than sub-Saharan Africa, were unaware of this. AU but one had discussed their elective with advisers. Four students experienced percutaneous or mucosal exposure to potentially infectious body fluids, three in areas with a high prevalence of HIV infection. 44 respondents (30%) had experienced at least one such exposure during their clinical training; 75% of these exposures were unreported. 34% (13/38) students who visited areas known to have a high prevalence of HIV infection took with them a starter pack of zidovudine for post-exposure prophylaxis; 53% (20) took latex gloves and 63% (24) a medi-kit None of the 27 students who were unaware that the areas they visited had a relatively high prevalence of HIV infection took zidovudine; only 15% (4) took gloves and 30% (8) a medi-kit. Conclusions Medical schools should produce, regularly update, and implement guidelines regarding protection from bloodborne viruses during clinical studies, including electives. Education and training in infection control should start at the earliest opportunity.	Guys Kings Coll & St Thomass Sch Med, London SE1 7EH, England	University of London; King's College London	Tilzey, AJ (corresponding author), Guys Kings Coll & St Thomass Sch Med, St Thomass Campus, London SE1 7EH, England.							Balter M, 1998, SCIENCE, V280, P1864, DOI 10.1126/science.280.5371.1864; BANATVALA JE, 1991, LANCET, V337, P1218, DOI 10.1016/0140-6736(91)92885-6; BANATVALA N, 1997, STUDENT BMJ, V5, P354; BERNARD RP, 1997, GLOBAL VIEW HIV INFE; Gottlieb S, 1998, BRIT MED J, V317, P11; GUST ID, 1982, P 3 INT S VIR HEP NE; *PUBL HLTH LAB SER, 1997, CRD, V7, P461; *PUBL HLTH LAB SER, 1998, CDR, V8, P227; Tereskerz PM, 1996, NEW ENGL J MED, V335, P1150, DOI 10.1056/NEJM199610103351512; *UK HLTH DEP, 1997, GUID POST PROPH HLTH; *UK HLTH DEP, 1994, AIDS HIV INF HLTH CA; *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P365; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P341; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P193	15	33	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1999	318	7177					158	160		10.1136/bmj.318.7177.158	http://dx.doi.org/10.1136/bmj.318.7177.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LR	9888908	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000078175100025
J	Ashton, CM; Petersen, MPHNJ; Souchek, J; Menke, TJ; Yu, HJ; Pietz, K; Eigenbrodt, ML; Barbour, G; Kizer, KW; Wray, NP				Ashton, CM; Petersen, MPHNJ; Souchek, J; Menke, TJ; Yu, HJ; Pietz, K; Eigenbrodt, ML; Barbour, G; Kizer, KW; Wray, NP			Geographic variations in utilization rates in Veterans Affairs hospitals and clinics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM; PREVENTABLE HOSPITALIZATIONS; OUTCOMES; MEDICARE; VA	Background in the United States, geographic variation in hospital use is common. It is uncertain whether there are similar geographic variations in the health care system of the Department of Veterans Affairs (VA), which differs from the private sector because it predominantly serves men with annual incomes below $20,000, has a central system of administration, and uses salaried physicians. Thus, it might be less likely to have geographic variations. Methods We used VA data bases to obtain information on patients treated for eight diseases (chronic obstructive pulmonary disease, pneumonia, congestive heart failure, angina, diabetes, chronic renal failure, bipolar disorder, and major depression). We analyzed their use of hospital and outpatient services by assessing the risk-adjusted numbers of hospital days (the average number of days a patient spent in the hospital per 12 months of follow-up, regardless of the number of hospital stays), hospital-discharge rates, and clinic-visit rates from 1991 through 1995 for the entire system and within the 22 geographically based health care networks. Results We found substantial geographic variation in hospital use for all eight cohorts of patients and all the years studied. Variations in the numbers of hospital days per person-year among the networks were greatest among patients with chronic obstructive pulmonary disease (ranging from a factor of 2.7 to a factor of 3.1) during a given year and smallest among patients with angina (ranging from a factor of 1.5 to a factor of 2.1). Levels of hospital use were highest in the Northeast and lowest in the West. The variation in the rates of clinic visits for principal medical care among the networks ranged from a factor of approximately 1.6 to a factor of 4.0; variations in the rates were greatest among patients with chronic renal failure and smallest among patients with congestive heart failure. There was no clear geographic pattern in the rates of outpatient-clinic use. Conclusions There are significant geographic variations in the use of hospital and outpatient services in the VA health care system. Because VA physicians are unable to increase their income by changing their patterns of practice, our findings suggest that their practice styles are similar to those of other physicians in their geographic regions. (N Engl J Med 1999;340:32-9.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA; Vet Hlth Adm, Dept Vet Affairs, Washington, DC USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ashton, CM (corresponding author), Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, 152,2002 Holcombe Blvd, Houston, TX 77030 USA.							[Anonymous], 1996, ICD9CM; Ashton CM, 1998, MED CARE, V36, P793, DOI 10.1097/00005650-199806000-00003; ASHTON CM, IN PRESS AM J MED QU; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; *CTR EV CLIN SCI, 1996, DARTM ATL HLTH CAR; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; FRISS L, 1989, SOC SCI MED, V28, P347, DOI 10.1016/0277-9536(89)90036-1; GORNICK M, 1977, SOC SECUR BULL, V40, P22; GRAVES EJ, 1995, VITAL HLTH STAT SERI, V13; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; Iglehart JK, 1996, NEW ENGL J MED, V335, P1407, DOI 10.1056/NEJM199610313351821; Kizer K W, 1997, Minn Med, V80, P24; Kizer KW, 1997, HOSP HEALTH SERV ADM, V42, P283; Kizer KW, 1997, ANN EMERG MED, V30, P804, DOI 10.1016/S0196-0644(97)70053-2; KIZER KW, 1997, COMP HLTH C, P3; Kizer KW, 1995, VISION CHANGE PLAN R; KIZER KW, 1997, VETERANS EQUITABLE R; KIZER KW, 1996, PRESCRIPTION CHANGE; KNICKMAN JR, 1985, INQUIRY-J HEALTH CAR, V22, P45; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; *NAT CTR VET AN ST, 1995, PUBL NAT SURV VET; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; POKRAS R, 1965, VITAL HLTH STAT SERI, V13; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; Restuccia J, 1996, HEALTH AFFAIR, V15, P156, DOI 10.1377/hlthaff.15.4.156; SCHAPPERT SM, 1991, VITAL HLTH STAT SERI, V13; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; Snedecor G.W., 1980, STATISTICAL METHODS, P365; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; Wilson NJ, 1997, HEALTH AFFAIR, V16, P200, DOI 10.1377/hlthaff.16.4.200; Wray NP, 1997, MED CARE, V35, P768, DOI 10.1097/00005650-199708000-00003	36	188	191	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1999	340	1					32	39		10.1056/NEJM199901073400106	http://dx.doi.org/10.1056/NEJM199901073400106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155JQ	9878643				2022-12-24	WOS:000077943700006
J	Horvath, MP; Schweiker, VL; Bevilacqua, JM; Ruggles, JA; Schultz, SC				Horvath, MP; Schweiker, VL; Bevilacqua, JM; Ruggles, JA; Schultz, SC			Crystal structure of the Oxytricha nova telomere end binding protein complexed with single strand DNA	CELL			English	Article							COCRYSTAL STRUCTURE; MACRONUCLEAR DNA; EUPLOTES-CRASSUS; BETA-SUBUNIT; 3' TERMINUS; IN-VITRO; RESOLUTION; GENES; YEAST; SENESCENCE	Telomeres are specialized protein-DNA complexes that compose the ends of eukaryotic chromosomes. Telomeres protect chromosome termini from degradation and recombination and act together with telomerase to ensure complete genome replication. We have determined the crystal structure of the two-subunit Oxytricha nova telomere end binding protein (On-TEBP) complexed with single strand telomeric DNA at 2.8 Angstrom resolution. The structure reveals four oligonucleotide/oligosaccharide-binding folds, three of which form a deep cleft that binds the ssDNA, and a fourth that forms an unusual protein-protein interaction between the alpha and beta subunits. This structure provides a molecular description of how the two subunits of OnTEBP recognize and bind ssDNA to form a sequence-specific, telomeric nucleoprotein complex that caps the very 3' ends of chromosomes.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; H Lundback AS, Dept Clin Pharmacol, Copenhagen, Denmark	University of Colorado System; University of Colorado Boulder; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Schultz, SC (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	schultz@mmol.colorado.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017155] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 F32 GM17155-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brunger A. T., 1993, X PLOR MANUAL VERSIO; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FANG GW, 1991, NUCLEIC ACIDS RES, V19, P5515, DOI 10.1093/nar/19.20.5515; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUSCHLBAUER W, 1972, EUR J BIOCHEM, V31, P1, DOI 10.1111/j.1432-1033.1972.tb02493.x; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HICKE BJ, 1994, BIOCHEMISTRY-US, V33, P3364, DOI 10.1021/bi00177a030; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; McClintock B, 1941, GENETICS, V26, P234; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saenger W., 1984, PRINCIPLES NUCL ACID; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; SON TD, 1972, J AM CHEM SOC, V94, P7903; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; VERMEESCH JR, 1994, MOL CELL BIOL, V14, P554, DOI 10.1128/MCB.14.1.554; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	54	229	236	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					963	974		10.1016/S0092-8674(00)81720-1	http://dx.doi.org/10.1016/S0092-8674(00)81720-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875850	Bronze			2022-12-24	WOS:000077759100011
J	Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ				Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ			Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; FULL-TERM INFANTS; CEREBRAL-PALSY; NEONATAL ENCEPHALOPATHY; BIRTH-WEIGHT; ASPHYXIA; ANTECEDENTS; PREGNANCY	Objective To ascertain antepartum predictors of newborn encephalopathy in term infants. Design Population based, unmatched case-control study. Setting Metropolitan area of Western Australia,June 1993 to September 1995. Subjects All 164 term infants with moderate or severe newborn encephalopathy; 400 randomly selected controls. Main outcome measures Adjusted odds ratio estimates. Results The birth prevalence of moderate or severe newborn encephalopathy was 3.8/1000 term live births. The neonatal fatality was 9.1%. The risk of newborn encephalopathy increased with increasing maternal age and decreased with increasing parity. There was an increased risk associated with having a mother who was unemployed (odds ratio 3.60), an unskilled manual worker (3.84), or a housewife (2.48). Other risk factors from before conception were not having private health insurance (3.46), a family history of seizures (2.55), a family history of neurological disease (2.73), and infertility treatment (4.43). Risk factors during pregnancy were maternal thyroid disease (9.7), severe pre-eclampsia (6.30), moderate or severe bleeding (3.57), a clinically diagnosed viral illness (2.97), not having drunk alcohol (2.91); and placenta described at delivery as abnormal (2.07). Factors related to the baby were birth weight adjusted for gestational age between the third and ninth centile (4.37) or below the third centile (38.23). The risk relation with gestational age was J shaped with 38 and 39 weeks having the lowest risk. Conclusions The causes of newborn encephalopathy are heterogeneous and many of the causal pathways start before birth.	TVW Telethon Inst Child Hlth Res, W Perth, WA 6872, Australia; Hornsby Ku Ring Gai Hosp, Dept Obstet & Gynaecol, Hornsby, NSW 2077, Australia; Univ Western Australia, Dept Paediat, Nedlands, WA 6907, Australia; Princess Margaret Hosp Children, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Badawi, N (corresponding author), Royal Alexandra Hosp Children, New Childrens Hosp, Dept Neonatol, POB 3515, Parramatta, NSW 2124, Australia.	nadiaB@nch.edu.au	Burton, Paul R/H-7527-2016; Badawi, Nadia/A-3179-2014					ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; ADINOLFI M, 1993, DEV MED CHILD NEUROL, V35, P549; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR EM, 1985, INTRAUTERINE GROWTH; BROWN MA, 1993, MED J AUSTRALIA, V158, P700; DENNIS J, 1978, DEV MED CHILD NEUROL, V20, P143; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GAFFNEY G, 1994, ARCH DIS CHILD-FETAL, V70, pF195, DOI 10.1136/fn.70.3.F195; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HAGBERG G, 1976, ACTA PAEDIATR SCAND, V65, P403, DOI 10.1111/j.1651-2227.1976.tb04906.x; HALPERIN LR, 1978, LANCET, V2, P212; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; KURINCZUK JJ, 1995, PAEDIATR PERINAT EP, V9, pA9; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P553; MALLARD EC, 1994, AM J OBSTET GYNECOL, V170, P206; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x	28	392	401	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1549	1553		10.1136/bmj.317.7172.1549	http://dx.doi.org/10.1136/bmj.317.7172.1549			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836652	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000077451700020
J	Nightingale, SL				Nightingale, SL			Jurisdiction over cloning technology to create human beings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-24	WOS:000077176600007
J	Pinedo, HM; Verheul, HMW; D'Amato, RJ; Folkman, J				Pinedo, HM; Verheul, HMW; D'Amato, RJ; Folkman, J			Involvement of platelets in tumour angiogenesis?	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; RELEASE; DISEASE; CELLS	Preclinical and clinical research show that tumour growth is dependent on angiogenesis. Activation of the coagulation cascade is commonly found in patients with cancer. We propose that platelets contribute to tumour-induced angiogenesis. The basis of our hypothesis Is that platelets are a rich source of stimulators and inhibitors of angiogenesis and their interaction with the endothelium. Presumably, the antithrombotic state of normal endothelium is disturbed by endothelial stimuli derived from tumour cells. This hypothesis may explain the suggested clinical benefits of anticoagulants in cancer and implies that targeting of platelet interaction with tumour vasculature will inhibit angiogenesis.	Free Univ Amsterdam, Acad Hosp, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cellular Biol, Boston, MA 02115 USA	Vrije Universiteit Amsterdam; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Pinedo, HM (corresponding author), Free Univ Amsterdam, Acad Hosp, Dept Med Oncol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.		Verheul, Henk/V-6462-2019; Verheul, Henk M.W./J-9775-2013	Verheul, Henk/0000-0001-5981-922X; 				BRIDGES JM, 1966, NATURE, V210, P1364, DOI 10.1038/2101364a0; BROCK TA, 1991, AM J PATHOL, V138, P213; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1996, NAT MED, V2, P67; Folkman Judah, 1997, P3075; Gasparini G, 1996, EUR J CANCER, V32A, P2485, DOI 10.1016/S0959-8049(96)00376-0; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; HEILMANN E, 1994, J CELL PHYSIOL, V161, P23, DOI 10.1002/jcp.1041610104; KAKKAR AK, 1995, BRIT J SURG, V82, P724, DOI 10.1002/bjs.1800820603; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Monreal M, 1998, THROMB HAEMOSTASIS, V79, P916; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pedersen LM, 1996, EUR RESPIR J, V9, P1826; SUN NCJ, 1979, AM J CLIN PATHOL, V71, P10; Verheul HMW, 1997, CLIN CANCER RES, V3, P2187; Zacharski LR, 1998, THROMB HAEMOSTASIS, V80, P10	21	292	300	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1775	1777		10.1016/S0140-6736(98)05095-8	http://dx.doi.org/10.1016/S0140-6736(98)05095-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848370				2022-12-24	WOS:000077246500045
J	Suzuki, Y; Yasunaga, T; Ohkura, R; Wakabayashi, T; Sutoh, K				Suzuki, Y; Yasunaga, T; Ohkura, R; Wakabayashi, T; Sutoh, K			Swing of the lever arm of a myosin motor at the isomerization and phosphate-release steps	NATURE			English	Article							GREEN-FLUORESCENT PROTEIN; RESONANCE ENERGY-TRANSFER; X-RAY STRUCTURES; DICTYOSTELIUM-DISCOIDEUM; MUSCLE-CONTRACTION; BERYLLIUM FLUORIDE; ALUMINUM FLUORIDE; COMPLEXES; DOMAIN; SUBFRAGMENT-1	In muscle, the myosin head ('crossbridge') performs the 'working stroke: in which ATP is hydrolysed to generate the sliding of actin and myosin filaments.. The myosin head consists of a globular motor domain and a long lever-arm domain. The 'lever-arm hypothesis'(1-5) predicts that during the working stroke, the lever-arm domain tilts against the motor domain, which is bound to actin in a fixed orientation, To detect this working stroke in operation, we constructed fusion proteins by connecting Aequorea victoria green fluorescent protein and blue fluorescent protein(6-8) to the amino and carboxyl termini of the motor domain of myosin II of Dictyostelium discoideum, a soil amoeba, and measured the fluorescence resonance energy transfer between the two fluorescent proteins, We show here that the carboxy-terminal fluorophore swings at the isomerization step of the ATP hydrolysis cycle, and then swings back at the subsequent step in which inorganic phosphate is released, thereby mimicking the suing of the lever arm, The swing at the phosphate-release step may correspond to the working stroke, and the swing at the isomerization step to the recovery stroke.	Univ Tokyo, Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan; Univ Tokyo, Sch Sci, Dept Phys, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Sch Arts & Sci, Dept Life Sci, Komaba 3-8-1, Tokyo 153, Japan.	cksutoh@komaba.ecc.u-tkyo.ac.jp	Yasunaga, Takuo/C-8316-2009	Yasunaga, Takuo/0000-0002-2494-9603				BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARUTA S, 1993, J BIOL CHEM, V268, P7093; MIKI M, 1991, BIOCHEMISTRY-US, V30, P10878, DOI 10.1021/bi00109a011; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; Yasunaga T, 1996, J STRUCT BIOL, V116, P155, DOI 10.1006/jsbi.1996.0025	26	156	157	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1998	396	6709					380	383		10.1038/24640	http://dx.doi.org/10.1038/24640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845076				2022-12-24	WOS:000077204000053
J	Ni, M; Tepperman, JM; Quail, PH				Ni, M; Tepperman, JM; Quail, PH			PIF3, a phytochrome-interacting factor necessary for normal photoinduced signal transduction, is a novel basic helix-loop-helix protein	CELL			English	Article							ARABIDOPSIS-THALIANA; G-BOX; GENE-EXPRESSION; LIGHT; MUTANTS; FAMILY; SEQUENCES; PATHWAYS; PLANTS; BINDS	The mechanism by which the phytochrome (phy) photoreceptor family transduces informational light signals to photoresponsive genes is unknown. Using a yeast two-hybrid screen, we have identified a phytochrome-interacting factor, PIF3, a basic helix-loop-helix protein containing a PAS domain. PIF3 binds to wild-type C-terminal domains of both phyA and phyB, but less strongly to signaling-defective, missense mutant-containing domains. Expression of sense or antisense PIF3 sequences in transgenic Arabidopsis perturbs photoresponsiveness in a manner indicating that PIF3 functions in both phyA and phyB signaling pathways in vivo. PIF3 localized to the nucleus in transient transfection experiments, indicating a potential role in controlling gene expression. Together, the data suggest that phytochrome signaling to photoregulated genes includes a direct pathway involving physical interaction between the photoreceptor and a transcriptional regulator.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	quail@nature.berkeley.edu	Ni, Maria/GVT-4942-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe H, 1997, PLANT CELL, V9, P1859, DOI 10.1105/tpc.9.10.1859; Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Anderson SL, 1997, PLANT CELL, V9, P1727, DOI 10.1105/tpc.9.10.1727; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; dePater S, 1997, PLANT MOL BIOL, V34, P169, DOI 10.1023/A:1005898823105; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Genoud T, 1998, PLANT CELL, V10, P889, DOI 10.1105/tpc.10.6.889; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; Hirschfeld M, 1998, GENETICS, V149, P523; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Kawagoe Y, 1996, PLANT SCI, V116, P47, DOI 10.1016/0168-9452(96)04366-X; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; Mancinelli Alberto L., 1994, P211; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Pratt Lee H., 1994, P163; Quail Peter H., 1994, P71; Quail PH, 1997, BIOESSAYS, V19, P571, DOI 10.1002/bies.950190708; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; Schafer E, 1997, PLANT CELL ENVIRON, V20, P722, DOI 10.1046/j.1365-3040.1997.d01-98.x; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; Smith H, 1997, PLANT CELL ENVIRON, V20, P840, DOI 10.1046/j.1365-3040.1997.d01-104.x; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Tobin Elaine M., 1994, Seminars in Cell Biology, V5, P335, DOI 10.1006/scel.1994.1040; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; Wagner D, 1997, PLANT CELL, V9, P731, DOI 10.1105/tpc.9.5.731; Wei N, 1996, PLANT PHYSIOL, V112, P871, DOI 10.1104/pp.112.3.871; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757	53	546	600	10	91	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					657	667		10.1016/S0092-8674(00)81636-0	http://dx.doi.org/10.1016/S0092-8674(00)81636-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845368	Bronze			2022-12-24	WOS:000077253700013
J	Kondziolka, D; Lunsford, LD; McLaughlin, MR; Flickinger, JC				Kondziolka, D; Lunsford, LD; McLaughlin, MR; Flickinger, JC			Long-term outcomes after radiosurgery for acoustic neuromas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-KNIFE RADIOSURGERY; STEREOTAXIC RADIOSURGERY; HEARING PRESERVATION; VESTIBULAR SCHWANNOMA; SURGICAL-MANAGEMENT; TUMORS; SURGERY; NEUROPATHIES; NEURINOMA	Background Stereotactic radiosurgery is the principal alternative to microsurgical resection for acoustic neuromas (vestibular schwannomas). The goals of radiosurgery are the long-term prevention of tumor growth, maintenance of neurologic function, and prevention of new neurologic deficits. Although acceptable short-term outcomes have been reported, long-term outcomes have not been well documented. Methods We evaluated 162 consecutive patients who underwent radiosurgery for acoustic neuromas between 1987 and 1992 by means of serial imaging tests, clinical evaluations, and a survey between 5 and 10 years after the procedure. The average dose of radiation to the tumor margin was 16 Gy, and the mean transverse diameter of the tumor was 22 mm (range, 8 to 39). Resection had been performed previously in 42 patients (26 percent); in 13 patients the tumor represented a recurrence of disease after a previous total resection. Facial function was normal in 76 percent of the patients before radiosurgery, and 20 percent had useful hearing. Results The rate of tumor control (with no resection required) was 98 percent. One hundred tumors (62 percent) became smaller, 53 (33 percent) remained unchanged in size, and 9 (6 percent) became slightly larger. Resection was performed in four patients (2 percent) within four years after radiosurgery. Normal facial function was preserved in 79 percent of the patients after five years (House-Brackmann grade 1), and normal trigeminal function was preserved in 73 percent. Fifty-one percent of the patients had no change in hearing ability, No new neurologic deficits appeared more than 28 months after radiosurgery. An outcomes questionnaire was returned by 115 patients (77 percent of the 149 patients still living). Fifty-four of these patients (47 percent) were employed at the time of radiosurgery, and 37 (69 percent) remained so. Radiosurgery was believed to have been successful by all 30 patients who had undergone surgery previously and by 81 (95 percent) of the 85 who had not. Thirty-six of the 115 patients (31 percent) described at least one complication, which resolved in 56 percent of those cases. Conclusions Radiosurgery can provide long-term control of acoustic neuromas while preserving neurologic function. (N Engl J Med 1998;339:1426-33.) (C) 1998, Massachusetts Medical Society.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kondziolka, D (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.		Lunsford, L. Dade/AHI-7993-2022	Flickinger, John/0000-0001-6900-1384	NINDS NIH HHS [K08 NS 017293] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEDERSON JB, 1991, NEUROSURGERY, V28, P646, DOI 10.1227/00006123-199105000-00002; CERULLO LJ, 1993, SURG NEUROL, V39, P485, DOI 10.1016/0090-3019(93)90036-Z; Flickinger JC, 1996, RADIOTHER ONCOL, V41, P215, DOI 10.1016/S0167-8140(96)01831-2; FLICKINGER JC, 1993, RADIOTHER ONCOL, V27, P91, DOI 10.1016/0167-8140(93)90127-T; FLICKINGER JC, 1990, INT J RADIAT ONCOL, V18, P1495, DOI 10.1016/0360-3016(90)90326-F; FLICKINGER JC, 1991, CANCER, V67, P345, DOI 10.1002/1097-0142(19910115)67:2<345::AID-CNCR2820670205>3.0.CO;2-M; Flickinger JC, 1996, INT J RADIAT ONCOL, V36, P275, DOI 10.1016/S0360-3016(96)00335-5; FOOTE RL, 1995, INT J RADIAT ONCOL, V32, P1153, DOI 10.1016/0360-3016(94)00454-S; GARDNER G, 1988, ANN OTO RHINOL LARYN, V97, P55, DOI 10.1177/000348948809700110; Gormley WB, 1997, NEUROSURGERY, V41, P50, DOI 10.1097/00006123-199707000-00012; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; KONDZIOLKA D, 1992, NEUROSURGERY, V30, P402, DOI 10.1227/00006123-199203000-00015; KONDZIOLKA D, 1997, TECH NEUROSURG, V3, P154; LALWANI AK, 1995, AM J OTOL, V16, P758; LINSKEY ME, 1991, AM J NEURORADIOL, V12, P1165; LINSKEY ME, 1993, J NEUROSURG, V78, P645, DOI 10.3171/jns.1993.78.4.0645; LINSKEY ME, 1993, INT J RADIAT ONCOL, V25, P227, DOI 10.1016/0360-3016(93)90343-T; Lunsford L D, 1993, Clin Neurosurg, V40, P475; Mazzoni A, 1996, SKULL BASE SURG, V6, P105, DOI 10.1055/s-2008-1058651; NOREN G, 1983, NEUROSURGERY, V13, P12, DOI 10.1227/00006123-198307000-00003; OGUNRINDE OK, 1994, J NEUROSURG, V80, P1011, DOI 10.3171/jns.1994.80.6.1011; OGUNRINDE OK, 1994, SKULL BASE SURG, V4, P87, DOI 10.1055/s-2008-1058976; OGUNRINDE OK, 1995, ARCH NEUROL-CHICAGO, V52, P73, DOI 10.1001/archneur.1995.00540250077016; POLLOCK BE, 1995, NEUROSURGERY, V36, P215, DOI 10.1227/00006123-199501000-00036; POLLOCK BE, 1995, NEUROSURGERY, V36, P427; POST KD, 1995, J NEUROSURG, V83, P191, DOI 10.3171/jns.1995.83.2.0191; Rowed DW, 1997, J NEUROSURG, V86, P456, DOI 10.3171/jns.1997.86.3.0456; SAMII M, 1992, NEUROSURGERY, V31, P615; Samii M, 1997, NEUROSURGERY, V40, P11, DOI 10.1097/00006123-199701000-00002; SHELTON C, 1991, LARYNGOSCOPE, V101, P925; Slatterly W, 1997, AM J OTOL, V18, P796; Slattery WH, 1997, AM J OTOL, V18, P596; THOMAS HAL, 1992, CAN MED ASSOC J, V147, P859; Wiegand DA, 1996, LARYNGOSCOPE, V106, P58, DOI 10.1097/00005537-199601000-00012; WIEGAND DA, 1989, LARYNGOSCOPE, V99, P179	35	543	550	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1998	339	20					1426	1433		10.1056/NEJM199811123392003	http://dx.doi.org/10.1056/NEJM199811123392003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VR	9811917				2022-12-24	WOS:000077051700003
J	Jones, EG; Pons, TP				Jones, EG; Pons, TP			Thalamic and brainstem contributions to large-scale plasticity of primate somatosensory cortex	SCIENCE			English	Article							MASSIVE CORTICAL REORGANIZATION; FREQUENCY-DISCRIMINATION TASK; ADULT FLYING-FOX; RECEPTIVE-FIELDS; MACAQUE MONKEYS; REPRESENTATIONAL PLASTICITY; FUNCTIONAL REORGANIZATION; SOMATOTOPIC ORGANIZATION; CHRONIC DEAFFERENTATION; DIGIT DENERVATION	After long-term denervation of an upper limb in macaque monkeys, the representation of the face in somatosensory cortex expands over many millimeters into the silenced representation of the hand. Various brainstem and cortical mechanisms have been proposed to explain this phenomenon, Reorganization in the thalamus has been Largely ignored, In monkeys with deafferented upper Limbs for 12 to 20 years, it was found that the brainstem cuneate and the thalamic ventral posterior nuclei had undergone severe transneuronal atrophy, and physiological mapping in the thalamus revealed that the face and trunk representations were adjoined white the normally small representation of the lower face had expanded comparable to the expansion in cortex. Reorganization of brainstem and thalamic nuclei associated with slow transneuronal atrophy is likely to be a progressive process, When coupled with divergence of ascending connections, it is likely to make a substantial contribution to representational changes in cortex.	Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA	University of California System; University of California Davis; Wake Forest University	Jones, EG (corresponding author), Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021377, R01NS035246] Funding Source: NIH RePORTER; NIMH NIH HHS [MH53369] Funding Source: Medline; NINDS NIH HHS [NS21377, NS35246] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLOWAY KD, 1991, EXP BRAIN RES, V85, P598; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BURTON H, 1995, J COMP NEUROL, V355, P508, DOI 10.1002/cne.903550404; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CAMPBELL AW, 1905, HISTOLOGICAL STUDIES, P86; Churchill JD, 1998, EXP BRAIN RES, V118, P189, DOI 10.1007/s002210050271; Cowan W. M., 1970, CONT RES METHODS NEU, P217, DOI 10.1007/978-3-642-85986-1_11; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DEFELIPE J, 1986, J NEUROSCI, V6, P3749, DOI 10.1523/jneurosci.06-12-03749.1986; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; DYKES RW, 1984, J NEUROPHYSIOL, V52, P1066, DOI 10.1152/jn.1984.52.6.1066; Ergenzinger ER, 1998, NAT NEUROSCI, V1, P226, DOI 10.1038/673; Florence SL, 1995, J NEUROSCI, V15, P8083; GARRAGHTY PE, 1994, SOMATOSENS MOT RES, V11, P109, DOI 10.3109/08990229409028864; GARRAGHTY PE, 1991, NEUROREPORT, V2, P747, DOI 10.1097/00001756-199112000-00004; Huntley GW, 1997, CEREB CORTEX, V7, P143, DOI 10.1093/cercor/7.2.143; JAIN N, 1995, J NEUROPHYSIOL, V73, P1537, DOI 10.1152/jn.1995.73.4.1537; Jones E.G., 1994, Cerebral Cortex, V10, P61; JONES EG, 1982, J NEUROPHYSIOL, V48, P521, DOI 10.1152/jn.1982.48.2.521; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; JONES EG, 1982, J NEUROPHYSIOL, V48, P545, DOI 10.1152/jn.1982.48.2.545; JONES EG, 1997, P NATL ACAD SCI USA, V94, P11007; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KALASKA J, 1982, BRAIN RES, V236, P35, DOI 10.1016/0006-8993(82)90032-4; Knecht S, 1996, BRAIN, V119, P1213, DOI 10.1093/brain/119.4.1213; KOLARIK RC, 1994, J NEUROSCI, V14, P4269; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570, DOI 10.1152/jn.1994.72.4.1570; LOEWY AD, 1973, J COMP NEUROL, V147, P497, DOI 10.1002/cne.901470405; LOMBARD MC, 1979, ADV PAIN RES THER, V3, P767; LUND JP, 1994, SCIENCE, V265, P546, DOI 10.1126/science.8036500; Manger PR, 1997, J NEUROSCI, V17, P6338; MANGER PR, 1996, P R SOC LONDON B, V263, P939; MELZACK R, 1990, TRENDS NEUROSCI, V13, P92; MILLAR J, 1976, EXP NEUROL, V50, P658, DOI 10.1016/0014-4886(76)90035-2; MOUNTCASTLE VB, 1952, J COMP NEUROL, V97, P409, DOI 10.1002/cne.900970302; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; Parker JL, 1998, J NEUROSCI, V18, P548; PETTIT MJ, 1993, SCIENCE, V262, P2054, DOI 10.1126/science.8266104; POGGIO GF, 1963, J NEUROPHYSIOL, V26, P775, DOI 10.1152/jn.1963.26.5.775; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; POWELL TPS, 1967, NATURE, V215, P425, DOI 10.1038/215425a0; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10420; Rasmusson D, 1996, J COMP NEUROL, V364, P92; RAUSELL E, 1992, P NATL ACAD SCI USA, V89, P2571, DOI 10.1073/pnas.89.7.2571; RAUSELL E, 1991, J NEUROSCI, V11, P210; RAUSELL E, 1995, J NEUROSCI, V15, P4270; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; RECANZONE GH, 1992, CEREB CORTEX, V2, P181, DOI 10.1093/cercor/2.3.181; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; Sherrington C, 1939, SELECTED WRITINGS C, P31; Shin HC, 1995, NEUROREPORT, V7, P33, DOI 10.1097/00001756-199512000-00007; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; Taub E., 1980, CLIN APPL, P371; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; WOODS TM, 1998, NEUR ABSTR, V24, P1512; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119, DOI 10.1152/jn.1998.79.4.2119	62	187	194	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1121	1125		10.1126/science.282.5391.1121	http://dx.doi.org/10.1126/science.282.5391.1121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804550				2022-12-24	WOS:000076887700050
J	Regamey, N; Tamm, M; Wernli, M; Witschi, A; Thiel, G; Cathomas, G; Erb, P				Regamey, N; Tamm, M; Wernli, M; Witschi, A; Thiel, G; Cathomas, G; Erb, P			Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; DNA-SEQUENCES; ANTIBODIES; IDENTIFICATION; MALIGNANCIES; ANTIGEN; FORMS; KSHV; RISK	Background Human herpesvirus 8 (HHV-8) has been detected in all forms of Kaposi's sarcoma, including transplantation-associated Kaposi's sarcoma. To investigate the possibility of transmission of HHV-8 through allografts, we measured the seroprevalence of HHV-8 before and after renal transplantation. Methods Using an enzyme-linked immunosorbent assay with the recombinant HHV-8 protein orf 65.2, we analyzed serum samples from 220 renal-transplant recipients for the presence of antibodies to HHV-8 on the day of transplantation and one year later. Positive results were confirmed by an indirect immunofluorescence assay that detects antibodies to latent antigen and by Western blotting. Follow-up lasted at least four years. Results The seroprevalence of HHV-8 in graft recipients increased from 6.4 percent on the day of transplantation to 17.7 percent one year after transplantation. Seroconversion occurred within the first year after transplantation in 25 patients, and Kaposi's sarcoma developed in 2 of them within 26 months after transplantation. Sequential serum samples were obtained from 10 of the patients with seroconversion, and in 8 of these patients, IgM antibodies to HHV-8 appeared within three months after transplantation. In the case of six patients who seroconverted, serum samples from the donors were available, and five (83 percent) tested positive for HHV-8. In a control group of eight patients who were seronegative at the time of transplantation and who received allografts from HHV-8-negative donors, none seroconverted within the year after transplantation. Conclusions HHV-8 is transmitted through renal allografts and is a risk factor for transplantation-associated Kaposi's sarcoma. (C) 1998, Massachusetts Medical Society.	Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland; Univ Basel Hosp, Dept Internal Med, Div Nephrol, CH-4031 Basel, Switzerland; Univ Zurich Hosp, Inst Pathol, CH-8091 Zurich, Switzerland	University of Basel; University of Basel; University of Zurich; University Zurich Hospital	Erb, P (corresponding author), Univ Basel, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.							al-Sulaiman M H, 1994, Transplant Sci, V4, P46; Blackbourn DJ, 1997, AIDS, V11, P249, DOI 10.1097/00002030-199702000-00016; Cathomas G, 1996, J CLIN PATHOL, V49, P631, DOI 10.1136/jcp.49.8.631; Cathomas G, 1997, TRANSPLANTATION, V64, P175, DOI 10.1097/00007890-199707150-00033; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Farge D, 1993, Eur J Med, V2, P339; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Lin SF, 1997, J VIROL, V71, P3069, DOI 10.1128/JVI.71.4.3069-3076.1997; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Parravicini C, 1997, BLOOD, V90, P2826; PENN I, 1991, TRANSPLANT P, V23, P1101; Penn I, 1995, TRANSPLANTATION, V60, P1485, DOI 10.1097/00007890-199560120-00020; Penn I, 1996, TRANSPLANT P, V28, P876; QUNIBI W, 1988, AM J MED, V84, P225, DOI 10.1016/0002-9343(88)90418-4; Regamey N, 1998, J CLIN MICROBIOL, V36, P1784, DOI 10.1128/JCM.36.6.1784-1786.1998; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SHMUELI D, 1989, TRANSPLANT P, V21, P3209; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395	25	220	228	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1358	1363		10.1056/NEJM199811053391903	http://dx.doi.org/10.1056/NEJM199811053391903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801396				2022-12-24	WOS:000076780200003
J	Tao, YZ; Olson, NH; Xu, W; Anderson, DL; Rossmann, MG; Baker, TS				Tao, YZ; Olson, NH; Xu, W; Anderson, DL; Rossmann, MG; Baker, TS			Assembly of a tailed bacterial virus and its genome release studied in three dimensions	CELL			English	Article							HERPES-SIMPLEX VIRUS; BACILLUS-SUBTILIS; 3-DIMENSIONAL RECONSTRUCTION; CRYOELECTRON MICROSCOPY; BACTERIOPHAGE PHI-29; 13-FOLD SYMMETRY; DNA; PROTEIN; MATURATION; CONNECTOR	We present the first three-dimensional reconstruction of a prolate, tailed phage, and its empty prohead precursor by cryo-electron microscopy. The head-tail connector, the central component of the DNA packaging machine, is visualized for the first time in situ within the Bacillus subtilis dsDNA phage phi 29. The connector, with 12- or 13-fold symmetry, appears to fit loosely into a pentameric vertex of the head, a symmetry mismatch that may be required to rotate the connector to package DNA. The prolate head of phi 29 has 10 hexameric units in its cylindrical equatorial region, and 11 pentameric and 20 hexameric units comprise icosahedral end-caps with T=3 quasi-symmetry. Reconstruction of an emptied phage particle shows that the connector and neck/tail assembly undergo significant conformational changes upon ejection of DNA.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; Univ Minnesota, Dept Microbiol & Oral Sci, Minneapolis, MN 55455 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Minnesota System; University of Minnesota Twin Cities	Baker, TS (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.			, Timothy/0000-0001-6543-8968	NIAID NIH HHS [P01 AI035212] Funding Source: Medline; NIDCR NIH HHS [R01 DE003606, DE03606] Funding Source: Medline; NIGMS NIH HHS [R01 GM033050, GM33050, R37 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE003606, R01DE003606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050, R01GM033050] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1974, Journal of Supramolecular Structure, V2, P253, DOI 10.1002/jss.400020218; ANDERSON DL, 1966, J BACTERIOL, V91, P2081, DOI 10.1128/JB.91.5.2081-2089.1966; Anderson Dwight, 1993, P859; Baker TS, 1996, CURR OPIN STRUC BIOL, V6, P585, DOI 10.1016/S0959-440X(96)80023-6; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Belnap DM, 1996, J MOL BIOL, V259, P249, DOI 10.1006/jmbi.1996.0317; BJORNSTI MA, 1983, J VIROL, V45, P383, DOI 10.1128/JVI.45.1.383-396.1983; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CARRASCOSA JL, 1981, VIROLOGY, V111, P401, DOI 10.1016/0042-6822(81)90343-3; CARRASCOSA JL, 1982, J MOL BIOL, V154, P311, DOI 10.1016/0022-2836(82)90066-3; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Caston JR, 1997, J CELL BIOL, V138, P975, DOI 10.1083/jcb.138.5.975; Cerritelli ME, 1997, CELL, V91, P271, DOI 10.1016/S0092-8674(00)80409-2; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; Dokland T, 1997, NATURE, V389, P308, DOI 10.1038/38537; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Grimes S, 1997, J MOL BIOL, V266, P901, DOI 10.1006/jmbi.1996.0843; Guasch A, 1998, J MOL BIOL, V281, P219, DOI 10.1006/jmbi.1998.1928; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAGEN EW, 1976, J VIROL, V19, P501, DOI 10.1128/JVI.19.2.501-517.1976; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; ILAG LL, 1995, STRUCTURE, V3, P353, DOI 10.1016/S0969-2126(01)00167-8; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; REILLY BE, 1977, J VIROL, V24, P363, DOI 10.1128/JVI.24.1.363-377.1977; ROSSMANN MG, 1994, PROTEIN SCI, V3, P1712, DOI 10.1002/pro.5560031010; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; TOSI M, 1973, J VIROL, V12, P1548, DOI 10.1128/JVI.12.6.1548-1559.1973; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; TSUPRUN V, 1994, BIOPHYS J, V66, P2139, DOI 10.1016/S0006-3495(94)81009-4; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; Zhou ZH, 1998, P NATL ACAD SCI USA, V95, P2778, DOI 10.1073/pnas.95.6.2778	44	184	192	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					431	437		10.1016/S0092-8674(00)81773-0	http://dx.doi.org/10.1016/S0092-8674(00)81773-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814712	Green Accepted, Bronze			2022-12-24	WOS:000076789600015
J	Ohlmeyer, JT; Kalderon, D				Ohlmeyer, JT; Kalderon, D			Hedgehog stimulates maturation of Cubitus interruptus into a labile transcriptional activator	NATURE			English	Article							KINESIN-RELATED PROTEIN; DROSOPHILA-MELANOGASTER; SIGNAL-TRANSDUCTION; WINGLESS; GENE; COMPARTMENT; ENCODES; BOUNDARIES; EXPRESSION; SUPPRESSOR	In Drosophila, signalling by the protein Hedgehog (Hh) alters the activity of the transcription factor Cubitus interruptus (Ci) by inhibiting the proteolysis of full-length Ci (Ci-155) to its shortened Ci-75 form(1,2). Ci-75 is found largely in the nucleus and is thought to be a transcriptional repressor(1), whereas there is evidence(3-5) to indicate that Ci-155 may be a transcriptional activator(1,2,6). However, Ci-155 is detected only in the cytoplasm, where it is associated with the protein kinase Fused (Fu), with Suppressor of Fused (Su(fu)), and with the microtubule-binding protein Costal-2 (refs 1,7-9), It is not clear how Ci-155 might become a nuclear activator. We show here that mutations in Su(fu) cause an increase in the expression of Hh-target genes in a dose-dependent manner while simultaneously reducing Ci-155 concentration by some mechanism other than proteolysis to Ci-75, Conversely, eliminating Fu kinase activity reduces Hh-target gene expression while increasing Ci-155 concentration. We propose that Fu kinase activity is required for Hh to stimulate the maturation of Ci-155 into a short-lived nuclear transcriptional activator and that Su(fu) opposes this maturation step through a stoichiometric interaction with Ci-155.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Kalderon, D (corresponding author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1992, DEVELOPMENT, V115, P21; Blair SS, 1997, DEVELOPMENT, V124, P4053; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BUSSON D, 1988, ROUX ARCH DEV BIOL, V197, P221, DOI 10.1007/BF02439429; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; FORBES AJ, 1993, DEVELOPMENT, P115; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; PREAT T, 1992, GENETICS, V132, P725; PREAT T, 1993, GENETICS, V135, P1047; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Strigini M, 1997, DEVELOPMENT, V124, P4697; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; THEROND P, 1993, MECH DEVELOP, V44, P165; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0	30	256	258	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 31	1998	396	6713					749	753		10.1038/25533	http://dx.doi.org/10.1038/25533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874371				2022-12-24	WOS:000077742800032
J	Boyes, J; Byfield, P; Nakatani, Y; Ogryzko, V				Boyes, J; Byfield, P; Nakatani, Y; Ogryzko, V			Regulation of activity of the transcription factor GATA-1 by acetylation	NATURE			English	Article							DNA-BINDING DOMAIN; HISTONE ACETYLTRANSFERASE; MEGAKARYOCYTIC DIFFERENTIATION; ZINC-FINGER; ACTIVATION; CHROMATIN; COMPLEX; CGATA-1; PROTEIN; CELLS	Modification of histones, DNA-binding proteins found in chromatin, by addition of acetyl groups occurs to a greater degree when the histones are associated with transcriptionally active DNA(1,2). A breakthrough in understanding how this acetylation is mediated was the discovery that various transcriptional co-activator proteins have intrinsic histone acetyltransferase activity (for example, Gcn5p (ref. 3), PCAF(4), TAF(II)250 (ref. 5) and p300/ CBp(6,7)). These acetyltransferases also modify certain transcription factors (TFIIE beta, TFIIF, EKLF and p53 (refs 8-10)). GATA-1 is an important transcription factor in the haematopoietic lineage(11) and is essential for terminal differentiation of erythrocytes and megakaryocytes(12,13). It is associated in vivo with the acetyltransferase p300/CBP14, sere we report that GATA-1 is acetylated in vitro by p300. This significantly increases the amount of GATA-1 bound to DNA and alters the mobility of GATA-1-DNA complexes, suggestive of a conformational change in GATA-1. GATA-1 is also acetylated in vivo and acetylation directly stimulates GATA-1-dependent transcription. Mutagenesis of important acetylated residues shows that there is a relationship between the acetylation and in viva function of GATA-1. We propose that acetylation of transcription factors can alter interactions between these factors and DNA and among different transcription factors, and is an integral part of transcription and differentiation processes.	Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Boyes, J (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389; Boyes, Joan/0000-0002-8705-9827				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Briegel K, 1996, DEVELOPMENT, V122, P3839; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V68, P597; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pikaart MJ, 1996, PROTEIN EXPRES PURIF, V8, P469, DOI 10.1006/prep.1996.0126; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	27	614	633	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					594	598		10.1038/25166	http://dx.doi.org/10.1038/25166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859997				2022-12-24	WOS:000077466800063
J	Peters, JW; Lanzilotta, WN; Lemon, BJ; Seefeldt, LC				Peters, JW; Lanzilotta, WN; Lemon, BJ; Seefeldt, LC			X-ray crystal structure of the Fe-only hydrogenase (Cpl) from Clostridium pasteurianum to 1.8 angstrom resolution	SCIENCE			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; IRON-SULFUR CLUSTERS; RESONANCE RAMAN; CARBON-MONOXIDE; ACTIVE-SITE; PROTEIN; GENE; PROGRAM; SPECTROSCOPY; ACTIVATION	A three-dimensional structure for the monomeric iron-containing hydrogenase (Cpl) from Clostridium pasteurianum was determined to 1.8 angstrom resolution by x-ray crystallography using multiwavelength anomalous dispersion (MAD) phasing. Cpl, an enzyme that catalyzes the two-electron reduction of two protons to yield dihydrogen, was found to contain 20 gram atoms of iron per mole of protein, arranged into five distinct [Fe-S] clusters. The probable active-site cluster, previously termed the H-cluster, was found to be an unexpected arrangement of six iron atoms existing as a [4Fe-4S] cubane subcluster covalently bridged by a cysteinate thiol to a [2Fe] subcluster. The iron atoms of the [2Fe] subcluster both exist with an octahedral coordination geometry and are bridged to each other by three non-protein atoms, assigned as two sulfide atoms and one carbonyl or cyanide molecule. This structure provides insights into the mechanism of biological hydrogen activation and has broader implications for [Fe-S] cluster structure and function in biological systems.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Peters, JW (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	petersj@cc.usu.edu		Peters, John/0000-0001-9117-9568				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADAMS MWW, 1987, J BIOL CHEM, V262, P15054; ADAMS MWW, 1989, P NATL ACAD SCI USA, V86, P4932, DOI 10.1073/pnas.86.13.4932; ADAMS MWW, 1980, BIOCHIM BIOPHYS ACTA, V594, P105, DOI 10.1016/0304-4173(80)90007-5; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BRUNGER AT, 1987, SCIENCE, V235, P258; CHEN JS, 1974, BIOCHIM BIOPHYS ACTA, V371, P283, DOI 10.1016/0005-2795(74)90025-7; Cotton F. A., 1988, ADV INORGANIC CHEM; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; FERNANDEZ VM, 1983, ANAL BIOCHEM, V130, P54, DOI 10.1016/0003-2697(83)90648-6; FontecillaCamps JC, 1996, J BIOL INORG CHEM, V1, P91, DOI 10.1007/s007750050027; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Gorwa MF, 1996, J BACTERIOL, V178, P2668, DOI 10.1128/jb.178.9.2668-2675.1996; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaasjager VE, 1998, ANGEW CHEM INT EDIT, V37, P1668, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1668::AID-ANIE1668>3.0.CO;2-J; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KOWAL AT, 1989, J BIOL CHEM, V264, P4342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CCP4 ESF EACMB NEWSL, P26; LESLIE AGW, 1994, ACTA CRYSTALLOGR D, V50, P760; MACOR KA, 1987, J BIOL CHEM, V262, P9945; MALKI S, 1995, J BACTERIOL, V177, P2628, DOI 10.1128/jb.177.10.2628-2636.1995; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER J, 1991, BIOCHEMISTRY-US, V30, P9697, DOI 10.1021/bi00104a018; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; OTWINOWSKI Z, 1991, DATA COLLECTION PROC, P56; PETERS JP, UNPUB; PRYZBYLA AE, 1992, FEMS MICROBIOL REV, V88, P109; SANTANGELO JD, 1995, MICROBIOL-UK, V141, P171, DOI 10.1099/00221287-141-1-171; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; STOKKERMANS J, 1989, FEMS MICROBIOL LETT, V58, P217; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; THAUER RK, 1974, EUR J BIOCHEM, V42, P447, DOI 10.1111/j.1432-1033.1974.tb03358.x; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; THOMANN H, 1991, J AM CHEM SOC, V113, P7044, DOI 10.1021/ja00018a057; VanderSpek TM, 1996, EUR J BIOCHEM, V237, P629; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; VOORDOUW G, 1989, J BACTERIOL, V171, P3881, DOI 10.1128/jb.171.7.3881-3889.1989; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Xia JQ, 1997, J AM CHEM SOC, V119, P8301, DOI 10.1021/ja971025+	51	1674	1703	8	291	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1853	1858		10.1126/science.282.5395.1853	http://dx.doi.org/10.1126/science.282.5395.1853			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836629				2022-12-24	WOS:000077338100039
J	Craddock, N; Lendon, C				Craddock, N; Lendon, C			New susceptibility gene for Alzheimer's disease on chromosome 12?	LANCET			English	Editorial Material							APOLIPOPROTEIN-E; ASSOCIATION		Univ Birmingham, Queen Elizabeth Psychiat Hosp, Div Neurosci, Birmingham B15 2QZ, W Midlands, England	University of Birmingham	Craddock, N (corresponding author), Univ Birmingham, Queen Elizabeth Psychiat Hosp, Div Neurosci, Birmingham B15 2QZ, W Midlands, England.							Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; Wu WS, 1998, JAMA-J AM MED ASSOC, V280, P619, DOI 10.1001/jama.280.7.619	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1720	1721		10.1016/S0140-6736(98)00075-0	http://dx.doi.org/10.1016/S0140-6736(98)00075-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848343				2022-12-24	WOS:000077246500002
J	Dobbie, I; Linari, M; Piazzesi, G; Reconditi, M; Koubassova, N; Ferenczi, MA; Lombardi, V; Irving, M				Dobbie, I; Linari, M; Piazzesi, G; Reconditi, M; Koubassova, N; Ferenczi, MA; Lombardi, V; Irving, M			Elastic bending and active tilting of myosin heads during muscle contraction	NATURE			English	Article							X-RAY-DIFFRACTION; RABBIT SKELETAL-MUSCLE; MUSCULAR-CONTRACTION; FORCE GENERATION; STRIATED-MUSCLE; THIN-FILAMENTS; FIBERS; EXTENSIBILITY; STIFFNESS; KINETICS	Muscle contraction is driven by a change in shape of the myosin head reg;ion that links the actin and myosin filaments(1,2). Tilting of the light-chain domain of the head with respect to its actin-bound catalytic domain is thought to be coupled to the ATPase cycle(3-6). Here, using X-ray diffraction and mechanical data from isolated muscle fibres, we characterize an elastic bending of the heads that is independent of the presence of ATP. Together, the tilting and bending motions can explain force generation in isometric muscle, when filament sliding is prevented. The elastic strain in the head is 2.0-2.7 nm under these conditions, contributing 40-50% of the compliance of the muscle sarcomere. We present an atomic model for changes in head conformation that accurately reproduces the changes in the X-ray diffraction pattern seen when rapid length changes are applied to muscle fibres both in active contraction and in the absence of ATP. The model predictions are relatively independent of which parts of the head are assumed to bend or tilt, but depend critically on the measured values of filament sliding and elastic strain.	Univ London Kings Coll, Randall Inst, London WC2B 5RL, England; Univ Florence, Dipartimento Sci Fisiol, I-50134 Florence, Italy; Natl Inst Med Res, London NW7 1AA, England; Moscow MV Lomonosov State Univ, Inst Mech, Moscow 119899, Russia	University of London; King's College London; University of Florence; MRC National Institute for Medical Research; Lomonosov Moscow State University	Irving, M (corresponding author), Univ London Kings Coll, Randall Inst, London WC2B 5RL, England.		Ferenczi, Michael/F-9510-2015; Koubassova, Natalia/AAI-6490-2021	Ferenczi, Michael/0000-0002-0349-331X; Koubassova, Natalia/0000-0002-0238-4920; RECONDITI, MASSIMO/0000-0001-5065-924X; LINARI, MARCO/0000-0001-6512-4897; Dobbie, Ian/0000-0002-5531-5865				Bershitsky S, 1996, BIOPHYS J, V71, P1462, DOI 10.1016/S0006-3495(96)79347-5; CECCHI G, 1982, SCIENCE, V217, P70, DOI 10.1126/science.6979780; COOKE R, 1980, BIOCHEMISTRY-US, V19, P2265, DOI 10.1021/bi00551a042; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; Irving M, 1997, NEWS PHYSIOL SCI, V12, P249; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; LOVELL SJ, 1981, NATURE, V293, P664, DOI 10.1038/293664a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; Piazzesi G, 1997, J PHYSIOL-LONDON, V498, P3, DOI 10.1113/jphysiol.1997.sp021837; Piazzesi G., 1995, Biophysical Journal, V68, P92; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; Yagi N, 1996, J SYNCHROTRON RADIAT, V3, P305, DOI 10.1107/S0909049596008928	30	128	131	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					383	387		10.1038/24647	http://dx.doi.org/10.1038/24647			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845077	Green Submitted			2022-12-24	WOS:000077204000054
J	Pellizzoni, L; Kataoka, N; Charroux, B; Dreyfuss, G				Pellizzoni, L; Kataoka, N; Charroux, B; Dreyfuss, G			A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing	CELL			English	Article							MOTOR-NEURON GENE; SMALL NUCLEAR RIBONUCLEOPROTEIN; WERDNIG-HOFFMANN DISEASE; MESSENGER-RNA PRECURSORS; HELICASE-LIKE PROTEIN; COILED BODY; MOLECULAR ANALYSIS; MAMMALIAN NUCLEI; SNRNP PROTEINS; SURVIVAL	Spinal muscular atrophy (SMA) is a common motor neuron degenerative disease that results from reduced levels of, or mutations in, the Survival of Motor Neurons (SMN) protein. SMN is found in the cytoplasm and the nucleus where it is concentrated in gems. SMN interacts with spliceosomal snRNP proteins and is critical for snRNP assembly in the cytoplasm. We show that a dominant-negative mutant SMN (SMN Delta N27) causes a dramatic reorganization of snRNPs in the nucleus. Furthermore, SMN Delta N27 inhibits pre-mRNA splicing in vitro, while wild-type SMN stimulates splicing. SMN mutants found in SMA patients cannot stimulate splicing. These findings demonstrate that SMN plays a crucial role in the generation of the pre-mRNA splicing machinery and thus in mRNA biogenesis, and they link the function of SMN in this pathway to SMA.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013; Kataoka, Naoyuki/H-6298-2019	Dreyfuss, Gideon/0000-0001-8129-8774; Kataoka, Naoyuki/0000-0002-4498-7420; Pellizzoni, Livio/0000-0002-9168-5628				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHANG JG, 1995, AM J HUM GENET, V57, P1503; COBBEN JM, 1995, AM J HUM GENET, V57, P805; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1988, NUCLEIC ACIDS RES, V16, P9415, DOI 10.1093/nar/16.20.9415; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mattaj IW, 1998, CURR BIOL, V8, pR93, DOI 10.1016/S0960-9822(98)70055-7; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJIW, 1988, STRUCTURE FUNCTION M, P100; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PADGETT RA, 1983, CELL, V35, P101, DOI 10.1016/0092-8674(83)90212-X; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Raghunathan PL, 1998, SCIENCE, V279, P857, DOI 10.1126/science.279.5352.857; Ramon y Cajal S., 1903, TRAD LAB INVEST BIOL, V2, P129; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; ROTH MB, 1995, CURR OPIN CELL BIOL, V7, P325, DOI 10.1016/0955-0674(95)80086-7; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604	58	457	468	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					615	624		10.1016/S0092-8674(00)81632-3	http://dx.doi.org/10.1016/S0092-8674(00)81632-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845364	hybrid			2022-12-24	WOS:000077253700009
J	Hasenclever, D; Diehl, V				Hasenclever, D; Diehl, V		Int Prognostic Factors Project Adv Hodgkins Dis	A prognostic score for advanced Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR-RISK PATIENTS; DIRECTLY PREDICTIVE EQUATION; COMBINATION CHEMOTHERAPY; STAGE-IV; MOPP/ABVD CHEMOTHERAPY; SALVAGE CHEMOTHERAPY; MVPP CHEMOTHERAPY; INTENSIVE THERAPY; INITIAL TREATMENT; MEDIASTINAL BULK	Background Two thirds of patients with advanced Hodgkin's disease are cured with current approaches to treatment. Prediction of the outcome is important to avoid overtreating some patients and to identify others in whom standard treatment is likely to fail. Methods Data were collected from 25 centers and study groups on a total of 5141 patients treated with combination chemotherapy for advanced Hodgkin's disease, with or without radiotherapy. The data included the outcome and 19 demographic and clinical characteristics at diagnosis. The end point was freedom from progression of disease. Complete data were available for 1618 patients; the final Cox model was fitted to these data. Data from an additional 2643 patients were used for partial validation. Results The prognostic score was defined as the number of adverse prognostic factors present at diagnosis. Seven factors had similar independent prognostic effects: a serum albumin level of less than 4 g per deciliter, a hemoglobin level of less than 10.5 g per deciliter, male sex, an age of 45 years or older, stage IV disease (according to the Ann Arbor classification), leukocytosis (a white-cell count of at least 15,000 per cubic millimeter), and lymphocytopenia (a lymphocyte count of less than 600 per cubic millimeter, a count that was less than 8 percent of the white-cell count, or both). The score predicted the rate of freedom from progression of disease as follows: 0, or no factors (7 percent of the patients), 84 percent; 1 (22 percent of the patients), 77 percent; 2 (29 percent of the patients), 67 percent; 3 (23 percent of the patients), 60 percent; 4 (12 percent of the patients), 51 percent; and 5 or higher (7 percent of the patients), 42 percent. Conclusions The prognostic score we developed may be useful in designing clinical trials;for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics. (N Engl J Med 1998;339: 1506-14.) (C) 1998, Massachusetts Medical Society.	Univ Leipzig, IMISE, D-04103 Leipzig, Germany; Univ Cologne, Clin Internal Med 1, Cologne, Germany	Leipzig University; University of Cologne	Hasenclever, D (corresponding author), Univ Leipzig, IMISE, Liebigstr 27, D-04103 Leipzig, Germany.							ANDERSON H, 1985, CLIN RADIOL, V36, P449, DOI 10.1016/S0009-9260(85)80183-5; ANDERSON H, 1991, ANN ONCOL, V2, P49, DOI 10.1093/annonc/2.suppl_2.49; ASSOULINE D, 1993, P AN M AM SOC CLIN, V12, P381; Bjorkholm M, 1995, ANN ONCOL, V6, P895; BONADONNA G, 1991, ANN ONCOL, V2, P9, DOI 10.1093/annonc/2.suppl_1.9; BRUSAMOLINO E, 1989, HAEMATOLOGICA, V74, P173; BRUSAMOLINO E, 1994, ANN ONCOL, V5, pS53, DOI 10.1093/annonc/5.suppl_2.S53; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARDE P, 1995, LEUKEMIA LYMPHOMA, V15, P31, DOI 10.3109/10428199509052703; Carella AM, 1996, LEUKEMIA LYMPHOMA, V21, P63, DOI 10.3109/10428199609067581; Diehl V, 1995, ANN ONCOL, V6, P901, DOI 10.1093/oxfordjournals.annonc.a059357; Federico M, 1996, LEUKEMIA, V10, pS69; Ferme C, 1997, CANCER-AM CANCER SOC, V80, P1124; FERME C, 1993, INT J RADIAT ONCOL, V26, P397, DOI 10.1016/0360-3016(93)90956-V; FERME C, 1995, ANN ONCOL, V6, P543, DOI 10.1093/oxfordjournals.annonc.a059242; FERME C, 1991, EUR J HAEMATOL, V46, P306; GAUSE A, 1992, ANN ONCOL, V3, pS49, DOI 10.1093/annonc/3.suppl_4.S49; GISSELBRECHT C, 1995, LEUKEMIA LYMPHOMA, V15, P23, DOI 10.3109/10428199509052700; Glick JH, 1998, J CLIN ONCOL, V16, P19, DOI 10.1200/JCO.1998.16.1.19; Glimelius B, 1996, LEUKEMIA LYMPHOMA, V21, P71, DOI 10.3109/10428199609067582; GOBBI PG, 1988, LANCET, V1, P675, DOI 10.1016/S0140-6736(88)91477-8; GOBBI PG, 1994, HAEMATOLOGICA, V79, P241; GOBBI PG, 1989, HAEMATOLOGICA, V74, P29; GOBBI PG, 1986, HAEMATOLOGICA, V71, P95; GOBBI PG, 1985, CANCER, V55, P389, DOI 10.1002/1097-0142(19850115)55:2<389::AID-CNCR2820550216>3.0.CO;2-F; GOBBI PG, 1993, J CLIN ONCOL, V11, P712, DOI 10.1200/JCO.1993.11.4.712; GORSCHLUTER M, 1995, ANN ONCOL, V6, P477, DOI 10.1093/oxfordjournals.annonc.a059218; HANCOCK BW, 1994, ANN ONCOL, V5, pS117, DOI 10.1093/annonc/5.suppl_2.S117; HANCOCK BW, 1992, J CLIN ONCOL, V10, P1252, DOI 10.1200/JCO.1992.10.8.1252; HASEGAWA G, 1995, NEFROLOGIA, V15, P1; Hasenclever D, 1996, ANN ONCOL, V7, P95; HENRYAMAR M, 1990, C INSERM, V196, P169; HILL M, 1995, J CLIN ONCOL, V13, P387, DOI 10.1200/JCO.1995.13.2.387; Holte H, 1996, ACTA ONCOL, V35, P73, DOI 10.3109/02841869609098523; HOPPER KD, 1991, INVEST RADIOL, V26, P1101, DOI 10.1097/00004424-199112000-00015; Horning SJ, 1996, ANN ONCOL, V7, P105; HORNING SJ, 1992, ANN ONCOL, V3, P747, DOI 10.1093/oxfordjournals.annonc.a058333; HUDSON BV, 1987, CLIN RADIOL, V38, P257, DOI 10.1016/S0009-9260(87)80060-0; Kaplan HS, 1980, HODGKINS DIS; Lee SM, 1997, BRIT J CANCER, V75, P110, DOI 10.1038/bjc.1997.18; LONGO DL, 1992, J CLIN ONCOL, V10, P210, DOI 10.1200/JCO.1992.10.2.210; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; LOTAN C, 1996, ANN ONCOL, V7, P114; MACLENNAN KA, 1983, CLIN RADIOL, V34, P491, DOI 10.1016/S0009-9260(83)80146-9; MUNKER R, 1995, J CLIN ONCOL, V13, P403, DOI 10.1200/JCO.1995.13.2.403; PFREUNDSCHUH MG, 1994, J CLIN ONCOL, V12, P580, DOI 10.1200/JCO.1994.12.3.580; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; PROCTOR SJ, 1991, EUR J CANCER, V27, P624, DOI 10.1016/0277-5379(91)90231-2; PROCTOR SJ, 1992, LEUKEMIA LYMPHOMA, V7, P17, DOI 10.3109/10428199209061558; PROCTOR SJ, 1993, LEUKEMIA, V7, P1911; RADFORD JA, 1995, J CLIN ONCOL, V13, P2379, DOI 10.1200/JCO.1995.13.9.2379; RANSON MR, 1991, ANN ONCOL, V2, P423, DOI 10.1093/oxfordjournals.annonc.a057978; REECE DE, 1994, BLOOD, V83, P1193; Schmitz N., 1995, Blood, V86, p439A; Simmonds PD, 1997, ANN ONCOL, V8, P259, DOI 10.1023/A:1008282020341; SOMERS R, 1994, J CLIN ONCOL, V12, P279, DOI 10.1200/JCO.1994.12.2.279; Specht, 1996, Semin Radiat Oncol, V6, P146; SPECHT L, 1988, EUR J HAEMATOL, V41, P359; SPECHT L, 1991, CANCER TREAT REV, V18, P21, DOI 10.1016/0305-7372(91)90003-I; STRAUS DJ, 1990, J CLIN ONCOL, V8, P1173, DOI 10.1200/JCO.1990.8.7.1173; STRAUS DJ, 1995, LEUKEMIA LYMPHOMA, V15, P41, DOI 10.3109/10428199509052704; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; TUBIANA M, 1971, CANCER RES, V31, P1801; Uziely B, 1990, Leuk Lymphoma, V1, P123, DOI 10.3109/10428199009042469; WAGSTAFF J, 1986, HEMATOL ONCOL, V4, P135, DOI 10.1002/hon.2900040206	65	1223	1285	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1998	339	21					1506	1514		10.1056/NEJM199811193392104	http://dx.doi.org/10.1056/NEJM199811193392104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	139VT	9819449				2022-12-24	WOS:000077051800004
J	Bishai, WR; Graham, NMH; Harrington, S; Pope, DS; Hooper, N; Astemborski, J; Sheely, L; Vlahov, D; Glass, GE; Chaisson, RE				Bishai, WR; Graham, NMH; Harrington, S; Pope, DS; Hooper, N; Astemborski, J; Sheely, L; Vlahov, D; Glass, GE; Chaisson, RE			Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; POPULATION; IDENTIFICATION; COMMUNITY; PTBN12	Context.-Recent studies suggest that one third of tuberculosis cases in urban areas result from recent transmission. Improved tuberculosis control measures such as uniform implementation of directly observed therapy might reduce the proportion of cases resulting from recent transmission. Objective.-To determine patterns of tuberculosis transmission in Baltimore, Md, after 15 years of community-based directly observed therapy. Design.-A 30-month (January 1994-June 1996), prospective, city-wide study of all cases of tuberculosis using traditional contact investigations, geographic information systems data, and molecular epidemiologic comparison of Mycobacterium tuberculosis isolates with 2 DNA probes. Patients.-One hundred eighty-two patients with culture-positive tuberculosis. Main Outcome Measures.-Proportion of disease defined as recently transmitted based on epidemiologic linkage by traditional contact tracing and molecular, linkage by DNA fingerprint analysis of isolates; geographic foci of transmission based on linkage of residences by geographic information systems data. Results.-Of the 182 patients who had isolates of M tuberculosis available, 84 (46%) showed molecular clustering with 58 (32%) defined as being recently transmitted. Only 20 (24%) of 84 cases with clustered DNA fingerprints had epidemiologic evidence of recent contact. Geographic analysis showed significant spatial aggregation of the 20 clustered cases with epidemiologic links (P<.001), occurring in areas of low socioeconomic status and high drug use, The 64 cases with clustered DNA fingerprints but without epidemiologic links shared common risk factors and demographic features with the 20 clustered patients who did have epidemiologic links. Conclusions.-Recently transmitted tuberculosis accounts for a high proportion of tuberculosis cases in Baltimore. Recently transmitted cases occur in geographically distinct areas of Baltimore, and location-based control efforts may be more effective than contact tracing for the early identification of cases.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Baltimore City Dept Hlth, Baltimore, MD USA; Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene	Bishai, WR (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	wbishai@jhsph.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036973, R29AI036973, R01AI040605] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36973, AI40605] Funding Source: Medline; NIDA NIH HHS [DA07061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Altman D.G., 1991, PRACTICAL STATISTIC; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Bishai WR, 1996, NEW ENGL J MED, V334, P1573, DOI 10.1056/NEJM199606133342404; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Braden CR, 1997, INFECT DIS CLIN PRAC, V6, P89, DOI 10.1097/00019048-199702000-00004; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P253; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Chaulk CP, 1997, CLIN CHEST MED, V18, P149, DOI 10.1016/S0272-5231(05)70364-6; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; CUZICK J, 1990, J ROY STAT SOC B MET, V52, P73; Etkind S, 1991, Semin Respir Infect, V6, P273; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; HERMANS PWM, 1995, J INFECT DIS, V171, P1504, DOI 10.1093/infdis/171.6.1504; Michele TM, 1997, JAMA-J AM MED ASSOC, V278, P1093, DOI 10.1001/jama.278.13.1093; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; YANG ZH, 1995, J CLIN MICROBIOL, V33, P1064, DOI 10.1128/JCM.33.5.1064-1069.1995	33	130	135	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1679	1684		10.1001/jama.280.19.1679	http://dx.doi.org/10.1001/jama.280.19.1679			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9831999	Bronze			2022-12-24	WOS:000076980700033
J	Lewis, G; Sloggett, A				Lewis, G; Sloggett, A			Suicide, deprivation, and unemployment: record linkage study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RATES	Objectives To investigate the association between suicide and socioeconomic status, unemployment, and chronic illness. Design Longitudinal study. Setting England and Wales. Subjects Individuals from the Office for National Statistics longitudinal study for whom 1981 census data were available. The longitudinal study is a representative 1% sample of the population of England and Wales in which census variables are linked to mortality data. Main outcome measures Suicide and undetermined deaths occurring between 1983 and 1992. Odds ratios estimated with logistic regression adjusted for attrition of cohort members. Results There was a strong independent association between suicide and individuals who were unemployed (odds ratio 2.6; 95% confidence interval 2.0 to 3.4) and permanently sick (2.5; 1.6 to 4.0), Those without access to a car had an increased risk (1.3; 1.0 to 1.5), but other measures of socioeconomic status were not associated with suicide. Conclusions The association between suicide and unemployment is more important than the association with other socioeconomic measures. Although some potentially important confounders were not adjusted for, the findings support the idea that unemployment or lack of job security increases the risk of suicide and that social and economic policies that reduce unemployment will also reduce the rate of suicide.	Cardiff Univ, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales; Univ London London Sch Hyg & Trop Med, Ctr Populat Studies, London WC1E 7HT, England	Cardiff University; University of London; London School of Hygiene & Tropical Medicine	Lewis, G (corresponding author), Cardiff Univ, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales.	wpcghl@cardiff.ac.uk	Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245				BANKS MH, 1982, PSYCHOL MED, V12, P789, DOI 10.1017/S0033291700049096; Charlton J., 1992, Population Trends, P10; Charlton J., 1993, POPULATION TRENDS, V71, P34; FOX AJ, 1982, LONGITUDINAL STUDY S, V1; Giddens Anthony, 1978, DURKHEIM; Goldblatt P, 1990, LONGITUDINAL STUDY M; HOLDING TA, 1978, BRIT J PSYCHIAT, V133, P542, DOI 10.1192/bjp.133.6.542; KREITMAN N, 1991, J EPIDEMIOL COMMUN H, V45, P195, DOI 10.1136/jech.45.3.195; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; LAST JM, 1988, DICT EPIDEMIOLOGY, P1; Lewis G, 1998, LANCET, V352, P605, DOI 10.1016/S0140-6736(98)04494-8; MARZUK PM, 1992, ARCH GEN PSYCHIAT, V49, P451; MOSER KA, 1984, LANCET, V2, P1324; PLATT S, 1984, SOC SCI MED, V19, P93, DOI 10.1016/0277-9536(84)90276-4; SAINSBURY P, 1986, SUICIDE, P17; *STAT, 1995, STAT STAT SOFTW 4 0; WARR P, 1985, PSYCHOL MED, V15, P795, DOI 10.1017/S003329170000502X; Warr P., 1987, WORK UNEMPLOYMENT ME, P1; Weich S, 1998, J EPIDEMIOL COMMUN H, V52, P8, DOI 10.1136/jech.52.1.8	19	232	235	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	1998	317	7168					1283	1286		10.1136/bmj.317.7168.1283	http://dx.doi.org/10.1136/bmj.317.7168.1283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GP	9804714	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000076963800023
J	Go, AS; Barron, HV; Rundle, AC; Ornato, JP; Avins, AL				Go, AS; Barron, HV; Rundle, AC; Ornato, JP; Avins, AL		Natl Registry Myocardial Infarction 2 Investiga	Bundle-branch block and in-hospital mortality in acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; bundle-branch block; mortality; thrombolytic therapy; comorbidity	LONG-TERM SURVIVAL; CLINICAL SIGNIFICANCE; PROGNOSTIC-SIGNIFICANCE; THROMBOLYTIC THERAPY; CONDUCTION DEFECTS	Background: Left bundle-branch block (BBB) is considered an important predictor of poor outcome in patients with acute myocardial infarction, but the consequences of right BBB are not well understood. Objectives: To 1) estimate the prevalence of left and right BBB in patients with myocardial infarction; 2) compare the clinical characteristics of and treatments received by patients with left, right, or no BBB; and 3) determine the independent association of left BBB and right BBB with in-hospital death. Design: Retrospective cohort study. Setting: Multicenter registry of 1571 U.S. hospitals. Patients: 297 832 patients with acute myocardial infarction who had left, right, or no BBB on initial electrocardiography. Measurements: Presence and type of BBB, clinical characteristics of patients, therapies given, and in-hospital death. Results: Patients with left BBB (n = 19 967; 6.7%) or right BBB (n = 18 354; 6.2%) were older and had more comorbid illness and congestive heart failure than patients with no BBB. Among patients for whom thrombolytic therapy was clearly indicated, fewer patients with left or right BBB (16.6% and 32.0%, respectively) than patients with no BBB (66.5%) received this therapy (P < 0.001). Fewer patients with left or right BBB (60.6% and 67.3%, respectively) than patients with no BBB (75.6%) received aspirin within the first 24 hours (P < 0.001), and fewer patients with left or right BBB (23.9% and 31.8%, respectively) than patients with no BBB (40.4%) received p-blockers within the first 24 hours (P < 0.001). Unadjusted in-hospital mortality rates were almost twice as high for patients with left or right BBB (22.6% and 23.0%, respectively) as for patients with no BBB (13.1%) (P < 0.001). Compared with no BBB and no ST-segment elevation, left BBB was associated with a 34% increase (odds ratio, 1.34 [95% Cl, 1.28 to 1.39]) and right BBB was associated with a 64% increase (odds ratio, 1.64 [Cl, 1.57 to 1.71]) in the risk for in-hospital death, after adjustment for potential confounders. Conclusions: In patients with acute myocardial infarction, prevalences of right and left BBB are similar. Patients with BBB have more comorbid conditions, are less likely to receive therapy, and have an increased risk for in-hospital death compared with patients with no BBB. Compared with left BBB, right BBB seems to be a stronger independent predictor of in-hospital death.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Genentech Inc, San Francisco, CA 94080 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Kaiser Permanente; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding; Genentech; Virginia Commonwealth University	Go, AS (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3503 Broadway St,12th Floor, Oakland, CA 94611 USA.	axg@dor.kaiser.org	Go, Alan S./AAE-7745-2019					APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BAUER GE, 1965, BRIT HEART J, V27, P724; BECKER AE, 1978, BRIT HEART J, V40, P773; BENNETT JC, 1996, TXB MED; Braunwald E., 1997, HEART DIS TXB CARDIO, V5th; DUBOIS C, 1988, CLIN CARDIOL, V11, P292, DOI 10.1002/clc.4960110504; Every NR, 1998, J AM COLL CARDIOL, V31, p173A, DOI 10.1016/S0735-1097(97)84464-6; GANN D, 1975, CHEST, V67, P298, DOI 10.1378/chest.67.3.298; GODMAN MJ, 1970, NEW ENGL J MED, V282, P237, DOI 10.1056/NEJM197001292820502; GOLDBERGER AL, 1990, CLIN ELECTROCARDIOGR; GOULD L, 1972, J AMER MED ASSOC, V219, P502, DOI 10.1001/jama.219.4.502; GOULD L, 1973, JAMA-J AM MED ASSOC, V225, P625, DOI 10.1001/jama.225.6.625; HAUER RNW, 1982, AM J CARDIOL, V49, P1581, DOI 10.1016/0002-9149(82)90231-4; HINDMAN MC, 1978, CIRCULATION, V58, P689, DOI 10.1161/01.CIR.58.4.689; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; HOD H, 1995, EUR HEART J, V16, P471, DOI 10.1093/oxfordjournals.eurheartj.a060938; HOLLANDER G, 1983, AM HEART J, V105, P738, DOI 10.1016/0002-8703(83)90234-X; ISSELBACHER KJ, 1994, HARRISONS PRINCIPLES; JONES ME, 1977, AM HEART J, V94, P163, DOI 10.1016/S0002-8703(77)80275-5; KONES RJ, 1980, ACTA CARDIOL, V35, P469; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; MelgarejoMoreno A, 1997, CIRCULATION, V96, P1139, DOI 10.1161/01.CIR.96.4.1139; Newby KH, 1996, CIRCULATION, V94, P2424, DOI 10.1161/01.CIR.94.10.2424; NIMETZ AA, 1975, AM HEART J, V90, P439, DOI 10.1016/0002-8703(75)90423-8; NORRIS RM, 1970, AM HEART J, V79, P728, DOI 10.1016/0002-8703(70)90359-5; OKABE M, 1993, JPN HEART J, V34, P121; OTTERSTAD JE, 1978, ACTA MED SCAND, V203, P529; RICOU F, 1991, J AM COLL CARDIOL, V17, P858, DOI 10.1016/0735-1097(91)90865-7; RICOU F, 1991, AM J CARDIOL, V67, P1143, DOI 10.1016/0002-9149(91)90882-L; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; SCHEIDT S, 1972, J AMER MED ASSOC, V222, P919, DOI 10.1001/jama.222.8.919; Sgarbossa EB, 1998, J AM COLL CARDIOL, V31, P105, DOI 10.1016/S0735-1097(97)00446-4; Stein JJ, 1994, INTERNAL MED; SUAREZ G, 1995, CHEST, V108, P83, DOI 10.1378/chest.108.1.83; TIERNEY L, 1998, CURRENT MED DIAGNOSI	38	123	124	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					690	+		10.7326/0003-4819-129-9-199811010-00003	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841600				2022-12-24	WOS:000076785200002
J	Seigneur, M; Bidnenko, V; Ehrlich, SD; Michel, B				Seigneur, M; Bidnenko, V; Ehrlich, SD; Michel, B			RuvAB acts at arrested replication forks	CELL			English	Article							ESCHERICHIA-COLI K-12; DOUBLE-STRAND BREAKS; JUNCTION-SPECIFIC ENDONUCLEASE; STABLE DNA-REPLICATION; HOLLIDAY JUNCTIONS; RECBCD ENZYME; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; SUBSTRATE-SPECIFICITY; HELICASE ACTIVITY	Replication arrest leads to the occurrence of DNA double-stranded breaks (DSB). We studied the mechanism of DSB formation by direct measure of the amount of in vivo linear DNA in Escherichia coli cells that lack the RecBCD recombination complex and by genetic means. The RuvABC proteins, which catalyze migration and cleavage of Holliday junctions, are responsible for the occurrence of DSBs at arrested replication forks. In cells proficient for RecBC, RuvAB is uncoupled from RuvC and DSBs may be prevented. This may be explained if a Holliday junction forms upon replication fork arrest, by annealing of the two nascent strands. RecBCD may act on the double-stranded tail prior to the cleavage of the RuvAB-bound junction by RuvC to rescue the blocked replication fork without breakage.	INRA, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Michel, B (corresponding author), INRA, F-78352 Jouy En Josas, France.	bmichel@biotec.jouy.inra.fr	Ehrlich, S./Y-2423-2019	Ehrlich, S./0000-0002-7563-4046; Bidnenko, Vladimir/0000-0002-0070-4839				Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ASAI T, 1994, CELL, V78, P1051, DOI 10.1016/0092-8674(94)90279-8; BAKER TA, 1983, J BACTERIOL, V156, P970, DOI 10.1128/JB.156.2.970-974.1983; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bennett RJ, 1996, P NATL ACAD SCI USA, V93, P12217, DOI 10.1073/pnas.93.22.12217; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; Bierne H, 1997, MOL MICROBIOL, V24, P1225, DOI 10.1046/j.1365-2958.1997.4381795.x; Birren B, 1993, PULSE FIELD GEL ELEC; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boudsocq F, 1997, J MOL BIOL, V270, P201, DOI 10.1006/jmbi.1997.1098; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; CLERGET M, 1991, NEW BIOL, V3, P780; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; CONDRA JH, 1982, J GEN MICROBIOL, V128, P613; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LANE HED, 1975, J MOL BIOL, V97, P99; Leach DRF, 1997, MOL MICROBIOL, V26, P597, DOI 10.1046/j.1365-2958.1997.6071957.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LLOYD RG, 1996, ESCHERICHIA COLI SAL, P2236; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MONK M, 1972, J BACTERIOL, V109, P971, DOI 10.1128/JB.109.3.971-978.1972; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; OSSANNA N, 1989, J BACTERIOL, V171, P303, DOI 10.1128/jb.171.1.303-307.1989; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Rice DW, 1997, CURR OPIN STRUC BIOL, V7, P798, DOI 10.1016/S0959-440X(97)80149-2; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Saveson CJ, 1997, GENETICS, V146, P457; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SKARSTAD K, 1993, J BACTERIOL, V175, P5505, DOI 10.1128/JB.175.17.5505-5509.1993; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sorokin A, 1996, GENOME RES, V6, P448, DOI 10.1101/gr.6.5.448; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TorresRamos CA, 1997, J BIOL CHEM, V272, P25445, DOI 10.1074/jbc.272.41.25445; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; UZEST M, 1995, MOL MICROBIOL, V17, P1177, DOI 10.1111/j.1365-2958.1995.mmi_17061177.x; WANG TCV, 1983, J BACTERIOL, V156, P1093, DOI 10.1128/JB.156.3.1093-1098.1983; WANG TCV, 1986, J BACTERIOL, V165, P1023, DOI 10.1128/jb.165.3.1023-1025.1986; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; ZIEG J, 1978, J BACTERIOL, V134, P958, DOI 10.1128/JB.134.3.958-966.1978; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	81	465	468	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					419	430		10.1016/S0092-8674(00)81772-9	http://dx.doi.org/10.1016/S0092-8674(00)81772-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814711	Bronze			2022-12-24	WOS:000076789600014
J	Hartmann, LC; Schaid, DJ; Woods, JE; Crotty, TP; Myers, JL; Arnold, PG; Petty, PM; Sellers, TA; Johnson, JL; McDonnell, SK; Frost, MH; Jenkins, RB				Hartmann, LC; Schaid, DJ; Woods, JE; Crotty, TP; Myers, JL; Arnold, PG; Petty, PM; Sellers, TA; Johnson, JL; McDonnell, SK; Frost, MH; Jenkins, RB			Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBCUTANEOUS MASTECTOMY; BRCA1; RISK; PROBABILITY; MUTATIONS	Background Options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic mastectomy. The data on the outcomes for surveillance and prophylactic mastectomy are incomplete. Methods We conducted a retrospective study of all women with a family history of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. The women were divided into two groups - high risk and moderate risk - on the basis of family history. A control study of the sisters of the high-risk probands and the Gall model were used to predict the number of breast cancers expected in these two groups in the absence of prophylactic mastectomy. Results We identified 639 women with a family history of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at moderate risk. The median length of follow-up was 14 years. The median age at prophylactic mastectomy was 42 years. According to the Gall model, 37.4 breast cancers were expected in the moderate-risk group; 4 breast cancers occurred (reduction in risk, 89.5 percent; P<0.001). We compared the numbers of breast cancers among the 214 high-risk probands with the numbers among their 403 sisters who had not undergone prophylactic mastectomy. Of these sisters, 38.7 percent (156) had been given a diagnosis of breast cancer (115 cases were diagnosed before the respective proband's prophylactic mastectomy, 38 were diagnosed afterward, and the time of the diagnosis was unknown in 3 cases). By contrast, breast cancer was diagnosed in 1.4 percent (3 of 214) of the probands. Thus, prophylactic mastectomy was associated with a reduction in the incidence of breast cancer of at least 90 percent. Conclusions In women with a high risk of breast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the incidence of breast cancer. (N Engl J Med 1999;340:77-84.) (C) 1999, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Plast & Reconstruct Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Clin Epidemiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; St Vincents Hosp, Dept Pathol, Dublin 4, Ireland	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University College Dublin	Hartmann, LC (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; McDonnell, Shannon/0000-0001-6201-369X	NATIONAL CANCER INSTITUTE [U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [U10 CA37404-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM SOC PLAST REC, 1994, PROPH MAST; [Anonymous], 1980, DHHS PUBL; Benichou J, 1996, J CLIN ONCOL, V14, P103, DOI 10.1200/JCO.1996.14.1.103; Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227; BILIMORIA MM, 1995, CA-CANCER J CLIN, V45, P263, DOI 10.3322/canjclin.45.5.263; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; *DHHS, 1970, DHHS PUBL; ELDAR S, 1984, AM J SURG, V148, P692, DOI 10.1016/0002-9610(84)90352-0; ERNSTER VL, 1997, DUCTAL CARCINOMA IN, P23; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fonseca R, 1997, ANN INTERN MED, V127, P1013, DOI 10.7326/0003-4819-127-11-199712010-00013; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GOODNIGHT JE, 1984, J SURG ONCOL, V26, P198, DOI 10.1002/jso.2930260313; Grann VR, 1998, J CLIN ONCOL, V16, P979, DOI 10.1200/JCO.1998.16.3.979; Hicken NF, 1940, ARCH SURG-CHICAGO, V40, P6, DOI 10.1001/archsurg.1940.04080010009002; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KOSARY CL, 1995, NIH PUBLICATION; LEVITAN M, 1977, TXB HUMAN GENETICS, P410; Lopez MJ, 1996, SURG CLIN N AM, V76, P231, DOI 10.1016/S0039-6109(05)70436-9; *NAT CANC I, 1995, NIH PUBL; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; OLOPADE OI, 1996, PRINCIPLES PRACTICE, V10, P1; PENNISI VR, 1986, AESTHET PLAST SURG, V10, P101, DOI 10.1007/BF01575276; PENNISI VR, 1989, AESTHET PLAST SURG, V13, P15, DOI 10.1007/BF01570320; PENNISI VR, 1977, PLAST RECONSTR SURG, V59, P53, DOI 10.1097/00006534-197701000-00009; *PHS, 1964, PHS PUBL, V1252; Powles T, 1998, LANCET, V352, P98; Schaid DJ, 1997, J NATL CANCER I, V89, P1632, DOI 10.1093/jnci/89.21.1632-a; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; SHAM P, 1995, STAT HUMAN GENETICS, P32; STEFANEK ME, 1995, PREV MED, V24, P412, DOI 10.1006/pmed.1995.1066; Veronesi U, 1998, LANCET, V352, P93; WOODS JE, 1983, ANN PLAS SURG, V11, P541, DOI 10.1097/00000637-198312000-00016; *WOODS JE, 1986, MAYO CLIN P, V61, P579; ZIEGLER LD, 1991, AM J CLIN ONCOL-CANC, V14, P451, DOI 10.1097/00000421-199110000-00018	39	901	914	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					77	84		10.1056/NEJM199901143400201	http://dx.doi.org/10.1056/NEJM199901143400201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887158				2022-12-24	WOS:000078016200001
J	Cavazzoni, C; Chiarotti, GL; Scandolo, S; Tosatti, E; Bernasconi, M; Parrinello, M				Cavazzoni, C; Chiarotti, GL; Scandolo, S; Tosatti, E; Bernasconi, M; Parrinello, M			Superionic and metallic states of water and ammonia at giant planet conditions	SCIENCE			English	Article							HIGH-PRESSURE; MAGNETIC-FIELDS; ELECTRICAL-CONDUCTIVITY; MOLECULAR-DYNAMICS; URANUS; ICE; NEPTUNE; PHASE; MBAR; TEMPERATURE	The phase diagrams of water and ammonia were determined by constant pressure ab initio molecular dynamic simulations at pressures (30 to 300 gigapascal) and temperatures (300 to 7000 kelvin) of relevance for the middle ice layers of the giant planets Neptune and Uranus. Along the planetary isentrope water and ammonia behave as fully dissociated ionic, electronically insulating fluid phases, which turn metallic at temperatures exceeding 7000 kelvin for water and 5500 kelvin for ammonia. At lower temperatures, the phase diagrams of water and ammonia exhibit a superionic solid phase between the solid and the ionic liquid. These simulations improve our understanding of the properties of the middle ice Layers of Neptune and Uranus.	Ist Nazl Fis Mat, I-34014 Trieste, Italy; Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy; SISSA, I-34014 Trieste, Italy; Abdus Salaam Int Ctr Theoret Phys, I-34014 Trieste, Italy; Univ Milan, Dipartimento Sci Mat, I-20126 Milan, Italy; INFM, I-20126 Milan, Italy; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; International School for Advanced Studies (SISSA); International School for Advanced Studies (SISSA); Abdus Salam International Centre for Theoretical Physics (ICTP); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Max Planck Society	Chiarotti, GL (corresponding author), Ist Nazl Fis Mat, Via Beirut 4, I-34014 Trieste, Italy.	guido@sissa.it	Chiarotti, Guido/A-9909-2012; Scandolo, Sandro/AAC-9081-2019	Scandolo, Sandro/0000-0003-3826-4813				Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; Aoki K, 1996, PHYS REV LETT, V76, P784, DOI 10.1103/PhysRevLett.76.784; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Benoit M, 1998, NATURE, V392, P258, DOI 10.1038/32609; Benoit M, 1996, PHYS REV LETT, V76, P2934, DOI 10.1103/PhysRevLett.76.2934; Bernasconi M, 1998, PHYS REV LETT, V81, P1235, DOI 10.1103/PhysRevLett.81.1235; BERNASCONI M, 1995, J PHYS CHEM SOLIDS, V56, P501, DOI 10.1016/0022-3697(94)00228-2; CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471; Datchi F., 1998, KOATSURYOKU NO KAGAK, P778; DEMONTIS P, 1988, PHYS REV LETT, V60, P2284, DOI 10.1103/PhysRevLett.60.2284; FOCHER P, 1994, EUROPHYS LETT, V26, P345, DOI 10.1209/0295-5075/26/5/005; Goncharov AF, 1996, SCIENCE, V273, P218, DOI 10.1126/science.273.5272.218; HEMLEY RJ, 1987, NATURE, V330, P737, DOI 10.1038/330737a0; HIRSCH KR, 1984, PHYS LETT A, V101, P142, DOI 10.1016/0375-9601(84)90510-3; HOBBS PV, 1974, ICE PHYSICS; Hubbard WB, 1997, SCIENCE, V275, P1279, DOI 10.1126/science.275.5304.1279; HUBBARD WB, 1980, J GEOPHYS RES, V85, P225, DOI 10.1029/JB085iB01p00225; Hubbard WB, 1995, SPACE SCI S, P109; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; Loveday JS, 1996, PHYS REV LETT, V76, P74, DOI 10.1103/PhysRevLett.76.74; MITCHELL AC, 1982, J CHEM PHYS, V76, P6273, DOI 10.1063/1.443030; Nellis WJ, 1997, J CHEM PHYS, V107, P9096, DOI 10.1063/1.475200; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; NESS NF, 1986, SCIENCE, V233, P85, DOI 10.1126/science.233.4759.85; NESS NF, 1989, SCIENCE, V246, P1473, DOI 10.1126/science.246.4936.1473; Podolak M, 1995, PLANET SPACE SCI, V43, P1517, DOI 10.1016/0032-0633(95)00061-5; PRUZAN P, 1993, J CHEM PHYS, V99, P9842, DOI 10.1063/1.465467; Sprik M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993	33	362	373	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 1	1999	283	5398					44	46		10.1126/science.283.5398.44	http://dx.doi.org/10.1126/science.283.5398.44			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872734				2022-12-24	WOS:000077976600042
J	Paraf, F				Paraf, F			"Smiling" alveolar macrophage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Hosp Univ Dupuytren, F-87042 Limoges, France	CHU Limoges	Paraf, F (corresponding author), Ctr Hosp Univ Dupuytren, F-87042 Limoges, France.			Paraf, Francois/0000-0002-3930-2618					0	1	1	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1896	1896		10.1056/NEJM199812243392605	http://dx.doi.org/10.1056/NEJM199812243392605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862945				2022-12-24	WOS:000077696600005
J	Grunig, G; Warnock, M; Wakil, AE; Venkayya, R; Brombacher, F; Rennick, DM; Sheppard, D; Mohrs, M; Donaldson, DD; Locksley, RM; Corry, DB				Grunig, G; Warnock, M; Wakil, AE; Venkayya, R; Brombacher, F; Rennick, DM; Sheppard, D; Mohrs, M; Donaldson, DD; Locksley, RM; Corry, DB			Requirement for IL-13 independently of IL-4 in experimental asthma	SCIENCE			English	Article							AIRWAY HYPERREACTIVITY; T-LYMPHOCYTES; MICE; INTERLEUKIN-4; EXPRESSION; MODEL; LUNG; INFLAMMATION; EOSINOPHILIA; INDUCTION	The pathogenesis of asthma reflects, in part, the activity of T cell cytokines. Murine models support participation of interleukin-4 (IL-4) and the IL-4 receptor in asthma. Selective neutralization of IL-13, a cytokine related to IL-4 that also binds to the alpha chain of the IL-4 receptor, ameliorated the asthma phenotype, including airway hyperresponsiveness, eosinophil recruitment, and mucus overproduction. Administration of either IL-13 or IL-4 conferred an asthma-like phenotype to nonimmunized T cell-deficient mice by an IL-4 receptor alpha chain-dependent pathway. This pathway may underlie the genetic associations of asthma with both the human 5q31 Locus and the IL-4 receptor.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Lung Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Dept Transplantat, San Francisco, CA 94115 USA; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7700 Rondebosch, South Africa; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA; Genet Inst, Cambridge, MA 02140 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center; University of Cape Town; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Corry, DB (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, T32HL007185, K08HL003344] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL003344, P50 HL056385, T32 HL007185, T32 HL07185] Funding Source: Medline; PHS HHS [03344, 47412] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bancroft AJ, 1998, J IMMUNOL, V160, P3453; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; COHN L, 1997, J EXP MED, V186, P1727; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GOLDSTEIN RA, 1994, ANN INTERN MED, V121, P698, DOI 10.7326/0003-4819-121-9-199411010-00011; GRUNIG G, UNPUB; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hogan SP, 1998, J IMMUNOL, V161, P1501; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; Watanabe A, 1997, AM J RESP CELL MOL, V16, P69, DOI 10.1165/ajrcmb.16.1.8998081	32	1598	1696	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2261	2263		10.1126/science.282.5397.2261	http://dx.doi.org/10.1126/science.282.5397.2261			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856950	Green Accepted			2022-12-24	WOS:000077645800048
J	Manoury, B; Hewitt, EW; Morrice, N; Dando, PM; Barrett, AJ; Watts, C				Manoury, B; Hewitt, EW; Morrice, N; Dando, PM; Barrett, AJ; Watts, C			An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation	NATURE			English	Article							INNATE IMMUNITY; PURIFICATION; RECOGNITION; COMPLEXES	Foreign protein antigens must be broken down within endosomes or lysosomes to generate suitable peptides that will form complexes with class II major histocompatibility complex molecules for presentation to T cells. However, it is not known which proteases are required for antigen processing. To investigate this, we exposed a domain of the microbial tetanus toxin antigen (TTCF) to disrupted lysosomes that had been purified from a human B-cell line. Here we show that the dominant processing activity is not one of the known lysosomal cathepsins, which are generally believed to be the principal enzymes involved in antigen processing, but is instead an asparagine-specific cysteine endopeptidase. This enzyme seems similar or identical to a mammalian homologue(1) of the legumain/haemoglobinase asparaginyl endopeptidases found originally in plants' and parasites(3). We designed competitive peptide inhibitors of B-cell asparaginyl endopeptidase (AEP) that specifically block its proteolytic activity and inhibit processing of TTCF in vitro. In vivo, these inhibitors slow TTCF presentation to T cells, whereas preprocessing of TTCF with AEP accelerates its presentation, indicating that this enzyme performs a key step in TTCF processing. We also show that N-glycosylation of asparagine residues blocks AEP action in vitro. This indicates that N-glycosylation could eliminate sites of processing by AEP in mammalian proteins, allowing preferential processing of microbial antigens.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Babraham Inst, Dept Immunol, MRC, Peptidase Lab, Cambridge CB2 4AT, England	University of Dundee; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Watts, C (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Wellcome Sci Bldg, Dundee DD1 5EH, Scotland.			Watts, Colin/0000-0001-6183-2087; Manoury, Benedicte/0000-0001-7784-3389; Hewitt, Eric/0000-0002-6238-6303	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BOTARELLI P, 1991, J IMMUNOL, V147, P3128; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Dalton JP, 1995, PARASITOLOGY, V111, P575, DOI 10.1017/S0031182000077052; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fineschi B, 1997, TRENDS BIOCHEM SCI, V22, P377, DOI 10.1016/S0968-0004(97)01116-X; Harlow E., 1988, ANTIBODIES LAB MANUA; Hewitt EW, 1997, J IMMUNOL, V159, P4693; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Lu JY, 1996, CARBOHYD RES, V296, P1, DOI 10.1016/S0008-6215(96)00240-6; MAKOFF AJ, 1989, BIO-TECHNOL, V7, P1043; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Pond L, 1997, J IMMUNOL, V159, P543; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RODRIGUEZ GM, 1992, J IMMUNOL, V149, P2894; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	21	299	307	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					695	699		10.1038/25379	http://dx.doi.org/10.1038/25379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872320				2022-12-24	WOS:000077694200058
J	Odorizzi, G; Babst, M; Emr, SD				Odorizzi, G; Babst, M; Emr, SD			Fab1p PtdIns(3)P 5-kinase function essential for protein sorting in the multivesicular body	CELL			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; PREVACUOLAR COMPARTMENT; ALKALINE-PHOSPHATASE; TRANSPORT; MEMBRANE; PATHWAY; MUTANTS	Sorting of signal-transducing cell surface receptors within multivesicular bodies (MVBs) is required for their rapid down-regulation and degradation within lysosomes. Yeast mutants defective in late stages of transport to the vacuole/lysosome accumulate MVBs. We demonstrate that the membrane glycoprotein carboxypeptidase S and the G protein-coupled receptor Ste2p are targeted into the vacuole lumen, and this process requires a subset of VPS gene products essential for normal endosome function. The PtdIns(3)P B-kinase activity of Fab1p, which converts the product of the Vps34p PtdIns 3-kinase PtdIns(3)P into PtdIns(3,5)P-2, also is required for cargo-selective sorting into the vacuole lumen. These findings demonstrate a role for phosphoinositide signaling at distinct stages of vacuolar/lysosomal protein transport and couple PtdIns(3,5)P-2 synthesis to regulation of MVB sorting.	Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Emr, SD (corresponding author), Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA.			Odorizzi, Greg/0000-0002-1143-1098	NCI NIH HHS [CA 58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; MORANO KA, 1994, J CELL SCI, V107, P2813; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	52	541	544	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					847	858		10.1016/S0092-8674(00)81707-9	http://dx.doi.org/10.1016/S0092-8674(00)81707-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865702	Bronze			2022-12-24	WOS:000077498800014
J	Hong, M; Zhukareva, V; Vogelsberg-Ragaglia, V; Wszolek, Z; Reed, L; Miller, BI; Geschwind, DH; Bird, TD; McKeel, D; Goate, A; Morris, JC; Wilhelmsen, KC; Schellenberg, GD; Trojanowski, JQ; Lee, VMY				Hong, M; Zhukareva, V; Vogelsberg-Ragaglia, V; Wszolek, Z; Reed, L; Miller, BI; Geschwind, DH; Bird, TD; McKeel, D; Goate, A; Morris, JC; Wilhelmsen, KC; Schellenberg, GD; Trojanowski, JQ; Lee, VMY			Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; SR PROTEINS; PHOSPHORYLATION; LOCALIZATION; SEQUENCES; DEMENTIA	Tau proteins aggregate as cytoplasmic inclusions in a number of neurodegenerative diseases, including Alzheimer's disease and hereditary frontotemporal dementia and parkinsonism Linked to chromosome 17 (FTDP-17). Over 10 exonic and intronic mutations in the tau gene have been identified in about 20 FTDP-17 families. Analyses of soluble and insoluble tau proteins from brains of FTDP-17 patients indicated that different pathogenic mutations differentially altered distinct biochemical properties and stoichiometry of brain tau isoforms, Functional assays of recombinant tau proteins with different FTDP-17 missense mutations implicated all but one of these mutations in disease pathogenesis by reducing the ability of tau to bind microtubules and promote microtubule assembly.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Mayo Clin Jacksonville, Dept Neurol, Jacksonville, FL 32224 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Reed Neurol Res Ctr, Program Neurogenet, Dept Neurol, Los Angeles, CA 90095 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Ernest Gallo Clin & Res Ctr, San Francisco, CA 94110 USA; Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Pennsylvania; Pennsylvania Medicine; Mayo Clinic; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of Washington; University of Washington Seattle	Lee, VMY (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.		Wszolek, Zbigniew K./AAB-1431-2019; Morris, John C/A-1686-2012					ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; LAVIGUER A, 1993, SCIENCE, V260, P219; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reed LA, 1998, J NEUROPATH EXP NEUR, V57, P588, DOI 10.1097/00005072-199806000-00006; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	21	780	793	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1914	1917		10.1126/science.282.5395.1914	http://dx.doi.org/10.1126/science.282.5395.1914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836646				2022-12-24	WOS:000077338100056
J	Carmi, I; Kopczynski, JB; Meyer, BJ				Carmi, I; Kopczynski, JB; Meyer, BJ			The nuclear hormone receptor SEX-1 is an X-chromosome signal that determines nematode sex	NATURE			English	Article							LIGAND-BINDING DOMAIN; CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; CRYSTAL-STRUCTURE; RETINOIC ACID; C-ELEGANS; GENE; IDENTIFICATION; TRANSCRIPTION; SUPERFAMILY	Organisms in many phyla determine sexual fate by distinguishing one X chromosome from two. Here we use the model organism Caenorhabditis elegans to dissect such an X-chromosome-counting mechanism in molecular detail. In this nematode, several genes on the X chromosome called X signal elements communicate X-chromosome dose by controlling the activity of the sex-determination gene xol-1 (refs 1, 2), xol-1 specifies male (XO) fate when active and hermaphrodite (XX) fate when inactive(3,4). The only X signal element described so far represses xol-1 post-transcriptionally, but xol-1 is repressed in XX animals by transcriptional and post-transcriptional mechanisms(2). Here we identify a nuclear-hormone-receptor homologue, SEX-1, that regulates the transcription of xol-1. We show that sex-1 is vital to X-chromosome counting: changing sex-1 gene dose in XX or XO embryos causes sexual transformation and death from inadequate dosage compensation (the hermaphrodite-specific process that equalizes X-gene expression between the sexes(5)). The SEX-1 protein acts directly on xol-1, associating with its promoter in vivo and repressing xol-1 transcription in XX embryos. Thus, xol-1 is the direct molecular target of the primary sex-determination signal, and the dose of a nuclear hormone receptor helps to communicate X-chromosome number to determine nematode sex.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRENNER S, 1974, GENETICS, V77, P71; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HODGKIN J, 1994, DEVELOPMENT, V120, P3681; HODGKIN J, 1995, GENETICS, V141, P527; KOSTROUCH Z, 1995, P NATL ACAD SCI USA, V92, P156, DOI 10.1073/pnas.92.1.156; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENEELY PM, 1984, GENETICS, V106, P29; MEYER BJ, 1997, C ELEGANS, V2, P209; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Nicoll M, 1997, NATURE, V388, P200, DOI 10.1038/40645; PLENEFISCH JD, 1989, GENETICS, V121, P57; Ramkissoon Y, 1996, CURR OPIN GENET DEV, V6, P316, DOI 10.1016/S0959-437X(96)80008-6; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILLIAMS BD, 1992, GENETICS, V131, P609	26	113	123	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					168	173		10.1038/24164	http://dx.doi.org/10.1038/24164			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823896				2022-12-24	WOS:000077013300052
J	Chen, J; Lee, KH; Steinhauer, DA; Stevens, DJ; Skehel, JJ; Wiley, DC				Chen, J; Lee, KH; Steinhauer, DA; Stevens, DJ; Skehel, JJ; Wiley, DC			Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation	CELL			English	Article							VIRUS HEMAGGLUTININ; MEMBRANE-FUSION; HYDROPHOBIC CORE; ENVELOPE GLYCOPROTEIN; ATOMIC-STRUCTURE; HIV-1 GP41; PH; ACTIVATION; INHIBITION; VIRULENCE	The membrane fusion potential of influenza HA, like many viral membrane-fusion glycoproteins, is generated by proteolytic cleavage of a biosynthetic precursor. The three-dimensional structure of ectodomain of the precursor HA0 has been determined and compared with that of cleaved HA. The cleavage site is a prominent surface loop adjacent to a novel cavity; cleavage results in structural rearrangements in which the nonpolar amino acids near the new amino terminus bury ionizable residues in the cavity that are implicated in the low-pH-induced conformational change. Amino acid insertions at the cleavage site in HAs of virulent avian viruses and those of viruses isolated from the recent severe outbreak of influenza in humans in Hong Kong would extend this surface loop, facilitating intracellular cleavage.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Childrens Hosp, Dept Med, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Natl Inst Med Res, London NW7 1AA, England	Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; MRC National Institute for Medical Research	Wiley, DC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	dcwadmin@crystal.harvard.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODIAN DL, 1993, BIOCHEMISTRY-US, V32, P2967, DOI 10.1021/bi00063a007; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DESHPANDE KL, 1987, P NATL ACAD SCI USA, V84, P36, DOI 10.1073/pnas.84.1.36; GarciaMoreno B, 1997, BIOPHYS CHEM, V64, P211, DOI 10.1016/S0301-4622(96)02238-7; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; GETHING MJ, 1989, CURR TOP MEMBR TRANS, V32, P337; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAY AJ, 1989, CONCEPTS VIRAL PATHO, V3, P361; Hoffman LR, 1997, J VIROL, V71, P8808, DOI 10.1128/JVI.71.11.8808-8820.1997; KAWAOKA Y, 1984, VIROLOGY, V139, P303, DOI 10.1016/0042-6822(84)90376-3; KAWAOKA Y, 1989, J VIROL, V63, P3296, DOI 10.1128/JVI.63.8.3296-3300.1989; KHATCHIKIAN D, 1989, NATURE, V340, P156, DOI 10.1038/340156a0; KIDO H, 1992, J BIOL CHEM, V267, P13573; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; KLENK HD, 1993, VIRUS STRATEGIES MOL, P195; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OHUCHI M, 1989, VIROLOGY, V168, P274, DOI 10.1016/0042-6822(89)90267-5; ORLICH M, 1994, VIROLOGY, V204, P462, DOI 10.1006/viro.1994.1555; Perdue ML, 1997, VIRUS RES, V49, P173, DOI 10.1016/S0168-1702(97)01468-8; ROSENTHAL PB, 1998, IN PRESS NATURE; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; Steinhauer D. A., 1992, Seminars in Virology, V3, P91; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)90795-8; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Turk D., 1992, THESIS TU MUENCHEN; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WATOWICH SJ, 1994, STRUCTURE, V2, P719, DOI 10.1016/S0969-2126(00)00073-3; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEBSTER RG, 1987, CELL, V50, P665, DOI 10.1016/0092-8674(87)90321-7; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P56; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	58	379	401	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					409	417		10.1016/S0092-8674(00)81771-7	http://dx.doi.org/10.1016/S0092-8674(00)81771-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814710	Bronze			2022-12-24	WOS:000076789600013
J	Kelner, KL				Kelner, KL			Note bene: Triplet repeat diseases - Innocent inclusions	SCIENCE			English	Editorial Material																		Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1	2	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					643	643						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841418				2022-12-24	WOS:000076607500032
J	Fuchs, CS; Giovannucci, EL; Colditz, GA; Hunter, DJ; Stampfer, MJ; Rosner, B; Speizer, FE; Willett, WC				Fuchs, CS; Giovannucci, EL; Colditz, GA; Hunter, DJ; Stampfer, MJ; Rosner, B; Speizer, FE; Willett, WC			Dietary fiber and the risk of colorectal cancer and adenoma in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-ADMINISTERED QUESTIONNAIRE; COLON-CANCER; ALCOHOL-CONSUMPTION; NUTRITIONAL FACTORS; RANDOMIZED TRIAL; MEN; FAT; RECTUM; HYPERTENSION; EPIDEMIOLOGY	Background A high intake of dietary fiber has been thought to reduce the risk of colorectal cancer and adenoma. Methods We conducted a prospective study of 88,757 women, who were 34 to 59 years old and had no history of cancer, inflammatory bowel disease, or familial polyposis, who completed a dietary questionnaire in 1980. During a 16-year follow-up period, 787 cases of colorectal cancer were documented. In addition, 1012 patients with adenomas of the distal colon and rectum were found among 27,530 participants who underwent endoscopy during the followup period. Results After adjustment for age, established risk factors, and total energy intake, we found no association between the intake of dietary fiber and the risk of colorectal cancer; the relative risk for the highest as compared with the lowest quintile group with respect to fiber intake was 0.95 (95 percent confidence interval, 0.73 to 1.25). No protective effect of dietary fiber was observed when we omitted adjustment for total energy intake, when events during the first six years of follow-up were excluded, or when we excluded women who altered their fiber intake during the follow-up period. No significant association between fiber intake and the risk of colorectal adenoma was found. Conclusions Our data do not support the existence of an important protective effect of dietary fiber against colorectal cancer or adenoma. (N Engl J Med 1999;340:169-76.) (C) 1999, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Fuchs, CS (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356, CA 66385] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, K07CA066385, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDOORI WH, 1994, AM J CLIN NUTR, V60, P757, DOI 10.1093/ajcn/60.5.757; Ascherio A, 1996, HYPERTENSION, V27, P1065, DOI 10.1161/01.HYP.27.5.1065; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; BURKITT DP, 1971, CANCER, V28, P3, DOI 10.1002/1097-0142(197107)28:1<3::AID-CNCR2820280104>3.0.CO;2-N; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; *DEP AGR, 1963, AGR HDB, V8; FRIEDENREICH CM, 1994, EPIDEMIOLOGY, V5, P385; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; GOLDBOHM RA, 1994, CANCER CAUSE CONTROL, V5, P95, DOI 10.1007/BF01830255; HEILBRUN LK, 1989, INT J CANCER, V44, P1, DOI 10.1002/ijc.2910440102; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P345, DOI 10.1097/00008469-199510000-00003; LANZA E, 1987, AM J CLIN NUTR, V46, P790, DOI 10.1093/ajcn/46.5.790; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; *NAT I HLTH, 1984, NIH PUBL; Platz EA, 1997, CANCER EPIDEM BIOMAR, V6, P661; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Southgate D A, 1976, J Hum Nutr, V30, P303; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	37	454	469	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1999	340	3					169	176		10.1056/NEJM199901213400301	http://dx.doi.org/10.1056/NEJM199901213400301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159YJ	9895396	Bronze			2022-12-24	WOS:000078202900001
J	Marszalek, PE; Oberhauser, AF; Pang, YP; Fernandez, JM				Marszalek, PE; Oberhauser, AF; Pang, YP; Fernandez, JM			Polysaccharide elasticity governed by chair-boat transitions of the glucopyranose ring	NATURE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; ALPHA-D-GLUCOSE; FORCE MICROSCOPY; ADHESION; WALLS	Many common, biologically important polysaccharides contain pyranose rings made of five carbon atoms and one oxygen atom. They occur in a variety of cellular structures, where they are often subjected to considerable tensile stress(1-6). The polysaccharides are thought to respond to this stress by elastic deformation, but the underlying molecular rearrangements allowing such a response remain poorly understood. It is typically assumed, however, that the pyranose ring structure is inelastic and locked into a chair-like conformation. Here we describe single-molecule force measurements(7-12) on individual polysaccharides that identify the pyranose rings as the structural unit controlling the molecule's elasticity. In particular, we find that the enthalpic component of the polymer elasticity(10,11,13,14) Of amylose, dextran and pullulan is eliminated once their pyranose rings are cleaved. We interpret these observations as indicating that the elasticity of the three polysaccharides results from a force-induced elongation of the ring structure and a final transition from a chair-like to a boat-like conformation. We expect that the force-induced deformation of pyranose rings reported here plays an important role in accommodating mechanical stresses and modulating ligand binding in biological systems.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, 200 1st St SW, Rochester, MN 55905 USA.	fernandez.julio@mayo.edu		Pang, Yuan-Ping/0000-0003-0838-2560				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BARTON DHR, 1970, SCIENCE, V169, P539, DOI 10.1126/science.169.3945.539; BOBBITT JM, 1956, ADV CARBOHYD CHEM, V11, P1; BRADY JW, 1986, J AM CHEM SOC, V108, P8153, DOI 10.1021/ja00286a006; BRADY JW, 1987, CARBOHYD RES, V165, P306, DOI 10.1016/0008-6215(87)80107-6; BROWN GM, 1979, ACTA CRYSTALLOGR B, V35, P656, DOI 10.1107/S0567740879004374; BROWN GM, 1965, SCIENCE, V147, P1038, DOI 10.1126/science.147.3661.1038-a; Bustamante C, 1997, CURR OPIN STRUC BIOL, V7, P709, DOI 10.1016/S0959-440X(97)80082-6; CHU SSC, 1968, ACTA CRYSTALL B-STRU, VB 24, P830, DOI 10.1107/S0567740868003250; Cosgrove DJ, 1997, PLANT CELL, V9, P1031, DOI 10.1105/tpc.9.7.1031; Drickamer K, 1997, STRUCTURE, V5, P465, DOI 10.1016/S0969-2126(97)00202-5; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; *GAUSS INC, 1994, GAUSS 94; JOSHI NV, 1979, BIOPOLYMERS, V18, P2993, DOI 10.1002/bip.1979.360181207; Kellis G.M., 1974, TOP STEREOCHEM, V8, P225; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Li HB, 1998, ADV MATER, V10, P316; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; *MOL SIM, 1997, QUANT 97 CHARMM; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; PICKETT HM, 1970, J AM CHEM SOC, V92, P7281; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SMITH NM, 1992, CHILD NERV SYST, V8, P258, DOI 10.1007/BF00300792; SMITH SM, 1995, ENG APPL ARTIF INTEL, V8, P271, DOI 10.1016/0952-1976(95)00013-Q; THWAITES JJ, 1985, P NATL ACAD SCI USA, V82, P2163, DOI 10.1073/pnas.82.7.2163	30	379	393	5	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					661	664		10.1038/25322	http://dx.doi.org/10.1038/25322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872313				2022-12-24	WOS:000077694200049
J	Eisner, MD; Smith, AK; Blanc, PD				Eisner, MD; Smith, AK; Blanc, PD			Bartenders' respiratory health after establishment of smoke-free bars and taverns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; INDOOR AIR-POLLUTION; BRONCHIAL SYMPTOMS QUESTIONNAIRE; PASSIVE SMOKING; PULMONARY-FUNCTION; LUNG-FUNCTION; YOUNG-ADULTS; OCCUPATIONAL EXPOSURE; HEART-DISEASE; FOLLOW-UP	Context.-The association between environmental tobacco smoke (ETS) exposure and respiratory symptoms has not been well established in adults. Objective.-To study the respiratory health of bartenders before and after legislative prohibition of smoking in all bars and taverns by the state of California. Design.-Cohort of bartenders interviewed before and after smoking prohibition. Setting and Participants.-Bartenders at a random sample of bars and taverns in San Francisco. Main Outcome Measures.-Interviews assessed respiratory symptoms, sensory irritation symptoms, ETS exposure, personal smoking, and recent upper respiratory tract infections. Spirometric assessment included forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) measurements. Results.-Fifty-three of 67 eligible bartenders were interviewed. At baseline, all 53 bartenders reported workplace ETS exposure. After the smoking ban, self-reported ETS exposure at work declined from a median of 28 to 2 hours per week (P<.001). Thirty-nine bartenders (74%) initially reported respiratory symptoms. Of those symptomatic at baseline, 23 (59%) no longer had symptoms at follow-up (P<.001). Forty-one bartenders (77%) initially reported sensory irritation symptoms. At follow-up, 32 (78%) of these subjects had resolution of symptoms (P<.001). After prohibition of workplace smoking, we observed improvement in mean FVC (0.189 L; 95% confidence interval [CI], 0.082-0.296 L; 4.2% change) and, to a lesser extent, mean FEV1 (0.039 L; 95% CI, -0.030 to 0.107 L; 1.2% change). Complete cessation of workplace ETS exposure (compared with continued exposure) was associated with improved mean FVC (0.287 L; 95% CI, 0.088-0.486; 6.8% change) and mean FEV1 (0.142 L; 95% CI, 0.020-0.264 L; 4.5% change), after controlling for personal smoking and recent upper respiratory tract infections. Conclusion.-Establishment of smoke-free bars and taverns was associated with a rapid improvement of respiratory health.	Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA; Univ Calif San Francisco, Div Environm & Occupat Med, San Francisco, CA USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Blanc, PD (corresponding author), 350 Parnassus Ave,Suite 609, San Francisco, CA 94143 USA.	blancp@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007185, K04HL003225] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO4 HL03225, T32 HL07185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbar-Khanzadeh F, 1996, Med Lav, V87, P122; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BAKE B, 1977, SCAND J RESPIR DIS, V58, P311; BECKER DM, 1989, JAMA-J AM MED ASSOC, V262, P799, DOI 10.1001/jama.262.6.799; Bergman TA, 1996, AM IND HYG ASSOC J, V57, P746, DOI 10.1202/0002-8894(1996)057<0746:OEONNM>2.0.CO;2; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; BRODER I, 1993, CAN J PUBLIC HEALTH, V84, P254; BRUNEKREEF B, 1985, INT J EPIDEMIOL, V14, P227, DOI 10.1093/ije/14.2.227; BUIST AS, 1979, AM REV RESPIR DIS, V120, P953; BURCHFIEL CM, 1995, AM J RESP CRIT CARE, V151, P1778, DOI 10.1164/ajrccm.151.6.7767520; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; *CAL ENV PROT AG, 1997, HLTH EFF EXP ENV TOB; COMSTOCK GW, 1981, AM REV RESPIR DIS, V124, P143; DAYAL HH, 1994, ENVIRON RES, V65, P161, DOI 10.1006/enrs.1994.1029; DELFINO RJ, 1993, EUR RESPIR J, V6, P1104; Diggle P. J., 1996, ANAL LONGITUDINAL DA; DIMICHWARD H, 1998, AM J RESP CRIT CARE, V157, pA505; EMMONS KM, 1994, PREV MED, V23, P35, DOI 10.1006/pmed.1994.1005; Gerlach K K, 1997, Tob Control, V6, P199; GILLIS CR, 1984, EUR J RESPIR DIS, V65, P121; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HOWARD G, 1988, JAMA-J AM MED ASSOC, V279, P119; Jaakkola MS, 1996, J CLIN EPIDEMIOL, V49, P581, DOI 10.1016/0895-4356(96)00004-2; JAAKKOLA MS, 1995, J CLIN EPIDEMIOL, V48, P317, DOI 10.1016/0895-4356(94)00157-L; JARVIS MJ, 1992, BRIT J ADDICT, V87, P111; JARVIS MJ, 1983, THORAX, V38, P829, DOI 10.1136/thx.38.11.829; KAUFFMANN F, 1989, INT J EPIDEMIOL, V18, P334, DOI 10.1093/ije/18.2.334; Kawachi I, 1997, CIRCULATION, V95, P2374, DOI 10.1161/01.CIR.95.10.2374; LAW MR, 1977, BMJ-BRIT MED J, V315, P973; LEADERER BP, 1994, AM J RESP CRIT CARE, V150, P1216, DOI 10.1164/ajrccm.150.5.7952542; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222, DOI 10.1164/ajrccm.150.5.7952544; Macdonald H R, 1997, Tob Control, V6, P41; MASI MA, 1988, AM REV RESPIR DIS, V138, P296, DOI 10.1164/ajrccm/138.2.296; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; MILLAR WJ, 1988, CAN J PUBLIC HEALTH, V79, P379; MORRIS PD, 1995, ENVIRON RES, V68, P3, DOI 10.1006/enrs.1995.1002; NG TP, 1993, J EPIDEMIOL COMMUN H, V47, P454, DOI 10.1136/jech.47.6.454; Ott W, 1996, J AIR WASTE MANAGE, V46, P1120, DOI 10.1080/10473289.1996.10467548; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; REPACE JL, 1980, SCIENCE, V208, P464, DOI 10.1126/science.7367873; ROBBINS AS, 1993, INT J EPIDEMIOL, V22, P809, DOI 10.1093/ije/22.5.809; SCHOENBERG JB, 1987, J NATL CANCER I, V79, P13; SCHWARTZ J, 1990, AM REV RESPIR DIS, V141, P62, DOI 10.1164/ajrccm/141.1.62; SHERRILL DL, 1994, AM J RESP CRIT CARE, V149, P591, DOI 10.1164/ajrccm.149.3.8118623; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; SINGLETON J, 1989, COMS 2 CALIFORNIA OC; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; SVENDSEN KH, 1987, AM J EPIDEMIOL, V126, P783, DOI 10.1093/oxfordjournals.aje.a114715; THOMPSON B, 1995, J OCCUP ENVIRON MED, V37, P1086, DOI 10.1097/00043764-199509000-00009; United States Environmental Protection Agency, 1992, US EPA PUBL; *VIT HLTH STAT, 1988, VIT HLTH STAT, V10, P1; Wells AJ, 1998, J AM COLL CARDIOL, V31, P1, DOI 10.1016/S0735-1097(97)00432-4; WESTERN B, 1994, SOC FORCES, V73, P497, DOI 10.2307/2579818; WHITE JR, 1980, NEW ENGL J MED, V302, P720, DOI 10.1056/NEJM198003273021304; WHITE JR, 1991, CHEST, V100, P39, DOI 10.1378/chest.100.1.39; WOODRUFF TJ, 1993, ARCH INTERN MED, V153, P1485, DOI 10.1001/archinte.153.12.1485; XU XP, 1995, AM J RESP CRIT CARE, V151, P41, DOI 10.1164/ajrccm.151.1.7812570	64	253	259	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1909	1914		10.1001/jama.280.22.1909	http://dx.doi.org/10.1001/jama.280.22.1909			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851475	Bronze			2022-12-24	WOS:000077364500034
J	Michael, WM; Newport, J				Michael, WM; Newport, J			Coupling of mitosis to the completion of S phase through Cdc34-mediated degradation of Wee 1	SCIENCE			English	Article							CELL-CYCLE; DNA-REPLICATION; F-BOX; UBIQUITIN; KINASE; PROTEOLYSIS; XENOPUS; PROTEIN; CDC2; SYSTEM	The dependence of mitosis on the completion of the period of DNA replication in the cell cycle [synthesis (S) phase] ensures that chromosome segregation occurs only after the genome has been fully duplicated. A key negative regulator of mitosis, the protein kinase Wee1, was degraded in a Cdc34-dependent fashion in Xenopus egg extra cts. Th is proteolysis event was required for a timely entrance into mitosis and was inhibited when DNA replication was blocked. Therefore, the DNA replication checkpoint can prevent mitosis by suppressing the proteolysis of Wee1 during 5 phase.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Michael, WM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	wmichael@biomail.ucsd.edu	McDermott, Michael Francis/GZM-5330-2022		NIGMS NIH HHS [R01GM44656] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044656] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MICHAEL WM, UNPUB; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murakami MS, 1998, DEVELOPMENT, V125, P237; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	25	127	134	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1886	1889		10.1126/science.282.5395.1886	http://dx.doi.org/10.1126/science.282.5395.1886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836638				2022-12-24	WOS:000077338100048
J	Looker, AC; Johnson, CL				Looker, AC; Johnson, CL			Prevalence of elevated serum transferrin saturation in adults in the United States	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			IRON OVERLOAD; HEREDITARY HEMOCHROMATOSIS; COST-EFFECTIVENESS; AFRICAN-AMERICANS; DEFICIENCY; MEN; POPULATION; FERRITIN	Background: A population-based hemochromatosis screening program that uses serum transferrin saturation has been proposed, but few data exist on the number of U.S. adults that such a program would identify for further testing. Objective: To determine the prevalence of an initially elevated serum transferrin saturation and the prevalence of concurrently elevated serum transferrin saturation and serum ferritin levels in the adult population of the United States. Design: Nationally representative cross-sectional survey of the noninstitutionalized U.S. civilian population. Participants: 15 839 men and nonpregnant women 20 years of age and older who were examined in the third National Health and Nutrition Examination Survey (1988-1994). Measurements: Single measurements of serum transferrin saturations and serum ferritin levels. Cut-off values used to define elevated serum transferrin saturation ranged from greater than 45% to greater than 62%. Results: The prevalence of initially elevated serum transferrin saturation ranged from 1% to 6%. Approximately 11% to 22% of those with elevated serum transferrin saturation had concurrently elevated serum ferritin levels. The prevalence of elevated serum transferrin saturation was lower in women than in men when the same cut-off value was used to define elevated serum transferrin saturation. The prevalence of elevated serum transferrin saturation in non-Hispanic black persons and Mexican-Americans was similar to or slightly less than that in non-Hispanic white persons. The prevalence of elevated serum transferrin saturation in persons 20 to 49 years of age was as high as or higher than that in older adults. Conclusions: A hemochromatosis screening program that uses a cut-off value of greater than 60% to define elevated serum transferrin saturation would identify an estimated 1.4 to 2.5 million U.S. adults for further testing.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Looker, AC (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd, Hyattsville, MD 20782 USA.							BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Bradley L A, 1996, J Med Screen, V3, P178; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; CROSBY WH, 1984, JAMA-J AM MED ASSOC, V251, P1986, DOI 10.1001/jama.251.15.1986; CUSTER EM, 1995, J LAB CLIN MED, V126, P88; EDWARDS CQ, 1989, J INTERN MED, V226, P373, DOI 10.1111/j.1365-2796.1989.tb01411.x; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELLIOTT R, 1986, AUST NZ J MED, V16, P491, DOI 10.1111/j.1445-5994.1986.tb02018.x; EZZATI T, 1992, 1992 P AM STAT ASS S, P339; EZZATI T, 1992, VITAL HLTH STAT, V2; GUNTER EW, 1994, LAB METHODS USED 3 N; HAMILTON LD, 1950, P SOC EXP BIOL MED, V75, P65; Hulthen L, 1998, EUR J CLIN NUTR, V52, P376, DOI 10.1038/sj.ejcn.1600573; JONSSON JJ, 1991, J CLIN EPIDEMIOL, V44, P1289, DOI 10.1016/0895-4356(91)90090-V; KARLSSON M, 1988, ACTA MED SCAND, V224, P385; LammiKeefe CJ, 1996, J AM DIET ASSOC, V96, P247, DOI 10.1016/S0002-8223(96)00075-2; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LINDMARK B, 1985, ACTA MED SCAND, V218, P299; LOOKER AC, 1995, NUTR REV, V53, P246, DOI 10.1111/j.1753-4887.1995.tb05481.x; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; *METH SUBC HNIS NC, 1996, AN REP GUID 3 NAT HL; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; MOHADJER L, 1996, NATL HTLH NUTR EXAMI; Monaghan KG, 1998, AM J HEMATOL, V58, P213, DOI 10.1002/(SICI)1096-8652(199807)58:3<213::AID-AJH9>3.0.CO;2-U; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; OLSSON KS, 1984, ACTA MED SCAND, V215, P105; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; SHAH BV, 1991, SUDAAN USERS MANUAL; STATLAND BE, 1976, CLIN BIOCHEM, V9, P26, DOI 10.1016/S0009-9120(76)80008-2; WITTE DL, 1991, CLIN CHEM, V37, P484; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Wurapa RK, 1996, AM J MED, V101, P9, DOI 10.1016/S0002-9343(96)00053-8; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; 1996, MMWR MORB MORTAL WKL, V45, P991	38	44	45	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					940	945		10.7326/0003-4819-129-11_Part_2-199812011-00004	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867746				2022-12-24	WOS:000077239200026
J	Phatak, PD; Sham, RL; Raubertas, RF; Dunnigan, K; O'Leary, MT; Braggins, C; Cappuccio, JD				Phatak, PD; Sham, RL; Raubertas, RF; Dunnigan, K; O'Leary, MT; Braggins, C; Cappuccio, JD			Prevalence of hereditary hemochromatosis in 16,031 primary care patients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			IRON OVERLOAD; PHENOTYPIC-EXPRESSION; COST-EFFECTIVENESS; SCREENING-TESTS; GENE; MEN; AGE	Background: Despite evidence from screening studies in northern European populations, the prevalence of hemochromatosis in primary care populations in the United States remains speculative. Objective: To establish the feasibility of screening for hemochromatosis and to estimate the prevalence of hemochromatosis in a large primary care population. Design: Cross-sectional prevalence study. Setting: 22 primary care practices in the Rochester, New York, area. Patients: 16 031 ambulatory patients without a previous diagnosis of hemochromatosis. Intervention: Serum transferrin saturation screening tests were offered to all adult patients in participating primary care practices. Measurements: Patients with a serum transferrin saturation of 45% or more on initial testing had a serum transferrin saturation test done under fasting conditions and had serum ferritin levels measured. Those who had a fasting serum transferrin saturation of 55% or more and a serum ferritin level of 200 mu g/L or more with no other apparent cause were presumed to have hemochromatosis and were offered liver biopsy to confirm the diagnosis. Results: 25 patients had biopsy-proven hemochromatosis; 22 patients met the clinical criteria for hemochromatosis but declined liver biopsy and were classified as having clinically proven hemochromatosis; and 23 patients had a serum transferrin saturation of 55% or more with no identifiable cause, indicating probable hemochromatosis. The prevalence of clinically proven and biopsy-proven hemochromatosis combined was 4.5 per 1000 (95% CI, 3.3 to 5.8 per 1000) in the total sample and 5.4 per 1000 (CI, 4.0 to 7.1 per 1000) in white persons. The prevalence was higher in men than in women (ratio, 1.8:1). Conclusions: Hemochromatosis is relatively common among white persons. Routine screening of white persons for hemochromatosis should be considered by primary care physicians.	Rochester Gen Hosp, Hematol Unit, Mary M Gooley Hemophilia Ctr Inc, Rochester, NY 14621 USA; Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA	Rochester General Hospital; University of Rochester	Phatak, PD (corresponding author), Rochester Gen Hosp, Hematol Unit, Mary M Gooley Hemophilia Ctr Inc, 1425 Portland Ave, Rochester, NY 14621 USA.				AHRQ HHS [R01 HS07616] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BORWEIN S, 1984, CAN MED ASSOC J, V131, P895; BORWEIN ST, 1983, CLIN INVEST MED, V6, P171; Bradley L A, 1996, J Med Screen, V3, P178; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Cox D. R., 1984, ANAL SURVIVAL DATA; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELLIOTT R, 1986, AUST NZ J MED, V16, P491, DOI 10.1111/j.1445-5994.1986.tb02018.x; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; HALLBERG L, 1989, J INTERN MED, V225, P249, DOI 10.1111/j.1365-2796.1989.tb00074.x; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LINDMARK B, 1988, NEW ENGL J MED, V319, P1548; Looker AC, 1998, ANN INTERN MED, V129, P940, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00004; MEYER T, 1990, J INTERN MED, V227, P397, DOI 10.1111/j.1365-2796.1990.tb00178.x; OLSSON KS, 1983, ACTA MED SCAND, V213, P145; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; TANNER AR, 1985, GUT, V26, P1139; THOMAS DR, 1975, J AM STAT ASSOC, V70, P865, DOI 10.2307/2285449; 1996, MMWR MORB MORTAL WKL, V45, P991	27	90	93	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					954	961		10.7326/0003-4819-129-11_Part_2-199812011-00006	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867748				2022-12-24	WOS:000077239200028
J	Adams, JN; Trent, RJ				Adams, JN; Trent, RJ			Aortic complications of Marfan's syndrome	LANCET			English	Editorial Material							BETA-ADRENERGIC-BLOCKADE; LIFE EXPECTANCY; DISTENSIBILITY; ROOT; DILATATION; SURVIVAL; DILATION		Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Adams, JN (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.							ADAMS JN, 1995, BRIT HEART J, V73, P265; BRUNO L, 1984, BRIT HEART J, V51, P220; FINKBOHNER R, 1995, CIRCULATION, V91, P728, DOI 10.1161/01.CIR.91.3.728; Groenink M, 1998, HEART, V80, P163, DOI 10.1136/hrt.80.2.163; Groenink M, 1998, AM J CARDIOL, V82, P203, DOI 10.1016/S0002-9149(98)00315-4; HABBAL MHE, 1992, AM HEART J, V123, P752; Haouzi A, 1997, AM HEART J, V133, P60, DOI 10.1016/S0002-8703(97)70248-5; JEREMY RW, 1994, AM J CARDIOL, V74, P369, DOI 10.1016/0002-9149(94)90405-7; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; REED CM, 1992, AM J CARDIOL, V70, P541, DOI 10.1016/0002-9149(92)91207-K; ROMAN MJ, 1993, J AM COLL CARDIOL, V22, P1470, DOI 10.1016/0735-1097(93)90559-J; SALIM MA, 1994, AM J CARDIOL, V74, P629, DOI 10.1016/0002-9149(94)90762-5; SAVOLAINEN A, 1992, AM J CARDIOL, V70, P691, DOI 10.1016/0002-9149(92)90215-K; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; SILVERMAN DI, 1995, J AM COLL CARDIOL, V26, P1062, DOI 10.1016/0735-1097(95)00258-0; TREASURE T, 1993, BRIT HEART J, V69, P101	17	33	34	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1722	1723		10.1016/S0140-6736(05)79822-6	http://dx.doi.org/10.1016/S0140-6736(05)79822-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848345				2022-12-24	WOS:000077246500004
J	Qian, YW; Erikson, E; Maller, JL				Qian, YW; Erikson, E; Maller, JL			Purification and cloning of a protein kinase that phosphorylates and activates the polo-like kinase Plx1	SCIENCE			English	Article							CDC25 PROTEIN; CELL-CYCLE; DNA-REPLICATION; PHOSPHATASE; XENOPUS; EXTRACTS; MITOSIS; CENTROSOME; INITIATION; P34CDC2	The Xenopus polo-like kinase 1 (Plx1) is essential during mitosis for the activation of Cdc25C, for spindle assembly, and for cyclin B degradation. Polo-Like kinases from various organisms are activated by phosphorylation by an unidentified protein kinase. A protein kinase, polo-like kinase kinase 1 or xPlkk1, that phosphorylates and activates Plx1 in vitro was purified to near homogeneity and cloned. Phosphopeptide mapping of Plx1 phosphorylated in vitro by recombinant xPlkk1 or in progesterone-treated oocytes indicates that xPlkk1 may activate Plx1 in vivo. The xPlkk1 protein itself was also activated by phosphorylation on serine and threonine residues, and the kinetics of activation of xPlkk1 in vivo closely paralleled the activation of Plx1. Moreover, microinjection of xPlkk1 into Xenopus oocytes accelerated the timing of activation of Plx1 and the transition from G(2) to M phase of the cell cycle. These results define a protein kinase cascade that regulates several events of mitosis.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.				NCI NIH HHS [CA46934] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BoucksonCastaing V, 1996, J CELL SCI, V109, P179; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; QIAN Y, UNPUB; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; YAMASHITA K, 1990, EMBO J, V9, P331	27	106	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 27	1998	282	5394					1701	1704		10.1126/science.282.5394.1701	http://dx.doi.org/10.1126/science.282.5394.1701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831560				2022-12-24	WOS:000077246600045
J	Strom, BL; Abrutyn, E; Berlin, JA; Kinman, JL; Feldman, RS; Stolley, PD; Levison, ME; Korzeniowski, OM; Kaye, D				Strom, BL; Abrutyn, E; Berlin, JA; Kinman, JL; Feldman, RS; Stolley, PD; Levison, ME; Korzeniowski, OM; Kaye, D			Dental and cardiac risk factors for infective endocarditis - A population-based, case-control study	ANNALS OF INTERNAL MEDICINE			English	Article						endocarditis, bacterial; heart valve disease; dental care; antibiotics; risk factors	MITRAL-VALVE PROLAPSE; AMERICAN-HEART-ASSOCIATION; BACTERIAL-ENDOCARDITIS; ANTIBIOTIC-PROPHYLAXIS; PREVENTION; CRITERIA; RECOMMENDATIONS; EFFICACY	Background: Although antibiotic prophylaxis against infective endocarditis is recommended, the true risk factors for infective endocarditis are unclear. Objective: To quantitate the risk for endocarditis from dental treatment and cardiac abnormalities. Design: Population-based, case-control study Setting: 54 hospitals in the Philadelphia area. Patients: Persons with community-acquired infective endocarditis not associated with intravenous drug use were compared with community residents, matched by age, sex, and neighborhood of residence. Measurements: Information on demographic characteristics, host risk factors, and dental treatment was obtained from structured telephone interviews, dental records, and medical records. Results: During the preceding 3 months, dental treatment was no more frequent among case-patients than controls (adjusted odds ratio, 0.8 [95% CI, 0.4 to 1.5]). Of 273 case-patients, 104 (38%) knew of previous cardiac lesions compared with 17 controls (6%) (adjusted odds ratio, 16.7 [Cl, 7.4 to 37.4]). Case-patients more often had a history of mitral valve prolapse (adjusted odds ratio, 19.4 [Cl, 6.4 to 58.4]), congenital heart disease (adjusted odds ratio, 6.7 [Cl, 2.3 to 19.4]), cardiac valvular surgery (adjust ed odds ratio 74.6 [CI, 12.5 to 447]), rheumatic fever (adjusted odds ratio, 13.4 [CI, 4.5 to 39.5]), and heart murmur without other known cardiac abnormalities (adjusted odds ratio, 4.2 [CI, 2.0 to 8.9]). Among case-patients with known cardiac lesions-the target of prophylaxis - dental therapy was significantly (P = 0.03) less common than among controls (adjusted odds ratio, 0.2 [Cl, 0.04 to 0.7] over 3 months). Few participants received prophylactic antibiotics. Conclusions: Dental treatment does not seem to be a risk factor for infective endocarditis, even in patients with valvular abnormalities, but cardiac valvular abnormalities are strong risk factors. Few cases of infective endocarditis would be preventable with antibiotic prophylaxis, even with 100% effectiveness assumed. Current policies for prophylaxis should be reconsidered.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA; Allegheny Univ Hlth Sci, Dept Med, Philadelphia, PA 19102 USA; Allegheny Univ Hlth Sci, Sch Publ Hlth, Philadelphia, PA 19102 USA; Univ Maryland, Baltimore, MD 21201 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Drexel University; Drexel University; University System of Maryland; University of Maryland Baltimore	Strom, BL (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	bstrom@cceb.med.upenn.edu			NHLBI NIH HHS [R01 HL 39000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLIN JA, 1994, AM J CARDIOL, V73, P887, DOI 10.1016/0002-9149(94)90816-8; BERLIN JA, 1995, AM J CARDIOL, V76, P933, DOI 10.1016/S0002-9149(99)80264-1; BOR DH, 1984, AM J MED, V76, P711, DOI 10.1016/0002-9343(84)90300-0; CHERUBIN CE, 1971, AM J MED, V51, P83, DOI 10.1016/0002-9343(71)90326-3; CLEMENS JD, 1982, NEW ENGL J MED, V307, P776, DOI 10.1056/NEJM198209233071302; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DANCHIN N, 1989, LANCET, V1, P743; DENTON C, 1957, CIRCULATION, V15, P525, DOI 10.1161/01.CIR.15.4.525; DOWLING JN, 1974, ANN INTERN MED, V81, P641, DOI 10.7326/0003-4819-81-5-641; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; GOULD IM, 1993, BRIT HEART J, V70, P79; HARFORD CG, 1974, ARCH INTERN MED, V134, P116, DOI 10.1001/archinte.134.1.116; HICKEY AJ, 1985, AM HEART J, V109, P431, DOI 10.1016/0002-8703(85)90543-5; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; KAYE D, 1991, ANN INTERN MED, V114, P803, DOI 10.7326/0003-4819-114-9-803; Lacassin F, 1995, EUR HEART J, V16, P1968, DOI 10.1093/oxfordjournals.eurheartj.a060855; LERNER PI, 1966, NEW ENGL J MED, V274, P199, DOI 10.1056/NEJM196601272740407; MACMAHON SW, 1987, AM HEART J, V113, P1291, DOI 10.1016/0002-8703(87)90957-4; MACMAHON SW, 1987, AM J CARDIOL, V59, P105, DOI 10.1016/S0002-9149(87)80080-2; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Rothman K, 1986, MODERN EPIDEMIOLOGY; Sekeres MA, 1997, CLIN INFECT DIS, V24, P1185, DOI 10.1086/513657; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WEINSTEIN L, 1996, INFECT ENDOCARDITIS	29	310	321	3	80	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					761	+		10.7326/0003-4819-129-10-199811150-00002	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841581				2022-12-24	WOS:000076984800001
J	Coffey, MC; Strong, JE; Forsyth, PA; Lee, PWK				Coffey, MC; Strong, JE; Forsyth, PA; Lee, PWK			Reovirus therapy of tumors with activated Ras pathway	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; DIFFERENTIAL REGULATION; MESSENGER-RNA; EXPRESSION; CELLS; AMPLIFICATION; AUTOCRINE; INFECTION; CANCER; GENE	Human reovirus requires an activated Res signaling pathway far infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient mice bearing tumors established from v-erbB-transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65 to 80 percent of the mice. Treatment of immune-competent C3H mice bearing tumors established from ras-transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required. These results suggest that, with further work, reovirus may have applicability in the treatment of cancer.	Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOS JL, 1989, CANCER RES, V49, P4682; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; COFFEY MW, UNPUB; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HERMANSON M, 1992, CANCER RES, V52, P3213; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LORENCE RM, 1994, CANCER RES, V54, P6017; LOWE PN, 1994, CELL SIGNAL, V6, P109, DOI 10.1016/0898-6568(94)90067-1; MAMAJIWALLA SN, 1995, ONCOGENE, V11, P377; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7729; NISTER M, 1991, J BIOL CHEM, V266, P16755; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SHERRY B, 1993, J VIROL, V67, P6119, DOI 10.1128/JVI.67.10.6119-6124.1993; STECK PA, 1988, CANCER RES, V48, P5433; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; STRONG JE, 1993, VIROLOGY, V197, P405, DOI 10.1006/viro.1993.1602; TYLER KL, 1996, FIELDS VIROLOGY, P1597; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	25	617	673	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1332	1334		10.1126/science.282.5392.1332	http://dx.doi.org/10.1126/science.282.5392.1332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812900				2022-12-24	WOS:000076982200049
J	Tucker, AS; Matthews, KL; Sharpe, PT				Tucker, AS; Matthews, KL; Sharpe, PT			Transformation of tooth type induced by inhibition of BMP signaling	SCIENCE			English	Article							TISSUES; HOX11; GENE	Mammalian dentitions are highly patterned, with different types of teeth positioned in different regions of the jaws. BMP4 is an early oral epithelial protein signal that directs odontogenic gene expression in mesenchyme cells of the developing mandibular arch, BMP4 was shown to inhibit expression of the homeobox gene Barx-1 and to restrict expression to the proximal, presumptive molar mesenchyme of mouse embryos at embryonic day 10, The inhibition of BMP signaling early in mandible development by the action of exogenous Noggin protein resulted in ectopic Barx-1 expression in the distal, presumptive incisor mesenchyme and a transformation of tooth identity from incisor to molar.	Guys Kings & St Thomas Sch Dent, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sharpe, PT (corresponding author), Guys Kings & St Thomas Sch Dent, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England.		Tucker, Abigail S/K-1788-2016	Tucker, Abigail S/0000-0001-8871-6094; Sharpe, Paul/0000-0003-2116-9561	Medical Research Council [G9800001] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		DEAR TN, 1995, DEVELOPMENT, V121, P2909; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Grigoriou M, 1998, DEVELOPMENT, V125, P2063; Houzelstein D, 1997, MECH DEVELOP, V65, P123, DOI 10.1016/S0925-4773(97)00065-8; Kantaputra P N, 1992, Clin Dysmorphol, V1, P128; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; Thomas BL, 1998, EUR J ORAL SCI, V106, P48, DOI 10.1111/j.1600-0722.1998.tb02153.x; Thomas BL, 1997, DEVELOPMENT, V124, P4811; TISSIERSETA JP, 1995, MECH DEVELOP, V51, P3, DOI 10.1016/0925-4773(94)00343-L; Tucker AS, 1998, DEV DYNAM, V212, P533, DOI 10.1002/(SICI)1097-0177(199808)212:4<533::AID-AJA6>3.3.CO;2-I; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	14	333	356	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1136	1138		10.1126/science.282.5391.1136	http://dx.doi.org/10.1126/science.282.5391.1136			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804553				2022-12-24	WOS:000076887700053
J	Garry, DJ; Ordway, GA; Lorenz, LN; Radford, NB; Chin, ER; Grange, RW; Bassel-Duby, R; Williams, RS				Garry, DJ; Ordway, GA; Lorenz, LN; Radford, NB; Chin, ER; Grange, RW; Bassel-Duby, R; Williams, RS			Mice without myoglobin	NATURE			English	Article							MUSCLE; EXPRESSION; GENE; OXYGEN; HEART	Myoglobin, an intracellular haemoprotein expressed in the heart and oxidative skeletal myofibres of vertebrates, binds molecular oxygen and may facilitate oxygen transport from erythrocytes to mitochondria, thereby maintaining cellular respiration during periods of high physiological demand(1-10). Here we show, however, that mice without myoglobin, generated by gene-knockout techhnology, are fertile and exhibit normal exercise capacity and a normal ventilatory response to low oxygen levels (hypoxia). Heart and soleus muscles from these animals are depigmented, but function normally in standard assays of muscle performance in vitro across a range of work conditions and oxygen availability. These data show that myoglobin is not required to meet the metabolic requirements of pregnancy or exercise in a terrestrial mammal, and raise new questions about oxygen transport and metabolic regulation in working muscles.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol Oncol, Dallas, TX 75235 USA; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Ohio; University of Cincinnati	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA.			Radford, Nina/0000-0003-0847-9514				DOELLER JE, 1991, AM J PHYSIOL, V261, pH53, DOI 10.1152/ajpheart.1991.261.1.H53; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Garry DJ, 1996, DEV GENET, V19, P146, DOI 10.1002/(SICI)1520-6408(1996)19:2<146::AID-DVG6>3.0.CO;2-9; GIMENEZ M, 1977, RESPIRATION, V34, P171, DOI 10.1159/000193811; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GUYTON GP, 1995, J APPL PHYSIOL, V79, P1148, DOI 10.1152/jappl.1995.79.4.1148; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Ho CS, 1997, P NATL ACAD SCI USA, V94, P1533, DOI 10.1073/pnas.94.4.1533; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; PARSONS WJ, 1993, P NATL ACAD SCI USA, V90, P1726, DOI 10.1073/pnas.90.5.1726; Sidell BD, 1997, P NATL ACAD SCI USA, V94, P3420, DOI 10.1073/pnas.94.7.3420; Terrados N., 1992, INT J SPORTS MED S, V13, P206; UNDERWOOD LE, 1987, AM J PHYSIOL, V252, pC450, DOI 10.1152/ajpcell.1987.252.4.C450; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1970, PHYSIOL REV, V50, P559, DOI 10.1152/physrev.1970.50.4.559	17	212	214	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					905	908		10.1038/27681	http://dx.doi.org/10.1038/27681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804424				2022-12-24	WOS:000076713400058
J	Suzuki, H; Terauchi, Y; Fujiwara, M; Aizawa, S; Yazaki, Y; Kadowaki, T; Koyasu, S				Suzuki, H; Terauchi, Y; Fujiwara, M; Aizawa, S; Yazaki, Y; Kadowaki, T; Koyasu, S			Xid-like immunodeficiency in mice with disruption of the p85 alpha subunit of phosphoinositide 3-kinase	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAINS; RECEPTOR TYROSINE KINASES; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; SIGNALING SYSTEM; GENETIC-CONTROL; INSULIN; EXPRESSION	Mice with a targeted gene disruption of p85 alpha, a regulatory subunit of phosphoinositide 3-kinase, had impaired B cell development at the pro-B cell stage, reduced numbers of mature B cells and peritoneal CD5(+) Ly-1 B cells, reduced B cell proliferative responses, and no T cell-independent antibody production. These phenotypes are nearly identical to those of Btk(-/-) or rid (X-Linked immunodeficiency) mice. These results provide evidence that p85 alpha is functionally Linked to the Btk pathway in antigen receptor-mediated signal transduction and is pivotal in B cell development and functions.	Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 113, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 860, Japan	Keio University; University of Tokyo; Kumamoto University	Koyasu, S (corresponding author), Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	koyasu@sun.microb.med.keio.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Suzuki, Harumi/L-1271-2013; Koyasu, Shigeo/J-5583-2015	Suzuki, Harumi/0000-0003-3616-9361; Koyasu, Shigeo/0000-0001-9585-3038				ALLMAN DM, 1992, J IMMUNOL, V149, P2533; AMSBAUGH DF, 1972, J EXP MED, V136, P931, DOI 10.1084/jem.136.4.931; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BRUTON OC, 1952, PEDIATRICS, V9, P722; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; KADOWAKI T, 1996, ENDOCR J, V43, P33; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERLMUTTER RM, 1979, J EXP MED, V149, P993, DOI 10.1084/jem.149.4.993; PONS S, 1995, MOL CELL BIOL, V15, P4453; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHER I, 1982, IMMUNOL REV, V64, P117, DOI 10.1111/j.1600-065X.1982.tb00421.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUZUKI H, UNPUB; TERAUCHI Y, IN PRESS NATURE GENE; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	37	403	407	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					390	392		10.1126/science.283.5400.390	http://dx.doi.org/10.1126/science.283.5400.390			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888854				2022-12-24	WOS:000078067000048
J	Galtier, N; Tourasse, N; Gouy, M				Galtier, N; Tourasse, N; Gouy, M			A nonhyperthermophilic common ancestor to extant life forms	SCIENCE			English	Article							DNA-SEQUENCES; G+C-CONTENT; ORGANISMS; ORIGIN; PROKARYOTES; CENANCESTER; EUKARYOTES; TRANSITION; RATES; SITES	The G + C nucleotide content of ribosomal RNA (rRNA) sequences is strongly correlated with the optimal growth temperature of prokaryotes. This property allows inference of the environmental temperature of the common ancestor to all life forms from knowledge of the C + C content of its rRNA sequences. A model of sequence evolution, assuming varying C + C content among lineages and unequal substitution rates among sites, was devised to estimate ancestral base compositions. This method was applied to rRNA sequences of various species representing the major lineages of life. The inferred C+C content of the common ancestor to extant life forms appears incompatible with survival at high temperature. This finding challenges a widely accepted hypothesis about the origin of life.	Univ Lyon 1, Lab Biometrie Genet & Biol Populat, F-69622 Villeurbanne, France; Univ Montpellier 2, Lab Genome & Populat, F-34095 Montpellier, France; Univ Texas, Ctr Human Genet, Houston, TX 77030 USA	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; University of Texas System	Galtier, N (corresponding author), Univ Lyon 1, Lab Biometrie Genet & Biol Populat, F-69622 Villeurbanne, France.							Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; DeRijk P, 1996, NUCLEIC ACIDS RES, V24, P92, DOI 10.1093/nar/24.1.92; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Forterre P, 1996, CELL, V85, P789, DOI 10.1016/S0092-8674(00)81262-3; Galtier N, 1998, MOL BIOL EVOL, V15, P871, DOI 10.1093/oxfordjournals.molbev.a025991; GALTIER N, 1995, P NATL ACAD SCI USA, V92, P11317, DOI 10.1073/pnas.92.24.11317; Galtier N, 1997, J MOL EVOL, V44, P632, DOI 10.1007/PL00006186; Gogarten JP, 1996, SCIENCE, V274, P1750; Gu X, 1997, MOL BIOL EVOL, V14, P861, DOI 10.1093/oxfordjournals.molbev.a025827; Hasegawa M, 1996, SCIENCE, V274, P1750, DOI 10.1126/science.274.5293.1750; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; RZHETSKY A, 1995, GENETICS, V141, P771; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; TAMURA K, 1992, MOL BIOL EVOL, V9, P678; Tourasse NJ, 1997, MOL BIOL EVOL, V14, P287, DOI 10.1093/oxfordjournals.molbev.a025764; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154; YANG ZH, 1995, MOL BIOL EVOL, V12, P451	19	269	280	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 8	1999	283	5399					220	221		10.1126/science.283.5399.220	http://dx.doi.org/10.1126/science.283.5399.220			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZJ	9880254				2022-12-24	WOS:000077976700039
J	Kulkarni, A; Colburn, HS				Kulkarni, A; Colburn, HS			Role of spectral detail in sound-source localization	NATURE			English	Article								Sounds heard over headphones are typically perceived inside the head(1) (internalized), unlike real sound sources which are perceived outside the head (externalized). If the acoustical waveforms from a real sound source are reproduced precisely using headphones, auditory images are appropriately externalized and localized(1-4) The filtering (relative boosting, attenuation and delaying of component frequencies) of a sound by the head and outer ear provides information about the location of a sound source by means of the differences in the frequency spectra between the ears as well as the overall spectral shape. This location-dependent filtering is explicitly described by the head-related transfer function (HRTF) from sound source to ear canal. Here we present sounds to subjects through open-canal tube-phones and investigate how accurately the HRTFs must be reproduced to achieve true three-dimensional perception of auditory signals in anechoic space. Listeners attempted to discriminate between 'real' sounds presented from a loudspeaker and 'virtual' sounds presented over tube-phones. Our results show that the HRTFs can be smoothed significantly in frequency without affecting the perceived location of a sound. Listeners cannot distinguish real from virtual sources until the HRTF has lost most of its detailed variation in frequency, at which time the perceived elevation of the image is the reported cue.	Boston Univ, Hearing Res Ctr, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University	Kulkarni, A (corresponding author), Boston Univ, Hearing Res Ctr, Boston, MA 02215 USA.	abhijit@enga.bu.edu						Hartmann WM, 1996, J ACOUST SOC AM, V99, P3678, DOI 10.1121/1.414965; KISTLER DJ, 1992, J ACOUST SOC AM, V91, P1637, DOI 10.1121/1.402444; KULKARNI A, UNPUB J ACOUST SOC A; Loomis J. M., 1996, P SOC INF DISPL 1996, P965; Oppenheim A.V., 1975, DIGIT SIGNAL PROCESS; Shaw E. A. G., 1997, BINAURAL SPATIAL HEA, P25; Wenzel Elizabeth M., 1992, PRES TELEOP VIRT ENV, V1, P80, DOI [10.1162/pres.1992.1.1.80, DOI 10.1162/PRES.1992.1.1.80]; WIGHTMAN FL, 1989, J ACOUST SOC AM, V85, P858, DOI 10.1121/1.397557; ZAHORIK P, 1995, P AC SPEECH SIGN PRO	9	143	155	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 31	1998	396	6713					747	749		10.1038/25526	http://dx.doi.org/10.1038/25526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874370				2022-12-24	WOS:000077742800031
J	Shah, S				Shah, S			Why leeches influence my physical examination	LANCET			English	Article											Shah, S (corresponding author), 420 E 70th St,6J, New York, NY 10021 USA.							EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406	1	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					2014	2015		10.1016/S0140-6736(98)09291-5	http://dx.doi.org/10.1016/S0140-6736(98)09291-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872267				2022-12-24	WOS:000077663000048
J	Cao, W; Henry, MD; Borrow, P; Yamada, H; Elder, JH; Ravkov, EV; Nichol, ST; Compans, RW; Campbell, KP; Oldstone, MBA				Cao, W; Henry, MD; Borrow, P; Yamada, H; Elder, JH; Ravkov, EV; Nichol, ST; Compans, RW; Campbell, KP; Oldstone, MBA			Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and lassa fever virus	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; MEMBRANE; DISEASE; MICE	A peripheral membrane protein that is interactive with Lymphocytic choriomeningitis virus (LCMV) was purified from cells permissive to infection. Tryptic peptides from this protein were determined to be alpha-dystroglycan (alpha-DG). Several strains of LCMV and other arenaviruses, including Lassa fever virus (LFV), Oliveros, and Mobala, bound to purified alpha-DG protein. Soluble alpha-DG blocked both LCMV and LFV infection. Cells bearing a null mutation of the gene encoding DG were resistant to LCMV infection, and reconstitution of DC expression in null mutant cells restored susceptibility to LCMV infection. Thus, alpha-DG is a cellular receptor for both LCMV and LFV.	Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Univ Iowa, Coll Med, Dept Phys & Biophys, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Edward Jenner Inst Vaccine Res, Newbury RG20 7NN, Berks, England; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Ctr Dis Control, Atlanta, GA 30333 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of Iowa; Scripps Research Institute; Emory University; Centers for Disease Control & Prevention - USA	Oldstone, MBA (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Div Virol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mbaobo@scripps.edu	Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X; Henry, Michael/0000-0002-7871-245X; Cao, Wei/0000-0002-8952-9159; Borrow, Persephone/0000-0002-3877-9780; Campbell, Kevin/0000-0003-2066-5889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009712] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09484] Funding Source: Medline; NIA NIH HHS [AG 00080] Funding Source: Medline; NIDDK NIH HHS [DK09712] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORROW P, 1992, J VIROL, V66, P7270, DOI 10.1128/JVI.66.12.7270-7281.1992; BORROW P, UNPUB; Borrow Persephone, 1997, P593; Bowen MD, 1996, VIROLOGY, V219, P285, DOI 10.1006/viro.1996.0248; BURNS JW, 1991, VIROLOGY, V183, P620, DOI 10.1016/0042-6822(91)90991-J; CAO WQ, UNPUB; CLEGG JCS, 1993, ARENAVIRIDAE, P175; DELATORRE JC, UNPUB; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; Fabiyi A, 1976, Bull Pan Am Health Organ, V10, P335; FAZAKERLEY JK, 1991, J GEN VIROL, V72, P1611, DOI 10.1099/0022-1317-72-7-1611; FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAY SD, 1991, J BIOL CHEM, V266, P3287; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; Oldstone M B, 1980, Prog Med Virol, V26, P45; Peters C.J., 1996, FIELDS VIROLOGY, P1521; ROWE WP, 1954, NAVAL MED RES I BETH, V12, P167; SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Yamada H, 1996, J NEUROCHEM, V66, P1518; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173; Zinkernagel RM, 1997, SCAND J IMMUNOL, V46, P423, DOI 10.1046/j.1365-3083.1997.d01-161.x	24	512	525	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2079	2081		10.1126/science.282.5396.2079	http://dx.doi.org/10.1126/science.282.5396.2079			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851928				2022-12-24	WOS:000077467100046
J	Dong, C; Yang, DD; Wysk, M; Whitmarsh, AJ; Davis, RJ; Flavell, RA				Dong, C; Yang, DD; Wysk, M; Whitmarsh, AJ; Davis, RJ; Flavell, RA			Defective T cell differentiation in the absence of Jnk1	SCIENCE			English	Article							LYMPHOCYTES; EXPRESSION; MICE	The c-Jun NH2-terminal kinase (JNK) signaling pathway has been implicated in the immune response that is mediated by the activation and differentiation of CD4 helper T (T-H) cells into T(H)1 and T(H)2 effector cells. JNK activity observed in wild-type activated T-H cells was severely reduced in T-H cells from Jnk1(-/-) mice. The Jnk1(-/-) T cells hyperproliferated, exhibited decreased activation-induced cell death, and preferentially differentiated to T(H)2 cells. The enhanced production of T(H)2 cytokines by Jnk1(-/-) cells was associated with increased nuclear accumulation of the transcription factor NFATc. Thus, the JNK1 signaling pathway plays a key role in T cell receptor-initiated T-H cell proliferation, apoptosis, and differentiation.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.		dong, chen/B-3181-2009	dong, chen/0000-0002-0084-9130; Whitmarsh, Alan/0000-0003-1184-6610	NATIONAL CANCER INSTITUTE [R01CA065861, P01CA072009] Funding Source: NIH RePORTER; NCI NIH HHS [CA65861, CA72009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DONG CH, UNPUB, P12720; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rincon Mercedes, 1997, Genes and Function, V1, P51; RONEY JW, 1995, IMMUNITY, V2, P473; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Timmerman LA, 1997, J IMMUNOL, V159, P2735; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	27	515	530	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2092	2095		10.1126/science.282.5396.2092	http://dx.doi.org/10.1126/science.282.5396.2092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851932				2022-12-24	WOS:000077467100050
J	Monath, TP; Cordon, LK				Monath, TP; Cordon, LK			Biological warfare - Strengthening the biological weapons convention	SCIENCE			English	Editorial Material									OraVax Inc, Cambridge, MA 02139 USA		Monath, TP (corresponding author), OraVax Inc, 230 Albany St, Cambridge, MA 02139 USA.								0	6	6	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1423	1423		10.1126/science.282.5393.1423	http://dx.doi.org/10.1126/science.282.5393.1423			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9867648				2022-12-24	WOS:000077110800024
J	Somers, DE; Devlin, PF; Kay, SA				Somers, DE; Devlin, PF; Kay, SA			Phytochromes and cryptochromes in the entrainment of the Arabidopsis circadian clock	SCIENCE			English	Article							LIGHT; PERIOD; PHOTORECEPTORS; TRANSCRIPTION; PHENOTYPE; RHYTHMS; MUTANTS; SYSTEM; RED	Circadian clocks are synchronized by environmental cues such as light. Photoreceptor-deficient Arabidopsis thaliana mutants were used to measure the effect of light fluence Fate on circadian period in plants. Phytochrome B is the primary high-intensity red Light photoreceptor for circadian control, and phytochrome A acts under Low-intensity red Light. Cryptochrome 1 and phytochrome A both act to transmit low-fluence blue Light to the clock. Cryptochrome 1 mediates high-intensity blue light signals for period Length control. The presence of cryptochromes in both plants and animals suggests that circadian input pathways have been conserved throughout evolution.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92307 USA; Scripps Res Inst, Natl Sci Fdn Ctr Biol Timing, La Jolla, CA 92307 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92307 USA.	stevek@scripps.edu	Somers, David E/A-9209-2010; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; Devlin, Paul/0000-0002-0168-3793	NIGMS NIH HHS [GM56006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; ASCHOFF J, 1979, Z TIERPSYCHOL, V49, P225; Casal JJ, 1998, PLANT PHYSIOL, V118, P19, DOI 10.1104/pp.118.1.19; Cashmore AR, 1997, PLANT CELL ENVIRON, V20, P764, DOI 10.1046/j.1365-3040.1997.d01-125.x; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HARRIS PJC, 1976, PLANTA, V129, P253, DOI 10.1007/BF00398267; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; JOHNSON CH, 1995, CRC HDB ORGANIC PHOT, P1602; KENDRICH RE, 1994, PHOTOMORPHOGENESIS P; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; NAGATANI A, 1993, PLANT PHYSIOL, V102, P269, DOI 10.1104/pp.102.1.269; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; Roenneberg T, 1997, PLANTA, V202, P494, DOI 10.1007/s004250050154; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Somers DE, 1998, DEVELOPMENT, V125, P485; SOMERS DE, 1998, GENETICS, V149, P523; WAGNER D, 1991, PLANT CELL, V3, P1275, DOI 10.1105/tpc.3.12.1275; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135	32	587	628	5	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1488	1490		10.1126/science.282.5393.1488	http://dx.doi.org/10.1126/science.282.5393.1488			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822379				2022-12-24	WOS:000077110800054
J	Ghooi, RB; Ghooi, SR				Ghooi, RB; Ghooi, SR			A mother in pain	LANCET			English	Editorial Material											Ghooi, RB (corresponding author), 697 Pocket A,Sarita Vihar,Mathura Rd, New Delhi 110044, India.								0	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1998	352	9140					1625	1625		10.1016/S0140-6736(98)07150-5	http://dx.doi.org/10.1016/S0140-6736(98)07150-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843124				2022-12-24	WOS:000076998900048
J	Frank, KM; Sekiguchi, JM; Seidl, KJ; Swat, W; Rathbun, GA; Cheng, HL; Davidson, L; Kangaloo, L; Alt, FW				Frank, KM; Sekiguchi, JM; Seidl, KJ; Swat, W; Rathbun, GA; Cheng, HL; Davidson, L; Kangaloo, L; Alt, FW			Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV	NATURE			English	Article							STRAND BREAK REPAIR; KU86-DEFICIENT MICE; SIGNAL; GROWTH; DEFECT; CELLS	The DNA-end-joining reactions used for repair of double-strand breaks in DNA and for V(D)J recombination, the process by which immunoglobulin and T-cell antigen-receptor genes are assembled from multiple gene segments, use common factors. These factors include components of DNA-dependent protein kinase (DNA-PK), namely DNA-PE;cs and the Ku heterodimer, Ku70-Ku80, and XRCC4 (ref. 1). The precise function of XRCC4 is unknown, but it interacts with DNA ligase IV. Ligase IV is one of the three known mammalian DNA ligases(2); however, the in vivo functions of these Ligases have not been determined unequivocally. Here we show that inactivation of the ligase IV gene in mice leads to late embryonic lethality. Lymphopoiesis in these mice is blocked and V(D)I joining does not occur. Ligase IV-deficient embryonic fibroblasts also show marked sensitivity to ionizing radiation, growth defects and premature senescence. All of these phenotypic characteristics, except embryonic lethality, resemble those associated with Ku70 and Ku80 deficiencies(3-6), indicating that they may result from an impaired end-joining process that involves both Ku subunits and ligase N. However, Ku-deficient mice are viable, so ligase TV must also be required for processes and/or in cell types in which Ku is dispensable.	Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Alt, FW (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA.			Sekiguchi, JoAnn/0000-0002-7178-4258				Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; MOGAN B, 1994, MANIPULATING MOUSE E; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Schatz D G, 1997, Semin Immunol, V9, P149, DOI 10.1006/smim.1997.0068; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	28	450	465	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1998	396	6707					173	177		10.1038/24172	http://dx.doi.org/10.1038/24172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823897				2022-12-24	WOS:000077013300053
J	Junghans, RP				Junghans, RP			Bone marrow involvement in acute leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deacones Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Junghans, RP (corresponding author), Beth Israel Deacones Med Ctr, Boston, MA 02215 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1375	1375		10.1056/NEJM199811053391906	http://dx.doi.org/10.1056/NEJM199811053391906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9801399				2022-12-24	WOS:000076780200006
J	Jasny, BR; Hines, PJ				Jasny, BR; Hines, PJ			A genome sampler	SCIENCE			English	Editorial Material																			0	1	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					651	651		10.1126/science.282.5389.651	http://dx.doi.org/10.1126/science.282.5389.651			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841419				2022-12-24	WOS:000076607500033
J	Bakin, AV; Curran, T				Bakin, AV; Curran, T			Role of DNA 5-methylcytosine transferase in cell transformation by fos	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; OSTEO-SARCOMA VIRUS; C-FOS; NIH3T3 CELLS; MORPHOLOGICAL TRANSFORMATION; SIGNALING PATHWAY; EXPRESSION; PROTEIN; METHYLATION; GENE	The Fos and Jun oncoproteins form dimeric complexes that stimulate transcription of genes containing activator protein-1 regulatory elements. We found, by representational difference analysis, that expression of DNA 5-methylcytosine transferase (dnmt1) in fos-transformed cells is three times the expression in normal fibroblasts and that fos-transformed cells contain about 20 percent more 5-methylcytosine than normal fibroblasts. Transfection of the gene encoding Dnmt1 induced morphological transformation, whereas inhibition of dnmt1 expression or activity resulted in reversion of fos transformation. Inhibition of histone deacetylase, which associates with methylated DNA, also caused reversion. These results suggest that fos may transform cells through alterations in DNA methylation and in histone deacetylation.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale, Memphis, TN 38105 USA.	fos1@aol.com	Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; Baylin SB, 1998, ADV CANCER RES, V72, P141; BRASELMANN S, 1992, J CELL SCI, P97; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; Curran T, 1988, ONCOGENE HDB, P307; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JOOSS KU, 1995, ONCOGENE, V10, P603; JOSEPH L, 1987, NUCLEIC ACIDS RES, V15, P3186, DOI 10.1093/nar/15.7.3186; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; Kho CJ, 1996, CELL GROWTH DIFFER, V7, P1157; KOISTINAHO J, 1995, MOL BRAIN RES, V29, P53, DOI 10.1016/0169-328X(94)00218-4; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MIETZ JA, 1990, P NATL ACAD SCI USA, V87, P2269, DOI 10.1073/pnas.87.6.2269; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NEUBERG M, 1991, ONCOGENE, V6, P1325; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; TROEN BR, 1988, J BIOL CHEM, V263, P254; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092	51	206	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 15	1999	283	5400					387	390		10.1126/science.283.5400.387	http://dx.doi.org/10.1126/science.283.5400.387			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888853				2022-12-24	WOS:000078067000047
J	Hyett, J; Perdu, M; Sharland, G; Snijders, R; Nicolaides, KH				Hyett, J; Perdu, M; Sharland, G; Snijders, R; Nicolaides, KH			Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; CHROMOSOMAL DEFECTS; GREAT-ARTERIES; TRIMESTER; ECHOCARDIOGRAPHY; ABNORMALITIES; DIAGNOSIS; FETUSES; ULTRASONOGRAPHY; PREGNANCY	Objectives To examine the utility of measuring fetal nuchal translucency thickness in screening for major defects of the heart and great arteries at 10-14 week of gestation. Design Population based cohort study. Subjects 29 154 singleton pregnancies with chromosomally normal fetuses at 10-14 weeks of gestation. Setting Fetal medicine centre in London. Main outcome measure Prevalence of major defects of the heart and great arteries. Results Of 50 cases with major defects of the heart and great arteries (prevalence 1.7 pet 1000 pregnancies) 28 (56%, 95% confidence interval 42% to 70%) were in the subgroup of 1822 pregnancies with fetal nuchal translucency thicknesses above the 95th centile of the normal range. The positive and negative predictive values for this cut off point of nuchal translucency thickness were 1.5% and 99.9% respectively. Conclusions Measurement of fetal nuchal translucency thickness-traditionally used to identify fetuses at high risk of aneuploidy-at 10-14 weeks of gestation can identify a large proportion of fetuses with major defects of the heart and great arteries.	Univ London Kings Coll Hosp, Sch Med, Dept Obstet & Gynaecol, Harris Birthright Res Ctr Fetal Med, London SE5 8RX, England; Guys Hosp, Fetal Cardiol Unit, London SE1 9RT, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Nicolaides, KH (corresponding author), Univ London Kings Coll Hosp, Sch Med, Dept Obstet & Gynaecol, Harris Birthright Res Ctr Fetal Med, London SE5 8RX, England.			Snijders, Rosalinde/0000-0003-1809-7886; Nicolaides, Kypros/0000-0003-1266-0711				ACHIRON R, 1994, OBSTET GYNECOL, V84, P69; ALLAN LD, 1984, BRIT HEART J, V52, P542; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; BRONSHTEIN M, 1990, PRENATAL DIAG, V10, P697, DOI 10.1002/pd.1970101103; Carvalho JS, 1998, LANCET, V351, P1023, DOI 10.1016/S0140-6736(97)08406-7; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; COPEL JA, 1987, AM J OBSTET GYNECOL, V157, P618; DOLKART LA, 1991, AM J OBSTET GYNECOL, V165, P688, DOI 10.1016/0002-9378(91)90310-N; FERENCZ C, 1985, AM J EPIDEMIOL, V121, P31, DOI 10.1093/oxfordjournals.aje.a113979; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Hyett J, 1996, ULTRASOUND OBST GYN, V7, P245, DOI 10.1046/j.1469-0705.1996.07040245.x; Hyett J, 1997, AM J MED GENET, V69, P207, DOI 10.1002/(SICI)1096-8628(19970317)69:2<207::AID-AJMG18>3.0.CO;2-P; Hyett JA, 1997, ULTRASOUND OBST GYN, V10, P242, DOI 10.1046/j.1469-0705.1997.10040242.x; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; MeyerWittkopf M, 1996, ULTRASOUND OBST GYN, V8, P8, DOI 10.1046/j.1469-0705.1996.08010008.x; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; RUSTICO MA, 1995, ULTRASOUND OBST GYN, V6, P313, DOI 10.1046/j.1469-0705.1995.06050313.x; Sharland G, 1998, LANCET, V351, P1662, DOI 10.1016/S0140-6736(05)77722-9; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Snijders RJM, 1996, ULTRASOUND OBST GYN, V7, P216, DOI 10.1046/j.1469-0705.1996.07030216.x; TAIPALE P, 1997, NEW ENGL J MED, V337, P165; TEGNANDER E, 1995, ULTRASOUND OBST GYN, V5, P72	26	380	397	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1999	318	7176					81	85		10.1136/bmj.318.7176.81	http://dx.doi.org/10.1136/bmj.318.7176.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880278	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000078087500021
J	Petty, GW; Brown, RD; Whisnant, JP; Sicks, JD; O'Fallon, WM; Wiebers, DO				Petty, GW; Brown, RD; Whisnant, JP; Sicks, JD; O'Fallon, WM; Wiebers, DO			Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention - A population-based study	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACKS; GASTROINTESTINAL HEMORRHAGE; CEREBRAL-ISCHEMIA; RISK-FACTORS; ANTICOAGULATION; EPIDEMIOLOGY; TRIAL; OUTPATIENTS; INFARCTION; PREDICTION	Background: Complication rates of medical therapy for secondary stroke prevention derived from clinical trials may or may not be applicable to patients with cerebrovascular disease in the general population. Objective: To determine complication rates for aspirin, warfarin, and intravenous heparin administered for secondary stroke prevention after first episodes of ischemic stroke, transient ischemic attack, or amaurosis fugax in a community. Design: Population-based historical cohort study. Setting: Rochester, Minnesota. Patients: All residents of Rochester who, between 1985 and 1989, received aspirin (n = 339) or warfarin (n = 145) within 2 years after first ischemic stroke, transient ischemic attack, or amaurosis fugax or received intravenous heparin (n = 201) within 2 weeks after first ischemic stroke, transient ischemic attack, or amaurosis fugax. Measurements: Occurrence of major complications caused by therapy. Results: Twenty aspirin-associated complications (1 fatal) occurred during an average 1.7 years of treatment, 8 warfarin-associated complications occurred during an average 0.7 years of treatment, and 3 heparin-associated complications (1 fatal) occurred during an average 5.1 days of treatment. Complication rates were 3.5 per 100 person-years (95% CI, 2.1 to 5.4) for aspirin, 7.9 per 100 person-years (CI, 3.4 to 15.6) for warfarin, and 0.30 (CI, 0.06 to 0.86) per 100 person-days for heparin. Rates of fatal complications were 0.2 per 100 person-years (CI, 0 to 1.0) for aspirin, 0 per 100 person-years (CI, 0 to 3.6) for warfarin, and 0.10 per 100 person-days (0 to 0.55) for heparin. Conclusions: Complication rates for warfarin and intravenous heparin given as therapy for secondary stroke prevention in Rochester, Minnesota, were lower than rates reported from earlier trials and observational studies. However, complication rates for warfarin were higher than in more recent referral-based studies and multicenter randomized trials. After adjustment for duration of therapy, complication rates for heparin were higher than those for aspirin or warfarin. These rates can be used to judge the applicability of complication rates derived from ongoing clinical trials.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Petty, GW (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006663] Funding Source: NIH RePORTER; NINDS NIH HHS [NS06663] Funding Source: Medline; PHS HHS [282910028] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1991, Lancet, V338, P1345; BAKER RN, 1962, NEUROLOGY, V12, P823, DOI 10.1212/WNL.12.12.823; BILLER J, 1989, STROKE, V20, P441, DOI 10.1161/01.STR.20.4.441; BRODERICK JP, 1992, STROKE, V23, P1250, DOI 10.1161/01.STR.23.9.1250; Brown RD, 1996, STROKE, V27, P373; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Davenport RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; ENGER E, 1965, ACTA MED SCAND, VS178, P7; ERIKSSON SE, 1985, ACTA NEUROL SCAND, V71, P485; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GROCH SN, 1961, ANN INTERN MED, V55, P358, DOI 10.7326/0003-4819-55-3-358; HAKIM AM, 1983, STROKE, V14, P668; HALEY EC, 1988, STROKE, V19, P10, DOI 10.1161/01.STR.19.1.10; HILL AB, 1962, BRIT MED J, P1003, DOI 10.1136/bmj.2.5311.1003; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KEITH DS, 1987, MAYO CLIN PROC, V62, P1101, DOI 10.1016/S0025-6196(12)62503-8; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; Kronmal RA, 1998, STROKE, V29, P887, DOI 10.1161/01.STR.29.5.887; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; LONGSTRETH GF, 1995, AM J GASTROENTEROL, V90, P206; Longstreth GF, 1997, AM J GASTROENTEROL, V92, P419; MCDOWELL FLETCHER, 1965, P185; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; ORENCIA AJ, 1993, STROKE POPULATIONS C, P238; PEARCE JMS, 1965, LANCET, V1, P6; PESSIN MS, 1993, NEUROLOGY, V43, P1298, DOI 10.1212/WNL.43.7.1298; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; Petty GW, 1998, NEUROLOGY, V50, P208, DOI 10.1212/WNL.50.1.208; PUTMAN SF, 1985, ARCH NEUROL-CHICAGO, V42, P960, DOI 10.1001/archneur.1985.04060090042011; RAMIREZLASSEPAS M, 1986, ARCH NEUROL-CHICAGO, V43, P386, DOI 10.1001/archneur.1986.00520040066022; RANKIN J, 1957, Scott Med J, V2, P127; SHERMAN DG, 1995, CHEST, V108, pS444, DOI 10.1378/chest.108.4_Supplement.444S; SULLIVAN LW, 1992, NATL STROKE ASS  SPR, V9, P1; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; *VET ADM COOP STUD, 1961, NEUROLOGY, V11, P132; 1997, STROKE, V28, P475	43	69	71	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					14	22		10.7326/0003-4819-130-1-199901050-00004	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890845				2022-12-24	WOS:000077744500003
J	Finch, EA; Augustine, GJ				Finch, EA; Augustine, GJ			Local calcium signalling by inositol-1,4, 5-trisphosphate in Purkinje cell dendrites	NATURE			English	Article							RAT CEREBELLAR SLICES; LONG-TERM DEPRESSION; GLUTAMATE RECEPTORS; ACTIVATION; TRISPHOSPHATE; NEURONS; 1,4,5-TRISPHOSPHATE; CA2+; POTENTIATION; LOCALIZATION	The second messenger inositol-1,4,5-trisphosphate (InsP(3)) releases Ca2+ from intracellular Ca2+ stores by activating specific receptors on the membranes of these stores(1). In many cells, InsP(3) is a global signalling molecule that liberates Ca2+ throughout the cytoplasm(1,2) . However, in neurons the situation might be different(3,4), because synaptic activity may produce InsP(3) at discrete locations. Here we characterize InsP(3) signalling in postsynaptic cerebellar Purkinje neurons, which have a high level of InsP(3) receptors(5). We find that repetitive activation of the synapse between parallel fibres and Purkinje cells causes InsP(3)-mediated Ca2+ release in the Purkinje cells. This Ca2+ release is restricted to individual postsynaptic spines, where both metabotropic glutamate receptors(6,7) and InsP3 receptors(5) are located, or to multiple spines and adjacent dendritic shafts. Focal photolysis of caged InsP(3) (ref. 8) in Purkinje cell dendrites also produces Ca2+ signals that spread only a few micrometres from the site of InsP(3) production. Uncaged InsP(3) produces a long-lasting depression of parallel-fibre synaptic transmission that is limited to synapses where the Ca2+ concentration is raised. Thus, in Purkinje cells InP3 acts within a restricted spatial range that allows it to regulate the function of local groups of parallel-fibre synapses.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University	Augustine, GJ (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, POB 3209, Durham, NC 27710 USA.	georgea@neuro.duke.edu	Augustine, George James/J-9228-2013					BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; BATCHELOR AM, 1994, NEUROSCIENCE, V63, P911, DOI 10.1016/0306-4522(94)90558-4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; Dichiara TJ, 1995, J PHYSIOL-LONDON, V489, P403, DOI 10.1113/jphysiol.1995.sp021061; Doroshenko PA, 1997, NEUROPHARMACOLOGY, V36, P865, DOI 10.1016/S0028-3908(97)00032-4; Eilers J, 1997, LEARN MEMORY, V4, P159, DOI 10.1101/lm.4.1.159; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Hartell NA, 1996, NEURON, V16, P601, DOI 10.1016/S0896-6273(00)80079-3; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JAFFE DB, 1994, J NEUROPHYSIOL, V72, P471, DOI 10.1152/jn.1994.72.1.471; KHODAKHAH K, 1995, J PHYSIOL-LONDON, V487, P343, DOI 10.1113/jphysiol.1995.sp020884; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WANG BZ, 1995, IEEE MICROW GUIDED W, V5, P15, DOI 10.1109/75.382374; WANG SSH, UNPUB P NATL ACAD SC; YAMADA M, 1992, BRAIN RES, V578, P41, DOI 10.1016/0006-8993(92)90227-Z	29	427	431	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 31	1998	396	6713					753	756		10.1038/25541	http://dx.doi.org/10.1038/25541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151WC	9874372				2022-12-24	WOS:000077742800033
J	Ferguson, AD; Hofmann, E; Coulton, JW; Diederichs, K; Welte, W				Ferguson, AD; Hofmann, E; Coulton, JW; Diederichs, K; Welte, W			Siderophore-mediated iron transport: Crystal structure of FhuA with bound lipopolysaccharide	SCIENCE			English	Article							ESCHERICHIA-COLI K-12; OUTER-MEMBRANE; ANOMALOUS DIFFRACTION; CELL-ENVELOPE; PROTEIN; RECEPTOR; CHANNEL; BINDING; ENERGY; TONB	FhuA, the receptor for ferrichrome-iron in Escherichia coli, is a member of a family of integral outer membrane proteins, which, together with the energy-transducing protein TonB, mediate the active transport of ferric siderophores across the outer membrane of Cram-negative bacteria. The three-dimensional structure of FhuA is presented here in two conformations: with and without ferrichrome-iron at resolutions of 2.7 and 2.5 angstroms, respectively. FhuA is a beta barrel composed of 22 antiparallel beta strands. In contrast to the typical trimeric arrangement found in porins, FhuA is monomeric. Located within the beta barrel is a structurally distinct domain, the "cork," which mainly consists of a four-stranded beta sheet and four short alpha helices. A single Lipopolysaccharide molecule is noncovalently associated with the membrane-embedded region of the protein. Upon binding of ferrichrome-iron, conformational changes are transduced to the periplasmic pocket of FhuA, signaling the Ligand-Loaded status of the receptor. Sequence homologies and mutagenesis data are used to propose a structural mechanism for TonB-dependent siderophore-mediated transport across the outer membrane.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	University of Konstanz; McGill University	Welte, W (corresponding author), Univ Konstanz, Fak Biol, M656, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de	Hofmann, Eckhard/GPF-5024-2022	Hofmann, Eckhard/0000-0003-4874-372X				Adam G., 1968, STRUCTURAL CHEM MOL, P198; ANGYAL SJ, 1995, CARBOHYD RES, V266, P143, DOI 10.1016/0008-6215(94)00253-C; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR 3 1; BUTCHER D, 1995, PEPT BIOPOLYM, V35, P109; CARMEL G, 1990, J BACTERIOL, V172, P1861, DOI 10.1128/jb.172.4.1861-1869.1990; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; COWTAN K, 1994, ACTA CRYSTALLOGR D, V50, P760; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; DOUBLIE S, METHODS ENZYMOL, V276, P52397; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ghosh A, 1996, CHEM BIOL, V3, P1011, DOI 10.1016/S1074-5521(96)90167-2; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARPLUS PA, UNPUB; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; Killmann H, 1998, J BACTERIOL, V180, P3845, DOI 10.1128/JB.180.15.3845-3852.1998; Killmann H, 1996, J BACTERIOL, V178, P6913, DOI 10.1128/jb.178.23.6913-6920.1996; KILLMANN H, 1992, J BACTERIOL, V174, P3479, DOI 10.1128/JB.174.11.3479-3486.1992; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; LOCHER K, 1997, EUR J BIOCHEM, V247, P779; Mademidis A, 1997, MOL MICROBIOL, V26, P1109, DOI 10.1046/j.1365-2958.1997.6592008.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOECK GS, 1994, J BACTERIOL, V176, P4250, DOI 10.1128/jb.176.14.4250-4259.1994; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; NEILANDS JB, 1952, J AM CHEM SOC, V74, P4846, DOI 10.1021/ja01139a033; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; WELTE W, 1995, KIDNEY INT, V48, P930, DOI 10.1038/ki.1995.374; WELTE W, 1998, P NATO ADV WORKSH NE, P239; YANG AS, 1995, J MOL BIOL, V252, P351, DOI 10.1006/jmbi.1995.0502	49	646	665	4	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2215	2220		10.1126/science.282.5397.2215	http://dx.doi.org/10.1126/science.282.5397.2215			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856937	Green Submitted			2022-12-24	WOS:000077645800035
J	Schroeder, BC; Kubisch, C; Stein, V; Jentsch, TJ				Schroeder, BC; Kubisch, C; Stein, V; Jentsch, TJ			Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIAS; FAMILIAL NEONATAL CONVULSIONS; POTASSIUM-CHANNEL; KVLQT1 MUTATIONS; PROTEINS; K(V)LQT1; FORM; RAT	Epilepsy affects more than 0.5% of the world's population and has a large genetic component(1). It is due to an electrical hyperexcitability in the central nervous system. Potassium channels are important regulators of electrical signalling, and benign familial neonatal convulsions (BFNC), an autosomal dominant epilepsy of infancy, is caused by mutations in the KCNQ2 or the KCNQ3 potassium channel genes(2-4), Here we show that KCNQ2 and KCNQ3 are distributed broadly in brain with expression patterns that largely overlap. Expression in Xenopus oocytes indicates the formation of heteromeric KCNQ2/KCNQ3 potassium channels with currents that are at least tenfold larger than those of the respective homomeric channels. KCNQ2/KCNQ3 currents can be increased by intracellular cyclic AMP, an effect that depends on an intact phosphorylation site in the KCNQ2 amino terminus. KCNQ2 and KCNQ3 mutations identified in BFNC pedigrees compromised the function of the respective subunits, but exerted no dominant-negative effect on KCNQ2/KCNQ3 heteromeric channels. We predict that a 25% loss of heteromeric KCNQ2/ KCNQ3-channel function is sufficient to cause the electrical hyperexcitability in BFNC, Drugs raising intracellular cAMP may prove beneficial in this form of epilepsy.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	jentsch@plexus.uke.uni-hamburg.de	Kubisch, Christian/F-1893-2011; Stein, Valentin/A-8025-2008	Kubisch, Christian/0000-0003-4220-0978; Stein, Valentin/0000-0003-1222-4928; Jentsch, Thomas/0000-0002-3509-2553				BARAISTER M, 1990, OXF MONOGR MED GENET, V18, P96; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943	19	406	435	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					687	690		10.1038/25367	http://dx.doi.org/10.1038/25367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872318				2022-12-24	WOS:000077694200056
J	Poltorak, A; He, XL; Smirnova, I; Liu, MY; Van Huffel, C; Du, X; Birdwell, D; Alejos, E; Silva, M; Galanos, C; Freudenberg, M; Ricciardi-Castagnoli, P; Layton, B; Beutler, B				Poltorak, A; He, XL; Smirnova, I; Liu, MY; Van Huffel, C; Du, X; Birdwell, D; Alejos, E; Silva, M; Galanos, C; Freudenberg, M; Ricciardi-Castagnoli, P; Layton, B; Beutler, B			Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene	SCIENCE			English	Article							LIPOPOLYSACCHARIDE BINDING-PROTEIN; TUMOR NECROSIS FACTOR; C-JUN; ENDOTOXIN; DROSOPHILA; CELLS; TOLL; CD14; 18-WHEELER; CACHECTIN	Mutations of the gene Lps selectively impede Lipopolysaccharide (LPS) signal transduction in C3H/HeJ and C57BL/10ScCr mice, rendering them resistant to endotoxin yet highly susceptible to Gram-negative infection. The codominant Lps(d) allele of C3H/HeJ mice was shown to correspond to a missense mutation in the third exon of the Toll-Like receptor-4 gene (Tlr4), predicted to replace proline with histidine at position 712 of the polypeptide chain. C57BL/10ScCr mice are homozygous for a null mutation of Tlr4, Thus, the mammalian Tlr4 protein has been adapted primarily to subserve the recognition of LPS and presumably transduces the LPS signal across the plasm a mem bra ne. Destructive mutations of Tlr4 predispose to the development of Gram-negative sepsis, Leaving most aspects of immune function intact.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; CNR, Cellular & Mol Pharmacol Ctr, I-20133 Milan, Italy; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Consiglio Nazionale delle Ricerche (CNR); Max Planck Society	Beutler, B (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Castagnoli, Paola/E-8288-2010; Eckhardt, Erik/G-1567-2010	Van Huffel, Christophe/0000-0001-6127-3027; Freudenberg, Marina Alexandra/0000-0001-5894-1805				APTE RN, 1977, J IMMUNOL, V119, P1898; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; CHIANG C, 1994, MECH DEVELOP, V47, P225; COUTINHO A, 1977, EUR J IMMUNOL, V7, P325, DOI 10.1002/eji.1830070517; COUTINHO A, 1978, IMMUNOGENETICS, V7, P17, DOI 10.1007/BF01843983; ELDON E, 1994, DEVELOPMENT, V120, P885; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hu JX, 1997, GENOME RES, V7, P693, DOI 10.1101/gr.7.7.693; Kuhns DB, 1997, J IMMUNOL, V158, P3959; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; MATHISON J, 1993, J CLIN INVEST, V92, P2053, DOI 10.1172/JCI116801; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MICHALEK SM, 1980, J INFECT DIS, V141, P55, DOI 10.1093/infdis/141.1.55; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; POLTORAK A, UNPUB; ROSENSTREICH DL, 1978, J IMMUNOL, V121, P1664; ROSENSTREICH DL, 1977, J INFECT DIS, V136, pS239, DOI 10.1093/infdis/136.Supplement.S239; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VOGEL SN, 1979, J IMMUNOL, V122, P619; VOGEL SN, 1992, TUMOR NECROSIS FACTO, P485; WATSON J, 1977, J IMMUNOL, V118, P2088; WATSON J, 1977, J IMMUNOL, V120, P422; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	34	6092	6433	6	589	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2085	2088		10.1126/science.282.5396.2085	http://dx.doi.org/10.1126/science.282.5396.2085			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851930				2022-12-24	WOS:000077467100048
J	Sharma, K; Sheng, HZ; Lettieri, K; Li, H; Karavanov, A; Potter, S; Westphal, H; Pfaff, SL				Sharma, K; Sheng, HZ; Lettieri, K; Li, H; Karavanov, A; Potter, S; Westphal, H; Pfaff, SL			LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons	CELL			English	Article							HOMEOBOX GENE LHX3; CHICK SPINAL-CORD; SONIC HEDGEHOG; NEUROENDOCRINE TISSUES; PROJECTION PATTERNS; FLOOR PLATE; EXPRESSION; SPECIFICATION; PITUITARY; ORGANIZATION	The circuits that control movement are comprised of discrete subtypes of motor neurons. How motor neuron subclasses develop and extend axons to their correct targets is still poorly understood. We show that LIM homeodomain factors Lhx3 and Lhx4 are expressed transiently in motor neurons whose axons emerge ventrally from the neural tube (V-MN). Motor neurons develop in embryos deficient in both Lhx3 and Lhx4, but v-MN cells switch their subclass identity to become motor neurons that extend axons dorsally from the neural tube (d-MN). Conversely, the misexpression of Lhx3 in dorsal-exiting motor neurons is sufficient to reorient their axonal projections ventrally. Thus, Lhx3 and Lhx4 act in a binary fashion during a brief period in development to specify the trajectory of motor axons from the neural tube.	Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA; NICHHD, Lab Mammalian Genet & Dev, Bethesda, MD 20892 USA; NICHHD, Mol Genet Lab, Bethesda, MD 20892 USA; Acad Sinica, Inst Mol Biol, Taipei, Taiwan; Childrens Hosp, Cincinnati, OH 45229 USA	Salk Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Academia Sinica - Taiwan; Cincinnati Children's Hospital Medical Center	Pfaff, SL (corresponding author), Salk Inst, Gene Express Lab, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037116] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37116] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Appel B, 1995, DEVELOPMENT, V121, P4117; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BRICHTA AM, 1987, J COMP NEUROL, V255, P351, DOI 10.1002/cne.902550304; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; Ensini M, 1998, DEVELOPMENT, V125, P969; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Fedtsova N, 1997, DEV BIOL, V190, P18, DOI 10.1006/dbio.1997.8691; FRITZSCH B, 1993, ACTA ANAT, V148, P96; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; Hobert O, 1998, J NEUROSCI, V18, P2084; Hogan B, 1994, MANIPULATING MOUSE E; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LEBER SM, 1995, J NEUROSCI, V15, P1236; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1996, DEVELOPMENT, V122, P659; NORNES HO, 1978, BRAIN RES, V159, P1, DOI 10.1016/0006-8993(78)90105-1; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Pfaff S, 1998, CURR OPIN NEUROBIOL, V8, P27, DOI 10.1016/S0959-4388(98)80005-6; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAUER B, 1993, GUIDE TECHNIQUES MOU, P890; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHARMA K, 1994, DEVELOPMENT, V120, P1315; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WETTS R, 1994, NEUROSCIENCE, V63, P1117, DOI 10.1016/0306-4522(94)90577-0; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	55	351	360	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 11	1998	95	6					817	828		10.1016/S0092-8674(00)81704-3	http://dx.doi.org/10.1016/S0092-8674(00)81704-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865699	Bronze			2022-12-24	WOS:000077498800011
J	Whitehead, H				Whitehead, H			Cultural selection and genetic diversity in matrilineal whales	SCIENCE			English	Article							D-LOOP REGION; POPULATION-STRUCTURE; HUMPBACK WHALES; ORCINUS-ORCA; SPERM WHALES; EVOLUTION; WATERS; BEHAVIOR	Low diversities of mitochondrial DNA (mtDNA) have recently been found in four species of matrilineal whale. No satisfactory explanation for this apparent anomaly has been previously suggested. Culture seems to be an important part of the Lives of matrilineal whales. The selection of matrilineally transmitted cultural traits, upon which neutral mtDNA alleles "hitchhike," has the potential to strongly reduce genetic variation. Thus, in contrast to other nonhuman mammals, culture may be an important evolutionary force for the matrilineal whales.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	Dalhousie University	Whitehead, H (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	hwhitehe@is.dal.ca						Amos Bill, 1996, Report of the International Whaling Commission, V46, P657; ARCHER I, 1996, THESIS U CALIFORNIA; BAKER CS, 1993, P NATL ACAD SCI USA, V90, P8239, DOI 10.1073/pnas.90.17.8239; Bakke I, 1996, MAR BIOL, V125, P1, DOI 10.1007/BF00350755; BARLOW J, 1995, FISH B-NOAA, V93, P1; BIRKY CW, 1983, GENETICS, V103, P513; Boyd R, 1985, CULTURE EVOLUTIONARY; BRAULT S, 1993, ECOLOGY, V74, P1444, DOI 10.2307/1940073; Buckland S.T., 1993, Reports of the International Whaling Commission Special Issue, V14, P33; Connor RC, 1998, TRENDS ECOL EVOL, V13, P228, DOI 10.1016/S0169-5347(98)01326-3; DILLON MC, 1993, MOL BIOL EVOL, V10, P296; Dillon MC, 1996, THESIS DALHOUSIE U H; DIZON AE, 1994, CAL COOP OCEAN FISH, V35, P61; FORD JKB, 1991, CAN J ZOOL, V69, P1454, DOI 10.1139/z91-206; Gladden JGB, 1997, MOL ECOL, V6, P1033, DOI 10.1046/j.1365-294X.1997.00275.x; HELMLICHBORAN JR, IN PRESS S ZOOL SOC; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hoelzel A. R., 1991, REPORTS INT WHALING, V13, P225; HOELZEL AR, 1991, MOL BIOL EVOL, V8, P475; Hoelzel AR, 1998, J HERED, V89, P121, DOI 10.1093/jhered/89.2.121; Janik VM, 1997, ADV STUD BEHAV, V26, P59, DOI 10.1016/S0065-3454(08)60377-0; JEFFRSON TA, 1994, HDB MARINE MAMMALS, V5, P355; KAPLAN NL, 1989, GENETICS, V123, P887; Klinowska M., 1991, DOLPHINS PORPOISES W; LALAND KN, 1992, ETHOL SOCIOBIOL, V13, P87, DOI 10.1016/0162-3095(92)90020-5; Lux C.A., 1997, Report of the International Whaling Commission, V47, P645; Lyrholm T, 1998, P ROY SOC B-BIOL SCI, V265, P1679, DOI 10.1098/rspb.1998.0488; MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087, DOI 10.1073/pnas.90.9.4087; Palsboll PJ, 1997, HEREDITY, V78, P284; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; Pichler FB, 1998, CONSERV BIOL, V12, P676, DOI 10.1046/j.1523-1739.1998.96390.x; RICHERSON PJ, IN PRESS IDEOLOGY WA; ROPER TJ, 1986, SCI PROG, V70, P571; ROSEL PE, 1994, MAR BIOL, V119, P159, DOI 10.1007/BF00349552; ROSEL PE, 1995, CAN J FISH AQUAT SCI, V52, P1210, DOI 10.1139/f95-118; Siemann LA, 1994, THESIS MIT CAMBRIDGE; TAJIMA F, 1989, GENETICS, V123, P585; Wade P.R., 1992, Report of the International Whaling Commission, V42, P533; Whitehead H, 1996, J ANIM ECOL, V65, P429, DOI 10.2307/5778; WHITEHEAD H, 1991, BEHAV ECOL SOCIOBIOL, V29, P385, DOI 10.1007/BF00165964; Whitehead H, 1998, J ANIM ECOL, V67, P253, DOI 10.1046/j.1365-2656.1998.00187.x; WHITEHEAD H, IN PRESS CETACEAN SO; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741	43	149	150	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1708	1711		10.1126/science.282.5394.1708	http://dx.doi.org/10.1126/science.282.5394.1708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831562				2022-12-24	WOS:000077246600047
J	Holstege, FCP; Jennings, EG; Wyrick, JJ; Lee, TI; Hengartner, CJ; Green, MR; Golub, TR; Lander, ES; Young, RA				Holstege, FCP; Jennings, EG; Wyrick, JJ; Lee, TI; Hengartner, CJ; Green, MR; Golub, TR; Lander, ES; Young, RA			Dissecting the regulatory circuitry of a eukaryotic genome	CELL			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR IIE; TATA-BINDING PROTEIN; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; GENE-EXPRESSION; NUCLEOSOMAL DNA; MESSENGER-RNAS; IN-VIVO	Genome-wide expression analysis was used to identify genes whose expression depends on the functions of key components of the transcription initiation machinery in yeast. Components of the RNA polymerase II holoenzyme, the general transcription factor TFIID, and the SAGA chromatin modification complex were found to have roles in expression of distinct sets of genes. The results reveal an unanticipated level of regulation which is superimposed on that due to gene-specific transcription factors, a novel mechanism for coordinate regulation of specific sets of genes when cells encounter limiting nutrients, and evidence that the ultimate targets of signal transduction pathways can be identified within the initiation apparatus.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Martinez, Octavio/B-7375-2009; Hengartner, Christoph/AAF-5132-2021; Holstege, Frank/AAM-9944-2021; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Madhani HD, 1998, TRENDS CELL BIOL, V8, P348, DOI 10.1016/S0962-8924(98)01298-7; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUN X, 1998, MOL CELL, V2, P1; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Tijerina P, 1998, J BIOL CHEM, V273, P1107, DOI 10.1074/jbc.273.2.1107; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yin ZK, 1996, MOL MICROBIOL, V20, P751, DOI 10.1111/j.1365-2958.1996.tb02514.x	65	1546	1591	0	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					717	728		10.1016/S0092-8674(00)81641-4	http://dx.doi.org/10.1016/S0092-8674(00)81641-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845373	Bronze			2022-12-24	WOS:000077253700018
J	Ting, CT; Tsaur, SC; Wu, ML; Wu, CI				Ting, CT; Tsaur, SC; Wu, ML; Wu, CI			A rapidly evolving homeobox at the site of a hybrid sterility gene	SCIENCE			English	Article							DROSOPHILA-SIMULANS CLADE; C-ELEGANS UNC-4; REPRODUCTIVE ISOLATION; POSITIVE SELECTION; HOMEODOMAIN PROTEIN; FUSHI-TARAZU; EVOLUTION; EXPRESSION; SEQUENCE; COMPLEX	The homeodomain is a DNA binding motif that is usually conserved among diverse taxa, Rapidly evolving homeodomains are thus of interest because their divergence may be associated with speciation, The exact site of the Odysseus (Ods) locus of hybrid male sterility in Drosophila contains such a homeobox gene. In the past half million years, this homeodomain has experienced more amino acid substitutions than it did in the preceding 700 million years; during this period, it has also evolved faster than other parts of the protein or even the introns. Such rapid sequence divergence is driven by positive selection and may contribute to reproductive isolation.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Wu, CI (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57Th St, Chicago, IL 60637 USA.	ciwu@uchicago.edu		Ting, Chau-Ti/0000-0003-1802-8864; SHUN-CHERN, TSAUR/0000-0001-8358-2015				Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AYALA FJ, 1993, MOL BIOL EVOL, V10, P1030; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CABOT EL, 1994, GENETICS, V137, P175; Caccone A, 1996, MOL BIOL EVOL, V13, P1224, DOI 10.1093/oxfordjournals.molbev.a025688; CARROLL SB, 1994, DEVELOPMENT, P217; Civetta A, 1998, MOL BIOL EVOL, V15, P901, DOI 10.1093/oxfordjournals.molbev.a025994; DAWES R, 1994, DEVELOPMENT, V120, P1561; Eberhard W. G., 1985, SEXUAL SELECTION ANI; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Hayward DC, 1995, DEV BIOL, V172, P452, DOI 10.1006/dbio.1995.8030; HEY J, 1993, MOL BIOL EVOL, V10, P804; Hollocher H, 1996, GENETICS, V143, P1243; Jukes T. H., 1969, MAMMALIAN PROTEIN ME; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LEE YH, 1995, MOL BIOL EVOL, V12, P231; Lemeunier F., 1986, GENETICS BIOL DROSOP, P148; Maiti S, 1996, GENOMICS, V34, P304, DOI 10.1006/geno.1996.0291; Mansouri A, 1997, DEV DYNAM, V210, P53, DOI 10.1002/(SICI)1097-0177(199709)210:1<53::AID-AJA6>3.0.CO;2-0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MUNOZMARMOL AM, Y10299 GENB; PALOPOLI MF, 1994, GENETICS, V138, P329; PEREZ DE, 1993, GENETICS, V134, P261; PEREZ DE, 1995, GENETICS, V140, P201; PEREZ DE, 1995, THESIS U CHICAGO; Saito T, 1996, DEV BIOL, V180, P143, DOI 10.1006/dbio.1996.0291; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; TABUCHI K, 1998, 39 ANN DROS RES C WA, pC545; True JR, 1996, GENETICS, V142, P819; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Tsaur SC, 1998, MOL BIOL EVOL, V15, P1040, DOI 10.1093/oxfordjournals.molbev.a026002; WU CI, 1994, ANNU REV GENET, V28, P283, DOI 10.1146/annurev.ge.28.120194.001435; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708	37	404	410	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1501	1504		10.1126/science.282.5393.1501	http://dx.doi.org/10.1126/science.282.5393.1501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822383				2022-12-24	WOS:000077110800058
J	Cho, KO; Choi, KW				Cho, KO; Choi, KW			Fringe is essential for mirror symmetry and morphogenesis in the Drosophila eye	NATURE			English	Article							LIMB DEVELOPMENT; GENE-EXPRESSION; COMPOUND EYE; DORSAL; FURROW; INITIATION; PROPAGATION; ACTIVATION; INDUCTION; BOUNDARY	An early event in Drosophila eye development is the division of the eye disc into dorsoventral domains. The dorsoventral pattern is displayed in the adult compound eye as a distinct mirror symmetry across the dorsoventral midline or equator(1,2). The dorsoventral axis is also implicated in organizing early development of the eye, as retinal differentiation is initiated at the posterior dorsoventral midline(3). Here we show that Fringe is expressed specifically in the ventral half of the undifferentiated eye disc, thus creating a dorsoventral boundary. Ectopic Fringe borders that are generated by clones of fringe(-) cells can reverse the planar polarity of photoreceptor clusters, indicating that the Fringe boundary is crucial for the induction of mirror symmetry. Lack of a Fringe boundary disrupts equatorial expression of Notch signalling proteins and causes a complete failure of eye development. Our results indicate that the formation of the Fringe boundary and subsequent Notch signalling at the equator are essential for organizing mirror symmetry and eye morphogenesis.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Dept Ophthalmol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Choi, KW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Choi, Kwang-Wook/C-1707-2011; Cho, Kyung-Ok/C-1705-2011	Choi, Kwang-Wook/0000-0002-8997-3065; Cho, Kyung-Ok/0000-0002-0760-2560				Blair SS, 1997, CURR BIOL, V7, pR686, DOI 10.1016/S0960-9822(06)00356-3; Borod ER, 1998, DEV BIOL, V197, P187, DOI 10.1006/dbio.1998.8888; BRAND AH, 1993, DEVELOPMENT, V118, P401; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Chanut F, 1997, DEVELOPMENT, V124, P559; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; Dominguez M, 1997, GENE DEV, V11, P3254, DOI 10.1101/gad.11.23.3254; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Heberlein U, 1998, DEVELOPMENT, V125, P567; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Kehl BT, 1998, DEVELOPMENT, V125, P1217; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; MA CY, 1995, DEVELOPMENT, V121, P2279; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Netter S, 1998, GENETICS, V149, P257; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pignoni F, 1997, DEVELOPMENT, V124, P271; Royet J, 1997, DEVELOPMENT, V124, P4793; SUN YH, 1995, GENETICS, V141, P1075; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WOLFF T, 1991, DEVELOPMENT, V113, P841; XU T, 1993, DEVELOPMENT, V117, P1223; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	29	147	149	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					272	276		10.1038/24394	http://dx.doi.org/10.1038/24394			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834034				2022-12-24	WOS:000077110400049
J	Wang, HY; Oster, G				Wang, HY; Oster, G			Energy transduction in the F-1 motor of ATP synthase	NATURE			English	Article							F1-ATPASE; MECHANISM; ROTATION; CATALYSIS; TRANSPORT; SUBUNIT	ATP synthase is the universal enzyme that manufactures ATP from ADP and phosphate by using the energy derived from a transmembrane protonmotive gradient. It can also reverse itself and hydrolyse ATP to pump protons against an electrochemical gradient. ATP synthase carries out both its synthetic and hydrolytic cycles by a rotary methanism(1-4). This has been confirmed in the direction of hydrolysis(5,6) after isolation of the soluble F-1 portion of the protein and visualization of the actual rotation of the central 'shaft' of the enzyme with respect to the rest of the molecule, making ATP synthase the world's smallest rotary engine. Here we present a model for this engine that accounts for its mechanochemical behaviour in both the hydrolysing and synthesizing directions. We conclude that the pi motor achieves its high mechanical torque and almost 100% efficiency because it converts the free energy of ATP binding into elastic strain, which is then released by a coordinated kinetic and tightly coupled conformational mechanism to create a rotary torque.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Coll Nat Resources, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Oster, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 1997, J EXP BIOL, V200, P217; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GERSTEIN M, 1996, PROTEIN MOTIONS, P81; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; MATSUNOYAGI A, 1986, J BIOL CHEM, V261, P14031; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Rojnuckarin A, 1998, P NATL ACAD SCI USA, V95, P4288, DOI 10.1073/pnas.95.8.4288; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; Yasuda R, 1998, BIOPHYS J, V74, pA1	19	362	367	3	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					279	282		10.1038/24409	http://dx.doi.org/10.1038/24409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834036				2022-12-24	WOS:000077110400051
J	Zhang, J; Yu, KF				Zhang, J; Yu, KF			What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Logistic regression is used frequently in cohort studies and clinical trials. When the incidence of an outcome of interest is common in the study population (>10%), the adjusted odds ratio derived from the logistic regression can no longer approximate the risk ratio. The more frequent the outcome, the more the odds ratio overestimates the risk ratio when it is more than 1 or underestimates it when it is less than 1. We propose a simple method to approximate a risk ratio from the adjusted odds ratio and derive an estimate of an association or treatment effect that better represents the true relative risk.	NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhang, J (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bldg 6100,Room 7B03, Bethesda, MD 20892 USA.		Trajman, Anete/C-7679-2016	Trajman, Anete/0000-0002-4000-4984				Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; MANTEL N, 1959, J NATL CANCER I, V22, P719; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212	6	2900	2939	3	74	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1690	1691		10.1001/jama.280.19.1690	http://dx.doi.org/10.1001/jama.280.19.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9832001	Bronze			2022-12-24	WOS:000076980700035
J	Hadjivassiliou, M; Grunewald, R; Chattopadhyay, AK; Davies-Jones, GAB; Gibson, A; Jarratt, JA; Kandler, RH; Lobo, A; Powell, T; Smith, CML				Hadjivassiliou, M; Grunewald, R; Chattopadhyay, AK; Davies-Jones, GAB; Gibson, A; Jarratt, JA; Kandler, RH; Lobo, A; Powell, T; Smith, CML			Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia	LANCET			English	Article							ADULT CELIAC-DISEASE; VITAMIN-E-DEFICIENCY; CEREBELLAR SYNDROME; SPINOCEREBELLAR DEGENERATION; MALABSORPTION	Background Ataxia is the commonest neurological manifestation of coeliac disease. Some individuals with genetic susceptibility to the disease have serological evidence of gluten sensitivity without overt gastrointestinal symptoms or evidence of small-bower inflammation. The sole manifestation of disease in such patients may be ataxia. We describe the clinical, radiological, and neurophysiological features of this disorder. Methods Patients with ataxia attending the neurology outpatient clinics at the royal Hallamshire Hospital, Sheffield, UK, were screened for gluten sensitivity as shown by the titre of antibody to gliadin. Those with other causes of ataxia were excluded. we carried out clinical, neurophysiological, neuroradiological, and, in two cases, neuropathological examinations. Findings 28 patients with gluten ataxia were identified. All had gait ataxia and most had limb ataxia. Those with more severe gait ataxia had longer disease duration. No patient had tremor or other extrapyramidal features. 19 patients showed some form of peripheral neuropathy on neurophysiological examination. 16 patients had no gastrointestinal symptoms. Distal duodenal biopsy showed lymphocytic infiltration in two patients, and changes compatible with coeliac disease in 11. Six patients had evidence of cerebellar atrophy on magnetic-resonance imaging. Necropsy was done on two patients who died; there was lymphocytic infiltration of the cerebellum, damage to the posterior columns of the spinal cord, and sparse infiltration of the peripheral nerves. Interpretation Gluten sensitivity is an important cause of apparently idiopathic ataxia and may be progressive. The ataxia is a result of immunological damage to the cerebellum, to the posterior columns of the spinal cord, and to peripheral nerves. We propose the term gluten ataxia to describe this disorder.	Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Clin Neurophysiol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Neuroradiol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Gastroenterol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Neuropathol, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield	Hadjivassiliou, M (corresponding author), Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England.							Beversdorf D, 1996, LANCET, V347, P446, DOI 10.1016/S0140-6736(96)90014-8; BHATIA KP, 1995, BRAIN, V118, P1087, DOI 10.1093/brain/118.5.1087; CATASSI C, 1996, P 7 INT S COEL DIS S; Chinnery PF, 1997, NEUROLOGY, V49, P1131, DOI 10.1212/WNL.49.4.1131; COOKE WT, 1966, BRAIN, V89, P683, DOI 10.1093/brain/89.4.683; DICK DJ, 1995, POSTGRAD MED J, V71, P186, DOI 10.1136/pgmj.71.833.186; Elders C, 1925, LANCET, V1, P75; FINELLI PF, 1980, NEUROLOGY, V30, P245, DOI 10.1212/WNL.30.3.245; Ghezzi A, 1997, NEUROLOGY, V49, P1447, DOI 10.1212/WNL.49.5.1447; Hadjivassiliou M, 1997, J NEUROL NEUROSUR PS, V63, P770, DOI 10.1136/jnnp.63.6.770; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HADJIVASSILIOU M, 1997, J NEUROL NEUROSUR PS, V63, P267; HARDING AE, 1981, J NEUROL SCI, V51, P259, DOI 10.1016/0022-510X(81)90104-0; HARDING AE, 1982, ANN NEUROL, V12, P419, DOI 10.1002/ana.410120503; HERMASZEWSKI RA, 1991, POSTGRAD MED J, V67, P1023, DOI 10.1136/pgmj.67.793.1023; KAPLAN JG, 1988, NEUROLOGY, V38, P642, DOI 10.1212/WNL.38.4.642; KINNEY HC, 1982, J NEUROL SCI, V53, P9, DOI 10.1016/0022-510X(82)90076-4; KRISTOFERITSCH W, 1987, J NEUROL, V234, P116, DOI 10.1007/BF00314115; Lu C S, 1986, Mov Disord, V1, P209, DOI 10.1002/mds.870010306; MARSH MN, 1995, Q J MED, V85, P9; MAURO A, 1991, ACTA NEUROL SCAND, V84, P167, DOI 10.1111/j.1600-0404.1991.tb04927.x; Muller AF, 1996, AM J GASTROENTEROL, V91, P1430; Mumford CJ, 1996, J NEUROL NEUROSUR PS, V60, P225, DOI 10.1136/jnnp.60.2.225; WARD ME, 1985, NEUROLOGY, V35, P1199, DOI 10.1212/WNL.35.8.1199	24	285	291	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1582	1585		10.1016/S0140-6736(98)05342-2	http://dx.doi.org/10.1016/S0140-6736(98)05342-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843103				2022-12-24	WOS:000076998900010
J	Werk, LN; Alpert, JJ				Werk, LN; Alpert, JJ			Solid feeding guidelines	LANCET			English	Editorial Material									Boston Univ, Sch Med, Dept Gen Pediat, Boston, MA 02118 USA	Boston University	Werk, LN (corresponding author), Boston Univ, Sch Med, Dept Gen Pediat, Boston, MA 02118 USA.		Werk, Lloyd/AAI-3704-2020	Werk, Lloyd/0000-0001-9892-898X				*AM AC PED, 1998, PED NUTR HDB; BIRKBECK J, 1992, NEW ZEAL MED J, V105, P221; *DEP HLTH, 1994, REP HLTH SOC SUBJ V4; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; HENDRICKS KM, 1992, NUTR REV, V50, P125, DOI 10.1111/j.1753-4887.1992.tb01303.x; Mehta KC, 1998, PEDIATRICS, V102, P569, DOI 10.1542/peds.102.3.569; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21	9	4	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1569	1570		10.1016/S0140-6736(05)61039-2	http://dx.doi.org/10.1016/S0140-6736(05)61039-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843099				2022-12-24	WOS:000076998900005
J	Takekawa, M; Saito, H				Takekawa, M; Saito, H			A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK	CELL			English	Article							ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; GAMMA-RADIATION; EXCISION-REPAIR; KINASE CASCADES; LEUKEMIA CELLS; CHOP GADD153; GENE MYD118	The stress-responsive p38 and JNK MAPK pathways regulate cell cycle and apoptosis. A human MAPKKK, MTK1 (= MEKK4), mediates activation of both p38 and JNK in response to environmental stresses. Using a yeast two-hybrid method, three related proteins, GADD45 alpha (= GADD45), GADD45 beta (= MyD118), and GADD45 gamma, were identified that bound to an N-terminal domain of MTK1. These proteins activated MTK1 kinase activity, both in vivo and in vitro. The GADD45-like genes are induced by environmental stresses, including MMS, UV, and gamma irradiation. Expression of the GADD45-like genes induces p38/JNK activation and apoptosis, which can be partially suppressed by coexpression of a dominant inhibitory MTK1 mutant protein. We propose that the GADD45-like proteins mediate activation of the p38/JNK pathway, via MTK1/MEKK4, in response to environmental stresses.	Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Saito, H (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.	haruo_saito@dfci.harvard.edu	Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Takekawa, Mutsuhiro/0000-0002-8027-3847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056699, R01GM050909] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50909, GM56699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARTUSO M, 1995, ONCOGENE, V11, P1427; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAZANTSEV A, 1995, SCIENCE, V270, P1003, DOI 10.1126/science.270.5238.1003; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1004; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Vairapandi M, 1996, ONCOGENE, V12, P2579; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZENKE BW, 1996, CURR BIOL, V6, P606; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	49	573	600	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					521	530		10.1016/S0092-8674(00)81619-0	http://dx.doi.org/10.1016/S0092-8674(00)81619-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827804	Bronze			2022-12-24	WOS:000077049400010
J	Paetzel, M; Dalbey, RE; Strynadka, NCJ				Paetzel, M; Dalbey, RE; Strynadka, NCJ			Crystal structure of a bacterial signal peptidase in complex with a beta-lactam inhibitor	NATURE			English	Article							COLI LEADER PEPTIDASE; CATALYTICALLY ACTIVE FORM; ESCHERICHIA-COLI; PROTEIN; REQUIREMENT; DETERGENT	The signal peptidase (SPase) from Escherichia coli is a membrane-bound endopeptidase with two amino-terminal transmembrane segments and a carboxy-terminal catalytic region which resides in the periplasmic space(1). SPase functions to release proteins that have been translocated into the inner membrane from the cell interior, by cleaving off their signal peptides(1). We report here the X-ray crystal structure of a catalytically active soluble fragment of E. coli SPase (SPase Delta 2-75)(2,3). We have determined this structure at 1.9 Angstrom resolution in a complex with an inhibitor, a beta-lactam (5S,6S penem)(4,5), which is covalently bound as an acyl-enzyme intermediate to the gamma-oxygen of a serine residue at position 90, demonstrating that this residue acts as the nucleophile in the hydrolytic mechanism of signal-peptide cleavage. The structure is consistent with the use by SPase of Lys 145 as a general base in the activation of the nucleophilic Ser90, explains the specificity requirement at the signal-peptide cleavage site, and reveals a large exposed hydrophobic surface which could be a site for an intimate association with the membrane. As enzymes that are essential for cell viability, bacterial SPases present a feasible antibacterial target(4-6): our determination of the SPase structure therefore provides a template for the rational design of antibiotic compounds.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	University of British Columbia; University System of Ohio; Ohio State University	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca		Paetzel, Mark/0000-0002-7408-5487				ALLSOP AE, 1997, RECENT ADV CHEM STRU, P61; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Black MT, 1998, CURR PHARM DESIGN, V4, P133; BRUNGER AT, 1987, XPLOR SYSTEM XRAY CR; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM YT, 1995, EUR J BIOCHEM, V234, P358, DOI 10.1111/j.1432-1033.1995.358_c.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; MANARD R, 1992, BIOL CHEM HOPPESEYLE, V373, P393; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas A, 1996, BIOCHEMISTRY-US, V35, P398, DOI 10.1021/bi9515578; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PAETZEL M, 1995, PROTEINS, V23, P122, DOI 10.1002/prot.340230115; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; van Klompenburg W, 1998, FEBS LETT, V431, P75, DOI 10.1016/S0014-5793(98)00733-9; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WHITLEY P, 1993, FEBS LETT, V332, P49, DOI 10.1016/0014-5793(93)80481-9; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; [No title captured]	29	262	272	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1998	396	6707					186	190		10.1038/24196	http://dx.doi.org/10.1038/24196			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139DU	9823901				2022-12-24	WOS:000077013300057
J	Therrien, M; Wong, AM; Rubin, GM				Therrien, M; Wong, AM; Rubin, GM			CNK, a RAF-binding multidomain protein required for RAS signaling	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DEVELOPING DROSOPHILA EYE; KSR-1 GENE ENCODES; TYROSINE KINASE; SEVENLESS PROTEIN; EGF RECEPTOR; C-ELEGANS; DOMAINS; TRANSDUCTION; ACTIVATION	Kinase suppressor of ras (ksr) is required for efficient signal transmission within the RAS/MAPK cascade. A screen for mutations that modify a ksr-dependent phenotype identified a novel gene, connector enhancer of ksr (cnk), that functions upstream or in parallel to RAF in the RAS pathway, cnk encodes a protein containing several protein-protein interaction domains, suggesting that it brings different signaling molecules together. CNK is required in multiple receptor tyrosine kinase pathways where it appears to be a tyrosine phosphorylation target. Finally, CNK physically interacts with RAF and appears to localize to cell-cell contact regions. Together, these findings suggest that CNK is a novel component of a PAS-dependent signaling pathway that regulates RAF function and/or targets RAF to a specific subcellular compartment upon RAS activation.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	gerry@fruitfly.berkeley.edu		Rubin, Gerald/0000-0001-8762-8703				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GOLEMIS E, 1994, CURRENT PROTOCOL MOL; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Karim FD, 1996, GENETICS, V143, P315; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LONGLEY RL, 1995, DEV BIOL, V171, P415, DOI 10.1006/dbio.1995.1292; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MELNICK MB, 1993, DEVELOPMENT, V118, P127; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schultz J, 1997, PROTEIN SCI, V6, P249; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; XU T, 1993, DEVELOPMENT, V117, P1223; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	52	136	140	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1998	95	3					343	353		10.1016/S0092-8674(00)81766-3	http://dx.doi.org/10.1016/S0092-8674(00)81766-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814705	Bronze			2022-12-24	WOS:000076789600008
J	von der Emde, G; Schwarz, S; Gomez, L; Budelli, R; Grant, K				von der Emde, G; Schwarz, S; Gomez, L; Budelli, R; Grant, K			Electric fish measure distance in the dark	NATURE			English	Article							OBJECTS; FIELD; CUES	Distance determination in animals can be achieved by visual or non-visual cues(1). Weakly electric fish use active electrolocation for orientation in the dark(2). By perceiving self-produced electric signals with epidermal electroreceptors, fish can detect, locate and analyse nearby objects. Distance discrimination, however, was thought to be hardly possible because it was assumed that confusing ambiguity could arise with objects of unknown sizes and materials(3-5). Here we show that during electrolocation electric fish can measure the distance of most objects accurately, independently of size, shape and material, Measurements of the 'electric image' projected onto the skin surface during electrolocation(6-8) revealed only one parameter combination that was unambiguously related to object distance: the ratio between maximal image slope and maximal image amplitude. However, slope-to-amplitude ratios for spheres were always smaller than those for other objects. As predicted, these objects were erroneously judged by the fish to be further away than all other objects at an identical distance. Our results suggest a novel mechanism for depth perception that can be achieved with a single, stationary two-dimensional array of detectors.	Univ Bonn, Inst Zool, D-53115 Bonn, Germany; CNRS, Inst Alfred Fessard, F-91198 Gif Sur Yvette, France; Univ Republ Uruguay, Fac Sci, Dept Biomath, Montevideo, Uruguay	University of Bonn; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universidad de la Republica, Uruguay	von der Emde, G (corresponding author), Univ Bonn, Inst Zool, Poppelsdorfer Schloss, D-53115 Bonn, Germany.		Gomez-Sena, Leonel/ABA-9531-2020	Gomez-Sena, Leonel/0000-0002-3076-762X				Atema J, 1996, BIOL BULL, V191, P129, DOI 10.2307/1543074; BASTIAN J, 1989, COMP PERCEPTION, P35; Bleckmann H., 1989, P501; Bleckmann H, 1994, RECEPTION HYDRODYNAM; Caputi AA, 1998, J EXP BIOL, V201, P2115; Ciali S, 1997, J FISH BIOL, V50, P1074, DOI 10.1006/jfbi.1996.0372; COLLETT T, 1977, NATURE, V267, P349, DOI 10.1038/267349a0; Collett T.S., 1982, P111; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; HARKNESS L, 1977, NATURE, V267, P346, DOI 10.1038/267346a0; Hassan E.S., 1989, P217; HEILIGENBERG W, 1973, J COMP PHYSIOL, V87, P137, DOI 10.1007/BF01352158; HOERL AE, 1954, CHEM BUSINESS HDB, P20; HOPKINS CD, 1986, BRAIN BEHAV EVOLUT, V28, P43, DOI 10.1159/000118691; Howard IP, 1995, BINOCULAR VISION STE; Kral K, 1997, J INSECT BEHAV, V10, P145, DOI 10.1007/BF02765480; LEHRER M, 1988, NATURE, V332, P356, DOI 10.1038/332356a0; LISSMANN HW, 1958, J EXP BIOL, V35, P451; MOLLER P, 1979, BEHAV ECOL SOCIOBIOL, V4, P357, DOI 10.1007/BF00303242; Rasnow B, 1996, J COMP PHYSIOL A, V178, P397; Schnitzler H.-U., 1985, P180; SCHUIJF A, 1983, NATURE, V302, P143, DOI 10.1038/302143a0; SCHWARZ S, 1997, THESIS U BONN; SUGA N, 1995, ACTIVE HEARING, P13; Von der Emde G, 1998, J EXP BIOL, V201, P969; von der Emde Gerhard, 1998, P313; VONDEREMDE G, 1993, J EXP BIOL, V181, P157; WAGNER H, 1982, NATURE, V297, P147, DOI 10.1038/297147a0; Zar JH., 1999, BIOSTAT ANAL; [No title captured]	30	146	152	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					890	894		10.1038/27655	http://dx.doi.org/10.1038/27655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804420				2022-12-24	WOS:000076713400054
J	Wong, JB; Bennett, WG; Koff, RS; Pauker, SG				Wong, JB; Bennett, WG; Koff, RS; Pauker, SG			Pretreatment evaluation of chronic hepatitis C - Risks, benefits, and costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS LIVER-BIOPSY; NON-B-HEPATITIS; RECOMBINANT INTERFERON-ALFA; TERM FOLLOW-UP; CHRONIC NON-A; VIRUS GENOTYPES; PROGNOSTIC FACTORS; COMPENSATED CIRRHOSIS; RANDOMIZED TRIAL; NATURAL-HISTORY	Context.-Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response. Objective.-To examine the cost-effectiveness of alternative pretreatment management strategies for patients with CHC. Design.-Decision and cost-effectiveness analysis using a Markov model to examine prevalence of genotypes, viral load, and histological characteristics in relation to the sustained response rate with treatment. Data were based on a previously published decision model and a MEDLINE literature search for hepatitis C, biopsy, and liver from 1966 to 1996. Patients.-A hypothetical population of patients with CHC infection and elevated serum alanine aminotransferase level. Interventions.-Combinations of liver biopsy, genotyping, and quantitative viral load determination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and conservative management. Main Outcome Measures.-Proportion of sustained responders, lifetime costs, life expectancy, and quality-adjusted life expectancy. Results.-Strategies involving hepatitis C virus (HCV) RNA testing had marginal cost-effectiveness ratios up to $4400 per discounted quality-adjusted life-year gained but would miss up to 36% of sustained responders. Empirical interferon treatment had a marginal cost-effectiveness ratio of $12 400 per discounted quality-adjusted life-year gained and reached all potential sustained responders. Strategies involving liver biopsy were more expensive and would miss 6% of sustained responders and yield slightly lower life expectancies. Conclusions.-Routine liver biopsy before treatment with interferon increases the cost of managing patients with CHC without improving health outcomes. Using quantitative HCV RNA testing to guide therapy misses some potential sustained responders. Empirical interferon treatment has a marginal cost-effectiveness ratio within the bounds of other commonly accepted therapies and misses none of the sustained responders.	Tufts Univ, New England Med Ctr, Sch Med, Dept Med,Div Clin Decis Making Informat & Telemed, Boston, MA 02111 USA; Metrowest Med Ctr, Dept Med, Framingham, MA USA	Tufts Medical Center; Tufts University	Wong, JB (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Dept Med,Div Clin Decis Making Informat & Telemed, 750 Washington St,Box 302, Boston, MA 02111 USA.	john.wong@es.nemc.org		Wong, John/0000-0003-4203-9010				Alter M J, 1997, Clin Liver Dis, V1, P559, DOI 10.1016/S1089-3261(05)70321-4; ANGELINI G, 1995, DIGESTION, V56, P199, DOI 10.1159/000201243; [Anonymous], 1997, HEPATOLOGY, V26, pS2; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BATTEZZATI PM, 1992, ITAL J GASTROENTEROL, V24, P481; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; CHRISTENSEN E, 1989, SCAND J GASTROENTERO, V24, P999, DOI 10.3109/00365528909089247; CIMINO L, 1991, ITAL J GASTROENTEROL, V23, P399; COLCHER MD, 1994, HEPATOLOGY, V20, P618; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1990, J HEPATOL, V11, pS72, DOI 10.1016/0168-8278(90)90168-Q; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DETRE K, 1995, LIVER TRANSPLANTATIO; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; FRIED MW, 1995, SEMIN LIVER DIS, V15, P82, DOI 10.1055/s-2007-1007265; FROEHLICH F, 1993, DIGEST DIS SCI, V38, P1480, DOI 10.1007/BF01308607; GILMORE IT, 1995, GUT, V36, P437, DOI 10.1136/gut.36.3.437; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Gold MR, 1996, COST EFFECTIVENESS H; GORDON SC, 1994, AM J GASTROENTEROL, V89, P1458; GRETCH DR, 1995, ANN INTERN MED, V123, P321, DOI 10.7326/0003-4819-123-5-199509010-00001; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; JANES CH, 1993, ANN INTERN MED, V118, P96, DOI 10.7326/0003-4819-118-2-199301150-00003; Kaplan MM, 1993, DIS LIVER, V7, P108; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KILPE VE, 1993, TRANSPLANTATION, V56, P554, DOI 10.1097/00007890-199309000-00012; Kim WR, 1997, ANN INTERN MED, V127, P866, DOI 10.7326/0003-4819-127-10-199711150-00002; KNAUER CM, 1978, GASTROENTEROLOGY, V74, P101; Koff RS, 1997, ANN INTERN MED, V127, P918, DOI 10.7326/0003-4819-127-10-199711150-00011; Lau JYN, 1996, ANN INTERN MED, V124, P868, DOI 10.7326/0003-4819-124-10-199605150-00002; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LeGuen B, 1997, HEPATOLOGY, V25, P1250, DOI 10.1002/hep.510250531; LEVEY AS, 1987, ANN INTERN MED, V107, P697, DOI 10.7326/0003-4819-107-5-697; LINDNER H, 1967, DEUT MED WOCHENSCHR, V92, P1751, DOI 10.1055/s-0028-1106036; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; MARCELLIN P, 1995, J HEPATOL, V22, P364, DOI 10.1016/0168-8278(95)80291-6; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MATTSSON L, 1989, THESIS KAROLINSKA I; MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5; McQuillan G., 1996, American Journal of Epidemiology, V143, pS32; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; PAGLIARO L, 1994, HEPATOLOGY, V19, P820, DOI 10.1002/hep.1840190404; PEREZ R, 1993, GUT, V34, pS139, DOI 10.1136/gut.34.2_Suppl.S139; PERRAULT J, 1978, GASTROENTEROLOGY, V74, P103; PIAZZA M, 1993, GUT, V34, pS128, DOI 10.1136/gut.34.2_Suppl.S128; PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7; PICCIOTTO A, 1995, LIVER, V15, P20; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1996, HEPATOLOGY, V24, P778; Prati D, 1996, GASTROENTEROLOGY, V110, P178, DOI 10.1053/gast.1996.v110.pm8536854; QU D, 1994, J HEPATOL, V21, P70, DOI 10.1016/S0168-8278(94)80139-8; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SERFATY L, 1994, J HEPATOL, V21, P12, DOI 10.1016/S0168-8278(94)80130-4; SHERLOCK S, 1985, J HEPATOL, V1, P75, DOI 10.1016/S0168-8278(85)80070-2; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; Tarantino G, 1993, Clin Ter, V143, P489; TERRY R, 1952, BRIT MED J, V1, P1102, DOI 10.1136/bmj.1.4768.1102; THALER H., 1964, WIENER KLIN WOCHENSCH, V76, P533; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; *UNOS DIV ORG TRAN, 1995, UNOS UPDATE, V11, P15; Watson JP, 1996, GUT, V38, P269, DOI 10.1136/gut.38.2.269; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; Younossi Z, 1996, GASTROENTEROLOGY, V110, pA47; Zein NN, 1996, MAYO CLIN PROC, V71, P458, DOI 10.4065/71.5.458; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; 1993, MMWR MORB MORTAL WKL, V41, P969	82	148	151	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1998	280	24					2088	2093		10.1001/jama.280.24.2088	http://dx.doi.org/10.1001/jama.280.24.2088			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149LE	9875876	Bronze			2022-12-24	WOS:000077606100032
J	Zhang, H; Dornadula, G; Beumont, M; Livornese, L; Van Uitert, B; Henning, K; Pomerantz, RJ				Zhang, H; Dornadula, G; Beumont, M; Livornese, L; Van Uitert, B; Henning, K; Pomerantz, RJ			Human immunodeficiency virus type I in the semen of men receiving highly active antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; POLYMERASE CHAIN-REACTION; ANTIVIRAL TREATMENT; DISEASE STAGE; HIV-1; INFECTION; CELLS; IDENTIFICATION; TRANSMISSION; SPERMATOZOA	Background Highly active antiretroviral therapy can effectively decrease the revels of human immunodeficiency virus type 1 (HIV-1) virions in peripheral plasma and seminal fluid of infected men. Whether the genital tract of HIV-1-infected men who are receiving highly active antiretroviral therapy and who have no detectable virus in the peripheral plasma harbors replication-competent virus is not known. Methods We collected peripheral-blood and semen samples from seven men with HIV-1 infection who were receiving highly active antiretroviral therapy and who had no detectable viral RNA (fewer than 50 copies per milliliter) in plasma and analyzed the samples for cell-associated proviral DNA using a quantitative polymerase-chain-reaction assay. Replication-competent viruses were evaluated by cell-coculture assays. Proviral DNA and replication-competent virus obtained from peripheral-blood and seminal cells were also analyzed by sequencing relevant viral genes. Results Despite the long-term suppression of HIV-1 RNA in the plasma of the seven men, proviral DNA was detected in seminal cells in four. Replication-competent viruses were recovered from peripheral-blood cells in three men and from the seminal cells in two of these three men. The viruses recovered from the seminal cells had no genotypic mutations suggestive of resistance to antiretroviral drugs and were macrophage-tropic, a feature that is characteristic of HIV-1 strains that are capable of being sexually transmitted. Conclusions In HIV-1-infected men who are receiving highly active antiretroviral therapy and who have no detectable levels of viral RNA in plasma, the virus may be present in seminal cells and therefore may be capable of being transmitted sexually. (N Engl J Med 1998;339:1803-9.) (C) 1998, Massachusetts Medical Society.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol,Dorrance H Hamilton Labs, 1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.				NIAID NIH HHS [AI38666, AI33810] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038666, R01AI033810] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; BACCETTI B, 1994, J CELL BIOL, V127, P903, DOI 10.1083/jcb.127.4.903; BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005; Cavert W, 1997, SCIENCE, V276, P1321; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Gil T, 1995, HUM REPROD, V10, P2923, DOI 10.1093/oxfordjournals.humrep.a135821; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1998, J VIROL, V72, P2422; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HINZI D, 1998, CELL, V93, P665; HO DD, 1987, NEW ENGL J MED, V317, P278; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; NUOVO GJ, 1994, AM J PATHOL, V144, P1142; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1996, J VIROL, V70, P628, DOI 10.1128/JVI.70.1.628-634.1996; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	38	349	356	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1803	1809		10.1056/NEJM199812173392502	http://dx.doi.org/10.1056/NEJM199812173392502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854115				2022-12-24	WOS:000077545800002
J	Aractingi, S; Berkane, N; Bertheau, P; Le Goue, C; Dausset, J; Uzan, S; Carosella, ED				Aractingi, S; Berkane, N; Bertheau, P; Le Goue, C; Dausset, J; Uzan, S; Carosella, ED			Fetal DNA in skin of polymorphic eruptions of pregnancy	LANCET			English	Article							MATERNAL BLOOD; PERIPHERAL-BLOOD; CELLS; WOMEN; MICRODISSECTION; AMPLIFICATION; DERMATOSES; PCR	Background Polymorphic eruptions of pregnancy (PEP) are common cutaneous disorders of unknown origin that occur usually after week 34 of gestation. Since pregnancy is associated with peripheral-blood chimerism, particularly during the third trimester, we studied the role of fetal cells in the development of the skin lesions. Methods We studied samples of skin from ten women with PEP who were carrying male fetuses and 26 women with normal skin or non-PEP skin disorders (13 carrying male and 13 carrying female fetuses). Epidermis and dermis were dissected from the samples, and the DNA was extracted. PCR with primers specific for the SRY gene was used to detect male DNA. Findings Male DNA was detected in dermis or epidermis from skin lesions of six of the ten women with PEP. No male DNA was detected in any of the 26 women without PEP. Interpretation Fetal cells can migrate to skin during gestation, where they seem to be associated with the development of cutaneous disorders of pregnancy.	Hop Tenon, Unite Dermatol, F-75020 Paris, France; Hop Tenon, Serv Gynecol Obstet & Med Reprod, F-75020 Paris, France; Hop Tenon, UPRES EA 236, F-75020 Paris, France; CEA DRM DSV, Ctr Hayem, Serv Rech Hematoimmunol, Paris, France; Hop St Louis, Anat Pathol Lab, Paris, France; Hop St Louis, Fdn Dausset, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Aractingi, S (corresponding author), Hop Tenon, Unite Dermatol, Ap Hp,4 Rue Chine, F-75020 Paris, France.			Aractingi, Selim/0000-0002-7766-2673				Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; BORRADORI L, 1994, ARCH DERMATOL, V130, P778, DOI 10.1001/archderm.130.6.778; DAHL MV, 1984, J INVEST DERMATOL, V82, P132, DOI 10.1111/1523-1747.ep12259679; GANHIRST D, 1995, CURR OPIN GYNECOL OB, V7, P103; HALL JM, 1994, ANN NY ACAD SCI, V731, P115, DOI 10.1111/j.1749-6632.1994.tb55754.x; HOLMES RC, 1982, CLIN EXP DERMATOL, V7, P65, DOI 10.1111/j.1365-2230.1982.tb02387.x; HOLZGREVE W, 1990, LANCET, V335, P1220, DOI 10.1016/0140-6736(90)92741-Y; KAO SM, 1992, AM J OBSTET GYNECOL, V166, P1013, DOI 10.1016/0002-9378(92)91381-J; LAWLEY TJ, 1979, JAMA-J AM MED ASSOC, V241, P1696, DOI 10.1001/jama.241.16.1696; LO YMD, 1990, LANCET, V335, P1463, DOI 10.1016/0140-6736(90)91491-R; LO YMD, 1989, LANCET, V2, P1363; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; MUELLER UW, 1990, LANCET, V336, P197, DOI 10.1016/0140-6736(90)91731-O; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; ROGER D, 1994, ARCH DERMATOL, V130, P734, DOI 10.1001/archderm.130.6.734; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; RUBINOW A, 1978, ANN INTERN MED, V88, P781, DOI 10.7326/0003-4819-88-6-781; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P441, DOI 10.1136/ard.47.6.441; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	24	133	135	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1898	1901		10.1016/S0140-6736(98)05121-6	http://dx.doi.org/10.1016/S0140-6736(98)05121-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863788				2022-12-24	WOS:000077544600011
J	Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ				Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ			Intrapartum risk factors for newborn encephalopathy: the Western Australian case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; FULL-TERM INFANTS; NEONATAL ENCEPHALOPATHY; CEREBRAL-PALSY; BIRTH ASPHYXIA; BABIES; WEIGHT	Objective To identify intrapartum predictors of newborn encephalopathy in term infants. Design Population based, unmatched case-control study. Setting Metropolitan area of Western Australia-June 1993 to September 1995. Subjects All 164 term infants with moderate or ne newborn encephalopathy; 400 randomly selected controls. Main outcome measures Adjusted odds ratio estimates. Results The birth prevalence of moderate or severe newborn encephalopathy vias 3.8/1000 term live births. The neonatal fatality was 9.1%. Maternal pyrexia (odds ratio 3.82), a persistent occipitoposterior position (4.29), and an acute intrapartum event (4.44) were all risk factors for newborn encephalopathy. More case infants than control infants were induced (41.5% and 30.5%, respectively) and fewer case infants were delivered by caesarean section without labour (3.7% and 14.5%, respectively). Operative vaginal delivery (2.34) and emergency caesarean section (2.17) were both associated with an increased risk. There was an inverse relation between elective caesarean section (0.17) and newborn encephalopathy. After application of a set of consensus criteria for elective caesarean section only three (7%) eligible case mothers compared with 33 (65%) eligible control mothers were sectioned electively. Of all the case infants, 113 (69%) had only antepartum risk factors for newborn encephalopathy identified; 39 (24%) had antepartum and intrapartum factors; eight (5%) had only intrapartum factors; and four (2%) had no recognised antepartum or intrapartum factors. Conclusions The causes of newborn encephalopathy are heterogeneous and many relate to the antepartum period. Elective caesarean section has an inverse association with newborn encephalopathy. Intrapartum hypoxia alone accounts for only a small proportion of newborn encephalopathy. These results question the view that most risk factors for newborn encephalopathy lie in the intrapartum period.	TVW Telethon Inst Child Hlth Res, W Perth, WA 6872, Australia; Hornsby Ku Ring Gai Hosp, Dept Obstet & Gynaecol, Hornsby, NSW 2077, Australia; Univ Western Australia, Dept Paediat, Nedlands, WA 6907, Australia; Princess Margaret Hosp Children, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Badawi, N (corresponding author), Royal Alexandra Hosp Children, New Childrens Hosp, Dept Neonatol, POB 3515, Parramatta, NSW 2124, Australia.	nadiaB@nch.edu.au	Burton, Paul R/H-7527-2016; Badawi, Nadia/A-3179-2014					ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; Badawi N, 1998, BMJ-BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549; BERG AT, 1989, EARLY HUM DEV, V19, P271, DOI 10.1016/0378-3782(89)90062-5; DESOUZA SW, 1978, ARCH DIS CHILD, V53, P564, DOI 10.1136/adc.53.7.564; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GEE V, 1995, 12 HLTH DEP W AUSTR; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P553; LUMLEY J, 1985, CONTROL CLIN TRIALS, V6, P120, DOI 10.1016/0197-2456(85)90117-5; Murphy DJ, 1997, BMJ-BRIT MED J, V314, P404, DOI 10.1136/bmj.314.7078.404; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; Oh W, 1996, PEDIATRICS, V98, P141; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Spencer JAD, 1997, BRIT J OBSTET GYNAEC, V104, P25, DOI 10.1111/j.1471-0528.1997.tb10643.x; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; vanHam MAPC, 1997, EUR J OBSTET GYN R B, V74, P1, DOI 10.1016/S0301-2115(97)02725-5; ZIEGLER AL, 1976, HELV PAEDIATR ACTA, V31, P299	20	434	450	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1554	1558		10.1136/bmj.317.7172.1554	http://dx.doi.org/10.1136/bmj.317.7172.1554			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836653	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000077451700021
J	de Rooij, J; Zwartkruis, FJT; Verheijen, MHG; Cool, RH; Nijman, SMB; Wittinghofer, A; Bos, JL				de Rooij, J; Zwartkruis, FJT; Verheijen, MHG; Cool, RH; Nijman, SMB; Wittinghofer, A; Bos, JL			Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT; DOMAIN; CELLS; GENE; C3G	Rap1 is a small, Ras-like GTPase that was first identified as a protein that could suppress the oncogenic transformation of cells by Ras', Rap1 is activated by several extracellular stimuli(2-7) and may be involved in cellular processes such as cell proliferations(8), cell differentiation(4), T-cell anergy(2) and platelet activation(7). At least three different second messengers, namely diacylglycerol, calcium and cyclic AMP(5-7,9), able to activate Rap1 by promoting its release of the guanine nucleotide GDP and its binding to GTP. Here we report that activation of Rap1 by forskolin and cAMP occurs independently of protein kinase A (also known as cAMP-abivated protein kinase). We have cloned the gene encoding a guanine-nucleotide-exchange factor (GEF) which we have named Epac (exchange protein directly activated by cAMP). This protein contains a cAMP-binding site and a domain that is homologous to domains of known GEFs for pas and Rap1, Epac binds cAMP in vitro and exhibits in vivo and in vitro GEF activity towards Rap1, cAMP strongly induces the GEF activity of Epac towards Rap1 both in vivo and in vitro. We conclude that Epac is a GEF for Rapl that is regulated directly by cAMP and that Epac is a new target protein for cAMP.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany	Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Max Planck Society	Bos, JL (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		Verheijen, Mark/GQY-5157-2022; Verheijen, Mark/AAD-8112-2019; de rooij, johan/C-1325-2019	Verheijen, Mark/0000-0002-3739-3755; Cool, Robbert/0000-0002-9845-2202				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Herberg FW, 1997, PROTEIN SCI, V6, P569; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SINGH TJ, 1985, J BIOL CHEM, V260, P3927; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; VOSSLER MR, 1997, CELL, V89, P74; WOLFHUIS RM, 1998, MOL CELL BIOL, V18, P2486; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	25	1535	1567	1	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					474	477		10.1038/24884	http://dx.doi.org/10.1038/24884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853756				2022-12-24	WOS:000077370100056
J	Duijm, LEM; Guit, GL; Hendriks, JHCL; Zaat, JOM; Mali, WPTM				Duijm, LEM; Guit, GL; Hendriks, JHCL; Zaat, JOM; Mali, WPTM			Value of breast imaging in women with painful breasts: observational follow up study	BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY; CANCER; MANAGEMENT; MORTALITY; PUNCTURE; LESIONS; TRIALS; CYSTS	Objectives To determine the value of breast imaging in patients with localised or diffuse pain in the breast in whom physical examination shows no abnormalities. Design Observational follow up study. Setting Radiology department of a teaching hospital in the Netherlands. Subjects Altogether 987 women referred for radiological breast imaging because of pain alone and a control group of 987 asymptomatic women referred for a screening mammogram. Main outcome measures Correlation of the radiological findings rath clinical and pathological findings over two years of follow up. Results Radiological examination of the painful breast(s) showed the following: normal findings in 854 (86.5%) women, benign abnormalities in 85 (8.6%; mainly small cysts or mastopathy), abnormalities that were probably benign in 36 (3.6%), suspicious findings in 8 (0.8%), and malignancy in 4 (0.4%), Biopsy of the painful area was performed in 10 of the 939 women with normal findings or benign abnormalities, in two of 36 women with radiological abnormalities that were probably benign, and in all women with suspicious or malignant findings. Only the four lesions that had been classified radiologically as malignant were found to be malignant at surgery, The prevalence of breast cancer was similar in symptomatic and control women. Conclusions Breast imaging in women who present with pain alone is of value only in providing reassurance-no abnormalities are usually found in the painful area, radiological abnormalities classified as benign do not generally have any clinical consequences, and the prevalence of cancer is low in these women, Biopsy of the painful area should be performed only where radiological findings are suspicious.	Kennemer Gasthuis Locatie Elisabeth Gasthuis, Dept Radiol, NL-2035 RC Haarlem, Netherlands; Radboud Univ Hosp, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; Free Univ Amsterdam, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Univ Utrecht Hosp, Dept Radiol, NL-3584 CX Utrecht, Netherlands	Spaarne Hospital; Radboud University Nijmegen; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center	Duijm, LEM (corresponding author), Catharina Hosp, Dept Radiol, NL-5602 ZA Eindhoven, Netherlands.		Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BRENNER RJ, 1994, RADIOLOGY, V193, P365, DOI 10.1148/radiology.193.2.7972744; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; Duijm LEM, 1997, BRIT J CANCER, V76, P377, DOI 10.1038/bjc.1997.393; Duijm LEM, 1998, BRIT J GEN PRACT, V48, P1421; Fracheboud J, 1998, INT J CANCER, V75, P694, DOI 10.1002/(SICI)1097-0215(19980302)75:5<694::AID-IJC6>3.0.CO;2-U; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HERMANSEN C, 1987, CANCER, V60, P1866, DOI 10.1002/1097-0142(19871015)60:8<1866::AID-CNCR2820600832>3.0.CO;2-Z; JACKSON VP, 1995, RADIOL CLIN N AM, V33, P1161; LOCKER AP, 1989, LANCET, V1, P887; NAB HW, 1993, EUR J CANCER, V29A, P1557, DOI 10.1016/0959-8049(93)90294-P; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; SICKLES EA, 1995, RADIOL CLIN N AM, V33, P1123; Smith DN, 1997, RADIOLOGY, V204, P149, DOI 10.1148/radiology.204.1.9205237; TABAR L, 1981, RADIOLOGY, V141, P659, DOI 10.1148/radiology.141.3.7302219; Tilanus-Linthorst M M, 1995, Ned Tijdschr Geneeskd, V139, P445; VANOORD JC, 1991, ROFO FORTSCHR RONTG, V155, P63, DOI 10.1055/s-2008-1033220; VARAS X, 1992, RADIOLOGY, V184, P409, DOI 10.1148/radiology.184.2.1620838; WARWICK DJ, 1988, BRIT J SURG, V75, P243, DOI 10.1002/bjs.1800750319; [No title captured]	20	60	63	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1492	1495		10.1136/bmj.317.7171.1492	http://dx.doi.org/10.1136/bmj.317.7171.1492			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831579	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000077338300028
J	Kadyrov, M; Kosanke, G; Kingdom, J; Kaufmann, P				Kadyrov, M; Kosanke, G; Kingdom, J; Kaufmann, P			Increased fetoplacental angiogenesis during first trimester in anaemic women	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN PLACENTA; IRON-DEFICIENCY; MATERNAL ANEMIA; PREGNANT-WOMEN; FETAL; HYPERTENSION; LIFE	Background epidemiological studies describe an association between relative size of the placenta at delivery and cardiovascular morbidity and mortality during adult life. Some determinants of placental size, such as maternal anaemia, have been acknowledged, but no plausible mechanism has been advanced to explain the initial of postnatal disease. Methods Placental villous vascularisation in anaemic women (Hb<90 g/L) was assessed in the first and third trimesters of pregnancy by immunohistochemical identification bf villous capillaries and compared with that of gestational age-matched groups of women with normal (Hb>110 g/L; control group) concentrations of haemoglobin, and an intermediate group (Hb 90-110 g/L). Findings Anaemia, especially in the first trimester, was associated with increased numbers of capillaries per villous cross section (mean 11.70 [SE 0.35] vs 4.14 [0.27]) located mainly in the outer third of the stroma beneath the trophoblast (94% [1.15] vs 67% [1.82]) and with increased numbers of villous macrophages and of proliferating MIB-1-positive cells compared with the control group. Interpretation Maternal anaemia in early pregnancy seems to influence the pattern of placental vascularisation. Such changes might alter placental vascular impedance during early fetal life, thereby exerting important effects on cardiovascular development.	Aachen Tech Univ, Dept Anat, Fac Med, D-52057 Aachen, Germany; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev Fetal Hlth, Toronto, ON, Canada	RWTH Aachen University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Kaufmann, P (corresponding author), Aachen Tech Univ, Dept Anat, Fac Med, Wendligweg 2, D-52057 Aachen, Germany.		Kingdom, John/AAF-2145-2020; Kingdom, John/A-3247-2013					AHMED A, 1995, GROWTH FACTORS, V12, P235, DOI 10.3109/08977199509036883; Allen LH, 1997, NUTR REV, V55, P91, DOI 10.1111/j.1753-4887.1997.tb06460.x; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENIRSCHKA K, 1995, PATHOLOGY HUMAN PLAC; Burton GJ, 1996, PLACENTA, V17, P49, DOI 10.1016/S0143-4004(05)80643-5; CROWE C, 1995, J PHYSIOL-LONDON, V488, P515, DOI 10.1113/jphysiol.1995.sp020986; GUIDOZZI F, 1995, S AFR MED J, V85, P170; Hustin J, 1988, TROPHOBLAST RES, V3, P49; Jaffe R, 1997, AM J OBSTET GYNECOL, V176, P695, DOI 10.1016/S0002-9378(97)70572-6; KAUFMANN P, 1998, IN PRESS MORPHOGENES; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; Lao TT, 1997, PLACENTA, V18, P593, DOI 10.1016/0143-4004(77)90015-7; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; RESHETNIKOVA OS, 1995, AM J OBSTET GYNECOL, V173, P724, DOI 10.1016/0002-9378(95)90330-5; SHARKEY AM, 1993, J REPROD FERTIL, V99, P609; Shore VH, 1997, PLACENTA, V18, P657, DOI 10.1016/S0143-4004(97)90007-2; Singla PN, 1997, J TROP PEDIATRICS, V43, P89, DOI 10.1093/tropej/43.2.89; SUHARNO D, 1993, LANCET, V342, P1325, DOI 10.1016/0140-6736(93)92246-P; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864	20	95	100	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1747	1749						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848351				2022-12-24	WOS:000077246500010
J	Emery, P; So, WV; Kaneko, M; Hall, JC; Rosbash, M				Emery, P; So, WV; Kaneko, M; Hall, JC; Rosbash, M			CRY, a Drosophila clock and light-regulated cryptochrome, is a major contributor to circadian rhythm resetting and photosensitivity	CELL			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE; SUPRACHIASMATIC NUCLEUS; PHOTORECEPTOR FAMILY; BEHAVIORAL RHYTHMS; VISUAL-SYSTEM; PROTEIN; TIMELESS; MELANOGASTER; EXPRESSION	Light is a major environmental signal for circadian rhythms. We have identified and analyzed cry, a novel Drosophila cryptochrome gene. All characterized family members are directly photosensitive and include plant blue light photoreceptors. We show that cry transcription is under circadian regulation, influenced by the Drosophila clock genes period, timeless, Clock, and cycle. We also show that cry protein levels are dramatically affected by light exposure. Importantly, circadian photosensitivity is increased in a cry-overexpressing strain. These physiological and genetic data therefore link a specific photoreceptor molecule to circadian rhythmicity. Taken together with the data in the accompanying paper, we propose that CRY is a major Drosophila photoreceptor dedicated to the resetting of circadian rhythms.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Brandeis Univ, NSF, Ctr Biol Timing, Waltham, MA 02454 USA	Brandeis University; Brandeis University; Howard Hughes Medical Institute; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing	Rosbash, M (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02454 USA.	rosbash@brandeis.edu		Kaneko, Maki/0000-0002-2489-6185				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ASCHOFF J, 1965, CIRCADIAN CLOCKS, P94; BAER ME, 1993, J BIOL CHEM, V268, P16717; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BRAND AH, 1994, ECTOPIC EXPRESSION D, P635; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Ding JM, 1998, NATURE, V394, P381, DOI 10.1038/28639; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kaneko M, 1997, J NEUROSCI, V17, P6745; KLEMM E, 1976, PHOTOCHEM PHOTOBIOL, V24, P369, DOI 10.1111/j.1751-1097.1976.tb06838.x; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNER J, 1992, FORUM PSYCHOANAL, V8, P1; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; LINC, 1998, P NATL ACAD SCI USA, V95, P2686; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PAIETTA J, 1981, P NATL ACAD SCI-BIOL, V78, P5573, DOI 10.1073/pnas.78.9.5573; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; REDDY P, 1984, CELL, V38, P701, DOI 10.1016/0092-8674(84)90265-4; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; RUTILA JE, 1998, IN PESS J BIOL RHYTH; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SCHWARTZ WJ, 1994, NEUROSCIENCE, V58, P573, DOI 10.1016/0306-4522(94)90082-5; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Shimomura K, 1998, J BIOL RHYTHM, V13, P305, DOI 10.1177/074873098129000147; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; ZIMMERMAN WF, 1971, SCIENCE, V171, P1167, DOI 10.1126/science.171.3976.1167; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	87	664	684	4	115	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					669	679		10.1016/S0092-8674(00)81637-2	http://dx.doi.org/10.1016/S0092-8674(00)81637-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845369	Bronze			2022-12-24	WOS:000077253700014
J	Lurie, P; Miller, S; Hecht, F; Chesney, M; Lo, B				Lurie, P; Miller, S; Hecht, F; Chesney, M; Lo, B			Postexposure prophylaxis after nonoccupational HIV exposure - Clinical, ethical, and policy considerations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; SEXUAL ASSAULT; EMERGENCY CONTRACEPTION; ZIDOVUDINE TREATMENT; DRUG-USERS; TRANSMISSION; INFECTION; RISK; MODEL	In the wake of recent breakthroughs in antiviral therapies and Centers far Disease Control and Prevention (CDC) recommendations advocating occupational postexposure prophylaxis (PEP), health care workers are increasingly receiving inquiries about PEP following exposures to the human immunodeficiency virus (HIV) through sex and injection drug use. The probability of HIV transmission by certain sexual or injection drug exposures is of the same order of magnitude as percutaneous occupational exposures for which the CDC recommends PEP. In such cases, if the exposure is sporadic, it seems appropriate to extrapolate from the data on occupational PEP and recommend prophylaxis. However, for individuals with continuing or low-risk exposures, we instead recommend referrals to state-of-the-art risk reduction programs. Clinicians, using local HIV seroprevalence data and their knowledge of transmission probabilities, can help exposed patients make an informed decision regarding PEP. Because of the large number of risky encounters that will not be treated prophylactically, even after significant outreach efforts, public health interventions that emphasize PEP as part of a comprehensive HIV prevention program should be confined to cities with highest HIV prevalences.	Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr AIDS Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Gen Internal Med, Program Med Eth, San Francisco, CA 94143 USA; Publ Citizens Hlth Res Grp, Washington, DC USA; Univ Calif Berkeley, Sch Publ Hlth, Maternal & Child Hlth Program, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Lo, B (corresponding author), Room C126,521 Parnassus Ave, San Francisco, CA 94143 USA.	Bernie@itsa.ucsf.edu		Hecht, Frederick/0000-0002-5782-1171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAGSHAW SN, 1988, AUST NZ J OBSTET GYN, V28, P137, DOI 10.1111/j.1479-828X.1988.tb01643.x; BASHAM T, 1990, J INFECT DIS, V161, P1006, DOI 10.1093/infdis/161.5.1006; Beauchamp TL, 2001, PRINCIPLES BIOMEDICA, V5th; BROWN WF, 1998, MAYORS SUMMIT AIDS H; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468; *CDCP, 1995, NAT HIV SER SUMM UPD, V3; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929; CHESNEY M, IN PRESS SEXUALLY TR; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CRAIB KJP, 1995, GENITOURIN MED, V71, P150, DOI 10.1136/sti.71.3.150; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; ELLERTSON C, 1995, STUD FAMILY PLANN, V26, P251, DOI 10.2307/2138011; EMERY T, 1997, BOSTON GLOBE    0113, pC1; Emini EA, 1995, ADV EXP MED BIOL, V390, P187; FABIAN R, 1994, VALUING HLTH POLICY, P118; Fishbein M., 1994, PREVENTING AIDS THEO, P61; Freeman RC, 1996, AIDS EDUC PREV, V8, P58; GAUGHWIN MD, 1991, AIDS, V5, P1025, DOI 10.1097/00002030-199108000-00016; GAYLE HD, 1990, NEW ENGL J MED, V323, P1538, DOI 10.1056/NEJM199011293232206; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; Katz MH, 1998, ANN INTERN MED, V128, P306, DOI 10.7326/0003-4819-128-4-199802150-00012; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LEBLANC S, 1996, YOUR MONEY YOUR LIFE; Ledray L E, 1993, AWHONNS Clin Issues Perinat Womens Health Nurs, V4, P180; Leland J, 1996, Newsweek, V128, P64; Li RW, 1997, NEW ENGL J MED, V337, P499, DOI 10.1056/NEJM199708143370714; Lipsky JJ, 1996, LANCET, V348, P800, DOI 10.1016/S0140-6736(95)12333-4; LO B, 1995, RESOLVING ETHICAL DI; Martin JP, 1998, 38 INT C ANT AG CHEM; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; Mayer KH, 1995, INFECT AGENT DIS, V4, P273; Montoya ID, 1996, J ACQ IMMUN DEF SYND, V13, P169, DOI 10.1097/00042560-199610010-00008; *NAT VICT CTR, 1992, NAT WOM STUD RAP AM; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; OKIE S, 1997, WASHINGTON POST 0204, pZ13; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; PADIAN NS, 1995, J INFECT DIS, V172, P1084, DOI 10.1093/infdis/172.4.1084; PAINTER K, 1997, US TODAY        1103, pD1; PERLMAN D, 1997, SAN FRANCISCO C 1014, pA2; Pinkerton SD, 1997, NEW ENGL J MED, V337, P500; RAMBOW B, 1992, ANN EMERG MED, V21, P727, DOI 10.1016/S0196-0644(05)82788-X; ROSENSTOCK S, 1994, PREVENTING AIDS THEO, P5; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; SEIDLIN M, 1993, AIDS, V7, P1247, DOI 10.1097/00002030-199309000-00015; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; SMITH LFP, 1995, BRIT J GEN PRACT, V45, P409; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; SULLIVAN A, 1996, NY TIMES MAGAZI 1110, P52; SULLIVAN A, 1996, NY TIMES MAGAZI 1110, P84; SULLIVAN A, 1996, NY TIMES MAGAZI 1110, P77; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Vanchieri C, 1996, ANN INTERN MED, V125, pI61; YOUNG WW, 1992, OBSTET GYNECOL, V80, P878	61	62	62	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1769	1773		10.1001/jama.280.20.1769	http://dx.doi.org/10.1001/jama.280.20.1769			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HF	9842953				2022-12-24	WOS:000077081400033
J	Jacobson, B; Bygdeman, M				Jacobson, B; Bygdeman, M			Obstetric care and proneness of offspring to suicide as adults: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ADDICTION	Objective To investigate any long term effects of traumatic birth and obstetric procedures in relation to suicide by violent means in offspring as adults. Design Prospective case-control study. Setting Stockholm, Sweden. Subjects 242 adults who committed suicide by violent means from 1978 to 1995, and who were born in one of seven hospitals in Stockholm during 1945-80, matched with 403 biological siblings born during the same period and at the same group of hospitals. Main outcome measures Adverse and beneficial perinatal factors expressed as relative risks (odds ratios) and 95% confidence intervals, derived from logistic regression of cases matched with their siblings. Results For multiple birth trauma the estimated relative risks of offspring subsequently committing suicide by violent means were 4.9 (95% confidence interval 1.8 to 13) for men and 1.04 (0.2 to 4.6) for women. In mothers who received multiple opiate treatment during delivery, the estimated relative risk of offspring subsequently committing suicide was equal for both sexes (0.26, 0.09 to 0.69). Conclusion Minimising pain and discomfort to the infant during birth seems to be of importance in reducing the risk of committing suicide by violent means as an adult.	Huddinge Univ Hosp, Dept Med Engn, SE-14186 Huddinge, Sweden; Karolinska Hosp, Dept Obstet & Gynaecol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Jacobson, B (corresponding author), Huddinge Univ Hosp, Dept Med Engn, F60 Novum, SE-14186 Huddinge, Sweden.							Breslow NE, 1980, IARC SCI PUBL, V32, P248; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; JACOBSON B, 1990, BRIT MED J, V301, P1067, DOI 10.1136/bmj.301.6760.1067; JACOBSON B, 1987, ACTA PSYCHIAT SCAND, V76, P364, DOI 10.1111/j.1600-0447.1987.tb05620.x; JAMES H., 1962, ANIMAL BEHAVIOUR, V10, P341, DOI 10.1016/0003-3472(62)90057-X; Nyberg K, 1993, Paediatr Perinat Epidemiol, V7, P23, DOI 10.1111/j.1365-3016.1993.tb00598.x; SALK L, 1985, LANCET, V1, P624; WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371	8	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1346	1349		10.1136/bmj.317.7169.1346	http://dx.doi.org/10.1136/bmj.317.7169.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812930	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000077081600018
J	Broun, P; Shanklin, J; Whittle, E; Somerville, C				Broun, P; Shanklin, J; Whittle, E; Somerville, C			Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids	SCIENCE			English	Article							CARRIER-PROTEIN DESATURASE; ARABIDOPSIS-THALIANA; DIIRON; HYDROXYLATION; MOSSBAUER	Higher plants exhibit extensive diversity in the composition of seed storage fatty acids. This is Largely due to the presence of various combinations of double or triple bonds and hydroxyl or epoxy groups, which are synthesized by a family of structurally similar enzymes. As few as four amino acid substitutions can convert an oleate 12-desaturase to a hydroxylase and as few as six result in conversion of a hydroxylase;to a desaturase. These results illustrate how catalytic plasticity of these diiron enzymes has contributed to the evolution of the chemical diversity found in higher plants.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Carnegie Institution for Science	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.		Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Shanklin, John/0000-0002-6774-8043				Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; BROUN P, UNPUB; Buist PH, 1998, J AM CHEM SOC, V120, P871, DOI 10.1021/ja971362i; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kim C, 1997, J AM CHEM SOC, V119, P3635, DOI 10.1021/ja963578a; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; MOREAU RA, 1981, PLANT PHYSIOL, V67, P672, DOI 10.1104/pp.67.4.672; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; VANDELOO F, 1993, PLANT LIPIDS, P91; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743	20	197	695	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1315	1317		10.1126/science.282.5392.1315	http://dx.doi.org/10.1126/science.282.5392.1315			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812895				2022-12-24	WOS:000076982200044
J	Baukrowitz, T; Schulte, U; Oliver, D; Herlitze, S; Krauter, T; Tucker, SJ; Ruppersberg, JP; Fakler, B				Baukrowitz, T; Schulte, U; Oliver, D; Herlitze, S; Krauter, T; Tucker, SJ; Ruppersberg, JP; Fakler, B			PIP2 and PIP as determinants for ATP inhibition of K-ATP channels	SCIENCE			English	Article							SENSITIVE POTASSIUM CHANNELS; SULFONYLUREA RECEPTOR; DIAZOXIDE; PROTEIN	Adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels couple electrical activity to Cellular metabolism through their inhibition by intracellular ATP. ATP inhibition of K-ATP channels varies among tissues and is affected by the metabolic and regulatory state of individual cells, suggesting involvement of endogenous factors. It is reported here that phosphatidylinositol-4,5-bisphosphate (PIP2) and phosphatidylinositol-4-phosphate (PIP) controlled ATP inhibition of cloned K-ATP channels (K(ir)6.2 and SUR1). These phospholipids acted on the K(ir)6.2 subunit and shifted ATP sensitivity by several orders of magnitude. Receptor-mediated activation of phospholipase C resulted in inhibition of K-ATP-mediated currents. These results represent a mechanism for control of excitability through phospholipids.	Univ Tubingen, Dept Physiol 2, D-72076 Tubingen, Germany; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Eberhard Karls University of Tubingen; University of Oxford	Fakler, B (corresponding author), Univ Tubingen, Dept Physiol 2, Gmelinstr 5, D-72076 Tubingen, Germany.	bernd.fakler@uni-tuebingen.de	Tucker, Stephen J./ABE-7468-2020; Oliver, Dominik/F-5845-2013	Tucker, Stephen J./0000-0001-8996-2000; Oliver, Dominik/0000-0002-8368-0923; Baukrowitz, Thomas/0000-0003-4562-0505				Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; BORDIN S, 1995, J MEMBRANE BIOL, V148, P177; Burnstock G, 1996, CIBA F SYMP, V198, P1; CAMERON JS, 1994, CARDIOVASC RES, V28, P788, DOI 10.1093/cvr/28.6.788; EDWARDS G, 1995, CARDIOVASC DRUG THER, V9, P185, DOI 10.1007/BF00878465; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FOSSET M, 1988, FEBS LETT, V242, P94, DOI 10.1016/0014-5793(88)80992-X; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HENRY P, 1994, CARDIOVASC RES, V28, P754, DOI 10.1093/cvr/28.6.754; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; King BF, 1996, J PHYSIOL-LONDON, V494, P17, DOI 10.1113/jphysiol.1996.sp021472; MOSBACHER J, IN PRESS FEBS LETT; Oliver D, 1998, BIOPHYS J, V74, P2318, DOI 10.1016/S0006-3495(98)77941-X; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; TERZIC A, 1994, NEURON, V12, P885, DOI 10.1016/0896-6273(94)90340-9; Tricarico D, 1997, EUR J PHARMACOL, V321, P369, DOI 10.1016/S0014-2999(96)00965-X; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409	22	429	435	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1141	1144		10.1126/science.282.5391.1141	http://dx.doi.org/10.1126/science.282.5391.1141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804555				2022-12-24	WOS:000076887700055
J	Gainetdinov, RR; Wetsel, WC; Jones, SR; Levin, ED; Jaber, M; Caron, MG				Gainetdinov, RR; Wetsel, WC; Jones, SR; Levin, ED; Jaber, M; Caron, MG			Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity	SCIENCE			English	Article							DOPAMINE TRANSPORTER; MICE LACKING; D-AMPHETAMINE; ATTENTION; DISORDER; BEHAVIOR; COCAINE; BRAIN; NOREPINEPHRINE; INHIBITION	The mechanism by which psychostimulants act as calming agents in humans with attention-deficit hyperactivity disorder (ADHD) or hyperkinetic disorder is currently unknown. Mice Lacking the gene encoding the plasma membrane dopamine transporter (DAT) have elevated dopaminergic tone and are hyperactive. This activity was exacerbated by exposure to a novel environment. Additionally, these mice were impaired in spatial cognitive fund:ion, and they showed a decrease in locomotion in response to psychostimulants. This paradoxical calming effect of psychostimulants depended on serotonergic neurotransmission. The parallels between the DAT knockout mice and individuals with ADHD suggest that common mechanisms may underlie some of their behaviors and responses to psychostimulants.	Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Endocrinol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA.		Levin, Edward/GLV-2991-2022; Jones, Sara R/K-4816-2014; Gainetdinov, Raul R/G-5875-2011	Jones, Sara R/0000-0002-3424-7576; Gainetdinov, Raul R/0000-0003-2951-6038; Jaber, Mohamed/0000-0003-2536-1913	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040159, P30MH040159] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-40159] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; Barkley R. A, 2014, ATTENTION DEFICIT HY; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Baumgarten HG, 1995, PHARMACOPSYCHIATRY, V28, P73, DOI 10.1055/s-2007-979623; Bosse R, 1997, NEURON, V19, P127, DOI 10.1016/S0896-6273(00)80353-0; Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; BRASE DA, 1975, LIFE SCI, V16, P1005, DOI 10.1016/0024-3205(75)90184-8; BREESE GR, 1975, PSYCHOPHARMACOLOGIA, V44, P5, DOI 10.1007/BF00421175; Broderick PA, 1997, NEUROSCI BIOBEHAV R, V21, P227, DOI 10.1016/S0149-7634(96)00048-6; BRODIE BB, 1957, ANN NY ACAD SCI, V66, P631, DOI 10.1111/j.1749-6632.1957.tb40753.x; Carlsson A., 1987, PSYCHOPHARMACOLOGY 3, P39; Collins P, 1998, J COGNITIVE NEUROSCI, V10, P332, DOI 10.1162/089892998562771; COOK EH, 1995, AM J HUM GENET, V56, P993; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gainetdinov RR, 1998, BRAIN RES REV, V26, P148, DOI 10.1016/S0165-0173(97)00063-5; GAINETDINOV RR, UNPUB; Geyer MA, 1996, BEHAV BRAIN RES, V73, P31; Gill M, 1997, MOL PSYCHIATR, V2, P311, DOI 10.1038/sj.mp.4000290; Gingerich KJ, 1998, J CLIN PSYCHOL, V54, P415, DOI 10.1002/(SICI)1097-4679(199806)54:4<415::AID-JCLP3>3.0.CO;2-M; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GREEN TK, 1974, J PHARMACOL EXP THER, V190, P109; GREENHILL LL, 1992, PSYCHIAT CLIN N AM, V15, P1; HARLOW H F, 1948, Res Publ Assoc Res Nerv Ment Dis, V27 (1 vol.), P446; HECHTMAN L, 1994, J PSYCHIATR NEUROSCI, V19, P193; HEFFNER TG, 1982, BRAIN RES, V244, P81, DOI 10.1016/0006-8993(82)90906-4; HOLLISTER AS, 1976, J PHARMACOL EXP THER, V198, P12; Hornig M, 1998, J CLIN PSYCHIAT, V59, P69; JAFFE SL, 1991, J AM ACAD CHILD PSY, V30, P773, DOI 10.1097/00004583-199109000-00012; Jensen PS, 1997, J AM ACAD CHILD PSY, V36, P1672, DOI 10.1097/00004583-199712000-00015; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Jones SR, 1998, J NEUROSCI, V18, P1979; KOKKINIDIS L, 1980, PSYCHOL BULL, V88, P551; KOSTRZEWA RM, 1994, BRAIN RES BULL, V34, P161, DOI 10.1016/0361-9230(94)90013-2; KOYUNCUOGLU H, 1975, PSYCHOPHARMACOLOGIA, V45, P163, DOI 10.1007/BF00429055; Kuczenski R, 1997, J NEUROCHEM, V68, P2032; LEHNERT H, 1993, PSYCHOTHER PSYCHOSOM, V60, P18, DOI 10.1159/000288676; LeMarquand DG, 1998, NEUROPSYCHOPHARMACOL, V19, P333; Levin ED, 1997, ENVIRON HEALTH PERSP, V105, P1320, DOI 10.2307/3433751; Lucki I, 1998, BIOL PSYCHIAT, V44, P151, DOI 10.1016/S0006-3223(98)00139-5; MABRY PD, 1973, BRAIN RES, V49, P381, DOI 10.1016/0006-8993(73)90429-0; MILSON JA, 1976, BRIT J PHARMACOL, V56, P77, DOI 10.1111/j.1476-5381.1976.tb06961.x; Popper CW, 1997, J CLIN PSYCHIAT, V58, P14; Reith MEA, 1997, NEUROTRANSMITTER TRA; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; RIDLEY RM, 1994, PROG NEUROBIOL, V44, P221, DOI 10.1016/0301-0082(94)90039-6; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; Robbins TW, 1998, ANN NY ACAD SCI, V846, P222, DOI 10.1111/j.1749-6632.1998.tb09740.x; ROBBINS TW, 1979, NEUROPHARMACOLOGY, V18, P931, DOI 10.1016/0028-3908(79)90157-6; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; Seiden L.S., 1995, HDB NEUROTOXICOLOGY, P825; SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pa.33.040193.003231; SHUSTER L, 1982, PSYCHOPHARMACOLOGY, V77, P31, DOI 10.1007/BF00436096; SNYDER SH, 1973, ANN NY ACAD SCI, V205, P310, DOI 10.1111/j.1749-6632.1973.tb43188.x; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; Swanson J, 1998, CURR OPIN NEUROBIOL, V8, P263, DOI 10.1016/S0959-4388(98)80150-5; SWANSON JM, 1996, CURR OPIN PSYCHIATR, V10, P300; TAGLIAMONTE A, 1973, LIFE SCI 2-BIOCH GEN, V12, P277, DOI 10.1016/0024-3205(73)90361-5; TAYLOR D, 1978, RES COMMUN CHEM PATH, V21, P67; TAYLOR KM, 1971, BRAIN RES, V28, P295, DOI 10.1016/0006-8993(71)90661-5; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; WESTERINK BHC, 1991, J NEUROCHEM, V56, P228, DOI 10.1111/j.1471-4159.1991.tb02585.x; WETSEL WC, UNPUB; White FJ, 1998, NATURE, V393, P118, DOI 10.1038/30105; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; World Health Organisation, 1993, ICD 10 CLASS MENT BE; Young SN, 1996, NEUROSCI BIOBEHAV R, V20, P313, DOI 10.1016/0149-7634(95)00022-4	70	629	650	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					397	401		10.1126/science.283.5400.397	http://dx.doi.org/10.1126/science.283.5400.397			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	157MV	9888856				2022-12-24	WOS:000078067000050
J	Kelley, SO; Barton, JK				Kelley, SO; Barton, JK			Electron transfer between bases in double helical DNA	SCIENCE			English	Article							DISTANCE DEPENDENCE; DUPLEX DNA; FLUORESCENCE; ADENOSINE; 2-AMINOPURINE; POTENTIALS; OXIDATION; GUANOSINE; GUANINE; MOMENTS	Fluorescent analogs of adenine that selectively oxidize guanine were used to investigate photoinduced electron transfer through the DNA pi-stack as a function of reactant stacking and energetics. Small variations in these factors led to profound changes in the kinetics and distance dependences of DNA-mediated electron-transfer reactions. Values of beta, a parameter reflecting the dependence of electron transfer on distance, ranged from 0.1 to 1.0 per angstrom. Strong stacking interactions result in the fastest electron-transfer kinetics. Electrons are thus transported preferentially through an intrastrand rather than interstrand pathway. Reactant energetics also modulate the distance dependence of DNA-mediated charge transport. These studies may resolve the range of disparate results previously reported, and paradigms must now be developed to describe these properties of the DNA pi-stack, which can range from insulator- to "wire"-like.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Barton, JK (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.		Kelley, Shana/ABA-7403-2021; Kelley, Shana/H-5856-2015	Kelley, Shana/0000-0003-3360-5359	NIGMS NIH HHS [GM49216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Arkin MR, 1997, CHEM BIOL, V4, P389, DOI 10.1016/S1074-5521(97)90129-0; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; Broo A, 1998, J PHYS CHEM A, V102, P526, DOI 10.1021/jp9713625; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Dandliker PJ, 1998, BIOCHEMISTRY-US, V37, P6491, DOI 10.1021/bi980041w; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; FELTS AK, 1995, J PHYS CHEM-US, V99, P2929, DOI 10.1021/j100009a057; Fukui K, 1998, ANGEW CHEM INT EDIT, V37, P158, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<158::AID-ANIE158>3.0.CO;2-L; Gasper SM, 1997, J AM CHEM SOC, V119, P12762, DOI 10.1021/ja972496z; Georghiou S, 1996, BIOPHYS J, V70, P1909, DOI 10.1016/S0006-3495(96)79755-2; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; Hall DB, 1997, J AM CHEM SOC, V119, P5045, DOI 10.1021/ja970366k; HOLMEN A, 1994, J PHYS CHEM-US, V98, P13460, DOI 10.1021/j100102a006; Holmen A, 1997, J AM CHEM SOC, V119, P3114, DOI 10.1021/ja9635600; HOLMLIN RE, 1997, ANGEW CHEM INT EDIT, V36, P2714; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; Kelley SO, 1997, J AM CHEM SOC, V119, P9861, DOI 10.1021/ja9714651; KELLEY SO, IN PRESS MET IONS BI; KELLEY SO, IN PRESS ANGEW CHEM; KELLEY SO, 1997, CHEM BIOL, V8, P413; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1820, DOI 10.1021/bi00221a014; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEADE TJ, 1995, ANGEW CHEM INT EDIT, V34, P352, DOI 10.1002/anie.199503521; Meggers E, 1998, ANGEW CHEM INT EDIT, V37, P460, DOI 10.1002/(SICI)1521-3773(19980302)37:4<460::AID-ANIE460>3.0.CO;2-U; MURPHY CJ, 1994, P NATL ACAD SCI USA, V91, P5315, DOI 10.1073/pnas.91.12.5315; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; NORLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095; Okada A, 1998, J PHYS CHEM A, V102, P1241, DOI 10.1021/jp972918r; Priyadarshy S, 1998, J BIOL INORG CHEM, V3, P196, DOI 10.1007/s007750050221; REGAN JJ, 1995, CHEM BIOL, V2, P489, DOI 10.1016/1074-5521(95)90266-X; Saenger W., 1984, PRINCIPLES NUCL ACID; SANTHOSH C, 1991, SPECTROCHIM ACTA A, V47, P1685, DOI 10.1016/0584-8539(91)80006-5; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; Seidel CAM, 1996, J PHYS CHEM-US, V100, P5541, DOI 10.1021/jp951507c; SPENCER RD, 1974, EUR J BIOCHEM, V45, P425, DOI 10.1111/j.1432-1033.1974.tb03566.x; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Stemp EDA, 1997, J AM CHEM SOC, V119, P2921, DOI 10.1021/ja963606p; WARD DC, 1969, J BIOL CHEM, V244, P1228; WOITELLIER S, 1989, INORG CHEM, V28, P758, DOI 10.1021/ic00303a029	44	804	818	2	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					375	381		10.1126/science.283.5400.375	http://dx.doi.org/10.1126/science.283.5400.375			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888851				2022-12-24	WOS:000078067000045
J	Phillips, KA; Glendon, G; Knight, JA				Phillips, KA; Glendon, G; Knight, JA			Putting the risk of breast cancer in perspective	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PERCEIVED RISK; WOMEN; AGE; TRENDS		Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Canc Care Ontario, Toronto, ON M5G 2L7, Canada; Ontario Canc Genet Networks, Toronto, ON M5G 2L7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cancer Care Ontario	Phillips, KA (corresponding author), Peter MacCallum Canc Inst, Dept Med Oncol & Hematol, Locked Bag 1,A Becket St, Melbourne, Vic 3000, Australia.		Knight, Julia/R-5617-2019; Knight, Julia/A-6843-2012	Knight, Julia/0000-0002-7610-7635; Phillips, Kelly-Anne/0000-0002-0475-1771				Alexander NE, 1996, J GEN INTERN MED, V11, P92, DOI 10.1007/BF02599584; *AM CANC SOC, 1998, CANC FACTS FIG 1998, P4; BAINES CJ, 1992, CAN MED ASSOC J, V146, P2147; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Dolan NC, 1997, CANCER, V80, P413; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; Hebert-Croteau N, 1997, CAN J PUBLIC HEALTH, V88, P392, DOI 10.1007/BF03403913; *NAT COUNC AG, 1997, MYTHS PERC AG WOM HL; *NCI CAN, 1998, CAN CANC STAT; Smith BL, 1996, SURGERY, V120, P297, DOI 10.1016/S0039-6060(96)80301-1; WUN LM, 1995, CANCER CAUSE CONTROL, V6, P135, DOI 10.1007/BF00052774; 1997, LANCET, V350, P1563	13	83	83	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1999	340	2					141	144		10.1056/NEJM199901143400211	http://dx.doi.org/10.1056/NEJM199901143400211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156RQ	9887168				2022-12-24	WOS:000078016200011
J	Qi, HL; Rand, MD; Wu, XH; Sestan, N; Wang, WY; Rakic, P; Xu, T; Artavanis-Tsakonas, S				Qi, HL; Rand, MD; Wu, XH; Sestan, N; Wang, WY; Rakic, P; Xu, T; Artavanis-Tsakonas, S			Processing of the Notch ligand delta by the metalloprotease kuzbanian	SCIENCE			English	Article							CELL FATE; DROSOPHILA; RECEPTOR; PROTEIN; SERRATE; CHOICE	Signaling by the Notch surface receptor controls cell fate determination in a broad spectrum of tissues. This signaling is triggered by the interaction of the Notch protein with what, so far, have been thought to be transmembrane ligands expressed on adjacent cells. Here biochemical and genetic analyses show that the ligand Delta is cleaved on the surface, releasing an extracellular fragment capable of binding to Notch and acting as an agonist of Notch activity. The ADAM disintegrin metalloprotease Kuzbanian is required for this processing event. These observations raise the possibility that Notch signaling in vivo is modulated by soluble forms of the Notch ligands.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Genet, New Haven, CT 06536 USA; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China; Yale Univ, Sch Med, Boyer Ctr Mol Med, Neurobiol Sect, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University; Fudan University; Yale University	Artavanis-Tsakonas, S (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084, R01NS014841] Funding Source: NIH RePORTER; NINDS NIH HHS [NS14841, NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Klueg KM, 1998, MOL BIOL CELL, V9, P1709, DOI 10.1091/mbc.9.7.1709; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; QI H, UNPUB; RAMOS RGP, 1989, GENETICS, V123, P337; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, THESIS YALE U; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SESTAN N, UNPUB; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Sun X, 1997, DEVELOPMENT, V124, P3439; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wu X., UNPUB	21	368	380	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1999	283	5398					91	94		10.1126/science.283.5398.91	http://dx.doi.org/10.1126/science.283.5398.91			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155ZH	9872749				2022-12-24	WOS:000077976600057
J	Kato, Y; Tani, T; Sotomaru, Y; Kurokawa, K; Kato, JY; Doguchi, H; Yasue, H; Tsunoda, Y				Kato, Y; Tani, T; Sotomaru, Y; Kurokawa, K; Kato, JY; Doguchi, H; Yasue, H; Tsunoda, Y			Eight calves cloned from somatic cells of a single adult	SCIENCE			English	Article							FETAL	Eight carves were derived from differentiated cells of a single adult cow, five from cumulus cells and three from oviductal cells out of 10 embryos transferred to surrogate cows (80 percent success). ALL carves were visibly normal, but four died at or soon after birth from environmental causes, and postmortem analysis revealed no abnormality. These results show that bovine cumulus and oviductal epithelial cells of the adult have the genetic content to direct the development of newborn carves.	Kinki Univ, Coll Agr, Lab Anim Reprod, Nara 6318505, Japan; Kinki Univ, Res Inst Anim Dev Biotechnol, Nara 6318505, Japan; Minist Agr Forestry & Fisheries, Natl Inst Anim Ind, Dept Anim Breeding & Genet, Tsukuba, Ibaraki 3050901, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Ministry of Agriculture Forestry & Fisheries - Japan; National Agriculture & Food Research Organization - Japan	Tsunoda, Y (corresponding author), Kinki Univ, Coll Agr, Lab Anim Reprod, 3327-204 Nakamachi, Nara 6318505, Japan.		Kurokawa, Kazuo/E-9130-2013; tani, tetsuya/AAR-7581-2021	Kurokawa, Kazuo/0000-0003-3549-4795; tani, tetsuya/0000-0001-5276-8941				BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BRIGS R, 1960, DEV BIOL, V2, P252, DOI 10.1016/0012-1606(60)90008-7; CIBELLI JB, 1998, NATURE, V280, P1256; DIBERARDINO MA, 1997, GENOMIC POTENTIAL DI; DORLAND M, 1997, J REPROD FERTIL, V20, P31; Garry FB, 1996, THERIOGENOLOGY, V45, P141, DOI 10.1016/0093-691X(95)00363-D; Inoue-Murayama Miho, 1997, Animal Science and Technology, V68, P443; JOSHI MS, 1988, J REPROD FERTIL, V83, P249, DOI 10.1530/jrf.0.0830249; Kato Y., UNPUB; REIK W, 1993, DEVELOPMENT, V119, P933; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROSENKRANS C F JR, 1991, Theriogenology, V35, P266, DOI 10.1016/0093-691X(91)90242-6; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	15	783	932	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2095	2098		10.1126/science.282.5396.2095	http://dx.doi.org/10.1126/science.282.5396.2095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851933				2022-12-24	WOS:000077467100051
J	Ungermann, C; Sato, K; Wickner, W				Ungermann, C; Sato, K; Wickner, W			Defining the functions of trans-SNARE pairs	NATURE			English	Article							MEMBRANE-FUSION COMPLEX; VACUOLE INHERITANCE; IN-VITRO; CLOSTRIDIAL NEUROTOXINS; VESICLE FUSION; YEAST VACUOLES; ALPHA-SNAP; DOCKING; NSF; SYNAPTOBREVIN	The homotypic fusion of yeast vacuoles includes a 'docking' step, which we show here to consist of two sequential reactions: a reversible 'tethering' mediated by the GTPase Ypt7, and 'SNARE pairing', in which SNARE proteins from opposite membranes form a complex in trans. The function of this trans-SNARE complex must be transient, as the complex can be disassembled by excess Sec18 in the presence of Sec17 and ATP without influencing the fusion rate. These data Indicate that SNARE pairing may transiently signal to downstream factors, leading to fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Ungermann, C (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Christian.Ungermann@Dartmouth.edu						BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JAHN R, 1994, ANN NY ACAD SCI, V733, P245, DOI 10.1111/j.1749-6632.1994.tb17274.x; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Sato K, 1998, SCIENCE, V281, P700, DOI 10.1126/science.281.5377.700; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9	34	286	290	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					543	548		10.1038/25069	http://dx.doi.org/10.1038/25069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859990				2022-12-24	WOS:000077466800048
J	Kiselyov, K; Xu, X; Mozhayeva, G; Kuo, T; Pessah, I; Mignery, G; Zhu, X; Birnbaumer, L; Muallem, S				Kiselyov, K; Xu, X; Mozhayeva, G; Kuo, T; Pessah, I; Mignery, G; Zhu, X; Birnbaumer, L; Muallem, S			Functional interaction between InsP(3) receptors and store-operated Htrp3 channels	NATURE			English	Article							INTRACELLULAR CA2+ STORES; CALCIUM-ENTRY; INOSITOL PHOSPHATE; PLASMA-MEMBRANE; CELLS; DEPLETION; EXPRESSION; RELEASE; INFLUX	Calcium ions are released from intracellular stores in response to agonist-stimulated production of inositol 1,4,5-trisphosphate (InsP(3)), a second messenger generated at the cell membrane. Depletion of Ca2+ from internal stores triggers a capacitative influx of extracellular Ca2+ across the plasma membrane(1,2). The influx of Ca2+ can be recorded as store-operated channels (SOC) in the plasma membrane or as a current known as the Ca2+-release-activated current (I-crac)(3-5). A critical question in cell signalling is how SOC and I-crac sense and respond to Ca2+-store depletion: in one model, a messenger molecule is generated that activates Ca2+ entry in response to store depletion(1,6); in an alternative model(7), InsP(3) receptors in the stores are coupled to SOC and I-crac. The mammalian Htrp3 protein(8) forms a well defined store-operated channel(8,9) and so provides a suitable system for studying the effect of Ca2+-store depletion on SOC and I-crac. We show here that Htrp3 channels stably expressed in HEK293 cells are in a tight functional interaction with the InsP(3) receptors. Htrp3 channels present in the same plasma membrane patch can be activated by Ca2+ mobilization in intact cells and by InsP(3) in excised patches. This activation of Htrp3 by InsP(3) is lost on extensive washing of excised patches but is restored by addition of native or recombinant InsP(3)-bound InsP(3) receptors. Our results provide evidence for the coupling hypothesis(7), in which InsP(3) receptors activated by InsP(3) interact with SOC and regulate I-crac.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Wayne State Univ, Detroit, MI 48201 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43216 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43216 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90049 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Wayne State University; University of California System; University of California Davis; Loyola University Chicago; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X; Kiselyov, Kirill/0000-0001-6683-2895				Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; KISELYOV KI, IN PRESS PFLUEGERS A; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MIGNERY GA, 1990, J BIOL CHEM, V265, P12579; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RAMOSFRANCO J, IN PRESS BIOPHYS J; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SHARP AH, 1993, J NEUROSCI, V13, P3051; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	25	529	544	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1998	396	6710					478	482		10.1038/24890	http://dx.doi.org/10.1038/24890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853757				2022-12-24	WOS:000077370100057
J	Yang, QH; McDonnell, SM; Khoury, MJ; Cono, J; Parrish, RG				Yang, QH; McDonnell, SM; Khoury, MJ; Cono, J; Parrish, RG			Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of multiple-cause mortality data	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Centers-for-Disease-Control-and-Prevention Conference on Iron Overload Public Health and Genetics / Meeting on Hereditary Hemochromatosis - Gene Discovery and its Implications	MAR 04-05, 1997	ATLANTA, GA	Ctr Dis Control & Prevent, Natl Human Genome Res Inst			ISCHEMIC-HEART-DISEASE; BODY IRON STORES; HEREDITARY HEMOCHROMATOSIS; RISK; DEATH; GENE; EXPRESSION; PREVALENCE; MORBIDITY; OVERLOAD	Background: Hemochromatosis, which can lead to serious chronic diseases resulting from iron overload, has an estimated prevalence of 50 to 80 cases per 10 000 persons. However, little population-based information is available on the impact of hemochromatosis on morbidity and mortality. Objective: To evaluate trends over 14 years in deaths and medical conditions associated with hemochromatosis in the United States. Design: We searched Multiple-Cause Mortality Files compiled by the National Center for Health Statistics for the years 1979 to 1992 for all records listing hemochromatosis. We used these data to calculate age-adjusted and age-specific mortality rates, identify medical conditions associated with a known diagnosis of hemochromatosis at death, and calculate proportionate mortality ratios for these medical conditions. Results: The listing of hemochromatosis on death certificates increased 60% from 1979 to 1992. Decedents with hemochromatosis were 23, 13, and 5 times more likely to have liver neoplasms, liver disease, and cardiomyopathy, respectively, than were decedents without hemochromatosis. Conversely, decedents with liver neoplasms, liver disease, and cardiomyopathy were 26, 14, and 5 times more likely, respectively, to have hemochromatosis than were decedents without these conditions. Hemochromatosis was 82 times more likely in persons with the combination of liver neoplasms and diabetes and 43 times more likely in those with the combination of liver disease and diabetes than in those without these conditions. Conclusions: Comparison of the reported prevalence of hemochromatosis among decedents with estimates of prevalence in the general U.S. population suggests that either the penetrance or the recognition of hemochromatosis, or both, is low. Nevertheless, substantial mortality resulting from liver disease, liver neoplasms, cardiomyopathy, and a combination of liver disease and diabetes in patients with hemochromatosis argues for the improved diagnosis and treatment of hemochromatosis in persons with these conditions.	Ctr Dis Control & Prevent, Div Int Hlth, Atlanta, GA 30333 USA; Emory Univ, Egleston Childrens Hosp, Dept Gen Pediat, Atlanta, GA 30312 USA	Centers for Disease Control & Prevention - USA; Emory University	McDonnell, SM (corresponding author), Ctr Dis Control & Prevent, Div Int Hlth, Mailstop C-08,1600 Clifton Rd, Atlanta, GA 30333 USA.	sem0@cdc.gov						Adams PC, 1996, SEMIN LIVER DIS, V16, P47, DOI 10.1055/s-2007-1007218; Ahlbom A, 1993, BIOSTATISTICS EPIDEM; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Baur M.P., 1980, HISTOCOMPATIBILITY T, P955; BOTHWELL TH, 1995, NUTR REV, V53, P237, DOI 10.1111/j.1753-4887.1995.tb05480.x; Bradley L A, 1996, J Med Screen, V3, P178; Carella M, 1997, AM J HUM GENET, V60, P828; CARTWRIGHT GE, 1974, HARRISONS PRINCIPLES, P618; CONRAD ME, 1991, AM J HEMATOL, V38, P150, DOI 10.1002/ajh.2830380217; CROSBY WH, 1987, HOSP PRACT, V22, P173, DOI 10.1080/21548331.1987.11707681; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FINCH SC, 1955, MEDICINE, V34, P381, DOI 10.1097/00005792-195512000-00001; GABLE CB, 1992, J AM DIET ASSOC, V92, P208; GITTELSOHN A, 1978, 2300032 NCHS HRA; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HURWITZ ES, 1995, AM J PUBLIC HEALTH, V85, P1256, DOI 10.2105/AJPH.85.9.1256; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KNEKT P, 1994, INT J CANCER, V56, P379, DOI 10.1002/ijc.2910560315; Knisely A S, 1992, Adv Pediatr, V39, P383; KULLER LH, 1995, AM J PUBLIC HEALTH, V85, P1198, DOI 10.2105/AJPH.85.9.1198; Lynch SR, 1996, J NUTR, V126, pS2404; MACDONALD RA, 1965, AM J MED SCI, V249, P62; MACSWEEN RN, 1973, J CLIN PATHOL, V26, P936, DOI 10.1136/jcp.26.12.936; MCCORD JM, 1991, CIRCULATION, V83, P1112, DOI 10.1161/01.CIR.83.3.1112; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; ROUAULT TA, 1993, JAMA-J AM MED ASSOC, V269, P3152, DOI 10.1001/jama.269.24.3152; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; Sempos CT, 1996, NUTR REV, V54, P73, DOI 10.1111/j.1753-4887.1996.tb03875.x; STEVENS RG, 1994, INT J CANCER, V56, P364, DOI 10.1002/ijc.2910560312; SULLIVAN JL, 1992, CIRCULATION, V86, P1036, DOI 10.1161/01.CIR.86.3.1036; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Yang QH, 1997, GENET EPIDEMIOL, V14, P493, DOI 10.1002/(SICI)1098-2272(1997)14:5<493::AID-GEPI4>3.0.CO;2-2; 1996, MMWR MORB MORTAL WKL, V45, P991	42	125	128	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					946	953		10.7326/0003-4819-129-11_Part_2-199812011-00005	http://dx.doi.org/10.7326/0003-4819-129-11_Part_2-199812011-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	143DF	9867747				2022-12-24	WOS:000077239200027
J	Hensch, TK; Fagiolini, M; Mataga, N; Stryker, MP; Baekkeskov, S; Kash, SF				Hensch, TK; Fagiolini, M; Mataga, N; Stryker, MP; Baekkeskov, S; Kash, SF			Local GABA circuit control of experience-dependent plasticity in developing visual cortex	SCIENCE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; GAMMA-AMINOBUTYRIC-ACID; INHIBITORY POSTSYNAPTIC POTENTIALS; OCULAR DOMINANCE PLASTICITY; KITTEN STRIATE CORTEX; GABAERGIC CELL SUBTYPES; LONG-TERM POTENTIATION; SYNAPTIC RELEASE SITES; MONOCULAR DEPRIVATION; HIPPOCAMPAL-NEURONS	Sensory experience in early life shapes the mammalian brain. An impairment in the activity-dependent refinement of functional connections within developing visual cortex was identified here in a mouse model. Gene-targeted disruption of one isoform of glutamic acid decarboxylase prevented the competitive loss of responsiveness to an eye briefly deprived of vision, without affecting cooperative mechanisms of synapse modification in vitro. Selective, use-dependent enhancement of fast intracortical inhibitory transmission with benzodiazepines restored plasticity in vivo, rescuing the genetic defect. Specific networks of inhibitory interneurons intrinsic to visual cortex may detect perturbations in sensory input to drive experience-dependent plasticity during development.	RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, Wako, Saitama 3510198, Japan; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, Dept Med & Microbiol Immunol, San Francisco, CA 94143 USA	RIKEN; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hensch, TK (corresponding author), RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hensch@postman.riken.go.jp	Hensch, Takao/L-4182-2019; Mataga, Nobuko/N-5531-2015	Mataga, Nobuko/0000-0003-0991-4354; Baekkeskov, Steinunn/0000-0003-0878-3188; fagiolini, michela/0000-0003-2807-803X; Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [R37 EY002874-20, R37 EY002874] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; Asada H, 1996, BIOCHEM BIOPH RES CO, V229, P891, DOI 10.1006/bbrc.1996.1898; Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BENARDO LS, 1994, J PHYSIOL-LONDON, V476, P203, DOI 10.1113/jphysiol.1994.sp020124; BERRUETA LA, 1992, J PHARMACEUT BIOMED, V10, P109, DOI 10.1016/0731-7085(92)80019-J; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Carder RK, 1996, CEREB CORTEX, V6, P271, DOI 10.1093/cercor/6.2.271; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; Dudek SM, 1996, NEURON, V16, P1097, DOI 10.1016/S0896-6273(00)80136-1; DUFFY FH, 1976, NATURE, V260, P256, DOI 10.1038/260256a0; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; FELDBLUM S, 1993, J NEUROSCI RES, V34, P689, DOI 10.1002/jnr.490340612; Fukuda T, 1998, J COMP NEUROL, V395, P177, DOI 10.1002/(SICI)1096-9861(19980601)395:2<177::AID-CNE3>3.0.CO;2-#; Gonchar Y, 1997, CEREB CORTEX, V7, P347, DOI 10.1093/cercor/7.4.347; Gordon JA, 1996, J NEUROSCI, V16, P3274; GREIF KF, 1991, NEUROCHEM RES, V16, P235, DOI 10.1007/BF00966086; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; Guo YH, 1997, DEV BRAIN RES, V103, P127, DOI 10.1016/S0165-3806(97)81789-0; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; Hensch TK, 1996, SCIENCE, V272, P554, DOI 10.1126/science.272.5261.554; Kaczmarek L, 1997, BRAIN RES REV, V23, P237, DOI 10.1016/S0165-0173(97)00005-2; KANG YN, 1994, J NEUROPHYSIOL, V71, P280, DOI 10.1152/jn.1994.71.1.280; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; KAWAGUCHI Y, 1992, EXP BRAIN RES, V88, P33, DOI 10.1007/BF02259126; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; KRATZ KE, 1976, J NEUROPHYSIOL, V39, P501, DOI 10.1152/jn.1976.39.3.501; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; Mataga N, 1996, NEUROSCI LETT, V218, P149, DOI 10.1016/S0304-3940(96)13139-6; MATAGA N, 1991, BRAIN RES, V551, P64, DOI 10.1016/0006-8993(91)90914-H; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MOWER GD, 1989, DEV BRAIN RES, V45, P211, DOI 10.1016/0165-3806(89)90040-0; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; RAMOA AS, 1988, EXP BRAIN RES, V73, P285; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Sala R, 1998, EUR J NEUROSCI, V10, P2185, DOI 10.1046/j.1460-9568.1998.00227.x; SEGAL M, 1990, BRAIN RES, V511, P163, DOI 10.1016/0006-8993(90)90236-5; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHAW C, 1987, DEV BRAIN RES, V37, P67, DOI 10.1016/0165-3806(87)90229-X; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SILLITO AM, 1981, NATURE, V291, P318, DOI 10.1038/291318a0; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; TALLMAN JF, 1985, ANNU REV NEUROSCI, V8, P21, DOI 10.1146/annurev.ne.08.030185.000321; Tamas G, 1997, J PHYSIOL-LONDON, V500, P715, DOI 10.1113/jphysiol.1997.sp022054; Tamas G, 1998, J NEUROSCI, V18, P4255; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; THOMSON AM, 1997, SOC NEUR ABSTR, V23; TSUMOTO T, 1992, PROG NEUROBIOL, V39, P209, DOI 10.1016/0301-0082(92)90011-3; VANBREDERODE JFM, 1995, J NEUROPHYSIOL, V74, P1149, DOI 10.1152/jn.1995.74.3.1149; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; Xiang ZX, 1998, SCIENCE, V281, P985, DOI 10.1126/science.281.5379.985; Xiang ZX, 1998, J PHYSIOL-LONDON, V506, P715, DOI 10.1111/j.1469-7793.1998.715bv.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	75	691	699	6	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1504	1508		10.1126/science.282.5393.1504	http://dx.doi.org/10.1126/science.282.5393.1504			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822384	Green Accepted			2022-12-24	WOS:000077110800059
J	Mulvey, MA; Lopez-Boado, YS; Wilson, CL; Roth, R; Parks, WC; Heuser, J; Hultgren, SJ				Mulvey, MA; Lopez-Boado, YS; Wilson, CL; Roth, R; Parks, WC; Heuser, J; Hultgren, SJ			Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli	SCIENCE			English	Article							URINARY-TRACT INFECTION; FIMH-ADHESIN; PILI; PATHOGENESIS; APOPTOSIS; BLADDER; PENETRATION; EXPRESSION; EPITHELIUM; PREVENTION	Virtually all uropathogenic strains of Escherichia coli encode filamentous surface adhesive organelles called type 1 pili. High-resolution electron microscopy of infected mouse bladders revealed that type 1 pilus tips interacted directly with the Lumenal surface of the bladder, which is embedded with hexagonal arrays of integral membrane glycoproteins known as uroplakins. Attached pill were shortened and facilitated intimate contact of the bacteria with the uroplakin-coated host cells. Bacterial attachment resulted in exfoliation of host bladder epithelial cells as part of an innate host defense system. Exfoliation occurred through a rapid apoptosis-like mechanism involving caspase activation and host DNA fragmentation. Bacteria resisted clearance in the face of host defenses within the bladder by invading into the epithelium.	Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	hultgren@borcim.wustl.edu	Parks, William C./AAH-6786-2021	Mulvey, Matthew/0000-0002-6016-7510	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI29549, AI09787] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; BRADLEY DE, 1972, J GEN MICROBIOL, V72, P303, DOI 10.1099/00221287-72-2-303; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DAVIS CP, 1978, SCANNING ELECTRON MI, V2, P315; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; ELLIOTT TSJ, 1985, J INFECTION, V11, P191, DOI 10.1016/S0163-4453(85)92997-4; FOXMAN B, 1995, J INFECT DIS, V172, P1536, DOI 10.1093/infdis/172.6.1536; FUKUSHI Y, 1979, INVEST UROL, V17, P61; HEUSER JE, 1987, J MUSCLE RES CELL M, V8, P303, DOI 10.1007/BF01568887; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; HULTGREN SJ, 1990, MOL MICROBIOL, V4, P1311, DOI 10.1111/j.1365-2958.1990.tb00710.x; Ikaheimo R, 1996, CLIN INFECT DIS, V22, P91, DOI 10.1093/clinids/22.1.91; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; LANGENAUR C, 1977, J BACTERIOL, V131, P340; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; MCTAGGART LA, 1990, J MED MICROBIOL, V32, P135, DOI 10.1099/00222615-32-2-135; MINION FC, 1986, J BACTERIOL, V165, P1033, DOI 10.1128/jb.165.3.1033-1036.1986; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; MULVEY MA, UNPUB; NOVOTNY CP, 1974, J BACTERIOL, V117, P1306, DOI 10.1128/JB.117.3.1306-1311.1974; ORIKASA S, 1977, INVEST UROL, V15, P185; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; ROMANTSCHUK M, 1985, J GEN VIROL, V66, P2461, DOI 10.1099/0022-1317-66-11-2461; Stapleton A, 1997, INFECT DIS CLIN N AM, V11, P719, DOI 10.1016/S0891-5520(05)70382-2; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Thankavel K, 1997, J CLIN INVEST, V100, P1123, DOI 10.1172/JCI119623; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALZ T, 1995, J MOL BIOL, V248, P887, DOI 10.1006/jmbi.1995.0269; WONG YC, 1977, AM J ANAT, V150, P237, DOI 10.1002/aja.1001500203; WU XR, 1995, J BIOL CHEM, V270, P29752; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	38	726	742	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1494	1497		10.1126/science.282.5393.1494	http://dx.doi.org/10.1126/science.282.5393.1494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822381				2022-12-24	WOS:000077110800056
J	Heffner, JE; Barbieri, C				Heffner, JE; Barbieri, C			Compliance with do-not-resuscitate orders for hospitalized patients transported to radiology departments	ANNALS OF INTERNAL MEDICINE			English	Article							DNR ORDERS	Background: Little is known about the effectiveness of do-not-resuscitate (DNR) orders during transport of hospitalized patients away from their rooms. Objective: To determine compliance with DNR orders in radiology departments. Design: Observational study. Setting: 248 hospital-based radiology departments. Participants: 248 radiology department representatives. Measurements: 10-item questionnaire examining the response of radiology personnel to patients with DNR orders who experience cardiopulmonary arrest. Results: Written DNR protocols and structured procedures for communicating DNR status were used by 18.5% (CI, 13.7% to 23.4%) and 18.1% (CI, 13.3% to 23.0%) of departments, respectively. Medical chart review was the only source of information on DNR status for 41.5% (CI, 35.4% to 47.7%) of departments. It was found that 20.2% of respondents (CI, 15.2% to 25.2%) would resuscitate patients with DNR orders and that 38.3% (CI, 32.3% to 44.4%) had resuscitated patients with DNR orders in the past. Conclusions: Most radiology departments do not have formal procedures to prevent patients from undergoing unwanted or inappropriate resuscitative interventions, and DNR orders are frequently overruled.	St Josephs Hosp, Mercy Hlth Serv Res Grp, Phoenix, AZ 85001 USA	St. Joseph's Hospital and Medical Center	Heffner, JE (corresponding author), Med Univ S Carolina, Dept Med, Room 812 CSB,171 Ashley Ave, Charleston, SC 29425 USA.							*AM COLL SURG, 1994, AM COLL SURG B, V79, P29; *AM HOSP ASS, 1996, AM HOSP ASS GUID HLT; *AM MED ASS, 1997, GRAD MED ED DIR 1997; *AM SOC AN, 1994, ETH GUID AN CAR PAT, P746; Casarett D, 1997, NEW ENGL J MED, V336, P1908, DOI 10.1056/NEJM199706263362611; CLEMENCY MV, 1993, ANESTH ANALG, V76, P394; *DHEW, 1995, DHEW PUBL; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; Heffner JE, 1996, ARCH INTERN MED, V156, P793, DOI 10.1001/archinte.156.7.793; Heffner JE, 1998, ARCH INTERN MED, V158, P1090, DOI 10.1001/archinte.158.10.1090; Heffner JE, 1997, ARCH INTERN MED, V157, P685, DOI 10.1001/archinte.157.6.685; Jacobson JA, 1996, RADIOLOGY, V198, P21, DOI 10.1148/radiology.198.1.8539381; LAPUMA J, 1988, ARCH INTERN MED, V148, P2193, DOI 10.1001/archinte.148.10.2193; MCDERMOTT VGM, 1993, BRIT J RADIOL, V66, P667, DOI 10.1259/0007-1285-66-788-667; MITTELBERGER JA, 1993, ARCH INTERN MED, V153, P228, DOI 10.1001/archinte.153.2.228; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; Terry PB, 1996, RADIOLOGY, V198, P17, DOI 10.1148/radiology.198.1.8539372; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; WALL SD, 1991, AM J ROENTGENOL, V157, P911, DOI 10.2214/ajr.157.5.1927808; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056	20	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					801	805		10.7326/0003-4819-129-10-199811150-00010	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841586				2022-12-24	WOS:000076984800006
J	Choi, BG; Huss, GR; Wasserburg, GJ; Gallino, R				Choi, BG; Huss, GR; Wasserburg, GJ; Gallino, R			Presolar corundum and spinel in ordinary chondrites: Origins from AGB stars and a supernova	SCIENCE			English	Article							SILICON-CARBIDE GRAINS; ISOTOPIC ABUNDANCES; INTERSTELLAR GRAINS; OXIDE GRAINS; METEORITES; OXYGEN; CARBON; AL2O3; NUCLEOSYNTHESIS; MAGNESIUM	On the basis of anomalous isotopic compositions of oxygen and magnesium, 14 oxide grains from two primitive meteorites (Bishunpur and Semarkona) have been identified as circumstellar condensates. One corundum grain has a high (18)O/(16)O ratio and isotopic compositions of magnesium, calcium, and titanium that are compatible with a formation in ejecta of a type II supernova that was about 15 times the mass of the sun, The other grains have oxygen, magnesium, and titanium compositions that are consistent with a formation around asymptotic giant branch (AGB) stars with a range of mass and initial composition. The large range of aluminum/magnesium in circumstellar corundum and spinel is considered to reflect various stages of back-reaction between condensed corundum and gaseous magnesium in cooling stellar ejecta.	CALTECH, Div Geol & Planetary Sci, Lunat Asylum, Pasadena, CA 91125 USA; Univ Turin, Dipartimento Fis Gen, I-10125 Turin, Italy	California Institute of Technology; University of Turin	Choi, BG (corresponding author), CALTECH, Div Geol & Planetary Sci, Lunat Asylum, Pasadena, CA 91125 USA.	bchoi@gps.caltech.edu	WASSERBURG, GERALD J/F-6247-2011	Huss, Gary/0000-0003-4281-7839				Arnould M, 1997, AIP CONF PROC, P179, DOI 10.1063/1.53328; BOOTHROYD AI, 1994, ASTROPHYS J, V430, pL77, DOI 10.1086/187442; BOOTHROYD AI, 1993, ASTROPHYS J, V416, P762, DOI 10.1086/173275; BOOTHROYD AI, 1995, ASTROPHYS J, V442, pL21, DOI 10.1086/187806; CATANZAR.EJ, 1966, J RES NBS A PHYS CH, VA 70, P453, DOI 10.6028/jres.070A.037; Collier MR, 1998, J GEOPHYS RES-SPACE, V103, P7, DOI 10.1029/97JA02245; EDVARDSSON B, 1993, ASTRON ASTROPHYS, V275, P101; FORESTINI M, 1991, ASTRON ASTROPHYS, V252, P597; GALLINO R, 1994, ASTROPHYS J, V430, P858, DOI 10.1086/174457; HALLSTEDT B, 1992, J AM CERAM SOC, V75, P1497, DOI 10.1111/j.1151-2916.1992.tb04216.x; HEINRICH M, 1998, LUNAR PLANET, V29, P1715; Holmden C, 1997, GEOCHIM COSMOCHIM AC, V61, P2253, DOI 10.1016/S0016-7037(97)00057-4; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; HUSS GR, 1994, METEORITICS, V29, P475; Huss GR, 1997, GEOCHIM COSMOCHIM AC, V61, P5117, DOI 10.1016/S0016-7037(97)00299-8; HUSS GR, 1992, LUNAR PLANET SCI, V23, P563; HUTCHEON ID, 1994, ASTROPHYS J, V425, pL97, DOI 10.1086/187319; Kallenbach R, 1998, ASTROPHYS J, V498, pL75, DOI 10.1086/311296; Lattanzio JC, 1997, AIP CONF PROC, P85, DOI 10.1063/1.53325; LATTIMER JM, 1978, ASTROPHYS J, V219, P230, DOI 10.1086/155771; LEE T, 1976, GEOPHYS RES LETT, V3, P109, DOI 10.1029/GL003i002p00109; LUGARO M, UNPUB, P34312; MEYER BS, 1995, METEORITICS, V30, P325, DOI 10.1111/j.1945-5100.1995.tb01131.x; NIEDERER FR, 1984, GEOCHIM COSMOCHIM AC, V48, P1279, DOI 10.1016/0016-7037(84)90062-0; NIEDERER FR, 1985, GEOCHIM COSMOCHIM AC, V49, P835, DOI 10.1016/0016-7037(85)90176-0; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; Nittler LR, 1997, AIP CONF PROC, P59, DOI 10.1063/1.51767; Nittler LR, 1997, PHYS REV LETT, V78, P175, DOI 10.1103/PhysRevLett.78.175; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; SELESNICK RS, 1993, ASTRPHYS J, V41, pL45; STREBEL R, 1996, METEORIT PLANET SCI, V31, pA136; TIMMES FX, 1995, ASTROPHYS J SUPPL S, V98, P617, DOI 10.1086/192172; TRAVAGLIO C, IN PRESS ASTROPHYS J; WANNIER PG, 1989, IAU SYMP, V136, P107; Wasserburg GJ, 1998, ASTROPHYS J, V500, pL189, DOI 10.1086/311414; WASSERBURG GJ, 1995, ASTROPHYS J, V447, pL37, DOI 10.1086/309555; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; WOOSLEY SE, 1997, NUCL COSMOS, V4, P445; Zinner E, 1997, AIP CONF PROC, P3, DOI 10.1063/1.53326	41	147	150	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1284	1289		10.1126/science.282.5392.1284	http://dx.doi.org/10.1126/science.282.5392.1284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812886				2022-12-24	WOS:000076982200035
J	Delbanco, T				Delbanco, T			Leeches, spiders, and astrology: Predilections and predictions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEPRESSION; PLACEBO											Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; BROWN WA, 1994, NEUROPSYCHOPHARMACOL, V10, P265, DOI 10.1038/npp.1994.53; DELBANCO TL, 1994, ANN INTERN MED, V121, P803, DOI 10.7326/0003-4819-121-10-199411150-00011; DELBANCO TL, 1994, NEUROPSYCHOPHARMACOL, V10, P279, DOI 10.1038/npp.1994.57; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; Hart Julian Tudor, 1998, Health Expect, V1, P3, DOI 10.1046/j.1369-6513.1998.00001.x; TYLE L, 1998, FATHER SPIN E BERNAY	8	12	12	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1560	1562		10.1001/jama.280.18.1560	http://dx.doi.org/10.1001/jama.280.18.1560			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820247				2022-12-24	WOS:000076852000011
J	Eisenberg, DM; Davis, RB; Ettner, SL; Appel, S; Wilkey, S; van Rompay, M; Kessler, RC				Eisenberg, DM; Davis, RB; Ettner, SL; Appel, S; Wilkey, S; van Rompay, M; Kessler, RC			Trends in alternative medicine use in the United States, 1990-1997 - Results of a follow-up national survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; ADVERSE REACTIONS; HERBAL MEDICINES; PREVALENCE; THERAPIES; COST	Context.-A prior national survey documented the high prevalence and costs of alternative medicine use in the United States in 1990. Objective.-To document trends in alternative medicine use in the United States between 1990 and 1997, Design.-Nationally representative random household telephone surveys using comparable key questions were conducted in 1991 and 1997 measuring utilization in 1990 and 1997, respectively. Participants.-A total of 1539 adults in 1991 and 2055 in 1997. Main Outcomes Measures.-Prevalence, estimated costs, and disclosure of alternative therapies to physicians. Results.-Use of at least 1 of 16 alternative therapies during the previous year increased from 33.8% in 1990 to 42.1% in 1997 (P less than or equal to.001). The therapies increasing the most included herbal medicine, massage, megavitamins, self-help groups, folk remedies, energy healing, and homeopathy. The probability of users visiting an alternative medicine practitioner increased from 36.3% to 46.3% (P = .002), In both surveys alternative therapies were used most frequently for chronic conditions, including back problems, anxiety, depression, and headaches. There was no significant change in disclosure rates between the 2 survey years; 39.8% of alternative therapies were disclosed to physicians in 1990 vs 38.5% in 1997, The percentage of users paying entirely out-of-pocket for services provided by alternative medicine practitioners did not change significantly between 1990 (64.0%) and 1997 (58.3%) (P = .36). Extrapolations to the US population suggest a 47.3% increase in total visits to alternative medicine practitioners, from 427 million in 1990 to 629 million in 1997, thereby exceeding total visits to all US primary care physicians. An estimated 15 million adults in 1997 took prescription medications concurrently with herbal remedies and/or high-dose vitamins (18.4% of all prescription users). Estimated expenditures for alternative medicine professional services increased 45.2% between 1990 and 1997 and were conservatively estimated at $21.2 billion in 1997, with at least $12.2 billion paid out-of-pocket. This exceeds the 1997 out-of-pocket expenditures for all US hospitalizations. Total 1997 out-of-pocket expenditures relating to alternative therapies were conservatively estimated at $27.0 billion, which is comparable with the projected 1997 out-of-pocket expenditures for all US physician services. Conclusions.-Alternative medicine use and expenditures increased substantially between 1990 and 1997, attributable primarily to an increase in the proportion of the population seeking alternative therapies, rather than increased visits per patient.	Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Eisenberg, DM (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Van Rompay, Maria/G-9452-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bouchayer F., 1990, COMPLEMENT MED RES, V4, P4; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P., 1996, MECH DRUG INTERACTIO, P327, DOI [10.1007/978-3-642-61015-8_12, DOI 10.1007/978-3-642-61015-8_12]; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; GoldbeckWood S, 1996, BRIT MED J, V313, P131, DOI 10.1136/bmj.313.7050.131a; GROVES RM, 1998, NONRESPONSE HOUSEHOL, P159; *HLTH CAR FIN ADM, NAT HLTH CAR EXP PRO; *LANDM HEALTHC, 1998, LANDM REP PUBL PERC; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; *MED INC, CUST REP MED BILL CO; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; PIEL E, 1991, THERAPEUTIKON, V5, P549; RASMUSSEN NK, 1990, COMPLEMENT MED RES, V4, P16; *RES TRIANGL I, 1997, SUDAAN PROF SOFTW SU; SCHAPPERT SM, 1992, ADV DATA VITAL HLTH, V2213, P1; SERMEUS G, 1990, COMPLEMENTARY MED RE, V4, P9; Shekelle PG, 1996, MED CARE, V34, P863, DOI 10.1097/00005650-199609000-00001; *US BUR CENS, 1990, US POP EST AG SEX RA; *US BUR LAB STAT D, 1998, CONS PRIC IND ALL UR; VASKILAMPI T, 1993, CLIN RES METHODOLOGY, P204; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; Woodwell D A, 1997, Adv Data, P1	29	4678	4788	9	271	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1569	1575		10.1001/jama.280.18.1569	http://dx.doi.org/10.1001/jama.280.18.1569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820257	Bronze			2022-12-24	WOS:000076852000022
J	Kiyono, T; Foster, SA; Koop, JI; McDougall, JK; Galloway, DA; Klingelhutz, AJ				Kiyono, T; Foster, SA; Koop, JI; McDougall, JK; Galloway, DA; Klingelhutz, AJ			Both Rb/p16(INK4a) inactivation and telomerase activity are required to immortalize human epithelial cells	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FIBROBLASTS; E6; KERATINOCYTES; P53; E7; ONCOPROTEINS; DEGRADATION; SENESCENCE; INDUCTION	Normal human cells undergo a limited number of divisions in; culture and enter a non-dividing state called replicative senescence(1). Senescence is accompanied by several changes, including an increase in inhibitors of cyclin-dependent kinases(2,3) and telomere shortening(4). The mechanisms by which viral oncogenes reverse these processes are not fully understood, although a general requirement for oncoproteins such as human papillomavirus E6 and E7 has suggested that the p53 and Rb pathways are targeted. Expression of the catalytic component of telomerase, hTERT, alone significantly extends the lifespan of human fibroblasts(5). Here we show that telomerase activity is not sufficient for immortalization of human keratinocyte or mammary epithelial cells: we find that neither addition of hTERT nor induction of telomerase activity by E6, both of which are active in maintaining telomere length, results in immortalization. Inactivation of the Rb/p16 pathway by E7 or downregulation of p16 expression, in combination with telomerase activity, however, is able to immortalize epithelial cells efficiently. Elimination of p53 and of the DNA-damage-induced G1 checkpoint is not necessary for immortalization, neither is elimination of p19ARF.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Galloway, DA (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N,Cl-015,POB 19024, Seattle, WA 98109 USA.		Kiyono, Tohru/H-5834-2011; Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Halbert CL, 1991, J VIROL, V65, P474; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HULBREGTSE JM, 1993, MOL CELL BIOL, V13, P775; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MUNGER K, 1989, J VIROL, V63, P4417; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	30	1005	1060	2	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1998	396	6706					84	88		10.1038/23962	http://dx.doi.org/10.1038/23962			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136HE	9817205				2022-12-24	WOS:000076852700059
J	Kim, HN				Kim, HN			Prescription for prophecy: Confronting the ambiguity of susceptibility testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUNTINGTON DISEASE; ATTITUDES; RISK		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kim, HN (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							ANDREWSL B, 1994, ASSESSING GENETIC RI, P146; BIESECKER BB, 1997, J AM MED WOMEN ASSOC, V51, P22; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; MARKEL DS, 1987, AM J MED GENET, V26, P295, DOI 10.1002/ajmg.1320260207; QUAID K, 1994, GENES HUMAN SELF KNO, P5; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047	7	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1535	1536		10.1001/jama.280.17.1535	http://dx.doi.org/10.1001/jama.280.17.1535			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809739	hybrid			2022-12-24	WOS:000076757200032
J	Fruman, DA; Snapper, SB; Yballe, CM; Davidson, L; Yu, JY; Alt, FW; Cantley, LC				Fruman, DA; Snapper, SB; Yballe, CM; Davidson, L; Yu, JY; Alt, FW; Cantley, LC			Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85 alpha	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAINS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; FAMILY; GENE; SPECIFICITY; MICE; CD28	Phosphoinositide 3-kinase (PI3K) activation has been implicated in many cellular responses, including fibroblast growth, transformation, survival, and chemotaxis, Although PI3K is activated by several agents that stimulate T and B cells, the role of PI3K in Lymphocyte function is not clear. The mouse gene encoding the PI3K adapter subunit p85 alpha and its splice variants p55 alpha and p50 alpha was disrupted. Most p85 alpha-p55 alpha-p50 alpha(-/-) mice die within days after birth. Lymphocyte development and function was studied with the use of the RAG2-deficient blastocyst complementation system. Chimeric mice had reduced numbers of peripheral mature B cells and decreased serum immunoglobulin. The B cells that developed had diminished proliferative responses to antibody to immunoglobulin M, antibody to CD40, and Lipopolysaccharide stimulation and decreased survival after incubation with interleukin-A In contrast, T cell development and proliferation was normal. This phenotype is similar to defects observed in mice lacking the tyrosine kinase Btk.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Med Serv, Gastrointestinal Unit, Boston, MA 02114 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Fruman, DA (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; DUCKWORTH BC, 1996, HANDB LIP R, V8, P125; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; FRUMAN DA, UNPUB; Hutchcroft JE, 1996, J IMMUNOL, V156, P4071; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRUITT KE, 1995, J IMMUNOL, V155, P4702; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; Woodland RT, 1996, J IMMUNOL, V156, P2143; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	24	546	556	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	1999	283	5400					393	397		10.1126/science.283.5400.393	http://dx.doi.org/10.1126/science.283.5400.393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157MV	9888855				2022-12-24	WOS:000078067000049
J	Hingorani, AD; Vallance, P				Hingorani, AD; Vallance, P			A simple computer program for guiding management of cardiovascular risk factors and prescribing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PRIMARY PREVENTION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HYPERTENSION; PRAVASTATIN; PROFILE; STROKE; TABLE	Objective To describe, and to test against trial data, a simple and flexible computer program for calculating cardiovascular risk in individual patients as an aid to managing risk factors and prescribing drugs to lower cholesterol concentration and blood pressure. Design Descriptive comparison of actual cardiovascular risk in randomised controlled trials of cholesterol reduction with risk predicted by a computer program based on the Framingham risk equation. Comparison of the program's performance with that of tables and guidelines by means of hypothetical case examples. Main outcome measures Average risk of coronary heart disease and myocardial infarction. Results The computer program accurately predicted baseline absolute risk in a UK population as well as the relative and absolute reduction in risk from cholesterol lowering for primary prevention of coronary heart disease. The program also allowed a more refined estimate of absolute risk of coronary heart disease than some existing tables and enabled the impact of prescribing decisions to be quantified and costed. Conclusions This simple computer program to estimate individuals' cardiovascular disease risk and display the benefits of intervention should help clinicians and patients decide on the most effective packages of risk reduction and identify those most likely to benefit from modulation of risk factors.	UCL, Wolfson Inst Biomed Res, Ctr Clin Pharmacol, London W1P 9LN, England	University of London; University College London	Hingorani, AD (corresponding author), UCL, Wolfson Inst Biomed Res, Ctr Clin Pharmacol, London W1P 9LN, England.	a.hingorani@ucl.ac.uk		Hingorani, Aroon/0000-0001-8365-0081				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; FREMANTLE N, 1997, BRIT MED J, V315, P826; Gould AL, 1998, CIRCULATION, V97, P946; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; Haq IU, 1996, CLIN SCI, V91, P773; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JACKSON R, 1995, LANCET, V346, P1440, DOI 10.1016/S0140-6736(95)92466-3; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; Muldoon MF, 1997, BRIT MED J, V315, P1554, DOI 10.1136/bmj.315.7122.1554; Packard CJ, 1998, CIRCULATION, V97, P1440; PYORALA K, 1994, EUR HEART J, V15, P1300; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; Ramsay LE, 1996, LANCET, V348, P1251, DOI 10.1016/S0140-6736(05)65536-5; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SCAND SIMV SURV S, 1995, LANCET, V344, P1883; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Skolbekken JA, 1998, BMJ-BRIT MED J, V316, P1956, DOI 10.1136/bmj.316.7149.1956; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; WIYNARD G, 1997, SMAC STATE USE STATI; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	25	96	99	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1999	318	7176					101	105		10.1136/bmj.318.7176.101	http://dx.doi.org/10.1136/bmj.318.7176.101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157XT	9880285	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000078087500028
J	Sourander, L; Rajala, T; Raiha, I; Makinen, J; Erkkola, R; Helenius, H				Sourander, L; Rajala, T; Raiha, I; Makinen, J; Erkkola, R; Helenius, H			Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)	LANCET			English	Article							CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BREAST-CANCER; RISK; HEALTH	Background Advantages and disadvantages of postmenopausal oestrogen replacement therapy (ERT) are still not clear. We aimed to analyse the relation between postmenopausal oestrogen replacement therapy (ERT), cardiovascular disease, and cancer. Methods We examined 7944 women born between 1923 and 1930, who participated in a mammography screening for breast cancer, and who were followed up from 1987 to 1995, The follow-up consisted of 53 305 person-years. 988 women were current users and 757 were former users of ERT. Information about hormone use and health events was obtained through biennial questionnaires and recording and linking information from the hospital discharge registers of the region, the national cancer register, the social insurance reimbursement register, and the national death register. We used proportional-hazards models to calculate risk ratios and 95% CIs, adjusted for eight confounding variables. Findings Current ERT was associated with decreased cardiovascular mortality and a decrease in sudden cardiac death. Adjusted risk ratio (RR) for cardiovascular mortality in current users was 0.21 (95% CI 0.08-0.59) and in former users 0.75 (0.41-1.37). Absolute risk per 1000 person-years for deaths from acute myocardial infarction (AMI) was 1.1 in never users, 1.2 in former users, and 0.45 in current users (p=0.197). Corresponding absolute risk for other coronary-artery-disease (CAD) deaths was 1.0, 0.81, and 0 (p=0.009), and for deaths from stroke 1.2, 1.0, and 0.15 (p=0.012), Absolute risk for sudden cardiac death was 1.6 in never users, 1.0 in former users, and 0 in current users (p<0.001). Cardiovascular morbidity was not decreased by ERT: the RR for current use was 1.07 (0.86-1.32) and for former use 1.11 (0.89-1.39). Incidence of cardiovascular disease per 1000 person-years was 24.9 in never users, 23.4 in former users, and 20.9 in current users (p=0.153). Breast-cancer morbidity did not increase with current ERT--the RR was 0.57 (0.27-1.20). Incidence of breast cancer was 1.8, 1.6, and 1.0 in never, former, and current users (p=0.242). Endometrial cancer increased with current ERT-the RR was 5.06 (2.47-10.41). Incidence of endometrial cancer was 0.52 in never users, 0.51 in former users, and 2.1 in current users (p<0.001). Interpretation Current ERT reduced primarily sudden cardiac death and predicted reduced cardiovascular mortality, but did not reduce morbidity. ERT did not increase the risk of breast cancer, but associated with increased risk of endometrial cancer.	Univ Turku, Dept Geriatr, Turku 20700, Finland; Univ Turku, Dept Obstet & Gynaecol, Turku 20700, Finland; Univ Turku, Dept Biostat, Turku 20700, Finland	University of Turku; University of Turku; University of Turku	Sourander, L (corresponding author), Univ Turku, Dept Geriatr, Kunnallissairaalantie 20, Turku 20700, Finland.							AKHTAR M, 1994, SUDDEN CARDIAC DEATH; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; *CENTR STAT OFF FI, 1974, OFF STAT FINL, V9; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Collett D., 1994, MODELING SURVIVAL DA; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Huikuri HV, 1996, CIRCULATION, V94, P122, DOI 10.1161/01.CIR.94.2.122; KATSOUYANNI K, 1997, J CLIN ENDOCR METAB, V82, P1549; LOBO RA, 1992, AM J OBSTET GYNECOL, V166, P1997, DOI 10.1016/0002-9378(92)91401-U; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Matthews KA, 1996, AM J EPIDEMIOL, V143, P983; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; PUKKALA E, 1995, CONTRIBUTION EPIDEMI, V7; SISMOND P, 1996, EUR MENOPAUSE J, V3, P227; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; *STAT FINL, 1996, CAUS DATH; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702	25	147	148	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1965	1969		10.1016/S0140-6736(98)05066-1	http://dx.doi.org/10.1016/S0140-6736(98)05066-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872245				2022-12-24	WOS:000077663000009
J	Bozzette, SA; Berry, SH; Duan, NJ; Frankel, MR; Leibowitz, AA; Lefkowitz, D; Emmons, CA; Senterfitt, JW; Berk, ML; Morton, SC; Shapiro, MF				Bozzette, SA; Berry, SH; Duan, NJ; Frankel, MR; Leibowitz, AA; Lefkowitz, D; Emmons, CA; Senterfitt, JW; Berk, ML; Morton, SC; Shapiro, MF		HIV Cost Services Utilization Study Consortium	The care of HIV-infected adults in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS	Background and Methods In order to elucidate the medical care of patients with human immunodeficiency virus (HIV) infection in the United States, we randomly sampled HIV-infected adults receiving medical care in the contiguous United States at a facility other than a military, prison, or emergency department facility during the first two months of 1996. We interviewed 76 percent of 4042 patients selected from among the patients receiving care from 145 providers in 28 metropolitan areas and 51 providers in 25 rural areas. Results During the first two months of 1996, an estimated 231,400 HIV-infected adults (95 percent confidence interval, 162,800 to 300,000) received care. Fifty-nine percent had the acquired immunodeficiency syndrome according to the case definition of the Centers for Disease Control and Prevention, and 91 percent had CD4+ cell counts of less than 500 per cubic millimeter. Eleven percent were 50 years of age or older, 23 percent were women, 33 percent were black, and 49 percent were men who had had sex with men. Forty-six percent had incomes of less than $10,000 per year, 68 percent had public health insurance or no insurance, and 30 percent received care at teaching institutions. The estimated annual direct expenditures for the care of the patients seen during the first two months of 1996 were $5.1 billion; the expenditures for the estimated 335,000 HIV-infected adults seen at least as often as every six months were $6.7 billion, which is about $20,000 per patient per year. Conclusions In this national survey we found that most HIV-infected adults who were receiving medical care had advanced disease. The patient population was disproportionately male, black, and poor. Many Americans with diagnosed or undiagnosed HIV infection are not receiving medical care at least as often as every six months. The total cost of medical care for HIV-infected Americans accounts for less than 1 percent of all direct personal health expenditures in the United States. (N Engl J Med 1998;339:1897-904.) (C) 1998, Massachusetts Medical Society.	Rand Corp, HCSUS Off, Hlth, Santa Monica, CA 90407 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; CUNY Bernard M Baruch Coll, New York, NY 10010 USA; Project Hope, Bethesda, MD USA; US Dept HHS, Agcy Hlth Care Policy & Res, Rockville, MD 20852 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of Chicago; City University of New York (CUNY) System; Baruch College (CUNY); Agency for Healthcare Research & Quality	Bozzette, SA (corresponding author), Rand Corp, HCSUS Off, Hlth, 1700 Main St, Santa Monica, CA 90407 USA.		Harding, Richard/G-9729-2012	Duan, Naihua/0000-0001-9411-2924	AHRQ HHS [U-01HS08578] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERRY SH, HCSUS BASELINE PAT; *BUR CENS, 1997, CURR POP REP SER P, V60; Campbell P., 1997, POPULATION PROJECTIO; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; *CDCP, 1997, HIV AIDS SURV REP, V9, P24; DAY J, 1996, CURRENT POPULATION P, V20; *DEP HLTH HUM SERV, 1998, ANN INTERN MED, V128, P1079; *DEP JUST, 1997, CORR POP US 1995; DUAN N, IN PRESS HCSUS BASEL; FINGERHUT LA, 1997, INJURY CHARTBOOK HLT; FRANEKL MR, IN PRESS HLTH SERV R; HAMMETT TM, 1995, UPDATE HIV AIDS STDS; HELLINGER FJ, 1994, HEALTH SERV RES, V29, P569; KALTON G, 1983, COMPENSATING MISSING; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; KISH L, 1965, SURVEY SAMPLING, V16, P643; Lam NSN, 1996, PROF GEOGR, V48, P321, DOI 10.1111/j.0033-0124.1996.00321.x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pamuk E., 1998, SOCIOECONOMIC STATUS; SHAPIRO MF, 1997, HLTH SERV RES; Smith D, 1998, J ACQ IMMUN DEF SYND, V17, pS17, DOI 10.1097/00042560-199801001-00006; WINSLOW C, IN PRESS HIV CARE; 1992, MMWR MORB MOTAL WKLY, V41, P1; 1990, MMWR MORB MOTAL WKLY, V39, P1	26	401	407	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1897	1904		10.1056/NEJM199812243392606	http://dx.doi.org/10.1056/NEJM199812243392606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862946				2022-12-24	WOS:000077696600006
J	Lu, XW; Horvitz, HR				Lu, XW; Horvitz, HR			lin-35 and lin-53, two genes that antagonize a C-elegans Ras pathway, encode proteins similar to Rb and its binding protein RbAp48	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATOR; TRANSCRIPTIONAL REPRESSION; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; VULVAR DEVELOPMENT; LEADER SEQUENCE; MESSENGER-RNA	The Ras signaling pathway for vulval induction in Caenorhabditis elegans is antagonized by the activity of the synthetic multivulva (synMuv) genes, which define two functionally redundant pathways. We have characterized two genes in one of these pathways. lin-35 encodes a protein similar to the tumor suppressor Rb and the closely related proteins p107 and p130. lin-53 encodes a protein similar to RbAp48, a mammalian protein that binds Rb. In mammals, Rb and related proteins act as regulators of E2F transcription factors, and RbAp48 may act with such proteins as a transcriptional corepressor. We propose that LIN-35 and LIN-53 antagonize the Ras signaling pathway in C. elegans by repressing transcription in the vulval precursor cells of genes required for the expression of vulval cell fates.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.	horvitz@mit.edu						Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BEITEL GJ, 1994, THESIS MIT CAMBRIDGE; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1994, GENETICS, V137, P987; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELLIS RE, 1995, GENETICS, V139, P561; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEDGECOCK EM, 1995, GENETICS, V141, P989; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Priess J. R., 1997, C ELEGANS 2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BD, 1992, GENETICS, V131, P609; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	64	257	281	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					981	991		10.1016/S0092-8674(00)81722-5	http://dx.doi.org/10.1016/S0092-8674(00)81722-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875852	Bronze			2022-12-24	WOS:000077759100013
J	Greenhill, LJ; Gwinn, CR; Schwartz, C; Moran, JM; Diamond, PJ				Greenhill, LJ; Gwinn, CR; Schwartz, C; Moran, JM; Diamond, PJ			Coexisting conical bipolar and equatorial outflows from a high-mass protostar	NATURE			English	Article							STAR-FORMING REGION; HERBIG-HARO OBJECTS; ORION-KL; SUBARCSECOND-RESOLUTION; PROPER MOTIONS; EMISSION; NEBULA; FLOWS; DISKS; IRC2	The BN/KL region in the Orion molecular cloud(1) is an archetype for the study of the formation of stars much more massive than the Sun(2). This region contains luminous young stars and protostars but, like most star-forming regions, is difficult to study in detail because of the obscuring effects of dust and gas. Our basic expectations are shaped to some extent by the present theoretical picture of star formation, the cornerstone of which is that protostars accrete gas from rotating equatorial disks and shed angular momentum by ejecting gas in bipolar outflows. The main source of the outflow in the BN/KL region(3-5) may be an object known as radio source I (ref. 6), which is commonly believed to be surrounded by a rotating disk of molecular material(7-9). Here we report high-resolution observations of silicon monoxide (SiO) and water maser emission from the gas surrounding source I. We show that within 60 AU of the source (about the size of the Solar System), the region is dominated by a conical bipolar outflow rather than the expected disk A slower outflow, close to the equatorial plane of the protostellar system, extends to radii of 1,000 AU.	Ctr Astrophys, Cambridge, MA 02138 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Maria Mitchell Observ, Nantucket, MA 02554 USA; Natl Radio Astron Observ, Socorro, NM 87801 USA	University of California System; University of California Santa Barbara; National Radio Astronomy Observatory (NRAO)	Greenhill, LJ (corresponding author), Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.			Moran, James/0000-0002-3882-4414				ALLEN DA, 1993, NATURE, V363, P54, DOI 10.1038/363054a0; BARVAINIS R, 1984, ASTROPHYS J, V279, P358, DOI 10.1086/161896; CHANDLER CJ, 1995, ASTROPHYS J, V455, pL67, DOI 10.1086/309814; CHURCHWELL E, 1987, ASTROPHYS J, V321, P516, DOI 10.1086/165648; DANCHI WC, 1994, ASTRON J, V107, P1469, DOI 10.1086/116960; DOUGADOS C, 1993, ASTROPHYS J, V406, P112, DOI 10.1086/172424; GARAY G, 1989, ASTROPHYS J, V338, P244, DOI 10.1086/167195; Gaume RA, 1998, ASTROPHYS J, V493, P940, DOI 10.1086/305161; GENZEL R, 1981, ASTROPHYS J, V244, P884, DOI 10.1086/158764; GENZEL R, 1989, ANNU REV ASTRON ASTR, V27, P41, DOI 10.1146/annurev.aa.27.090189.000353; GEZARI DY, 1992, ASTROPHYS J, V396, pL43, DOI 10.1086/186513; GEZARI DY, 1995, ASTROPHYS SPACE SCI, V224, P45; GREENHILL LJ, 1988, IMPACT VLBI ASTROPHY, P253; Hu XH, 1996, ASTRON J, V112, P2712, DOI 10.1086/118215; JONES BF, 1985, ASTRON J, V90, P1320, DOI 10.1086/113837; KLEINMAN.DE, 1967, ASTROPHYS J, V149, pL1, DOI 10.1086/180039; LUCAS R, 1992, ASTRON ASTROPHYS, V262, P491; MENTEN KM, 1995, ASTROPHYS J, V445, pL157, DOI 10.1086/187913; MIGENES V, 1989, ASTROPHYS J, V347, P294, DOI 10.1086/168118; MORITA R, 1991, CANCER RES, V51, P3; PHAMBCK RL, 1990, ASTROPHYS J, V348, pL65; PLAMBECK RL, 1995, ASTROPHYS J, V455, pL189, DOI 10.1086/309830; Rao R, 1998, ASTROPHYS J, V502, pL75, DOI 10.1086/311485; Schleuning DA, 1998, ASTROPHYS J, V493, P811, DOI 10.1086/305139; SHU FH, 1995, ASTROPHYS J, V455, pL155, DOI 10.1086/309838; SUGAI H, 1995, ASTROPHYS J, V442, P674, DOI 10.1086/175472; THRONSON HA, 1986, ASTRON J, V91, P1350, DOI 10.1086/114110; Torrelles JM, 1998, ASTROPHYS J, V505, P756, DOI 10.1086/306205; WARDLE M, 1993, ASTROPHYS J, V410, P218, DOI 10.1086/172739; WRIGHT MCH, 1995, ASTROPHYS J, V455, pL185, DOI 10.1086/309829; Wright MCH, 1996, ASTROPHYS J, V469, P216, DOI 10.1086/177773; ZENSUS JA, 1995, VERY LONG BASELINE L	32	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					650	653		10.1038/25299	http://dx.doi.org/10.1038/25299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872312	Green Submitted			2022-12-24	WOS:000077694200045
J	Hung, LW; Wang, IXY; Nikaido, K; Liu, PQ; Ames, GFL; Kim, SH				Hung, LW; Wang, IXY; Nikaido, K; Liu, PQ; Ames, GFL; Kim, SH			Crystal structure of the ATP-binding subunit of an ABC transporter	NATURE			English	Article							PERIPLASMIC HISTIDINE PERMEASE; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; TRAFFIC ATPASE; PROTEIN; IDENTIFICATION; RESOLUTION; HYDROLYSIS; HUMANS	ABC transporters (also known as traffic ATPases) form a large family of proteins responsible for the translocation of a variety of compounds across membranes of both prokaryotes and eukaryotes'. The recently completed Escherichia coli genome sequence revealed that the largest family of paralogous E. coli proteins is composed of ABC transporters(2), Many eukaryotic proteins of medical significance belong to this family, such as the cystic fibrosis transmembrane conductance regulator (CFTR), the P-glycoprotein (or multidrug-resistance protein) and the heterodimeric transporter associated with antigen processing (Tap1-Tap2). Here we report the crystal structure at 1.5 Angstrom resolution of HisP, the ATP-binding subunit of the histidine permease, which is an ABC transporter from Salmonella typhimurium, We correlate the details of this structure with the biochemical, genetic and biophysical properties of the wild-type and several mutant HisP proteins. The structure provides a basis for understanding properties of ABC transporters and of defective CFTR proteins.	Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.	shkim@lbl.gov						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; Bianchet MA, 1997, J BIOENERG BIOMEMBR, V29, P503, DOI 10.1023/A:1022443209010; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KIM SH, 1993, HDB EXPT PHARM, P177; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKIN DL, 1993, CELLS HEPATIC SINUSO, V4, P26; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pal E.F., 1989, NATURE, V341, P209; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	30	596	604	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1998	396	6712					703	707		10.1038/25393	http://dx.doi.org/10.1038/25393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872322				2022-12-24	WOS:000077694200060
J	Li, FZ; Ambrosini, G; Chu, EY; Plescia, J; Tognin, S; Marchisio, PC; Altieri, DC				Li, FZ; Ambrosini, G; Chu, EY; Plescia, J; Tognin, S; Marchisio, PC; Altieri, DC			Control of apoptosis and mitotic spindle checkpoint by survivin	NATURE			English	Article							CELL-CYCLE; PROTEINS; MICROTUBULES; EXPRESSION; FAMILY; DEATH; BCL-2; GENES; IAP	Progression of the cell cycle and control of apoptosis (programmed cell death) are thought to be intimately linked processes(1), acting to preserve homeostasis and developmental morphogenesis(2). Although proteins that regulate apoptosis have been implicated in restraining cell-cycle entry(3) and controlling ploidy (chromosome number)(4), the effector molecules at the interface between cell proliferation and cell survival have remained elusive. Here we show that a new inhibitor of apoptosis (IAP) protein(5,6), survivin(7), is expressed in the G2/M phase of the cell cycle in a cycle-regulated manner. At the beginning of mitosis, survivin associates with microtubules of the mitotic spindle in a specific and saturable reaction that is regulated by microtubule dynamics(8). Disruption of survivin-microtubule interactions results in loss of survivin's anti-apoptosis function and increased caspase-3 activity, a mechanism involved in cell death, during mitosis. These results indicate that survivin may counteract a default induction of apoptosis in G2/M phase. The overexpression of survivin in cancer(7) may overcome this apoptotic checkpoint and favour aberrant progression of transformed cells through mitosis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy	Yale University; Vita-Salute San Raffaele University; University of Turin	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, 295 Congress Ave, New Haven, CT 06536 USA.	dario.altieri@yale.edu	Li, Fengzhi/GXF-0115-2022		Telethon [496] Funding Source: Medline	Telethon(Fondazione Telethon)		Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; OSBORN M, 1977, CELL, V12, P561, DOI 10.1016/0092-8674(77)90257-4; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; TAMM I, IN PRESS CANC RES; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	24	1605	1887	1	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					580	584		10.1038/25141	http://dx.doi.org/10.1038/25141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859993				2022-12-24	WOS:000077466800059
J	Jayawant, S; Rawlinson, A; Gibbon, F; Price, J; Schulte, J; Sharples, P; Sibert, JR; Kemp, AM				Jayawant, S; Rawlinson, A; Gibbon, F; Price, J; Schulte, J; Sharples, P; Sibert, JR; Kemp, AM			Subdural haemorrhages in infants: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEAD-INJURY; SHAKEN; ABUSE; BABY	Objectives. To identify the incidence, clinical outcome, and associated factors of subdural haemorrhage in children under 2 years of age, and to determine how such cases were investigated and how many were due to child abuse. Design Population based case series. Setting South Wales and south west England. Subjects Children under 2 years of age who had a subdural haemorrhage, We excluded neonates developed subdural haemorrhage during their stay on a neonatal unit and infants who developed a subdural haemorrhage after infection or neurosurgical intervention. Main outcome measures Incidence and clinical outcome of subdural haemorrhage in infants, the number of cases caused by child abuse, the investigations such children received, and associated risk factors. Results Thirty three children (23 boys and 10 girls) were identified with subdural haemorrhage. The incidence was 12.8/100 000 children/year (95% confidence interval 5.4 to 20.2). Twenty eight cases (85%) were under 1 year of age. The incidence of subdural haemorrhage in children under 1 year of age was 21.0/100 000 children/year and was therefore higher than in the older children. The clinical outcome was poor: nine infants died and 15 had profound disability. Only 22 infants had the basic investigations of a full blood count, coagulation screen, computed tomography or magnetic resonance imaging, skeletal survey or bone scan, and ophthalmological examination. In retrospect, 27 cases (82%) were highly suggestive of abuse. Conclusion Subdural haemorrhage is common in infancy and carries a poor prognosis; three quarters of such infants die or have profound disability. Most cases are due to child abuse, but in a few the cause is unknown. Some children with subdural haemorrhage do not undergo appropriate investigations. We believe the clinical investigation of such children should include a full multidisciplinary social assessment, an ophthalmic examination, a skeletal survey supplemented with a bone scan or a skeletal survey repeated at around 10 days, a coagulation screen, and computed tomography or magnetic resonance imaging. Previous physical abuse in an infant is a significant risk factor for subdural haemorrhage and must be taken seriously by child protection agencies.	Univ Wales, Coll Med, Dept Child Hlth, Llandough Hosp,Acad Ctr, Penarth CF64 2XX, Vale Glamorgan, Wales; Southmead Gen Hosp, Dept Child Hlth, Bristol BS10 5NB, Avon, England; Frenchay Hosp, Bristol BS16 1LE, Avon, England	Southmead Hospital	Kemp, AM (corresponding author), Univ Wales, Coll Med, Dept Child Hlth, Llandough Hosp,Acad Ctr, Penarth CF64 2XX, Vale Glamorgan, Wales.	kempam@cardiff.acuk						ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; *BRIT PAED SURV UN, 1991, 6 BRIT PAED ASS; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CARTY H, 1995, BRIT MED J, V310, P344, DOI 10.1136/bmj.310.6976.344; Department of Health, 1996, CONF ENQ STILLB DEAT; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HALLER J D, 1991, Pediatrics, V87, P262; KAUR B, 1992, SURV OPHTHALMOL, V37, P1, DOI 10.1016/0039-6257(92)90002-B; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; OHARE AE, 1984, ARCH DIS CHILD, V59, P860, DOI 10.1136/adc.59.9.860; SALMAN M, 1997, PAEDIAT TODAY, V5, P42; SHOWERS J, 1992, CHILD ABUSE NEGLECT, V16, P11, DOI 10.1016/0145-2134(92)90004-B; TARDIEU A, 1860, ANN HYG PUBLIQUE MED, V13, P361, DOI DOI 10.3917/EP.039.0174; Wilkins B, 1997, ARCH DIS CHILD, V76, P393, DOI 10.1136/adc.76.5.393	23	196	201	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1558	+		10.1136/bmj.317.7172.1558	http://dx.doi.org/10.1136/bmj.317.7172.1558			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836654	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000077451700022
J	Himanen, JP; Henkemeyer, M; Nikolov, DB				Himanen, JP; Henkemeyer, M; Nikolov, DB			Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2	NATURE			English	Article							NEURAL CREST MIGRATION; TRANSMEMBRANE LIGANDS; COMMISSURAL AXONS; NUK; GUIDANCE; COMPLEX; PATTERN	The Eph receptors, which bind a group of cell-membrane-anchored ligands known as ephrins, represent the largest subfamily of receptor tyrosine kinases (RTKs)(1). They are predominantly expressed in the developing and adult nervous system(2) and are important in contact-mediated axon guidance(3-6), axon fasciculation(5,7) and cell migations(8-11). Eph receptors are unique among other RTKs in that they fall into two subclasses with distinct Ligand specificities(12), and in that they can themselves function as ligands to activate bidirectional cell-cell signalling(4,13,14). We report here the crystal structure at 2.9 Angstrom resolution of the amino-terminal ligand-binding domain of the EphB2 receptor (also known as NUk)(15-17). Th, domain folds into a compact jellyroll beta-sandwich composed of 11 antiparallel beta-strands. Using structure-based mutagenesis, we have identified an extended loop that is important for ligand binding and class specificity. This loop, which is conserved within but not between Eph RTK subclasses, packs against the concave beta-sandwich surface near positions at which missense mutations cause signalling defects(18), localizing the ligand-binding region on the surface of the receptor.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA	Memorial Sloan Kettering Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nikolov, DB (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	Dimitar@ximpact3.number.lnuk		Henkemeyer, Mark/0000-0002-7525-1061				[Anonymous], 1997, Cell, V90, P403; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BRUNGER AT, 1993, XPLOR V 3 1 MANUAL; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WU Q, 1995, DEVELOPMENT, V121, P4005	30	87	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1998	396	6710					486	491		10.1038/24904	http://dx.doi.org/10.1038/24904			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853759				2022-12-24	WOS:000077370100059
J	Rutherford, SL; Lindquist, S				Rutherford, SL; Lindquist, S			Hsp90 as a capacitor for morphological evolution	NATURE			English	Article							STEROID-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; IN-VIVO; DROSOPHILA; NEUTRALITY; MUTATIONS; HSP83	The heat-shock protein Hsp90 supports diverse but specific signal transducers and lies at the interface of several developmental pathways. We report here that when Drosophila Hsp90 is mutant or pharmacologically Impaired, phenotypic variation affecting nearly any adult structure is produced, with specific variants depending on the genetic background and occurring both in laboratory strains and in wild populations. Multiple, previously silent, genetic determinants produced these variants and, when enriched by selection, they rapidly became independent of the Hsp90 mutation, Therefore, widespread variation affecting morphogenic pathways exists in nature, but is usually silent; Hsp90 buffers this variation, allowing it to accumulate under neutral conditions, When Hsp90 buffering is compromised, for example by temperature, cryptic variants are expressed and selection can lead to the continued expression of these traits, even when Hsp90 function is restored. This provides a plausible mechanism for promoting evolutionary change in otherwise entrenched developmental processes.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Calif Irvine, Ctr Dev Biol, 4205 Biol Sci 2, Irvine, CA 92697 USA.							Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DEJONG G, 1976, GENETICS, V84, P77; Dickson BJ, 1996, GENETICS, V142, P163; DYKHUIZEN D, 1980, GENETICS, V96, P801; Falconer D. S., 1996, INTRO QUANTITATIVE G; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Futuyama D.J., 1998, EVOLUTIONARY BIOL; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Kauffman S. A., 1993, ORIGINS ORDER SELF O; Kimura M, 1985, NEUTRAL THEORY MOL E; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Polaczyk PJ, 1998, DEV GENES EVOL, V207, P462, DOI 10.1007/s004270050137; Raff R.A, 1996, SHAPE LIFE GENES DEV; RENDEL JM, 1965, GENETICS, V52, P1137; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WADDINGTON CH, 1953, EVOLUTION, V7, P118, DOI 10.2307/2405747; Wade MJ, 1997, GENETICS, V147, P1235; WAGNER GP, 1984, BIOSYSTEMS, V17, P51, DOI 10.1016/0303-2647(84)90015-7; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; XU Y, IN PRESS P NATL ACAD; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	37	1602	1677	1	215	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					336	342		10.1038/24550	http://dx.doi.org/10.1038/24550			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845070				2022-12-24	WOS:000077204000040
J	Usui, T; Ohta, T; Oshiumi, H; Tomizawa, J; Ogawa, H; Ogawa, T				Usui, T; Ohta, T; Oshiumi, H; Tomizawa, J; Ogawa, H; Ogawa, T			Complex formation and functional versatility of Mre11 of budding yeast in recombination	CELL			English	Article							DOUBLE-STRAND BREAKS; MEIOTIC CHROMOSOME SYNAPSIS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; INITIATION SITE; CELL-CYCLE; DNA-REPAIR; MEIOSIS; GENE; PROTEIN	Meiotic recombination of S. cerevisiae contains two temporally coupled processes, formation and processing of double-strand breaks (DSBs). Mre11 forms a complex with Rad50 and Xrs2, acting as the binding core, and participates in DSB processing. Although these proteins are also involved in DSB formation, Mre11 is not necessarily holding them. The C-terminal region of Mre11 is required only for DSB formation and binds to some meiotic proteins. The N-terminal half specifies nuclease activities that are collectively required for DSB processing. Mre11 has a DNA-binding site for DSB formation and another site for DSB processing. It has two regions to bind to Rad50. Mre11 repairs methyl methanesulfonate-induced DSBs by reactions that require the nuclease activities and those that do not.	Natl Inst Genet, Shizuoka 4118540, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Osaka University	Ohta, T (corresponding author), Natl Inst Genet, Shizuoka 4118540, Japan.		Oshiumi, Hiroyuki/G-1645-2012	Oshiumi, Hiroyuki/0000-0003-1567-8722				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BHARGAVA J, 1992, GENETICS, V130, P59; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DETLOFF P, 1992, GENETICS, V132, P113; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McKee AHZ, 1997, GENETICS, V146, P797; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Prinz S, 1997, GENETICS, V146, P781; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tsukamoto Y, 1997, MOL GEN GENET, V255, P543, DOI 10.1007/s004380050527; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x	35	290	300	2	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					705	716		10.1016/S0092-8674(00)81640-2	http://dx.doi.org/10.1016/S0092-8674(00)81640-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845372	Bronze			2022-12-24	WOS:000077253700017
J	Bunz, F; Dutriaux, A; Lengauer, C; Waldman, T; Zhou, S; Brown, JP; Sedivy, JM; Kinzler, KW; Vogelstein, B				Bunz, F; Dutriaux, A; Lengauer, C; Waldman, T; Zhou, S; Brown, JP; Sedivy, JM; Kinzler, KW; Vogelstein, B			Requirement for p53 and p21 to sustain G(2) arrest after DNA damage	SCIENCE			English	Article							CELL-CYCLE; HUMAN FIBROBLASTS; CHECKPOINT CONTROL; S-PHASE; KINASE; EXPRESSION; INHIBITOR; MITOSIS; GROWTH; CANCER	After DNA damage, many cells appear to enter a sustained arrest in the G(2) phase of the cell cycle. It is shown here that this arrest could be sustained only when p53 was present in the cell and capable of transcriptionally activating the cyclin-dependent kinase inhibitor p21. After disruption of either the p53 or the p21 gene, gamma radiated cells progressed into mitosis and exhibited a G(2) DNA content only because of a failure of cytokinesis. Thus, p53 and p21 appear to be essential for maintaining the G(2) checkpoint in human cells.	Johns Hopkins Oncol Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Div Biol & Med, Providence, RI 02912 USA; Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Brown University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Vogelstein, B (corresponding author), Johns Hopkins Oncol Ctr, Howard Hughes Med Inst, 424 N Bond St, Baltimore, MD 21231 USA.			Dutriaux, Annie/0000-0002-4398-4850	NATIONAL CANCER INSTITUTE [R01CA057345, R01CA043460, R37CA057345, R37CA043460, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57345, CA 43460, CA 62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUNZ F, UNPUB; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1995, CANCER RES, V55, P1649; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1994, ONCOGENE, V9, P2261; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MICHIELI P, 1994, CANCER RES, V54, P3391; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olive PL, 1996, RADIAT RES, V146, P595, DOI 10.2307/3579374; Paoletti A, 1997, Prog Cell Cycle Res, V3, P285; PAULES RS, 1995, CANCER RES, V55, P17563; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEWART N, 1995, ONCOGENE, V10, P109; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang BB, 1996, BIOCHEM J, V314, P313, DOI 10.1042/bj3140313; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	48	2491	2568	1	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1497	1501		10.1126/science.282.5393.1497	http://dx.doi.org/10.1126/science.282.5393.1497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822382				2022-12-24	WOS:000077110800057
J	Liu, SP; Widom, J; Kemp, CW; Crews, CM; Clardy, J				Liu, SP; Widom, J; Kemp, CW; Crews, CM; Clardy, J			Structure of human methionine aminopeptidase-2 complexed with fumagillin	SCIENCE			English	Article							ANGIOGENESIS INHIBITOR TNP-470; TUMOR-GROWTH; IN-VIVO; METASTASIS; CANCER; AGENT; REFINEMENT; CARCINOMA; PROGRAM	The fungal metabolite fumagillin suppresses the formation of new blood vessels, and a fumagillin analog is currently in clinical trials as an anticancer agent. The molecular target of fumagillin is methionine aminopeptidase-2 (MetAP-2). A 1.8 Angstrom resolution crystal structure of free and inhibited human MetAP-2 shows a covalent bond formed between a reactive epoxide of fumagillin and histidine-231 in the active site of MetAP-2. Extensive hydrophobic and water-mediated polar interactions with other parts of fumagillin provide additional affinity. Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1, and the three-dimensional structure also indicates the likely determinants of this specificity. The structural basis for fumagillin's potency and specificity forms the starting point for structure-based drug design.	Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Kemp Biotechnol Inc, Frederick, MD 21704 USA	Cornell University; Yale University	Clardy, J (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.		Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005	NATIONAL CANCER INSTITUTE [R01CA059021, R01CA024487] Funding Source: NIH RePORTER; NCI NIH HHS [CA24487, CA59021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Dezube BJ, 1998, J CLIN ONCOL, V16, P1444, DOI 10.1200/JCO.1998.16.4.1444; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; HANSON FR, 1949, J BACTERIOL, V58, P527, DOI 10.1128/JB.58.4.527-529.1949; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawarada Y, 1997, PANCREAS, V15, P251, DOI 10.1097/00006676-199710000-00006; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; Konno H, 1996, CANCER-AM CANCER SOC, V77, P1736; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; MCCOWEN MC, 1951, SCIENCE, V113, P202, DOI 10.1126/science.113.2930.202; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohta Y, 1997, BRIT J CANCER, V75, P512, DOI 10.1038/bjc.1997.89; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Singh Y, 1997, BREAST CANCER RES TR, V45, P15, DOI 10.1023/A:1005826129756; Tahirov TH, 1998, J STRUCT BIOL, V121, P68, DOI 10.1006/jsbi.1997.3940; Twardowski Przemyslaw, 1997, Current Opinion in Oncology, V9, P584, DOI 10.1097/00001622-199711000-00015; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang Jieyi, 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P98; Wassberg E, 1997, EUR J CANCER, V33, P2020, DOI 10.1016/S0959-8049(97)00337-7; Xia JL, 1997, J CANCER RES CLIN, V123, P383, DOI 10.1007/BF01240121	28	371	405	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1324	1327		10.1126/science.282.5392.1324	http://dx.doi.org/10.1126/science.282.5392.1324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812898				2022-12-24	WOS:000076982200047
J	DeLeo, VA				DeLeo, VA			Skin testing in systemic cutaneous drug reactions	LANCET			English	Editorial Material									St Lukes Roosevelt Hosp Ctr, Dept Dermatol, New York, NY 10025 USA	Mount Sinai St. Luke's; Mount Sinai West	DeLeo, VA (corresponding author), St Lukes Roosevelt Hosp Ctr, Dept Dermatol, New York, NY 10025 USA.							ADKINSON NF, 1989, ALLERGY PRINCIPLES P, P1212; Barbaud A, 1998, BRIT J DERMATOL, V139, P49; Breathnach S M, 1995, Australas J Dermatol, V36, P121, DOI 10.1111/j.1440-0960.1995.tb00953.x; Markss JG, 1997, CONTACT OCCUPATIONAL; ROUGEAU JC, 1994, NEW ENGL J MED, V331, P1272; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9	6	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1488	1490		10.1016/S0140-6736(05)60323-6	http://dx.doi.org/10.1016/S0140-6736(05)60323-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820294				2022-12-24	WOS:000076862300004
J	Florence, SL; Taub, HB; Kaas, JH				Florence, SL; Taub, HB; Kaas, JH			Large-scale sprouting of cortical connections after peripheral injury in adult macaque monkeys	SCIENCE			English	Article							SOMATOSENSORY CORTEX; PERCEPTUAL PLASTICITY; LIMB AMPUTATION; STRIATE CORTEX; REORGANIZATION; REPRESENTATIONS; DEAFFERENTATION; AREA-3B; HAND; CAT	Distributions of thalamic and cortical connections were investigated in four macaque monkeys with long-standing, accidental trauma to a forelimb, to determine whether the growth of new connections plays a role in the reorganization. of somatosensory cortex that occurs after major alterations in peripheral somatosensory inputs, In each monkey, microelectrode recordings of cortical areas 3b and 1 demonstrated massive reorganizations of the cortex related to the affected limb. injections of tracers in area 1 of these monkeys revealed normal patterns of thalamocortical connections, but markedly expanded lateral connections in areas 3b and 1. Thus, the growth of intracortical but not thalamocortical connections could account for much of the reorganization of the sensory maps in cortex.	Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA	Vanderbilt University	Florence, SL (corresponding author), Vanderbilt Univ, Dept Psychol, 301 Wilson Hall, Nashville, TN 37240 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036469, R01NS016446] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BURTON H, 1995, J COMP NEUROL, V355, P508, DOI 10.1002/cne.903550404; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1995, J NEUROSCI, V15, P8083; GARRAGHTY PE, 1994, SOMATOSENS MOT RES, V11, P109, DOI 10.3109/08990229409028864; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; HALLIGAN PW, 1994, NEUROREPORT, V5, P1341, DOI 10.1097/00001756-199406000-00012; Jain N, 1997, NATURE, V386, P495, DOI 10.1038/386495a0; KRUBITZER LA, 1990, J NEUROSCI, V10, P952; NELSON RJ, 1981, J COMP NEUROL, V199, P29, DOI 10.1002/cne.901990104; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10413, DOI 10.1073/pnas.90.22.10413	16	342	348	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1117	1121		10.1126/science.282.5391.1117	http://dx.doi.org/10.1126/science.282.5391.1117			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804549				2022-12-24	WOS:000076887700049
J	Nightingale, SL				Nightingale, SL			New drug to treat HIV/AIDS approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	34	37	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1472	1472		10.1001/jama.280.17.1472-b	http://dx.doi.org/10.1001/jama.280.17.1472-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809716				2022-12-24	WOS:000076757200004
J	Lawson, M; Thomas, M				Lawson, M; Thomas, M			Vitamin D concentrations in Asian children aged 2 years living in England: population survey	BRITISH MEDICAL JOURNAL			English	Article									Inst Child Hlth, Childrens Nutr Res Ctr, London WC1N 1EH, England; Off Natl Stat, London SW1V 2QQ, England	University of London; University College London	Thomas, M (corresponding author), Inst Child Hlth, Childrens Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.							ARNAUD SB, 1976, PEDIATRICS, V57, P221; Gregory JR, 1995, NATL DIET NUTR SURVE, V1; GRINDULIS H, 1986, ARCH DIS CHILD, V61, P843, DOI 10.1136/adc.61.9.843; Lawson MS, 1998, ARCH DIS CHILD, V78, P420, DOI 10.1136/adc.78.5.420; THOMAS M, 1997, INFANT FEEDING ASIAN	5	87	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					28	28						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872879	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000078013100022
J	Masera, G; Baez, F; Biondi, A; Cavalli, F; Conter, V; Flores, A; Fontana, G; Bellani, FF; Lanfranco, P; Malta, A; Mendez, G; Ocampo, E; Pacheco, C; Riva, L; Sala, A; Silva, F; Sessa, C; Tognoni, G				Masera, G; Baez, F; Biondi, A; Cavalli, F; Conter, V; Flores, A; Fontana, G; Bellani, FF; Lanfranco, P; Malta, A; Mendez, G; Ocampo, E; Pacheco, C; Riva, L; Sala, A; Silva, F; Sessa, C; Tognoni, G			North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD; FEATURES; HEALTH; ONSET	We describe the La Mascota twinning programme between La Mascota paediatric hospital in Managua, Nicaragua, and hospitals in Monza and Milan, Italy, and Bellinzona, Switzerland, The programme was based on the belief that an attempt to reduce the gap in mortality from cancer in childhood between developed and less developed countries should become an integral part of the care and research activity of a haemato-oncological department of a developed country and not simply an exercise in solidarity. This programme for acute lymphoblastic leukaemia shows that intellectual, organisational, and financial resources can be generated by a twinning programme, What is vital for such programmes is a long-term commitment to a comprehensive and holistic strategy that incorporates supply of drugs, training and supervision of health professionals, and the care of the children and of their parents.	Univ Milan, S Gerardo Hosp, Pediat Clin, I-20052 Monza, Italy; Manuel Jesus Rivera La Mascota Hosp, Paediat Hematooncol Dept, Managua, Nicaragua; S Giovanni Hosp, Dept Oncol, Bellinzona, Switzerland; Ist Nazl Tumori, Dept Paediat Oncol, I-20133 Milan, Italy; Ist Ric Farmacol Mario Negri, Milan, Italy	University of Milan; Regional Hospital of Bellinzona & Valleys, San Giovanni; Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Masera, G (corresponding author), Univ Milan, S Gerardo Hosp, Pediat Clin, I-20052 Monza, Italy.		Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016	Biondi, Andrea/0000-0002-6757-6173; 				ALBER JL, 1997, ANNU REV PUBL HEALTH, V18, P463; Baez F, 1997, ANN ONCOL, V8, P247, DOI 10.1023/A:1008200210674; CHANDY M, 1995, MED PEDIATR ONCOL, V25, P197, DOI 10.1002/mpo.2950250307; COREA AM, 1993, ANN ONCOL, V4, P892, DOI 10.1093/oxfordjournals.annonc.a058400; Flores A, 1996, MED PEDIATR ONCOL, V26, P258, DOI 10.1002/(SICI)1096-911X(199604)26:4<258::AID-MPO7>3.0.CO;2-I; HALLORAN ME, 1989, AM J PUBLIC HEALTH, V79, P424, DOI 10.2105/AJPH.79.4.424; HALPERIN DC, 1982, NEW ENGL J MED, V307, P388, DOI 10.1056/NEJM198208053070634; Howson CP, 1998, LANCET, V351, P586, DOI 10.1016/S0140-6736(97)11452-0; Jareg P, 1998, LANCET, V351, P819, DOI 10.1016/S0140-6736(97)11454-4; Lamontagne JF, 1998, SOC SCI MED, V46, P403, DOI 10.1016/S0277-9536(97)00184-6; Magrath I, 1993, PRINCIPLES PRACTICE, P1225; Malta A, 1997, INT J PEDIAT HEM ONC, V4, P121; MASERA G, 1993, ANN ONCOL, V4, P37, DOI 10.1093/oxfordjournals.annonc.a058354; PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408; PIZZO PA, 1993, PRINCIPLES PRACTICE, P1226; Reading R, 1997, ARCH DIS CHILD, V76, P463, DOI 10.1136/adc.76.5.463; ROBERTS H, 1997, BMJ-BRIT MED J, V314, P122; TOGNONI G, 1993, ANN ONCOL, V4, P7, DOI 10.1093/oxfordjournals.annonc.a058366; WAGNER HP, ANN NY ACAD, V824, P193; Walt G, 1998, LANCET, V351, P434, DOI 10.1016/S0140-6736(97)05546-3; World Bank, 1993, WORLD DEV REP 1993 I; 1997, SIOP NEWS, V17, P32	22	90	90	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1998	352	9144					1923	1926		10.1016/S0140-6736(98)07077-9	http://dx.doi.org/10.1016/S0140-6736(98)07077-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863803				2022-12-24	WOS:000077544600044
J	Muntwyler, J; Hennekens, CH; Buring, JE; Gaziano, JM				Muntwyler, J; Hennekens, CH; Buring, JE; Gaziano, JM			Mortality and light to moderate alcohol consumption after myocardial infarction	LANCET			English	Article							CORONARY HEART-DISEASE; U-SHAPED CURVE; BLOOD-PRESSURE; RISK; MORBIDITY; ETHANOL	Background Although heavy alcohol consumption increases total mortality, light to moderate consumption decreases cardiovascular and all-cause mortality in apparently healthy people. Since data are sparse on the relation of light to moderate alcohol intake to mortality in patients with previous myocardial infarction, we did a prospective study of mortality in men. Methods Of 90 150 men in the Physicians' Health Study enrolment cohort who provided information on alcohol intake and who had no history of cancer, stroke, or liver disease, 5358 had a previous myocardial infarction. We estimated alcohol consumption by food-frequency questionnaire. Findings During a mean follow-up of 5 years, 920 men died. After adjustment for several potential confounders, moderate alcohol intake was associated with a significant decrease in total mortality (p=0.016). Compared with men who rarely or never drank alcohol, those who drank one to four drinks per month had a relative risk for total mortality of 0.85 (95% CI 0.69-1.05); for two to four drinks per week, the relative risk was 0.72 (0.58-0.89); for one drink per day 0.79 (0.64-9.96); and for two or more drinks per day 0.84 (0.55-1.26). Interpretation Men with previous myocardial infarction who consume small to moderate amounts of alcohol have a lower total mortality.	Vet Affairs Med Ctr, Massachusetts Vet Epidemiol Res & Informat Ctr, W Roxbury, MA 02132 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med & Cardiovasc Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Gaziano, JM (corresponding author), Vet Affairs Med Ctr, Massachusetts Vet Epidemiol Res & Informat Ctr, 1600 VFW Pkwy, W Roxbury, MA 02132 USA.	gaziano@maveric.org			NHLBI NIH HHS [HL-42441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARKWRIGHT PD, 1982, CIRCULATION, V66, P60, DOI 10.1161/01.CIR.66.1.60; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; Longnecker MP, 1996, CLIN CHIM ACTA, V246, P121, DOI 10.1016/0009-8981(96)06232-8; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MARMOT MG, 1981, LANCET, V1, P580; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; ORENCIA A, 1993, JAMA-J AM MED ASSOC, V269, P2392, DOI 10.1001/jama.269.18.2392; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; SHAPER AG, 1988, LANCET, V2, P1267; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; THOMAS AP, 1994, ALCOHOL CLIN EXP RES, V18, P121, DOI 10.1111/j.1530-0277.1994.tb00891.x; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701	23	139	142	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 12	1998	352	9144					1882	1885		10.1016/S0140-6736(98)06351-X	http://dx.doi.org/10.1016/S0140-6736(98)06351-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148QZ	9863785				2022-12-24	WOS:000077544600008
J	Jacobs, MD; Harrison, SC				Jacobs, MD; Harrison, SC			Structure of an I kappa B alpha/NF-kappa B complex	CELL			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DNA-BINDING ACTIVITY; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; CYTOPLASMIC RETENTION; STRUCTURE REFINEMENT; PROTEIN; SIGNAL; P50; ACTIVATION	The inhibitory protein, I kappa B alpha, sequesters the transcription factor, NF-kappa B, as an inactive complex in the cytoplasm. The structure of the I kappa B alpha ankyrin repeat domain, bound to a partially truncated NF-kappa B heterodimer (p50/p65), has been determined by X-ray crystallography at 2.7 Angstrom resolution. It shows a stack of six I kappa B alpha ankyrin repeats facing the C-terminal domains of the NF-kappa B Rel homology regions. Contacts occur in discontinuous patches, suggesting a combinatorial quality for ankyrin repeat specificity. The first two repeats cover an alpha helically ordered segment containing the p65 nuclear localization signal. The position of the sixth ankyrin repeat shows that full-length I kappa B alpha Will occlude the NF-kappa B DNA-binding cleft. The orientation of I kappa B alpha in the complex places its N- and C-terminal regions in appropriate locations for their known regulatory functions.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	harrison@crystal.harvard.edu						ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunger AT, 1992, X PLOR VERSION 3 0 S; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; OTWINOSKI Z, 1993, DATA COLLECTION PROC; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1095, DOI 10.1016/S0960-894X(00)80294-2; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1089, DOI 10.1016/S0960-894X(00)80293-0; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	63	660	691	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					749	758		10.1016/S0092-8674(00)81698-0	http://dx.doi.org/10.1016/S0092-8674(00)81698-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865693	Bronze			2022-12-24	WOS:000077498800005
J	Locher, KP; Rees, B; Koebnik, R; Mitschler, A; Moulinier, L; Rosenbusch, JP; Moras, D				Locher, KP; Rees, B; Koebnik, R; Mitschler, A; Moulinier, L; Rosenbusch, JP; Moras, D			Transmembrane signaling across the ligand-gated FhuA receptor: Crystal structures of free and ferrichrome-bound states reveal allosteric changes	CELL			English	Article							ESCHERICHIA-COLI K-12; MICROBIAL IRON TRANSPORT; COMPLETE GENOME SEQUENCE; OUTER-MEMBRANE PROTEIN; ELECTRON-DENSITY MAPS; CELL-ENVELOPE; ANOMALOUS DIFFRACTION; PHAGE T5; BINDING; TONB	FhuA protein facilitates ligand-gated transport of ferrichrome-bound iron across Escherichia coli outer membranes. X-ray analysis at 2.7 Angstrom resolution reveals two distinct conformations in the presence and absence of ferrichrome. The monomeric protein consists of a hollow, 22-stranded, antiparallel beta barrel (residues 160-714), which is obstructed by a plug (residues 19-159). The binding site of ferrichrome, an aromatic pocket near the cell surface, undergoes minor changes upon association with the ligand. These are propagated and amplified across the plug, eventually resulting in substantially different protein conformations at the periplasmic face. Our findings reveal the mechanism of signal transmission and suggest how the energy-transducing Tons complex senses ligand binding.	ULP, Struct Biol Lab, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67400 Illkirch Graffenstaden, France; Univ Basel, Biozentrum, Dept Microbiol, CH-4056 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Basel	Moras, D (corresponding author), ULP, Struct Biol Lab, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, 1 Rue Laurent Fries, F-67400 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Koebnik, Ralf/J-5627-2014	Koebnik, Ralf/0000-0002-4419-0542				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1016/0168-6445(95)00003-U; BRAUN V, 1973, FEBS LETT, V34, P77, DOI 10.1016/0014-5793(73)80707-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DOHERTY AJ, 1995, NUCLEIC ACIDS RES, V23, P2074, DOI 10.1093/nar/23.11.2074; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DREW HR, 1982, P NATL ACAD SCI-BIOL, V79, P4040, DOI 10.1073/pnas.79.13.4040; EDMAN P, 1956, ACTA CHEM SCAND, V10, P761, DOI 10.3891/acta.chem.scand.10-0761; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HANTKE K, 1975, FEBS LETT, V49, P301, DOI 10.1016/0014-5793(75)80771-X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KILLMANN H, 1995, J BACTERIOL, V177, P694, DOI 10.1128/jb.177.3.694-698.1995; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Locher KP, 1997, EUR J BIOCHEM, V247, P770, DOI 10.1111/j.1432-1033.1997.t01-1-00770.x; Locher KP, 1997, J BIOL CHEM, V272, P1448, DOI 10.1074/jbc.272.3.1448; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; NAUCORNELISSEN C, 1994, MOL MICROBIOL, V40, P843; NAUCORNELISSEN C, 1998, MOL MICROBIOL, V27, P611; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plancon L, 1997, J BIOL CHEM, V272, P16868, DOI 10.1074/jbc.272.27.16868; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; SCHIEPEK G, 1995, PSYCHOTHERAPIE FORUM, V3, P1; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; Stevens MK, 1996, INFECT IMMUN, V64, P1724, DOI 10.1128/IAI.64.5.1724-1735.1996; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Unwin N, 1998, J STRUCT BIOL, V121, P181, DOI 10.1006/jsbi.1997.3949; VANDERHELM D, 1980, J AM CHEM SOC, V102, P4224, DOI 10.1021/ja00532a039; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0	47	445	456	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					771	778		10.1016/S0092-8674(00)81700-6	http://dx.doi.org/10.1016/S0092-8674(00)81700-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865695				2022-12-24	WOS:000077498800007
J	Nonaka, S; Tanaka, Y; Okada, Y; Takeda, S; Harada, A; Kanai, Y; Kido, M; Hirokawa, N				Nonaka, S; Tanaka, Y; Okada, Y; Takeda, S; Harada, A; Kanai, Y; Kido, M; Hirokawa, N			Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein	CELL			English	Article							KINESIN-LIKE PROTEIN; ORGANELLE TRANSPORT; SITUS-INVERSUS; NERVOUS-SYSTEM; MOUSE EMBRYOS; DYNEIN ARMS; EXPRESSION; GENE; MEMBRANE; MOTILITY	Microtubule-dependent motor, murine KIF3B, was disrupted by gene targeting. The null mutants did not survive beyond midgestation, exhibiting growth retardation, pericardial sac ballooning, and neural tube disorganization. Prominently, the left-right asymmetry was randomized in the heart loop and the direction of embryonic turning, lefty-2 expression was either bilateral or absent. Furthermore, the node lacked monocilia while the basal bodies were present. Immunocytochemistry revealed KIF3B localization in wildtype nodal cilia. Video microscopy showed that these cilia were motile and generated a leftward flow. These data suggest that KIF3B is essential for the left-right determination through intraciliary transportation of materials for ciliogenesis of motile primary cilia that could produce a gradient of putative morphogen along the left-right axis in the node.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, 7-3-1 Hongo, Tokyo 1130033, Japan.	hirokawa@m.u-tokyo.ac.jp	Takeda, Sen/I-8462-2012; Kanai, Yoshimitsu/W-3486-2019; Nonaka, Shigenori/I-2132-2013; Okada, Yasushi/N-5067-2015	Takeda, Sen/0000-0001-7090-2139; Nonaka, Shigenori/0000-0002-8093-0325; Okada, Yasushi/0000-0003-2601-3689; Tanaka, Yosuke/0000-0001-5376-5726; Kanai, Yoshimitsu/0000-0002-0375-6853				AFZELIUS BA, 1975, J CELL BIOL, V66, P225, DOI 10.1083/jcb.66.2.225; Afzelius BA, 1995, INT J DEV BIOL, V39, P839; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Beech PL, 1996, J CELL SCI, V109, P889; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1990, DEVELOPMENT, V109, P1; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Dufort D, 1998, DEVELOPMENT, V125, P3015; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HANDEL MA, 1984, J HERED, V75, P498, DOI 10.1093/oxfordjournals.jhered.a109995; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P2; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; ODOR DL, 1985, AM J ANAT, V174, P437, DOI 10.1002/aja.1001740407; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sambrook JFE, 1989, MOL CLONING LAB MANU; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; SHAKIR MA, 1993, NEUROREPORT, V4, P891, DOI 10.1097/00001756-199307000-00013; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TAM PPL, 1980, J EMBRYOL EXP MORPH, V59, P131; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; TANAKA Y, 1995, J CELL SCI, V108, P1883; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; WOOD M J, 1987, P255; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387	47	1190	1219	0	105	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1998	95	6					829	837		10.1016/S0092-8674(00)81705-5	http://dx.doi.org/10.1016/S0092-8674(00)81705-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	148HG	9865700	Bronze			2022-12-24	WOS:000077498800012
J	Tanaka, S; Kunath, T; Hadjantonakis, AK; Nagy, A; Rossant, J				Tanaka, S; Kunath, T; Hadjantonakis, AK; Nagy, A; Rossant, J			Promotion of trophoblast stem cell proliferation by FGF4	SCIENCE			English	Article							PLACENTAL LACTOGEN-I; TRANSCRIPTION FACTOR; MOUSE EMBRYOS; EXPRESSION; BLASTOCYST; LOCALIZATION; GENE	The trophoblast cell Lineage is essential for the survival of the mammalian embryo in utero. This lineage is specified before implantation into the uterus and is restricted to form the fetal portion of the placenta. A culture of mouse blastocysts or early postimplantation trophoblasts in the presence of fibroblast growth factor 4 (FGF4) permitted the isolation of permanent trophoblast stem cell Lines. These cell Lines differentiated to other trophoblast subtypes in vitro in the absence of FGF4 and exclusively contributed to the trophoblast Lineage in vivo in chimeras.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Rossant, J (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	rossant@mshri.on.ca	Nagy, Andras/G-6465-2013	Nagy, Andras/0000-0003-4311-0413; Tanaka, Satoshi/0000-0002-4745-550X; Hadjantonakis, Anna-Katerina/0000-0002-7580-5124				Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Chai N, 1998, DEV BIOL, V198, P105, DOI 10.1016/S0012-1606(98)80031-6; CIRUNA B, UNPUB; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DARZYNKIEWICZ Z, 1997, CURRENT PROTOCOLS CY; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FLECHON JE, 1995, PLACENTA, V16, P643, DOI 10.1016/0143-4004(95)90033-0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARDNER RL, 1972, J EMBRYOL EXP MORPH, V28, P279; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HOGAN B, 1994, MANIPULATING MOUSE E, P265; IOANNIS D, 1998, DEVELOPMENT, V125, P1529; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; NGY A, 1993, GENE TARGETING, P147; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; PARTANEN J, UNPUB; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Pownall ME, 1998, CURR BIOL, V8, P673, DOI 10.1016/S0960-9822(98)70257-X; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSSANT J, 1978, J EMBRYOL EXP MORPH, V48, P239; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Rossant J., 1986, EXPT APPROACHES MAMM, P97; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	40	1008	1034	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2072	2075		10.1126/science.282.5396.2072	http://dx.doi.org/10.1126/science.282.5396.2072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851926				2022-12-24	WOS:000077467100044
J	Tong, S; Baghurst, PA; Sawyer, MG; Burns, J; McMichael, AJ				Tong, S; Baghurst, PA; Sawyer, MG; Burns, J; McMichael, AJ			Declining blood lead levels and changes in cognitive function during childhood - The Port Pirie Cohort Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AGE 2 YEARS; ENVIRONMENTAL EXPOSURE; CHILDRENS INTELLIGENCE; PRESCHOOL-CHILDREN; IRON-DEFICIENCY; ADULT MONKEYS; PERFORMANCE; ATTAINMENT; BEHAVIOR	Context.-Many studies have found a significant inverse association between early exposure to environmental lead and cognitive function in childhood. Whether these effects are reversible when exposure is reduced is not clear. Objective.-To assess the reversibility of the apparent effects of lead on cognitive abilities in early childhood by testing whether declines in blood lead concentrations beyond the age of 2 years are associated with improvements in cognition. Setting.-Urban and rural communities surrounding a large lead smelter in Port Pirie, South Australia. Participants.-A total of 375 children followed up from birth to the age of 11 to 13 years. Design.-Long-term prospective cohort study. Main Outcome Measures.-The Bayley Mental Development Index at age 2 years, the McCarthy General Cognitive Index at age 4 years, and IQs from the Wechsler Intelligence Scale (revised version) at ages 7 and 11 to 13 years. Results.-Mean blood lead concentrations in the children decreased from 1.02 mu mol/L (21.2 mu g/dL) at age 2 years to 0.38 mu mol/L (7.9 mu g/dl) at age 11 to 13 years, but cognitive scores in children whose blood lead concentration declined most were generally not improved relative to the scores of children whose blood lead levels declined least. Changes in IQ and declines in blood lead levels that occurred between the ages of 7 and 11 to 13 years (r = 0.12, P = .09) suggested slightly better cognition among children whose blood lead levels declined most. Conclusion.-The cognitive deficits associated with exposure to environmental lead in early childhood appear to be only partially reversed by a subsequent decline in blood lead level.	Queensland Univ Technol, Ctr Publ Hlth Res, Brisbane, Qld 4059, Australia; Adelaide Womens & Childrens Hosp, Adelaide, SA, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; London Sch Hyg & Trop Med, London WC1, England	Queensland University of Technology (QUT); Womens & Childrens Hospital Australia; Royal Children's Hospital Melbourne; University of London; London School of Hygiene & Tropical Medicine	Tong, S (corresponding author), Queensland Univ Technol, Ctr Publ Hlth Res, Brisbane, Qld 4059, Australia.	s.tong@qut.edu.au						BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BINDER S, 1993, JAMA-J AM MED ASSOC, V269, P1679, DOI 10.1001/jama.269.13.1679; Caldwell BM, 1985, HOME OBSERVATION MEA; COONEY GH, 1989, DEV MED CHILD NEUROL, V31, P640; CUNNINGHAM RD, 1993, JAMA-J AM MED ASSOC, V270, P828, DOI 10.1001/jama.1993.03510070049021; DANIEL A, 1984, COMMUNITY HEALTH ST, V8, P218; DIETRICH KN, 1991, NEUROTOXICOL TERATOL, V13, P203, DOI 10.1016/0892-0362(91)90012-L; ERNHART CB, 1993, JAMA-J AM MED ASSOC, V270, P827, DOI 10.1001/jama.1993.03510070049019; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FERGUSSON DM, 1993, INT J EPIDEMIOL, V22, P891, DOI 10.1093/ije/22.5.891; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; HARVEY PG, 1984, SCI TOTAL ENVIRON, V40, P45, DOI 10.1016/0048-9697(84)90341-3; HATZAKIS A, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P211; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; McCarthy D., 1972, MANUAL MCCARTHY SCAL; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; RICE DC, 1988, NEUROTOXICOL TERATOL, V10, P207, DOI 10.1016/0892-0362(88)90019-0; RUFF HA, 1993, JAMA-J AM MED ASSOC, V269, P1641, DOI 10.1001/jama.269.13.1641; Ruff HA, 1996, ENVIRON HEALTH PERSP, V104, P180, DOI 10.2307/3432787; SCHINDLER AM, 1993, JAMA-J AM MED ASSOC, V270, P828, DOI 10.1001/jama.1993.03510070049020; SCHROEDER SR, 1985, ENVIRON RES, V38, P144, DOI 10.1016/0013-9351(85)90080-5; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; *STAND ASS AUSTR, 1985, 2787 STAND ASS AUSTR; Tong SL, 1996, BRIT MED J, V312, P1569, DOI 10.1136/bmj.312.7046.1569; U.S. Agency for Toxic Substances and Disease Registry, 1988, NAT EXT LEAD POIS CH; *US EPA, 1990, 600889049F EPA; *US EPA, AIR QUAL CRIT LEAD S; WASSERMAN G, 1992, J PEDIATR-US, V121, P695, DOI 10.1016/S0022-3476(05)81895-5; Wechsler D., 2003, MANUAL WECHSLER INTE, V4th; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755	39	101	111	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1915	1919		10.1001/jama.280.22.1915	http://dx.doi.org/10.1001/jama.280.22.1915			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851476	Bronze			2022-12-24	WOS:000077364500035
J	Morris, K				Morris, K			Treating HIV/AIDS information overload	LANCET			English	Editorial Material									Lancet, London, England		Morris, K (corresponding author), Lancet, London, England.								0	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1866	1866		10.1016/S0140-6736(05)79940-2	http://dx.doi.org/10.1016/S0140-6736(05)79940-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851425				2022-12-24	WOS:000077337900074
J	Lu, HP; Xun, LY; Xie, XS				Lu, HP; Xun, LY; Xie, XS			Single-molecule enzymatic dynamics	SCIENCE			English	Article							BREVIBACTERIUM-STEROLICUM; CHOLESTEROL OXIDASE; ELECTRON-TRANSFER; KINETICS; FLUCTUATIONS; SPECTROSCOPY; BEHAVIOR; ENERGY; TRANSITIONS; DIFFUSION	Enzymatic turnovers of single cholesterol oxidase molecules were observed in real time by monitoring the emission from the enzyme's fluorescent active site, flavin adenine dinucleotide (FAD), Statistical analyses of single-molecule trajectories revealed a significant and slow fluctuation in the rate of cholesterol oxidation by FAD. The static disorder and dynamic disorder of reaction rates, which are essentially indistinguishable in ensemble-averaged experiments, were determined separately by the real-time single-molecule approach. A molecular memory phenomenon, in which an enzymatic turnover was not independent of its previous turnovers because of a slow fluctuation of protein conformation, was evidenced by spontaneous spectral fluctuation of FAD.	Pacific NW Natl Lab, William R Wiley Environm Mol Sci Lab, Richland, WA 99352 USA; Washington State Univ, Dept Microbiol, Pullman, WA 99164 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; Washington State University	Xie, XS (corresponding author), Pacific NW Natl Lab, William R Wiley Environm Mol Sci Lab, Richland, WA 99352 USA.	xsxie@pnl.gov						AGMON N, 1983, J CHEM PHYS, V78, P6947, DOI 10.1063/1.444643; CHANDLER D, 1987, INTRO MODERN STAT ME, pCH8; Colquhoun David, 1995, P397; Craig DB, 1996, J AM CHEM SOC, V118, P5245, DOI 10.1021/ja9540839; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Edman L, 1996, P NATL ACAD SCI USA, V93, P6710, DOI 10.1073/pnas.93.13.6710; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEHLEN JN, 1994, SCIENCE, V263, P499, DOI 10.1126/science.263.5146.499; Geva E, 1998, CHEM PHYS LETT, V288, P225, DOI 10.1016/S0009-2614(98)00322-4; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Ha T, 1998, PHYS REV LETT, V80, P2093, DOI 10.1103/PhysRevLett.80.2093; Ha T, 1996, PHYS REV LETT, V77, P3979, DOI 10.1103/PhysRevLett.77.3979; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; Jia YW, 1997, P NATL ACAD SCI USA, V94, P7932, DOI 10.1073/pnas.94.15.7932; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; Lu HP, 1997, J PHYS CHEM B, V101, P2753, DOI 10.1021/jp9634518; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; MANSFIELD E, 1986, BASIC STAT APPL, pCH11; MULLER F, 1992, CHEM BIOCH FLAVOENZY, V1; Neet K E, 1980, Methods Enzymol, V64, P192; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PALMER T, 1991, UNDERSTANDING ENZYME, pCH9; RICARD J, 1974, EUR J BIOCHEM, V49, P195, DOI 10.1111/j.1432-1033.1974.tb03825.x; SCHENTER G, UNPUB; SCHMIDT T, 1995, J PHYS CHEM-US, V99, P17662, DOI 10.1021/j100049a030; UWAJIMA T, 1974, AGR BIOL CHEM TOKYO, V38, P1149, DOI 10.1080/00021369.1974.10861299; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; van Kampen N.G., 1992, STOCHASTIC PROCESSES; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; Vasudevan PT, 1996, APPL BIOCHEM BIOTECH, V60, P63, DOI 10.1007/BF02788060; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; WANG J, 1995, PHYS REV LETT, V74, P4317, DOI 10.1103/PhysRevLett.74.4317; Wennmalm S, 1997, P NATL ACAD SCI USA, V94, P10641, DOI 10.1073/pnas.94.20.10641; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; ZWANZIG R, 1990, ACCOUNTS CHEM RES, V23, P148, DOI 10.1021/ar00173a005	44	1247	1292	9	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1877	1882		10.1126/science.282.5395.1877	http://dx.doi.org/10.1126/science.282.5395.1877			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836635				2022-12-24	WOS:000077338100045
J	Matsuoka, S; Huang, MX; Elledge, SJ				Matsuoka, S; Huang, MX; Elledge, SJ			Linkage of ATM to cell cycle regulation by the Chk2 protein kinase	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; S-PHASE; YEAST; SERINE-216; PATHWAY; MITOSIS; CDC25C	In response to DNA damage and replication blocks, coils prevent cell cycle progression through the control of critical cell cycle regulators, We identified Chk2, the mammalian homolog of the Saccharomyces cerevisiae Rad53 and Schizosaccharomyces pombe Cds1 protein kinases required for the DNA damage and replication checkpoints. Chk2 was rapidly phosphorylated and activated in response to replication blocks and DNA damage; the response to DNA damage occurred in an ataxia telangiectasia mutated (ATM)-dependent manner. In vitro, Chk2 phosphorylated Cdc25C on serine-216, a site known to be involved in negative regulation of Cdc25C. This is the same site phosphorylated by the protein kinase Chk1, which suggests that, in response to DNA damage and DNA replicational stress, Chk1 and Chk2 may phosphorylate Cdc25C to prevent entry into mitosis.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.				NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JB, 1994, GENE DEV, V8, P2416; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Goggins M, 1996, CANCER RES, V56, P5360; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; OGG S, 1994, J BIOL CHEM, V269, P30461; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Tomlinson GE, 1998, CANCER RES, V58, P3237; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	21	1071	1116	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1893	1897		10.1126/science.282.5395.1893	http://dx.doi.org/10.1126/science.282.5395.1893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836640				2022-12-24	WOS:000077338100050
J	Christie, JM; Reymond, P; Powell, GK; Bernasconi, P; Raibekas, AA; Liscum, E; Briggs, WR				Christie, JM; Reymond, P; Powell, GK; Bernasconi, P; Raibekas, AA; Liscum, E; Briggs, WR			Arabidopsis NPH1: A flavoprotein with the properties of a photoreceptor for phototropism	SCIENCE			English	Article							PLASMA-MEMBRANE PROTEIN; BLUE-LIGHT RECEPTOR; HIGHER-PLANTS; PHOSPHORYLATION; THALIANA; SEEDLINGS; IDENTIFICATION; TRANSDUCTION; PERCEPTION; KINASE	The NPH1 gene of Arabidopsis thaliana encodes a 120-kilodalton serine-threonine protein kinase hypothesized ta function as a photoreceptor for phototropism. When expressed in insect cells, the NPH1 protein is phosphorylated in response to blue Light irradiation. The biochemical and photochemical properties of the photosensitive protein reflect those of the native protein in microsomal membranes. Recombinant NPH1 noncovalently binds flavin mononucleotide, a likely chromophore for Light-dependent autophosphorylation. The fluorescence excitation spectrum of the recombinant protein is similar to the action spectrum for phototropism, consistent with the conclusion that NPH1 is an autophosphorylating flavoprotein photoreceptor mediating phototropic responses in higher plants.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Univ Lausanne, Inst Biol & Physiol Vegetales, CH-1015 Lausanne, Switzerland; Novartis Agribusiness Biotechnol Res Inc, Res Triangle Pk, NC 27709 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	Carnegie Institution for Science; University of Lausanne; Novartis; University of Michigan System; University of Michigan; University of Missouri System; University of Missouri Columbia	Briggs, WR (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	briggs@andrew.stanford.edu	Reymond, Philippe/ABG-2385-2020; Reymond, Philippe/ABG-2852-2020; Raibekas, Andrei A/A-8555-2009	Reymond, Philippe/0000-0002-3341-6200; Liscum, Emmanuel/0000-0002-8672-9315; Christie, John/0000-0002-9976-0055				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BASKIN TI, 1987, PHOTOCHEM PHOTOBIOL, V46, P127, DOI 10.1111/j.1751-1097.1987.tb04746.x; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; Briggs W. R., 1997, Signal transduction in plants., P107; BRIGGS WR, 1983, PHILOS T ROY SOC B, V303, P347, DOI 10.1098/rstb.1983.0098; GALLAND P, 1988, PHOTOCHEM PHOTOBIOL, V48, P811, DOI 10.1111/j.1751-1097.1988.tb02896.x; GALSTON AW, 1949, HDB PLANZENPHYSIOLOG, V17, P492; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Janoudi AK, 1997, PHYSIOL PLANTARUM, V101, P278, DOI 10.1034/j.1399-3054.1997.1010204.x; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; Lin C., 1996, PLANT PHYSIOL, V110, P1047; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LORENZI R, 1994, PHYTOCHEMISTRY, V36, P599, DOI 10.1016/S0031-9422(00)89781-2; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; OLNEY MA, UNPUB; PALMER JM, 1993, PLANT PHYSIOL, V102, P1211, DOI 10.1104/pp.102.4.1211; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RAIBEKAS AA, 1991, J BIOLUM CHEMILUM, V6, P169, DOI 10.1002/bio.1170060306; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; Salomon M, 1997, PLANT PHYSIOL, V115, P493, DOI 10.1104/pp.115.2.493; SHORT TW, 1990, PLANT PHYSIOL, V92, P179, DOI 10.1104/pp.92.1.179; SHORT TW, 1992, PHOTOCHEM PHOTOBIOL, V55, P773; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; Wald G, 1936, Science, V84, P247, DOI 10.1126/science.84.2176.247-a; Zeiger E, 1998, J EXP BOT, V49, P433, DOI 10.1093/jexbot/49.suppl_1.433	32	493	513	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1698	1701		10.1126/science.282.5394.1698	http://dx.doi.org/10.1126/science.282.5394.1698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831559				2022-12-24	WOS:000077246600044
J	Huang, HF; Chopra, R; Verdine, GL; Harrison, SC				Huang, HF; Chopra, R; Verdine, GL; Harrison, SC			Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: Implications for drug resistance	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; POL GENE-MUTATIONS; CRYSTAL-STRUCTURE; NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; COMBINATION THERAPY; MINOR-GROOVE; ZIDOVUDINE; SENSITIVITY; MECHANISM	A combinatorial disulfide cross-linking strategy was used to prepare a stalled complex of human immunodeficiency virus-type 1 (HIV-1) reverse transcriptase with a DNA template:primer and a deoxynucleoside triphosphate (dNTP), and the crystal structure of the complex was determined at a resolution of 3.2 angstroms. The presence of a dideoxynucleotide at the 3'-primer terminus allows capture of a state in which the substrates are poised for attack on the dNTP. Conformational changes that accompany formation of the catalytic complex produce distinct clusters of the residues that are altered in viruses resistant to nucleoside analog drugs. The positioning of these residues in the neighborhood of the dNTP helps to resolve some Long-standing puzzles about the molecular basis of resistance. The resistance mutations are Likely to influence binding or reactivity of the inhibitors, relative to normal dNTPs, and the clustering of the mutations correlates with the chemical structure of the drug.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Harvard University; Howard Hughes Medical Institute	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	verdine@glviris.harvard.edu; schadmin@crystal.harvard.edu			NIGMS NIH HHS [GM-39589, GM-18621, GM-44853] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, P01GM039589] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Erlanson DA, 1997, J AM CHEM SOC, V119, P6927, DOI 10.1021/ja9710666; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Hostomsky Z., 1993, NUCLEASES, V2nd, P341; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAGER J, 1994, STRUCTURE, V2, P869, DOI 10.1016/S0969-2126(94)00087-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Richman DD, 1996, ADV EXP MED BIOL, V394, P383; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Tisdale M, 1997, ANTIMICROB AGENTS CH, V41, P1094, DOI 10.1128/AAC.41.5.1094; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	48	1271	1309	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1998	282	5394					1669	1675		10.1126/science.282.5394.1669	http://dx.doi.org/10.1126/science.282.5394.1669			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143GJ	9831551				2022-12-24	WOS:000077246600036
J	Harbury, PB; Plecs, JJ; Tidor, B; Alber, T; Kim, PS				Harbury, PB; Plecs, JJ; Tidor, B; Alber, T; Kim, PS			High-resolution protein design with backbone freedom	SCIENCE			English	Article							AUTOMATED SEQUENCE SELECTION; DE-NOVO DESIGN; COILED-COILS; ALPHA-HELIX; HYDROGEN-EXCHANGE; ENERGY; CONFORMATION; OPTIMIZATION; PREDICTION; DYNAMICS	Recent advances in computational techniques have allowed the design of precise side-chain packing in proteins with predetermined, naturally occurring backbone structures. Because these methods do not model protein main-chain flexibility, they lack the breadth to explore novel backbone conformations. Here the de novo design of a family of or-helical bundle proteins with a right-handed superhelical twist is described. In the design, the overall protein fold was specified by hydrophobic-polar residue patterning, whereas the bundle oligomerization state, detailed main-chain conformation, and interior side-chain rotamers were engineered by computational enumerations of packing in alternate backbone structures. Main-chain flexibility was incorporated through an algebraic parameterization of the backbone. The designed peptides form ct-helical dimers, trimers, and tetramers in accord with the design goals. The crystal structure of the tetramer matches the designed structure in atomic detail.	Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Massachusetts Institute of Technology (MIT)	Kim, PS (corresponding author), Whitehead Inst Biomed Res, Howard Hughes Med Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dvorak@wi.mit.edu		/0000-0002-3320-3969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162, R01GM048598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55758, GM48598, GM44162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; Aurora R, 1997, J BIOL CHEM, V272, P1413, DOI 10.1074/jbc.272.3.1413; BALDWIN EP, 1993, SCIENCE, V262, P1715, DOI 10.1126/science.8259514; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Bryson JW, 1998, PROTEIN SCI, V7, P1404, DOI 10.1002/pro.5560070617; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; CORREA PE, 1990, PROTEINS, V7, P366, DOI 10.1002/prot.340070408; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Dahiyat BI, 1997, J MOL BIOL, V273, P789, DOI 10.1006/jmbi.1997.1341; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275; DURE L, 1993, PLANT J, V3, P363, DOI 10.1046/j.1365-313X.1993.t01-18-00999.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hellinga HW, 1998, NAT STRUCT BIOL, V5, P525, DOI 10.1038/776; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HOLM L, 1991, J MOL BIOL, V218, P183, DOI 10.1016/0022-2836(91)90883-8; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOEHL P, 1994, J MOL BIOL, V239, P249, DOI 10.1006/jmbi.1994.1366; Lazar GA, 1997, PROTEIN SCI, V6, P1167, DOI 10.1002/pro.5560060605; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LEE C, 1994, J MOL BIOL, V236, P918, DOI 10.1006/jmbi.1994.1198; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; PABO C, 1983, NATURE, V301, P200, DOI 10.1038/301200a0; Peters J, 1996, J MOL BIOL, V257, P1031, DOI 10.1006/jmbi.1996.0221; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; TEMBE BL, 1984, COMPUT CHEM, V8, P281, DOI 10.1016/0097-8485(84)85020-2; TUFFERY P, 1991, J BIOMOL STRUCT DYN, V8, P1267, DOI 10.1080/07391102.1991.10507882; [No title captured]	52	377	395	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1998	282	5393					1462	1467		10.1126/science.282.5393.1462	http://dx.doi.org/10.1126/science.282.5393.1462			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822371				2022-12-24	WOS:000077110800046
J	Sack, RB; Siddique, AK				Sack, RB; Siddique, AK			Corpses and the spread of cholera	LANCET			English	Editorial Material							EPIDEMIC		Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh	Johns Hopkins University; International Centre for Diarrhoeal Disease Research (ICDDR)	Sack, RB (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.							Glass Roger I., 1992, P129; Gunnlaugsson G, 1998, EPIDEMIOL INFECT, V120, P7, DOI 10.1017/S0950268897008170; Rodrigues A, 1997, AM J TROP MED HYG, V57, P601, DOI 10.4269/ajtmh.1997.57.601; Swerdlow David L., 1994, P297; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418	5	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1570	1570		10.1016/S0140-6736(05)61040-9	http://dx.doi.org/10.1016/S0140-6736(05)61040-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843100	hybrid			2022-12-24	WOS:000076998900006
J	Heymsfield, SB; Allison, DB; Vasselli, JR; Pietrobelli, A; Greenfield, D; Nunez, C				Heymsfield, SB; Allison, DB; Vasselli, JR; Pietrobelli, A; Greenfield, D; Nunez, C			Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Hydroxycitric acid, the active ingredient in the herbal compound Garcinia cambogia, competitively inhibits the extramitochondrial enzyme adenosine triphosphate-citrate (pro-3S)-lyase. As a citrate cleavage enzyme that may play an essential role in de novo lipogenesis inhibition, G cambogia is claimed to lower body weight and reduce fat mass in humans. Objective.-To evaluate the efficacy of G cambogia for body weight and fat mass loss in overweight human subjects. Design.-Twelve-week randomized, double-blind, placebo-controlled trial. Setting.-Outpatient weight control research unit. Participants.-Overweight men and women subjects (mean body mass index [weight in kilograms divided by the square of height in meters], approximately 32 kg/m(2)). Intervention.-Subjects were randomized to receive either active herbal compound (1500 mg of hydroxycitric acid per day) or placebo, and both groups were prescribed a high-fiber, low-energy diet. The treatment period was 12 weeks. Body weight was evaluated every other week and fat mass was measured at weeks 0 and 12. Main Outcome Measures.-Body weight change and fat mass change. Results.-A total of 135 subjects were randomized to either active hydroxycitric acid (n = 66) or placebo (n = 69); 42 (64%) in the active hydroxycitric acid group and 42 (61%) in the placebo group completed 12 weeks of treatment (P = .74). Patients in both groups lost a significant amount of weight during the 12-week treatment period (P < .001); however, between-group weight loss differences were not statistically significant (mean [SD], 3.2 [3.3] kg vs 4.1 [3.9] kg; P = .14). There were no significant differences in estimated percentage of body fat mass loss between treatment groups, and the fraction of subject weight loss as fat was not influenced by treatment group. Conclusions.-Garcinia cambogia failed to produce significant weight loss and fat mass loss beyond that observed with placebo.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr,Dept Med, New York, NY 10025 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Heymsfield, SB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr,Dept Med, 1090 Amsterdam Ave,14th Floor, New York, NY 10025 USA.	sbh2@columbia.edu	Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425; Allison, David/0000-0003-3566-9399	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645] Funding Source: Medline; NIDDK NIH HHS [P30DK26687] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badmaev V., 1995, NUTR 1995 NUTR DIET; BRAY GA, 1993, ANN INTERN MED, V119, P707, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00016; Burstein L., 1989, MULTILEVEL INVESTIGA; *COMM PROP MED PRO, 1997, NOT GUID CLIN INV DR; Conte A.A., 1993, AM J BARIATR MED SUM, P17; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DRAO RN, 1988, NUTR RES, V8, P209; GIROLA M, 1996, ACTA TOXICOL THER, V17, P25; Graham J W, 1994, NIDA Res Monogr, V142, P13; Heymsfield S. B., 1996, HUMAN BODY COMPOSITI, P129; Heymsfield SB, 1996, AM J CLIN NUTR, V64, P478, DOI 10.1093/ajcn/64.3.478S; Heymsfield SB., 1992, MODERN NUTR HLTH DIS, V8, P812; HOBBS LS, 1994, NEW DIET PILLS, P161; Lewis Y. S., 1965, PHYTOCHEMISTRY, V4, P610; LOWENSTEIN JM, 1971, J BIOL CHEM, V246, P629; Martius C., 1941, Z PHYSL CHEM, V269, P33; *NIH, 1992, AM J CLIN NUTR, V55, pS487; Niklson IA, 1997, PSYCHOPHARMACOL BULL, V33, P41; Pietrobelli A, 1997, INT J OBESITY, V21, P110, DOI 10.1038/sj.ijo.0800374; Pietrobelli A, 1996, AM J PHYSIOL-ENDOC M, V271, pE941, DOI 10.1152/ajpendo.1996.271.6.E941; RUSSELLAULET M, 1991, J BONE MINER RES, V6, P411; SULLIVAN AC, 1974, LIPIDS, V9, P129, DOI 10.1007/BF02532137; SULLIVAN AC, 1972, ARCH BIOCHEM BIOPHYS, V150, P183, DOI 10.1016/0003-9861(72)90025-2; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; SULLIVAN AC, 1974, FED PROC, V33, P656; Thom E, 1996, INT J OBES S4, V20, P48; Vasselli JR, 1998, FASEB J, V12, pA505; VONLIPPMANN EO, 1983, BER DTSCH CHEM GES, V16, P1078; WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3; WEBSTER JD, 1984, HUM NUTR-CLIN NUTR, V38C, P299; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907	31	222	237	2	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1596	1600		10.1001/jama.280.18.1596	http://dx.doi.org/10.1001/jama.280.18.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820262	Bronze			2022-12-24	WOS:000076852000027
J	Dickey, W; Bodkin, S				Dickey, W; Bodkin, S			Prospective study of body mass index in patients with coeliac disease	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE		Altnagelvin Hosp, Londonderry BT47 1SB, North Ireland		Dickey, W (corresponding author), Altnagelvin Hosp, Londonderry BT47 1SB, North Ireland.							CIACCI C, 1995, SCAND J GASTROENTERO, V30, P1077, DOI 10.3109/00365529509101610; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; JOHNSTON SD, 1996, ACTA PAEDIATR, V412, P61; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P	5	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1290	1290		10.1136/bmj.317.7168.1290	http://dx.doi.org/10.1136/bmj.317.7168.1290			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804717	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000076963800026
J	Bergmann, A; Agapite, J; McCall, K; Steller, H				Bergmann, A; Agapite, J; McCall, K; Steller, H			The Drosophila gene hid is a direct molecular target of Ras-dependent survival signaling	CELL			English	Article							PROGRAMMED CELL-DEATH; RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; EYE DEVELOPMENT; MAP KINASE; TRANSDUCTION PATHWAY; GROWTH-FACTOR; INSECT CELLS; APOPTOSIS; EXPRESSION	Extracellular growth factors are required for the survival of most animal cells. They often signal through the activation of the Ras pathway. However, the molecular mechanisms by which Ras signaling inhibits the intrinsic cell death machinery are not well understood. Here, we present evidence that in Drosophila, activation of the Has pathway specifically inhibits the proapoptotic activity of the gene head involution defective (hid). By using transgenic animals and cultured cells, we show that MAPK phosphorylation sites in Hid are critical for this response. These findings define a novel mechanism by which growth factor signaling directly inactivates a critical component of the intrinsic cell death machinery. These studies provide further insights into the function of ras as an oncogene.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BARRES BA, 1993, DEVELOPMENT, V118, P283; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOS JL, 1989, CANCER RES, V49, P4682; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson BJ, 1996, GENETICS, V142, P163; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1997, DEVELOPMENT, V124, P261; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; GRETHER ME, 1994, THESIS MIT CAMBRIDGE; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; Jarvis DL, 1996, PROTEIN EXPRES PURIF, V8, P191, DOI 10.1006/prep.1996.0092; Karim FD, 1998, DEVELOPMENT, V125, P1; Karim FD, 1996, GENETICS, V143, P315; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; Miller DT, 1998, DEVELOPMENT, V125, P2327; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Robinow S, 1997, DEV BIOL, V190, P206, DOI 10.1006/dbio.1997.8696; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WASSARMAN DA, 1997, ADV DEV BIO, V5, P1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	60	391	398	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 30	1998	95	3					331	341		10.1016/S0092-8674(00)81765-1	http://dx.doi.org/10.1016/S0092-8674(00)81765-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	135FE	9814704	Bronze			2022-12-24	WOS:000076789600007
J	Nguyen, T; Chin, WC; Verdugo, P				Nguyen, T; Chin, WC; Verdugo, P			Role of Ca2+/K+ ion exchange in intracellular storage and release of Ca2+	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ENDOPLASMIC-RETICULUM; SECRETORY GRANULES; CALCIUM RELEASE; ZYMOGEN GRANULES; CELLS; BINDING; TRISPHOSPHATE; GONADOTROPES; PROTEIN	Although fluctuations in cytosolic Ca2+ concentration have a crucial role in relaying intracellular messages in the cell(1), the dynamics of Ca2+ storage in and release from intracellular sequestering compartments remains poorly understood. The rapid release of stored Ca2+ requires large concentration gradients that had been thought to result from low-affinity buffering of Ca2+ by the polyanionic matrices within Ca2+ sequestering organelles(2). However, our results here show that resting luminal free Ca2+ concentration inside the endoplasmic reticulum and in the mucin granules remains at low levels (20-35 mu M) But after stimulation, the free luminal [Ca2+] increases, undergoing large oscillations, leading to corresponding oscillations of Ca2+ release to the cytosol, These remarkable dynamics of luminal [Ca2+] result from a fast and highly cooperative Ca2+/K+ ion-exchange process rather than from Ca2+ transport into the lumen. This common paradigm for Ca2+ storage and release, found in two different Ca2+-sequestering organelles, requires the functional interaction of three molecular components: a polyanionic matrix that functions as a Ca2+/K+ ion exchanger, and two Ca2+-sensitive channels, one to import K+ into the Ca2+-sequestering compartments, the other to release Ca2+ to the cytosol.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Internal Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Verdugo, P (corresponding author), Univ Washington, Dept Bioengn, Box 357962, Seattle, WA 98195 USA.	verdugo@bioeng.washington.edu	Chin, Wei-Chun/A-6068-2008	Chin, Wei-Chun/0000-0003-4881-9085				AITKEN ML, 1995, EXP LUNG RES, V21, P1, DOI 10.3109/01902149509031741; Belan PV, 1996, PFLUG ARCH EUR J PHY, V433, P200, DOI 10.1007/s004240050268; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; Davis C. W., 1997, AIRWAY MUCUS BASIC M, P149; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FORSTNER JF, 1975, BIOCHIM BIOPHYS ACTA, V386, P283, DOI 10.1016/0005-2795(75)90270-6; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Hehl S, 1996, CELL CALCIUM, V20, P515, DOI 10.1016/S0143-4160(96)90094-9; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; KAO JPY, 1994, PRACTICAL GUIDE STUD, P155; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LOREZ HP, 1978, EXPERIENTIA, V34, P663, DOI 10.1007/BF01937020; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; OROURKE F, 1994, BIOCHEM J, V300, P673, DOI 10.1042/bj3000673; Sasaki S, 1996, PFLUG ARCH EUR J PHY, V432, P538, DOI 10.1007/s004240050167; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; VERDUGO P, 1980, NATURE, V283, P764, DOI 10.1038/283764a0; VERDUGO P, 1994, AIRWAY SECRETION, P101; Yule DI, 1997, J BIOL CHEM, V272, P9093	30	167	168	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 29	1998	395	6705					908	912		10.1038/27686	http://dx.doi.org/10.1038/27686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804425				2022-12-24	WOS:000076713400059
J	Ristinen, E; Mamtani, R				Ristinen, E; Mamtani, R			Ethics of transmission of hepatitis B virus by health-care workers	LANCET			English	Editorial Material							ANTIGEN; INFECTION; RISK		New York Med Coll, Dept Community & Prevent Med, Valhalla, NY 10595 USA	New York Medical College	Ristinen, E (corresponding author), New York Med Coll, Dept Community & Prevent Med, Valhalla, NY 10595 USA.							ALTER HJ, 1975, NEW ENGL J MED, V292, P454, DOI 10.1056/NEJM197502272920904; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNOLD RM, 1995, ENCY BIOETHICS, P1250; Beekmann SE, 1997, INFECT DIS CLIN N AM, V11, P313, DOI 10.1016/S0891-5520(05)70358-5; Boxall EH, 1997, BRIT MED J, V314, P144, DOI 10.1136/bmj.314.7074.144; Calman KC, 1996, BRIT MED J, V313, P799; FRIEDE A, 1997, RECOMMENDATIONS PREV, P281; GOLLAN JL, 1966, INTENSIVE REV INTERN, P591; Halle M, 1996, BRIT MED J, V313, P576; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; Henderson DK, 1997, INFECT CONT HOSP EP, V18, P349; *INC INV TEAMS OTH, 1997, NEW ENGL J MED, V336, P176; KATZ J, 1995, ENCY BIOETHICS, P1255; Koziol DE, 1996, HOSP EPIDEMIOLOGY IN, P829; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Poole CJM, 1997, LANCET, V350, P218, DOI 10.1016/S0140-6736(05)62384-7; REISSLEVY EA, 1994, MED J AUSTRALIA, V160, P524	17	11	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 24	1998	352	9137					1381	1383		10.1016/S0140-6736(98)03095-5	http://dx.doi.org/10.1016/S0140-6736(98)03095-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133NB	9802291				2022-12-24	WOS:000076691700050
J	Thor, S; Andersson, SGE; Tomlinson, A; Thomas, JB				Thor, S; Andersson, SGE; Tomlinson, A; Thomas, JB			A LIM-homeodomain combinatorial code for motor-neuron pathway selection	NATURE			English	Article							HOMEOBOX GENE; C-ELEGANS; DROSOPHILA; EXPRESSION; PROTEIN; DIFFERENTIATION; LOCATION; EMBRYOS; DOMAIN	Different classes of vertebrate motor neuron that innervate distinct muscle targets express unique combinations of LIM-homeodomain transcription factors(1,2), suggesting that a combinatorial code of LIM-homeodomain proteins may underlie the control of motor-neuron pathway selection. Studies of LIM-homeodomain genes in mouse, Drosophila melanogaster and Caenorhabditis elegans have revealed functions of these genes in neuronal survival, axon guidance, neurotransmitter expression and neuronal function(3-8), but, to our knowledge, none of these studies have addressed the issue of a functional code. Here we study two members of this gene family in Drosophila, namely lim3, the homologue of the vertebrate Lhx3 and Lhx4 genes, and islet, the homologue of the vertebrate Isl1 and Isl2 genes. We show that Drosophila lim3 is expressed by a specific subset of islet-expressing motor neurons and that mutating or misexpressing lim3 switches motor-neuron projections predictably. Our results provide evidence that lim3 and islet constitute a combinatorial code that generates distinct motor-neuron identities.	Salk Inst, Mol Neurobiol Lab, POB 85800, San Diego, CA 92186 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Ctr Neurobiol & Behav, New York, NY 10032 USA	Salk Institute; Columbia University	Thor, S (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.		Thor, Stefan/Y-5804-2019	Thor, Stefan/0000-0001-5095-541X				Appel B, 1995, DEVELOPMENT, V121, P4117; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Callahan CA, 1998, CURR OPIN NEUROBIOL, V8, P582, DOI 10.1016/S0959-4388(98)80084-6; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; HIROYAMA Y, 1987, PEDIATR NEUROL, V3, P54, DOI 10.1016/0887-8994(87)90057-9; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Hobert O, 1998, J NEUROSCI, V18, P2084; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; Landgraf M, 1997, J NEUROSCI, V17, P9642; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SHARMA K, IN PRESS CELL; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; Surdej P, 1998, MOL CELL BIOL, V18, P2892, DOI 10.1128/MCB.18.5.2892; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANVACTOR D, 1993, CELL, V73, P1155; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WRIGHT TRF, 1987, RESULTS PROBLEMS CEL, P95	30	247	251	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 7	1999	397	6714					76	80		10.1038/16275	http://dx.doi.org/10.1038/16275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155RD	9892357				2022-12-24	WOS:000077959400051
J	Armstrong, GL; Conn, LA; Pinner, RW				Armstrong, GL; Conn, LA; Pinner, RW			Trends in infectious disease mortality in the United States during the 20th century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH CERTIFICATES; EPIDEMIOLOGIC TRANSITION; ACCURACY; SURVEILLANCE; AUTOPSY	Context Recent increases in infectious disease mortality and concern about emerging infections warrant an examination of longer-term trends. Objective To describe trends in infectious disease mortality in the United States during the 20th century. Design and Setting Descriptive study of infectious disease mortality in the United States. Deaths due to infectious diseases from 1900 to 1996 were tallied by using mortality tables. Trends in age-specific infectious disease mortality were examined by using age-specific death rates for 9 common infectious causes of death. Subjects Persons who died in the United States between 1900 and 1996. Main Outcome Measures Crude and age-adjusted mortality rates. Results Infectious disease mortality declined during the first 8 decades of the 20th century from 797 deaths per 100 000 in 1900 to 36 deaths per 100 000 in 1980. From 1981 to 1995, the mortality rate increased to a peak of 63 deaths per 100 000 in 1995 and declined to 59 deaths per 100 000 in 1996. The decline was interrupted by a sharp spike in mortality caused by the 1918 influenza epidemic. From 1938 to 1952, the decline was particularly rapid, with mortality decreasing 8.2% per year. Pneumonia and influenza were responsible for the largest number of infectious disease deaths throughout the century. Tuberculosis caused almost as many deaths as pneumonia and influenza early in the century, but tuberculosis mortality dropped off sharply after 1945, Infectious disease mortality increased in the 1980s and early 1990s in persons aged 25 years and older and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-year-olds and, to a lesser degree, to increases in pneumonia and influenza deaths among persons aged 65 years and older. There was considerable year-to-year variability in infectious disease mortality, especially for the youngest and oldest age groups. Conclusions Although most of the 20th century has been marked by declining infectious disease mortality, substantial year-to-year variation as well as recent increases emphasize the dynamic nature of infectious diseases and the need for preparedness to address them.	Ctr Dis Control & Prevent, Natl Fdn Infect Dis, Natl Ctr Infect Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Armstrong, GL (corresponding author), Mailstop C-12,1600 Clifton Rd NE, Atlanta, GA 30333 USA.							ARMITAGE P, 1994, STAT METHODS MED RES, P402; Baldry P., 1976, BATTLE BACTERIA FRES; Banatvala N, 1997, EPIDEMIOL INFECT, V118, P221, DOI 10.1017/S0950268897007425; Barendregt JJ, 1996, B WORLD HEALTH ORGAN, V74, P439; BENAVIDES FG, 1989, AM J PUBLIC HEALTH, V79, P1352, DOI 10.2105/AJPH.79.10.1352; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Black FL, 1989, VIRAL INFECT HUMANS, P451; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P165; *CDCP, 1998, MMWR-MORBID MORTAL W, V46, P1245; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; *CO DEP HLTH, 1984, ANN REP VIT STAT; Cox NJ, 1998, INFECT DIS CLIN N AM, V12, P27, DOI 10.1016/S0891-5520(05)70406-2; CROSBY AW, 1976, EPIDEMIC PEACE; FALELLA FJ, 1998, NEW ENGL J MED, V338, P853; Institute of Medicine, 1992, EM INF MICR THREATS; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; MACKENBACH JP, 1994, J EPIDEMIOL COMMUN H, V48, P329, DOI 10.1136/jech.48.4.329-a; MODELMOG D, 1992, CANCER CAUSE CONTROL, V3, P541, DOI 10.1007/BF00052751; MORROW RH, 1995, AM J PUBLIC HEALTH, V85, P56; MORTIMER EA, 1994, VACCINES, P91; MORTIMER EA, 1994, VACCINES, P41; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; *NAT CTR HLTH STAT, 1996, VIT STAT MORT DAT MU; *NAT CTR HLTH STAT, 1996, VIT STAT US 1992 A, V2, P1; *NAT CTR HLTH STAT, 1900, VIT STAT US 1900 199; *NAT OFF VIT STAT, 1956, VIT STAT REP DEATH R, V43; NIELSEN GP, 1991, VIRCHOWS ARCH A, V419, P143, DOI 10.1007/BF01600228; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Rogers N., 1992, DIRT DIS POLIO FDR; Washko RM, 1996, PUBLIC HEALTH REP, V111, P251	31	448	474	0	49	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1999	281	1					61	66		10.1001/jama.281.1.61	http://dx.doi.org/10.1001/jama.281.1.61			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153JE	9892452	Bronze			2022-12-24	WOS:000077829300036
J	Macleod, MA; Houston, AS; Sanders, L; Anagnostopoulos, C				Macleod, MA; Houston, AS; Sanders, L; Anagnostopoulos, C			Incidence of trauma related stress fractures and shin splints in male and female army recruits: retrospective case study	BRITISH MEDICAL JOURNAL			English	Article									Royal Hosp Haslar, Dept Nucl Med, Gosport PO12 2AA, Hants, England		Macleod, MA (corresponding author), Royal Hosp Haslar, Dept Nucl Med, Gosport PO12 2AA, Hants, England.		Anagnostopoulos, Constantinos/AAM-4381-2020					HOLDER LE, 1985, CURR CONCEPT DIAGN N, V2, P3; MATIN P, 1983, SEMIN NUCL MED, V13, P104, DOI 10.1016/S0001-2998(83)80004-X	2	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1999	318	7175					29	29						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	156QG	9872880				2022-12-24	WOS:000078013100025
J	Heath, I				Heath, I			A seamless service	BRITISH MEDICAL JOURNAL			English	Article									Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, London NW5 2UP, England.							*CTR ADV INT ED, 1996, PRINC INT ED; NEAL MM, 1992, NEEDLEWORK SCH	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1723	1724		10.1136/bmj.317.7174.1723	http://dx.doi.org/10.1136/bmj.317.7174.1723			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857147	Green Published			2022-12-24	WOS:000077742300037
J	Kondru, RK; Wipf, P; Beratan, DN				Kondru, RK; Wipf, P; Beratan, DN			Atomic contributions to the optical rotation angle as a quantitative probe of molecular chirality	SCIENCE			English	Article								Chiral molecules are characterized by a specific rotation angle, the angle through which plane-polarized Light is rotated on passing through an enantiomerically enriched solution. Recent developments in methodology allow computation of both the sign and the magnitude of these rotation angles. However, a general strategy for assigning the individual contributions that atoms and functional groups make to the optical rotation angle and, more generally, to the molecular chirality has remained elusive, Here, a method to determine the atomic contributions to the optical rotation angle is reported. This approach Links chemical structure with optical rotation angle and provides a quantitative measure of molecular asymmetry propagation from a center, axis, or plane of chirality.	Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kondru, RK (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.		Beratan, David N/C-5098-2011; Wipf, Peter/AAG-1771-2021	Beratan, David N/0000-0003-4758-8676; Wipf, Peter/0000-0001-7693-5863	NIGMS NIH HHS [GM 55433-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055433] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS RD, 1982, CHEM PHYS LETT, V87, P23, DOI 10.1016/0009-2614(82)83545-8; AMOS RD, 1987, CAMBRIDGE ANAL DERIV; APPLEQUI.J, 1973, J CHEM PHYS, V58, P4251, DOI 10.1063/1.1678981; BAK KL, 1995, THEOR CHIM ACTA, V90, P441, DOI 10.1007/BF01113546; Born M, 1935, PROC R SOC LON SER-A, V150, P0084, DOI 10.1098/rspa.1935.0090; BREWSTER JH, 1961, TETRAHEDRON, V13, P106, DOI 10.1016/S0040-4020(01)92206-9; Costante J, 1997, ANGEW CHEM INT EDIT, V36, P885, DOI 10.1002/anie.199708851; Eliel E.L., 1994, STEREOCHEMISTRY ORGA; FIRSCH MJ, 1995, GAUSSIAN 94; Freudenberg K, 1933, LIEBIGS ANN CHEM, V501, P199; GOULD RR, 1970, J AM CHEM SOC, V92, P1813, DOI 10.1021/ja00710a001; HELGAKER T, 1997, DALTON ABINITIO ELEC; Jung TA, 1997, NATURE, V386, P696, DOI 10.1038/386696a0; Kirkwood JG, 1937, J CHEM PHYS, V5, P479, DOI 10.1063/1.1750060; Kondru RK, 1998, J AM CHEM SOC, V120, P2204, DOI 10.1021/ja973690o; Kondru RK, 1997, CHIRALITY, V9, P469, DOI 10.1002/(SICI)1520-636X(1997)9:5/6<469::AID-CHIR13>3.0.CO;2-M; KUHN W, 1933, STEREOCHEMIE, V8, P394; LAKHTAKIA A, 1990, SELECTED PAPERS N MS, V15; Le Bel JA, 1874, B SOC CHIM FR, V22, P337; McKendry R, 1998, NATURE, V391, P566, DOI 10.1038/35339; MOFFITT W, 1956, J CHEM PHYS, V25, P467, DOI 10.1063/1.1742946; MOSCOWITZ A, 1962, ADV CHEM PHYS, V4, P67, DOI 10.1002/9780470143506.ch2; MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588; MULLIKEN RS, 1962, J CHEM PHYS, V36, P3428, DOI 10.1063/1.1732476; Nakanishi K., 1994, CIRCULAR DICHROISM P; PAO YH, 1966, J AM CHEM SOC, V88, P4157, DOI 10.1021/ja00970a008; Polavarapu PL, 1997, TETRAHEDRON-ASYMMETR, V8, P3397, DOI 10.1016/S0957-4166(97)00453-9; Polavarapu PL, 1998, J AM CHEM SOC, V120, P6160, DOI 10.1021/ja980838a; Pople JA., 1970, APPROXIMATE MOL ORBI; RAUK A, 1977, CHEM PHYS, V25, P409, DOI 10.1016/0301-0104(77)85151-3; Rosenfeld L., 1928, Z PHYS, V52, P161, DOI DOI 10.1007/BF01342393; RUCH E, 1972, ACCOUNTS CHEM RES, V5, P49, DOI 10.1021/ar50050a002; SATYANARAYANA BK, 1987, J ORG CHEM, V52, P3170; Snatzke G., 1991, CHIRALITY WEAK BOSON, P59, DOI 10.1007/978-3-642-76569-8_4; TINOCO I, 1963, J CHEM PHYS, V40, P160; van't Hoff JH., 1894, LAGERUNG ATOME RAUME, V2nd ed., P30; VANTHOFF JH, 1874, ARCH NEERL SCI EXACT, V9, P455; WALDEN P, 1894, Z PHYS CHEM, V15, P196; WROBLEWSKI AE, 1988, J AM CHEM SOC, V110, P4144, DOI 10.1021/ja00221a008	39	115	118	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2247	2250		10.1126/science.282.5397.2247	http://dx.doi.org/10.1126/science.282.5397.2247			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856945				2022-12-24	WOS:000077645800043
J	Wells, PS; Ginsberg, JS; Anderson, DR; Kearon, C; Gent, M; Turpie, AG; Bormanis, J; Weitz, J; Chamberlain, M; Bowie, D; Barnes, D; Hirsh, J				Wells, PS; Ginsberg, JS; Anderson, DR; Kearon, C; Gent, M; Turpie, AG; Bormanis, J; Weitz, J; Chamberlain, M; Bowie, D; Barnes, D; Hirsh, J			Use of a clinical model for safe management of patients with suspected pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article						pulmonary embolism; patient care management; models, statistical; probability; ventilation-perfusion ratio	DEEP-VEIN THROMBOSIS; PERFUSION LUNG-SCAN; IMPEDANCE PLETHYSMOGRAPHY; VENOUS THROMBOSIS; D-DIMER; DIAGNOSIS; ULTRASONOGRAPHY; ANGIOGRAPHY; OUTPATIENTS; VENOGRAPHY	Background: The low specificity of ventilation-perfusion lung scanning complicates the management of patients with suspected pulmonary embolism. Objective: To determine the safety of a clinical model for patients with suspected pulmonary embolism. Design: Prospective cohort study. Setting: Five tertiary care hospitals. Patients: 1239 inpatients and outpatients with suspected pulmonary embolism. Interventions: A clinical model categorized pretest probability of pulmonary embolism as low, moderate, or high, and ventilation-perfusion scanning and bilateral deep venous ultrasonography were done. Testing by serial ultrasonography, venography, or angiography depended on pretest probability and lung scans. Measurements: Patients were considered positive for pulmonary embolism if they had an abnormal pulmonary angiogram, abnormal ultrasonogram or venogram, high-probability ventilation-perfusion scan plus moderate or high pretest probability, or venous thromboembolic event during the 3-month follow-up. All other patients were considered negative for pulmonary embolism. Rates of pulmonary embolism during follow-up in patients who had a normal lung scan and those with a non-high-probability scan and normal serial ultrasonogram were compared. Results: Pretest probability was low in 734 patients (3.4% with pulmonary embolism), moderate in 403 (27.8% with pulmonary embolism), and high in 102 (78.4% with pulmonary embolism). Three of the 665 patients (0.5% [95% CI, 0.1 % to 1.3 % ]) with low or moderate pretest probability and a non-high-probability scan who were considered negative for pulmonary embolism had pulmonary embolism or deep venous thrombosis during 90-day follow-up; this rate did not differ from that in patients with a normal scan (0.6% [CI, 0.1% to 1.8%]; P > 0.2). Conclusion: Management of patients with suspected pulmonary embolism on the basis of pretest probability and results of ventilation-perfusion scanning is safe.			Wells, PS (corresponding author), Suite 467,737 Parkdale Ave, Ottawa, ON K1Y 1J8, Canada.		Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; BRADLEY MJ, 1995, CLIN RADIOL, V50, P232, DOI 10.1016/S0009-9260(05)83476-2; CELI A, 1989, CHEST, V95, P332, DOI 10.1378/chest.95.2.332; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; GINSBERG JS, 1995, THROMB HAEMOSTASIS, V73, P35; GOTTSCHALK A, 1993, J NUCL MED, V34, P1119; HENRY JW, 1995, CHEST, V107, P1375, DOI 10.1378/chest.107.5.1375; HILDNER FJ, 1967, J AMER MED ASSOC, V202, P567, DOI 10.1001/jama.202.7.567; HOELLERICH VL, 1986, ARCH INTERN MED, V146, P1699, DOI 10.1001/archinte.146.9.1699; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SASAHARA AA, 1983, JAMA-J AM MED ASSOC, V249, P2945, DOI 10.1001/jama.249.21.2945; Schluger N, 1994, J Thorac Imaging, V9, P180, DOI 10.1097/00005382-199422000-00013; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wells PS, 1998, LANCET, V351, P1405, DOI 10.1016/S0140-6736(05)79444-7	26	735	763	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					997	+		10.7326/0003-4819-129-12-199812150-00002	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867786				2022-12-24	WOS:000077471900001
J	Van Doren, M; Broihier, HT; Moore, LA; Lehmann, R				Van Doren, M; Broihier, HT; Moore, LA; Lehmann, R			HMG-CoA reductase guides migrating primordial germ cells	NATURE			English	Article							COENZYME-A REDUCTASE; DROSOPHILA-MELANOGASTER; EXPRESSION; PHENOTYPES; MESODERM	The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is best known for catalysing a rate-limiting step in cholesterol biosynthesis, but it also participates in the production of a wide variety of other compounds'. Some clinical benefits attributed to inhibitors of HMG-CoA reductase are now thought to be independent of any serum cholesterol-lowering effect(2,3). Here we describe a new cholesterol-independent role for HMG-CoA reductase, in regulating a developmental process: primordial germ cell migration. We show that in Drosophila this enzyme is highly expressed in the somatic gonad and that it is necessary for primordial germ cells to migrate to this tissue. Misexpression of HMG-CoA reductase is sufficient to attract primordial germ cells to tissues other than the gonadal mesoderm. We conclude that the regulated expression of HMG-CoA reductase has a critical developmental function in providing spatial information to guide migrating primordial germ cells.	NYU, Med Ctr, Skirball Inst, Dev Genet Program, New York, NY 10016 USA; NYU, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University	Lehmann, R (corresponding author), NYU, Med Ctr, Skirball Inst, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	lehmann@saturn.med.nyu.edu		Broihier, Heather/0000-0003-1363-3088; Lehmann, Ruth/0000-0002-8454-5651				Boyle M, 1997, DEVELOPMENT, V124, P971; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROLHIER HT, 1998, DEVELOPMENT, V125, P655; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CLAYTON RB, 1964, J LIPID RES, V5, P3; Corsini A, 1996, CARDIOLOGY, V87, P458, DOI 10.1159/000177139; CUNNINGHAM FM, 1994, LIPID MEDIATORS; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMPERTS M, 1994, CIBA F SYMP, V182, P121; KATZNELSON S, 1995, KIDNEY INT S, V52, P112; KIM SY, 1995, KIDNEY INT, V48, P363, DOI 10.1038/ki.1995.304; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Moore LA, 1998, DEVELOPMENT, V125, P667; Perrimon N, 1996, GENETICS, V144, P1681; RUSSELL J, 1992, DEVELOPMENT, V115, P475; Van Doren M, 1998, CURR BIOL, V8, P243; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	20	137	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					466	469		10.1038/24871	http://dx.doi.org/10.1038/24871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853754				2022-12-24	WOS:000077370100054
J	Lemon, KP; Grossman, AD				Lemon, KP; Grossman, AD			Localization of bacterial DNA polymerase: Evidence for a factory model of replication	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; BIPOLAR LOCALIZATION; SPORULATION; CHROMOSOME; IMMUNOFLUORESCENCE; VISUALIZATION; ORGANIZATION	Two general models have been proposed for DNA replication. In one model, DNA polymerase moves along the DNA (Like a train on a track); in the other model, the polymerase is stationary (Like a factory), and DNA is pulled through. To distinguish between these models, we visualized DNA polymerase of the bacterium Bacillus subtilis in living cells by the creation of a fusion protein containing the catalytic subunit (PolC) and green fluorescent protein (GFP). PolC-GFP was Localized at discrete intracellular positions, predominantly at or near midcell, rather than being distributed randomly. These results suggest that the polymerase is anchored in place and thus support the model in which the DNA template moves through the polymerase.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Grossman, AD (corresponding author), MIT, Dept Biol, Bldg 68-530, Cambridge, MA 02139 USA.		Lemon, Katherine P/AGS-8572-2022		NIGMS NIH HHS [GM41934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BENSON AK, 1993, J BACTERIOL, V175, P2347, DOI 10.1128/JB.175.8.2347-2356.1993; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HELMSTETTER CE, 1996, CELLULAR MOL BIOL, V2, P1627; HENNER DJ, 1990, METHOD ENZYMOL, V185, P223; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KORNBERG A, 1992, DNA REPLICATOIN; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; Niki H, 1998, GENE DEV, V12, P1036, DOI 10.1101/gad.12.7.1036; OGASAWARA N, 1985, EMBO J, V4, P3345, DOI 10.1002/j.1460-2075.1985.tb04087.x; POGLIANO K, 1995, MOL MICROBIOL, V18, P459, DOI 10.1111/j.1365-2958.1995.mmi_18030459.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Trun NJ, 1998, ASM NEWS, V64, P276; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WEBB CD, 1995, J BACTERIOL, V177, P5906, DOI 10.1128/jb.177.20.5906-5911.1995; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; Yoshiakwa H., 1993, P507	30	417	428	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1998	282	5393					1516	1519		10.1126/science.282.5393.1516	http://dx.doi.org/10.1126/science.282.5393.1516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140WA	9822387				2022-12-24	WOS:000077110800062
J	Guadagno, TM; Ferrell, JE				Guadagno, TM; Ferrell, JE			Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts	SCIENCE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; CELL-CYCLE EXTRACTS; PROTEIN-KINASE; DNA-REPLICATION; IN-VITRO; MOS; OOCYTES; VIVO	The p42 mitogen-activated protein kinase (MAPK) is required for progression through meiotic M phase in Xenopus oocytes. This report examines whether it also plays a role in normal mitotic progression. MAPK was transiently activated during mitosis in cycling Xenopus egg extracts after activation of the cyclin-dependent kinase Cdc2-cyclin B. Interference with MAPK activation by immunodepletion of its activator MEK, or by addition of the MEK inhibitor PD98059, caused precocious termination of mitosis and interfered with production of normal mitotic microtubules. Sustained activation of MAPK arrested extracts in mitosis in the absence of active Cdc2-cyclin B. These findings identify a role for MEK and MAPK in maintaining the mitotic state.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM46383] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; Chiri S, 1998, J CELL SCI, V111, P2519; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GUADAGNO TM, UNPUB; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Murakami MS, 1998, DEVELOPMENT, V125, P237; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Philipova R, 1998, J CELL SCI, V111, P2497; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	29	82	82	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 13	1998	282	5392					1312	1315		10.1126/science.282.5392.1312	http://dx.doi.org/10.1126/science.282.5392.1312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	138PV	9812894				2022-12-24	WOS:000076982200043
J	Krijnen, P; van Jaarsveld, BC; Steyerberg, EW; 't Veld, AJM; Schalekamp, MADH; Habbema, JDF				Krijnen, P; van Jaarsveld, BC; Steyerberg, EW; 't Veld, AJM; Schalekamp, MADH; Habbema, JDF			A clinical prediction rule for renal artery stenosis	ANNALS OF INTERNAL MEDICINE			English	Article						renal artery obstruction; angiography; prediction rule; hypertension, renovascular; creatine	RENOVASCULAR HYPERTENSION; ANGIOGRAPHY; DIAGNOSIS; INTERVENTION; MODELS; TESTS	Background: Renal artery stenosis is a rare cause of hypertension. The gold standard for diagnosing renal artery stenosis, renal angiography, is invasive and costly. Objective: To develop a prediction rule for renal artery stenosis from clinical characteristics that can be used to select patients for renal angiography. Design: Logistic regression analysis of data from a prospective cohort of patients suspected of having renal artery stenosis. A prediction rule was derived from the regression model for use in clinical practice. Setting: 26 hypertension clinics in the Netherlands. Patients: 477 hypertensive patients who underwent renal angiography because they had drug-resistant hypertension or an increase in serum creatinine concentration during therapy with angiotensin-converting enzyme inhibitors. Results: Age, sex, atherosclerotic vascular disease, recent onset of hypertension, smoking history, body mass index, presence of an abdominal bruit, serum creatinine concentration, and serum cholesterol level were selected as predictors. The regression model was reliable (goodness-of-fit test, P > 0.2) and discriminated well between patients with stenosis and those with essential hypertension (area under the receiver-operating characteristic curve, 0.84). The diagnostic accuracy of the regression model was similar to that of renal scintigraphy, which had a sensitivity of 72% and a specificity of 90%. Conclusions: In the diagnostic workup of patients suspected of having renal artery stenosis, the clinical prediction rule can be considered as an alternative to renal scintigraphy. It can help to select patients for renal angiography in an efficient manner by reducing the number of angiographic procedures without the risk for missing many renal artery stenoses.	Erasmus Univ, Dept Publ Hlth, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Univ Hosp Dijkzigt, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	Krijnen, P (corresponding author), Erasmus Univ, Dept Publ Hlth, Ctr Clin Decis Sci, Room EE2085,Box 1738, NL-3000 DR Rotterdam, Netherlands.	krijnen@ckb.fgg.eur.nl	Steyerberg, Ewout/C-1509-2018	Steyerberg, Ewout/0000-0002-7787-0122; van Jaarsveld, Brigit/0000-0001-5871-4952				Akaike H., 1998, P 2 INT S INF THEOR, DOI DOI 10.1007/978-1-4612-1694-0_15; ANDERSON GH, 1988, AM J HYPERTENS, V1, P301, DOI 10.1093/ajh/1.3.301; [Anonymous], 1987, ARCH INTERN MED, V147, P820; Bijlstra PJ, 1996, J HYPERTENS, V14, P1033; DAVIS BA, 1979, NEW ENGL J MED, V301, P1273, DOI 10.1056/NEJM197912063012307; DERKX FHM, 1994, LANCET, V344, P237, DOI 10.1016/S0140-6736(94)93002-3; DUNNICK NR, 1991, RADIOL CLIN N AM, V29, P497; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; EIPPER DF, 1976, AM J CARDIOL, V37, P48, DOI 10.1016/0002-9149(76)90498-7; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; GRANERUS G, 1992, J INTERN MED, V232, P15, DOI 10.1111/j.1365-2796.1992.tb00545.x; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HARRELL FE, 1997, DESIGN S PLUS FUNCTI; HESSEL SJ, 1981, RADIOLOGY, V138, P273, DOI 10.1148/radiology.138.2.7455105; HOSMER DW, 1989, APPL LOGISTIC REGRES, P135; KAPLAN NM, 1994, CLIN HYPERTENSION, P1; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; NICHOLSON JP, 1983, LANCET, V2, P765; PICKERING TG, 1991, CLIN CHEM, V37, P1831; Pickering TG, 1996, J HYPERTENS, V14, P1265, DOI 10.1097/00004872-199611000-00002; PICKERING TG, 1991, CIRCULATION, V83, P147; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; RUDNICK MR, 1994, AM J KIDNEY DIS, V24, P713, DOI 10.1016/S0272-6386(12)80235-6; RUTTIMAN S, 1993, ANN INTERN MED, V118, P905, DOI 10.7326/0003-4819-118-11-199306010-00015; SIMON N, 1972, J AMER MED ASSOC, V220, P1209, DOI 10.1001/jama.220.9.1209; SVETKEY LP, 1990, SOUTHERN MED J, V83, P743, DOI 10.1097/00007611-199007000-00005; TEGTMEYER CJ, 1996, RENAL VASCULAR DIS, P363; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; vanJaarsveld BC, 1996, CONTRIB NEPHROL, V119, P54; vanJaarsveld BC, 1997, ARCH INTERN MED, V157, P1226, DOI 10.1001/archinte.157.11.1226; VANJAARSVELD BC, 1995, J NEPHROL, V8, P5; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	36	144	154	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					705	+		10.7326/0003-4819-129-9-199811010-00005	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841602				2022-12-24	WOS:000076785200004
J	Griffith, MJ; Gammage, MD				Griffith, MJ; Gammage, MD			Radiofrequency ablation of macro re-entrant arrhythmias: cure or adjunctive therapy?	LANCET			English	Editorial Material							TYPE-1 ATRIAL-FLUTTER; CATHETER ABLATION; TACHYCARDIA; PATHWAY		Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Trust, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham	Griffith, MJ (corresponding author), Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Trust, Birmingham B15 2TH, W Midlands, England.							BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; Brignole M, 1997, CIRCULATION, V96, P2617, DOI 10.1161/01.CIR.96.8.2617; Cauchemez B, 1996, CIRCULATION, V93, P284, DOI 10.1161/01.CIR.93.2.284; FELD GK, 1992, CIRCULATION, V86, P1233, DOI 10.1161/01.CIR.86.4.1233; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; HAISSAGUERRE M, 1992, CIRCULATION, V85, P1262; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; LESH MD, 1994, CIRCULATION, V89, P1074, DOI 10.1161/01.CIR.89.3.1074; Marshall HJ, 1998, HEART, V79, P543, DOI 10.1136/hrt.79.6.543; MORADY F, 1993, CIRCULATION, V87, P363, DOI 10.1161/01.CIR.87.2.363; Paydak H, 1998, CIRCULATION, V98, P315, DOI 10.1161/01.CIR.98.4.315; POTY H, 1995, CIRCULATION, V92, P1389; Stevenson WG, 1998, CIRCULATION, V98, P308, DOI 10.1161/01.CIR.98.4.308	14	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1404	1405		10.1016/S0140-6736(05)61259-7	http://dx.doi.org/10.1016/S0140-6736(05)61259-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9807984				2022-12-24	WOS:000076719500004
J	Farrell, RJ; LaMont, JT				Farrell, RJ; LaMont, JT			Rational approach to iron-deficiency anaemia in premenopausal women	LANCET			English	Editorial Material							GASTROINTESTINAL-TRACT; ANEMIA		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Farrell, RJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA.							Bini ET, 1998, AM J MED, V105, P281, DOI 10.1016/S0002-9343(98)00260-5; Galan P, 1998, EUR J CLIN NUTR, V52, P383, DOI 10.1038/sj.ejcn.1600561; KEPCZYK MT, 1995, DIGEST DIS SCI, V40, P1283, DOI 10.1007/BF02065539; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; Milman N, 1998, ANN HEMATOL, V77, P13, DOI 10.1007/s002770050405; Rockey DC, 1998, NEW ENGL J MED, V339, P153, DOI 10.1056/NEJM199807163390303; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303	7	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 26	1998	352	9145					1953	1954		10.1016/S0140-6736(05)61326-8	http://dx.doi.org/10.1016/S0140-6736(05)61326-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872241				2022-12-24	WOS:000077663000005
J	Power, L				Power, L			Good times	LANCET			English	Editorial Material											Power, L (corresponding author), 605 Hidden Valley Dr,Suite 206, Ann Arbor, MI 48104 USA.								0	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1999	2000		10.1016/S0140-6736(98)11283-7	http://dx.doi.org/10.1016/S0140-6736(98)11283-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872262				2022-12-24	WOS:000077663000043
J	Bhat, KM				Bhat, KM			frizzled and frizzled 2 play a partially redundant role in wingless signaling and have similar requirements to wingless in neurogenesis	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SEGMENT POLARITY GENES; DROSOPHILA-MELANOGASTER; TISSUE POLARITY; SPECIFICATION; CNS; NEUROECTODERM; LINEAGES; PATTERN; FAMILY	The Drosophila Frizzled (Fz) and Frizzled2 (DFz2) proteins function as receptors for Wingless (Wg) in tissue culture cells. While previous results indicate that loss of function for fi has tissue polarity defects, loss-of-function effects of Dfz2 are not known. Here, we have examined the requirements of fz and Dfz2 during neurogenesis. Our results indicate that both Fz and DFz2 function in Wg signaling, and loss of either of the two affects the same subset of neuroblasts as those affected by loss of wg. While these defects are partially penetrant in embryos lacking either fz or Dfz2, the penetrance is significantly enhanced in embryos lacking both. Since the penetrance of the CNS phenotypes is not complete in double mutants, additional components that allow some degree of Wg signaling must exist in vivo.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Bhat, KM (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.				NIGMS NIH HHS [R01GM58237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BHAT KM, 1995, MOL CELL BIOL, V15, P4052; Bhat KM, 1997, DEVELOPMENT, V124, P1675; Bhat KM, 1998, INT J DEV BIOL, V42, P127; BHAT KM, 1996, DEVELOPMENT, V122, P2911; BHAT KM, 1999, IN PRESS BIOESSAYS; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; CHULAGRAFF Q, 1995, NEURON, V15, P1041, DOI 10.1016/0896-6273(95)90093-4; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; DOE CQ, 1992, DEVELOPMENT, V116, P855; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GUBB D, 1993, DEVELOPMENT, P269; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; Hays R, 1997, DEVELOPMENT, V124, P3727; Jones KH, 1996, GENETICS, V142, P205; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Matsuzaki M, 1996, DEVELOPMENT, V122, P3567; MERRILL PT, 1988, DEVELOPMENT, V104, P495; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MULLER AHJ, 1999, IN PRESS DEVELOPMENT; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEIFER M, 1994, DEVELOPMENT, V120, P369; Schmidt H, 1997, DEV BIOL, V189, P186, DOI 10.1006/dbio.1997.8660; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wieschaus E., 1986, P199; Zhang J, 1998, DEVELOPMENT, V125, P3075	40	99	99	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					1027	1036		10.1016/S0092-8674(00)81726-2	http://dx.doi.org/10.1016/S0092-8674(00)81726-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875856	Bronze			2022-12-24	WOS:000077759100017
J	Shiau, AK; Barstad, D; Loria, PM; Cheng, L; Kushner, PJ; Agard, DA; Greene, GL				Shiau, AK; Barstad, D; Loria, PM; Cheng, L; Kushner, PJ; Agard, DA; Greene, GL			The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen	CELL			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR COACTIVATORS; STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; ACTIVATION; COMPLEX; PROTEIN; SUPERFAMILY	Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators. Receptor agonists promote coactivator binding, and antagonists block coactivator binding. Here we report the crystal structure of the human estrogen receptor alpha (hER alpha) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hER alpha LED bound to the selective antagonist 4-hydroxytamoxifen (OHT). In the DES-LBD-peptide complex, the peptide binds as a short alpha helix to a hydrophobic groove on the surface of the LED. In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LED. These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Chicago; University of Chicago; University of California System; University of California San Francisco	Greene, GL (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	ggreene@huggins.bsd.uchicago.edu			NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031627] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-14599] Funding Source: Medline; NIDDK NIH HHS [DK51083] Funding Source: Medline; NIGMS NIH HHS [GM31627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1996, XPLOR VERSION 3 843; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; GREENE GL, 1980, P NATL ACAD SCI-BIOL, V77, P5115, DOI 10.1073/pnas.77.9.5115; GREENE GL, 1988, MOL ENDOCRINOL, V2, P714, DOI 10.1210/mend-2-8-714; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hegy GB, 1996, STEROIDS, V61, P367, DOI 10.1016/0039-128X(96)00042-6; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; JORDAN VC, 1982, MOL CELL ENDOCRINOL, V27, P291, DOI 10.1016/0303-7207(82)90095-8; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MUELLER K, 1988, B SOC CHIM BELG, V97, P655; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; ONATE SA, 1995, SCIENCE, V270, P1354; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROBERTSON DW, 1982, J MED CHEM, V25, P167, DOI 10.1021/jm00344a015; SEIELSTAD DA, 1995, MOL ENDOCRINOL, V9, P647, DOI 10.1210/me.9.6.647; Smigel K, 1998, J NATL CANCER I, V90, P647, DOI 10.1093/jnci/90.9.647; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	59	2114	2199	0	161	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1998	95	7					927	937		10.1016/S0092-8674(00)81717-1	http://dx.doi.org/10.1016/S0092-8674(00)81717-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	152CX	9875847	Bronze			2022-12-24	WOS:000077759100008
J	Pitti, RM; Marsters, SA; Lawrence, DA; Roy, M; Kischkel, FC; Dowd, P; Huang, A; Donahue, CJ; Sherwood, SW; Baldwin, DT; Godowski, PJ; Wood, WI; Gurney, AL; Hillan, KJ; Cohen, RL; Goddard, AD; Botstein, D; Ashkenazi, A				Pitti, RM; Marsters, SA; Lawrence, DA; Roy, M; Kischkel, FC; Dowd, P; Huang, A; Donahue, CJ; Sherwood, SW; Baldwin, DT; Godowski, PJ; Wood, WI; Gurney, AL; Hillan, KJ; Cohen, RL; Goddard, AD; Botstein, D; Ashkenazi, A			Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-MEDIATED CYTOTOXICITY; TNF RECEPTOR; APO-2 LIGAND; APOPTOSIS; FAMILY; EXPRESSION; MEMBER; DEATH; ACTIVATION	Fas ligand (FasL) is produced by activated T cells and natural killer cells and it induces apoptosis (programmed cell death) in target cells through the death receptor Fas/Apo1/CD95 (ref. 1). One important role of Fast and Fas is to mediate immune-cytotoxic killing of cells that are potentially harmful to the organism, such as virus-infected or tumour cells(1). Here we report the discovery of a soluble decoy receptor, termed decoy receptor 3 (DcR3), that binds to Fast and inhibits Fast-induced apoptosis. The DcR3 gene was amplified in about half of 35 primary lung and colon tumours studied, and DcR3 messenger RNA was expressed in malignant tissue. Thus, certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Stanford University	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.		Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; COLLOTTA F, 1993, SCIENCE, V261, P472; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Gelmini S, 1997, CLIN CHEM, V43, P752; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Medvedev AE, 1997, CYTOKINE, V9, P394, DOI 10.1006/cyto.1996.0181; Moretta A, 1997, CELL, V90, P13, DOI 10.1016/S0092-8674(00)80309-8; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190	24	635	730	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 17	1998	396	6712					699	703		10.1038/25387	http://dx.doi.org/10.1038/25387			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150YT	9872321				2022-12-24	WOS:000077694200059
J	Hennessey, KA; Schulte, JM; Cook, L; Collins, M; Onorato, IM; Valway, SE				Hennessey, KA; Schulte, JM; Cook, L; Collins, M; Onorato, IM; Valway, SE			Tuberculin skin test screening practices among US colleges and universities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1997 International Conference of the American-Thoracic-Society / American-Lung-Association	MAY 18-21, 1997	SAN FRANCISCO, CALIFORNIA	Amer Thorac Soc, Amer Lung Assoc			UNITED-STATES; EPIDEMIOLOGY; INFECTION	Context.-Concern about transmission of Mycobacterium tuberculosis on college campuses has prompted some schools to institute tuberculin skin test screening of students, but this screening has never been evaluated. Objective-To describe tuberculin skin test screening practices and results of screening in colleges and universities in the United States. Design and Setting.-Self-administered mail and telephone questionnaire in November and December 1995 to a stratified random sample of US 2-year and 4-year colleges and universities. Main Outcome Measures.-Type of tuberculin screening required; types of schools requiring screening; number and rate of students with positive skin test results and/or diagnosed as having tuberculosis. Results.-Of the 3148 US colleges and universities, 624 (78%) of 796 schools surveyed responded. Overall, 378 schools (61%) required tuberculin screening; it was required for all new students (US residents and international students) in 161 (26%) of 624 schools, all new international students but not new US residents in 53 (8%), and students in specific academic programs in 294 (47%). Required screening was more likely in 4-year vs 2-year schools, schools that belonged to the American College Health Association vs nonmember schools, schools with immunization requirements vs schools without, and schools with a student health clinic vs those without(P<.001 for all). Public and private schools were equally likely to require screening (64% vs 62%; P=.21). In the 378 schools with screening requirements, tine or multiple puncture tests were accepted in 95 (25%);test results were recorded in millimeters of induration in 95 (25%); and 100 (27%) reported collecting results in a centralized registry or database. Of the 168 (27%) of 624 schools accepting only Mantoux skin tests and reporting results for school years 1992-1993 through 1995-1996, 3.1% of the 348 368 students screened had positive skin test results (median percentage positive, 0.8%). International students had a significantly higher case rate for active tuberculosis than US residents (35.2 vs 1.1 per 100 000 students screened). Conclusions.-Widespread tuberculin screening of students yielded a low prevalence of skin test reactors and few tuberculosis cases. To optimize the use of limited public health resources, tuberculin screening should target students at high risk for infection.	Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Univ Penn, Philadelphia, PA 19104 USA	Centers for Disease Control & Prevention - USA; University of Pennsylvania	Hennessey, KA (corresponding author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd,Mailstop E10, Atlanta, GA 30333 USA.				PHS HHS [H75/CCU312238-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1996, MMWR Recomm Rep, V45, P1; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BAUGHMAN AL, 1994, JAMA-J AM MED ASSOC, V272, P1127, DOI 10.1001/jama.272.14.1127; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P19; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P253; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; DAVIS TM, 1995, OPEN DOORS 1994 95 R; Driver CR, 1996, PEDIATRICS, V98, P97; Henry P M, 1996, Minn Med, V79, P43; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Levy P., 1991, SAMPLING POPULATIONS; LIFSON AR, IN PRESS AM J EPIDEM; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; NELSON ME, 1995, AM J PREV MED, V11, P48, DOI 10.1016/S0749-3797(18)30407-0; PENDLETON EH, 1994, PETERSONS GUIDE 4 YE; Quillan S, 1990, J Am Coll Health, V38, P165; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Snedecor GW, 1980, STAT METHODS, V7th; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STARKE JR, 1993, PEDIATR ANN, V22, P612, DOI 10.3928/0090-4481-19931001-10; STERN JD, 1995, PETERSONS GUIDE 2 YE; SUSMANO S, 1990, J AM COLL HEALTH, V39, P287; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211	25	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2008	2012		10.1001/jama.280.23.2008	http://dx.doi.org/10.1001/jama.280.23.2008			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863852	Bronze			2022-12-24	WOS:000077462300031
J	Furuta, T; Ohashi, K; Kamata, T; Takashima, M; Kosuge, K; Kawasaki, T; Hanai, H; Kubota, T; Ishizaki, T; Kaneko, E				Furuta, T; Ohashi, K; Kamata, T; Takashima, M; Kosuge, K; Kawasaki, T; Hanai, H; Kubota, T; Ishizaki, T; Kaneko, E			Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer	ANNALS OF INTERNAL MEDICINE			English	Article							S-MEPHENYTOIN 4'-HYDROXYLATION; DOUBLE-BLIND TRIAL; AMOXICILLIN; JAPANESE; CLARITHROMYCIN; METRONIDAZOLE; POLYMORPHISM; POPULATION; MANAGEMENT; DISEASE	Background: Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased. Objective: To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacter pylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin. Design: Prospective cohort study. Setting: University hospital and health service center in Hamamatsu, Japan. Patients: 62 patients with peptic ulcer and H. pylori infection. Intervention: Omeprazole and amoxicillin, Measurements: CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer. Results: Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection. Conclusion: The results of the genotyping test for CYP2C19 seem to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.	Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Clin Pharmacol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med 2, Hamamatsu, Shizuoka 4313192, Japan; Honda Motor Co Ltd, Hamamatsu Hlth Serv Ctr, Hamamatsu, Shizuoka 4338501, Japan; SRL Inc, Hachioji Lab, Res Testing Dept, Hachioji, Tokyo 1928535, Japan; Int Med Ctr Japan, Tokyo, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; SRL Inc.; National Center for Global Health & Medicine - Japan	Furuta, T (corresponding author), Hamamatsu Univ Sch Med, Dept Med 1, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	furuta@akiha.hama-med.ac.jp						ALASSI MT, 1995, AM J GASTROENTEROL, V90, P1411; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; CEDERBRANT G, 1992, J ANTIMICROB CHEMOTH, V29, P115, DOI 10.1093/jac/29.2.115; CHANG M, 1995, BRIT J CLIN PHARMACO, V39, P511, DOI 10.1111/j.1365-2125.1995.tb04488.x; DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594; DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419; Furuta T, 1996, J CLIN MICROBIOL, V34, P2421, DOI 10.1128/JCM.34.10.2421-2425.1996; Goddard AF, 1996, GASTROENTEROLOGY, V111, P358, DOI 10.1053/gast.1996.v111.pm8690200; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; GRAYSON ML, 1989, EUR J CLIN MICROBIOL, V8, P888, DOI 10.1007/BF01963775; Ieiri I, 1996, CLIN PHARMACOL THER, V59, P647, DOI 10.1016/S0009-9236(96)90004-1; Kubota T, 1996, CLIN PHARMACOL THER, V60, P661, DOI 10.1016/S0009-9236(96)90214-3; Midolo PD, 1996, ANTIMICROB AGENTS CH, V40, P1531, DOI 10.1128/AAC.40.6.1531; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; *RES MULT EUR SURV, 1992, EUR J CLIN MICROBIOL, V11, P777; SOHN DR, 1992, J PHARMACOL EXP THER, V262, P1195; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; Unge P, 1996, SCAND J GASTROENTERO, V31, P74, DOI 10.3109/00365529609094541; WALSH JH, 1995, NEW ENGL J MED, V333, P984, DOI 10.1056/NEJM199510123331508	20	281	297	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1027	1030		10.7326/0003-4819-129-12-199812150-00006	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867757				2022-12-24	WOS:000077471900005
J	Shintani, D; DellaPenna, D				Shintani, D; DellaPenna, D			Elevating the vitamin E content of plants through metabolic engineering	SCIENCE			English	Article							PROTEIN LOCALIZATION SITES; TOCOPHEROLS; GENES; BIOSYNTHESIS; PURIFICATION; TOCOTRIENOLS; CELLS; FATS; OILS; CDNA	alpha-Tocopherol (vitamin E) is a Lipid-soluble antioxidant synthesized only by photosynthetic organisms. alpha-Tocopherol is an essential component of mammalian diets, and intakes in excess of the U.S. recommended daily allowance are correlated with decreased incidence of a number of degenerative human diseases. Plant oils, the main dietary source of tocopherols, typically contain alpha-tocopherol as a minor component and high Levels of its biosynthetic precursor, gamma-tocopherol, A genomics-based approach was used to clone the final enzyme in alpha-tocopherol synthesis, gamma-tocopherol methyltransferase. Overexpression of gamma-tocopherol methyltransferase in Arabidopsis seeds shifted oil compositions in favor of alpha-tocopherol. Similar increases in agricultural oil crops would increase vitamin E Levels in the average U.S. diet.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	DellaPenna, D (corresponding author), Univ Nevada, Dept Biochem, Mail Stop 200, Reno, NV 89557 USA.	delta_d@med.unr.edu	Shintani, David/A-8790-2011	Shintani, David/0000-0001-9557-0476				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; BECHTOLD N, 1993, CR HEBD ACAD SCI, V1144, P204; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DHARLINGUE A, 1985, J BIOL CHEM, V260, P5200; Eitenmiller RR, 1997, FOOD TECHNOL-CHICAGO, V51, P78; ERIN AN, 1985, BIOCHIM BIOPHYS ACTA, V815, P209, DOI 10.1016/0005-2736(85)90291-3; FRYER MJ, 1992, PLANT CELL ENVIRON, V15, P381, DOI 10.1111/j.1365-3040.1992.tb00988.x; Garcia I, 1997, BIOCHEM J, V325, P761, DOI 10.1042/bj3250761; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; Kaneko T, 1996, DNA Res, V3, P109; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; *NAT RES COUNC FOO, 1989, NAS NRC REC DIET ALL; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Norris SR, 1995, PLANT CELL, V7, P2139, DOI 10.1105/tpc.7.12.2139; Norris SR, 1998, PLANT PHYSIOL, V117, P1317, DOI 10.1104/pp.117.4.1317; SEFFENS WS, 1990, DEV GENET, V11, P65, DOI 10.1002/dvg.1020110108; SOLL J, 1985, ARCH BIOCHEM BIOPHYS, V238, P290, DOI 10.1016/0003-9861(85)90167-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYVAOJA EL, 1986, J AM OIL CHEM SOC, V63, P328, DOI 10.1007/BF02546039; TAYLOR LA, 1988, NUCLEIC ACIDS RES, V16, P358, DOI 10.1093/nar/16.1.358; TAYLOR P, 1981, CHEM IND-LONDON, P722; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; TRELFALL DR, 1971, ASPECTS TERPENOID CH, P357; *VERIS INF SERV, 1994, VIT E FACT BOOK; WHISTANC.GR, 1970, BIOCHEM J, V117, P593, DOI 10.1042/bj1170593; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	30	394	482	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2098	2100		10.1126/science.282.5396.2098	http://dx.doi.org/10.1126/science.282.5396.2098			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851934				2022-12-24	WOS:000077467100052
J	Levinson, W; Altkorn, D				Levinson, W; Altkorn, D			Primary prevention of postmenopausal osteoporosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HORMONE REPLACEMENT THERAPY; BONE-MINERAL DENSITY; BREAST-CANCER; WOMEN; ESTROGEN; RISK; MORTALITY; DISEASE; OLDER		Univ Chicago, Gen Internal Med Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Gen Internal Med Sect, Dept Med, 5841 S Maryland Ave,MC 6098, Chicago, IL 60637 USA.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P509; 1998, SCI AM MED, V15, pR11; 1998, OSTEOPOROSIS INT S4, V8, pS1	17	17	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1821	1822		10.1001/jama.280.21.1821	http://dx.doi.org/10.1001/jama.280.21.1821			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846765				2022-12-24	WOS:000077176600010
J	Nightingale, SL				Nightingale, SL			New alcohol warning required for OTC analgesic/antipyretic products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-24	WOS:000077176600004
J	Selwyn, PA; Arnold, R				Selwyn, PA; Arnold, R			From fate to tragedy: The changing meanings of life, death, and AIDS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HIV-1 INFECTION; PATIENT; PHYSICIAN; PROTEASE; PAIN; CARE; COMMUNICATION; SATISFACTION; ADHERENCE	The advent of highly active antiretroviral therapy (HAART) and quantitative Viral load assays has revolutionized the care of HIV-infected patients. However, this paradigm shift has also had unexpected, sometimes adverse consequences that are not always obvious. Before antiretroviral therapy, physicians learned how to accompany patients through their illness; to bear witness to sickness and dying; and to help patients and their families with suffering, closure, and legacy. Since we have become better at treating the virus, a new temptation has emerged to dwell on quantitative aspects of HIV management and monitoring. although the skills that we learned earlier in the epidemic are no less necessary for providing good care. Our new-found therapeutic capabilities should not distract us from the sometimes more difficult and necessary task of simply "being there" for patients for whom HAART is no longer effective. The definition and practice of end-of-life care for patients with AIDS will continue to evolve as AIDS comes to resemble other chronic, treatable, but ultimately fatal illnesses, such as end-stage pulmonary disease and metastatic cancer, in which clinicians must continually readdress with their patients the balance of curative and palliative interventions as the disease process unfolds overtime. The coming challenge in HIV care will be to encourage the maintenance of a "primary care" mentality-with attention to the larger psychosocial issues, end-of-life care, bereavement, and a focus on the patient as opposed to the illness-alongside our new antiretroviral paradigm. Otherwise, we run the risk of forgetting what we learned about healing, from a disease that we could not cure.	Yale Univ, Sch Med, AIDS Program, New Haven, CT 06511 USA; Univ Pittsburgh, Sch Med, Ctr Med Eth, Div Gen Internal Med, Pittsburgh, PA 15213 USA	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Selwyn, PA (corresponding author), Yale Univ, Sch Med, AIDS Program, 135 Coll St, New Haven, CT 06511 USA.	peter.selwyn@yale.edu						American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Aries Philippe, 1975, W ATTITUDES DEATH; BARTLETT EE, 1984, J CHRON DIS, V37, P755, DOI 10.1016/0021-9681(84)90044-4; Breitbart W, 1996, PAIN, V68, P315, DOI 10.1016/S0304-3959(96)03215-0; Breitbart William, 1996, P359; Byock I, 1997, DYING WELL PROSPECT; Callahan Daniel, 1993, TROUBLED DREAM LIFE; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; COHEN PT, 1994, AIDS KNOWLEDGE BASE; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIMATTEO MR, 1992, ACHIEVING PATIENT CO; DYE NE, 1995, MEDICAL, V1, P134; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HALL JA, 1981, J HEALTH SOC BEHAV, V22, P18, DOI 10.2307/2136365; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; *I MED COMM END LI, 1997, APPR DEATH IMPR CAR; Larue F, 1997, BRIT MED J, V314, P23, DOI 10.1136/bmj.314.7073.23; Lewis CE, 1997, JAMA-J AM MED ASSOC, V278, P1133, DOI 10.1001/jama.278.14.1133; LEY P, 1982, BRIT J CLIN PSYCHOL, V21, P241, DOI 10.1111/j.2044-8260.1982.tb00562.x; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Rabkin JG, 1997, ARCH GEN PSYCHIAT, V54, P1049; Rosenfeld B, 1996, PAIN, V68, P323, DOI 10.1016/S0304-3959(96)03220-4; SQUIER RW, 1990, SOC SCI MED, V30, P325, DOI 10.1016/0277-9536(90)90188-X; Zuger A, 1997, JAMA-J AM MED ASSOC, V278, P1131, DOI 10.1001/jama.278.14.1131; 1997, MMWR MORB MORTAL WKL, V46, P861	29	40	40	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					899	902		10.7326/0003-4819-129-11_Part_1-199812010-00012	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867733				2022-12-24	WOS:000077239200009
J	Rubinstein, P; Carrier, C; Scaradavou, A; Kurtzberg, J; Adamson, J; Migliaccio, AR; Berkowitz, RL; Cabbad, M; Dobrila, NL; Taylor, PE; Rosenfield, RE; Stevens, CE				Rubinstein, P; Carrier, C; Scaradavou, A; Kurtzberg, J; Adamson, J; Migliaccio, AR; Berkowitz, RL; Cabbad, M; Dobrila, NL; Taylor, PE; Rosenfield, RE; Stevens, CE			Outcomes among 562 recipients of placental-blood transplants from unrelated donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UMBILICAL-CORD-BLOOD; BONE-MARROW TRANSPLANTATION; HLA-IDENTICAL SIBLINGS; VERSUS-HOST DISEASE; MONOCLONAL ORIGIN; STEM-CELLS; LEUKEMIA; RECONSTITUTION; CHILDREN; ENGRAFTMENT	Background A program for banking, characterizing, and distributing placental blood, also called umbilical-cord blood, for transplantation provided grafts for 562 patients between August 24, 1992, and January 30, 1998. We evaluated this experience. Methods Placental blood was stored under liquid nitrogen and selected for specific patients on the basis of HLA type and leukocyte content. Patients were prepared for the transplantation of allogeneic hematopoietic cells in the placental blood and received prophylaxis against graft-versus-host disease (GVHD) according to routine procedures at each center. Results Outcomes at 100 days after transplantation were known for all 562 patients, and outcomes at 1 year for 94 percent of eligible recipients. The cumulative rates of engraftment among the recipients, according to actuarial analysis, were 81 percent by day 42 for neutrophils (median time to engraftment, 28 days) and 85 percent by day 180 for platelets (median, day 90). The speed of myeloid engraftment was associated primarily with the leukocyte content of the graft, whereas transplantation-related events were associated with the patient's underlying disease and age, the number of leukocytes in the graft, the degree of HLA disparity, and the transplantation center. After engraftment, age, HLA disparity, and center were the primary predictors of outcome. Severe acute GVHD (grade III or IV) occurred in 23 percent of patients, and chronic GVHD occurred in 25 percent. The rate of relapse among recipients with leukemia was 9 percent within the first 100 days, 17 percent within 6 months, and 26 percent by 1 year. These rates were associated with the severity of GVHD, type of leukemia, and stage of the disease. Conclusions Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution. (N Engl J Med 1998;339:1565-77) (C)1998, Massachusetts Medical Society.	New York Blood Ctr, Allen Lab Immunogenet, New York, NY 10021 USA; New York Blood Ctr, Hematopoiet Growth Factors Lab, New York, NY 10021 USA; New York Blood Ctr, Wolf Szmuness Lab Epidemiol, New York, NY 10021 USA; Duke Univ, Med Ctr, Pediat Bone Marrow Transplant Unit, Durham, NC USA; Mt Sinai Med Ctr, Dept Obstet Gynecol & Reprod Med, New York, NY USA; Brooklyn Hosp Med Ctr, Dept Obstet & Gynecol, Brooklyn, NY USA	New York Blood Center; New York Blood Center; New York Blood Center; Duke University; Icahn School of Medicine at Mount Sinai; Brooklyn Hospital Center	Rubinstein, P (corresponding author), New York Blood Ctr, Allen Lab Immunogenet, 310 E 67th St, New York, NY 10021 USA.		Migliaccio, Anna Rita/GWZ-9323-2022	FRANCO MIGLIACCIO, ANNA RITA/0000-0003-1800-271X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL048031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; BALCAREK KB, 1993, J INFECT DIS, V167, P1433, DOI 10.1093/infdis/167.6.1433; BALDUZZI A, 1995, BLOOD, V86, P3247; COX DR, 1972, J R STAT SOC B, V34, P187; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; Ford AM, 1997, BLOOD, V89, P281, DOI 10.1182/blood.V89.1.281.281_281_285; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1909, NEW ENGL J MED, V337, P373; Hongeng S, 1997, LANCET, V350, P767, DOI 10.1016/S0140-6736(97)03098-5; HOROWITZ MM, 1990, BLOOD, V75, P555; *INT CORD BLOOD FD, 1997, CORD BLOOD MAK INF C; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KURTZBERG J, 1994, BLOOD CELLS, V20, P275; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; MAHMOUD HH, 1995, MED PEDIATR ONCOL, V24, P77, DOI 10.1002/mpo.2950240203; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rowley JD, 1998, NAT MED, V4, P150, DOI 10.1038/nm0298-150; RUBINSTEIN P, 1986, TISSUE ANTIGENS, V27, P209; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; RUBINSTEIN P, 1994, BLOOD CELLS, V20, P587; Rubinstein P, 1993, J Hematother, V2, P207, DOI 10.1089/scd.1.1993.2.207; SULLIVAN, 1989, BLOOD, V74, P1180; SULLIVAN KM, 1989, BLOOD, V73, P1720; Szydlo R, 1997, J CLIN ONCOL, V15, P1767, DOI 10.1200/JCO.1997.15.5.1767; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Wagner JE, 1996, BLOOD, V88, P795	28	1066	1143	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1998	339	22					1565	1577		10.1056/NEJM199811263392201	http://dx.doi.org/10.1056/NEJM199811263392201			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZU	9828244				2022-12-24	WOS:000077176100001
J	Neul, JL; Ferguson, EL				Neul, JL; Ferguson, EL			Spatially restricted activation of the SAX receptor by SCW modulates DPP/TKV signaling in Drosophila dorsal-ventral patterning	CELL			English	Article							TGF-BETA RECEPTOR; SHORT GASTRULATION GENE; THICK VEINS; I RECEPTORS; ACTIVITY GRADIENT; EMBRYO; DPP; XENOPUS; FAMILY; REQUIREMENT	Dorsal-ventral patterning within the embryonic ectoderm of Drosophila requires two TGF beta ligands, DPP and SCW, and two type I TGF beta receptors, TKV and SAX. In embryos lacking dpp signaling, increasing the level of TKV activity promotes progressively more dorsal cell types, while activation of SAX alone has no phenotypic consequences. However, SAX activity synergizes with TKV activity to promote dorsal development. Functional experiments suggest the two receptors have different ligands: DPP acts through TKV, and SCW acts through SAX. Furthermore, SOG, a negative regulator of this patterning process, preferentially blocks SCW activity. We propose that spatial regulation of the SAX pathway modulates TKV signaling to create positional information over the embryonic ectoderm.	Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Ferguson, EL (corresponding author), Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA.		Neul, Jeffrey/AAF-5324-2020	Ferguson, Edwin/0000-0003-4125-4253; Neul, Jeffrey/0000-0002-5628-5872	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050838] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50838] Funding Source: Medline; OHS HRSA HHS [ST32GM07281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Bier E, 1997, CELL, V89, P681, DOI 10.1016/S0092-8674(00)80250-0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Das P, 1998, DEVELOPMENT, V125, P1519; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Hudson JB, 1998, DEVELOPMENT, V125, P1407; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; Khalsa O, 1998, DEVELOPMENT, V125, P2723; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; Nguyen VH, 1998, DEV BIOL, V199, P93, DOI 10.1006/dbio.1998.8927; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERRACOL R, 1994, GENETICS, V138, P165; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Vincent S, 1997, DEVELOPMENT, V124, P2741; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	53	81	85	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 13	1998	95	4					483	494		10.1016/S0092-8674(00)81616-5	http://dx.doi.org/10.1016/S0092-8674(00)81616-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	139VB	9827801	Bronze			2022-12-24	WOS:000077049400007
J	Gardner, MJ; Tettelin, H; Carucci, DJ; Cummings, LM; Aravind, L; Koonin, EV; Shallom, S; Mason, T; Yu, K; Fujii, C; Pederson, J; Shen, K; Jing, JP; Aston, C; Lai, ZW; Schwartz, DC; Pertea, M; Salzberg, S; Zhou, LX; Sutton, GG; Clayton, R; White, O; Smith, HO; Fraser, CM; Adams, MD; Venter, JC; Hoffman, SL				Gardner, MJ; Tettelin, H; Carucci, DJ; Cummings, LM; Aravind, L; Koonin, EV; Shallom, S; Mason, T; Yu, K; Fujii, C; Pederson, J; Shen, K; Jing, JP; Aston, C; Lai, ZW; Schwartz, DC; Pertea, M; Salzberg, S; Zhou, LX; Sutton, GG; Clayton, R; White, O; Smith, HO; Fraser, CM; Adams, MD; Venter, JC; Hoffman, SL			Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ERYTHROCYTE SURFACE-ANTIGEN; BLOOD STAGE ANTIGEN; MOLECULAR-CLONING; MEMBRANE PROTEIN; GENETIC-ANALYSIS; SERINE-STRETCH; REPETITIVE DNA; SERA GENE; DOMAINS	Chromosome 2 of Plasmodium falciparum was sequenced; this sequence contains 947,103 base pairs and encodes 210 predicted genes. In comparison with the Saccharomyces cerevisiae genome, chromosome 2 has a lower gene density, introns are more frequent, and proteins are markedly enriched in nonglobular domains. A family of surface proteins, rifins, that may play a role in antigenic variation was identified. The complete sequencing of chromosome 2 has shown that sequencing of the A + T-rich P. falciparum genome is technically feasible.	USN, Med Res Inst, Malari Program, Rockville, MD 20852 USA; Inst Genome Res, Rockville, MD 20850 USA; Texas A&M Univ, Dept Biol, College Stn, TX USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; NYU, Dept Chem, Lab Biomol Imaging, New York, NY 10003 USA; Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA; Inst Genom Res, Rockville, MD 20850 USA; Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; J. Craig Venter Institute; Texas A&M University System; Texas A&M University College Station; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); New York University; Johns Hopkins University; J. Craig Venter Institute; Johns Hopkins University	Hoffman, SL (corresponding author), USN, Med Res Inst, Malari Program, 12300 Washington Ave, Rockville, MD 20852 USA.		Pertea, Mihaela/AAT-2705-2021; Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019	Pertea, Mihaela/0000-0003-0762-8637; Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Gardner, Malcolm/0000-0003-2180-5089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040125] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40125-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAVIND L, UNPUB; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; Bonnefoy S, 1997, MOL BIOCHEM PARASIT, V87, P1, DOI 10.1016/S0166-6851(97)00033-9; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; COPPEL RL, 1984, NATURE, V310, P789, DOI 10.1038/310789a0; CUMMINGS LJ, UNPUB; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Dame JB, 1996, MOL BIOCHEM PARASIT, V79, P1, DOI 10.1016/0166-6851(96)02641-2; DEVINE SE, 1994, NUCLEIC ACIDS RES, V22, P3765, DOI 10.1093/nar/22.18.3765; DUFFY PE, 1993, J EXP MED, V177, P505, DOI 10.1084/jem.177.2.505; duSart D, 1997, NAT GENET, V16, P144; EAKIN AE, 1989, NATURE, V342, P132, DOI 10.1038/342132b0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOLEY M, 1994, EXP PARASITOL, V79, P340, DOI 10.1006/expr.1994.1096; FOSTER J, 1995, PARASITOL TODAY, V11, P1, DOI 10.1016/0169-4758(95)80092-1; FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V44, P115, DOI 10.1016/0166-6851(91)90227-W; Haucke V, 1997, TRENDS CELL BIOL, V7, P103, DOI 10.1016/S0962-8924(96)10052-0; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; HIGGINS DG, 1989, NATURE, V340, P604, DOI 10.1038/340604a0; Jing J., UNPUB; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KEMP DJ, 1985, NATURE, V315, P347, DOI 10.1038/315347a0; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KUZIO J, 1996, METHOD ENZYMOL, V266, P554; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; Lechner J, 1996, FEBS LETT, V389, P70, DOI 10.1016/0014-5793(96)00563-7; LI WB, 1989, MOL BIOCHEM PARASIT, V33, P13, DOI 10.1016/0166-6851(89)90037-6; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OQUENDO P, 1986, MOL BIOCHEM PARASIT, V18, P89, DOI 10.1016/0166-6851(86)90053-8; QUAKYI IA, 1989, INFECT IMMUN, V57, P833, DOI 10.1128/IAI.57.3.833-839.1989; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROST B, 1995, PROTEIN SCI, V4, P521; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; SLABAS AR, 1992, PLANT MOL BIOL, V19, P169, DOI 10.1007/BF00015613; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Smith MM, 1996, MOL CELL BIOL, V16, P1017; SU Z, 1995, CELL, V82, P89; SUPLICK K, 1988, MOL BIOCHEM PARASIT, V30, P289, DOI 10.1016/0166-6851(88)90098-9; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; VERNICK KD, 1988, MOL BIOCHEM PARASIT, V28, P85, DOI 10.1016/0166-6851(88)90055-2; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Watanabe J, 1997, MOL BIOCHEM PARASIT, V88, P253, DOI 10.1016/S0166-6851(97)00073-X; WEBER JL, 1988, MOL BIOCHEM PARASIT, V29, P117, DOI 10.1016/0166-6851(88)90066-7; WILSON RJM, 1991, PARASITOL TODAY, V7, P134, DOI 10.1016/0169-4758(91)90276-T; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269	73	403	430	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1126	1132		10.1126/science.282.5391.1126	http://dx.doi.org/10.1126/science.282.5391.1126			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9804551				2022-12-24	WOS:000076887700051
J	Welch, HG; Burke, W				Welch, HG; Burke, W			Uncertainties in genetic testing for chronic disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FOLLOW-UP CARE; INHERITED PREDISPOSITION; INFORMED CONSENT; CANCER; BRCA1; RISKS; RECOMMENDATIONS; INDIVIDUALS; MUTATIONS; SAMPLES		Dept Vet Affairs Med Ctr, White River Jct, VT USA; Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Welch, HG (corresponding author), VA Outcomes Grp IIIB, White River Jct, VT 05009 USA.	gilbert.welch@dartmouth.edu						[Anonymous], 1989, NEW ENGL J MED, V321, P406; Bacon BR, 1997, GASTROENTEROLOGY, V113, P995, DOI 10.1016/S0016-5085(97)70196-3; BAIRD PA, 1995, PERSPECT BIOL MED, V38, P159; Black WC, 1997, AM J ROENTGENOL, V168, P3, DOI 10.2214/ajr.168.1.8976910; *BREAST CANC INF C, OP ACC ON LIN BREAST; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CLAYTON EW, 1995, JAMA-J AM MED ASSOC, V274, P1786, DOI 10.1001/jama.274.22.1786; COLLINS F, 1997, ACAD PHYSICIAN SC JU, P6; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; HENIG RM, 1997, WASHINGTON POST 1013, P23; Jonsen AR, 1996, NAT MED, V2, P622, DOI 10.1038/nm0696-622; KNOPPERS BM, 1995, JAMA-J AM MED ASSOC, V274, P1806, DOI 10.1001/jama.274.22.1806; MEADOR CK, 1994, NEW ENGL J MED, V330, P440, DOI 10.1056/NEJM199402103300618; Pauker SG, 1997, NEW ENGL J MED, V336, P1243, DOI 10.1056/NEJM199704243361708; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; WAGENER DK, 1995, ENVIRON HEALTH PERSP, V103, P75, DOI 10.2307/3432564; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Welch HG, 1997, J GEN INTERN MED, V12, P118, DOI 10.1046/j.1525-1497.1997.00017.x	27	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1525	1527		10.1001/jama.280.17.1525	http://dx.doi.org/10.1001/jama.280.17.1525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809734				2022-12-24	WOS:000076757200027
J	Tong, JK; Hassig, CA; Schnitzler, GR; Kingston, RE; Schreiber, SL				Tong, JK; Hassig, CA; Schnitzler, GR; Kingston, RE; Schreiber, SL			Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex	NATURE			English	Article							MI-2 AUTOANTIGEN; TRANSCRIPTION; PROTEINS	The dynamic assembly and remodelling of eukaryotic chromosomes facilitate fundamental cellular processes such as DNA replication and gene transcription. The repeating unit of eukaryotic chromosomes is the nucleosome fore, consisting of DNA wound about a defined octamer of histone proteins(1). Two enzymatic processes that regulate transcription by targeting elements of the nucleosome include ATP-dependent nucleosome remodelling and reversible histone acetylation(2,3). The histone deacetylases, however, are unable to deacetylate oligonucleosomal histones in vitro(4). The protein complexes that mediate ATP-dependent nucleosome remodelling and histone acetylation/deacetylation in the regulation of transcription were considered to be different, although it has recently been suggested that these activities might be coupled(5). We report here the identification and functional characterization of a novel ATP-dependent nucleosome remodelling activity that is part of an endogenous human histone deacetylase complex This activity is derived from the CHD3 and CHD4 proteins which contain helicase/ATPase domains found in SWI2-related chromatin remodelling factors, and facilitates the deacetylation of oligonucleosomal histones in vitro. We refer to this complex as the nucleosome remodelling and deacetylating (NRD) complex. Our results establish a physical and functional link between the distinct chromatin-modifying activities of histone deacetylases and nucleosome remodelling proteins.	Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Schreiber, SL (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.							Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; DeRubertis F, 1996, NATURE, V384, P589; ELGIN SCR, 1995, CHROMATIN STRUCTURE; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Tavladoraki P, 1998, FEBS LETT, V426, P62, DOI 10.1016/S0014-5793(98)00311-1; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	14	535	557	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1998	395	6705					917	921		10.1038/27699	http://dx.doi.org/10.1038/27699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	133XT	9804427				2022-12-24	WOS:000076713400061
